From e1b7252ff6d89b4655f781d35f35b4298e61b5bd Mon Sep 17 00:00:00 2001 From: Matthijs Berends Date: Wed, 12 Mar 2025 15:09:28 +0100 Subject: [PATCH] (v2.1.1.9193) new antimicrobials for screening --- .gitignore | 1 + DESCRIPTION | 4 +- NEWS.md | 5 +- PythonPackage/AMR/AMR.egg-info/PKG-INFO | 2 +- PythonPackage/AMR/dist/amr-2.1.1.9192.tar.gz | Bin 10087 -> 0 bytes ...ny.whl => amr-2.1.1.9193-py3-none-any.whl} | Bin 10280 -> 10280 bytes PythonPackage/AMR/dist/amr-2.1.1.9193.tar.gz | Bin 0 -> 10101 bytes PythonPackage/AMR/setup.py | 2 +- R/sysdata.rda | Bin 93568 -> 95212 bytes data-raw/ab.md5 | 2 +- data-raw/antimicrobials.dta | Bin 468998 -> 473642 bytes data-raw/antimicrobials.feather | Bin 132674 -> 133194 bytes data-raw/antimicrobials.parquet | Bin 105270 -> 105634 bytes data-raw/antimicrobials.rds | Bin 43436 -> 43628 bytes data-raw/antimicrobials.sav | Bin 373428 -> 376324 bytes data-raw/antimicrobials.txt | 26 ++- data-raw/antimicrobials.xlsx | Bin 75989 -> 76455 bytes data-raw/eucast_rules.tsv | 221 ++++++++++-------- ....txt => gpt_training_text_v2.1.1.9193.txt} | 48 ++-- data-raw/reproduction_of_antimicrobials.R | 103 +++++++- .../reproduction_of_clinical_breakpoints.R | 33 ++- data-raw/wisca.xlsx | Bin 10779 -> 10186 bytes data-raw/wisca_params.xlsx | Bin 12872 -> 14528 bytes data/antimicrobials.rda | Bin 43456 -> 43700 bytes man/AMR-deprecated.Rd | 2 +- man/antimicrobial_selectors.Rd | 16 +- man/antimicrobials.Rd | 4 +- man/custom_eucast_rules.Rd | 20 +- man/eucast_rules.Rd | 2 +- man/mdro.Rd | 2 +- 30 files changed, 319 insertions(+), 174 deletions(-) delete mode 100644 PythonPackage/AMR/dist/amr-2.1.1.9192.tar.gz rename PythonPackage/AMR/dist/{amr-2.1.1.9192-py3-none-any.whl => amr-2.1.1.9193-py3-none-any.whl} (86%) create mode 100644 PythonPackage/AMR/dist/amr-2.1.1.9193.tar.gz rename data-raw/{gpt_training_text_v2.1.1.9192.txt => gpt_training_text_v2.1.1.9193.txt} (93%) diff --git a/.gitignore b/.gitignore index 7aa85485d..54dfafbd4 100755 --- a/.gitignore +++ b/.gitignore @@ -21,6 +21,7 @@ packrat/lib*/ packrat/src/ data-raw/taxa.txt data-raw/taxon.tab +data-raw/CLSI*.pdf data-raw/DSMZ_bactnames.xlsx data-raw/country_analysis_url_token.R data-raw/country_analysis2.R diff --git a/DESCRIPTION b/DESCRIPTION index 9ca155bc8..d3a5982d2 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,6 +1,6 @@ Package: AMR -Version: 2.1.1.9192 -Date: 2025-03-10 +Version: 2.1.1.9193 +Date: 2025-03-12 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) data analysis and to work with microbial and antimicrobial properties by diff --git a/NEWS.md b/NEWS.md index 3696aec4c..e05755f12 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,4 +1,4 @@ -# AMR 2.1.1.9192 +# AMR 2.1.1.9193 *(this beta version will eventually become v3.0. We're happy to reach a new major milestone soon, which will be all about the new One Health support! Install this beta using [the instructions here](https://msberends.github.io/AMR/#latest-development-version).)* @@ -61,7 +61,8 @@ This package now supports not only tools for AMR data analysis in clinical setti * The selectors `lincosamides()` and `macrolides()` do not overlap anymore - each antibiotic is now classified as either of these and not both * Fixed selector `fluoroquinolones()`, which now really only selects second-generation quinolones and up (first-generation quinolones do not contain a fluorine group) * `antimicrobials` data set - * Added "clindamycin inducible screening" as `CLI1`. Since clindamycin is a lincosamide, the antimicrobial selector `lincosamides()` now contains the argument `only_treatable = TRUE` (similar to other antimicrobial selectors that contain non-treatable drugs) + * Added agents used for screening, with an ID all ending with `-S`: benzylpenicillin screening test (`PEN-S`), clindamycin inducible screening test (`CLI-S`), nalidixic acid screening test (`NAL-S`), norfloxacin screening test (`NOR-S`), oxacillin screening test (`OXA-S`), pefloxacin screening test (`PEF-S`), and tetracycline screening test (`TCY-S`). The ID of cefoxitin screening was renamed from `FOX1` to `FOX-S`, while the old code remains to work. + * Since clindamycin is a lincosamide, the antimicrobial selector `lincosamides()` now contains the argument `only_treatable = TRUE` (similar to other antimicrobial selectors that contain non-treatable drugs) * Added amorolfine (`AMO`, D01AE16), which is now also part of the `antifungals()` selector * Added efflux (`EFF`), to allow mapping to AMRFinderPlus * Added tigemonam (`TNM`), a monobactam diff --git a/PythonPackage/AMR/AMR.egg-info/PKG-INFO b/PythonPackage/AMR/AMR.egg-info/PKG-INFO index 3c2d263c5..6034054c3 100644 --- a/PythonPackage/AMR/AMR.egg-info/PKG-INFO +++ b/PythonPackage/AMR/AMR.egg-info/PKG-INFO @@ -1,6 +1,6 @@ Metadata-Version: 2.2 Name: AMR -Version: 2.1.1.9192 +Version: 2.1.1.9193 Summary: A Python wrapper for the AMR R package Home-page: https://github.com/msberends/AMR Author: Matthijs Berends diff --git a/PythonPackage/AMR/dist/amr-2.1.1.9192.tar.gz b/PythonPackage/AMR/dist/amr-2.1.1.9192.tar.gz deleted file mode 100644 index 5cbd2f3d9627cb77378561424f7cf413442182f4..0000000000000000000000000000000000000000 GIT binary patch literal 0 HcmV?d00001 literal 10087 zcmcgwRZtvYlf>PFJHg#uc5w+3Ah=6#3+}tP1$URA!JXjl!4?hf?hu^4{8#sUZ+G=g z*K~Dt%{)zY)khVBg3^OIZ4C!Cb980r;o$!Fgt>)zINZ%#Va@|=y;j>AOhJpaTOQM* zX|4`>l@u@EFMW>L)_nwH;@8(7x~KN)Xz-F|4m^L2YBLI3zYo85J<)3-24~X+H;G;+ zpf1NS7odD0Kx+n@7J}vh&(r9xFCXX`?t5N7E>U-nzhfcoe)EjqALz3YdR6UsyMV1> zLW#m&2R%3%|M>75D^q1Uf-!mf+Qywn?3_xi6av|u@;Z5b<}`na`0)WT_5s+Cn07pq^YmBs?Yy5U_d=Zfl)iUt(vV$&POTjc2Ij z9dy^|8N?$(DXxvQwF-f%8JkcBBtC%z-vCJJU!I}av(O*A|Ge7&?X}T_=HDSJ-GU~b zO_nkTq>L{8PNxN-ePv9u(1B!Frk9=9{5WJBC^n_*JLtzV=%S-#QBY9=5|L-4>cD084vXiI8d^egjSm*!7ON!WN^+}f_^D)B8Lk$ zS3VAxXK9Qy=QvyzPA>q+ZWmg^3EM|1Uff!UFiazmYSyPrf@MGAvDkv~dj|POOztR{ zu$#;$$rq3G=1*Ig8AU-N!f3E$;=N^7X{UBPuzHl~>(pB67x`}bihKX1AAxNgh_DD4 z8E0H4qV%q(umeSdJ*%|8Bs^6yeW>m!Y0z0Jq9f{G&8RJg*TU4!coN76iHob|$_l5C zqEE<`9#HsXq)*blY>J*=7(lUJG4l$l%GDkDTQ&fXV{;yrg*O z1(8O`2ntx~)J3063uGFJ2lH_YLY0tmeLtE1f_+U$&<~x9kktL)x|hLEGZJVts@PVA zD$E{{V~}{-0gW>)XJ29_LgL_{yqC%x1b=O(2emK$`AH-285s^miotfqJkOxgI=h#z zxfrKrU`XwwZUJh57v)ni`EiDX61)ucNNA&B%E37#;C0VOy22=LowI_^og6=mDaM;*Y*Ljj;6W*nS{zXNS2x9D z!S-W~4R+q7-+%0xDYD}r1=6Pm0aGtjkmpVyK^Ve1;n@Z?jJ@_Dx@_Da(25hcpNs^aaDpCYfi3#b5Xf`1BW zU=>Sncxp;vrT+I6BurM@nYy28i3F1@JQjqk5t*{+>v!9raQo?ufuW|gN;g`@D(!u4 zT^vLt5!xgYJa}WRFFh$sI$9>sAtv_#4o6cFMuENh!}AlMzTmcuK+vh|emuh#fFt>Xb-eRga@sRdJgkHfM`% zy)A9;eeOJP!uQEwxXrKkxEaJ0L<(zjh1NK_K^BCc#pznNI9E^6MgjIf5v;l!?9amd z7Pc`{10B6D4)vW7_}kHj3plFJ+3SduA?qEzCJ>MH5)5D`<(|i01kU;=xXM!v+a{IG z>Wod4BF>MIturlYEM_J2q7LK&p>04$)`UIE!DE zEPCMbnVX7y&RE`^xEx_!sU{>b4&y|PlSKE&81CDzm>KEKV7p$!1-PHEnio&BjN|r_ z-M=3ll@LQ6h7`dH;Q%u21Rgsc+LS^A*rcbm)L0`3Swxya<;?xvp9?k zT2>P$dR1@`YX8qJ8artEA85&6P{pbJIyCj{w@<;FNyzb*r5|+3z2GlMd@!}s0ZSw* zq@M6S__A8QqHJsGy+AIb@|aP!;t+}Q1FD?FDlFt7@|y}FpFzbg=oLN|5$7~)uz`Ay zg|E1;$5@{bTEAT73`r;en+LdV9{bn6Dg2tKF(bxM#pyBO27He!QAfTo92o{%A_Bat zs&Z*70$f@T&Ik>>kp!_8IQWl-8Q(>m(7Xb;7@e>v&mTp;Fk-eT=(U~gq8SQ0J^@!d zWXerzk$+2g1&@|>2E~>hvkN6iB9qpS@e2h6&ivK~L{@q{Jil54io^%6N_0+8s{KNJ3lI(Xo>Ul2flN^^CVwF?gB)x@LmkS z&5CY)Xmp#GXxTZA=5+j2eScaDtk+pwOmC zcp*^^1w{#3?Io2Q*3~$&afUl$0yK^ollNDLZp5c0#aT%OV&C7nw0XHRCg@p0#3Q`0 z!fJ;$Cip|6cOuupw%P%>g73qaCO|GniHCrtbiR(B_(-F)?LB8OQE>`FfQ6!eH=v4@ z^ij(+0={8nqz2mpS&fjsZE02Q>tM6^&aQG_MO(HkY_vRXdQa{pH4_8h*S$3G>ke%E zXEC&fqxqC*PI{8%8sg!@u^T~EIen=iO~D3b34@Qt5qY*$M`f7)qG60RHlt&4Vy14Y zF>YzJoEkb`V_b*}8Ovb{s3c+(@!JKsW@j*#6p<|C2FR2sxWoIe#6kp29$%}y?I6!G zO$+<%&W`aLY%qOed9s>E)g8hlYslC9hvn3Xla18}lTRHFy7su!jf+NZSWQs{oqnqj z377X^8;{J!VhQw+i}N5W_XijcH2>ueZ@>E+6Pk_Rs80HDzf|)2E4g5uc7tAv)zQxs zkle|Lyd>@seuC$N{@x6Ohe_^fXn6Y?joC56Lq80#U&_U2`<6?&02^u9?9So02%vI4HesZR{N%i z+-W)%t+rw}#W6#$$(Ju>9QIz@xd-&?6Nl_AePUE*WlJvxXjpeHjwf3pjzu{*$I8a( zL}Ie+z;(~_9nJzJU)H$O=s)&sYR`5dpQ{hHFl93(JlUEpS=C!Y`AhRe6@ z5EOTeLi;mBd&S9Oz=9gVR)L+k5Fs91^pg9|3WxCC=XvNB$+?ho%QOPcL4mBKBo6kuIdY)r$}Ex%~=9V1CN z8Rz3KYjUDNG3gK9xT@W;-ukC_=sP%WxeCJk%_}0=-C7PQ)O8dbC1NRN^DCAFs@ezC z^cZ@785%f&wvQ5ew<|p|)gME}4=6U9>9ft_mLeqT!zi8M0vo9#tr#RS`|qFBurRAn z_sPSFvnEDc93I_q^#-RW6pTrYaVA7^f{;$mY*H)p_8LzvXm>cNmHqFIo{=sQc>MhQ zbW-e`_Ur}Shl#w`f9Wo&rWGd*nPm&%)=xE^BbFedr_WYR8(!FQjTE=OeYG)|@ujSH zcJl|mXf;3)gGu|lI5kRdjl57K;a|hAev#0N`x20LkmBxk~PD>Duwq=9%!lu zTMFn5N^~D+ejMPVXMD-2ctRNarlPo$O_!~v!kooSL&uk;CWo5j^HGK)R(s}SpGS7F zdW-_8qT)_Ixj=rF2A`&sawDQZDZ-c-?loghHFXL3LJIX-{D!~&c%AZCq<`hpmlWzu zyhMjfX9;>9WklhxPf_iyu|=}MR?3ld&Kk)f4IKqt{N_VM?8>AWDvRaSQ<(-X-D`NA{b@tg=k8IhUromyiSJ^TkJI|XAw4% z;b;&(l+^9bp_M)E1%$R6hS3=%K1WR%~ zgb{td-`8~R@>;xj9?4XkX43wY&w#!3s z%2Ut$b=z_7XO=^w+&yU8Yq4>;Rm3kQ$gCG~BdXfU{rft7(H*n($pnzvPy&cwojEVO zyC}&uQF-LbX9eE%e{0f1GhjuNy;_rTL8&PjG*1Zo=X(R<%nGBMqg@-?lxz9lGjR2s zo;+Q*j33eG8jGLUOWuqT1_ux0;B6SMA84r=y1i#4MUQ&~F}cz8ospo?*Po`#Y?zN9 zfF?M3c^$JFRW zKu1{#MjIn4H+;(!y&dC+cQlf*4y$h$8iHN+j|Tgsk546?( zb$joKnpDxhe~$@i<5u;-hlG@qOLM-#D^AX|I=dgMO|QzED_mvhKJTOZ;X;3w;D z@njrqjU?DqZ;72(YHCFpQpR)qp%Hh>fhQXtMTn;#^^4kT;phC<%Jzy0?P>+1mY+&S zEq2l;4O+7QV6Ty0eNxO}(9Gnq^3(XAAo@>W(M+%YlhE#ZG1ey#g>^q&#}3&jwL8RKvlxFYqhymOrptVJo))lY&eGM zy#j}3tfXiIi%5WA*a8mz#Ei;b091vkuR2JsLszU1OW>Ro^fA~{MYyFko$Byrk!b|% zrdzO#MkTY%jZ(uBkBr*=^_vzs8V)4@W}Ulg73x!uy2C3|C|WsED+X6lpAf3a%~4nk z-;oSVk9Q6CWLL&EDung>^LED3cKR5N`{Dv_{xHCJ{;7f z`AZw#6zWvAl9n>?uTHQ43fl<6s;K(UNIwsI|4B?_CjNt6i)mpCoY{5OTB`w%HbDm3>@AV%CmFRk zTan~Dm&L4KbR+z5@lP0JY6}0!l?_)%SK^|AxQ&Y-rW>WAsxm#4`0Uq8s8q`(O&*RsV4B|oZgkp$}%Wwl4QBGF30p`eN ztPFAZ|MG^=1-M>_j@O`texOeAy>&FkE2Jq(jAYp7W-)~?(9Zy|)W_Ac#LE%>8~^nb z`NAqc6S>V~Q6L#%*NIsUmEsOgH0RED?eF>ctCKRK90womyQ4UUc+(vnHvC1D5|pE; zaeH6buQKT(O9#P$4w6Uu{|V52ME0w=@w&;y+9%lkDGzk*8u|>YxYO^=rrqggnYPv1 z-y==KZ9QH}35G zKQh5z({$UeD^$i4Cl~$xB>pLe)BN^mvfCq{6c~vhzS?wb;*d_u{FgV0q#5p8@h1e* z8kKzNb&99E46voVVq-iC(}0FUpxRva;FD)o=cZAdZCX7MX$EidjsS5Uj+ZQH?o1)a zxYTBloO?jtM(b>*K(V(|;!Oj4Q)iX5vVlzn!~Re9Cc_1qQud}V$#dZt%pNnpQ#{F- zl6IIo;dV0Gc=Jit!EcJITQCc9;X3HdW|1)v3$ zq$t+o#S~w(OxrUnis-*ANb7!I;P3iov+FfAHiK{0d3wzL^0S3wykfkd5R2kCEyj9^ zU+f@tH!G(=H3udckH!XqT#2@1d?@Pi2I_p4fBOOLq;3VMn`=NP?zkgs8+tjHb#qain%ns*pPD017-EVRQ0!E+mvpVsFV6vxE z-=QC$LGGQ^&=DmlAo88c@e~>~_o@U9dGC1~iI3pi?DT#SK7d|ZY7{}`caJSKp=z^+ zHX;8$RX5AuK`PS0r~MH<8dTUT;t;tv^+U}1<4mOfnK1%JskvX#4%v_PFf$z9b!F?1 zgSX}R!^u~cgkL=aT^)Uo`iuxoqwD5e&e;}awok>jMRli}mgq3j&*FhEG&T4H5%UZf za9SNycS9CXl9l12OWjm;W%YA-RM{E)EbIWb6kd%2V@3$mtPS zCu8(`B|-1!{r#}`<2MguL)X1kp*(pqLaw!a#PXyNWJi1;yT?M#x4W+LWM>KjjHKOWc>(!rL2sUDxP5TB|Kt84QAE7pDdA)xRSgB5 z$Dw=gwP0GJTlEOS^(D--ixGnh`?&DT)7!%);87nqFe*BeVWFEC#d^V+*V*nH2xk47 zNPzUYF1|}<Pm@

8JwkXNqAHt> zsh&{CKTI>^?1?FVX}gpI8fG+zYVGFesKY34rQD#*_ykK-j_jfAz`@ltmOH0Zz`fns0L@c~??L<}Xt_|pn? zdk>Vicyqth3GQ>J%CW;QvVu#4gGRyyp5~W;R{?R4Kjh=GZ+LATM})+E-3twPWA$mNI3PX|IFzNwAIY*wzJDc`BlOGf0&r#$E_SUvbBrV%Xulw=Qp*VR3 zJ5faQ?g6f8l37z?VV(FuHA(i)E|K=vv zkZgy9D;ab~=~u^@GnzKynQ=TTEca2hPfKW=a^9QXPT9lQ4h!bpU!^p2D6Q9IP*}$u z)(~hq5%HO(mB&Aa21QpAQ|07QNXSn&V_#=SEIEgC@t&{0-%98swtx!G0X@FYcjv5~ z@X+3U`XE^EtLF#gYqx0_&G#)$q&1m>GEUB`X%J?3Z9axvCqkuDW+Sxww!&hnP;>eW z5OQJim~o7RdrafmgHTT<5>M_V73|9v%&>Xh6Ikgs`t~p*7A~Wh_oIzx8ML|UGW{6k zji|sgL0wNO2}|bEB^Fa9d>U4G4wiJ0g25-e{DH)7KX$J^P?r3HK%=q>Ga3!>l%PDQ zji-Mo37Y{kASt`|>akxu**s0^@+5&#z`yo4@ZcRtox#{{!8G5EqaA-EeHP)t8*1A` z4f#?v=bMoB2eVgZ@Ch}9fXa3GSPbqr>oD|emNu4bMy8zajzxJVL>jHJl1axfr<@EbFEIi`JFmS3KRCj;a|UXPny0NMlNrWiT+1Vl?SgOH_a73q#CesiSf8+2htEfv zMEFU3%@S8M2b+j392&oPOC4VmB@rD!O*&>)w-j$nnDlxyOR}s<=1}Tfja~3d<0b|x zk(%nQ<-2#j?_&}Kl^2UR4EAX5y$D<3+Dy__GW04QCp7fRQr9bqJyO+WH-k=vfr2Kn z+%@W}j5c}Mx9XM>Xq|gH%Xcko6OO2RS62#~`uA~`fkjeJdZ5`MM-;&WQ;?9QETs0xXiE9$}6Z5hpiE0Jti z1Xt^i=6-ZC+Ubp=?>7Es8nc>NUrWN>`!diTid?_!HW4<={4G%i>i)wEGx;6W;7gq( zcZeL_Z1oE5=%kmQ01@tRJB~7&1hgbh3<|7(xr-R&z+8gEyo<*t<7oNz!%g zAOm>E!87u3<0T*-fpSfs#;3r|+(WG1ng-MyZ*8K01_ z+m*!NqkL%UZ?5>Wi&RSfdiQAK&qC_`N~|&hPBIqPr+ zMGRMt33-GNSspUd)szgeV9JV%FNGjnj+A}o5f;w6=)Wnd#YOXs6?Ou;s>C7dB@e)+ z#X|by{iicpPVrR!OdcNIAa(S8;9->C-9`9ho2&z-_dZik5CDIXkRXkV=xS1&T2J1d zy>ef!T%fzBM!R>k`j`h~kN~-hOrikf*r@V>f+JnNx*SH?!fZ25JpEL(X^`C?$&yC> zf^uS%-?v@d5uo>;UJamOU=a7K0nOqBY?uIjmWU$PA& ze_QZkiT{f@SOLAd6kC*lf;ZzelfR-V_{r}UQLsGV!X_+r`d@zyad_F}vG*TTYGEec zyz3baf?#y|%g|kbNgjQ~jlyy~l6`nL)Wu+pkHakn8TN`;n$@q*L1&d9-`RaO!_;XHp~x|VQS>5t!x{Y;#Mp5FqyTdo=%qDz4t&VpGhPEDWj z+;&=_fp5>Tf!BZUHOt=|9Xm{ixih{wntzt^qL#$CyQ3*)aWNMX%2Z|;7+E8Yl^Ymy z`2rGxiHgZj(wFHs;9*6x9A}v-p(crgjE%W_`}@n&-Nlsk7!xL5DOlE}#>5TgCbl)2 z4l5XTdtaAEhN>O7xq}38pWqZaVdw&1E~y%~AKkiK&YLAeZnj5%#}Oqqnr0gX-Eswp zRmBd5$Fh>H3=SufNLX|6E{&_wBA23l5KY;}!f1Af@FlN~nr*@R&o3*b^v5!NkUO`a znD~2r5zg_jYcU%w?(>FV)UZ2d+t2Xmq2NG?t2e1T0OI1#d`jd*9@O)ZdCetCqp9sId?2PoH_4y~f?8}Tj=Y}h zb>GJZah~6wz*UHf`}p$^W7e$}FZG5bu%F-YK0Kd9M-)O7hqoEiqOSYMx8as76Mx5S z2D=gWD6j2s%ap!d>sC&0FF}C;KCZ5>y6!Q!$Q`Ou=uIFqM@@qN3eXIb37y4!OX$s68%X1%5PX?*pA1rB*+l=wd3NCIViUl@zO>$q&x3C)u^7kd|P93h0^Jiw8E(~XZ|(UIX6>u)Yg?VHJc*ebC_?yH5*jffzMQ1D$;>)Pq*Q_%aZZ+ z`Ish=AS;5u@O%EFe%l$Q_KN-f6ZuC#3{p_@BE~xW%HQC>$94`zF%fQfmS=} zS#@DQ8n%Y!8_qv?1*n1u?!1;9T&@I*4EC=)BBU&vTPDz=tHOa)4yLZ2+*#$Gujhsv z1iJSWS_Ik(MV0Y1_liSVt0Fa3PkhMMo56eD;( z?G}wv?FzHbud4dZP=j-*_Dj#g`=!xKPwmFL>(kwn7N8TeXY2j4&s2=uX%f17>|OO2 z1Q_&qdL3(Anto|n*?y6F*&yA$qBTM`5ud-`6U^c_EQ%m3*JgEDAO2@r zd$-36^w*+JOIG?5K>U;${oqBVQ z^%tb`-pU=!`T~VXABUFS^i;e$vp}=|AL#RY<@qKkxBRlFd;M+GR-|rP9C{7BOnTe= zu|4K(@veqskqX_H{-B6hhBg?XY2V8gd|fVb}{;=9K$ zc<#T`O>bH9=8IPZ+|Me?0%k1de8bJ*UYHa0`SdE?$+JZz z8I31z6|G{F-E1IM#mfwonY>n64k&m=xl9S9PF~}i5F5}u79dsw;>6q{T_Zh1Aha~J zG@iUxU1D;Liat|v3N$H)l3Ww@)%0>QZkE6bTjkP^7VsUo&AGcO3$3lYcgP9 zc(D6CQ(u_ow++l(Cmh;7nSZ!spwXnUK$orJm#()@nc@Av!LsjrC#+g&q4+sZBx0tM z!7xRLbHS>0$i!`^n&WMyGD> zKYniut9SQ|8yABv?U``XP&Xs5F=&6b?`~aQeY>=HrSHOwN*jJvckMe_anxjrrp3Kin$sLF@!+Vxa(Qp62i0CeGnrXEbk>rh(t;$;Y!8JuZ1w z#n#Wk+Y;UI&b^J{Xzy6b3biU7XP(i zx~2RNg;#3o%Em~M(1QZkE6bTjkP^7VsUo&AGcO3xfDT4cb$ zaAEg-p`1xc2JLbIfnu&Ay{!6@VTYO`I@AK5yng+r$9S*B`+qt1HIMhK;5z#=;9lb? zVH+j+%d2hHMx9oVk8-%RJa5m-diCDdxkvBpt6FyG?5z89^v-3;M_jX(xzVrgTe7Gn zZ2!EcTh4_{a;>Q}c&L+-CE4k-MDEnw+iO;d|Fr4pTkh}tKB<9I>VN&FWmYd2t*dhv zd8>crbmykNL`TC4j;DMM2M zPyF@y>mIL}_nyQ5Sz^!3mKjr@D;x}wX_mDsd820TDDl^M)0)pmo8BI4Saf~mI@SFh zVKHsHE}y>>CG`K4vfPeLkuTBpCGAfROfs=Lo~o~MVsHK?Q7>J;UBU+O_ZJ%T9+G5e zmJje|WD;S9r-sS8YF3~`FgXiKFITfhq=i>%>dHn)k>u+d;^^WS;)rYrD0!Hu>j0BS dqPh$?u{3~rYt>c227yw*Hx_n3K#$Y diff --git a/PythonPackage/AMR/dist/amr-2.1.1.9193.tar.gz b/PythonPackage/AMR/dist/amr-2.1.1.9193.tar.gz new file mode 100644 index 0000000000000000000000000000000000000000..1e0bb75f1fd2a5617cead529657b3d3830143d3c GIT binary patch literal 10101 zcmcgwWl$V2n?@Jt;_izt6n9D~UZA)XcXxMP+#QO$Ly_X{?p}&J6o=xv$9HqT@88`d z&*YgmnK#KKc_pAIWaPmgv*vJ6Lt7_i4i@(J@`?QuCyR@r6U>>fxAR(4o%vgiLT}+I z^JGiWtiWx>V)@BKf`@|5&mx+`H4k0X(18hxos&!UIU2V`znE9A=Wk6U2>P62@ya&3 zbAW41Bn!B1J1$}iOq-jyCrPO1w{yR|fuc9w+(FitY&?qYJ%_`V{GTvZ!bUm zt-pmP9dW&RlS0X&d7gaop+Qe_U9%-|%g{3e3E$&15frlc$wPg;=X(-E=6(M zQ*?FNRJlu>un1R?pJxb<^IAwF&zgVwcliS)HrNR`8Hz!S2%sj3fsBYRrx6UBruC$S z6jL6R8yU92C!N4Z77>5!aU)EKgg?$lOP6Ejh<(7NSf5pbGzefQHxk6 zN4MXQ zwsP8H2eN8E>_Ir0zwOr};Qc(~w=|TUMC6}<`weW%wSTc&0fc9_*+t>U64%RF!p%v^ zSiyo)DXZits>t}Egw|OY$?5_9#P;}V05+)2b z5U3N*0k;;*72m(DVWP^1zeW!% zUdsZ8{4^Z1fU$94`RtHzSUq;wC!mLc$OVlL(nKnoUiwd!C}zT&0OcfDE(+pfZ?-Fn zv|`qLj26E~CJeK>>Y$-QFVVCFHQ5Xf(Ph$RVO91e-9-l>HK%)HT2~>p#q;5c*yq}c zcZu@7vFbKgWf7e2B6iV&rN+1HP}RoR$~^T1qI!)_lT2EFOE93EI^IL1)g}A&{Jc(m zRx0F4h)M=qCgO8qMtvudr|SP+DozI_qVCyydt!q+qCGDxJ8y zkYZ4-2b?gXHnu_Q>}Ik^LLaw&(iC6o9*6}Pp%iD0z&)2N73li+(!0a=lQ{dP6R~oe5?(om^>TQx#yAY~Y4kJc3M1c|n9( zfF#=ELQ{s3NH%@EysxcU6)i%wy|O<4_74w8`~~xpnu!duo$x^kW1+uJ+P)03qM?a$ z;A72qWOCRrkKWF8MLOV3caUN%VkkCE(3J`7d^%p0$Z-Hl8J(_*vY`JU&Ao$1t?9+@ zo_g{&{998p29`{|-~w(=lfY0ciDQdL7nV_4EUq9{Yx?*ASpsI(cy76lhNHC+Esr4+ zWZ%bm)gY$GvcAS1a=gc_x=`gW2;HL1L{Fe$Pb0XM`a=E>XGz*sqjMB`zZCIWN#C)w}NRO)u01a<^p1_rN(fp zndIpgCG7pyyiKzgp5j2!rX3n7n#o*lMhhbDbgZ#0wRjWf^RYg=zg1%6l0Ro|Z&v0t zyU1^DZt+@J`oCxlHPkh%%%#LEvNmMcVws`Kh~AaBG%dV)E3Q!H{@h!nE7W%@?D!c*IGy;|CB_ z*ckS~i?WuxD(`r*i&~#}AE%X~^w?4a2ba=56 z(z(vCM3@PpP)kjvF2zsZG`q=VvXo0wJJJeWOT`$47grtJ^Cts&9a4dnE7uYE4-N_S z4$H%MEp}S}0-D@IzW3^3MEY(cBq(^ol6;;2oF)t)qaUE-WjneKvQv8!$*OASB@lYV zI-~4UH>v`9l>$WP3gR_I!k`^e;w$UJo6nu-(-WoF2qRkO}~0h8Y&xk+8EX(-1d$YNz5;E8ceewz zs$qGpPC7|ChK+KV%N+}AKd}O33+QeL7F1NAdsTNvf=s7GciWl8^vu;5%dT?=l?CsfUpwK~lyI0r{0z!FBA($Q za$MRF;uXH|w*1i#%_qnLkre}KEF)cj_W2q4v;sA$TSRY0 z8T%%N_UiHNS2g_>K>#|5NnEooXazlo$;zRoIrli++IwI)Cs5b1IUMeL992rU?x_L2 z85iDOO5n?BK(ykQ4{d)J79yvMi8QJ$h6qOg@w!Q9^$l|J*2!*YQ|*Q2SVQLGNIX7= zfU7M>mSY7lou?w56AGE;%E$0`XG9fd;e@|*5G2vN*kTss6ICa14Mm4GC-WDe4fb4< zj`}EpdE`le0*KLKW_Eo~ zv#G|e4^-E*EB*bNufaFMEdR>^By7sD*ru+aqW9h!0A4y1WwQO=(x+scXg+5=<=NVm5aC-$c6i)t9dJjiY19YG-L`lv5F zZ?)c{JXyea>E?yqB43g~{E|8UtqNFyAfF1${IQ`uGUD9s?EF==ywnG_;!_Hvt-po> z2AWRumUkrZShp9>!`@PTEi`*(aNJt}<@08!P?c*0qF;Ecd_z{oicPlb=0|pE7@KyP za#YiB{>*~DsWH;M;QWyd@jF^Vv`w(}#&fELYH;0f-EMo6iSESJlOi}}X7_84JwC$h z!~j^OO%OU-p6}AB)3+t&Ot$cNw2)Vg2BNHdJ{mvA;&vD18#kJ`Gg=nG;? zghI~R+D$oM3gT(>fWq;rUh7Czb}`%iFE z8d)|35}^FHO_5+WvZOJMfH?i}v6D6|iB2;E4y9qod(!PF@M-r-e_BYUT#MWA(Hm1N zu@UcD^kI<}E|H~Kea@VYKrJ^YWfD}nuU6`iG8l@M+M(lKW@yJat-@#QQna&)vh7`) zH6r1%wXFT{r(h62=Kc!-M>l88#k&$3VMI<%`nnQlYDwbye)t0JtOVs~c3^SudYfb5 zS;m4DR}jXYFue);cikn|%EpJb=|~$S_x+CGUVk2KbU5pSYAoCZ=ZlN^7*P(1$UlR z9Cscm+=vs-m$qG-a`mqH%L5E+D$}D2(W1r|O(uxqvzW?Uo z%wRpnjxR6r^y^0;GnT%)C;{v8=={Nx8UzMBe4h%frxHmw-mS#5$@=zZt2C=A52O7b z%PCI{QoAM6h5$y>>fdHvJPnnUf!Rhh^OE-qFX7Z>*Z)W#l5QQBBAd!sTf&5g!DPp$ zfM=lM42(6qKC?v`S=jpb5~{gIs6uY!h3VRls0Ux=F{|w5;FkJRzfiC2yCL2eqi2%~ zmJ*`s<;%uKZ`e&EH6O`k9yLZod-li#nw6nq(rXs{ufY-c99j`NzuK)-|JJFl&zSyH z3ue()4Pnu4q;y%Xpn3;){$`yLUGU=_w#d3o74NW;RIF4reFsUP zQPszHtl;2Ut1{C6uD}ziRa1S3EplXI#XGFz-bZEUX)yLNVdqAzqnWGqf2x3E?D`pp z-*(gwMP15a4;zrY;A(HQGREH&*a`UCnvEm(R#^*Ym6Lyy=N842OH1@eKxJvtd|zv- z=O@0yrSzC6kgv>Os{)Z!=bNSlERqu-+>|>vM3-U^U$l#DbI&&5GwgwOPnP@D_i!`F z5Ub?JKM_G6=SC=CQDYMpPw#VFw}zteq%ywjR|IMqjJUv~l6^C?HTVXn#^xFZrap>g zH-3uVHs9CV-JDz;ViGlE1JO{*3!QCP60DFcS$eERWyIqEt{CAufB0+wTf>j?cYD{- zmS&yek5(PRHjWqIt0(b0P-|cqwam6P?aI7kFs45uX&C^(R57`h-;MB?lnC1rMx0?S zeDu6`ZN+_O0!PCE59@G#{B!7x8aTCVq?EO3y>Jy_dsD7D-s>?6->jPu%j4R54nS2V z*Ktoa{OHk;?)Hi0NWx7UiHjg@aq@!eUm;l=NN(7!2DLWSrT2ZzW;qF_jq&r(J^1Y} zWs_PXe|-(ivC6go(+)>(%-sI2{b-xUv<7UpP?@>osq<6xdUjtWo5y|-#I$ZvxCMg`jR6DZQ-R;{S7lx2PZLBXh^Fo=yL)hIVK-49BpUmIAnRUMdFVJY{ z>oLrGYiyAiIf@uQ_s-q+yIoR;WU%8-!o?9+Ua<}^)|xRjhUOAaFqPpn`u|W)Yi0fW zo|$PI0HhsDDqFg~y&gC#f8e~|7Z~ES5uh$+Q<3P{Ux_?@m&S6M?gL7YN><_YXoOYF zD010KA3KtFWi>^F3Lm4B^Ctkq@xiu)iervu**QJbK=MEyo8BH}6kd{RUn3+#M*dh_ zt1(OY0z5P$&40CgJk0l;9bsTpdrB3aj z-he))<7UIzpX56}GT32?K3L`r1+PUG^^_})?D(43VSkmgS}lyP53b)GqiLYH@I|x1 z6b)b#JN3rxO{cHHK>`eSh9hrDDoFyV_5eTbTx@MJHL%9AT z@sZ#3fp-;l(ekf9v3WvxQuU3^BVkWkY!}Helb)4!dq+Ht`71n?YU;g{C25lww(qtK z5#P?oBFQO!*-PQGXy$hcyf7&Dn>Wo-n3Q6@T;|)L+b5~o+=PiTyl`q=s$UMaPY6eE zTl2e2^#eZIMf_Wo$&$v9h+et0)YY9H2aVG8X5RzlMehU^J6wYfrA*fSk$wCph?haYgIdgsnY7+3Et3qqIZ-{xIe zH%6uiyjl)B?w-2?Wm~w7*m$uEq@yaxE5wEEz8zhjy0EE|U0b*G$bw>@#2yZ9Ja{Ci zH%p@iDZ3Q-pORmpCj2o_@?i*4;kVjpf+y%6;Yj0=@g3A_fsXbL!j&V>a|XRJ@p_5j@tAmn{#b!7 zanZD}_&fk_uj1F8Z5KeU877atRd7EtmMFIXW964^4Fui3=g+tcboIo6wBfoEXQr6M#BdjJa<7!Jrbe^{i< zAX8}T|J%Xe9&8un8XR0i+EH& zZg@4MABZ+l=2*(n?OC98W0of8MdF}h%_xg z*G$CY)lJ!o7>ar!1qc};?24XB#j2CnMN|Bqmp{C`{Do6D14ne8Z&i>nB)WOh@}6u^ zq{NmyM%YYGJ4T4<*M^Ao#}Az_qkc zoCDqP0>iH9J&p9K!iUY9e$VquaKsWD0Yjwyk+M3DkjIqVQoc6vLwpsJe~~n*Jr9JG7!ZPNnBh`{r_6FI8u20g+mMzPs>F<1mkUW9ICq zEy}(r{Wh0qlqM;a>E?x8KmUl|CjGbF%*5gL_ys|2pBHn-KBVy{V+?LQus`Yw|$;#el)oWjy0O4@0n_NTa!^<6R`{HjA&C}9Rtc0uB+Z}Z2stw2{S~| zF$p{ivF8;G7?Th>I-Xz_sa>}ttLAD5{32UCWBqRmuY3T~3iBfAJ${A1bc9*EV8|NV zPOgci<0@U4LH=EVtuH~82w{#4C0e!BMSFzh^>6Z%_O~4=7aF_YUcSlHQnCV>QiJ6a9-4G|u!PeQRkV7R*Q)y>(@t z@do~Iufm++{rke-{NZ-~wIQBNAYtQHnTcZXijDwN{T*s$bA}5oo@?7K3qEHX>bINy zSy^7B<7N*L5gZJ|2j999ZQII3)bm--X74w_?)>LW--CtPrY^E z-#yKQeJ`kY=lpM@q-?dl0Zm4*QVI91=IRQY78V}NscFRMdYajx3Rztc`UN=EqAi31!|r6yY67Xl4JML zTL+n97)HVtGvyx&hrBenR9zYcFU1@-S-$kBF{fyka1EY2PK6<}M{1g%~+BJNXbB%NLA=xBF$%rQr zjyTQB6JOJLHY%VA9zGBUE}!s9&_b~;MF+&?!{4d^W4QtlNqNb?-e!aN(zmk81;cU8 z8Wg~>SUFB>kDCuACIpLPPB7oc60((C!Fh0kk@Ihr8@PeOXCoT8XMU^*ah~`YFMFe(qDy(A)4Li4{dc67S>?kKp84#@)9%Z| zSU+X6CHX5^__Lg`KEXut0_%VugCW6GG|}M6wj|qLm%te6Z;`SeMd@buu*btI|0wLL z*^a*%9$ z(UT48UhFEB-;ow{bs%7O7Y~v@tV-&d9n^68Bm-8Cx;C|F{;Gych?e*RV6-SI$goo= zbIMn1Qmt*2h2tys?R?A%H|i63sGyG!7ib}ly_)eQ zu+OL2+!;?K-7MqZd`+tN1+TaORe4M&E;}Cw$@Kz2j>Dj0Agg0tMipCyg{bYCeO5{8 z%^|@QrpwgTU3-N1yI zb&a61J-BxE3|ikq$xJG|atu_~+T+d(Ci2EDLZnD7mF&Ozm5M)F?9CxSoP*}w7+FN_ zk>52bJAh)db1iA!AAMyk?&$^hZl90yb=r8GHS#P?qjRaoj;>}$^H_FCn8|sE9QgPH zpd9J6#mFCKJ!|xD5uR z1fEWPxggT)=s7CSP77wb`53Ct+3NBF?3l)s`b+ejclC|7=d{T z^7Igl0aUcZyA^IU_?gO8o3lOp>?swU=8-Dufv%Rx)I>IPAAz*1S2>o4gDW<4?m@;6 zu=tvU3@QXq!p~JL-KV@#41m{RTzD54T}!eKX{X)RJhQY|&g4xVbHuds;ixam9}r|| zecJp{r0Q4*sWS_~IJgp`=fSuXv{p9lAzdj0Y>Q(x7+R!SQJay3b{ye4Fef>(5_J$)+E7(^$mXjJW0!cLJGO7xZo~H*+J%#gn~R#9F2AH-Gcj2tn9VAu zq9VO-7ARx6P^Y-Y~GNBRoYQlkiJIrsT&o2}?U7k-n$Cr~)7eI=+znt0} zkI@t?n|kBIdnW%Lg>ASc0aWQ7cY^xPH_xv=cH8Ef1ac8>n|8SMx)zkQDFZdo+oxNS z*MDax=JC%bD{h8_lIBB=5h5t-uz`ep^GK-`6cO87CLHh4@S_D6F&emE>Gc2xGgXMD z6}eBFgYkpO(8t(f3d`8~(NPxPQL!Y$BWe9r2wFiu0;8_VAyntedzZ z4<>@cM;CPQ(=a=<{tvg^UDFx6akqVqO8~U7OzNf2dJO&8*fyNu6-^SuUy%@{>QTsqoYaf(60+@q)u+yMu*mm$ko6A)B^qqOcXMOzZnQJR+pj#;5JYTd02raI4m+G(UitT@dk zs5zDpf#1h654S=ydO2C7xsg`0y9T@w*7^JDGBao8M!L^x0gqkT?ArQZwU^9)TehOCJkh0eY)LV_nCitaR`u;mtwyS z-loI$uYsz+USo$o9T;@x)lpMw#i88R7tzGFzu{bb`sewU?lI%9hr&{)Ib%G^(dTPD*bJW5S*ygn z+<$=VSZ~+yYM9piICQ>zVIoHOt;PA^-LhuIpzpi(*q2#zs{)ju3G23y*|gX_@$LVL zbiv|@Geu3wM5SM8Q;3sh$3$@zRSNIZ-6@E=F6K|r&5_%`Ak$??xmw{bbHwH8Oh3kB zXyeiwHQk93t&c?IWC8)udgKfav^}hdh5hI@2$Sef%^F<|wP6riKUVbk+GOmiFUGK^ zHp98F)emWw-weM_&FD4-9&Z87&u|otqEbX6nD~G%-07eD59g~0kA`JP##bH^sh2}j zej(mMoxip2)T~>8NbRXTTgSfGusEcr23z;EbvGpN^tZ|yI1c>YTK4C)tsay&SH zSfhVqTi<^la@WcIv@O|&?tH7bl(flLxgF^F?{oH-h~Tq00KaL)_X(*cF%oOCm$poU zOseIL_Us`2Ky8<=Ro#{O`WMAR5bn31SNbu~_93Wl)1z}VG^lszL5MgjddTVp5-sEE z`ak_vFY3F{gNNMv4#85W5Md0@6Li$VsbB~?-11=Ff92k{({Hc{UU;baZ;dC`AgIvd zlT{;BXqglW4$3Enf_D2ZR==|E|6tY~D9{x-k|X-(6_w zhex-#D~S3_^VO9}#edX)f8oW0$_+wPt~UQ4=)%3eE%eR0tPA?&bq^`s?h$l_3Z=`B z-$CL+!MibULPXK3FR7BP3%@lQxz%iARJDy4|Bq;QPgU*5xB5uvOXCoPJX-Cb&Dt{UR*v*Vd=GzXYe+Gidxa1KcbR`Lp& z0*IlD_d>_dAXi_q-R|bMy;psXH;mz=$!id}@Tm4bhqJ>d(6M+0pCEjSAk`I|&N;jg z;tg`)7ib*krP=*BJSf<5`+No1SM`w}81yTVr2>1t6ewym6C6gaZ+c-5KzDS(ny9P8 zi_}WU(8)N?5%9n&`q#)m3}hgEhuUsW{{cTi?ZZ+Mozn|G3DKGTSauj5>uhJroCY1F z68Y9)-8laB*PHRSSG~=!ULLF-x>go+xh;JL-BW@oA53m>LE#$y0jdPQj$6Gj^S~$} z&e?tRfj>e^ch=+)lpkK{^M*@#bWX3~dByeI6vgwIt+R3y?3a&sIU}pcyTRiP7P+~_ kuv}lbQ_5v@kCju~7K&M1|5w@-cmjoAK_M80*@A`nFQ3B*fdBvi literal 0 HcmV?d00001 diff --git a/PythonPackage/AMR/setup.py b/PythonPackage/AMR/setup.py index 0e3d2bcfc..80ba01633 100644 --- a/PythonPackage/AMR/setup.py +++ b/PythonPackage/AMR/setup.py @@ -2,7 +2,7 @@ from setuptools import setup, find_packages setup( name='AMR', - version='2.1.1.9192', + version='2.1.1.9193', packages=find_packages(), install_requires=[ 'rpy2', diff --git a/R/sysdata.rda b/R/sysdata.rda index edc93be3bae95c3285aa18f7d52e71b7cc1d1fd8..100de7fe2846b60e4197f55b0cebb5fc01b0513a 100755 GIT binary patch literal 95212 zcmV(pK=8l)H+ooF0004LBHlIv03iV!0000G&sfanrmFA$T>vQ&2UJ%gRpOV>D zs)9rkVDrO9@CKe(@YEJUC64e(;J;M!@wQ4Ob64- z)eZFQcAVpiw3))oO~DeTs~l6J1i*)Bv0!|^REgHMul@5VN-mdjHhOoD2`8g2$2(SB zMU5AOl)A3fWF!an9dsP<-MAC}q$DuVIJ{Pm=2ad(B1 zYNn3;h8$!am9vA5;Mm-NwB~%7jCMO=j=t2ZA_djPoKBnH>-f@43MuQ-I>zFjr{aDd z`y%JL{I7?mGa_G$lxx6MoGwpGe%bFK9# z$H5j(Dib-Cm-K+my@lQUg=}2 z@zQ^)r|&;q8FSi`1c|(^RrBh!h@Ol-e?pmuXc48X7qDVjG1s=Y_R&L`U?MyK#0;rp z=nh2H{~4$0{8_E>s_9&ssO_>!W6@zGEV>&YxJPHo6L6S9%&*H9V$3-jjfjL?|J<98 zQAr})XbwhtLHI_ZO0FWibP%9Xr0om?kPt^p(jCLK{2+UoE5bxEF7NP6wLc_~zbOus zsg7_@W!`cdm~93tH9)4;U)c2g=BI`lk_APttgv)Tz*7ljNtBnjp`7Yu1i9Q9QCYp^ zSsf-~aIlp#o^-R_mq3jD?4@+a3ul-F9=q#O< ztSY+c{WCf^U%H3K^V2&u70ZG*XNAIM(-__y@uATF^V$Qegg5Qs@;P(~oV*vV&u3`G{tn@S^x2wm+A-P<--Afk=g7hbouF~pBrl) z3rY$oXtvz3F`B(ptVk8OJQ@EW9Vj=SuCxd`KOygn5x0`Q!O@C!z0E?n-)IZMjlI=h zyrq>q*GW#c(5-@jiZ+-<|C z`G?pOpLx#BJ4T#8houFW!;lXZ7RG&|CnRM^3%*gx7w=v?m5PulhD{WtH(8wtT#C~G zP-nN{X9d;@I19p-)AJ}f#NmBMz4~dCm})FkF*80Om2RoZA{gmYIz+?Sc-h8g6X}#m zAnvfLHw2@(T_u{F9?9LW!b+DLoG9}Mpq_tgamrap*|sj9g3y*jH&-8L7~*>8Zoe&N zB6Zzwa1W(A>xHiD>0euuA#&hK~ZIm}KLIeiIkVjL`X13aC#?qjJKQK@Wy5E@I2-!a~?q zn>2C&y(1t%v0J7d3*NPO)DtI*F|&3pMAMFyY5E_cv~-|Eu_mEdDNGObz*YZoJo2K` zt9pJ5RK_cdIx)0wLD%I=0?`HMB70ueAyc+Lc_C>>R6c=!S*F$=`I-O+Oo--7Xp<5ILeUx{4b#=Hth~KPGBGN?D7a}ZDINUGIN*ljA>!@Jnyy@kcfLVy|?G!ub)%OmhdIU0Hh+l}tq0t{iMJiAh2&#O zFi~yN8)c+B({Iy}y3xvxvOgt;BUiuxnjw4A|I|&rFgtdbC~9fLf;{ zw3r)X#nE9yIJAkRj7%0GK>5CL+$*F|bz-tZ*BimTIG+HCm9?sCJB63qDL!pfE42yj zFi3I#kW-y!pqKwZqW(67thU*~Y%#zLhV6B(42541U?~`yB$vNqX4|sRpM^Z^1{JCd zl2Dv}SYErB3GyKJ?(Fg+{AVR48f>ni2c`+JUA^jH;L9M@J1Kv_6RQ$iuhz=Amc->5{nc&28t)q=tHQ zGdM2uO712s;*TQIUPDuM_ef-yeYniuGOYCUis^?@-U3CxpwCIPP@pFb5Ni~psJomZ zFloc4XCF{E|S@y)741-jYq(NnTVhE*-`;Cb`gh^-lt@y0ebV~&fgXV>3D2Gr`getG! z;C=CDJfpE1h{1$Zt5nDI4cuPfIy_=^ zjnx)cJmvK_X!_KU9DisDg!r0mGbyP3bI{L3^K3`%I{=}ZLL7vkwdvPZB9T<%pW54}?aZM((n!DkQryEZI?aQ-7v% zun%<|qET=#cLjgD++`NGWVF=qD&H|tg(q-7lL>t6bgpjrKQdVkA85u50p+r!q1T7B zu|gbirXRcQju5m1*wPiOW;h61MbLfzkY*TC5_LB&X!cGTKU}J2ZAv~!k$}N;bl@4lm>+`oH|p?@h@-_ zM9a<(#H@7`U`tKZ`P`@ZDKP7K46O%J$b?tRyK+3p6pByc-Y>XCJb_g)z?+8&z&uif zjF`?7sTwX_PDFOP5`z|{D9#Aw<~(*%=#fKI^6 zgU~TzPr2g3lHP<{2|ai(t=8SLo7)N z)JIx}B*_{7lCBVU?K1^4p9(gqsIZTBAkXV7H2 zA}%QnrQ~)oh^VX653NnJbzB;;)3s=s1~qvuJrYyhtR_uiSQq9yhYx8F*AY{5WHVHm zHVFHz{XtaR9nNg$L$)$wb9460|Fk!oD3NdHm}d{__c&1u`ShBHYj7&+by61{x|pV9 z1v^WpHzx(t$##{61qds?bv>PnZ9|p}pf>^08=CgZC5rPt!JA`{Poy@{j~|0UG9O~K zb}*=jEtK|e+FUAO2Vy{vo{mj)7j*wAnQ8ZE^vr~lNM=|E@5Fr6dzt>8>H{K3*7nO%O&{GP>C5ZbWH|iRPV^NI%x{6p!e%L z(6t#RnQCE|>e>&cy4*&j7tFECx^&j74A$1XDS_IqEf1q!`0zTL|9fJV$nZL2)}ap@ zCH%SRDt9n{$FL8#`ZOY)HvO`P?2y@LndLgHS z73n3tV9-;kQ|=E3(zlTwGY$TyZWN(il%OkR$bM=O?iSKCvKx20i?|CBt1MPW%h&aMo&oLbAcJT}v zP9?s-1EN<46{H>nSfiW=^+!8RD=nJ6@wPRE^D47CHTih6T*zNC{|FKHf$MNG-cdm! z_C+TbvlZk6BCD$LPm@t@g zqhwA^jW5q2yd5hvzmjW}9VbeMy#YU;gX+v5yjAiy2Y|Sr+cO7GW5=^KO~~@v=t5JPp79 z9&9$mp4N=<+RL4xTlzx&wug0^g3RWs(tmAguw`364L(!Xg_fO@Wl`UrKJ`z@_BU=k z3z;ZY-*@)KEgI@^E@Vs9K>=d(`<=pr;FMQ42XJ0Vav9}BZ8&SnE?;w{8WZ-q$@n$K zFd7)v?8sp3WPl5&)}Eswryx%Ti*bhXU?*k6$3sTtY3YEiV9Mpm5pK>+Vs&;YOU}## z6$wMeuiZ}7=Az!+%~U^+T)lY|@EYm3*&LwCCz9JZPwT5HRs{hpf#(i`Mt!l9~*QotVyRv+@Q_cDK)R?=1+?5E$L0G z?Ro@7p$G&rY6@61wx+uif0I{^KlGyO=AH<^Y>`9=6l1`wFUVoeCc4u5J(H2@hlJHp zyei~{f$$DBax<1Q=QeqgGVaQ0ZwL{x+;W{`Alij|2e2g{a5I>FD9Gv<0%G#MXy?(* zidZrWMeoWY;RN!@=9t!YiJ@BckjNLt7_)MFMC+-$oR6`FmMQ<&vNHNJ{D^ZD{<##p zOCMG&N9m2ASHQtc%e;iO-3y>oxNJi)h1|cSs--1$zX#Cv%>&VaW&iGWuCk8?QY(?w z_Nv}nD`4g*x};$KyHw9W=);7YwLWt?JzOVm(BNpq;>43vDdNU&I4s@J29a?=c`1ui zMLeMsg@2%P$91-KhrHRb0*`ps@>2JracB9vXZCT#e@wt*6}^i#KdDgA0>TKk!}kS# z6C#Ln;V{2w;-+Vj)@ffTfJ~5fp(?(fBvF`7u`*J(iif} zS7qZY5uLJrv`C(3$&8xI-=+V}+Sy>T%=rA<(~4XF)5T@$9XY`b#%o6{l}lG?J!nm^ zCg*=A*c<}&&{v>$+5MwG;g>2#ZLx;tO<^@ zaUmfD+4tr)`5N$qUnp%SWlp|t+!?-p>GzCEjK7{ZC>7IRfRiI%$+|ic$&@~s3TptI z)jfvt9g+lreskEGZsp?pu0pC*`!uZt^hZa}&};koOHYBy7L{$S&^z8{=Zy>&BAIS* zL}9vGGlUZ#j1WZcYO@HS4se6C8|kD0_D-n|`7Uk*I?DJID7YLR3XB`LQ%O*C$7k8jKGSJ93URr^yzufOcPG+Ak z7@H3djoB)Dt2#V*3W|FoF$T!PBI(DyqF1ee-*`x8yjgG=sBeum6@xw*!@Rwo!`4`+ z<1s>n2@4r&x*r%)?W}pT3*(%?|9R*j^Dm%$Zo&hky|axO7gl)qn3QMQbQ4-QQxsoI z3M^o8E=oL9>9F@L=W9~zY7|jDj=s~CrVy$VC!KyWBXTBFyiE$H3?0IzS0MtV?cX{BI*djU<^f;iXgM}kv7pM6H${X>*-Lt%6>ywZ9cuN!t6F4Aj8zKOM#?}i(&3-s% zUGr5#R(Hg)B3T~d{_i7~D6x&>NPy}UiZ)Yy5I*x6~ntX?;h}~V`sdk9Ug>mH{n-#+izr+Ipec}mZW-GpURN9=A3f{ zBbE4Ie3C?m{GkWZh`!e}qYjr@W@Bgs2#yiCl=ps3Ei3ZshGe7Zb9|UOc~wn1Jb`@! z2X+c#9QmG}V9e4tRVX)P?eM<&kmUY%yK3;oD#BMJ9@3$qH zSVSw97o`}qx;DWItK55CoZ!lh_IaFhe`OsS?4)g%qcofDehx}XNQ783xf@T~f+bEY z>g|LoTtYJ+3VPEl5?|sVkKN%s3brs*R305p+O4>8W&m8WvWx<+?eCju(@3rl*h4oX z-#co|de85ol_IA4a36?}Be|9fk;qR{32)edc~Q;EtD_xOk>dHTM?xZX`OsDvC*$GZ zOrd@zY(lNn{jW9`{idJ}rU*4Sqv-H&;3|C$v06FkWy`6k1pnus)RW)0 zytD~cMs;-SMZBp<_)6gVJ1M9cE1N9{r(^lP#6I#W58^l)KxL@~9$<=HKHPA%k z(G*6?>S`VQz(FS?NhNHZ;(LI9hi>&WQn_Cn2?S5JWCJf1%I>yYrRF+D2z?Mpd{>dH z@C$_4ierwl*_L1yJJw+`Ely%+^ZP2ZOTe%qjzcL`L{=%j;M`=HTgE-2LN!hSTZQ`m z70uGhymEu)lx^bkl@)``-9Jrw+$<&Vs=GDvtAkEOs~s}nC{JiBpD%bP5&ZfO3m{%- zi*b-9sTW`H)0thvEEf8%pv9w4_7K{rPbXw8@%r}CUon;v=x+~}WpU`2Bsxa2O6LkO zRPvCw;n7j{_b{!Tt^o%U`=aq-D#Gsxv(MQsKHCU62xT1f#hq}J>5HfSK#MJlPj)dN z1qp})(q#tHPgubV+7A4D7pZCwQfbDV8}6h%c&euUpmW$4c>ORia)>e91B=?fGVd8U^x=h z$UN7b#Sw{`phmIRDchC9Tdn@HGHNmA)E*(cT^JzJf_2`V0wj>lV4vR@*|-3M+xoA&L?h0$enQxwZC14G@^L4>Ai_GE(}<`qG*grSkR+U>Ow?!pbIb z=>pOA1&`B=kfltxi|4BzA-_^d_3r1nEw)hiev)?=9&0d)f!rRzr_gumQT9`zjV_xr z>BgkVQzRFaid&O!;^#H%;=^Ehaf1np6qYN%At4kt6_+%3Yp$bB3N*l~7M5)nLhC9# z*MQuVAuQL<*`wzp(PeT1v8xcrnT|_a`b94bs-?4-Sm$6&hMUr zik%`-v-4;viz~mhgtbq6@1av!1TEI9T21XoiTQ2?G|Lx@sWz~gNwP+FUYc3b7toYg ze^e1g%ofK|j`D$ZgdKaxAI7JQ#mZ#Is{G&WPbRMj@*KQOTaAjV_-E8A6*g3ehNn0> zWTmqIS|2z!V;wwd`;rIf4t{(XLO%37hj(37Z%rr>Jt1l%&Q%i}tJW2L%z0~chmC_y zqfFtpzv=fKo8?B*X`UEbcv*8zh7Ai@IgvW~#$K}n5Ua`yd2fAIJU z(w?jTAD+HHx?+nL`HHqWK8Gm?`2jKVZ=pPRq=-4R7&AQfBH)*_Zp^FOEk z38(h7V&;C7dwh%oU+Mm_D~X%5K)dJNA>D9 zYDJLz2nZ_o48?33h*nla zIKDhjSCWe&%RCi!+&@lz9$-r^vF{CD76Nq1-$Ih)Ck>2qHENo+*s5?yphKNxW(>ZD zc$x$~q*(!SGUaRy2P(9@vcQX9HfyGU91{Yw&j6)Wi}C$crbZjYMDP0_31?oPtCSQ3 z^8eIjF)ahWp3;>Bs#k}y!b4B3XH%mx<}b$CMi7|Z7CN;xG0r=GRAa|E1`wIaPM~`x z#I5@ov1xX{a&UJIk|EtYFYasI6;MJHA6E=?jW1ne5qq8WicgthEdUHti-ol;}x2&8hzHc15 z0gRgXxa_WQ=F5}*0pDie1rY{ob4}TnHlzTWYuOG~RI8GI>4jRo4`KJORQW7(MLPPa z&`aQbqc7;Lo0zd@ zvVU*ak27odZrPNk=?`xbk59}-BUcw-c*NkjK#_NcF1BH7nwLb8iyHqr{y+HNm7(qO+V-;vjt?^JkkO=1L@3nWP|_U2n& zjMPuGV6Z&%@zG>7jZr+!A^b>V)>Vwu4@gwYQ%5FYR>`};&QZ6jf#>hekr<|r4}$2V zquw&`z?SeRp8b5KW4f^nXS0jGUyE`Ud<*k}t#=ek!o6$uj9BIAr4O&eN&eRE zWf~o5sqY7{rf9QR)IA+|1RK> z9OSSs+=6x~Jsq7?3LQg4?$||e9K3B%Pofy=ErZk+MYQu%>8bKUUJ?t@Fz-|AVEBQS zL0caAmZ0@*#){<6Y*JV?rKspe*Fpac+~Inm#ce4FyVyIM(*3Nb@q=or<*agn)=S|f zOuBChzd+u%mG4&O{9Uc}d3fKRTYng+UOgafIj@k!PG>d4WmtanSuUp#Y6V1JRdU4{ zmEE>bt1G^UdUjc+o`Ir_7TE$~*v@PDhrSzFVhH<$u3fc|6%coaAr+WuAC}3U1B$*J zaZBQzDF~b-3H)(Fqfvfjy2h@VP8D{~1`p})JyHb{li zeUXcf{Orrk-^%P8Ox;(*6y{Di8}_RHgIIagXt)%cMJc(SOF!Z|0cbMg?4*x`)zCNZ z*2mglwyKS$Cw8JNxWlNBYo0}~b$t0gwAeB9ubz+Z6@xs1jZzh8fqvQ5&HaBjPZ`@V#ck0Td)w`b zl;X1QMj$X-gST{pLSYja=+jSy2wFFpI31G2KUG3vjhTN{HBlimX>o>v(g(DhyaVL` zEL43H@{1jhtOoq(eoMkzP5v!^UV2R@Pmz_5dlTP%OA&qlKSGA8zSSugSO;_@;x?@k z$ceR*aM@FAh*PpNGGABe?`#1qPw(LiUFWfPkIa+Y;oun#7-+$|pOli6q9%<_-4*Aa z3sC+QavepGy*B(v3R*`gznRo$a&kF!X)qr$?;))nG7RCjDZCn%n9|h!f7J_#O%VL9 z_U@$&C~&fT7nsVkF^dzzjj3+7T$9+nYvE-yT>N)APHa(Fe;KN%+7>J29R4bVPZfNu;{g>qXZJu?CNkh{`)jhW1N^Y!p^e;Iz3Y z@LEbP4-Vn&7RgNIo3q{HG2(+r%XzRA*Y^)~k4$(?y3b$8mQ_!iGL*_qVzr49CwryV z1pPk)S5`3-(A|8H&JzLZ+b9*nlH)(JF%p5NEaw^mNYgU86xW`tSclN}vafISD1lqR_<)B11_8T3-IeJ8Y3dnesOA09Wz*S_cI+Jp8UF*SYZ#ayXB>% zm2;#qAlM`Sso`>uh~Z8UK^wSvm+g7egNP>{g0q9KWEblE?EquAJh`SiSc7Nc?L7|5$7e%n8anW( zb2S<)U9%Y|yxs+u-P`IX zmBPA-=eLk>Uxt!Pf}S?`&>)*ozo-#iXxm)XhVORIz`g->L*Bag+ zJy{o=-!O7l>C-p*r>%|ivu1A)lTJ=+C^B4e!9$?8&G@2b`^f+~@a;z)nHhy-Bzn$p z#4&=c%RBxi#hVm=ucL5MJM9zugA|-|T|{Bq_9~Diq7DkvHiE&YSZyEoH(`(=QvWn+8Ha1j&G~@tk z>5NsyzWA8Uj=67#+(LwBIK&lBu6$0FtW|^l?;TyT{0vs~0LPVjjT9yl!S*Rfd3rgH zWP2O0?xWzKNSSoW4;vnZcNFtDPI*OpeKvy-cCe`#fGSfFui&gj4hDx}6nLme_S}%sH4z zVyp{~S|OGi)=<&+&rjAm3~5(9L6=9>#vGcjDU=%^aGig)BjYEn%6gj8Cw}YgFRPwlDQlRBlw7lnL?h_;q|Ayhs|!)^!uO( zRHSH4xg!;5G|b3p6pn?1KbbU8v+~{!^G(d676E zD7t5aN=@o|Y4`@WLjs1+J0_*gt?xj>)_x`tXgzn~-N`G;{P?`}E?@{0T1vb}N}1U# z?)G5mn{d@wZp3L&c(~iq_W2+L3$vQr>fUaA_Nw&nH)C( z+RdSpK^64LDT6dcZEhZv<>fk&75 z+iNmcSiy54mDYo)mKACooZ%7MYy=XO?5M)`pX~Bp7<7baqMpmy*%?qX1w$VK4w4Oj z9&&I>{SwMPOfXF*k1InZ*Un;P5w`Ey$2nW@u?a2!Axwgd<0;vmG?~lXQ%)(qBq!3*0Pe8MXM0CEE$ySbn^%9HfAISKew6(!sr0^7vkPf5e zQDHEPGASOi?)wbj?{*x3Dc|(Pzq2%)3dA<`7y9vqUu@EgIbHBFkCjk>au;?${2 z6OE@wvv=9*iB5k$!`?N$>Zb0TVM+`bJcS7|R?^}@-Y1IzwltP3)6R!Od>G+<` zm&aP7Ft1qICY4(1J+h~Jx}^ct`uVKE-)~@VH+@9H($6=il(06EWV+nbD4}@hb|&iE ztO{=aIf%9RdVDW=|O;5k^C6VVIQX@!V)x&#NNVKG8d&O%w)-L^^ykV zAw-U5%;fXY%~71v!jiUyqj9XN(M)03Lx@ARU0t8Is3uI>{jGZ$xj-JXv@CJ53uZ_B zEp!*<>f^U6bLv*#0YBUDijNEubLTST0BBu{o{`BF`Ln%Z-J-&kp8PDFf} ztgxO?aS%}8B(vdic-972w!peCqGu^>6tXSuT)mL48x}V3fMZhIE6t3WlF%E?oPFR` zhOuYOqT3|eFGCTrqoYo`OfHMPB%W^rN)@Krx(oYNKzNFXoS2ONAyM1h-q}Jz; zIR2I?lEdze$}z?$RlTw(WHYgeD#YBQyBa7wjC9N#f(Pt#ebVbNoL>_BHP5%STgw9*%?U` zH5Vf0BYwD9pF+9ekoilwheEc_B7QmWqIavV7!7sNy%op~i;LSt2DA}*=xi0L*2NQZ z*$OqYGd8a;LZ3M!*P*ZoRS!;)%lm1#HC%zvm^osJb9GX;Fk!7J6_i1>oBXGtoO7w= z0d4cR?P#B-3B%R;OE6H97u2yW-)I2eT7{!RPU&1BF+jkasq^te;TP4JxZQswB9r=7 zz@GE3H)#1|eA4n9JjZ@3jZd|^CWH0n20$WOcOY89+|G?-dq^=UAEwdF_mb3AjOBMV zqrkKcEtqbEyUMtK11ci2Qn^h=JG3Ia6;=pq4U}l{-_jGKbHO`-X}lX%&^u+|IpH2g zsa~XYwnkr>ae~ZhC8umUC1`6dAuK`nS3yy*lu`h2%CrwX2NIt~u+^X>GP*qsJ(hg_ zm%e6Z%73*Upe@)NvQnN2u?HnK}KDtZi5EpWR3=YagIE{7MXoTp2oD>VOVe`L9rKRDpX#s3* zH1{|-WSZS)Ln7+>2lqDnQxO8xX72?*ce*fEGXOfA@D3!EjGSFH3x0bk4&$W8xOMwH z3nK4zETNAEZOmRK&tfYaq~Jt2ci02rEPIhrfnBrg0hgD-<)tiv%)Tc*edYN)aB}W8Sr1>#6LiuxvvK({-vF*u z3zI2ggOP$2^jb9-oxZjb1NhiCqWnDKl*jk(GW-U+uW)Bi{Qbb2`sq)xV_=;nY7ig} zpBlclZ4_eDNg0xXhOfed$b}IetT@p7Lo&yfbpKL$myfE^02KQ z{^2)%urOh$#tGQtWd{eqVCU4Reh?qVGIbLfRoi1O8_OT&v8<3pI;Q6N zISK0x&ND+V|JwdeV`*bJNXH|A!4Y58(0 z0Eq_T_{`-9=Uo=Ky;6Zk56wKuYmoCNREn)>sZsnI|6}%9P_xmL6X#H8O4UH9i4pIF za1nc=pTQT*1h-HWt;#m}PagD$iaKQFD+K2v`-qndf|?QmGB-&niao~mO$Bs!H1_xe z=SL;Eg76Jace%yaB#0`kmcg$sa>MV`SD$j+zbdS9+Rx#B|KX;xpcY4O5?^T}*dhAZ zDsZI9V<8s|RV2PJ5o#%D|G}!Oj2sIcIVwK^vepg_xQxe0|95B`Wt>tG&F~Ro)=T7G z^j)m9QyodE_m$Pch1jyH*1q1>NkTSn&M34a?I4()Pt969W%q9f`(M67LW>&^5Tr7W zoIZN0u4qJkRiJ?t7GEq?zTn!+U`_qVlJ4e~U?d>e{XwVnu*@?Ch*pQZ9)mJf^#uCOfKvvIl z@83fbWNcfGJladXXjE64>>yQ*w}kWW*QfB~6DugAeT@J}p;vW#LUw(!op2B>HxNuL?- zuleW@HqTRlt1yN(&iG`+YS~yE>^evlm)PuUQPQ6Aq8Eo=Xs}~-1_Vtf5gURwCj9Hs zrf0nWlf?XXr|{mM#BJ6*19*LzHJ_l>vnxpTk~8dh{XTx;Bt;fJ?C)_BK{}%-t^uJLtM(T>QIByG)N|H;s56>XutPV4 zdjN>zRG|SM%s{RaAA4qvYF<~Ztl+Jmfd}* zpMpe9fPN6uB&>xKgjKXM*uqAk=rMVBUJA*ZT)i0nMO508H-4 zWj{pMAN`=jT&=xox8!wdu;zr&=SmVsl2h8r@J#iuR;_$3SpAv*IgN|nEFWVkL7I~f zlj}hNg`2D(-X3QX@vLcQ6mG3wO`pvviN*xkZ2uh2oL#I`^?Z;|Oel)S^FQ+45a%rs zb{&T(z`dVua?c;eQD54d=glizt*x(gc#tCK_4|~K2w`$U>>7S(z(2>r=CjYA25xvudqRylW@&B`u?s-u*`lo_*HKb@_40Z8>->@Oq##E+z3Sch0a z&;xm^32bK-)HGG2XT6@=MfC%jlWbtyN`LFN_z;U^Ob!|aS19yDURx%0loa7p6d!OA z+>wLayc-z#Uje;*{^Skqo2zg;(l9c~RFOF16dJD|=?UYc<|^_ORT#RZz2geHIlad8 zuaVwuJ#~1fVA;^b$E(PhQ001>~RoGjM8mY!b6p@p>TlEWPjzk*Yj|Ek6?g!R-1h;uqafYIA zk8&uqZbKhtCSkzdq#;`yOnDO0J3w+J31%sWv~))(VGyBfrqWV2V^t;iP%}}_fZ3r= zRe&Tn5R~M|l{woUbc@*N*NgqC!Y5Wxn_@hy?xzQ9N=+|f`|dvIyl%W+mD?!eZS+{f zL1DibNp6utgq=I(Ikb!%xa>+}G=5(BX4KwPC?!irQF*^-R4Q*03=%RNuw~Mk2a7ru zn#(XB7=1v%BvaZPqAakW*7FTyg{G$fuvzX>=s%-)*nFxnDsl#1Xh7nuNonEPhZ&w$ zsl;0hO9EnTn&U%BOS9v2t7KVtFIJr?B^w&uf-<&6fW(sQsK0uHXs<&k0w{cz?}ny{ zmAyf!0%R#O>sUl>Upq#ZT}^V=j2j2WczmV0(|t&}>%r1kK$w-Dk!ape8cQd;7sT16 z$(C|}E~bFL6}ZTxnOlXYaL8n)AV!d6Hs}v3p;Wp4&l^5)mc`fANE0~L+Yt?Nl%cbcgWXdVp;1%`RpqMv`;ayDd_AyIH~Q4J?X{+?7s0gnh%g2IX5cE9ri@b# ze!h8bP5+k}M?YSt@k@}WidCcQ8Zm$Q9`B5NgO7NniFSLo!w8vC9e|v@Y+fAaP{1Nu zY`we4<=1-)#R4HV-%6Ved6d}v%W=CB^h77sI4vUOW&Q}>HQ=0HB$*BF^X9RyJjnYt zXju{t_lvIkIzO8Q1M?d{xJ&_<<}|xV(7>6G6A3{TEVq^s3zy%t;Kid#DoA+ zL447YOBC%-ffbi7Y>(ca3!U>swAivsR8sQm>OWy?6E(vbmH1=5KAZ9h2$u~+iGXYq zy_cLaci%s-eOM1JS9Gi7PShN>$=~W+pNM8M1SdH9F3Hr;mb$AdARKN6Ba!t*mi1Lv zpkpBcPCyRtAyHXe)=)#K6YYzww+wcm2f?Y20&UZ@@$mqC!#vMn@Abid<381cEK_!4 zyU(s zE=nZxbm-pqjRIEmp?2ZUW^^UBv+K@lh~>=7mF3^<)ZvfP^Bb-kZ_s<-)t=CAazqLI zSKE0ZAv;zY>(Ydy9~N(i%}p>D7bDQ8eW*w+Y^a1_t?bu=)|w3@gX|H{kKp`^zdWr> zjxjcR)ui57jRx;YTBeFmU&Kl_tM=Wc_iaCw9t3DRIo;ulS|w&PRBTRAl%SL8te}+G zuM%qA0b{9=pcT!nf>D#U>`>YLf!OV*J6zCt;Z3Sk2u`z<0p~}-Bu$8>+ssFzww7F}yx^)JS{XMjFd#ZjepMVFHe;A8Jc^|$c%B@5sO4)j)TUiIMI=7s4 zMZ#4q13UteT-QKiQWHV5dak6w*BpvUufdPi={H4TuJn|$&t}pV!4_RfIX_Bb)j{|I z&fKd2NnFMmFy`v!*uU`FKW~|$yo*}*4!AoMOo1Xpf);HGn8KU=|1U$;{RRW$%C zjWDD;zVSzjP=nN0OE2y)XlU1Gw{7q$1YrJsq2>NlH@weemKQ3%gUH$eXZ{ilS=Jxr z4keOMp@QC?St+(K2?HxS1nJOqC-F}1VMMID>*sWDl~C@o9^)RhBJHu^Pv)bQ5hQ}* z{$NDm9rvB4L$?s7RI`O0UA3|Al}XsO zF4LNaIDgDSFbJ9V%2qU10TaMeJ+us8JwhK}F43tAj83E5WldThfxw)Od?Kb!3(xLv z$Th)aS?E>z@5U~3d5o+4VguzLFv346YZ(GdFxAGCBGb{64O=dr z?yPOd^~JKNP}MEZ16iC2S_G&yiE?2GD$ixTFmMAxzK`g5MTHwEe@n=eS|4cNh-%#r zpxEsEnv1>1=eyO2Y#XvU+^frffq$1?W%=|J141I@z}06&#^|IS?J;oxl>pxUVr80k z3f$>&_KxMo7YFx5;ZO7X_j|go>CQ?xH<gH6*5KO6N%l*H2ZxLkd zMo)Q0!u2w1TZW$#={%m;%yK|xD>BY;%$;Vb_?}^5QkR)eS%b{GRR?MS5O3ki9XCp^ zlyIUbAE@L7mM}9(1FN|lJJe4dYVad{2Ni$l2FO)^zZB>IjVhzL#9UZLJWV7OUqmTW8HWI)PEjvdHDLW z>x$yiFR|P7L2G2z^KbRWP_Ihg`H--SQA+|~ymQxU+;3}m31z;6calYsU*HwQ1lc(( zs5Uza#6l&;dg(}UWrO(?T%2K%WiK5v#3t)}&_{x4`!~y&jXmLkb(pcdJl)6C*wwNZ&@trJ2sT zhYbhrb?2_()_nn3u!e<`kT51Y%k8HdsK!4`YP#I$w#+omYKRABi3D(cb+QdSbBrUy zVxCN$z*q;`MVDJlRHV;%IZ3+-aUE7dOcti5Gu{fmmy5;b7X;wE9sSY=|3rxI08guu$WP79N{%RUvuo|qF|7HUxfr#TY-xPLa-Q7C$X zokah%W`{lr^$_y^GdyZT^&~3Nk3D(-!7Py<2&PR$E(v)Pj6d#he&QBhFpJYi7COP= zK(P)Mx$Sf@QT97D6ObmHX0rJYSh&pNs{>(goLTIhFr?Dq%4*$6Kut~w%0mUY#^4pU^P7X-#3u8pfcBUB#p;wlgarPW z&B|LscF|NK)L)+frRg-4+q6D_;JWy&bxb0x6wR){37HsS33Tt+dhDU6LeEP{mOy!9tMW z(m^{M$^0;@r40IM_x2jHb=*(q8izBePL`gzkvOh7EOiR+@U%z|w$;ei?seKVCG%hR zU#hEj_p~GHyK3%c2Qq?2oq-3%;F8#&Y0FA|uwRG++?p}Kd zdn_=@ZWbmO&-$x&ZpTdRBY^s7OPZPP6!S@Slu^_DSPe#t##n`NsHx0P$y-K5;VD9% zHSB4b?QX3QQLFNV#Lbh;W!$&=R`LT0O-Aa&Hawq)0uyA=uwMcxx%FaOi7LG^(dS6y z>+^P2IsEiiKy(%aD$uFUownX>)tzPgH9s;eJM*gtLotId3q3Q-RgDjwSv6YkTWDG_j7d{pG#N{aE`(T$<|QAq z4TFNva8(h)FP+n8uL}F@mc=xmr#mrjI;h{NRV6s&%ec1l|vf8Zwl#^si!Z%H~$%P#`ot5IfE2ig$NT6ILbbVM|)0<@1H4K zWCE>K=`L5JBzsq{CiNqa8N!HelXW%WT5cOK%sbbEbD0gpY9zkB{b111X7MUY?K|d_gs) z&C{ZR%uf6X>uD}Jx5?;Ufkga5LpxSZQSn0RZ}RC+0;y8OODlcd=Z=no#srRg@0ypD zYB9}GLU{WWk++_vjL|69r=)IX>^I`oa{`b8f4KU6@=2PVLlRLejLnvJ{VYP3G~);} z?Oek*{L-ncy(HOCki{}D=iBr9XtAEIag~QrS1qkHsL z^Ri;7H$AHHX&qUQ$^I&(AuUQ!Sa&M-f4(9}<-H0FhZm;jLnY@F*mel?`dw2t->!z{ zv9pIt!R0HjAB&A-2QJ^?3a71#NXtrL=YTK@mvHXVj$7dO`WzV~;-}z=b)FL0=EIBa zw<4I@qL6d3j{U@3w3}4J&GQlUf+*!)YKVy+Oz@GNYZWzkger*v-zrjeclJXPpF4n! zlZj7C4Qfq5bv4yAvj42Xo@@&=ZVpUsmN2OdQzBTsq`dUrJCp1oP=alzM9w4 zE@@t;yiJE%+u^Jw$W%XY(fDf1)MhfwNUXt@)K-5J+;XRlCK<Ob)>?!9g#Giuu_ zNAiT!$tvqQ`*lro+(||=V{_Vez`AS4Z$6B|=M*Q{H^rlVC<8VDZXl=j{c3gzrb+!v zocZxFzeG&X58r@}C!-|xJoH|6AGoWZ^m;E=Chbpjm@0v<{LAdx6-E1O?5SJ(!q5^< z`0j_qOCym4%&ugufq?3y@C$}=`!wixk>@%GT^`*mcUS;4RsyN+gqD(9WIvl_mvTn? z4Z#CrVcP6_XteU0&T|>bLp&R9z3$bHBF`=2oNkLq8CrMqeqaIljr0BZmlyP2$8oQYO(W;P(<)O6i9vCQy?47wE?>QEW5kb9+!8543-lY@Oox*~0F`P}WM95h@H&G?Bw zEHrCGje0)6jE3Jy?S@EB3gRz*m2lRi`2B7$zWATqzzxRD5A_X&@s{iGrJ%}c3u5PW z=!}t7E&jxiJ$vdL)=YqI)cthPMOe}4@7{kp8wZSuukPBfbbDToJofo(;nC(l#g$0zXZ`5dbyYr2C5PB?nvCRDI)F%?tHGR<+D{&Jbcsym4cz}sIYb^D@*kRe7jQMN4c^2Ov z>22o~YEPvdrR+rA^%T3(B7$>~))d4VNa?;r-oO|2QxMp_jEtfa=}*b%dAp3>?d~T1 z(>-IcO4;U7N=IRPJ8F$Qrwq^H)q&{i^mKqi8+V5pe28^1ga9yRB@VGr>g$|26>j7o zc4MlpKWmUgD+SCeCES54xNl_0%?W=EzXLt?hf#YKI>mRQrm|k1Fn6?+v56yd*Fsmbyq)& z>!`JQiEwwy=%BKw(P?l%rVKLF2?<6;Xt4Ea+|Y;6Y^AD~HF&o2bQeTeii-C(c_cj5 zAK)J?R}O9d9b)opZIZvrW0N^wLqC}AM%x>5Md2?mt?OcAK!_b6HmIyi<{zkAk@+V( zkzZ=KQL~dV%CkuCYJi|(y7<{yRDugj@wV(l*n{kySVwj+sT$AC#ziEa5?boJu(5Zj1ziF*kI z0a@+ol+j_aa3?-GDK9atiXd6opJfEbus#qvm>Y#KDfWTs%wMS)uM&xoJQT{B+WT}@ll$t*b*aI8X-R*qymPs z?*Oa@GfLcgBDzvvCokQ$D3xk`PaE;u$|*l-RvO$Q!$dg~6hB#^pe6)d*RX!O?9r&x}*C!eFxDc$HEQ{ zxp&)Qb2&4<-&(=azSi+ZNFVNK|Jmx2YN8{yTZ&Gm<{O0M^^YO(Q;HpWC2Ml?cReN! z{q5J?Q>tq8NNU49%ri@HLO}H9EdrCwDN_KfD(QS<4X@wR(|Qf8A2=cs81>-5U^*CN zVLfsI{n)N~wtT^V{7mZZ+3i3y2os}VHo-Xzv|f+o$A2&%2HOb=WcK6xz zYlEOSv}`LR2XES6n#dMhCEqFMc)^G!FIv_TM#r^&N!LH3wv!NA3i0FOR(>v8>^lD% zD9l1Fs4f*owWzu?u3V!2QeQq=;-v~*O+AyI%MM_F~GWh2LDBHz3e??srp(bobre zx4oomlfE7hp&_D$vLBK)OzY9YvZ_bQSIhjbzSQfZo#>HGjhs2`Y?Jg73SiFs?D%gD4e~{!I-_s|msvD-VcFhC_wD>S0mHfXV*VdVeG(+u zlGE*HNU79~*A8&SKO1@Ra$If8;LxwiR)~Q2<#slYS)FZBW&y158&G-ejEI&X`(Fu+ zuM3K!GP- z-r?+zq9XA$Dw9^!;q)mMyiJbC#$I&1H*i;sU?Qh2x6@kwU(m01ic7;u6&uh`7;Wxa z)OFug(QxmZaaB#g{O@bRfY~p8`Cm~^;W93$$ z{cPPZ@)nGYEGxgqi7}vD;^C^A3LzVZ)5mEu&F~DRZq?o$yU4N;s1O2^dr}(1;Ob2r ziuU3mTk9578`f|wHCO5*B5HmP9B`!7sE3(}BMtR_WXk%aT*qoYa-SkMLalWVhBMJn z-I4BP>BB}&A7l+?!xn00E<-#^>8`GS<&-(3fHSxr@)Nuj-)rl?%~hoXp!z^ zu@Ae1!)^MSP5SrjK#L;y<>9J6szaWKd9x5)le!Wm0m=rSAPSkx$EnXO(hUn{Gv*xWV9!f*I?MouYyZDcxu>*@g+_2KNW?*Te@H)feWNN>d6M^v_X15ezmx1i{2 zfAQD^488fwQ=O%Ul@Ro!c=TB>;asme>cukaRq7?x8m5Vd(f>MEomIHi3eC?>haN{J zR|bwgW6t=k$Db)}o~N8sD*mr`>bH!PR6&1}q;zq0G8Z232($!hgD&G5p7KAtxxUh&AuZ{X(V)$h4 z+7U>P1pncn?M6uvx|`Kz0XRPs2N*OiW3ZQ^6uGrz#dKQ?m*Ekxq@H8$EOZMiSQyG# za2d{4q!8jG|8yQc!e6;qM(*p2cvBK3zzwqw8D7Q&n@{2Io<7fwn8_AfMuEeeC4aY0 zPgvlf8(W;rV#+&3DDk~}_Eo5JY=`MM#9ExfI;UI=sjNSybfhJZ16V9Fa4^9>9O!uM z4;oM>1anN_FJEz<+x?TZyXZ;Do0f^b>xpRNrwz1r4t(28k*$I^qcbg*MpzJV(SA5$ z_s-A4C;hJhum({Q@lqc_a&4R&ECEM$Nt>zNT}43oRz++`C-QE)r7vai)C$a$Q+qQ%agsGF(uCJUfzXNF-9+A?9)oi_Qq2N3e$&V1RKor-UYs#< z&FS1n7CEC{-u(;40(|vauUS{9352lGvMwA*MSd{uJyq9U%pg^NP-I;?FivyNS-@ux z)v`QTAH08jcYzzh)%E1(2QUUzA@x<%3B@~z8j_Fj2K-}-Od`|~o9pxVKG3{5|AAa0 zeNL@?X0f|L$!7Al?=*d050K3t$iq-?oLN1uFdyQ<+>NO2{lRB9J`*AC{dgsBfcB4! zYvZo+)-*se=8h1yB7=h7*GW#GM`w2aQ{A+Fr>0UX@rFw#>T)Qt z`7EIASK~Nly;4oK98O#pr6yc|@2HbAvd0%z=ozv z8+$#A4xZ#kmQUvZm;!G7ljdt>NcYH`fES0M+OL@*K2sMfMm#GSoq=mvP_x43C(pJG zL9vA~m!=SpNK1`(!3Ysmt3^kp5S4nR%|IFv*U+o3^~rkamqv4I_>H~RpvC`tH{pI1 zyZ+KSToZ|FCAN5*jrb1@V?}S5{`ozc^!NpqlPNE%gdR4bKxIUNwTLm9Hxiec);XwO zcrefYAy$l$@=Lcli6XY|?ZN(sFFtUn)yC2XkriQI2rdoASwh`&ZmP+2oaIvAH=8+4 zA->uqbw-!m7NMql6pvp#yz<&P0JIbNZVa*eb|3(;hX_*YL{+*b$% zrBWBTdsqH8w>a1PwyXKC$SS(w+LiH|nb(A;Foxo0%gqDVsFndxv-t<@tZ3~!so*EI zK8C#JjLM7-TJEe&_Hky0JLdPlvct6p&~Sl__k{J zCowK1357+pwv{6ex7ct7QjN?M#2xIa9FkY5!wa_1KZQ)#G@ZLhYW4%1v6Fw8qAhDR zSehqL7e>oM#uw9*i>gkCr09vV>DiYX^TtWs%g`l=>Y;fn7NYWll^NNPYzHsr!le_@ z4lZ_oIlR+u-x^)~zryBP)UiB}N96B7l8OL4%l@)F$Kvy!wsf!8OH9E$*lZPAuKC0B ziTP(NQg!s1i!d~yvImLk)MN}DpKk>#!ov#!VG5n;NNUYy)!?k6D{d|W9PNz|8W&Ra ze%Sd2CK#r58(?0C!A|k{v4ozAe|?GThJ)35J)w9SxZankg%m5>iaMC9HmQKEzOH-6 z^A3CxJ(4*hiC}8TVY&b{Mt0l7)Dox;pe3|)rWiwQcU%wTPGxgffSa&m=9~n8FC)&P z1{c%7*H9)6fk_IjeOl_2qwVj2H*1_1CYm+mEWft^zsb`?_d)=%mvrHEQgcjU~juE z#JvPZ6*?nn*iF5XT3i9!{Co+g0lnh}qlN2vhENQ30y&y2%u)zKFP=gaQM#Fs2;sll zrBcx?z^@EvWg(1`5y{Kc$q%`i$x9>`u?`!4H-n}wiQcGGn@lggwJ77*)-Jjvou@bj zV-n&Wy|5bFnYaVy^-}TPn`d*ixLZI3=fIB>*DK(m6`(6&g@BjkKMpy1@Eg~}v~=?V z#^6?Nyu;gO3&I}D1UBD}L$b|#+(iDa!$qmd@uGQP#keBhj=6pf5AK43NYt)};Bp%G z;ay=KD&xKoYr}SED4h-%SO<};=kE3+?(Ch572hBPmQ}zo1g}PUi={*-hM>wc?rJ>| z8*(62XqT^c8s=^3%5{~1_8Vrpc z;iec+G^V*Lw?Z)C?9j4Mna*yS?N3GEMA!#^u_zw@l>i{%A}#I5eWr!ZgGh~jM}6dy zZKw#VrGtL&qL)OR0YCaW^-r_L3I^q>k?|!}2hIG>7o_d&x~0p__K$$5yKfIs{~2<; zai}D>s?r=Op&h$1yoMU?B0m>TGF0G;jzQ zL^-B0<$1vBDO4&NfeIfuH{(~@n~`IC7LK5H7ij+g)aT2(gbiQikd~h?wE^eJpX>rk zYcq-K&5oaKo{<}RijG9PzuLEf(h{h+oT;fX&0p$_I-b1Es5FJ|oibvsJG#kv)O;X! zSXLp2ORXQxf4G2F%4z@o{?qX~oT+sqs9bBOC_nBq2y9CJ1IOsn_nEqH#3z_fxsNCF zs0kSADqf*>nDjrWzwqQ&_=~Sz-aVrFhZP=0{C7ORwv>eN5D7#r*iLuUz`p^_QH$th znUxQQtM`wcA+r$3=eJExmIfwsU=>~I*~;%j0eRe_D76SPWX1_REi#PBp!;_HZTpKK zU}J?Xs@r~D-3{2Xr!iCD)&W{?;I;SRpJO`IOXT32YZX$h1mGJ(UQ|#2gdvN9V=y*9 z5YL`XsvJ2WY_`#I&5OA)vI?EmuR`l+|8}DK z=`}LiEL_t04s(g6z4R#+M*^;ZjW!|vMfA_X>8G({{Z%8NY}Ph`^^EwgJ#K+?r^v|y zDbaB)R**tZjC_E(QKWF+noAOGmxOvamb|l}r98s>VTnw;#D@%7A%G`JCrKu_!XfEd z)5c;qp0(z^&%2z4!gJ~ESkby`G^oE-iCPV^`|&=_UIs}!n89~B#A?{S+-}I%$gbJOD@$@v1nW%(qNM_AHfiFLvwL zvD;F-fH~{lT)=Gy;Wp3Oz@=-tYI71y;YeABZu*hLMSL=d5$P<>75j1pGC%Qn|g_{YCcp(-Z zWIH=)fQ$@acv&CQ;#N-DdLSUv&4y+dvHx}6_2YI=$=OaJ95TQU)7pWno(1i5ZZSDv zWlPj@I||n!e(j zyy=(eZi@Lx%l1Cr06m8*iT$QV4XbD|0)@RtjgwJzOLi#rW z!;K~&n$HvzPZ|hI#D_p?BBoaIjEi5M89tM@nG69;h`38ocy5DJ=TjQ}1f1{Y#wL%@ zGhnxGhgb~YfO;@XronX%hh8GN*GSIM<@m!!vv#k*FOdNJHkePK1olH=5kXmfWX8}h z^~z)V+@3jvF_9mTMRff+Bvv*h z3v;oBA#u-uEJvQ&F|DLi~SwU}N~%uS~R z-jiDH$Ccd7hM??HE*tg+=Ef+8Qsyefb{GIYoWdJpT8+k-^gIEvl^y1C$rb52{chX$ znd_35O=r=Gip=+eK8ik0O&egPx6u6l%4Fq8iy;xu^kdyYs8by?YY;62H$OGl-8>a1 zwR}Kgm=h0ez8o`O{gz<}#zJn#4ps(*(4a|8Sk*bKgmuiLU-PyK`H{fq z$_%I`Ji;yvJd$>!5SJC&yyp|1JD!Jsoi3V#HseLZj^Ut-{m%q5UXx!|;S$#cvZ1=u zdgcxkP4<_UYzRa$qT9w;Mk2|7m{BW9r{ZO4!< z>hNG&a|r*1m}m?24aQfMx*sy3UP!spmpmo?1%sO_nCj%f?IL1%rCAdLTIGN_>7lqoNRpjSr zfeA`&pTlOd?Sx1=ZZez8`&Ku+j?I1Qzck;AU%Nd&K$TKlY~JX|=d-|Ioh1h6F(q;H zTIgADVBqi}J)YEU_7r7_ec2xGVVvx+MMOIwM@jZ(Af2>=jvCx?v-!%2x~(%*#vhZH zTvKSO^qUBW+}y7g$(D)o%jov#@_4E8#eoPX+|(_Z7S?ojaBQ|pV?I*WI~_!hlSW;= z>@w`(U#QTG+w3yESLeY1cf$V{4~oWxGeKmYq3bRRltK5_g7JXD71`!n-R_SX4i979 zFPq}YRAc_97!6`&EaFX8guGLWm`w3D!~dtx`nP z;bz=!<+Iubl)LbXY*jW)RfODY#IeaS=Xk}b8We+hh=TG&8>)AF9TiL5?p7&7dwB4| z(uyVYq|q?(=KI|Y_Lb1zqa{D;7#)Y80%n9nZmeKnAewbF7dUP=YYB=tDqF|3yBAkh z9nK@S6q#I!ign2$r(8AehTng*>SLT(Je$&DMzGwr5(sOJ!P)S^m6sX1P|vuZ;Qa68 z^Qi70o6ahjqTi5e@Tw?L1LqnDUvrPgx%@D~>z&5v1>#f@G&px0Q%>>67!X2dP2JXK zKpK|uPW+N@F6n*&Azz&ItFb9+aY-xt-&ttV4uC>gbDfokj2NwuE*1A#xPDbopHjB# zQumGq&bkb)*-~jX&C$rIkh0_QNx&CD=+*PS>yzfw)fC3LyM`2b7QFkt6D#XY*h8(= z$xo2^%^LdKSJYPIRsHj72IY|iVJ#-pMTSDgdyk)h>s}{M^o(WOMv>Idfi{1!y>MrK+)@26)DbZMpn^ptC|I17L5X2AR<5oT3q@Y#QA} zZiO#(N20Ab>YAj<|LGC6Z2E8@dKQ(F^c_Iux5&5Dh*GM$gWLj#DtS7oF z;5ePdT=9|&De)vbJmA!-g|Q3vr(XsOutu?y+iu5ef^8Zy<$;4G9BgoQZ>Sr7?u&?8s-`ZY+Af2^FLalkg4FK@wL869G+uGg zo~_{eBRpNUTzI#M?XfLaXXSlhS2{Wo0v`*N%1V>UzaS3k=cj<8tQB+D0mbaA=#<_Y z656@F<%TTp+;Hdl#Eh_Ed2}OeMD%nby@4R zPRXa>EeSPQB-FSFspPrKQC0&K)@3q(bG2|XTGW&s8a-qo0+JhCFxv`>`eL7V!>kyyxFN#$AUtK_oiLqfB1jhHf=g<+o6%*D5W;xzxP+l&Yq?ie z6eg;D$bs+LomjY6!+M792fmRc zsDJ7vh6tsCHYeZT;!wpGm@Izq)f3FOavUQ;>?mgvtyKyL;Tj}44;-1EG$b+?wArbf zRF>gz)+a5NtD*#mR}B#y-HL*LRE+j5o6m^UZek{ga{9t;|6HMr^l2INEWf-a!nD7+ z{;>S8-pjKEJ>u9cA4wjwJSUSwLcvmvr( zEi%TNBq~e-&EBeYU~N+}k2~TTMVA!gpi`3<8O-;kS3%fJSE^9Ovr2KDgFDDgElnD4 zf`I4sJx#Y0u2q3cn=F&9D7ooE#xpt62=o8iBak;FenO;@8Cje=c{?rnR_rkyW}wkj z`)0_9x20*C<5n@){qKGXDnRS*Luf8zmr(p!HEL!*ZKkLQT`ur&7G16ykqEywthBk_ zOdFM%+Or%*n*r~&2S#3-dhWgnvYLIlVWo*#ph{q5+fVK!dca2lVbJ1e4<;?eMuq-n_mT@Th|fk~@bH&XdauR~q2ieQ zz<-uU&gJaHRmNAhgtE~F&$zdCrF(Dd6e-qB1A$~-s2y*sn9+%+M8b4P-*;IlVsk~Z zAEY0pY_$%|uYNbka_U=A_R%6BLLq_`T(hJyszb&W!iJF)df^ML9~jU1MxEr(LWcM* z4AW1WsFQE8q!Pwt!bQFrJkvP0NQrvhL%w8pCyBRQbPub2Ke{ zUfJp121*{D_cMglzR4mTX5a7Ll>IC98v{`m(L!)Am728kl~%C@xg3!hy9G%)sTj2K z_mrzND3f)=P4ymi>EDpE`#(Zq{7e@pgx$1%d6lXu)nb%f+IOFK^{oTy=amm{=v;i6};@@rVh7*InKxWX>D7_AUAUhIq)>+^EN5G z^rh%f4DNG+Os@-elH6YmS#%(`{5)L>Hm;09u-fD4(Kl?!$J|+XAYXD&*z!)jy7FrR z%duSY#US9HP3n?37yuFNlhHunY=kG@_ne4JY}WV+jevVA29gZ#+@R)~VOa6CC~^a( zR+8VH(`1YaH&(D)G!L!&F&jkvGsK}8%<5%8 zLNA2eHJX=o9AMmmMKJWRS_3!~(FU;!IW%xj%D%#nP;LV+%@4ZeN)(=w@JwWr{C(7y z$BK^AP~2_HQ$a>KZA1%Ks$zj+O|H`5WdFckfnBdjEIiUkFkbT*dk3YRkRYBvMDkdIwIYgj+=F_;8>EV{ z`L-(Yq}1%DGOky(JZ=o|0n4ti*;*o>zsQ|UKq+S9lXt;|#{U9)$V|zzulv=kmXi1t6WB5-#Yd5%Y;+V`n|amG84MAJ9{u!f6)j zveu{jVJrcz)g6VrjjakEqfih9r+G_#N6V~WFGU5Ss%f%!4IpNn2GoSj6kw9n2sI`G zU6|*aY#j*%CD<0;p`~n+&~_d-!Qbd3#RDfEO~5iub`lM&8g7Qa<9)43(3Q=~t`k#-xj4U?k?wQ?e`j5#TxR5T z>T82_E-@j%)i2f`VIzV+OVM+UV$2tf1(7_WPlBHDPW`W@&De=c19tWXi438t!^pg= zes>V6m3$(B8T%KC#Heg?Nh|bVj=2O*;~<2I?Dx|WJt((_UbH(`R=*4xcf#in z@_@wL*HXyu1dU%HDhdkN0^|?*Cl~Q#*mO9+28H)&wf?Lfib=!s8o?(x;78%AK_xJW zKuTzn2xOx6FNR!kF8Ti z3_oLACNM^9tB9BVySY5OHyOBN*df7PoAXy}fIF-_yuSMA1{L}gpawFkz`Zb1@y&Rp$2D}j7i)UZIojD1iAwD zTw1$}?Q%zGdhwZXoT*RgemCBF>OHTAm?PF2Z1lQjPy_`D9~#vB!)?OCu$0daGyERm z7#9{CAb)#306d^l0L0Y>fUurLD@*%BoYBJYJ_cf{pqF+nhe~KGm0%k7;f_Q8_#wN7 zkpAtTV5etU!g0w*+`||_N>hXmRjNviu-3ShEtvpWV3r7_ML=uCHy{#>uw^;SqgeCP zAaEAdSs-cl>QHMu;o#MrN1$S$8EcK2S0|Ueq1AJP?l7b^0&+Wkxo_+harQ~zN*B0D zy>i0Hzr5kHI-pr90XwN0t?I&SCFmM!#r~EmivFgU%s{I49P%t4n^i!}^m89*MW~Xs zIun4#a-{;4KQxyQEYLdc3 z?ni2LvuO}Cq&tsBDG?bC6{C*{cSL?Qd@7wOu4OPJXudYo`=RH%D|}dPeLiprhueqS z<&HZV_u|D_wFEhz&BmWOSPQX661~OEQ3M(fO(9(bIuUUGr{+l|$6%JnIfwX$RgR!Yq4#Dt(w3flLERYg1KU|D&3lprBwPw5#XTFa2&yT z@82$R5oiMj+jx(1f=VOs2p>&kf(93d5j#i0CtZa? zPGkZXV~Uc2=a#4b_hty5qshze6en>x;H-Av^yzRwF`R+Fu0DoQI$o>oy?pneELeXz z@j+RDryVL#J~^(RmUfLwL@Kw?^nfwgI@%Vh((Jg;|6;A2e@)6j%jHAGxaRfA2i6<~ z`2hydTKpNr-)p;@F2VURX?yo*8bL-tniZy7kaErp|JQph#*CHLQBM0Wni(!w$@d#-S%)FZn-}O~Xjrt711}I%1-+ z5B1aT1yZ0)>|7phmVY!%77vFC5Q=+UdCE-yzk-E1K_QMPQo*(t8pbF=Hxzn&fs3lnw4Xw~F)B`bz#cAMX zL}`mvo5n_&UH^G{l|Xg`+&N=^Z40UKe}5ewyHh59lThp|)A8D&I4n2i&}j`s<3wpB zi)6r1A*_|?St*J+MWMOQ9o}a`AP&UDY+P*%u`?lTgOViSH+O0sL5MI1Ko*_BH#S9!B*q*R1C(pX9M7;4G`+@#rPBv77y@)cDpm2P5* zEbeHfx?ogj-BYVH$S~C5<&1`6nR-w|1Xt^_%o=2-OM4=G4>ZK0$kS|g$Gu@bJ<&~) z%OqHG52M(%BVlq(cUYPGA#;WWglf8=;7(Z2RZE$qA>` zzEi`{3hONEon9W=vb%wi$>7!?1QQ49qI+odE#P7Wjg_6SKhz#k12e_VUc}RN)D=S5 zJ5j5Q9M}KK5Da4*+1UklWZKS?nOV_mh45^hTDIn3(fTM*9Fe21hOJ!i_B{Iq%8v^WvcgM<8|=;715( z`ol`YD-wbX;hTzOpV}CN3Q6~hNz|%4wv?4%cXu4MkTvg59IZCkagO?)`gcNCgq#(^ zhxk*QHBQxbj>i>S|CrN^In(V?yeLjk8NI);%I|N(#V1gSQ@x&7Edba%a-T1GX(r)g z>7z|nhp?kl!`{XyJO`|g1LmEAgR~Et4*w2c6k13BE_6bgJm{J#wE2d`%u#UBx!RfO z%21=`#=Rlhcmge;gH?)`B>#@3_a5o%jtRF_&kU z>nQ`}@u!$cC}6m@55VOMg|V(WKi|8)!#@X9>j+HGU*ylMDwG}ETaloRt{tuOZxI-b zyu@mmX24`QBCF@nj_S%^7}-HXk8M7W))BF*ADLKoB->nfb7Mp1?(Y|x#XC_jeiz{? z-!{wvqF&`MKoFZCUl|t7?Kqi#dqZQfAH!f=Qp5CjUvTI?rG7MnZ^+l1Y{gQI1JQuC z4R$&>c$_peU(2*hWSn47|+Oi>vvsZ4ZI|^{gx{EsdIL@ zbkw8NTd5}DAnqlTVx0gI+MEQ>TKV&7+rFs}B1TEhmdZ)7={mbcxZam=(5qrV-ZJ&m z(XJp@jk2mvJc){~eDj*Z=(?x(T+@ZqBlRTz34|mIF?@8gNg<@(i+WB0*iI4@ssJwk z$9v?q$zw=KIn1tg?^5yNae6((&m+P)gu3c68*%jim1HD3ZR5mE&6+b?dHU1oGOxRB z-$lVbUrt9f20Wh`6>8uSsGT@=#Mt^;p!2FWZwMv=la0*1VmGm3#2I1Ee_lrz_BzstfX^jJR6KT=BALH~b$@tmZEfCxGy%WW3zB6b~f+!n|ri)FWnD-_lcyVMcl}!)eN^A!t_tCJ4;P<^3gxC zduS>>lt*?V#v50COn3Y)=fMtzYzv@jWkL|AHgY8oJ;W90ot9&Bmrq29Ru%5il5^d=NcJnl52+Of*&@W`62yY=Jzg|NoQIcvSDmqZ`@#zsZP zALur}F=vKbM+f04RQjjE)FsgL1`*0kdA2KnqG}>>kB+<6P?}wEU<;_=46y7wkYxq7 zL2Nd;5N$>i73X?;6B;_u;^0$!2i~i#_9DC!|52yDE98;nrx{4nqD#Kp=~_Z8>K)*q>2+H|0+%r}n2I#^`!aZnYP)la?hn z6U_It0S^|UAAF|S6oJ!DJ8+(BVz4~wXJfG+yYK*cp&~n3yO^zd6F++J2`;Omy4*ta zh1R?hV(G?I9e?m>G7$WOp!yz0%44O48_JHm+p$vfGA7)`nJu_=5G*00MGv>hM!ncQ z@Rk9wT(t?sSceV0q77+n>`GxX&naVP)Kn~A0@0Bu4_{0SAZxkFAtPlh=PYY1j~7*; z6Qop4h+Yo7ce;3cDc^H_S!O7CglSofuKu!+ZP^65Mf1{gt|vBblViWntI4$jAGeXH8UeM~Nr(qopuN+ZFo9Op)4Z+K_Yv3K=PsbY*nT}rpd?pNWVh7Bhv0Fo# zR=zK3%>JpbzDeLH#^7LfGYJYv(Yt}pbMNi)=uj-szxSarWKQ{5jg`vj>dWfIDNh?# zQwi~h<@0X;C&n#Qgnntm+XY=+8u-xk%OTKbAhZEN)+a#8z;ikxOZWd+;9z7M{CfKE zVTVrSHw(Ez+;P7L_S6?}{P2f#Svn%L4Sj;{wh2*kVD-#CcD%};4|)1YQg?T9fyeW4 zap-dMqw_&-tjM@Cy2+G4K}CxRBB|Jh>-7KSzC0lH@TbKty!ikzK+eC#izV$vl+%(2 zDnoR>0-Vk*{4a)b2^oBe@H#i+kFuGoAgadODFwV~%FRh+6z+(PJxQE*aAMCGUZCno z193{4@NzEK?nu1NKVz~{X2|Fnqxjy+X58YAcRM}{Pg!F^G+49CPjD3=CVDHFecup6 z$hPd?OY<*O!_ZdlSZr!`G*`dHe1Cy8kXG?LB^LY4+%Ro-G2o`;4ZWXot-#ViF0I58 zei96d1>S)B{*3^moatlcq<8!txA^x}4GjzNPy*M9rm9BcW!*p{Ey^TnF+xWfzGB+R zL?}}B0l7Br6z6Db!)#(gVLBCwJ^m5)6^wRo$q>l%?HtXU!!ju2FIjBx4YanjF-SG15rhzdXREG|@1O8Xdfw!ax z;EjvXpD!4Y!!!Rl^bLnUG>$s(_q@3#S}XZA_=XEc;5h6A60+Nx`c#kQl5@nMAjN3K zlshGlJQeSUtlGy%zq%%Nvva$ONI(RuM-fze5U^#VBd@p#|2}10F?r`@_L@_w<0&sZ z(YS6ES%$gJbFEsDcca~f!5JtQ3{L_zs&((y*7mSmTvsr7Rs}q1xO}zCAQr6RF;2QG!5xiezAAJ9g85=Gv$sG? zZv)qi+_OVDIx+}JX>OV#0TGh5g3kQe$l=vYe2U~Zm{KjuK!08SOqci=lK-Q66GioV z3L^Q{^9`6ns?sg2{1R;%U=Oq~hH}q^+h4a!NzIQ6xc^4`mTRRLWf!oeUx7D=2OW8v zoC{k(-vsV1r)3SFX5b;NVy3o=Ker_Ih_y9BT^pW=eiQgs+xpiOB2@85Z0_RCy%!nV zB4%qGrJp{N8>gu+THS93;P!`JC)z7U=k2UW{<JmDWh`a#?z zIdmbXZkXL6R%WqFRMrv*Azxkq!a!t3CT>Dqy>XR|N%=w`T>w%cHyei}FQO}Sy*xDS zlOOp$Q;<)#MJ7C?)vl7J`Z6Y#<$n=~7d8BVtLsZ5`T=xSIoUXqRWB1;Z6HhU5vz_A zJBHp?)4H99G+a{*+LDmQL1=mH^$(5#$(!SMEOz{AS0NPERnNAKvH=Qec^rk-m7-Sn z`n+*E&_)uRC{jP65HyJoHwM6MH`rrNPqmSa8L1I-6DW)D=d91YiAM&vYh}$bZE7Yk zep1)Ze1SR?D8mb-1S5v|i6qoa_asxJ5 zYAnW`)cvk6f0=IpZZm|n?KnCH_|o~MHhEg17FM-mTErIHmYe=E@KsAcddGs*=iz6m zDlOV!vI?$(!=B8uK$eXLDno?QuT8~bQwELEE#A*(nzbWZE00>>(%LUK7WX01;-#&gdEYAjhVHOgLb%+jmA{Hl`~--0%oBvybUy_lCx>1~PvuV8Ep!5ljqcthK1cD+Rm zU@rZV-Y;>KFm@Le=>%UX9TR#oZP7>IOdKBeHp>!>2k>(_L7uB@fh_GYZR?a7o>` z+M^qdiWk_JIPRe~@=F<06_~1P@ipWLdCQ!9>v=UWn4Xy~ zk>PF89XRhn0NM~NK%JEbK7jmhi$=5$j`ZC&6|p<`5mTAplbqHo`iB00h-MO}q%QSW zU!5mnD((TlM2|LBdg`-^ZuKz2StBjN6z!8z^q2X|e_|~?I{N+&PDs9|Pq32qdn6mo zu^-0V;I>vaLBkrQFtDmZoxALmcuk^{FhE>T=w9=b)O z>#yz?n%c6QXI&wbs1iMGTS6ljV3*YLjrmdwIvT2U(vKPTZ|5xL>h16O&UIV6LNh1Q zZ5CS)3^epj=1mwPspSIKG^E17%%;O(=hOt7T>CfM3j(fnd2JV(NEjH8Mf)|FfFk)n zb$WIny$GIWUQyN-3oU=qTX|8RZ7R7YgN!WUc6$i_TL<{U6Sa|1(L)=rEs68o-Sl=` zd=y(uoy|6jD!h7B60Qss*xt1;{|6i0Rd`6(->rGdYd*=2xEc_teM*eNeTR-BnU(@K z0_w_T7U&a*E%%&t^h(!{Ht9Cu@3?4;*B#{S5$9!MD`d?lltxx0ST+k zk47kOdb&pZyQAjJ2^qOd4lij2x21q)3#UiV$thXQM95p;iX6}w3R>g7BP{9+=m{k# z106)QIxa+H2G=2N8CrJ#uL3yG^402MWfT$uhK6P$Ee{w{mJa@0IcSI{acATWY7CY) zEx+LNry!d#V?RO90V^k*&c$0+J(BO8^3Z9jU!4NMu08Oj zv&`0^q~N;o+-A|qj1&fAcfeR>bfAFzs5;RTXB_EsFq6ub57FU4xAqlZH<U0Pif zuFJ9&G>f8I3?DsNMCjne%Jo)rR!(c1Nv4N%H#qE|#YR6>iVp8qQ{Qu<3JCbK@%aGb)qYlAVJ2q0DQF$@1ogey@vVS?Rb%hI?j$ zgOA%hQ2*!RFT6g5i^4B{gD|Pd?R|22Gk@8^b%fW!I)9kvtBuN6@U&wUrhH9c7w~a{HsI$1BDx#EB`Wk9Xm3L(9lta(=-bKt(%%n)m z>t(04j(QO2oklp^hkRcyCXM`i2sbHJXLpDs(b4wrlQ(1CuZ6pV|I?IRdbF3$*>~45 zz&wXa`4K(FVG!E$SOAD@^iy!<&-dDkOgBOSk4z-JY0ei#&;<|myt@giy}#kRrf&GNZB8dLq%76`4%Olsm89LiXhVRE8rX)j4Ao~FMs^&hCa&Ny z_5!4CQJKF*JWhffGUzlj7@n*?J1ah9*>kDHIm~kX#VJ+M)+U`_guDp-+F@)RPh3){u3)%EY=m>p8M2U)mnDVE9Ey32KMf#TsD>`$ z@SRGK@{Q;joib4jzs)aRcm}54A`#;!4@2JQ{X+(jZ;znEY7KV(h(-Yvx6zyqDl55F zJmKBqlbtbzK~L0Q=~e2qb|C;jy#G|E=Quk!IIs5O!GcMzb1u!vs||^FC^Pa?qM>|< zT1*-0y6#kN1Kng(I8g6Kh^VVIN>9i)2>(+;V4Zhp#&_B3R(SFL&C2O09HBy6<*mmF zDH?qX&(9o<`HPF8A_q@QPO}4!TE4?ECWh(aOSgj|sp`$WTTFg)j~(=YJ5tKQ-_-ZM zjQ97F;yR}BKy&Jgfc9QdF~{ga325OuheI^HZwg6gfTtAftS+y48oLk7Y&KW-i9tmx ztn6rl0DtOTCkz^437tYvqG-aL!l>!m>8y5SdRd7%WVP*g^0O{40IOcd1ZWM=H*Tmf z!7;-k#f-`-@|OnPxY88a#D3;Lw{!d*M-v&53=ii1n!0MaKrlKWQ}!Lb_DU~%`ntvg z(0`DM({?3|8tZ@dY=GqlES|U-{<1 z0Gt+wt7NR18Va(lbF=Bd_G8%AmHpt^$8=hNyFAwop-S!KrYESpoBfxjDF9*kuNlW5 z^R|H*VPf3<4xqQG1~s;Dn`5EvXl1#0B`ZMHYwwe7!3DKa+dKa5?T1M7t|w0|Rx%negu@jm#! zAPm?UwN}CbhaQM5wbE=Ed2c#_Ejn(GW=qeB%>Y%8ldJt95Q^_9AANBcyB=b^yXKPI zWtylrczUS!+f1_|zp(Xi*FEYCjXQnyY2#x2na=6?hX+**$HyZ&_*)j^un5!!c9n3p z3=oDa(cQ=q>H+A{pXc>D(^+$XdK2S$#e(?bEpU2h{Ftg&l7v}f*EGpA_D2#}F3CjC zbo%xVhUW6J?K=ZuVwWKG9euy9vr*ny&Ibt)d018~<1djt=U}It+mR*Jk!}~ZWfqo8 z*(62fwr6-y88H^qGh%Ec4~$ux60n-~q<0;fkF84W(m!(i)JIv<{~t~K7w=Ibm!TSK zGm+rxvaZHvJ-Ut1?A+A>csXPBG>F-;rt8FsVUWG_Z& zhkbBk*?^Z}=XaF->1p&%o76W*!Y($G0i14LOzro6g>kDR9`hKbCaG5J`v3C@vSCMQ z4xLtQo|lcV2f`(UmGo8R3@0#qE6~e|5x#gY!;2;?%A7vYpV=PnE!yz;O3LFcID>wG z$C`a5b{rj>ZtC>~U?SPXVEnj-dw88IQb6&(MPGuBe9jL*DbWraklD}-m5!}rRQqnl zGtpnPl^f#QZR^@2WfPM~gHgHFIud8bG7WD8ONqdP)a~@QS0%Br^cJ4?U>HMxVq~*? zXHDg5S#=rHTI+m1PkvuHU~!8gL8Yu(3Gk`Si8Ie>C?D-Cv6WphoXwo=@ZnO=+?6{} zoMQ5Eg=)7-zt^U;H!uu&-v6wHBJV5AVrYeF-nzC`C@j_@1k!RMZ7iWC)8RoAO(H)o zm!z?8VsuEco+HP^L)K2aW)I?bOP&IBorB9}EqDx03BgjVkUHgCOmS?7Xse;S?k zRjzDxRFOLU|4Z2d$qAEMO_`%I@MT&j9_SMY(&~{6tqRHM2F%7Xi$26Ob_e z1vD;BJP?dy%*3^@A+6{ZXKbawuno#a#EEtyda0Kr_sliN!##-7pQ-p}Jh8Qy!$}pn z_(dR3Q6{3l(6634@L8dxoEa}*rF{`!$u9fxkGd%oqak!cyL|#T8ReL9*Fn)iu`v@k ze(O6lgfsv>vhS}EoBd~W)bT{W>9!J0GGfYl++VgegzJGWC0ZTs*_f4dx^Cmw!!U8i z9SdD%B*7siyn7416pFF;*EO}q-OaojCi=$b-B%8p?Lgd8%D>BIV;I^No~bR@ zqEHJ?M??@xa#A2F!yAP9bVYSn-5~uii(4iqV0a*TFyA#+^b2k{>tH)=OMhmjJ)tGZ z%-r&_dy;Sx&2Kn;rEdlfXY7Nr=#4Jo{^rHPx5N|$jVzB@-g4xL7T$g1b;dRn${^x5 ziNwZO80oRK^APvz-juaR8b%O}cL_z1zc{d?57@6bubv?oj&WC}QBZp$`mJquZ1q)e zJRhq?LYpicOi1%|j8r4WBqYy>K3e%8SpOaPu?yK)H^D0T1QM*{__?o< z>X`sG=fXCqx0_z5Q*OP*i#XdArlrI04C2qRTb122>_JU2%}9`~ekd$i0R)=Or!Qms zY#+^M?W44U@ydpC3x0K;)d4`S==`(@q>XJRC$}2ZV9H7PXwjaC-{V8T5EeZL)I~>xjb8=@8 z0MR%9d632)cB1c#=C+Pk5mtv>xXpMlU?53CX8(E@EyaQ~p#gJ4m~G&+vZg~jzd3}O z5(ALlUpnfW%pxF6U05Z>E5{e|K)A;2cq@z(Fz;%}bwX$;#LiV3hiYkgObox>CRlkt z4!Mv-N!Rx{Ed^NEH!dDsQ&?G*u2{5-r)Me?5Mb{~p1*c(>5VI0$~_dd1GskebBbyi zXm5WPFDg)?2PhTfhl7-aN5MXa+nT<<>Y)Qs!`4xXG$hM?`?v8sa{Ayyj|5iNOZr6L zZ~s7abHN5SMWb;bA?I^Kh7b<Ht(0c9Z43k6yWX-j|0^U*;bV zTi$Lwo8o5}Q!g@)Xa!SSmEziK`_Uh(Q1lb8Q{9K{cvztrSBr`%Bj$19*1~xuDpo(( zN9G=8FnqVBkdQCvXtwa83z{I1$0SwKc!YOQTbS`Ex2Tb88Z`qoG8a$8Pw^$aAVFK2 zgit*OLay+>#HKgM>$tUL+!gX+kasZ7RIE>U%zXlPXVX<=o=aGF19$p#AGEFHT^H?+ zAPCN>#a=A)hc6WOuxDK|rpN}9g%eAvygM+_`vXbDp*vTAMn=AnM%1%{T18{$-UF7SV^7vvK@!E>|O?0 za0mEOP%!KlWj$$LFa5lLNh}>UA3ZuvPR2Suwx#V$&3Ykq^z(|X%l*EMRNMk)dwvzw30OhG0d@uu# zl?eQ~ZDNg}Z$bs-v1`cD=+HySgywG?9~yZ&K(Yqik#mC{DRO>O^>yQ4*oa`96oLMj=z-OSJ z`Xev#mQB^3#d}oXfl0Jw4(FDKPX9EgX=;b>@T?(tW{dVgqa~PRLQ}M2scDUI}ofQE?om zE71|Qcnt7RY#r5{r7gfQXA}~#i7_XKsGD}tP!b!{$4El_-F@BocS<$04kok?OnLAg~eUsyl)2Vv!XCD%m zw&13*!aQ%)oQ%Yrf#V=#9n>Zc|FeA7-fTOmJ|`}I{40!g;Gr1Wz#T^O=mL#esaL%m zmx2gc#q-%6Uez0IWh!nFb0))KeJv18r>rCNDR zFrxx1`aXe9`JZ)c5-%ExdBBPUmAIY56V z>NR=Kh6>TTI8;7Q;iBn?uZG!YgKKfyNNc3$98#6KV}5PkES3Si(z0F#M8BP@u;xEa zvW&HnuyYGL2xspN&CPdTl#vH=42E&MuVNFhWlB zy)EDv_kguf!a4Fg8E>?Q)en{hzU9Y(s~$a9Yyt5yv62}Ro{0A931hTQz?T=LirA^m zPUAY+u*1|-u4(3eLhFUdcGoa9cM+K&20F3Q4B}k1#V8_uo@qHMulsu&g;Gka8nYi9 zUcJ$^+cOVO;tBO!jR}`PqT6E=8P+3Ix7Uo<8kSFuqA6 zW{{Qv&=%zd1*NqN--@_R)c(5KPECXyu0WLe{@+`Yq{E~PHM6#nJznum#F-NW4*$~` zE%&B*r`r(DI&bM!;UaFZ5Hf>zWUiu z)&p#!ru0n_*{(;-cBwf2wg&qf2(;m;axrI5Jw7;X05gCMO2oa9*!1HzYu3p!Yc#bCp=8^R4>?(1tD{9E`4BA0aa=*NIU2$?E7xcA z{cX;oZB%4CJ7o3E3wap`!EZ6wgDNZqmlWaOq za!m%4sRbzDqH}17RhxOl#8aEc70(E!1Mw1*d2}z0z?G*`HV<^=Fb&(mC_1M27Y^l} z<<0d_FB&)+fi^GX`T1Iv)HnL)iJdn9hOB>BykIdD8;n>t8e`rtl=yJ6x7q8M+mXRF z=?H-IYD0GU2`^;;EQ7Q_W~!yJ96z~OmGT)%?}0b^Vvb-2x~N?Jvw<$M4!@z&9aFj_ zOMhB}U$`0=9ZGo`^H=5yZmK%y=1l0dCy0+7P6rJQV3WPHxZ*1KE))6h_;1)(>U5fd z)*hlCs5c&Rp=lZ;>>W7z=`C`bpsmN3Yt7OM2;HRlmScI%Be2uU8-4^E6st3UT9+z7S6+bH1ol3YV%_F8SwZr`4%w_T?-nsVhFR%&H1R3)a-Ha)S#)0;MPZ9XCw)w8 z50DviwotrZj#lFR-ILLNBkjN{0}_P!uPWXg3L=6Hj3!6ws($zhm=yP%h|R?|{hXnB z@eSseLUF&KO@6w^VYQdoW&DxwnWRDhTW8X%483#bvRCrzT+quF~{5@t6qooN+xAxOVj7}k8H6D);2pph~nqrqr8ux6jB907}kJ*3oRmf}I}EbE(Q5LaI+;0&?g!MThAp zvwi>|85>pTCGVyUmWq+jj7C+4(dq>V`x6t0`{$E7RMQD*+d~1lgHq^D)gH-yN~937 z6rAtrr@f@(VtHEZX6<6sM2asdA#-{+m_d>^yv=1#$WStCuVqP78Cg)Uk&P_Ff zIUcdOz&Vckm_zMoy?*-0^GnF~huhq}?ly?(kgb~7q8{64lAE4?l68$E28Yv|5FB9c z3m2#-i{VukAU-aCk`Pw9JoZrjIknV7GQLI5_yYcSI+(mM=$`WOE7He7Z8Dp%My*K6)ecrHsf@W_L}*v5}+Kfa7Ks_hYb}6 z$_YQ|1IT*pzy#jSI5+$Lm*%$R@OE;C;BT=Kvo75C;D+A5r}{{;8vptMp;oA@?W?E0 zZ1eSuq@%m0V0{9}5aBlrUehO&*zjRBf53B5lC1vT34X8o`hxRX;MvVwYF9teralNS z7V@5JnEB;4b2jZ`n|f>Q*WRmR!K$<=jZ^-Ow!|vzogpB61NS{zwb0R@%~RB|Gu&1L z*ahDY`q}ILtj{kCF61kE_(WX`@)2SeTL6sCEuS+YsK z8N4&0#>fcJDvC%Jrj0nl7@rsD9XW-IcOYYKnX7TgTp*t3s&Uzh5U&`e0R3l9P;d5* zf}1E3cd;YCM07TGAhR3N27i(!xgIH&(YtPqHK_M3fg-!PtqQHza*A7H&&i)OZr>s| zMj%1_s|Z(iHa8vWeQ*1|z)K>$Pujzbi@YCfHR+J4Ywv4@gn6_M#Bxs<#VzjSsOd&b z{~>FiFjVy^+^jf&M8v$1>~a_mZ|b5$lq!-y&?C;JwT`C*6tpy zH8ZbjV46mL(4fcbv3PEglmv8p54vnD9f?}bi$DctlY0iFYFQ;8)b@svTqh5JZ`!VF zybJP>8#l+$*cuB$d=bQrS-1ei)yA!3Ke6!Pp|+Zs@5W4FeElrkvavF@jX_Fm!Q^J3 zh?lMk*^u@NF1AQ`8STh-;I-az^9=vQO!;JyUD-Z_(B=3WcLMzZ-KTfr$0-c7!Rufq z>Zkz^D5RcVw~;!GoTv7NlC=UrOoO6lW^sHSQ7jTi8&IlB;S^-DfyTt9vRCVw$C^K9 z%H=M}0qq?ee9545O+X^Y<-D$jYFjgV_<-Hk;6g04yUNHU zdzM#Ovo0gIi)VZ);CDlw|7_?!>xw9Gs0-RTU(l(B{_RSYpAnSI#HuxA^*0lrqZc)U zX+i3XM-NkW3ao-EcCWZ!dZ)`qStBS5fd1u4jrTr9?+QqKRIUoir{NV zZI=uyRB3#7m)x94<#v>wsSNF6Y22-?yD%%kKvoA=Lx(`sYU74(SCUa=S<8t$g}<)q zwFUXJ9lU^_6xX6jt(-h1x9Y6N&_|MCQxDS^QmRbcIOcK^bFYlo>-n9FL;-IR)$~lK zOi7dLqK2Ty?g!wgn_W+wPr441h;%uVk#^T-*{q7|i2ne~q$?4G>5ju52ZM2An-+w( zQ!L#Y`e}w))xOeKpuDfoPFnMnz58L)VAalPr0EueN9J=k$uV++?;+f`FJVEb$Y*=0 zlrZd6tT=#FKsN7o;BHOgZCfs-;GKtREeto&hOtkJ5L~gSVad&9mPtgDv75R5rGq-i zk4wHRC!Yq!GiB;IoXgraula`ev@en5=tT&vK?Z5ZKX25wkjP?Bb=fh4T|TsjMH7u^ z7$enQD^;jqpL9Ec8zVOi&xe2b9{5|;^aIv`){i~CGc4&YF452z#sF~AnFv$t=PL&U z95yNVI*q6+IZz;$TodSBoCOUyZwYQDa+NJh(5AkGAO%_@=_C{=?E z`{uSjV{8>D4rq*vN8kV{TX3%cyfv?~1s2r;bd~+k*O>v33P;*)+^|eXN~R+I{vJ55 zBR{sTE`6f&-|U^>S;AyDQj~7=h!iTiWBC|0P9V#f&f+Fgb+RN9&3c`jpQ7**sj8Vn zsZs5tiX$>*D8Vm8$6GjSEq|mc%^)euOSv)jY+?>X{S79rukL^l=D1sEss)e?-w2$8 za4a)zHBX@lM7uR90Uas0GVdd~qwrIs#SU42g-S1sMJN^m0+8K+l>U_*qFtVvQtkMq z1?`TQabggw>l!v*@XsTp^>U5O$Dk{0QKJXzujZ>FY-Qa(gDfy{67UYvr)&5S%D6IHS)I>8X{o0xcM8(UNX57 z2%AJ$_Tu+=6f}4qB`iNf768V7u_#7B%=QzO`_`?Inrdf7)z5?quXWrXgZD@B=063< zl?nY&9>FGDlgK-)LzSY-mulZQ;|cHolXm7}e(-lX`z{b8s6!YF(|`r1Mkt)@65#681-q48?eH8$55#UCl-sdB5HZ5`4-Kb|+1 zxh`NZM(`zLJ5;WNy=0~sjTIgUMM}3&O2e4Mr8dp?h6NbjWlO_iomzAkg|JYJtBUKO zr3=Fz0DO1xc4@#Ds&S;ZzXUmbEUIC>eSnrZ{Pk8&y+kk*qA3vA*oVfs;MeTxq4STY zVm^EE)O-H4_4!bFYwjNzuSSP#nziAdE3hgkc8i`AH&cj2vF*NqMKaCvSnMFwjE8v6 zyD#e8u-!o)eCdq4&JHS^YXd#Do>Wf3J+8b^k?h{1==QZ~%OXP}q&)i2O2Li0>%F>` z<-sgKXLdAAYeKtNH34L=@*H+V-lBi=$d`!|uQ2!fPN6V-4597BkzNT|PXM0a(7{sr zn0TgANw-U@>W4ZLjS3YqO(TZvM*z~$xjiX9oN*V$m_+~~9j(bi_-MaKE$nf5SpCj! zGWyWSRrJ9|Mjvf%PALcl{wW2NbTtuf=7b)g4HZ>%2o$y=67Zhwz#k4GXz7sHfC_8k z{UpMkYnF?kunBliOivlue>!S;KYA{7@w=OWWyEQ3dCIU;llR*Fd9|XuU(^L0u2ua7 z)7Eu_&#*imhjqLTg6(Bt=H9oaEr?^ntLduFZ0>6Go;CA(rnH`Yorr2dtY9{Z8i8P@InJND2#w=u1G{5 z4H~;tWAMR;S>*j(3yFV}DZ-bQ6r6D!HD*W-3+-OM0e`ZvwyXr{a*J{WTv6?r8j3;>{d5 zxg(Z&awgL5&CHWYZP>PcVZM88Hb$6jpR@}~XDq(Ju}~hmxKQ84`OiJvY7}9GB|K}# zs2l$_BVu0PwD-*og}4Q$4uX z*q?T8U`_Xp){bXER2TgZK?DVkr=yFhH{IViyNGs4pQYTfhx5vIpdX4p{UIu1!he`- zXqyWYnIHr~KdrJc%^>u6mL0F?#D{sA-&s%KT;H*ia#QmIaGs(*H|N~mdIML;{s_Bm z`>2{OcG0|Bv1u)HWqB#NgKDn+jNz_iK)TfH>Xs|sKsqm=>Mx?tew2(_{y7So=oLlr z%gwRg>7j>`IIqq(u)xEB;S;+(sG_y`XCJ^IwGO<3hR%+V)iVJ9d%PL0NyNo&@EJMx zEQbk;FOn5zymBcnKj7NFU9z57RT8ue>*+YF!Vtm2U0guqL+az2wlc5U^6N3+QATlD z-7;{GZWh4g=GN1gSN&nT&J$2fNm1h&466!C0=k^}+WR9^V16*^r|2nFl!<(EgJ~&p zWT(>~8@y5Z0BRYh2g1|-jHb$q{)rlix-{?*Ri z7o+)t|H-?}hn#(u#Vm!$GUFbM8`ZGItyyVBb&gqvl`nTE9M<6`;=Z$mtmFsFlFh@0 zw$SDknPH4fg3~Ym2D&$mwUiYG%1HbxNhFsIdiqx!fTi9E?}YAZFHF4^0P!2=a|9EH z1U=8@SF}C<5Z}NoBuxSluVcKilkK!3EGHN!)eIHHo$}}ElmXs`@v4l4)C1wHJd5*J zZnE+k?|Oq;JA~_|fA|dh#elEWRzc*n5PNBV$*3qPrkq*@g$5BmuC|CH4MX+$bhBA3 zw927dIGD`ZsD?akH!3gN7~P3+={}w_J?K$p11lO^@X;*qe;bhCfNHtk)eXdvwiI-# zU@3%M#97u^PZbI#IACFKrxcI4R}qGRGBkO~>^|M*R*WJc*Z}bO4|~Pga|9ZzFURr_ z$%ACbI;wor5CWnq38(y>kME%}r5gB9@{;xas8`4JMn>Y=7vlbG&OobEjj^E@qgBAh z%uGfLAN8DI4Wd{8GP&%Rp6TY{c&;Tt?Sw&WcnM52fn-R9~}c(5?*t;6=iW7|IJqu@c6P{L)On@e+b6L6V&Ii?nSr38z!!Cc|O0MMX=x-u5JrLm;csuaT zHOfh&X9tyGg1$i-s$&@fX@MDT$I3wB=+r!6iNmjAXyB$FJSm|adw6ur<0^FZ|8(uyS+8>)UCUxxsU&om}gG!3OaH zz8OyB$z2SfeS*+CXtChod||%aruqUk$b)uH*~cy5Rnh;H*<$Gql3WhMHnBta!uXts zw7k^#y)*)qdRna`I0xwu(9+k&(yO?amKLc#?Kx35$FP!D%T0{{vxQsywFEtJQ+sfZu&`TW4SKn#aoOhBGb>8u(%JTdkd@j_ zeY~N=TGG8Jr0WwGOS>M_Mxi1`Cv5m%G2pdxowYaA6=aqB2w`>Jm3mGY<7;QCd`eV$ zuDtPabfhgjQZaNPb?h$XEyEcri_eW4I5^g2Bwx)#(Oipyn>GOWJX#v}5$pNyr4Uo8 zv~xJ~8K%VLs@7qnrdj#MLFP&?>lHLc50wo@frzjC9Io;v7IIRXWk6JlLVNUXv|ju< z$2AjYk>*&?)JmUoFea@g>0Hs>$xS2mH(&2zQgfgAA0|&dG^CiTtQ}!q0hfw2YRiVJ zY&X^u*x`ym&B;xjbf!09Z5rJ^2-CVR^JHL$=-kO;|CahsK?#^8!IVbNH+V-3^~KVB zD?w2%DJ-b`H@kF9f=Kh^=5;?%q8Soap$x$7N0-_M{mVb)R1$p*Q;9yYMng5+rr*?K z@Hox2Hd%8ev8KR|WaF;)KF4c?Q5|NKFhcl(?77foj(P@il7U%ye1kTY(Qfk|81Hl#&h+Swvcf!RpLbj2NyxNhrb)!*l$>J;o5q79^dfz7AX;Qd|Ac!aFl&jj}Tl9(gNJzvo@Pr0cqu zEN2IZcs0W9fayeeX_0#ro-m1N(IYk$!)*=azAL8w3GVkjmvd3 z0P_pkND!<4y3Nl8lB~yWh7IPDQAp}_eMDkyWv4*`Cj!SCYDS=ZsCOvIE&j_)69Z1N zieDnx@i|ZM|B)~B)mN&ORkc%Y>dZ>{1wZ^ zu7b<1GgEojcJH}qyI*y%+++s5)yd&DC#&^*O*uA7UZDy_r=5U9zXZ|#Xj78WuA>3k zxmO3DSPP|2hgV>EES_W#k<%f)qOkn$ZR76wjdO8*Tta3B|E zm_Ux>?uMOdT5~s2LV%UXJ6QONeUTm&T_~1{ZC>>j6Y)vRtXJ+G0&P+hOU| z%7~-OAc6rb*lhG#4xw(K56kLFsgXuS%%J!L9HSE349x}!FkA;SeDy`V`O>=aKelWJ zbpXif20sUxyeRe2^n09ZYb)N1O(xEiT{x!Gk4Kvrz_LIVKH$}zCKEiv!A?Dz%{m9ZN}|&lvE|abIS~v#(UUJWboCv zI`m{O%<%J51l*uT&!U>x4jQBad0g^F-(4cFj$rt50tec%-lX@u6EDWJW-=6?i{19c zbl@B$$hP<(-coj7Qrk*0B2QZpSWHGKFE>18(AiloC34F<_8y)^qH(g#fHt9*7_2vi zIb!stvQ5p{N@I%`ETkU+;?Oxoys};+7}z~6)LJg~-jbHZIH@&RjS zkX=WtsO3s|jSh)!>}v-WEU>5*HyFKwzY_3f<`)Q5hW9|BnY?kL&#|pgBU_!5Q7t_HI>MD$uK>Y?5 zcb$xWE19mXeo4{FV@|_=19cd6H!Ei=r66Erz5cS|aediTJ2D?Plaa75$TQ}|vD%Oz z5pqLUY2txdFn160+JV<$8I-)tJsm7oi{702d_R%rH!w@L%)yg zlm#y+SD7sVcH>s8KEa;iri!$3IRM^q3Vw7?C>5yN%2f-(|MDIKfkeI{)>ELlJ|v}| z?!NEWl(Gdnuj7v2-HKBfnLFx@P)EgLYb+X$>>hA)Gf{CAaJTP^6dY1}uL1uBj*Lqi z{&o|i53LsKk%0>!ydU;2TadDuR(tq2-_^4~7R1!vM;hl3kHOOa z$ggHHj6coFpr5bziW}RfyO3LO7Z4bii7%z$q7670C|Ca|=LaN%!to5$Tp3`0p?l>% z*p>0P3$PiozIJG!&~c6hgBE}oK8r9Ju9fn#eJ~0~sr{HWn&TP;iuFs$JELj%X}&Tf_HX|b~gsVwhCaC88M{_o1E7i z6^IZ@$328M)f~w_{&$NlWjO9bF?ae@H%kS{_S>; zlvx5$a(7FzsDkP$P1+`2ENTyZNWkMRH_tf$<}s!_MGL#-mH;0aMb;jau1_Mda1$T+yCK_6Z@tu0ufvjy6>iHh zBH|f%0h+>a(6K>8TE7XPtiypAmRbyB%#p^kmSxwuyx?$WC2q}U9m_9Jn%nU* zl83&WOO^;Us6&$kNTu-88~dq}g1sm(#W&}Auhk?(RB&$7w>hW9pG{94qWtiNVOmJk zR)IDLPHa=&_7B*^Wk(0Em%4*1Pv)Y~F_95MeXcO_rw9^xbRYd$0PB- z-iHN|SV=n$L_A7wQ8AKtLPv+xJJ?btn~H0Uk(_oP5yYHx9Lk0a8jCRx!0qt2wk5ZD z_uyk;A;9{kREb|SgAJ5TJx;`Uqqb7mkkmnu=yYx%5&ewcb069R$zag}p zpFV;9iuwxJx3S57V%R+_?Y49c9QfijVZRzn<#({Y$e=B9OCHc@S4&1R53->R#CiPaZh<92nTQ66Iz=TY#;p%Nw>;%xa9!WRGwRwV(g=mMH+e5*F3 zbW1rZ4a&SjJ>Y-;IGK>`8zEi(CcK862oF?MT&FPd>w&f1#^V7Bt_P96>+5Q}u%jCa zrXgpGa5s9)VD{)lr2u_qT*YI%YHsR!q~U9Plx;^N%m)*ogPy$C#D)sGN4SvRB)yvM z-0g-m2VO_=rIaCvP4GeRB0R#XSi5>|4|w|RYgV#(#f6J#isA~c7;i<4Cx35r+mK=X zx+U9ylTc}!(5U6%wG~tGOY)1;0wC>#e1F1GARsBErzgT1o9>L@aSwu!dbM5v0)(sq zM#DmGsnnfvWZ~K3OImB~$E)UR=6^$P0rpQ^wA%Ul9EmX7$)uw9;|Y~8SM+upa9q}- zFa_grEOayr>%rCpv9o^)po4l=cYXs|v-%de?IvI^88?^c6dwHrNS)FRhg~9-wHhuq ztD2idh;mbKod*3@g5|M(6T(#BR9HauuolsR0LJA2hAyJ%VZ4j=TVyaHtihdlWJ;T& z?4W&=PO(&!_hA0p(x=MceXm1`ANlKtu?r&4p~+#p+5=hZx+Au>ia6atA0V*y?qP2%F?o8hoBG3jD|2H|5si=J&9_b$XT37{a z3VEnA_7!VYA?Ba4A$s}a^uSe)Y8wiot!MmXHn4HTH(V20XDzxO#tkYcj)g$_lO!5> zif@7XGo@-dHV7s}5{PFB{IJUjh`ypcLexYb0?*r(P?YuI$TN-Y?0j-#dETsM!2Gj# zf4AM`UCU3-1JQv#b5D^wSS>cO3lTkDKj61jZ*fS6ew$*-CxDvM_~N9Rx)rrM|8}aZ z;2c2*0v$JSPnc{he2XC9>ka}Vu54pMac&d<-?>+DVpUN|R~`l;EL41KpI^*`o5TUz zaB-hKt|m3(2d->VF)gAY+q96QtE+4Eg&HK%+4uRjevu@e^pLgd5xYgDwS>Ire6MGg z9;HB^E6zIQ$ry23Tp#bX)lHoJ<=xIUP@!t6pXSW-q{+e?M|w|8L3xSD0B5@c`OsUY zHYRY*%onY;xHJ9wDxbc@s8%;4t&0uE-m6v;;5%Ha&F#cL7BoZOY`(s3F;Rc zC_28V^&?vtv39pH#j9nJQ(Gjk?gNcWZtyV>LM7G8TDr;i>eV)oIZboWRLr#b81=l( zaA+zK+>H?ivY*cs+WM3NUUI-wmKv|}q`s2gq7@uRez%OTiUPO%G8k-bb zq_sFH+Z~i_TVz*&4Cm<&BbSZRFfa|HZ?uxlHyQqC?{h}UWkwYrds#m1lm1W@$p)tH zQB2OwrkG(U7=q`184$+xRg+4P<=vC7WFav3{zCqWX{^tM{rV|YZEHZHuqOcXP6O=+ z-2BUR68fj$0>AoQb&nge|ORKcMP!}xfS zE=G23FYvOpy2HIWy|+nkA?*Nm)X;e&H=@xWUo~q;J^7!q-LU<6q^GSK7pE^VA6j7sxMM8N_=<|%^ynR-(oMr z_f8p{PnX2BhVtikk$0ZcXlsyY{%Jwy3)s*M<11t!8tq(Z8w2<#U9y4hs)12%t*N0J z)*I@uq+vP8c~$U1j*&~a;GyIZ5_)#Rq{HsXxgeq(6#A4mcdZDeQL53#2jD+puc%~e z!kb~sFEH#qy$$NY9}++a(Ln*XI|E5%?$-&Kf}+xOqwYtvqWyR8JQ#Wsug}GA**Lkw&3Bv z{OP3qlP^N@re+$YX3>vJp*vmkk2EG6)XU>0yHdAD=$sP*U z5e|@JEqc={(c2&)a!nQ6MiD4NFq&k$2EFUK`J_~2TY6Nd8+>0wzhxV;X`lCFi_wl76%CMxC^;basaYu-Ayy?xo{`)~M1hoX z*tI2qBej@FcVM|C0)~2_304K3>yZZr=&j|r-W3-XC^ z;ZQ6MW<%NhJv~x_KuJjI$KWI&(w=ZleYOkrc1mX$=g0QAFPzxdVf};fK_>{YK@^>| z^!FhhzzXi_BC&Q&i{ki7E6~jbaSRjOZ=p*Zzty#Ya>}fzp_~*L@?B~+pPdSZ22?ls zfEB%HFYVh0RD0TC7t=aF`4Q7c<21E?ud6$Zk%E(N5S36!lVRCekfGqR5j}hoT2#;! z&m5=7q_56^V zRGBNm!E)d-dP4C42GFfsMb$wtu!2HiQ33vfVM_%sbkcp~AQ@CpD|y|mdS4LS&JKkW zUKpeG+tZ?q3MrnRX=|1Sj$TITJQiK=*)ov~Uvz~XbVA&)p~6NQaX6?OvJ7saQ}WKv zeLzr6?9OB+-@WTBYUmV@-sH~05YD#FY*Kshlf^cy6eWn;&+C=Q zyGD?E<#_UffUQK_mfVLr(v68yKyYeDyUa5eA^!NIs}XVzyD-kyI#*ZBxU(?V@N(F& ze%SWeT&)>K%Ic84IHGRO#+TE@5(Z9W&(xvyor4|c2M#P8AxMOgi@RW?J*#H1MpSB+ z*#Df^JZ%vybsEG~X3MK>{u=(+q1#P)a9|PI@IEZ_x%_q(b_}Q1`3U9?HJXGpep|VWT)g{T@1id%hdF< z@>0Yctw(o$hC6M9T=5_A{TC^Qs5pbB=5LwOl7wT=Tz$MW$!aZ~XE(9jx(El#uh8GP zZBd-Sq^eCPkR0w2Vr**i^9GK>BKx`(#$vTR5&aPQN{k6fjP`>vGYQPt2Q`3+_QT16 zIY0~hj#*jW1-7-=1?LH-rS73s(ueGxa((b3>crnYbH=L?}3$Zjcf zg5eJgh5lHNKqZ+sI5c=$KM8?4sHQz5GDV+=LIezOEW8Gc=et_lK@+K;)~kHw19F;y!6o8B8+YE7;C zs$1fcT_WF9gzi#C$Q$N$IpKCJaT;gYtYA^fxJ`%bp3Ss8t_wJpxCCZPQ-xc?RFcPT zb}+B2W0e5 z!*N^A@^hNeN}U82Y6mxuGJ~CYA8$2(dG#jf5YlDafz66!U#LQUfkC3SK9iF%De zl+fcpAA;Rl+bhi;pp!=r1Xib4HiFX{N%Y>z|Aw3XjdhqT5-r^f{*F@5w4P?#fsDt9gt zbHn{MXip}CWaF;`q(6TrPOT7dgX@<-Ej=gOT6hKyswuWFE`_N?Lmp_U#ImxXx;eWy zVuS0qLAWf_eW;rS{&J7Fp>tKgM^UQ{{zc#YQ7oq|+xg)E#W_z5b^>);k~;Th@hPNl z0BQL1g%m-pv2nqT6NjG16X-jG0%vEOA~p_sZ*@Sge+=*xQbe1L+O*-n2q5G%|M0n82U=R@-ZbqfXK)77$2NPJ^411^O!K8 zJ84+7-5KAtC0;i$9@@kzjYWS$uSdyrw$}enexympinCyEUv|K~8$m!Z-xEy=QX~O8 zy-qZ>(Cf2Im?_38NLhy;V<=uo?QO@`vJyGPBhWLC@QmiP7Fi|vk8z3tC};=D=bF!r zt~KX?=v@jO`F1i}6}PDkEtJ3!GQcb$2ad5y!@+xziSx_a_etmSB6Uz}cBgucK7rD~ zBwz2gBHYw1)c|GNJcALlwh06k68Uwxa?evelBrM6F)#qO28O7;Jaa z{`&t>ye~auUt~5wcmINgbttF>F;LR>16im<#sS@8IT!OR_wSfWFK3-R4 zns9Ozx}59VaC6dFHB54?V}YN{pbdK?%+<1Om&b*UB+h4W`2tB<-%8+RGKfE$RU zrHPtbV8m+h`J)g?fKVI1cfYeO8oVoD^OT;4wu1vOQ8%=)axVgk@k^s%ewZLasY@Wd zbtnKYcejEaAwRRgIY-Sv19E(bJ)%@cAxE~IP@C<{E54RnBPB5k>UQ2E8ZtkrM@9s@ zCM%y+lvC_0ngKpA7ytaz-&1c}janOttst)9TtJI`?jjUI>-10&1o z8hzrdGoz;o8 z>h26q_S;TspD@Z;V{?K;u!9W1UFvKZ(Tu5|LU6L9p~$;jCCGF(3zFzo;!e0J9CALW zB5`g{PCuyJlYRbnjg837F%>WK3J_2QcF#oHiwn5>YMIFc(NYL{EZ@r$lxZV@3*yR! zp5!>-m^L@_NckI=T3VhA6+!we8z~{r_q6d1T4e;C8=@E!V1Xb!e2U7BM;*5yaPl9; zKCH?~S7Hzvhw?gPkN%z5dI%g)eNrSdziM>?OpZ@La9V7t+y=JV79-w#y`89)v&Gc~ zvvv%rBm&ag7>i+cMT6WTPLF4`^8k$_4*p)>&SeLol^(y%z6Ze3 z46UBtzwxaOo(b&Wil{%EvQKKiJyL^G{5o2qd*FIyW|7XeI7aj3ef+M}d?LyuJTRY* z^oC1AeV4d1!~RqW)uq6E4p8mi;N<+UrErg3$_Ko{rkV*O6x7hstZ}MX5ua~$Nc&c8 zHcyf%p%R0~#FV-hOtI+MAoY<|iV{(W~vPHSVf!@Ovr?_jkb9 z;bMJ1Qe4ETy{Xr{x22{STG?Lk%1*@eJ+8~uTHvNKkVZ4j2%f)Ds7xhzT*Ev?muUA! zmoP!&J>%~zi*um>#l|?c<8jq~IAtE4FM%5iim(5Rr(X!}{Pz3vp+^Nzt7^yjVRk{sP#Gzp^Fleek`xBof5r2|_Ez|@ z4ciQk0E^YxfuS(C^8BDDm-2Sh7|;oMP?DsAhtxndS`gl{cwe*@{8bsdfX!AaoYND7 zSrG;-vOBRcF_}|XOEeG<3UQaDXq~S;_5>AHG@p?o{Fi9%fy1Q9=S0WvWFqrCU5;x_ zgrAUG8d7(37*d15$2<50NPWN{{o%^66Z>0L*-&UoH~IE`f^c?Jb}PpB;D~a-s;0=1 zo||q%Tt6jdI9K#u`C#5ORJ@LPfmP`Q7xw*T&Cp}QT%|33F$lI4 zr1Hq#lT3|j`$7BES(Sb4Ud}(dc4&+`4o4*#jDjZ&as9NV)opf>IBEY8;a`M-fe}j& z{Tx{AojYO9q zp5$UV2-{!RfnYo)Oy`Gw(;bsRpo>>VgSH0rCqlyTt#FWsY@3`bj{1u=yZe zjyVHGej`>FU&kRw5rG3+C(tL2NFMT>rfE_?poO43XbHKJxJ1QxuXFxuJ9fp+H9NV; zrt3DcInfJV#3XB1rHQE6sZrNp7Gj_aAfgdfI~U^e@g=#Yd`ZUF*d*j!?SaOL25qwx z15nA-!O&>iWX6XD6Hfr9mC_PNEg>(mX#=YYc=KL$Z8dKwKm{~F0|ZDmSE&gBeB^_ zBZ-qijRXL&md$mGP#RN}1(N2tZJoC9*`GbApX3?jx=FE;4{=EfWQllDC3=__9AYMw zUqE!Ya!WnXV1ZRc4XkxpnvWNYEL*{QE1#6z>bSdtf8VK&(j4iIDi!~?)o{b`CJY`n zv|FOa7@;FKc6#=Qm{?f~e=-?xzwS7Q3lmuVR}yQB?30q6)qhpqXiDo#7SJWE%D6R8 zYn8k}cEt{PD4%nt4}v$T$wU>p^j|+t!;=sjE%va{eL31120;*)&4*|z2Dqc_O?HIP zaA5?#-zBYY!~4R0OJI??n->maN;gRb}Z>!=U>rbr>L?jm?mooZ|maR)$|ZG zqbZ=NhF#F_LM>#xxFjTAH-E4nsWSRI7g5>HQ`M5MuWr|> z3*&6={WY;soLG~s`6v7#d$VlLyKg(o5K%|2jTHF0I>q{tU)G+no+uRgMkmzf1A`5S zvGw|Ym7`B+)H{M;$YA~|^{eJD0IYi~v6)N>*4R~XUEK!kU2DnxS6*bGZ*HFjyMkIi z-=OEwjR+B7=Oz_~a}$%?wVcU2t!_{c6far%mJ>ze+{}+9rnB`4p>5l{=&0&yPfQ3{ zHv2uaKwE!&8Y&R-(vB>2^flo}UXjZo)iKseN^HW9)c}y$hjMTL^BK)m>cd@;3>^eQLW*qmscU@aU}Fy7->8mm}<-4n*+TW<4Kn(m8DR5f3r!1 zQZ^(5!8&WqE>R?L5OO-t;G7{1e5N%jgYgSn-dyog3K8v2x4P2~dIM|FnDd< zSG%+8I#RYt#$9lnqSRsm@L`+lX5l^2VQnlouSGHvrOZOGJ~hV@s~oGqNlnVct6M@- z7B`#CtmJL`4}wYPmMj)0N1Ge_qLRSm^)tU?jD)wUybJO`RR@PTT*lJJc0-qmqL}`s!w~<^u|FmNev_!Ro}Jwk>Lb^&>yP~_)P&W6b6(|P|@yhGQeDTT1)E)<@uM*F;6!h zFkZj$r85}#S|$2H0$qZV3`v)%!!Sm0t!fWL%__4v&XCHm0`hH?!5~=PPy>|X!glIu z34S8BYyV%<_q1b7UqjQw0K^C9-2-ZZiYKUT1Pee(h)g+Wr zWER7~P7Rc72G~RuvSw#w^7c0+0)AGm3~zT8-~0NK(bs)goAY{RW=fdQAu8spaHXk2 z=z0qZK->Rx)LL;U1@aW&AC|gi<+)yB)Tg+v=zKt_gIXFa;mYDZ+SJk?{G|eeAboDH zJGxD7aI3taI0Jp+5kiF0)jVX=&E60a1+-9+wOvQ*)%sZdgw6i0s~X8fm7vYwiam*t zzUJAep>yOV#j`U^bZRm<3`7laR-A-Wa-&_qFNuY?P-6i+K?RhuWk1F$Mp^sV^~F4t-D8Tdl}gaKZX!-_!C(E8#A8Z2CJ}#FW5{swm0EX7;T@k2H!vNm42y3GusDKJx`iwm2g8a_w9;?ee z%b8pMQLbyb5@u%8UeR(M|BwnI+Dc3K&ggLsr>FN|GU0<88rW1q`=HnM*!4y)D~d~rm4pgn zvA|^%9J#vXSqp>)-9_-_Lx8+WOOc(Bw_Z@*of=VT=f;Gu5<_Gq{S*qes1J)|CWcPN z$-3)Bky*D7EJC+EjFW`(RrpDZEDAvc1t{mK(}vHxjwQ%GtYaT$9;+Q4H_I(s6?nAy z|Hr!fAUPixbNQ|y@7RO#v&Bpg5hD?>=L#J-F>wP=;qTeZiJ8E$t|UzqUm}nmSYk?O zOd~w$ZYLGYDIZSxhz1tlKYXz38+4kq2g_IUTMZS$S<(+Syy{W7i zM*t~4xhNV1x53TENr*BTe}MsSYbCVHZuXRRfu0|zVz2gIb>WKtb}{IVKM3|Agl0=MmM9JMZeio1N)7>BsDqq*x*#>)#=7TCpH$ z=uV{_Y!Ol-+l}8l-vRU51#OvN1kcxUDJi8E>Qs^4#R?g#{Gb+(s$Xcznbk8~&LO5f zu4e*O98jKw@WR5LZ7HJ%W&s5>R$_W$XpTRl{Tz|erAcrj4*=kCW-hx-H)6BMf#4$w z%m^6gQou_qgD2^|;qNNkaU)$Yr;gKdq93HHhvH^%oK=N!byC)d5&FE^BLe5l@jaM1 zA_OF^$_&Bl?+ZyXbh z*nL?Ie8oiI@ys-{L7U%6i-`BZmvSUu)CShP%{8XD)1myvaR~iN^LZoEnG+(}ym=dB zzGPmxo;V4QfWFVG9Ym5jDJ$a%J={qd1(u`fIe-*hJ@iB2l#H1@(Al)jOhXE@8S=?t z^;>L0WlE*%eU*^jP)q65;`0e;<-Y7k)#~EQARLJ$%p3lw_l+=ZjRMoQZBCwqJyEGq zkh9&u>^aG+vM7|l4+QixFua%Js){G#qGq+4ZI$*fQQgHouQ776gq5fzt1Fi3mZv4yJ}b(iq@P0t7=#ltcDf!WttZqfoTC9jKD(b z6=r^t{x%NYOIZjB)YsHrB(a>$O&AC>q(f-y$cpsJ;+A-q#rl-7*m4apamdNW*{-tkYJ0=j|#0(tF5kxyrn=jIlR!9W!Yu)hYq za?=67jjWxrGa^GlpNJ09F$t`|6C;MU>~atE|CP5x3@zIbWbHpqpzxJ|=($$!J6Hx( zG(|mxXIKd8`#SC(!s4Afz{n~(+1M!pkqr4i9Iq~zH(*I4|J2rID{+<^@g3n`KVke< zj&^_R5x>Y(v5eO==a=1>(yqo|4uhyUAOX&S2Cy67U39QX0{px}q{dWf(~ITuF>oYG z-$tY1$KjzfB`NwzD=;aMUaV2Vj)Vv@$kM~X+wj%RSD(gRG?-H^*Z$Owb85kDWO^H5El1bebokZShSSpn$#iww(=sEuudT;^MQ?Q8e;#Frlp8G`yYlVyz4UofM(^{dj}1iWtzJ0}1( zUvhKM0~}hOM0DEo%)w>{voOxwZ?^iE((ZYl#W!oU3EynL$EIPGCS5ckv&au*J%fm1zLT$xM%E20r;z8WlR^*4~C)Mm%ru!_eLoIg{$1S z=A&{{*eR~nU=fti-uMZG7U`uZ>T}-w|M8IAR8o$)Dzd5J$k)Etii;OSf98E-lSNa` z?2z2h8djGg>&ox!rHNAY_pVk?`>b$#)l_|dG{wcz|89ul&29C%Kg(Lx zOQT*bcx*!hXtm|4imOvx^5u%GDFxcD`xSU%N!lppDI08sWc=xZFO-M_!lb>9|0_&x zaVJ2!8NQ|=mJ+gHcss-SOAUhIJmOM{y>WmH7)~PY5Uo)<`s}{kmf|Hq2?X(Utne0ioS)Rc|5s@`tdO^< z>q?x|7;6ljzhnBGHf)cB#jB+5V1@cf`9*i1nH~Ns<`t7CIJqW<5h|DQ9mCyf5k(sP zA~CHt$O0xGAr?Z&E{wKCXb*tP1>J{BX&ADXFLB@(3jH9RTcbg!n(JtN=~(zthk+rk z+|jhDRD+1DFr3&vz%dxDjhpQ;N(cf_Jj$Pek23-1o0#7IYrp^0`KJ)}3qAC@Z=o*W z(19*HWV;J8yNyHNFoAdUv-EkD>vCr}4?7XEIWnVhF?!AdcT^^6>PMMuP{s1CRH_4~ z0bdk6NF=7OhVaAFv!=H73S`WOBVH(%bW>Gxk(E5s5rm3jIo5bM9HCS*|(1X!F{p|NWjvn%2!8y7GXAnKRX8D zftz7j3s$$UupoM1GG(!Z=J8lZdL7zaaWZ}}zw~x6iJ>ueJj|T4eqg$pDzo*(aUfY)5k;7Rl(7&1lP@u5bDM0a5#%G>4-Aw2z zu*ryIQCW4|#p@Q<~^$AY_;)X09?Cnm|}Z1o;U_;JBvL-fL-Sunf< zB>zlQ=Ekr8-vGxvpc-d#XBuV1_0+~qR$snFc+PhT>l-odJI9DpRw}YSc8HmeYf*vn z-Qz5w0Ec}vH@0E=O+V->F->lyC(KVt+Du=_Vih?glCsr^O6wX^L&qo$(>sDuiE;dbq3t0kB_lx!jak&>xhA zC)#}9S8+>W_OpwMloM`)hl`IdP)4(BP0m1e@{AZ~gK;uunZ>*HLw7W)cbFdEIOJzX z5#r5{D?VI*?+--3_mZuZ>%-`gZ(zw&6q>Q*Na=VyVUCSzxd>NL_nj%7^=?}NFQD{S zT(Qvh%yvVTNSOH{!L*)4=TO#Ec>(>$Op5=UX{Le}_wZ?pShuIw8V9sD_f1XGd{za_ zhfXYShhfYWfu7}2sY@YO2EGalhb0=7BRJfaf_~^0L_3jG zcvEVx3MK;`5aVuv#+mIG;#~>;8JVKbDeL%-m-OUA66*|v)acv&>e|h-1w6L4*-Jc$ z#(M5zj#D)m!PBk7=I5FWcTc^qj=xzEd2eyod6nq-d^^<$+S^;Edc)re)$6_5<8|(V zwD{&BY_LV-9<9g`QoObFN%3WCM-@nr>k{Y8R;&A|ObuIeiFD#{kHR&TmgP5r_! z$kEgMQp;s#K1MiCB^|WGEy2DMgZ0hs3P1oeih)v<~3U^y4pc(1Mv5Wt0;ZDiwguW-Ptrvm2lJBukxNjx&5XvBT@804)2HfygYEBY z(XD{qmGJ#1u6Y=n!h-${9VbkPJ9v5=MG`Z( zr;IXmJgZhFgXK~4c`q!CWiH51B$Jtx@>m~!H0@s^?#cAu6es^z7hM;%bCn_)6#0no z4E#9WRQEw{?q17J@lV-coOxaYygDfsvOjD;c0VIk zVw!>t+TuC5ISS^_8DoUzhrh3aczUynIKf<-i_PPBS%Vu7W@e%tn5o}hT)YBkwjs!x;t(X&Z<2rUkCw@Dsi=-DGR=}PdLrtaT9+L z`X{vl9pxJTggM({7mV^or%hmjjdM>fI`FNc|8haQ(TJ7Bu~9amZ@qtTtI8{*CqwG= z-K!1baqN##F5j?*%Ssr{8q1-xMPL|(d_s^0QQe&aSC>lpGS<@nalL!%ojijb$``Qm19c&CIa$!&7s z+|j2Xn{S)5&E2Ppq2TOw-Qj#l%Y%2^k&Z}dA=lFbO^6V;W7=zUY(YV)p(3!Hj@O)e zYJtL8)qGEowleJX4`*R&H80!dk^b?x@5&^!e{_-BnDJo6Ad({D=8-9`4_NJrRAJWY5r z4BoL%?jcrwa| zL+2hN;W_$bCc~!3(+ZJQ>s!G#D2rc%uRoilP{op&t5%(}>mNg}uoVIACQ`a9P}dVO zi4K~#SS$mhuhHlYew4{FCzudWE8LzdV}|7o9BZuP96L^kyg9KT?xsyWpn#lQYLBcq zG?fol?}}32lO(Jnim*mebT51;eKb*SBfuCl_I$HEMG{aazn-PpI2uV-*eFP%b-Vuq z zED~f@o8J)q?UDD&Pq*l~NWuhM`>HTu%4|<{iV=}*Ed>3@rdc`vlNZg+v%%V5k;RAW zH#5O0hJ@NpcW6@t?z-5E1jx z(Cnu!Ure5POYDn}h)*Xq+(7~>eANo=%GL+AIw|+4kM)~;pX;)saktKP`JC9oOwG>+FDtMVE;a3%Ii)6 zYNV=SE*8C~U5--u#Z#(3Syt?GwjBxYEQu2;3QLJ?9^FT=^!~mqLM22y8;7~1?+SXEwjWI+E*J)Bj=PxOcUusTBm(F7Z*H& zz7@?i`%}Hk*XyKN#0tP`T+zk^wSd(j$D`tH>zk>i-49-G|10s(j_%sK`dxp}_6~~E z!Q^9TdI1+kuJ03)jT2^L2=k)F#uG$q*O-jaI(;yhQ>E6jBLj{EaxY^{rQY(n>2*f` z5(M(%NRI2gDgRx2=2}{aC3GJDTedrARBr5qh=+w7X>nmp2b8G47nCV_#0hmOGG0n+ zn1R8e314l}#y~3;o+f3{(U^=NtY#*8oChWf#gV|ijiK{FF9g5A{ym}UhX&xZ%c9N3 z?XpP$FFJ;l3tw{`Ue`yRsmjpHk^mUod_H>869F8OqWa7-uYtN0*|u>P*Xp!M zehd$JFo4#)IWEV3=+ERm97|@EL4Jpe@V_tk8zUHGSX@uw2&Xx)`wbkcKfO?1YdzXX z;V@%;tj2lh2w>`fgc6`kei}TR#SnPfi4;b|n|a|*t=@fWNxCeU4ZRqY^I;zbX3C}6 z?D_*n5AX#Ny-zED(M0VU8Q;P>C;ci6n{XS!g6*eVCnzWz+;&iAZpV>~?c|FOTZlq& zxZ4BxIG!G73Wj^DMSDFJTIBZ<>#3_8o< z;eK}?I^+tR;vV^|DhJ;oP3M2l(}$o;gyQmHX?YnVn=zsRr|T<(e!r z*4w6)o%egq+Tg`bd0Tq|`8-jKC|05@aw(Jvbg+Y+&7x}1dx-ZxO(f4_MTZ_QXK{qn zpU9eTJE|6{5=N?4)w%*$pk&SScC}Pey(fe+1$PO(rPwgFt!&r-ps_V2zws|4S1z_* z?8j1yRvvEbX|Ku1-T&EKghP(R*0AUS89%O9ltTCW4B2{7&cq>m=C)?Hf8FABYvnjz zZ{8#@)Tlur#vF0Ns*32iBTMj?)V6w;w7%Z9VKsEbf zwgYNGnC5gzXM1z4XgJ;iU_*N4T3=3`7PD}?tI625D1mH_JQ<)TCO_A9HaZZZn4u$G zD7Z49sxc&&!2)j!W!O~ODBgaR93c@zSuie_>6*D^JPNBAAX%D13s~~CEDQu70wgIl zZ`3pIt02A4s9|S&Vh5&x1t)~-DyI&7;COgNk$RA89yC3BJ{vDrCvp)8+r5b|TC5_| z$A-c$vUVVMnApZJP#E4=_^OEOk#3g~o9czEpI6pwI&-Ay;B>&hzj;QcMHpK0wtU#$ zFGv=Th=HlHZ=I zi^DeyE+pf_f78ALy3Rbtu7|NRjH0M1mH|JoX#}MzD|l@(I+wzNW^e-UoTCl`Bc&`6 z`9v&0r3YJ)6RIcZXnN&Rs{=EQB5d=jOA`#$)_YoIj08P`d7_&|JoPzeJSKQnhv<+v z3h6-3K21X$s0+W5q~6PZ;gLKCEx~A{z|--Dqy-R`kSJg^k-Pios;Uh)nfHTMLB#%R zw?8fOL8ietKi-UES5rZauFDtA);t>vdTPeSIc;6=0OK|Ds;mWoF@G9F++{5IlQ@YdBZnUfVXe! zwECQoSm*#bK*qmM65#*aW8Up?Altw|1=3ViR$z_*zShoBqMGlGJsIwDp zX!mz2+imQRzU@Cl2~~(|z^cO$=eesLE6jjUuYREx9ujLgGBsdI;3JbC;z;T$-e5T0 zKI}4_e#*TA*K6KB#NoykC5N~`h0VukB3BpN!81H}B1|Pb%?#~DI~XP6pxomkY;+4) zapHnpG6919(PEWzXyECGwhVG_ZY!~BRFEODi(3w~Ypb{;!in^j1p{D==$!vhMSNt0 z5vVCNOhe!#$tUz;_usn;r_Dk#JG9jbHqS0KIFmm6gazJ#jRXGt*=Tik1szeX71Y}# zCQxI%nAi4JVwq{lxm8V%eMmd)=>NzBohk3Uy(N8?ToljeM8+RFA!67jKen^ZrtJ`w zp7diG#4Xsi#tr9A;$n7OGS#j#22K3bH0EH1sSu? zEI|=(f4n@$8;_v95BhVeL|Ui*a!Wya4nzBuUlvkJIh5`4 z_?z`O%lWs{(TKybOPz~J%h47~_oPyJb)B(aD4K9)JPC{3RXLk*YY7q53o#qd=`Lq& zzta8;bm)RcRY`#M#zyfdQObUjS_vAiLwnn>ZWl4l9$P+IOa)Z=XQe>(eQct04o^h% zfN90p|0X+&K}k+xX)v>?+Kb-Bu`c*?1OeG26kwaS*euqOr(uOBkRV+6s8-l@WO68tcHIcdT$%c3W(wkN&vz9hwXHx3b3)W@RlLYlEYh)8Ynh5+IMm1xk9^P7lD zLiz-#06gp#^&7Obbr^X%!soK@M+`cH+WT0yT6%JHW`y_$2S$M#A6!+=0nZ5^tEJ0d z>U+21v8HDtGv=kIDnZwNh#%DB_#l)=g4bMO;Tk{52Yf{4s;U_25~dH4nX94o&OXpb zZ=;h8iHgf`Eol4~4#7-nleZY`X|U@|7-_s#M^M`6VThW|0S*M$eD9l`27?s#u^4Tv znBUZV{wNp;A)iRPuK;KX#AnJIGFa#uqfZfBbj}C4{1|i_`UTx^^_X$(Z`Fo-A?%xi z5ySLQmrQ7PpQQc&)?@}EJy0mL2gYQ%stm4raMoqEBLQkfdo8wq&>=hw1+l_R-`UXfls5v=>Q>i=@$WlAh<)&bmpH+o z>R{zMkc_ro`iBq0nkRHC=e6R2<&uZA0?i9V;vX#dF5ZFenf=oSyu1oX0DP0cdj zwRdi9LH=k-?}DX?(C9@W3;EioSEQXrezQ5lB|T`Eo9>2QQKjVi^rIsuJRBWxug zl2>C&gKbzUb2^`KlWLwfUT69wMMX#xI9^JAm0|H_W`R*yC?%x%4coPApoTwqaNKd@ zo`OZn5UtmFhN;5@;2MZ{)gI`QXTfni3%c-D%DA|npJ;_WAyN=o9-#Vr1WmV}j#7w5 z&kjHcHW8*fYw$`?P-K-TA_qZjud+`dRC8nc2@x2S*jkC9tVGHefa#WoZ~l@e6TG8r zX6R4vG6WHt+oWDbzq2)Cx|l9)bj=@O4|23+QvsoN%VI2I^?YRN513`K%WrNvx!{^u z_$BMT4qQ!}{cfWJn8PdY7k?@;6)T!Nh@{3RIu3f$-{wSm^caQ<-iVZ{85*#>D20m# zgH5icLX&MTq3U(Ix+)gGTWnSpxj7Ljh@56cLeK)RVSW+dxsB4#{o4!OfN5CzLg|nR z#}JXJDWtZ58Y*mUkWQUz&kxKy*G|XV;WNxf+d_7OFIlk>OrHcv7$kCnu@7FC|ExbH z@Tm-MC?!PT^I%59zZob_PwX7Ns5bSLAMZ-V0+QlerHyf?7_oj_zY2nS`oZ24gvAAV zE{N-x`!3UOm?%LQQBEd_GqE{Nspva_Q#mQx!j#i_o7VFI*wSzS?FNr3+_+vg8dAX5 z{6T*Qm#&>A&t003aJ?y$>~+GP8ASGbsGT7Ho`P)&s5?g1F=hD+q#1a1O zQHm;1Gg|6(%%k`U)iEK_fGf_s@kJdaMsUxnp(a~|SWx7w2{t+Xm@nc}LoGR6mY7Ch zC1EanW+-Ah1nmI5)ZdXx@mn~|2D*JsUS2T7)pY{pEeAjQca2*u|cNXMdo(hjD zM23FBRa$=N&j`u92qIz)T=8DP5L97ff|z{61^w>E6i9?sV*W+>cZ;MGu=+0pI#o#0yaESEP)q0Z3wrVKp5g%k*Q_gu)l_<=G+BDecchf*9^$B_m(Mo zi&kVl{kOGb%!re5QD(M(7I5^H(Fzx$=vWLjSKWc#k`*;7dfu+vp$dPIee1 z0U#MMb&@U9;5M_oU4*$<>|`oFZ(q8*AKL>Ke0`M_BvvOdDcOByD}S+^0$K&cnP}!a zdn_#m$;D3?!P;ebKkJFHd!Q%EaPMzVM}IRBrvTHm?`UVcIZ>MzivGRzm>BXWTs-Q3 z{tkP}QP;OqF{nL}jm#w}+oe1HBTLZ>-i`>H$dI#FNF^E0AfcivkPhlHf!3}9yx*x< z`211JHk=tIexml(aoFBKp?K#!%RjBclP@r9=!N^<^>}^{DP-$x3h9+Xlkka2jFNOE z_S!{u;nNLuEUQI7HQWOFT5pVwC2SA%aAISP^A>lThpB#JAybwTJ@4?m?TA$Pa1Tia zG%`F-;L@u9c-hdTC}dJAa0mj`a80dM7YZUxK$7n1`BFD~KT$x@gYCCw!4WSYLZ$H$ zcoCbR8ua8;#V=yi(*Eoqf#CR(n_sQjfNQ3Ct&WTv(~Jh} zTY!A0TMyR82>2~6tRjqhHFW>0{#q=ySAdV!K85EYn2efVdAj0f1Wf+YMyxQ@RDAB`N`<4$&V+G8l9vChApow63|%*Ro~;9@kvoD z>F9$TtlBw28G8uiF5=lm)vHm+r#E?=?}yM`{226U&DyCZ8T$)GQGhx~T5+|~u&{2zjvmoR>0^H8jEKtO6TdhaU1 zRh4-qXahl5xN7{C{q>Ak8@TY}HbKg?x%wu7sI6kSxO3!Drba~X7~TF`Kz z3=?;rI$d2LSwr60yM!a(e$alyue56H$uQDlS$0z`fz9@CC8u=r6O}|%BUG@IJA2Mu zBkh;ckHIa8NZRQsb1N<;hIK%SqEC3tABt%S!@wMzq`xy_*cg-LQe|4t#u<^9E8cGd zW&t}%pwxG0+c@*gAc;H_zyv-F=mD*xEe+|UP*ne?Ai6jqtlob)^4#WC%A2g{1Dpxz z+b!8~1ZBMO>I1BK=s_@Wy&i`pN?2+CU*8kkgicZZ>##kjz{2q7n=vi=gx5Sb$ZgrX zC>;J)+?zPtZhtGhmOdz_!gpMjr~7`x5d+(q)OJf!H+k*?6x~gsmyi*AdQOC?>sNs6 zPWYS)X`3xDYC3rE{C@fDo0mS`noU`qmAF$rv{mgWnj#CB=G-1x2n~6SwVYi|ii8H8 znCdcJRxYr+(4D;I+~J){OFLf$9RK89F*;F&Bu~YiOwqU}@yH|&#N_oQrpw~5*kQ4P z(7|z&!*;QM#Wu);SQDqsKMPI#?n~>&sAq1#^!doZF=1WADRXm%-RN@rN+<++GyiUg zQlTKh2n{p|xT?kWSZFYGAWa%KlqyhI@w7~;%Jufch5MOH8x~mhXd1Ib$=4RtenI|x=C`8PIrBzn1dX?s1R3)mF+kKBhkX^ zn>%-S)Hj5NY!+n;_5$Vf{k()gbsHxEao(Qi4+~Ng7E@W%-VASWCS|5~)+RAfV3QXy zTQ|5DO*k1Ys4y3>&rfDhVqZZ;cBAf!*Sr_-EGX~d{1!9uB-*Njpoj-y6nikEB)0uDSbYRTwOQ^OP8jHuEiBN#rQnG+YjAi6){YebN;iT`pPR^ftBW~CP-()1Id|B z<9%GJE#$rubj<&lN9ueO_)so_P%{rm!U2q;o@6rX06J1HyI7t}VrdaU%_3dt1GRkj@q=N|R?NVoxZko%3&wWoS~&c+ z1^CFM=hjjS(Ym7|ip92V1cqc~&&;<(NJ$Ns^IA-U3?eHyny>-e;#}{^eJ(_dglu44 zJWNx~0r%<61`eCOeSS6IjdKi_mR|1p8ZM(7q#j8or48$}mI}CIm)m)6QzCe^GVyQC@PGAE<@u7No8fikJR(1_3&*bF6e9XK?p~7Dr6AgOQMh6 zx1tJ0autSUdVngb6HU!o;j@DT7iPdI>zGOgPxUU2)kTiqa;z;Ta85LaqVfHGRPKs< z)8As2&Ik>{o_YanW6T|>0)kw&Rw0A%wpJ|Tk~n`<#pw!6jAfETeiQ0|{MISsRfcMO zLw!}uYCV&!yHEL98!Yt4KTqs`G{X>37u6yG7@P-dm*K3;L&&IwmL*=#|x z6!;?#t03i+45lVvb7V@F7FK|%)6k~~Y&^Z<+jDC@lAN-ON7#Izg zR;JrQYFW2pi;!)AZT7O04*5MWvA&d{M8sFnTUo#%%a^yWb2~1krB5}?OLsQM6z@jW zD}a_gZX97@Sx7u}$Tvf>1hv)Q~CtEux9<$aeA`Y`8NBb#djuDyQ}2GsYdvwJ8%#j+Sk!&jGCL zVI_~?wiA-xHy9EmNA*2Y1}J|>VVII94l$S`RU1DNiCk4+_G^OYar#Uj;g=Qh|`ZibvSx zP+%T5#(=v$AN*l9S?=t>FZ94~aVT|-Vd;|JSwi*Jp^-ladA)q?nGwp=KC+<=p=mCE zLYT#K{N3r9wGX50TS}RwM#Bblej6UX*Hr;^ z=`)M1Te=<;ac$m|VqHU|@2dhEOWe`OQu{IG)D*}C$j1S7&orW~mPedQ+28V62rIT7 z2-P^UHV$?=#5@1LoZNWAJ6~Yo2PwNg+$+(Kfx`2E(JFE484orGy2S)8%=kF~wKWqs zho}^?cLbgvw;?sdCSaL&P3%trZ8TpvU<%D(+7;)llP&+=H6#LaU-a3C(8;MIE{yxw zni^Qj7Nw3ND9IK{cGZ+hwKLHg%A}#@uM}BVi&@XYKe+9lalcjse0aIAfe^XkrJ@R` z#%toQi~rpF?=n*y3}FaVa@i2nJhjFr38@A`-y@UE+OMnsk6 zB4pqPx)m1*P5oI$C}U-x=|Wr6fUx!l`WTpo{cc*DNu45S{5^aN0}KxBZ2>0Dq<1bt zuBW#^`B_hU`PS-ge%OP77Ya^cP7$<(cN7+vI*~Z-lMtuHCr!?EoIE}x+T>dVr&Bm- z$k9XgQ+#|84c0M!iuGltQn%3sQVE^DbSY+H7n0&$A17x{~Q<_nO7E&vQ{+BA~k3pat3+@IOrSHALwjmw(CC|uFg|#H4foP z5m%`AkSd7){Fl-F#u=e2cjkJPM<+QLnOF}ZSU0ipav}?+(>&a!9F#&&21>za$}S?C?7U_S2K-O4P*Eyg9yk4t0nn)lKxHYoZL%yCR*v#Pgliu$1HP?vOaOAtG zYjO5dw2yng1PiAaYXfH4U`s6%+VB8g|A;-Yp~mAptF@GHM*YSz?L&4T?e6+(!WhC* z^-er_hW=9T{4QLSt*amhj?hg_!@9mo_dd;!aHT)=OwoF2F@LIxSc`pbNTNXSGGk#&S-br(B!-TrYy1BTJIHJlc&)smO zQY7UFu$9&)hBhqF=7jf}&feS*7+j(uDdwBt)UX=1P|OvD#}y#E0mj?%BOPDV{129k z2VVy<J@3Q)nIwY5TKrWzoT`TyFXI3sTjo*+df$N4Ikg zt80Ipnbg1>Iu2Aj%n5FsRPk?#CcSH|=P&&OhZL+3_x%mHX*Op5<|Vf9-yv37DQA+u z;jo{(N=@G#&)r$s%iOaovM;L->?&a8=AjwZXwDJQt?`|j`JZepf{$sjd}Q$T^&qg9b}JtTG$Dkv57!kj9>5> z;Ypb9GfIsI`3%D{B!g1Y7YK}f12=7He+!Y)Dji5BzR6A!N$srN0?(^yIwz3aks0R_ zZOAEdHmCz=KJzfot@1x9$&c;@Sr!AKN?F7xW9R z!2vk*l07f7ae_;sucHA)_HSU^p-!G>CQ}5E`4obCzT6XDL0nPJDtbNv;5t$kPt!>c zC*;03Z^!W~xnR;-aqrxf@HfI&xG>A4_R#zAoyP@1N?fpkrYyEmGZ!0N3g(Kfe(tZx z#qf#Ugcj>%ml*2xCWo=j2hvrv$Y`J&D?{m*&MV+|Q8W*BB11I@3@SX zZWXX7)}QE9ChBH`tl;`~=mmuvua%{l;cF7+j_W?MYj~@CkHv2m zf2TD}o&r0((fYUa!xY6+&a1~8(w>$$Ypsp(f-#w|klRf!KJmA;#Ao}r9o798niW;C zO&{8YK?+NhXeF0^r*4`_NZj3lndMFVc#QRfpeqJUJFkIcI)eC2SJ-uqA_AEtP3&f)N6) z_|h!i{ymurkoI!g6OX$!zJ2(nc6-XMV9fl65fLcvs~Sj*cFnC;=J&=oF8JmR$t7q> zQ142DiY?4)z|d_z+7b!_EV6M!7G#qjWDl>I%IV*$%iVj7%q}Sro8Y=CH2R4gCm+0` zMqBnfM+~p7a<`Dy^u&bwwtSiGTqfZHU4o*(GA@Nv5<70MKkIO0GJt~|92Y0z#+W?s zfwmfUk$-qz&GawpKJ?TG?vTL!2-XZAv0kJ_#st6`%rx*a5r=niz`VzG%2RkS?hnky z8i^Nl0Gw*nY!rIZ<-^UR*jX%6;=E14<>>xslPrE#@9)eO-5x>ZB@p8&n`8-`0{u~1O<*@y*W>m<{UnWRj)Emqr*u}B(z0)$ZEeN;CX$OFbCe(n9`MERf+TEp~6 z>+0mo?R`c5!QlSf%`1vp(Mk$*&xKfk9P!t^7k=u`w_}DakVW+R{EThW$LXW$__0TQr=(HbzyWn?h2`HUUY557h>~_gL`SUJFuL50or{O=*i(~T+~m#9u?#IN7VK+!AaJLLCHMtfP_8lk5FSMB$hy@ezQP>?8W zLoCCh_S9=GW~A+m?f|cjdEVJng|or8>OFVY|L_RPJ@8)pi921bTBx6Cog1MWslP0A z&zpPa3`JtqdgZZG_?g2IxNfhr9{oqs`RllW_E*NsEt5z}^;Y?>Avqab!Un8TIDn2g zzz8wpL|8I3D=76$T10=*Y+iWM1#-a+al11Us-! zMD(T$pH;BSbftJOb}NtIktq5x!T-T$(?pa-%ooI?U*~`9gJz7U({0y3v)b0duWnA^ zTBxEtM5@b#;SABCnE;T2S6l96@vIKBr6E&Sx~oa@0Fme*1D-e1IDX_gQcq z`Zi3e=IsT?{z(0fmB^4tAGNGT8s|Kw1$&|9DtQ1kJ_y%j4`X5YoL@nuQG_-)*i*)r z&Znhqt`Bkg+>I8eSipG;G68!mvN(R?p)Zd4SZQLCT;}n@M(X183y-^}_KZAz+J0ta+-rMOroEG{Y zvqmI!K-!BNQxLNgR(dx#lC-i8Ifxygq`c$??>AN!Z4FkaR6eYL!-bYtn^)_`#J|da zZDo#Z&5)X?hw=fkN z!_VSSE-V9a{26mlKStSW=BEA@i8=f1FDgrUVY|1ec`6q2{ktrb(& zRHrHv%dsJQ+(|l>z5P|+joCwIfPML$izXCk2U`EL7vVo!LHeR8)qp`?FHEJ>!8S`S z#%_l`T5g>L!0@p6a#yU(*E4qO<$1JLExg}c7eo4}H`4wV=JIe}W}M!x7db>IiS}N9 z)rGI`-!6hYc!iPII7ReLjVg1hZk=g4sKs*Fj7MaBH>Z_9`#BvF0}2JuSvm6!kg=z3 z3h20*cN(2LgfYf*xkdD(D!F|U7LU|wn7d=I>jo_FNJ8j6~rZQeki*2m||4jh% zsv9TzDf;mx7ol($EYPd^Y7j8SMe@dwl<=I6t|(%Y1A567FoZYrNeF5@*Dn%!bkoDO2~npRM`|05c4}RD zKruT_M;)H#z(balbpP{A``2&z>BT(b!BBx6uMv^2BT5qwQQj+%;V~&&&nb0B%c;&= zwVWLUsmX3&dCf^^W`!U9PCr3}B@8%{6Ls+Lj(gxI2Oy1{w8KE_Dlkpv9jd+w4&?l?q?a_>&XGz*{@`FX|K`le*(VC zij;mg>?;)x;iZa9+MWE;GU5r4d$;gCnU|7Te!(Q66UwUISL~C=ZKD=_ww^$$?(_5` zfY3;*x;x4B$lidY&m_S!D5oWBu-qcy9wtn;ofry>L!A_25P~BF2>cgNV9t>V$Qoo99x--u049~-{~sT4`59D zCcw@_Ckd33IVhxzZJ);gCIEiSf1j;16KXLA9e6J1Yl}Q2$oPrZYo%>s^@;6__%tYJvxE=O6eZ#-$dQ}E)Pn5 zD|MLliiV!_ks1Tp9!UvibGQ}dbSO=+)M^YjstgG=Z&9L8P?T;&sG5{QzHwQWVU=Qi zfTD^Oze>;l;8{@@|HgdXM&N@$!dGTrh|7H*PqAXstrCAIw&|KWaL^fZaf?4_Ph?pP zx7WL6w&VXr&3QkDMMIwW?lQCzjC5TDyOeOSHPVbI{CsJ4l!& zP@q2rb>t6korvUVnLay5x9#>%J@93!;)QxoX>a?s_*V1mwz!x~i4Jsva$dK7FCqUt z>y3RBlmd(PjeT(0?^ISd?jOahL=9IpEh*vmCa==c%1I^@kyGDuMPMGdrgZ z!grVKk>5qy4N1siD*7sqZ_pA{J4^0jL7vXHk}t z^XHv|K)Ar|QiOmuaJZIcFJdz!OpQ0~@E_o0LMK2^51V4uup}L`08i?nxBu*TmHJuv zhxPCrt}G!bg^#rPE{8bwf{;{^lO#I8AWHOW$5**1KyClb)BuW`u1I{Ui~_my$H~$7^iA>e4ogX zIUVjNm6)7*%3liIUANH|3E+d6)Sk+zku? zfM?|nu>wn`MpNk53wLL$%91K!Lnr1;JC|aqq}(TR$9bpC{iud{X2Pz?A=72Ff?glY zLZU+M!4$^P!fc#b+)3MGgv^`sW&RO&NwRoUy^6#W)DrCebKI`z&vPgyGbU29Pmhah z^>>pCn8O6*>RDYK`u&a4-N}=} z`P{}AG43Sq(mQHE8&p_@Qj(JrHiuB@J9TfjiZTstrwo&m6>Ev*PNu>cz+tqV@LNCh z$ofEqqtPR#gP!=VWRWvZm}G)7RbJ&fQ=vuZ|8C-7v_aac_Kf#Ov?`xndKItf>6g}M zX@m>QSVzXj8LXP6D+o2R3KLlIo)gC$&D56Y(=jOG@E>+!ZUv3sHi0&D1fqt=ZkK#% zIx3jUKlVYC{R#7`o1E zby0=xi*F3Q&;jPWO?ar;fd%OKf}1W+wUA;`kHI&K?~83LQ6YckyNx=!ZTV?QgwDVx z{@W>}4Y1N2QK3$vZE5zO%QJbW4Rw?Y9PH+ri%kdtM2t*M6xiN)i?Z-7m8hyOw_$r0d4peLh&UtkbIS@gC13;aEfwJ|ly?4v#0 z50DcZs9n$l@thE0UJquZM`^O-0X&Xt#n<&%2`bHdEYm8YnjkWNNm6 zqA7RqhlEku$n2=%N6gGAT%#cQ{UEHcNq?LSQ4l$jnR?jTs;~nOnYyx9erhSN8Rp3G z+O&!fN^yqbf>Q2m3q2!(dX7U9zW9YntXxk&Q0|OISX+CMvpW=B0jKW2 z-?th(H~Ayt_r)b+!2$$i5>JN$F+@>jl-A3q>O7Dc1cmkrt2nF&LAG%y3jw4eiUl^@ ztduhfGf||m#eF+1phik-A(NyoL-@pOlJ_F<4f zje9uYOvc>IXJRz0W!dh6_uGrFJ-pBHsysQhhvs5`#OrWi$(8Vy^!JYDZLLM^s?Ix( zo48(dLq5aYJ2x~SE8ByGsh=PL4q<$S)>g&I95g3t`&4{``VD~5<1{2d8DYKjh|nrd zWBnyYcPsGmUW7e7_Z(4g?N}>qV14j-x4N9VeRV_(i%W4-S>Z6?{crORs?c~ZyvX47 z(L*V_8o{jX$zEfHvY<~MIK8fz`!R72sDfDNqz~WAdxu+Gyc-mp}Y8X0`hll*I|5_^^DmUX36bk>A82kA=mFYb(Tv|p#LFFywn7G8B z+R584-u`G?==iu#{T{pmrO9y;M4U3XmME|b5w1$kEAxaD-BXXb+NqAbHUe%2Aj}Nw ztVceUC-0}etg!D)3?3}~*)#^t3Y974$r5SY-$qCGFZ;IFmZW;_?&>T>FbXJ9A|4gc zW3+TBQJ}GxW`C@WR7))h8E-Ly))E{N8o}x^NJ_r3Vjub=x`2GgdU@Wq2yKQ?@DbO< z3>C~)J1@~u*QjthTIeD9dIX2+sCwVze*Na{dn3$X_|~(6y5&deJpT#0kRlFk|C^(R zb7mh7Bb~LqrT>$x$0j7xp`%13MTSLpl?PQ=6|B#szjRC~J!iE=K_*qTBBewcrSI zk_F;CST!Kiv$*w~irk>D#YBuVJqN+Yh>EKOuLIV>7&qS$N$=JL)QkRFP+H(Sl)dL( z;ULM@k6u3Tyg&6pGBkbA{=ua4BsjU@b@dr396?lzlH6EIzI0dHafKKA6p#jNjfi^~ zZP;J7BjI#sX0sKHZ)u>6~#(WV(OwO2&_9)0*Nc*aJP>1U|0WGMO<7f$&Wwj8cD%+1IUw zt==qJD!mg{m`d33@yWNpq~ZsphHS$Bgpd7M&il=yZV7x(LiqJF>C=N#7i6;~gL#A1 zRh?+Ha5Gzh-b-G|E6`&uSdR^H>wm@YH)In6^DSO8QSvBG?!gl~L94~K6E5=> zA$U-ZIiRUysk!sHdaL(=W=x;J^W1`kCbsnswXIM_*8k=7cR z#k`pHr%ox)5alI|L+KA(;{&(+Kl~aqSV0{ZAL^wG#KX$+MB+Si3xYeO-OkFEHLQudHDZ7=RN6sIOt8AY>nZg%7*l$E z5SE4io z(6}${*qA%E7LdR*OkGRUw@bjTO(xzR@wWZ4io z3nVo3+&8MLrQs(vMd#$Oo5V=&%z0cF0}$=EXlSGO;wqn4*@n&Z|21io=$l{5{#w@Q zL0fG$XW_OG9W%|;SySjSAXKVTuP|+W zJ5gkA)E1)P1j$l1DL49=6bIFB-kz(FC%g=8>B*iq4UW0nYG6%i?LDGGS5qQ&=UNI4 z4}6H|NK(4-^S{2M9y7xG1{cMB2h4&!=UFECI5*vJ`KE}XH|d-70ZrrDL6Us{Iq+UXljMaU8wS^y|Dwjme|V7n>?#BtYI^c+)R;f|x)%d@k9xk4(`!T~7G9t6h0JI~@) zoTLW$s(c+WKZJRyjv##G3~J>D!dF)ewubf`Ra?UtEtXE2QHf11M`Uyv$DYFTztm3p z#IKf2p0G#|C65Eu><_O+eJT3BW+9s#HQLN8!{7M!f4TfNpEY#`= zF#2gSWDky~NX92|iTJIBSU+=m>*)?{Rt#&DoCyK>)2A?a;pix_C`{ zlcWdbmR9TN1uNb&Tae+jT6CDzWfoe{XT+Q7 zZYUXh)IrBI*#i+#3e+--3UamiPHaZVUJ6*1AD(>mu7;R%`*j->Hq_Dyf^qeK6besL znt-VBCrzJ#L+)b-1qBkCz>~rczFmwsAo5UCCRTtoF^=PO6y2M9kho>Kv)>D9El%&LlPErw>;<7wEeFa_ z*FW!ao#O}b*|8jg%&DYW zAIKOiGK}ffWE{IMLe|*(&nlI34vh2dsjPm?u3z!p=T+%9>_TdR24_rOg58WCIW#~- zdWlA>;X*0E+dP^4xzUhO%O>7{c(>2ey%s}+8PwN?jYtZ&$FLWX?cXMv0J*)eYSt>g zn=KrEA)$$6iLX$>sEvyEI)zs?1E|$R_abz7Oi5i12qFJ1{4)OHFGeedq=Wh&Tq@V7 z4%U?UxxdO-JxAI%^FBRVu`j*4Q@q%ov<^g# z`sOzG8*#u|J|wpYL)-X!J4eR5HP|+OdstYVhh5Lm-AN_;e?>VPV|UzO{6DxH!cv+ib0^}MB-c*N+QT+tMzqaEGcr># zCwu;0PG+u+%a%oi)|oaW46ni%Z#$ru1oDW7FY@{S`-hFxFBqxsceDfhH;{x(^~Ce` zxJOQ67LWj}h-8&)!(VjKF7JOrT&~lt?B*a56>MZqLBgBm*_zQF?F+dQfW#Zi#GZSeEa=O1X

5|_-0*=8fh?H|~EtByr-Fajb+ z){65=8CebJoUBQS?pap^TS+|S;9Y+rSHHGWSNd}bZSmH124aa*NN+|#4%0hR{3gtQ zJd+yJ|IRnFrE)s}gXEE6`}j;h)RFlIvsr$3mA^y*inW^^We`i^)k+m!7|8c!6U5=D z+tMuw6R*=xacMtti^lpXIeV#N#tg@F8poB$tspQYQyjYipnB>DnJ|HEzpURgotnyO zS__+xCcx*Z<9}yNm`B%lzR6!&M`=@?5m+aX@}v8Zrc|yy!10F`mTi0&JJyGy-`!& z7?d+zuu5f|@?cq6CEhNwS6yFlL)V4{soajO^MO|o3A^ZjhOwSMZ9OogCqO8nlm63-cFOG?BM^->Ku8At)O7I>CltQDh976}V)q7PG#JfFhDs zTlG2iCA1@!v>mg3w2a1UISQLoI=yyfJd4D`+hG_&0e3dJ@o(b=({*v!(*|n_1R)er}X4 zfxEF(HnLc2-ohB|@l}@Fn0{0Rx=aAD?~qCiynpP?{mL5`gYiu5?Db&7oI;K*2l!Ab zU^`KaQV!EU=NP!J+!co0PVG*z6#HDF}{7>THHW5de~vROTR@A&d`u9tEHn zpNZ=+bVD>;H{wulH0WW?8!vt%2+ZUT`+2ctUiUOhIkJ_lIgdQQW1LT)518+;A5R_} zu4!vR*0*!6Q3z0dH1Loeh@^F{`@~08#cT}LeMuuPj4ytdu^9D9_>5IE*ZJ-C_2>0S zR;>-8GtEk#Cut$zpmhO+4CIFkUUPOuu>A^Wb71W&tUNeULI~P5 zsPpcW*Kyuq{yc7}i}O@l`FE(VKc1Sz0@-%rW=icZ0!!&78f_ZFkTk)p4Xk=H(t#ht zo~)r!R}{)i{1g5T3?99L7hB zhpcxdRnAqR!W>QrdlYpYyvy(mKZLY0>;wNRk5#?Vcu@uk3JS%0>^|;7nc702u1~_P zu}}45($S}TKyw7?yIbK!)(a?1fm#Tip=gU|czsmC%>t5DI1mOaOTpB9RbguDb9D3u z$`(5A^qrl_y?Qj%Gxxs!qtfB90RuDq%%LYantLiYf1v4&s5ENuF1FQi!&y>7kuxdr zuLwe*$4}ac>gGYln}~LFiKwX*ir@ljOa#BKdfXkV* zS$u|v#Gk3?Ku7Qd(s$ORt{p=Hv%g}W-s^UNH^r1EQ}LfdNORO-*8IR%^oK}AfbHkZ za;`qJI_mMxp6QrbyrWTrHB6zputDuJAlD{XrK8WSJqFLG{{~499M1f)(#WwKLiC~2 z0!n6~iI84N{J6y*AGUnHb4u!cV7uWRx^@%3iUQs&QqPy}$ro)T9tUc-P1fL<$4b|` ze_X60-|LH0;Ck&zi`NL6b47MeSYN}v_s3y3#0SWOQyoO_b|(7#FL+^wvk1i+VcBLx z-|km~`V$fGii8%fJ%Ol^0o#^Fm z#qc#Y>=ROxV6uR^6+74n9q=@@Vh+^DelhzQ7iA9r01m0~IeKHA50^iyvZ!0qSNu}k zC7+G_fle;#?^5;GEOamfoO9cNiW%aH=NZ))WJ7>4;$zbYmkwnT-ElhsoSniwNjEcN z@2ug;QK)4}+`H=5F7x1iv0+L}8OMjix={4utBjBnIFn}?Zl5Wv$=RZ=jtx+~>K%+M zeg56IgR@@(yMyXia&6(b9w4pb>XG^CdOQ=OkdG+6kDoHI%(2wGQZk%17br2V#EAlo z1FO`!Jg;)CfomBpXxe545>fy__Vl#qVsp%OF&B@1&u@SqxG&-)+)Pt+7yM+}XJ;Dt zP=6#R#D%t(6zpr)qQ!*#$DOV)Xi(hiL(gTyEzTWsn`5h~b|LPHI1+;5s&ubAqH^aw zuSBjx`Ahu>LelG5&R@ip{O(rF(&!I@Sdd_Ws146ZimpH2f8VoJ(qWKi3&qH$^JgtG zV~m-f$Yk2z-)75rYcyD_(!l}&&+$axykdk}D#|@x8PQ6d^nzs09dQjTA!uq#OS%u6 ziio_@D@KgMYSG=GBU3+Hbqm*j9ZAh@9(l3T$5IbPLAo!~+H?TB+5{nyi0P2@+owDV z?hZdl{Em|nVde-bEEa!QZygETXTvGe<4hc5{ExaC<~hu^$xfQ(Bq?33Lfu12g@)tp z0Lll`Q1J#CECFri>Jbf2W%R*Z-Fx9CdT(cj?Gk;z3d9ZIbffT0;9&Zd(BLRcqEJWA zcxl2Lf3bXK*$E|yx7Py-8UIa86e0|cw88=8b8i`R98rQ?n}WIfIJ)Zr?`b~ z?)3N#mO@f2p6W9Zb6Yfz2;EBc!z`#xhD>nYFxV!>071|47W0OqTotdxhF1zHzBwcp~8#mf8=n z##rB1|EGjrTUln4{uBV*?>tOoqME|b9kwI*d|n4kIEJiqv57l60qI^mJ0n|EaRe2v zCiM?8gKtT8v5Bpbq0s&j8qTHH_zPwZbC-)0VI~NB@!(RgAr&#_^>l8x;aK+4>T-We z$^MwIckYyejYVhVPTnbmm-e+*RZm3aM@T7x)JMFroyBwwGJ!u4=^acH?&!Hx<7KP} z;Ee5zibM?ymaN-dz_L)^>&*FO&c4GFv_J8DeH!rGprOdjifS@^I5c?JTqU{AIz{iE zfXaX^zyiP6B8@DQXmE}e{UTqp@MAjM4k}$dLKX~!V(1d@1i=*lL21%(yU6GC2(U5EiHP@xP0bW4!ZT zC1Rof2J;qRn~r5#=XK$@MZ&JTUh5oUDbTAw388~Do)~u8OYQo1SnftX(qEEvT597J z{?jgirP2sjHXmISy=RDci&FRSz7d4_(VUU1q|bFNB>`A%Q=#Nbn;zXK`w_U^1}MX} zSBdq|yXazcN)0A|X$nl&b$Y?&EGl_gFB5X>y*EuFguWlT3BO*5CK!0+e??FfG5Sf5 z&~PUJdp0zay96SV`Cdp*n5MGQ`3q>S6L#6LX@?UYgV}=BEnu|f zH^r17Ke*$AE9b6|P@!7As0_AHyNx5G0A55jsMQuJovsQMLbiBU2U9SB| zF*_(N&GFtgb4=d=7i$rqe0=v{LdF&uQ0 zdq&OH1HE}Y%x1a^h`V)kzyppN8@@+kcm$jNGEJ93EZ=Z){8y;KViy^8c1$=kW<3~sqC&8fYjVy za@aO{!3vj?PHKob;DJ=K0_8`G-DL58LqdIZNR1BS`MLmc7fPZ4e@+HyNkUo2Fhbb;vcs_j}9Ux<<^s}K@nMP)c zpAgmHJcq|Tb;a>6eHyV9-l{>zo%=2t&oJMDHQWlK9khh58>Xsp;ZrXWE*$Vmi4{`+ zuL~k4i;4&!1Js|tSFuW2#?E5nGIibP91paL&zA$?F9#mRK@!>=L{-6GGYg)T^_N!&-=2fp!YnVQLA3OHx zg=F1mhI4tAB>XP{eWtyN$=6nME^XV;CmOOmRa?Y!TVh+SH-ez-`_mg^jwqM_r;*6M zT`BRAN#&u~KB`xRPh^_^eSMoS$4rXr$ zL70IKf^1#h_u>Zm@XZnLW!VYqU*u)U{)ZW8sS@!+G-N*uX$()5-rS^vs%Ir$UN$5v zx1-G&iJXF9x=e6Z;_C%r@&$UrDYjOiK~FRT31c1dpo%1vtHdh{w?5MyxIAixf4B9P zv{(Xu#uQk5QmKP^7JXYx@0{0P8q*6cCOg{Dx+*;VoW~t*<99Q`$x;=GypO0>MMKLE z@Zk#{CG9$%spVGTHKyS(T)m+a!tU45WkvGH6ld7|VJ8WG7I##iz)u25e0tJ-rzaC> zdd$E=|ETOs9G)IrABJeC*WKR@CZEt<4Jug7)|=^VLGRwI{4L%Zi)($fbu&)A)Z!Z$ zr|D@-v^Q+6rg-a$ZU>**nizMOm&2>)Oy}HU`I}?_+_0_C@)3al zL*4YCrmG2lSGOb0V;Ig%h>(1w4^|_vQ zU7>=Rkgbw~D>dXxO1-|x^|k-4WpPiQg_`oQ`LWn<#v00#-(&^7<>(x#Mxf-GwZg82yMlaYld4LuPn0KK8$#!bR2B_|A{mM|s`Lz6ba0bt zA$QRb+6*Q>W_V|U`gkcbtSH)}YKb9;+5YC(8stDR`PUHKoJj4t-Q^2rVH+LHKwij1 z&LQsE=QT5g^$B_+WRn| z0giep8H9h=jnf7-idrPpj`#5W7ot84FF`1}`zX;Kd8<048*rM7X+7bOB=;+Y6{+IZ zrQEp+)6Uy!>?AdNggM?g_AIg&i8Z4!9Pk}{^vo05gw*@>#~Fd#P{?NUYXgVj+Jaj$@)!VG<+0WWLAD1q`HCmS)FNUuAuJl4$q-v-Q2*M|>77KwhUk;RW z^@=P<$taw-Q`wO|P;YXn7GhKtP&1#uX`{xh1@LphH|@q~Q5-o!ML!Nj3f@gs>&W3OM=xY12JVFJZU0Pj<6H?I9xYiI9P*wYm86MBuYP zvDFjpCfkWHd`rTY9zR1ZsY}t!D|FtkNx{un|6|sY;*VC;Xw=q|2oDm#D%1p7Pk}Gd z%O&(#DCB7aJ@~dNO^^1l{Q|M)CX-uzzBMR@7Lw0At#>tWYI}8LJK!`v!8&J0rZo5l zO_)*P)RUQSN~>G&Pt?sj<^O>$<;r|!X^Dv-CVUYNxdgU2;t~`8Q>Uo2AQLr6NxU2@Yp3-$7B!+JtAK~a9 zPA8lnfDmcnw=CbSKlSXVw{~yS+(u4P(J(;5fq78bQ9538*1Z4F`A2n$`m9+XD>sPA zo(F!5q5;j7kCQG|epVU{IWXq@6!bf!MOh5&&tdG2krzPRP!=?@dohQjxMV1x3MonJ zslNaMQ%3X>kaijf*}-P|X=Cs?t|%(BREUWt3k;WY%n}VO)=Tm&4gNCg8cba#K<6Sb znZ2mj=pQk8PXkELl>}dc3T0Vqu4?k>*A?PjRvNb;FdvUM30}!eJ*q)q7C~5s=$qRS z30|Db#U6!F)!6a~gT&uYdYr@iZVlp5obxx>_{P8bLH{z6{KUlY3O~>&N-}nhYYdje zv3)Zdr6gM=K3WVB1W+_k*8KRK#u2AXA*`<0>Wp=R)u5!54iE6V6fBU+1}m7BXPL^0 z99y0|Px}c|sn(uS(O8N%z3?hjS$yJgU3p2sz?;0RHAmk5RBo*@82|C^t4fc*5Opl2 zfuLe8hTHN;#zCVU0}F{U6_%*fRO{BM5x)5vxk0}&W_U>B?&x0kJxS#<&F6*DQC{m! zBup~9$Qo{R@DTv5e{egaWB8K7b6opV`z?m<1TN0O$bc8M=8033^14&_rPXXy;k4BeX?vTk% zi8kQ_l#;;KRjIT};6ZW>FMow7chg3;0>^8l$qy{)8bK}Ojk5g1Rw^s`B?vKx_&Vlm zj=a)~Bt%YsnUP#I@q|Wo$>n8jTl!A4zy|EVF{h_Hy3bZ@>9sDD9)GYe{LOgMw;)&m z^%s+useoh;vN;Whb=TASwF_pI@y99L(_g2;=1u&Sj|?A_6)L3o1?2k&y1reD26tJ? z$qe-Ps5zLjX5duM^BuF@XqCZ^iX(ltL(3eF@@wgk;ktrDoCrba2tnyxb^ZiNwO8yo z@_)p;LrmK&C*wO_5$ovE)bWs!FITL$J9_#mVUGD@hkxmS{D-ygi}&9-uR3~UYGn8T z;hjZVXSkH~lUl3(g>Fe3J5MeD#ZEtckoK{s=vtzUnb4 zjrtB*_H~miN@@6020*JQErwBd$1g%LTH%22$3RKeS=c~$BMYch-czf;_pSHrPUD1M zM>q|k*1Z}ZHd@fBc5v%s>dL&m(l|FNVd`Y^CF$ zEJ^Sx===7d0zr_AtsB9yRhy}MMKX6pZ1C%r8*b__$CH|j6BnU)5=ueJJmMC=5f5uH zZ@TyMNpWxw6TY%X$_0KXofbS1mdS5$R#g|h zqq>SFmSI*;djCk}50;DaUua^0!>HS+}r5YAFGaS2AV8zSa8ve@9u?Z`lfne*pgM&t{clMqtNi zRH=&OClpGb0T5EB_0kdr@Ky49d>Tzp;iC%gQs&$T;B|ksh&bI7F4PBSEQ|4o3sVSy zxpO{ngqHQ|PGW>+cvqf-A9_>h$9b~<3H4UGVgynnX|iLQC?55dmfTn|02Wp9Wl&F~ zC_)8RDl$@RW)PF7B+YODQ73I|L2dwHB{d`l69P+a;Oph>j$=n339_)KN&9R)EN_BAQcsErCE| zJgTzo&J>1OX5GK6STH?edc*!nvNnAlx3uqS!CfB@8hf#P_I0u3YAj5 z9O%pz?~+Y)Xm!Xu)_WpAZza0^InaA=PWz28X~6gnm<~S|9GLa!ncJ;nDgfh@vL`Eo#FiYAmcMjV1Djytv-H%qzZPcf0jMNHKM$3rA)w70?qd5d1% z3waAbCa;Ta`3!UDd9~8vMUA_AGR8YfqDsE$`d0s7x#!% zd#~a)pfDD`AX_~hI*O`Lp?FUddKqM-tq!N9zLW; zqm~(wXZ1q!HL()$NU3eE{{yWQNvF$4!+zB+E>D~97siKG&#-oXr5%CCR2$PUO z=1L+2nF{#ox~yY1w6K9L(MG-Q6BJQSF@>r?)7?d!zUHB~4JKWw)ng3kuV>!A82bvq zWwKH;ZJAkJg_4N6XLZX8XMr%LhpfmOdD7aY0fIsMh*?Jj#0WD@tt$L6+g6*HrO!G+ z8s{K3$7>wCinFwo4KTz^%;C$K1CZ_>(;E?x9jLWe!VQJchXS~{8}Sq2)r^sVZ_2(!4fp@?0R^5?j91o` z@C|@P(qwdpjfFVp$MyNn7slN}D6J~`Ledz{g>1c=CrbbI2HRZoo8%csea^VC0}}>~ zp%s-SKM|%IRqapGy7)vxx=bCF?UB6DBKoynRO0u^E3%%I`K5rUpi&0N!kj8Dd3G|Om)UqcQ+vKHiTe6$H z{$hmN4h(ZF%z?oBQCcpSD3}AFjp`9ylH3_KY1YM2NM8Pz;rCk&dr?LcO9p zGDomN^{x>{9ed!H#n8cP@1}aHn2CY++4+Aqtrdvi{vYG0uXDz+)B}Q5@cL|3Bz>aC zpSCA6dM*xjj$o-pXu82Up@e?cB>^5r+4+Li&C$XNj*F18M#- z*P=#%xw?fRb#IHwdOog780oSg$j}4DFDPVD4b<**pqLanGdAz7IlFr%7OK^m2s1g`IB1FN7IkP++$qvjeWW#l& zC{}f=&aB5e0*_2RB;%!MbbzXM?Xep#=C~%=#Ws772+1wSDQjn*Pn)Y!XB3Z-I9%1(6P<`BY2Evczjf-!~4$UxlA6k?c(y)F+eE;?D}$`P`B%p9SGB)aiaWbGNq2=1f}kL%NoTw=Dt2K zCAUwyPQJjR9(P;m2n2vf89=b!DVs1;F3* z6uRh|$SbuZjWNnkQfn-Ds714(E^JpAzsltHVpe1Ru8GP^UIB z-t2a{yu4&fI>>}b^byXJeCXM#j90i~N4h7|d&iAfLL6ErwbR{{L#)P=%}`z76{s32P%pZzT+Ng z#*)?_*%b9u5%zg7olQmUU~$U~T}4odmbY1(B4op!>eTetl1b49e+AjYIEI9;Z(z^Y zXYlsoAJ8K+qADH_+%kkU6Bu-I#h#d@nv4VNIr@w)^UyqX2(!AJg>qCdL(f zFw~iGMI~-0D`BgKTuD&!Rg z#VS@C6yzWi2>XOS_Pl*vY4AG=jr%xQv(37w+Rg(;0J`eFg-V4Vj3Pikt`bpqTfpL0 zgW)<%HjKcARzXiU;Wv@6EcSLxdi%<**beZsI*Op1e##^S^Sj_CIvhCg6pm<|3XOQ6 z9N_ILFy`iAe2?Rw2>v9z1Occr1(*yoIV>s~l|6~y9u8q|o-zso1|iI^i%ay-;wX~G zh*+(4QPwN%rCp@dH8hcIP+g#r*F(Qh&ngwf8O`qChj8&ERqq zAX)OUB`zZ&%iinBwTAxL?GwuRtTi%Lu-`8FwS`v>e})p9axNC;lS`|aatCT4!F1Ou znbdMoqq>8|+Wh_L^uo1fkgSDYIkSK<4UB<_WY8GjD}9_A8MyKmYrL8p{R-0lS{D7d z^7y&|aj1!S_Q@j5$#3LUWox|_&m%;|oQ%&=WwESEt-VtYlv3{e9addneri%#%v|F@ z(eh4}A71B4)QzYIaE`ZwaerSh+Ebo{QUcR^*udNB1$eZ(RNkDO?6d*02W_sALQ_#DGv)teE4kt%`F8=K?dKG|Oa;T0;a6et~9E z-e3Z;^w5HFYyI4PyCqC2N_%s65?NKryuh;ec83As%=r zugI`%3X5l4p;6l~@_VKct{Dolf?Ie73Q}Wz%^+z-tZTAb0_I{vyE5JiU|jO6K#=mW zY>>PQ)mH_`H2r0{Zg7)d<~+UFvkzr3M)4o?>(6fBqTTp8+66GVqyf@ylBz5Sna5~1=!dotG2xxif@ z!@VEOq5%!rs?P?69TbEh2Hc}_fUNo$oiJ0}af@gswQD4;;-90%!oO(>dY!9w4rb2R z1hoN$F#%M4Fyp+_B8^5i3^z8HrK1sLTOed3nsbN@fK{FQnL< zt01#)SBMt(+?iY=O^h04_t;d&JWEE9P3pe^|7Tin1|$69P0jx-aMnAd*U4NsT#7p+jY~U9Zv2oERFdv-`a$G@MgRVT(U-WU>^Z$C6Pz>PW$P2~L z7xHB5SSSOAf|E-Xo<1xOBL!&fXGl`^l1^Iy> zxq^V$P4ik3+<{fip%^`c-x7A3m`vQCj$VO4!ei^cf-!L8<_xNHLHW)kEe+C{Y>IB5 zhQT^N_q^$>9K`9ZBf={b2Pz)600>-r0e8m2nak9X$+ooRH7KGho3*~6^QNSYgK|~W z{NI_d$pAnRa+@0J-dq^LamsGq)OG|h&4e^~x+3pD8ZIEzjs*kp@VXIxzdhUP5vN(x z%I5_ws>N=z)7l&I;-VE~JdqCotwS-Cv*LI;*$REW`SlpCALb8!Sv!-3ODPgyA(5Jb zWI)njK~l$#o{2QO;y28aBa@FAjNjeaG;NlnoL^D~81PB)@d3Uo6<;7kPk{U9;RK6%Cov96**6 zBpNTf)SMA%1{j~xW9n$a!(|NcXZ3Vc79A9s+T#WesWouE5^SD8QS9u?p2Onb0DRW+E6*91FUw$McbnZ?Bg)ATPR-^A{XM(d%hI zD6&+kAG2~%Z^7cBly}BY)z?MO4NUs_WP$WTu&E)-7Vii$9-FHDHNvC28~FQ-Sqn0*B2fK_WR%h#x^Pt*`MR^-=2|Sa>IV z?Ps=BNfF$ZGt$yamJU2`m|{x&4fiag{j|>in&L`*K_pjt6|(&@00Hbnimx_SKz#xJ zd{peazSAnX&FP%Ok#%7gn(BreBP*v#i_G9v{pEinSC`A<@z78jMXV+^x+s*izuo37-8>e)fB12a(EN=(juO z(TJA?K~&}y0(GyZ*qoeVK~fUY1$fsMSwARY%oo6_Qysha!{pu+T`JO6y|XTF=$#>kou!;H)=9>rLY9mHNb1mc5veNtvv#Lmr)5=8q%JqJd080fxpp z#xEW;Ik3vcFJ@p>>@S94?trXJ-Ktk@UFlVjI(eoQYvof0&JU9==Uw$=@NL}CPBj&secY0Z6b zHf{H+{KLl(4A=LsUYLO3Uw4Bw=T_O9VAq2sljkH9VByOxU(;?szg>J1IW_Lz}XZibNv#nyGj^($9haW z!>SLk)U6}fKuVe^G)^o+tDTNZRaIYS$%s6Bo{IK@&tKg4Z92ikQ;o|i^Z%@0>2ZhP z`KWA1p(yPC@(u%meaKB{2*NI!Dj**+2fw7%Fmk{OigZi=1S;WI24fE}aiXn;WU{Wx zEjGw9@TOxVHJ%OiVBx&6Q?00U{0Z<~k5VoUS|gp~oQWyFOtR*I16%PgV5!`W?&{xF z5^}T|5lS369#++IDLlM;x@%7bdf_Pri?a?+SdZFy=ujENIlctSK6orTySN0T%ca&) zIR>P;xJg`69x~)ZAtJ>3pH4o!Nb_rWQ!=#0cJLUF7dXMntDD&W~yc{1wB0iSCQF zei4146m$noiw#XFC=4wN7f&LO< zY!?WlL9gjRuoN@d_H$2lh_?}OA_zu+R&_UvbR_7JJAd=;OD4oICo|H7JhJh$($NHjf$SSkf_v!CFg21Nx4ze5{3EjnUGz2rqE zwgp3Bl(v#@gFmAjcV`(Q4%){gC`bs*XfsyD`ZGwRSvG(J2TPIebUyBSB@Gmp<>RsA z2DboXy^y71aTn^$W@ml0h(_IjH+fqCVP&S5%8{2_?X8d_`Tvj`uuo2Lba(C7z?2q^ z4c-k;Zds7kSGv@%KIR*s+@LButWs_xg~UMysu z$c@$NIKK~m=*Z{&p^`fF+G>xHM36+n@K(+Gz6_5$h?9&Z!k*}N6f}7=e4N|2S{uU9 zV#&GVJVilGLC~Kw=a8gZ}Qos9%?K!J~VVN}I&y>_!kD zO*$=HZ)zsx`(_d-9{%;h`YeLp7%e>iXXa$1vTl4LFfnW0ap%q5G2R94FRp8+ncfZ6 z+rP=F0FNcwhQ)H^j9X`!GC@$T2=j!V@J)OCaLK#Pv%?4@LMI6ec5$OJ~)Bw_418zUkQnE0XXiH35~^-IN-w)mUa{ z>V7+EeH>&{#ty=h3K06Eo3Ru_a@i@26T84%l$8X}n{VxPQ$WExWL(XyE^k9_rPiX~ zYtDroTHCrf!!sV=b+6RFtfbl&5rU%9S;0_h&VB0BH6uSYP>3Rf0Kc55$VzN^)_vQp za)dUs)QuYRj_kEZ)*r^iv=I{56qe*i<4oIjd+-U$gLQU@I`7_FfTTX8_x zssuCwMP5SJmQ;z~QY7->z>2F0ZNrgCQ`x!(=BB98a;XNA2Lhj&eDuc&{^%%*(4QrG zK1N=Yc!rZ7hQ7@7tQo|4c9k<<1h#|l>nfoA#iP;>7R^GK0gve z#bTrF)Y$Sxv&d-9j|6NfynUu04y|XhVZxT?$~W)O45V|ene^)(Sj#ORm1U4B7URgk zh(iva6_8{&JVAfHEI#lEN11b63l@5FS;GW?Q-MlcC?G?iK@So;eE+r4hb6AkOw?f~ zfq@9~I@qRv6JtskK;wJHS|U{)Ftfg!gZnqvjRSmn-O~VTjrG%eoYmwLsucaD@0E)u zS9;u4ooDRi1cQ@q2>Rf96Y|Uc<)Y==NZe0*PKozk-c3pup1-!8(DWMhkT=Xo*+1$E zeWrW(b7WKVRPLF~_IeClF_Z{bJn|(yCzb(knKp=p;%bkfC9g!IJG{v9x_nu3CT33n j00000-IpQO00G741;qI*thicEJ}?c70ssI200CKA*XqX1 literal 93568 zcmV(zK<2;wH+ooF0004LBHlIv03iV!0000G&sfanfG_XvQ&2UJ%gRpOV>D zs)9rkVDrO9@CKe(@YEJUC64e(;J;M!@wQ4Ob64- z)eZFQcAVpiw3))oO~DeTs~l7O2`!hl*#OfGZI}YMQa`~XmqTp+=PW~Rrkkl4hTf=E zO0LDPu*Mv9p<`(IFXEb#93SIX6z9fF498!tQz7QUx85kyX^_!{u)JDh@%vkn9MpBT zr~i{OfJfxQfYRyw5Cr@!l-oK=mZfFjx<-NUu7>ky$Kwsb^bm8KIRJ`EDz=sc8b&dJ z{*_Y%!koliq8h%+Od8>8sVoy}FvdrW-V($z4v~9CsM)~nu?bMYWLS}Yfm*y_2kbnG z5eDo3Y3I!SC6T@<6&o+lSy+y$P8jSWO9bSljf<(_NHpiFH#P_y0qPW&LFkUO=<;66 ziRlTv>s6|8oc%eKQ>?=Ak{L)fp7qr{o$K^+o>C+r zkPu)`WKW`8#8uy$aW${bl09dUei)^)lj4xhqTar!Fhq4lq`Vo$)byKiM)4qyxu81H z0Ujq>xcL?~IxnUTiU)vKwdEOyo$n_FIdUD}sbk%D?)TU*c^Kh47GZ#w`Lbidqf+by2VH*QlNUFGv!2 zi*WVdKe5WtnQI~_^OKK>Q94CTQ4r-oz=s$j+Kn_avYg)==qt>8dD)Y3VqBA z@+8(h6_KDJh++Qp@1Lwo=yv7I6T5X~VwI{jE<+Dg2x1w7f4U^BKKp7qTF`L?EfcYF zj{2RR>a(RVrWg_idF6Em5d`hxm+-Foy&n^5{AP~6vGpPF-c&v}gJWdm;K2zY)e_t= z#9?~&F6j^X3 z&~{QN_^#2j>%f+ee=XSlrJgYT?L(4;Ng=5FDio7Xbvvc~VJ8vIod>F+K~HZBB88cVzgR1U zJN=?Tln?ryfww)F!US*evZh!oqm#N9u^d|;);8;^u@YUM4V;~XD%_?nVZxaVgMic5 z!MP_-jRCkdagwj9q3h>C1O@d(S=aLCalWeONUhGmWr3GOT1CuRfFBV}nOV)BcM8>c zAvd7*xTx5B!ort~zbvBsvZVTP-Yr7)h^ZYR0bDYq1vt7%n0YjlDo|BfOPX__!>~ql ztp!@6G!3&n_M=d@CU>@$7Fdog%kECUT1&a#1B5 zSbxKXBUS7g68mONLA@8u+fcg!`f$RJ@~B=Ix*_&tN$aDvnQag5!L1wuM~pex7E?& zwK%%DKIuf@F6-weJTP0TW8nOUx((^Vx0rM zZor3+k?$cMJ|>~E#G|~kjB?9)AHEs4PL3uoXWOqc^dR9TK(~g5D#x$N#xYCG!h8B< zd&p=#TuagA`oo)T@%XmG*bUH+64!5vNDM-0PB&Y`EbUTOg3YzGKry)Gz-28sJwzIj zl(Q;N(;G8V;S??FYj0Ay`B`>y-j2_oQy*TaLV|}EAczQdXribPd7oZ{!o><&W=c2k ztU>g@eqQ!IG4MyTFYRrSedFT;n1spY=L_go^LYgl){kRk3k|7qP?J1GY-)pQo{gq5 z#f|6mPazC+Up&TsvTWA*NIjlihk7tc(V{2+Ez&Qq#&MNGG zNJs>XgFIc`>)?lQ0lmklY4t>#fH9TJ%SE7q6r%x1VOQIp+wGn9fp>H(# zGG)j3ggj^yf0!bT^393=oiAN>>r2M6nkja?aZA6n0ai&WFbyMG{JVKG zgQ;NnusmtEN;Yu%CqH9g%d85_5cpT4agxp!e=h&p5ms_dPfcc##nymTdQ_Hn#^gr9 zu|#nl8DalrqU+UBt1e1<-wpxnxyj{~)~MP?k;4C?dY*n4j7bi0&oQ`mGcr3&lsk$Q zZ56D-k9d`-92avGFLwqpeU~1Qx9CTKU_Hr(Z->A){&$yF$0gW8*`JZrH~vw0$SpG) zYalAB6O5`TH63QS+<$|6{JQ0!nV8x5Gimk@u5Miy#<&b#pminHxq;j^UAk>Z7SpGN z36xS?V2@B~IXl#kC^fMl(jZ8+JT%Po$}S1hPC$W-BqX2z>7Z$CMj?6~>F3V6j0X1VRfzQbxiU%K%5dMC!z}9K|4yq*j#r~Qr2%9Ao?FR;t z4XtkaJ++VUFQmyv_aCSB31eMLbVHHTChPRRkBm^z@l@OCrUWUF$yVfWqsxAiU1Z0N z-UjIGXLPD4!6|@Cz9^wT&J3Dw3hUHt(&mE?I&~u#(?J-Y$x7phN5ZFZ=d!(w%Ri8? z&RD5Kfb~hm&8K9$F;!%L{ z2f#_$i>D?LF@Rz()BmO5;=_0eV;qqEhaficyRdU6(mrZ zQUcyc*vNeCxb2t$K&qrw)o=S=b}_4kY(nIn>b&Ln1j+_%pR#ac$3r2?37}`9F`J4? zsP`3x%ZxBk#$f-dZsi8YSNw+!I+nMU0CZld_G>_^mPmNxXoFy3A)6g5YnrIw<4-~} zEA@%iWLpvJlEMwVW09tbRPuRSdQrgYvgfb0g2jz%3V0jyZdfdb!vO~ZUZPl3NJc$z zk)t8^3W^4Q2pCBVc&MeqCvr%*4dt8qSQNiAC<+3;hNNoAI!Y@{izaB7;$|(LZ-znK zK^fqE6tNGyG0`e)nK=^rb{RO|TB1rG*G60l`(2o9q}H)#RT-g!pQ|D#q}SQJ6Z=~n zccY*j&Ct#e)zBXY#~!thbdO4NTk>1|Lbr&(gc^vvwz}eKT=vZPxghC8)e&p@OM5xT zQYcw2YjEWSr`$_0L;0%Y;c&iDp5)ROF4^s^Y$v62JPm0a;vQTgTk zt{4eTxJ~+5kZS0omCsN05vj$~?H3R#^@Nv7Hr6@ru>&5FD_r7!ik}FK*`HP%LUSm~ z`pP+4Ncd}sxJ@^B@?V@J$6^LBc!DTI{GQ`JklK_Da=t_kp;NV4LKZ|7>hVQ-sbFH_ z&Y1YQSQlE}%Sf~XgQf&i<9{pEGi#xAg&ewhO&w@W^RC3?1uP0<$)@Kep#p62q_9Y@ zwBuhxB=Ac!xeq`m;G|WF?X3bh-2c>jnXW<+TyPHlMc}{C6qf_d%umrhiif869lRe( z)?1>~#mRgjxD%(MY6nnn3W*rq=koT<4ZQCgUsPY+m7WMTH@PYVzgblq zwTf}EIaa>GB|Hg-0&y{e0Rms_O_JF*)vG8bX6}ctsB8=byHXu6yPtyD*;~>w1)Ub7Sz}>nl@KV@ zE3m3wLF3UOkZ>-RUz#y#tMm?%OVz|>FqNZ>HEjrsac)pTuj91B&0U2NS!r6-Qjbtj z!uifJj6ErqXN;S@`UMNP3dM(+n(UExIjfql2fz<`@WwX3-dUCdX-dgtp-fNyp-|t; zL0Kf>=W=NW0iTPAXZV*ioxviv5bK{yVDYrb*PF`twp&xCRtZLf-^-={g>}q5=Kwn= zh)W^fxw_0dH;R0;HZZmNhpDy)<(WIO$MzyMPzU$q5ZaX%uV z8Rw=Xz~KMpRV3o8`?N~wqo8zg8Foo!C(jzl6ac~Ao_Qt;>0Qp^-o=yhjcnow1Q@v2 zr>qLcr1XS3SfA%R#a+#Y<3Lw*J}`<#7M4pZq*ITc1Y51{C$&E$u~Q$h>4jLG`N{5z zYvwjEA0UU7p0Tbh<+BCOu$zbl0NHc`{w@ryzZejWsApJ$NQ8)gfsd*Vc3szT<+jCQ zck2Fn5WYxIlh=e@iP1b1MIedZX^ zzM7z^r{i}_8jy8EN`H~0G5abx1kEU=N#+z-Jq9F~AA=&L__~6vJCV*Fm#_I-yp`RE zp>QaKxZ0~V?Er;PUiz_v8?`+KhN)R*Rq3kKY3~-4#|dB$342Y}uGfHGtm(vYYbY;_}%Kw8&iUuRbTLJ4kAe$)>WY8ajfHV&m}j zA*2_b8^0}qSba>;Or_Q+`YfASZwXi{?=JM0K#Rfmf&;F(_32!)`8IXMoT)8Yko#y* z7KCjd9u;DsMrA+l?$T31Nl#R&pI?+*yAu7hdp+(HPV9Z}`%-w`EZ$+c{Ay9OLNH9U zss%u1_#>&_?7pzUo3Zb^Rwqzg!g@KON5$5YMKEf(zQ$aRlA^2tl5dVHFYh4+@|p(X zJo!=XYel#B`xgglqexn-!zdIVWgNl_ZxCZja)*JuE7z zB*Q?y#bz&i{_-wlXtRH!Od1TJdoP$rP6uaI*L zSSl9y`hDt}peeK>fmtCqBz z?^JTMyLuR#S>M%aI?$q?F6fn_-uf3{I*`|9J8>D4R<;*UtvuxR)xkEkV_DrVw@*eq zDjX9!k%-!z*(XA%yB3te+&-**1t_qy6JdOcGrYO^O4=>)qXmV#APkg@&%o&;);y52 z!iE21^O**jFH3?Iir8`pGF1%4+DWj52_xtpUA7j9j(B@P!z2op??(uZh8l_w1k=go=#qd>=`zcDP8Z1%~b(pXs%>G zJ`Vdogy;_Ab23;fJRckxwkMgh4ea!vgdNBHwvq`t9!(Bf1nA&DUpbZUrWm<}URQF* z2&{n#jLfKln0QYIJ!Jp{y!aB5~)zG zU3j27gBPYx$xwuqs!-ukw@0GS>v->D5kB<4a02aoD7ROQtz|+VTS-YvHiQX~#x9)EFGVr+o79@&MZP-+Pb=hAsSrm^w>bPq6ta9m3Pr_toXHP1^;e70>!+B!?6wYln?$6AxnxC@}?Eo53E%po>gX zEV~mcqI;F8(n=TjK+sWUV4^7O@lTMznP z^G{y@Rg%LcwqQ7nx#{QPqv~+{bBsSE{w|t1axvp&MxsTjAy?-QH5f1?WJPH8>1@+K z_YjauX!dSt_mn`1>JU@|So)0IN<~#Z<%x+kK43G~=8`l^8sZsyn(Ec~QsAzFkmhb+ zU^BW@krVDyeVXPJn0Hd@yr@`)4NZ&VUJO(z8hAF~ppnrq_c$5d|RYwpeK zuoU}4x+6|P7p$$@Q(RvA-A3V&TH!Qg?BVZ2Ehz%$VQgbPs+o%o@g`It*0(f3by&{^Hx=qjwsq-Fm2$rx~YHlUBXzFm;@ zgd3^%ZvBoG+4v zAWKPbY%|5Z7+~K}3A+O>NC8{fvisY78r+$T=Q9$(1!22XVKFneK~kQ};Yv6-VnP(2 zjKkPpe*lOw47rnBF-}Y^B<9OQeMv2iQqwr4LUU^A=w{BZ4m|DF`FKL}U$I0gC8RGx zyy?OS>a*Hout?FUjN+#ayqCQ&M(W$I1IIoej$;uJAh;4j5$md?rK`2P$Q9j&T1GGG znvV+9h;40UnokS?gZ!M!CZG6v;bMC7zHo^#KCpOe3Yz4*tLh4u6*bn3 zTdX-n8w%!AT;rEq7WL;#c<7A^9zy>Crw7sAnG_2j_r(HKXMI0~LVBuvfFF(6uZ%`pOIuAhm zyJWt_AR;a=`b^(JNkInVLDCYtwm&Xsf`M+}S*@qVw5oo= znl05C;YcV`Ynf>|164ngikdM6JCQvGY+oNc-Y9m1QFgx%PHtnK@$3vANPn=OMZv$hccN7?`8#@W4m)p13^gREc>5`wN&cC#n_|0!t-Ty!Kr|~y;x{I z^Rc_V^g7>4G$x6pXjeac__n(URO&EY*ZN}w=Tg`+*lv$VN_#4CKO1$Gph|OtW79uj z@Y)((6tiDkldD>PjlQ3be0yraEk;61CzAnhtFwsu6|SEiu(_T&5JBF_D1e}gD9G&k z@%nJfCaAnOs)5j#6GHNjb;)n4`3s**;xmGLc6X@8|I>xD|5`L@zmHi&CIkcG5GjP3 zraUun2fu1YCH~qKu+OT&AX>+TGEAGMY?2iEuaoe3IEyRLxeyi2f_kvjGWX?Krb}Q; z732yj)iv8xpFTAR2j>U5IV)%d9J*5KBcaWDH}t1X`#_zzyZn1VEYC;J0wO|1Ik}}0 zY&QX{vJ5s9gf1C_HJ!M{fw;o-@7(G46LV|+c^1c$L+{`=!iBqeDhh^%tlC6;Y|N3{ z;99Ef5?9_D948W&mMQ}Ux{L#??04x~x~t#M;f`6J=~ZDlpSaqA6O~QFYJ`@`os7m3 zO22jic)b|uuT=8Z@X?@>q^>Kk^*F<9p}K}+Ue$oDbAiBJ8Z*-W4&wzj?Bj&6m(uQ^ za5=clpW(vZwDHt;xfXq9da?gE7ze^5p7GQ|=3lZx;N^*2rOm>}5jJ@aznD5;L_r>_ z=eBo}(`Cw}1QSdet^=*=-k?BKWycdI$xcN*w!`<24w1dPJ-)iIU)bN=60m_&Ys%f&KkH2CNm<{6-AA4)3A^#JP*j^ea_ zD<$fmKfMY|h#Z#w_U z`OVva!ZU5lcizi?5a~PpL{BmQAD#~ z{kCG1s>i^OcL2&sxpx$J{}*EJB7~_Mh^(So4H%oK>bha*IJnv;p!oBQ@oh`4mw`G? zY`-8(G6o$6@=&~yN*7;MHE=AOCvbbrC zGfZOgJ*Xi!1_l=hAlx#fd8YQ5K?xMf&9Ks`6BI~=BzIhtyHw@h$7{Y!VK$Pmy^)_Y znINHeRD1BLt+H&n8WMg`0{i)?%V-r&M`wE5wY&gANK>QeXd~1CO#OTr&!7Ke{OtJj zpoV;S{I=9586g33tK~HRLEm|r7A#Y8*cRE8kFOaVQi*ZZp!ZrVy0wjFR&CgN>UA~R zjDXLP{^*?Q;gD)o3b+0?YQVY3e=wN&A<;&@tTrZ?HIdeQPW&ZDqE%-)=>jCHQ8xx9 zEzt2_#h#w7Qs0uGaisISvNq!6%#Z6yD^~C<}YOh|2%s=t6>H@eFD}DMOuJu zSabrd&$Wf07(sf($9Hr0Fi%)TT&;r8sh2+YNP1rXy*H5Cl*?_=lwv~D0@4gu{4oW# zvNSgkbP#qGtkjfO8Q6Y0Xjn+p?zxD zoKO~~4#OEqNM;mJKrqPA4qOjy`^KnQJYp<#qc^6~VL`CeK9bUD6%(Kl=KRWCGx|%V z^G@K6qAtCMu@9fE?m)1}jf!A@VIzoX+xw?j8m``u@wKnuf*C1FFkf(_gM|GCx;xPy zb92(xY&OR7Z_T6ildzH01WP()QaCoNqK5Tw7bIdquZX>p-Ye37ff8d=-g^%NOG0gq zm_ita?QtqZBU~f31%m5|j@^42ynv8N?J?yg4h~fa}N%D<3W){!@vUnOYJy({TI>k>kNZKvBSfjH!H6lnRcCW zT>7x!j0s|bJg<>BBCn>OoCz2YymtypO45_EZ?)3{PO?YaudC~R1e9faoN!&hV(@wm zOfKV1@VbCz7k@Ge*`nCz@eDm6*vA z02u?pYT|7DE9&jI!JTi2&_Eg~P?)ym9>qg5#?n!nmOTv-tdVnkg(OSK2OkuF0-Yv0 zcC-U0U!L-$$?wk@;DVd-bzbn7ba6uhZZ*CFMe{v-(SgnsMPdBeRTeXO@OyM9ActG_ zC(pAeX4KcS5yt+ug)%L6G_|3b)i8^jzhG~U@)W`rU9dg?7 zAb1!$!GSrQX)fKfDl3u=Ke>^Nx3;tb^g9%}QyQaxOtMs*#C;x3ot2GJa_1~5S%JLXl>IiD zWFV}LRPZHXRgQjds8oNtYKVF-{OE$(qyA*#)LOy|fa1U8`ciH9P>wv32DC5!P|LL3 z0smqr<3hXCE2}Z&wn2oCnT9v6!n@%7?p?sC#fZTN)J;L>=<5r(6W9%lb%l1t#!MQ@ zupSlh+dC!|yl`vy?V^6=_TPmeKpk21kQ|Pn13*uHDNlw{v2>wkPf-!WW}Zq=LMuks z8Cm-QJ{iMBfD0y_tfVy~U@hT~t1ad(yA|vZWc9c}vDDjUnB*_qS-{&uaKwZh61g2x?ohBvIQ)rLEXg5mVV0M!PHy?feLT zo20oD93Jq2nF7SjmC0`K+b{k=q~<|#;4wSl`8NjhSO(^MfWr)yr5;iGS~lAvKYo%< zDnno*Le6>kz3vTM@4=2!jR0|fy_@Kd)tJ0)hltsxcWd`YD+$I$d7$`cuw=j0gT~>V zD!G6`q$xyOEmmcvDV$MKEH%vLwcRVy-to%%3uM}VdpN}LCWU){kGbNklVjROC8IUC z(uP`2seVNfM;>X;^Yxij-<55pD4Bi@&^NX`n|Yk$-{DuVRfK`Xb5YodnrBL$u_DU^RlL$GGEua$GMW zf?3Nu2l&=T0xNNmK!5eli5vX3??VNh1$wdkS3LFUbOgt*q zZw`rd>TsoYK&9_2!H1^*xssz9=!jOfRf>w$_12sqn;m6JeN+bld+lc_`1=w|St*tN zAA=a|z^`LE@w;!SeIG2Mu)Q!0&Ag zV>1iUi&4Y%F6v0x9Mc7iyAy*GTP(3etV~Ia31ca8%x&-WpJAs@d@Nngea0sCJJwNA zs-J595~0QUUmQ`{t(@@t*=hdyk!l~{7mfxG{`v89&eAb<+L$s5>3Ycd&mBqgdBYZj z4eA0`hp@!Nr&TUH>{FppB2H6KmtKSXoE8ov2dPr+3;-De>BIUA_3U+!+)n^lZbX^U%9=>vK5H1o$xm{zY(BYQOiB7TWxndIsaplBoSi7n4ma`ZpV$Ta zO1McZF~Nv>en^yMKsguDC^j4P$x$_lW?~c_ygDvHa8KBDe1;6HXN2s%eqi!W^CjDT z_)*WBx3;y>i`?PmEfO|($*UOu?10Mk_slX+De-+v^CH05^I$Qcl`yNIUje28xsn~0 zRg>d^Dpn#nQgyRe6i3Bhgj>y~Rd~$v1hQk&BB{_miYoL&@^#ty?=(Pii0{$YSt&Lif@lW#X2&QyXHs`^+ar%?v$oA-lRSRpZ)@{S6t#@V$UKD z#|(w1MV@A!`1b9vFL-|cTPjcG0(wIr!oa`xr-Ot>CIYXx9{r>NMiSl&cT+H;&E46M zePLoV=nkbUJcdf7SR5R(?@(_;EiAC*Dkreu2ONBJlqxjRIB=RfK}D?&OgNgu}O&R|N~+{i`&8ce*_n-M$K0m*I3W zR`UxY@kXrT^PAz$3)h%1gYI%S!Xi_N*~e{}9;lEW*~_%!u!g*$rb8p0MtoR1us_^H z4|jMBXpiUXG&!{@;Q*y!A|t@TdsYAU8+qDjLa}&6>Jx)#`i1?xtt?>MqzgeZ24GXf z)cmjB$mh5dO$rzGOPD(tkM`NX0T4_VJ@jf26D1N8=e+d2r>s!aIkgxDlaPE0j=8g? z`Db4*)y$=izsd6I0@TNwuRJYEV4yhnVOHJ|P%Bl-HvfwP^){s=75G zhUQKcv<~y8OXa2n=~AitF#Zt>8-H?5ET0rEq#KD)5t0Mei>OAa-)i^W1txN0cvE6vs^`alhnT>b>RztWa<0TRHrD)|aez4SG+yztbA5v&%jKZ2e#!vCg83?`LFTsucy@GV$6L^ud2#5=+l&#r-8{)%W-ugX(Y+Z+A z=0m4p4Y#H4;dyjkuy=hTV4zVRoJaK~%Rd|lK`~kIkGoejp=;fxY=s>Qcn#h4{ol)j z{rL_~fO`qe20Kq3(Kd!=gj5p6ACIq}{~@7OcyvP^k$h~A3LezAG6fQdR)Ou@hXF=- zbsC%n4v$~Gd29sQ(G~q|l#K2XpmoFZhGYu*y4RybUa&>07O_`^b5xwZ(;k10-t0hv zPtas+w$Op88XPtL8%+|rcVZ%M@PD5f8&J3_==enzJj>Bt9yNk}tPHWS6yw{Yqn<0G zAUBu!PL@S{u0QaDpRBj!8)7<9ALZ#y_vF=TOaDOPFzhbYDxxAOI>|-R#aPw z%{40LC5Ld}l~P#T!d$~8!CB>Uvgc%DO+s3LIYBvmm&Rp0UoB#P?Y8x9TnCY5O(CnPSmXR;X1Bi10%ablMbN$<0kVlUjXEKId508C!s-BM~nNz|bV z5~{(8pAKV(5iRw8PGxXCuWF#nX6J>>du&a!UVtaqCPtpJOhb6B=vQwlz8%pW^ra-Z z(%AK}VRpf2y?5m1UBeR~X8dJ1N_S6ViM>(GqT4f$|m z%8ZHTTs1x0fR6yD({97+f7+iKHgue5=)t$TfK?tEhZ0_%(aRdy;^?^9wl2k zduH*@!gUBQ^mWVYZDk;;MSBG8GY6QTK%FQa3s+eQ&i=?^E}YF88U(1^M5SXIaBYzW zH;(bl#uZQA$N8@m7YKSe$Y{vk;KbMGV-X)hr>np;>2+aD)gn@2J-wHq8Hqj+BBahA zTzH(3@ZGpD_gpB*7TI@H@|UUj{*GnJ>~5oC#WmRT zI+G#wICx;A0u1VpNNwP=v zhZ6>^4L0wx`t{v>-Il>2UBY6oFBa(lirp#8Sd>5H3C?P`2Vh?()sR{L_JRFAuxc3S zG_XkRl;k^B&;`-4wPRwbwfj+#kk9iXUfCb&ya=6ik4T>2;wdeurp0=La(+;0L+Yvp zj=RKS6(YKt`$C1q z7`eeas$#(`>aSmTI@h1be`v)rspi!I=N`OGTGuI4~^{-p3$ zdpx!uCRc_8o6MvEZpc8r%^D&FT9ix6U@Zb_67s5780gWZGAhft*|Qh?UpdM z>+EW_#4tI#P;nbU={(%X@8h4t7~NJ` z&wuW>MM=k{0q_9Yh_l*=j_O1`#WXWj5ch*5O9qjp(GY)y=-2$qDFubJkP4G%yK-dK zobE+x;%>RDSHGXhU#f;QejJ<{!OdM8lqhrP%UBD~bKGD-C?x#@Dt(<7n8R~h`IcJl z7KG`rkgC=~5&nO+-aQXsAU9{+iUE?(GB{)_dGvDKTt(}>*Qx_1+IvdXu~fw5wXIKL z#I31e?*v)EBA9P%?i&wE@cBO&l@^oM>ZuDui8#rXb6h`=M!3hxo!$5wA+k+b_ z1K;DOk{=NIRX~iH686v;**4&b1`&%Gvwa4knmlYzv5ayA#;hMw!!l$&*)gigPO?q- zAQ+Ro$f9ILLpHkLR6dS|GPuabO7N}c9vD3(CQmN$snFz$5NOm$_c4n*rz3k7LCLD$ z(U9tEI{v@KC^0Zn$55t3XVD4yyhLT&DQhB2Pa7I9VlcZoGz2T-sRf0K6P_PmJ}l0w z#d6ptgZZ#gos)*~M{LWQT<*iAd2|8sM>0{j+FK%Yx5!SnM|3OR9*1c5c{&Ly0IOd5 z`h{Psp-X7(+-4W&TIF)-}x*OgB0lT-=^#rIC4LJ+|D5N`HaDG zxHK&*=-s}(FRntyDehyRPFmqJyfgL>qDf0`u!H=5^dfwLePWUezYg?(vAk4)F( z6vS@nc}RXn!Q9O((dr%nMsw`jHLSqwIm<1>@g*YvG} z9l>2O#)8vO*l(~B;L%74^rku{O|n>hOpf;=E3Sm#6JtLrd}aiz55vJDn~WoVUb);w+=kL6 zVu-o!>bEU#7*SI`!*cWTCDR4b(AMG5f&Q#e=R>7?RqsQ)B;o&IT#|?J*}Feu3xCts z;OXQL`i{^4)#{CBAu!x*IImvWX2H)~@b|XN0fL@DnwW()XpLbFqr`9a;xZ%R9U{;P zR*(k)_UGf4&HHX*Aq<{9;l*Y~rF!7`2Xzb2IO0?L#+SjpX*CA1d9)ui#6^K*H0#F# zvR?Y0i}F{PS-j>iVTjTuEwlKkgEDAXskAFWi$(T`lZ}R12ki_6*Qd9ip}(qh!N?YE zwjj16B6_!Ak>O#(SAsR8)D3(?|^aJOr8Zj z)wjI&UY6`gS(z2q<_7Z<+1fuv!PrJjy&<_a4R}x=7Hhv zx&3AS{@u8AXa)`CnB05DmVrfa^$;Tg)09wRa_0W!6s_bt7!#61l7Tcy6kTKHb@<%k zJpD_6f@fExgFxYTpZvAtod|@8Vcd-|^Ag_K|7BOZu0gaoSJBGudX66ot|#y3hM+Fh z3G;PGaf`=%cCU6!`T;Rtt3t`9ZPFhUHA2OLkdn*x^tt=-iYwF!$s<3X)5|hta{|pt zgxWoK`67eOg4R26@>`p6Lv!a4Uc}qFK)o^r8FxUrCPF(K^Xz2v5he>#17pjIIev!e z(MHT8u~yPC#%2$^seO-8Rq-<1_t>k@!=#iwxd8Y!(oYF|6T?aMwFxdx*B-E8x^Bay zL4Djp4p}<%g=K|H?gm{XP2aY@$xjuQqP4qep-}B5IH~TcC%jWv1FUMxs#-CIz*kd) zg}KzQAR1BIM|_q(J8C&aNJiPkJB}16keJskI4ukp)Wbg#GHV|Cu^DRqr+P%ELrK%u z)ceYym=h{wTY>%oxsx=^r%slDVw#Jwm_Va`4fmdA;M@qq$G)SbW>)oUe&9pKRegXWS&K$M-N9aIvIvwyYzQ+Xet* zW->QTh5Tuc$be)SpB#29=xL;}&WxgS;*WBCPvROcixCW)mg1-Hlkm5Y1i>_*! ztzFx3VNFhCd!3?5YQyRVsz*jNtArJd{ajG6 zs?kxFFN40oH{xriw2Hloc3ndioYA?l{HyzIWOG9hibT8Ff?$uMw5IhBAfeRhKdVHh zye`t@g{0G^l7Hoj>BR&(@3l(l?|yM91v5*rnv090 zlBY(_S@^8|8T1A&@xQZZ>(di6K?-&;1gjnhh>8KSlJY`%f+RpyY+L1ZxHVYHO+-qD z(aNM6Xmg&1+Qc6)Rja+EE_GdCc~%Sy1ld77DA46;ZZc3!0-~)Cr9ultQW~0QW%NB= z>gZ(i_AugUL<6-#gpMVvo~&?@@uNTDF_*eBRjE>q2pxJ@)0}=Q zsF;<3=Z_eR8Eik^I(U82ev9U~@azey-*+i6APg4LJ2*;GKy;88OO=Gpg#{`*rQL;@ z^f^r{123i47{tn%q{_U8Ui5NH<=t$`yqV%KJTOEDu{zBV4iSen&R+%AY93VPguYS{uBBdd9PA)J69X0 zY}kRq2J1OBKe)=d$+6#4w5zX0@qId-M|u2}(v)t0dCO-pW;ijYG}U8F`6X6Rs1~tT zct$UeKoNq=!aFp6)76r_rU0v49>-YljBXafpGx*6=pUApK__H$S9ST+1oNTZcryBf zbHDvPefc*2)R*bUv1iOA1}$gyEbUP)nLAA;;8hv4B@4MY9HYYm(f?Yzn@ zaU+P34svwQNT0n?%CG|+$2PL5(nCd8a-Q@Fp;MRtSit=)&^givX6Y?^=wDA~{QO~p zwtG2(B(GEyK0@B5V|`EJ2ja|FQeN0COu8llYrdDzkQOn*hJOF7)-e)d_C}}M-yEj3 z-M1oCRUrsl}TI~FZtaE%ne)B(f=WS8C`yh`)#LH2y#C}aok~{Y~U=1ko ziNTbAt}@5Yy`4`m8>+8>LtFLMHg5;bFfD6z>thMw6omxJ@sLe2O|V29VlOMpJBQVl zzbVuLmU4YIhO^Vo*=m45GwDqii=wf`wDisNBS=ELnMh_L2zggF&|_edDYFv7V4@1g zo+&vA{0`kZlp-2|b!|7wm!`vK(bQE^+7H?2CZlJH4D`C5Dk(1jJUK85#e8eRs}x_f z<>RFODkXQ+G1F>kCBGUwV=NIf;mw8E&h$lXk@c~HA3C#agJ*BL;_EV3&!#b<9OaaS zCb{P>_ECF zV?;zpxxvEw|FWQhK3`(#I{`*rs%pu!490%_m>YpmS44MPM@Ao|YeDravv_yOq#K$J z7}Hur+ct$3_Rhv~jXY#xhYCG)iagVap7h8ArY8J>g@9OtpUFW)+9743QSMx`hc(S0 zBjnLiUM%cOD7&rGIqvO8jPsCV9_U2YtY|o+iyH9$RrvGbJ~1pxVZ1}_byK8x?<}}o z{k84w*-G?XU)@LXSS+PiBkMPRi@dsUWO=zdp~^^Nw%one*-wBe%@?}=gUDaMSr0{C zU*ZyJ-{Yf68q{n=$<$)(Oy0r;@uuVfZg2ppwlv!q)4x^l?y4WpmDqkZkn*j6URC9q z3HJ~m#WZR~&cSVaN<8~fo`OXu0)rE66x<@fPFuQ*DiZMAE*At2d}6CDT@a0P+ytA3 zH_N7x2qiUd5ua=tZ9s`uH)=c&3&S?Qo&N1~!7)#jU93W~iI4Aq|ck=Ke|b!-9?Mk!venqlm> z%)$HyNE@kE2ODbZJ#)Qe!lD2d4epAU8>MB66d#x%@tu^%EAD0*>wg*Ue(NOqgWCAf znS(yL#`w#{qY$yO$~Of<>s%6-6hdcvoN;M`ohyR|+TgDMRC7gcJ%D5^TDx(ZZjry` zAFf$&Tw+x}S}c0a`2WYVHGVQCY^x^^yTgw-v1GA-`oDY{Ea#G%;Xps!F*XEStivWJ zP&X*5(wecDq3k54k|$bDP=GqgglQ39#pb0_t9ney)sf1F`jS9dX=2G105?F$zrk;<^FoOUSO~ny ztxf77>ew;?KC6YiQy?N=o8x%FKm<1^e z^vkHsH?YFgpsxrC`LlE}K4bFz+3Q>F%x8mmHY(qo(XP{Jb=Ch8evvNL1a|BGa&z{R zJOCI5Nn(T2=?z7qyc=~h4w2)2DGAn2L-y^po`@&X+uj!&J5f&~nAzF#EE$Hs674=X zBVcCYbNP1ZwsMSPqesxPU6EPtma^qy;2o#8ZE~VR9`HLa9$N%=_>%@?3!+GZTZ!R58PXMWX&gJ~+7V?I zOn{dTx5{|{T@C|KC_Jf?6DH;)%%92!grQ!E2N&K-6!*^#Hl-l{l7lpjtZ>E-=}8EV z)S!aa0&!T_M2dw+#S>N)S%e?H#p}(fqOA`dOWEX2e1`b8UuC0kpys7Qk~n8z8dQ9G zj?gk6;Wj!t}-s#gshzX3! zqT==8vFrtAOX;%$2`16>b*SP9tcx`8xjiKxL;n{@WQIb~lh(_T$kFY&&LjI8gpd!d zh5abt&;>I*h=#S*7_4Fe9wHe+kK#-wq;?JE;i9?D{xQAr$Ym;sncaPw3)k>LY3nLGS z9W1+_`bd<-19u%S63O*>&`50`=++R2O+YjzsyLeRvhLya?I@7OBh;jq9cc^<1?{ z0MxF@mR53RLZ(qZGd}aGV8sWYv+#(E&(P1<^49#8{}r-`E+2RtpD`Go%Gn+PD*N4; zN~Pl{6F32ik5lyB1>TDbb(fYcdhs#b0*3BSapE@|BN^dlVr8)G>aUT^^Vx^66d*lY zTZ*dK_X-mU_T z`^!q3(H*%$TdnF|SAI%EfIt3OXlWS1MGnz8B@zVAEGjK+*;#pD)d1pzFR@hzt-yTk zc&{9%Qw*fJOqW;p*g1{dfnLKYcab1VH}0BVH$)`z0M2C*CvEsR&I0_V8*20yKyV-6 z4Y~o$qH-6rtIOw#pEG=%=FSZG<16_#^rO)Y=?zTxL9qHc5*X*8dLYW`9h%tC_Ts)q zC}^9%BYlO$d%YIuI4~r!LpePQk(FiDHCUe~QyeG` zUBsk&CtTB|f(YBdVi$5HzEZq|UDk`Mx|zg+P-&j!{c)hYj%=s&xsz@KDC$L7)RZQS z$OaKf!j%j5Ply(W)iJB@a$(clwV$Q0vWj69Ri<|$VR-WLBR(ka1ux(L9> zm*d{`x{gf!FZx9r42SML%i->Zbt3aBKkBzd*Ek~8L&QE0exDFpo}S+^eo08SrVj6__(Dl}nC;=`kD6wd6>^zERLzshTqF!?sylz=> zM@RKuuo%6{YihkHRPwnyh5!WWynJ+#q&t|?=hdcZfnbP;*pJOkx(=jRwLSS zLob$$e6K&jBROoy4wNfYLLnOC5?}nkRI5IgOiXq%`|SMlY%2QIh8-yGF+7fRsVwjs z)rA11@&s=_g@cCbe(Rx6t$m}DnM7Cub9Vw*O?tfa{6{BwbssD+iILkYqZuTM!(j|H zmObugwl0Am5)D7>hX3z9e>+ED14C)xS_4@&yvSMl?x--0} zUi@gM+zX0BoQL|+OAy+KQ4cX*fZ8&~f;@x6f`WJDd1^RxI=xA&P}9u|^~+>^^6h0F zC7>DW*U(tf-#O^YjlI6t>O%Kvg3_Wl(Q%5nR19@{-uqT_5#`aw-)V4J2o+lU{N*lk z?J0iaO8Vp+s=h_Q5TQm-0(?6-J1bm4;cioW#M83#qcS^ZW4G%{6+mhy3|6C?Dlfki zu;4O`sKpI_Po-Q*x^0%JPzm2O(v3H_@9tREMdF*|5MDV5SDgA`9sas&jC_wVJ-i=8 zC+F=8jFePBHBV~Wsf#k{p$AkPqieY+->JH#yVx%7_J-Y=G$3G4z86tJl5RlqH+ZIR z>0Ce{nM1eWXh5oMA0;=SmGd8I9ig1b(D)`zIYSkI8=RY}kk~t|?Hr+RkPi}Nyx^Ob zb6&jdKdRWoIxy{2vGPbhr~{zvOY#qBQRkY}x`qpKX777WuWV$vH-PPK{ODx)7eQMm zq**@RoF#d`Ma9}qtPT<&GQ50KX=lNW%hr*dPnt%5B+?B`#lE9jgol4GrqwGZ0idE) zlD^k-K~yvY5rz|t5)MGoHQIj-TthE#KeRbQ4zA({S@ zVy2owtAP+&VfKaAxr1sAkp_Bw3DHS*lxU?DUmv# zWA2Nbhx~#9p&789MY^<>j0wC)^t|cUz2kAPEXa^kD#+LLm*5{xj&zo{3NfSa}J^Ic7AVTB}jn>QMc#-2Ie>7+V z&V*A(MD`Smh)2IZHV(!{%(U)Qq%q35x+(?nfx&9k@I-m3q2N zDw@d&?hNwY@L6Lel;(t<2PIU+e)|33I$+3CSsd%VI+&dEhT zHnG;DIL4Yd#D|@3U+XZ+wG3MtJOTU(57$eNV+g;N1oT?B)=m?Dx{ghet7IIDvYa_5 za;|}T9#_?z5!@OV8bhT~CJ~Uiv?6Ud?kngMW=opg-g8ivgSP68Pol`-)G6B8qtJn z5;0^i8pO}vmT9yEX7R@sl892>39{WzCw8kc7(tVl(ME3b3qbgb6Dlb`1yzqBGqI8B z=GbBZh>~g|9*1qlRHzC?Urxt_5b4TlAj{AL(dY~XRH;kEAke+YN1fURj+xJkPAV?0 z#-n~BNd$f(Tshl8yPE_sqN;*6D$3{UPQK8C-Y!@tN>pNE0^gG<)H1V!LV1U$c6;vM zC>C~Jrka*!-Z6c- ziL3g+k^HS!p$tCA94{$Xk3pb4jC#^9Mq4iGQ~r;8i0a!67Ad)J+wH^6!JCR@RP-vx zPPw{6y48Rl?Hbb*oCNu>?)iM)`M(qM4?um3_3gH#UjsB(^GJy4eKK+O9lWU>;2@r_ ze=Gc+DaGy4b<-kUNGz=pk;bf1r2fxa+69$<4w8VH^TjOw(AL2pM*6vB4mKMGAxM{H z=|Phq~Z5;C*JB6lXHOI+z`qA136=F1e0HhCC& zk*8i$qw>9ghv!31_1!O__-%`5|fwR zRK08BMa|+ihUEl2$$K@0juKmFc2pE1!OMp(V^4Z zictYDa=}ZbZHUl(V;6B)$+> zJ$ljHV`Og!Ts4fO3o9}r^;Rbt8%*K=9OOnFIvJrN6+DgI;Rr$LlQ(w`wvhdpUNTRo z>UwmM+KCQH+KCJfgf&f0Vf&2o$~smjQ?NAQdk>r8y( zm-<|NqOH(q>*QS`_kM778^IgU9!%v^{f^c>@f#a~G(YAex?vYNWj3S?Os#KW-3a6} zsB=_1)OTAKuCpKM*zauTyNOCSVKS|IWl0I5W730N?(uRwrj*Q9nwhp6rH!OH^Ftak zci~KKOSyLs(4Tv^F$|?rm;M$JHP~YOWP~4pBB9L@PpJ!B4Iw5>C=?WU7FL>L$}iP3 zu~act2A8P-oruoZNWJ?ovQ|LZ*_B61pY}*WfB{JD5`7#pRDk4>OJ|w>4h)9{=SrAX z8>Cym8RB_YyQZ)_l`pxb5R)0B!$S-04T4~h!hQXcw9+W9_v5kw=e7^C^!g)93TgXI z^MCr#DeWdKa&w(6GOmnvD!~&2D=^jf3Epy0M{ftqD{XwAlcmU<-16w{`& z@UMkB!Df%4He2e|=Np< z9H~UXXa&e|{BSrZ1!F*zAI4&P&}FENB*z`Y4NYXnybJ(4@`#C1PLkJgE;_-lN3DX= zGc#Fx>+t}r^iuj5OEJXQUikc8m}vC1e=`iLw5362OFR^u=-uza){7=?W_e7v&-b3P zoD-NQu*)A%%F7gX#q>ua+hi^y=~5ldN~KKhUU^ABqGdXtXh^eGmZiGBrpsWI_)x~Q zfIQeE4JYTtQYr$Ve;_!C0r<}2!wfW`Ui3*Mlo=pdvZ=H(ysq{CQJEAH^ z6_Q0m-r!JA1J^@l z5`HEpU5qF_h~616n$TZAq}8I}=;QP^E+GTxH2nxG?*GLfe`Wl!@DWNj$`9$l3 zo!}JCA9`|^v{bk@<{=>GE|tsH9gt*u31(|$28Qvv zuO`O$@FT{>dZQE`ZX8=6{oxGPZGf2dHnziC$@N5Wtm!!c69tcjJn-fXGJXM9z5&BE z(z%un(T&a;)L>_mUE-6%gH|CZ6kzayn|y8al@@Xu)Q58H&O7a&>n{e{=*p(q)o&b! zUb_f&k}9>6>OxRybXA5PuC ze9GudfsL#}-G&j}s}guztk4slkl!{do25}@>);Lo{j7I}&zO&Fx#WS|4RCz*`aM#^ zByG~oYt>RsKg>f_H)X1`8Q*Jj8&{PxAR$Ih@F6dC=}=qzJ7qwxHB_jhr#FaG6S)me z30WgnT^Q5YrpTrCg5W~Oc7+?8U!@2KZjm|N#$iO8q$j|xG*LLd=k_e(ijo(-BE4cW zazl1NF$cXF6GOfw(NyFG$-s-yhAt1Y2JZM zz5eR+lV8ChWOJ~6N+RXjP|A{410z4JT?MufxAaPBIp!ERqm+hNc0<39EHj9eCadH? zU;4{)ga2TP1%c@L_r+C+-qM4|S83zlpbg9m3U0RS=4OITqgg-4CMwVNe?=U4`naWt zn!7dh;-&RM7p4~cocsgc?I@w-hCffCDrfXG z7PJc5)x{&dzN|+daSIZMJN^#YF!%4J;KQcTEXNN0#gc0cr1Vn7NU;G5>l)KTjnW=Ko^j)l5K;TX3a>`*Cl%ts$vT0BZcVwuPO z0zI(-Kevs`tb-%TU96%|gH`StTacMLQR?C5d7*AckFA{f@VQXIy_0Y%GX9BlQyw?I zrM{29Zce5=uUzkaK$(Td@(4^&jkYcvQh@R4Y*gq8HW?+sScuG~SndpK2V0+XO6A=f zKQ}F=mFk~Q<4i{{82r5RPLJj#|7FEmJK<%4AHaZ@{kYACoO1??L82KluFv`jm_WBZ zIsJGbv?`RrHMjkGo!~|Rd9aYpTY3e@8n8W&zgO*8%(OC{P#T4p{=a8@w&HMXd778Y zz~$8>r)^kgLG&FOILoJ_Wzx?$KqhPTHGHlL^= z5;LTSCE?u3BO@d_yRMeo?_Du;-mmINpdh+8*cIfyZ_`U*CO@_m*7s=W@Kskn1d6T; zLqYIN6I>}PL%eD79Z2Vhb(F4atOEaUNtqy1i}{3Y3^Bf5Be=YZaTL3^5)0ddu~CE#x2SmTc6 z_Z}4jTez?PqE5?o)Xsx%GuIVwNHCHS!XaX&GRy2}17tV-jfxvp1&l^CfTT~-ZLEW< zwx*}skMTXpFfXh5m;g>2K=j&a`y@E%Vd9d9de4k6$K9{-p)USBa_xl?G4NY{uI8?OrvV(S7e-1GdJN&W$DszHKnC_>yl1riHAYn)Jyc@ zKNwIK%zxLm8W=*{;9=EDGo$(y1{=7UJHJq`5JN-#rE!rC5j4wFFEb(jt(!vnC?*Vv zK#<;{%c+E(fY(4C8j||souha`?+rz~B;LHVSyZt6+MO%{b}sF90w&>wHc)&W&F-(&=QAu#4lKHhJ$n?I1L}<_^b<)LEV%q9x@-Ri7d)3 zy^1ZsE_P~<_VhM?7O=}?@(vTw!H*~<#WAc(eiq<~I`fxy+XR!ZLD1}B z(3EGf(W)0y$u;s1)+T`GETXJ%VN_ol;mul)gx#<)I+1P9!0~=2C#!3xBa11CRiCur zz?QV7i>9iv<-%-~Np7%{Q?6jJO`61Yo<}ycNj9mD$GdkCi@$wDn%*KDo4^#OBVNNC z7kEk`@@GV|Dz{K>0MAOk(GP;$c?LXtFraaDg!K(Q8q6M#GNm@g`G-+Z7+}}{H!-f} zHvFnMINfKnngF9+qy<#g;v2;0aJSf%y-Z!HamX+~FQmrDZ`^6qQTD>vZfoncTTQOH zzH95doHWR(5xqQ3yYFTMvOt$VI{RS%=Ng$v)OUA@pYG+O8?$3{%NMfKk(-J@k8 z?Bh*KvT_Z_I-P60)&KXp8vL)1XGmm{PL$AAl1?pfjf{)s3}P?+qXAI!T_YT99(m#p znA9Vv5#I-rmW)q6Y)Kl6aq0MBc6Xl*I5MBoLft5A5sjZwg z6m&DkNsMqzbWg*9*V>i>Vj=hv^=6{|K!k5dH2}#% z+e{tw1L!QFSX+{6;U&_*D=KcSdm2oJDkkH+NY35!QDfc}eE`$=h9kGjShm0|$mLO+ z9grj}r>-)EHm`X@o!4kJ^PT~czH6o%zQ=ZzP`SV!eq$h=M&9gn-gTZ~|K=`rh?f%F zjb9fn;qr3`F@EKe;)gYWJW$jukbSOv*w*mprtourE`x{OAqbilo#1=jRmBX9G*MVH zoY9Zgb_h@Rq#onU(Z|diJ`yK`TWA>BoD#2I%ow7#l(M|LH}MUCmFis*LuUS0xbH>l zECPP9mghL+9;crE+DMr14=n0E^B5fbq@&%e1N^|%J=HeDxl6@$V4^Dk%^{nunob$9 z8ehBB9wRECfNEiAf7N4-S@yb(L1DO`fcz}#aiv*!0NQX}#lU}zfU!wxDd6Dk59%u{ zlh;$|$OC*uoB2e=I$_Ez2ibAV{i16F4euxNI5XAs<36tG6Tu8;Bu|tUL|wbE7v%I5 zK}54GdnAH;x=y&_+Gf155yrXSG_O(|eGfN<1aKl{3OA3Payo1e;F-aFSGG}=64eD9 z8M|ED>~*G;mt8yE2F`{9Fk=PIV08)I8i;?-8YY^BI{dFm3|HtQ!y=jJVFiGrg^nQv zLPV@d{$(zS+sP#_;vz;jH(MB`-^W_ehiJczY}EU)+{I>0_D?U?Q^sY+l6NANA)qFT zv$lS1dYfIGT@aiyR|hG;3%oVXRT4*q7=x4*(0Y@_Vlp`a0rPL;uDc1KSv$XLo@iuN zr#*$zA0MzyZ!;@m|EpV1Bx7-xBR0F54lJNUJh(>bQSSL2zlAYt`{fPe9r)&fs+Z}T zH$V}^AYS*_kBkT_rqNHkBX3*NkkO-yx`~{LIkM90ojGOgpCsI>UJGQ#!lv{R+XKXf zq3{d6<8m=cc(Pvy5F%ik;kTcs5KmAOS)vF8DBUjjjByg;?OZ@LVHv>Olww$e(OH=` zuxVOCPkRok$ZQ32hcPmtetJK0qznB$QSlb^UnrT6#O?^_35xu(-2SZQ_r*jNz^`o)? z{xse98S*mb5pqU$Fi|)4t)O-VcGaWft!Rq;k^(l@E8$_C|Bg-gjQ1w?=TuBic$G*l zR;4Ul!S@W7*ID|VgA5GqdJ-f3g0485+t3;2cA)?C)ybSLGi0QGXB1MBM;v&%N@rO} z7H7D42g6|n;nm^c4MEN2a=}k%C^@J)E~Q5D!EDiK^Ul)V;vlMeRWDLCL)wAJ+}GdakYoPD{J1%?x2V=| z;ld>gViR!r$UwDrAZ>t-w@*dnM`G%e~C5~ZZ zmM=n}4CP$tz}RMW*PuEzlOHaN+c>x$1mNLO5Rzw7B1H%hCXAAUxANdz(;C_pwAOlPV%J%)^`@WkB?O&Yc+)x8{VE$D89A1$`t+8r1> zuGI~6X5w{p?zzH5=jIh9iG++UMEJK+W=~5N+p~`L0-H2F4L5~>5jg2KU^eGQtI2|& z{NRuIzW&j)>%|J5hJ_7md`IbIKTPW!f;e#5Am>5175Y3&Zcv&@bfhsSz$>_3+u)VP zBg|lC+XOqytY0U~P|cwjoIfisLxFec(C6wTSZfSR6v-wfd)z>}&$MQ})befRM1Ou= z6TNwY9A#hKuNvi*l|o@_1_iF+a@ug(kPI1SiJtT0hvUzOJYscRU(a$NNrrJPB8~5TUj@3i#lWUR+sfGf zGj7@*EKEHj&@S%t+{Y6R@CzA;2@!=YzvwqGS~rIW7?VRym2b6UAkIlD)#*N*wCY$% zceHkHT5%frc_BU9Q!>vOyGc(vma*WQlXX9YY$Fm}9_1j0%5L zxOXB}{WI5|u-ogvuiZpzTkRDkUmD)r%MS>Uvdr!>Phc|}2(JhGBax+9w)Wdbs}|nF z5GHtOHyVQN;leb(*xZ_)aEch*@y>px$_oS=zj09#^sej{dxHG(Y)((A3K2Vw>qy=uQ%e|=nHf- zm<($AtO(+!ycNPGnpC|&P1$mb$u#)$Hf3lWHyYgr$mMDlx6Uc{##{S{A1 zNAl)ldh@H3r;V&db(^5PTq1FL3+c!mZxL=Hezl9P?x8Jd3!Us=l|ujSxv7#d+M>+C zKjYX`>7;1sCFy#Jz7To&lGfg_34wDiC9}PC9oZo+_0=Tc*Ltl_{*?+v^&BO zV>=3V43&25?aY)aKUNWi-AlQg8cP;-gMiA=?oHY3Z{P>QhSCH!KZozJep25mpV^$= z<n`B7&)-fq?SBG&@=9a_s< zctzt#;e*@(BMXv(UEPS#nV|s9zSDn^=(E=XXTZw;pyopMp=c@_57kV%;nHb)+<+$i z(26KAX{7t!KjS;mPu4PC$?M$YAsjLtg(8m%Nvs1fn*6DjJd@2A#GTj*wa4t~(qJE=x<$sF6& zM?_(*=`ksKR3YiB$OQ>PbwxNAHB$C8SRvH!$68NfFvVJ0!5m#^ zGtb(c(PJLf0Hti1-_Fj4+!Rt(X8S8gM?r27VRU01ia*X&ySofi7!p_nz0(KSTNfzkCsMNgsqP51Jcx)a;Kt#!F$vnzme^S-8Y7)&?2KQUjqs-9m%j!jU9)T)t!pPLcG6Aqwi z-T>0my6Lkr%L3kY{6qK3?-fx6u%lI4{VKeV{RjKrVCCW6Zq2N@jwk>t^@AtVVoU;& zAo|DC-U=D;7T_F~odI&A0m;L1O=$6)9V?@ywFr$T zT|Dk20|$@`QZ@H0Uc`^MtX$jV$_JaBa!LngjXhPxG_neP(IUI*4n7RzZv7|ms#%=G zH$eKLgH30bF{X1l3Gf=EfHLgKG^Yi@U@ZJ1+{;JMw zvv3H0Tqvw_#8j4H1@Wi>ff?{M5CBIXGhQzUNzGP*(ceh7X(fq61o(65#iXM%^ zmEmLueQi$!!*@$}PZKulb^v5+)hP+{S4?eT^^;h`GXYnCrjN?Y=9zLKkye3e zAkbkdq^2uE-%s;JgW~KX-Nk#s9+tg!P{9`Jep6~1-8v?;@Fx67Yxr}OW2%(?d6X13 zTE|%~-{s=#a$~L3qW&C@(Is=9Jr!Y*t?LEvZ15g#E0~TGe>%bsPFlTR*GOncxGR%o z-qBW!y+Tq0vCbjZjyj)A69JS-PX*8TdW`=FtI%k5vC5?zKjbl2Mek%hzgQT*%|cn5 zHycjI7nVm$xI~@!`gXdTBHD?`*z$Z4Lnl^6O~u%V-S0cQaL{A31(znYhbiJee?DxV zdl+cHWG5-k1c*vgQmBss2jQN!dCB-^{+#ur#IarXvdFfEXup)`V(R)mWr(Q#U*!6< zMq|tKjowW&;=GxW5@Rdrci@@L@}1I?ybfW8mV(ZzcWJusb1aqG!g8Y`j3SP9(lvux zxQQx@FF91qw>Z`J@L!&cMDQ7o)Jf?Fk#c zS%pRqRt4`uMboxkg&B$&lG+VX8bei6OeNb+jW8c9_TQ2ToH4ZsHj4|Xi7vV%NrfVq z5yelDRKSn0{zjAgpFG+fL~|M_Y9pnActPHJU_#Fhb{*||AL_?HSN;&&2d3%)nwb`Y zAB*(qRWV1IXgP4B4|zEYZvRi|$17Vb9O})A9JrF~S{g8U`OtB(S`Pd<~8Ax^<>I) zeuG&%QuyHr9&vzKs8wIR2#(fgw<4#WF+SrR-ZbzNu6XzGo0wlCLfN4feWyt9kt=8m~sb>e@Z)%)5?@Y(vg~ook>;|M*MW?XhhzvK5F{W;JHV!MszgV48K^FfbP;& z?hvqof~qG|X5=MGHdEh&5$I-LiYf_fwo`kD=B~W6UDgv!DKfKcA~&f<6fI4Zr_!&1VF_qG;3o?Q~vmh(e#Noau*Fr?J<3}VUATuDV<7ObFMx;a*R@- zv1kUGR&EcWcXERb8-C5$!%6MFLkFuSg|Tf}HjJ1}S<0g(#r}a@-1^>eb7XAkhv{JnLR|$|#R2erPPK6pY)~(Eu zdUT8BjUiclw{q0;+B<3p7GIY|=hIfEs?+mpgNzxb zXJNX6tDTaBllnWibITzrb&wtoSfmwtED{^YF@JP#SC>HQs3Zzzv6(FF)T78nP{lS2 zOhC18ta`@)=BlGxT*w0w{WYX5o%1#)Wag`$6`C(d+=LgA1C!1Bgq}dUv&*EvtDpyB zIUXs5{}aJFgi`SxEAyT6n%E$HX428|$&)5#dSfDX`AP*E`Qn{UW2P>Lul<7@a^5P; zl0+P)C&HmG8DAa_BBS#t2!9wn*uB(x=W79Z)f$v+QC{bxNWZLYkmk#QGDkB4`@8;% zLeory3(`g(-e%R zSu(Juk2TRFvdFnyOLOqt8iVvEUn+p23+$q$fD0%ReGB7LLMmCYLGKy62#hwsAq(e| zGCI^ar0bX{av+c}S~&HEDtLueFL;aS=-IGH5#w-&8^DpKWF5GkstsP!2##m5cn*d{)ut^4ddT|yP z0l!rj#CIir(b=ryloA5Rho;s7*ZafK6Qh_+LT^wdxI%4Vfe5ORjAj4k(`#Yb0KSYZP9;5b* zZm5F`rn*jt;gb2eYvP`7qc8FDQlDYhxMoSi99Ob0LPQMB<`JsUWA%#zfx(m~LZnmV zjx{7k8@ebe5n7PdT)G3hT`z!1n8EstJ?N*_~me$Wsy%!-3a&bcd%sFK|N-I zE!CmzWDhZ_-wBukQGXu`%D`G0?yBpB&t+)9HPUL~qdvR~So4W8VdY}8nxO>o$u)Rw z{NGZz(nHzaF8h?~k*}oUz93{x^hvW^r~h8ns3X>*V}26_(W-F1Q5yYhQIp3&OBY%z z4`wn(k3$6+J7x&woXPD%^9=z`hdV77RRd(5d<#XsuaLYD;QTafa4_a5#RDk~kd#=chq={RWp!WfriraEEkJg*g_Y#MDrPkf~#s~Rq zAjC(ZD*?W2QB>V!rGZu_IkHUiYd1Fl;wSOz8(FerUm?QCYccQ+|J1>5^@yPEtTJxC z5h2PfaxU}GOfrS}{x@J|(`8*T)v|?4hn9Yr;dOZ+bqHijJT6^gTGM6E-cA|b|Hwf^ zh~sZ&?^#l6^|XdCz0bN{XI@l=^F9Io$9MLMxHngjwQlC@P*9|oVwwDt7&ETR?@BsE z-5v#m8i1%&Ob&>|8~ERa^3gVr1~XGxP9y}I>e0we0x#3DGw?eZ@mP`w)G!lfvB)k) z?VKEZ`&wEf(MG0b7P0*Chru)R5;8OzX}&A_Z-(!eEp`xEvTJ2hvaxlrYFg++$Fa0S z$yi}0(G(}>=b1edut=g_rA|J0^b+f9*41WOCRQ5c85)gFLt9^cK%|m-rh%ElQATd0 znOjjj8#Yx7nnCZK4>@tJyY%tiMmtBbSC_{(=n*?H0#@vVD&!MZ%(g%d>t95>3x(M; z7oirN*b~q!JFT|3yIBFga{zV24E#}LlQ7eZ8v}P@4_E!I_R(35aXe?rv@w~p83{W8 zTTmR>kAJqh^i}T+i9iOqVFXt|=ELKW41^E93r7)$QnkEDI&MDdvm*1*{dIzqm9V@f z(Z}P8P|(T>TDI;eqeH&UWbfhGGX~B*&4QgzzseOmkS`2W9eVAJkQIHbBf)?!;|LxRM&@4(O7iM=L-G=`z_WdI&b z8Drz3X>p7y6~sr%{y9&-x&wRMd^5%RdKuqXr9SrE>**e^b=+Gj+q4+7Xi|I-G<}c& zsZ?Fk(lMyr_V&+n!?H#F>1#GfIaE&`u)s#yQR~IB&%3UZhAk~Cq7oVQbK;<^zJX+1 zc|wA-=2Gv-WgQjA5OThGyJ`YEn;0v2!Dl#;K2Di-d1ix~8%_C67UuCQhEQY!=5F6t zNJ*J`?0z_{e#~Gu?NnAa?Apj@#3Ib5CfxGma}pq@cDjqn-Kg|w4gLEX)g?i?mSoWZ7;6E^@-maPiZXqi67KC z*36RsFEbq8iG4#b-sV_+?+qwf>AQ9gL>H1N!^`i%Q_%TTgioPnLAzeB;jcma-pHrF zF8GE$@sJ8dI^GYiIj=XKONa6YGs@v?nMVr>eX4FE0KLB0)O?RnqbRA&K zMmHnAs}D2t1gTqp2z#4hAQ7az(!0ZKaTN@`x*QSiPkyH07Mz8J_jBPKIYt2bGQFpQ z*~*JK!w3LbkV8q zk7J5u0_tPBi=hduLG|s|PXX=qtMz$F*0q#Wv||;O2fqM==9bIro!Z>8xy1sf$??d1 zty2JSkB4x_kr|<1nZ66e!|J$YXwU?hGTJL^>)CILxzz1eLTpdUWkA19Cw1WD6*4STy>xs1~!eG?+-f4dd~=A?vW#} z=A24LyTe0jp8Rb@HI#ffI`D zuWQJ+HeuUpI^j3Owz-;b&xj-qy*%IuCmsR^zSZd2!R5Ch$2KI~L$v7}fsuFWDYt(q z!s+ok#7Nbo@I*tnFKpxAVJ?)Q&99E=0L2K^L zpgvPO?!H!o4p?RQ;m}hrAMYDX!J}uNNLbK@Iw8{ZKN->3NCiw`gA_hUf#cxu^?kZ* zX}xLJe?Pz7dS=8Hw}*lXCx2~W5o3%*fsmWufZGL|~R+8id% z_?pshwBB+$;aW%OhjsKgtxig&=XYEssaNF37XBD4O|bJj{atWhDO=U!yEzQW)rX1S zTa!c9mSL7vl`UeumuCCc1fXK(03UTEt_W2Rm-{k69B+?H_ZPF`R-&DTqK(Q4`+GgZtB)62XzHp}8(SC-a4BZVLq68I`xP$MF$*xK)N)HY&m#1XCfhB}rT*u6MOh?ovDt$Z1To>&Q*dy2hC zj4EJs7wtrQY{(l+MtB<|m20}cnmUvf+x;7;Y4GnBSLygjxo+%DT^7!CU*+#}Azkxf z)MI?V06ZwByRe=MXMhU!>a)os1A4c%o|wQj>KR_824(%xO{G#~?Q$?!?tSUjBH=5O zG8b(lddBQ&_}7Odzjw4#nbMm)iCR>dT~w8Yqq#MnEC5l@8|W1R56c3W}C)le12gFR(u zTzXan?}=i}J{+Hl&Ut$)A72XlnD+!Ml)Y%8+4GDqf(wPZ=(G72(| z@1F9(Ne|OYaC6O%KVZA2*PCEc|4^T^6h?zGS>f>iG|R>?F-+M2&fipP#a*TbN^zhO z(tNznkxz`wN}9^+LtHnhIhhY$bI4xMVRt2z7Z{4Zf$!r^;FeV)c0p?2S}5- z&3+)A>--EIYWk~Xu(fsboFkVOxN?_91cEZ!qYI}hqV5jpOYz?3vl2HCU90d=x1fr^ zQHA!x`gqT-bu!-2j-Cr7du6!^1Wl>`DikZXM%bGa7vd6i9Y}k&;^94|ZTbAS{5MuGQob!sZL(V?a(=$lR>uAfK0Q?5 zIT|?{PUfg{Py$hLJuL7>uRJi48dJU&%NMvD zUev{~cE|4U9d9qtk;+!=AmX1a{)9X-F---I#$q>D9tE!IQ~Yja1>Y_(^y!z$r;$v| zBQ4>H9I_NjIM8siRF5V1dyNN`+d8guJWfo)|6ya!_LKRX?mI2OxdSv}jE-M8$WSbT zSs7{8^dDvXyf59Ki1k&4ka%{y(b|qau&dq&*x4G5VlK_`ld1JoYun@c)NF(|eT$+p zAJ@7deIS={7k{gwfrg}mTpt~{1w7!HAkKU?z+C_!-!Qiy% zjVIl3esOdbhhQwu%w9CFw#gj1owl?2<+Ub`b=d?G5IyCC9?O`6WCsq^c`9UA-tn*V1972)!$Be*EEf-Gbl`STp}6{(8aXs|rd(NW%%qD-D&7PYh2I z>v-$1b7gLzY|DYJdC0Uotiep7H*^QXUybYBJ7-1I6{jLFmiBEXlEl2elKGMMY8*0J zpu$`rUKb785;4&VGX*OEYMB_gxhRVNTbTYGx(0ouCen#sz(Wot=&clxh)5gYF!KZ4 z<4bV6`2KfW>W^B3T~+$?)J|Zf?T9XLir3jLPqa_#Y}?%f{5Z=l5A?-W$0%pJ;?*xu zlrnnXs`Ea)Ac~JeDb@9+BFplpaSpxoyJ{+m7lVuseyQ>8hCrFM4)QDa2RMiT@B+W?I zC57stai;KT_xjyfA;F@6`EGtLyVJnuhq!13w}jvTStGDbO8vvQ0okC%o4<)HERZTh zvHwt(JSdH1IhkcFMq-4jGte$P)g-HC-qAZL!J#^vGRZ@KAXEX82b<~w4^g{nnL!Wa zg&4sv+WfwjlXc_?z*xeR6ns1bAos-0n2=IMvYbC}b%lxccl}b?f3os3#cnO9;jPqy zT&39m?^G=nwVRK6v+fNbg@jYx1>MsY&1?suG)XEr;o42wT;Y~sm;rz| zG(1mg#TKbx!D3U*Ht?BAXDrHDIOUDO-u`PlRZZ|>HAll|*v^k$=FQdPc%G7c5vP3H zFbDfH|91B!^u-&dVV1m)&xxu8rvpF&HwJd^ zV5Ea+^o*wQh%bduM)|=olJRO)+nClahW>H?# z=G2oA)sQ?-a9(;YHw3sVHLbU(DD-I%f*1TnZqEoOJQ@3^H)N8xQ0=J^tXxIpgea~G zv)Om^WYanf=ZXG2-(vByRg4y7_1RpRiY-U^1hw!ir6xxRi!J!%_V2vM zMgT6L{m9Ya90cHS3O;TKy?Xu^<`&Q@@1E(wW!MAGfoq*=g(9?ve5x_>SIpVeJnVRm zty}2SnA_(6Z1)?r9qN$!&aoc84bYRCIBPMAlSWGI<}L*NsAo{#8pIHfd(1p)N+Pct zBZnI*CQH)OoC!t4d4kFGvFtx@qr!|F#AO0pOIa5b*fE>+NZu-0I=?|})0@mb5jRc1 ziYQ$Yrndrj`pO$f?OyP4*4yA?_ZN40jXTeGu6|1M&ZsGVv`e3N7LViRJ9iXIuncG` zwhtJ@3v~97MFjH-REL0`$r{p9Tr~XTu5$ano>Qqutr)} zpTd^3e(j!_@7WF#btD)Q#GewBFZMF+J7C0B$a9dWu?H*&Ik6?RO)klQ~P+jgK~KbC8S zz=abr5k4d*ZhmKPuR&=tKClInXn_@NgBoO8zyQCk!WwB}GQXIdT=ocB0Dn((?5-Yz z-15Q3F|e8W_VTzeu{F)=B3HHM12shc4WYyPW7zS9p(bWD7MA2i=`?M=h_X?y=Uy#WmLe1>*Z%MFf`j z22|5G)1>iPP{u)92gD7tlZLdiS#eB!R2zgQIk}TkX2?JQ9)Sz~FIv7>BWhW4l;SzO}mjxu-;NQ0wrH)PE0 zfT0EBG4v4X3D?NS8pjo9D?%FJi@@y5#50Q(NAV>MKmvwY@9GXa3SK8;nBo#S+}IU% zBfdU{a3a!5koI;<%I(E*XsuTf8uAlZjbqfmhqLTlV^j4ak6DJU*piH`RC*mAV-zg~ ze)0m5vv}UzGTi2x7vL~za2>p2geC&h2aT!gAZ~eA`bs?Y7Adm5lE8py1nOS0v zPsYvE-CyH-#316U;9HBytZmEwPdF3}6ioJy)TdPhYsyUdh%SD}7mtosk#-GI`w3i8 z%dIm34|#~C!X!r1kc3X%f2g**+elsgTAYE0Kr`(N`lSg6|LLp)%C%YAM~R zTsOJda8~{T^QzhSlBwdARJ&s2)Rq8ZutLOrzd0FC+Yu}p32{D}1+r(j)5xRa@dVV) zNGau(4#f}!DxfFbQYEPaR9E$Syt?(sJ&Hp@tAKi{6bw1Y#~w~#F#Hz{5B5LCu{*Rl zvw*~WQTUm!NRVxhb1~Qj`oSz8>I7!RHwP=$Ys4v!{!FLjpMyVZ9J}?4Y^r8F6?}&R z#&q@$t7lgz)?wLuFfPj}^D*w8uhVs4l_yF1HXpAXZPw$QCS;c;hJWv-77g*JSqY?o zSt8~}vNm-I)~(Ds|951V6F&MAY3#e2G+J-kL4xvEi>(v zwDae!=Hl!#bGuk>IL*sfYuhC+|HS>AYRm9L%Iwk*uimRl#Vijt(d`LSkx$cd??t$RY zJSgf2SLYzRIATc`EE>0E` zypzCmD-&B)L%E%7y9L-#8{_@^8;kaYYUoew`I%y;!9iZsXP31)8~e&yDz>dLIvCq- zNjT=4`VUJBJOhhkX40`lR}#6R_2G-ayIY?HP)kuhZ!)`jKRqz$lSAPO-t@7APX=SV zfty0t8RhK@@-O|c3z#$28ar-~jq(tGo4H<+qQtRdt=|SyC4GK5KQ^i@hM*oZb5CzC zARV>@focaE!VOKSP?4h;Zi4ayNY$}nD0Pc!dJ6?$FqN;F8TT)O&b1^TU z;`E z(3xA>AGB{r7{apj!VeHsUGL*hz8#3}@@@blH){!e(8`sY%2(nsGm3bgXdydH7 zhz3c28^_@Iga&&Vu^Su`ZqH*Lg`<}xMk?iNO-j_+hS?PP(Q)|ql;#zKDIYlY;vLnH zk&9cChaZU`f3N+J9L)R@Dj@z`Gs}*Tb@I=J!uexlh}ioX1cIE3rd|z}uAv0Fk969R`D5RnU>M<7S@?FP$rATZ7U=OMX(1 z_3{_92efaal2i53DO<7UO!*jAUVr53NI~M3%WGm)wD7M>+5oQDchRODc0|)6f*)>; zN8=N`8Oc$HdMclCT#aThdmk$MO&qI&&681MYOU}SI6O)o_5BKC(m`N?_kXM!)2Rp1Fd((-raO+}c& z^i#p9754`-_r^NFPBDoQ!0SyObbT2ZF9SJ6L+h%onw;&YUzGd?qJd|Crq_)z`E$HD znDv_s5S%vxT!iiPQ<41I&g8`wRkU2fHaYFeVissxA8P^%XkVl7ygRWTCzNc%8TObO zLwc*i+BXC6AskV3$q-8>uU1arxS%=$x|#4YRddr;YF*K&=aJaGG?$nB?^zcF#GUD= zS~i6V4ROSh94nGN7OsZtMFP6+i&DR+`9@7vG1%{!_mO+-<)d~|rUB_J3uZcDEQ8O8 zk@X(rNeKex=)=`AtdJ}j-vxP2LQjy$#bTg%Rh^lkbqQp1KDBSl`6*%@zDsLiSa>~3 z>TpWOsO@sTR-9w&=eXT1kW2Y#Lz5jf<$8$^H7)0(-8bW)yUD4q+` zBX|KJG^e)#AD^PZl7OXN-^ENl4stw3GR?RI+KTgX*m{gJ?3<$gI{zN#GaU-`WO#>D zoeU-GhC3L+z#sjFNXEPuqrgt|V-1%9dv1cIxJbaxL*}gL=k`cNQ+Sa&c7Mh#8GK4c zueD|sQP$%t@`!!x57wL_@Oi{4a3V{(gAevvLHWVq=gPQRQMFv&YDGzttf6va`0wB6 zpugk|o>N^y-gRjIyRPQRRo=I1atASGohDc$v={viWMHxpy>j&6n|01lB0}sbR!AT@ zi){s@MFVis-=Kabs*}q=DI7Uo2mnWr6v<`sQ@MWdpf{19?)j&9Q+N=}r)(ChFzK#wKvJ<}sS;NhMD}+bFk>bQoEC&yUP3T#eve zH~hU!IOX`1!IuC=*W)b?G@7-UeEMehalqpitHT+B#O1`K;eM;`Y?I@z`@(1j-5bIu9#W}8sL4dD4c?|=39fsDJl z@!4#Ozu#Ml*x4upj*#**EGv`dAMVp-R}f1cDXDJD$MqWuD(UHjG#$RTP72kBJ=1Ty`t-677X32dw;+WdY&8{C1vh*DB81@XM(gf*C{r&Yk^2VXg*gw!i>cn< zEb#Lrt5+7;=(0K-=kW1vD^Cg6L*PT)ntBY3un7ciC84+b>xp2-ix3|WN#bF3ALHKm6hEFqW$X-K!IDC(e?ulq=;_3O>Yva%m z)W%dx^8!~3kFbjtB*YIcu`Sxn!2t`c2==rAhA94H+aOdQo>c=EiI+hS`EV002|-wP zw2d>@h5>nl6~VEQwdj>_$o+i}b}u5j8CEbx;jw|XjGaavL#s78wW#tHrz#;S6mm9` zh!fP26OD#5S~U&Z!`kL> zTJN3#xst)NImL?XKBpve19r2mUA_&j*W30m<>zm!%NTCbITi=zUt%Ag=a-AEsCrqA zJ1I< zLSuvg;_2BLH=1tcN&2B_L!q&GwoKe^5ZKohMmZ zvol(c=xkJb= zkf&;cgXU6bXGb)}g(iL+qOJ?MSRre9YtFn`9KSv+%1Hn|i6Y6~D&}475ok#4x?SmK z?TP_L4ouY-lL#LoYTnC9Eve0X6-KAvxVy>+qUEk*;~tf>0|?EtE0e`ET{(|Hd;Fly zRaEYJqax3+b8T0^EmyFMDR4&?H7_F=h)W|1gxMbn?OyY%ZYQS{DVo94r26Q}{mn7N zE1)u7#-r66AJm%8Dn1W_bG&3wS!VO{+aTA<6?-7HpW0$7(R>Dj6^4Z>GxHiQ5iz<6 zo-SFUn+jDpKTKW7Fn9~^%)H=dg5KsySjwBgR~>xqMqw^UyEw5tI_v)mS)>MMm%+g< zX(_<~#wGa*9_CCc)oq^~gTsd?NOri|+@{idj;Tf`aK0i-T2&At8s6jZ#@0~m z&NV9i*O&R;AUZ0x0$ArGS{R;9C7OBVk; z>H~JV*n@>^9VTjwo&0-y^ptobRy!(qS;r1Xyie81yeuB{wm;NG~qNBtX`K-z*>nsU`~< zv-Ik+K1SkLx*#nnJR|Tp+dVImegkXKs>P&0Aj(!mb*TE>={@dEfbF5ai;K%1>#0yi zN+p098O=6Dy>V6-r?ZzRf?V-%IkxSy+@*y&Zk(SF*rx(P2+jksjI|dVL~CivNdHrK z2sQE$S5@;MXwn?q__L$1eNVRzqHC&J3lq$UH1cm`-fn)MN>1%-Y?-_-WvmcG+(`5b zxUHZQnF{N&+ULi?&k2pUL@cUMwaEn*I)l87od|f2wqPwCpM98}Q`s`H*E#976h0cC zFY1LEKo3ga=MF*z_8@Xg(!H7Hqou5fMk(6e_x$9TLh2(J#uR-!jwqSvAmnhL6R{=) zlx^-N4vN@7xutU}Ajz@&TCm7BR`zUskwnh1d|~YaORFNo*zlw_Z59X&QE$B`9dOnL z(G2N$N-4))G{mV0z>A6Bu7%B(9v0Ujq@vVy^-wGSL6 zjjf>9J(8j;$eBr>L+G-I`|9sja0i<0L-H6ZMWCBRyjJdQdeEDZ-9nJR?39hF?1eH( zS*2H!93O9qT^-0Je?&rcUpsS8i$0WnZ7>B0^-ty2=^=Ji_& ziP(^dw;R|P!!jCtjTi%U5^xoJ+i)+)<3joxqbX=Hhf5N#@yEK%B+tUKt>WxI{Rp(z zKMe#MEG#`1jT4!n;=|A3@}kRtQ7}+-6P3e}kM^Q|{nhUVRtJ<7k*uUtv)g9=0Q3H8 zQU}wYzbuOS<;zqw;B72Z!3IY{Up$Lzw-SQ&_g3s4;I#@%TFq1cU2;dz6@BQo5*|>U{6Gjn)$Lw5#~0!m#2( zyX6czU}eC5ClWZC8ww`k3o;|Vr|7~QI5M44$%!+jY1^*ivab4P5eKYh-RTsdZ=g{g z1V+AP7%%iJuWA0a0|@CA&$+tTv#E_n zqY&Z1XvF0kFu}k9%j3;VTX-ND#N-o+F#ZjN#+O)dbaFhg4i^Rg4WL1z%FFc-Zdo7!h*uFBKJcO?Rz?q(8_G6-ESC$uQa@E5q2t($_XOjeE0)+!Hj zak=q$+X|tSkKiF#U*B(I5!QF{44cAV$HyBhS|$1_A9cKsH(Rc5TiCME&K_0{HjTveyma9@+;@VO%TY9r6G$?Ye*6m^Xa^ zy+8dQw;Qg5o$h~vd*pA}iNzettIx@}vQW1eHrmMXZub}3__eq!_xw*1xvLta#gj9@ zi5ONG)CJrcPNkU;)PsZsa{dXsT{2sbOX@|PtQKed&AJTlAAvN9lX8?eFN`e~-G6Tl zb#b7bpkKb(leH_`aurs~Wt zl9_2&rP}M9WKz47;poBSKjaabh=%mIjTVM3hXbz;!>xYoZ#^V1o~T)OVSw7L<_t2 z$KF8YBo+15nT)HdWrdzM@L|2%*FoHL@LK z;7chAYo|*NH9kKyS3xF_ov}55d@cp;Cmaw|W4xt|*h04S z1e{m>6ebaP=0%-c*7P$yfdEGxJIe^3t*>@Dp8rM9_{f>QpKBp!eCoykp-vm=p zHUsuY4igx=o5Zyvk3W_4GlNhhIbb!Nu^eE+gW*0nLlkHa`62^8_pAuiVaG%X-ujv> zLZn_B#NUiaQ^g=Zj&(59vfRRJYhS=&)dzW7mfQGD)&EzoV6a-V%3T3H{~ocNIkXBN z61&qb@CMvCV&`q-m->V|CS(d(Q#h|HUw61l4`BUvJ;J@W@Gk}3Ex?j=rl-?=k^@c1 zQwJfGTzGl{-p14)5|$s~|s1Y8WE4BG#~jUhxzSa&4Ja-+D%8w3ekK!_p9( zS#$^LFw*b7I|%`Fx5_6YI?p^z+zdqRn1Ro@Nog*=%1(9W#ak7oQCiS>*M}Hu<}@y8 zWLF3`v#3{;;~R7?=xPDgO?=HQF(uNOT z0uPOmB=-Ap)v6%C{$2*OnT6NxsZrUIyn3;Kq%RQCDUSe?bviFS4$fhNRE>9A1DAS` zEyi3g!FXPV*5Yru(&t=3nOX0ZKTf*kAFrpH;IgJ*jk>3r=_Flgf`sVhGHc6omP(a~ zyw)peEa^pWvm6s53_ZP^L=B9gGqpE2oGoCg76rLD&Um2qU_h$3aFF@%B1}#fQ?&z$ z@2>jF$EXrOrZciI-&NY|XnueTB@_bw=;T>$0q3(&)V2M;VQU@g$t}wqLZ`^YVZZUV z^)&49zEWV>F;ow9;4gHdT)pE%5umzpvAsDTpa%82+8-F6*fOd?-3`FZz!fwpoQKoW zCJ~*Dl0QTN0at{=m<1c-aPhq`5q}uJr3@|&5bRa!z_*3QdB#xK*hoZR8gDGWqOkZl z<2e*j7evM|3OAr?q>tMwHi#ixC3Za+d9W(EwPC%<+hZ9wjC!Yb zf@`$AbtX|?XHPSz%ylOOzGqT`ltKIc-ll-ppsrFd{Ef9_Y%TTn`>~A+!Kfo1CY`2)YCe3QGzIKD{3H3pZvY^ongX) z{j=j^kM5_J2isSHm7l;Tb954ZETs)F8AkG4=5-{NH|EyogD6h<>Z+tyBv~#GM8X5j zebjchc`(l7D)``g#9ixrtQ}78JCur$Bs2c_GUa&CtntQUozFL^GUmC>-r&3!j4qs( zFpxbAvmFM`9eU%P@Vr>rjCxup0GzLw#in~UWYB6Jl9Tnu#C+(}I0 zrLBp6TG{5>Y zEf+2%&#wLm7bm~!)DcUotAVg(*8LXDzY%F7m*Mw$^mMCMq&W=*5ie0;1RDBbuBH6j zIbs1Ns=*6{(3Sz;M8UovO8V;KL5@w~63bW%64_FQK-atj8wx^p+pR52_Q)eY&z}I_ zCw4yUVb-L;uArpu{t(s7`&*l-1ys{>vTS+OdlQkeq@!2Xy^uPi6I{+D`eH>KTz zV02Wa=XdUEzaknw!SfCZO1|9UtD<=Gx;S$FQLkiUU`Kqn7j1H}w5p>begj_2req!r zA;aG{bKuQlQAm=Q*3$;bndep-qWsh~fG>5d7QRnj@PnSsAx>oHZtInQU1sx)Bs2Hj z5m^>YUFFHX%nhveJ*f6bdN>i4-U0ZkvIC%}lECE_z8Z+Ba(rw(fw8-CqF&&V2S8iD zHucFlRE~E8RE5jEr>ETO3qvRa&BoI1x+F0d*)!W;hRtuZoBEyF>Wr`c2oC*1t)eZV z2pfRom+)G&iA!j&T|ChY$eTue9iQG}M1<0*20-_0@JdGyU*B8)(X6R?c%=_pp0 z2Wx+N>JcgEBH^0%@m(cjn|YwW(yBhpv2t&l#0|{Z5R?U+v`(kvYb$ZuX}vM!tPyZ# z!YnusHh$J#(zTF1TQKaU@EQwz?$b{j?S=NCIb~dLzcBtrJt&zy`$`cp z#y&4MWSopsxH{U`)Hy8{gwh$lUCar(KpnRQRKFX^0`Vy5#+Xh_=j#<`Gc6WdC9J<4 z-f26Hl@1trM)dzJc6;kY)NPz;A%|6Lt;juI=be@U z%Y({tq^L1vih`;#Ya%r9Z@w$jMJ%aQFk&Z<+?h`J>ixvu+D4lE?xX|%M9q~a{r9q| zS9?NwPjGi!hF}Ywru=Y*2PL(JezilQ8%i94~J7F zrF<;Ye^etuDf%bOx(HUty0h>!x`3x|jn`SjgvM-gk|i@@HyG=^D|OV)eN+aNXBcf6 zA6j=0FQpjhlC8fD^-DU5b*;!Xs9!vazfNGSsB-o;&-6*}` z#0Oauoyb(%0A#18ePQKt{28Kjyj)IGrM;Wg5W-htf34_fP0#pvQ;m(f-) z@}ChmIOMU^_3cpjI{J5dkv9Pm?w^{G=yk2_ch0-(NP@jRKv&U-1MiUM=KdQ&CBF>j zP^WEdGB5ulnAY}uQbuO6lJ~2rI3MT|=v*2}-Y9*ZupqsPG!(2f&$uaq)J$L*;_*a! zE^F^1$R^#?*Gr?7E;7)oT(uf{>rdH^KtMi~{J-J}UpYtHz@Z?0z5{DLazOvnA4;<#%762Ii{Rae8gJp~dz)ghbF z9^LW=d2R_kR|oc!wS+T?UAIS48XrG)(bD2NMI3Iy=B`oPpaG(S*c}(!4k7P$EP(a= zu^B{1WDL2q%%!?m@THx^@)M;eeia(+OtuOPK57#uHw7xHTo89sCE1D5_;8+w*6K^7 zQ~!7#Nj~pM%i(zH-#4?mle-Qy9d{MK#A|(n6`>@6rtEIe$5G;XGNkJz6lrpsM#3Vw z&i)~u?;I}&8$TAHKznq0T)WrfB@=KKTpM2DYIkWq&RjVQVu0rmpMhEOMo4%B?FI-e zanWS&is*52CYu?Qz68!^?fmdDbwluFKb=O6n(vweEPc%$U13O@cr3$W;US&C;PMCe zY6cvLyZR(G*rUk%z-c`JctE7mm9Ik-AQ;^qY~Lye!sm&H>y3D7;6U!*($xA_VU*`i zbQFUxk0xCVP6n<81eqk9TC6AWA|WpNRkfZNjJvpPq9$>@yMvGLc=>iCxodNS*hqXN zhYdHTfnjEvA?rohr9tmq@~AQL^l=bGNIs9BI)k?Ul{3I}6fJ^zv4`icvEofxIk_8u z{e@bWRTbK7J#ka)D>44W-!yP&;VvJJisBGuE3HFLc+kIv1OUUg@$_L>D?Z6|~tFgM!;H#&!{2!PWS$N|p+10B*w>+UfGov@{xvolaR*k9k!@s0N>$@=vF;3q~}R zC5kQs0Fgu6w+-!NlP|)4O#=a4s6#VI4wS-A;``y6Gbr9cY_6@Ql@@&Xh1E(u%E0I$4 z^1uT!s%|nxHwX(L9k+!>1?t<0HEeBd4+37hyLJkA^KVsH+*tU1lhO_wV8dg*?8n)K zdz*3P<{hWyi#2G*TV~rjJ~q(c(dtCL@?)#*1UBo#ogMdr?`{y}Q_t$3`h$m@`^l%_ zt9mo(-4tSOGqQPFd2Ui9-yD5AN8MO&=$Nw#Y~_F%_SWy^?a5sB+LheUd-USP%$d@VJR88|VO!hHxA$6|LpJbq!+!8+h$7FqP`*nc z@KEpG3njOiQc<^6q%IbbSwnGyb3u!L!pJgwj?R>su0`X|Qk)(AsraMBcE20}VZpHY zB#KReh=6und(i+>ehtD+yJzzV+BA(^pp9 znT&qv1Qq#J%*Ka&buP>pGz#+(*19Gs6E5LSmmC5$r+|XA#rv)MQMS+|iFJxwzax^o zzcWUGDVF#C71|OX_k5^4+c0#|JNx-wvyIxcBw=v@6_pald$T9R4oL@8`oUhX&bYR( z?xOHz524Dtp*dAsCI%PM^0;$<aRB5-05J~3%SU9)|dX>j^O!Oz! zN%=0AHVH!b7EY%In8QV^GBWyE*>Y6}j(M9BoFTO#N-TWzD#OL`C9ExyN?86~5W<2% zQA;2grs~&nQdGWlhukf75TTEKy??XcJ>Ei7brf26c|7`>MG)1L3HK7YfKnDM%BoA4 z^pj9p427B~j3KBc&HoX65^VcKV->njsmls(|qx&|1Gl)kCJ8dtCF=8jx+D>c}RRLAm^v*Hzq^a=?<>Y0MdQ0Nv+}47hZ|SG6}RKAcs-Cf$u_ zJW2vTdm=9oUV;sj`PbFB`#MW8e##y@n;l3uFZTKwZ19*yunB<;;dN)_)xWf90dxtY z;QXIsw3Z#<-oE(@o0+{lY6q^On{kdS)-*wz9usQ;TNL$Vv+;r$rD-m z*f>8G$=j^#tKAWPg8xp{Lw|zdLb4R?AMJn_Vr4Q%G6u?r1@2yUL#ecpDXb399U)k}Q3ksDZ?(U-vLKbJiZtrnM6c-S==uYu)%I9-@`;vdi`EK~ zOsAzuT4TiPM%0EP2cPK#GR}z?8dA_Mq|aJKiYjASy#mJG*MF|iaJ?5aN8BW}rCQVY zhv}Q@9kH%;M)~Q=4fpors0ZHrer*_B7412AcFE&A;V!la@e3;_4jDqhcYa7l^nmzV z@uK7!vB#?`@d8Dw21M@R+Fv96P zqOV`&C3Zpl<0mLM78TBiApX&=L@<(6qh5f5I*xLEG-RJ%e4XXQ%-V$EMu|8|!B_svioad*ptNxTrL)n{(F zS?E>&u?tLUfA%#bG2ZC+I!#knTfg`K%fV)Ib{J5z|H2?K{^)dJkEF1Fsa< zWu8akpt|ll1bI&@An2i#xmT-Ea_XmQ1O-QmM-d2@!A3;1oYdVo5ARS4O6*$TLo9)r z5#42pEua7JnksMMMH21Orq`~K`o@C6a3?Z~B)^*SbF7lbOP?`Gy{Z4{0ocO^${-tn za;z*0{SM`^e5rtTTWHRJu_)P%!U>E2yC3(x$C2{M*$4;KR{|SkbPnUldXoADBa4a~0{q#4y!EkoNgx zC2x_(MfQ)B`7!;br!A8qGJ^i9eM0HP@ew76iTja~06{>$zt2ZR+02ewBBUYKhYevV zuoqigISMX;k0q(ARjzRS`I`-H6AqZZ1|TN&sGr{szHnr-|H5FYVP0Ly{KmxP@VpKbIS= z!C(MsJT}B_k_e9fVH!w9Ygvoj={j4h_|dyEud0ewhEUmqr#+GQ+k=8fvI?RPhibJ= ze(Ob(QFzn|=0&6b3c@Qe0*+XzIrRDPHwvhf)t2xdr1;EX(*UoWX=dEvWCbS?hRvqHhgF z#Zllz7$a$~1dcso?^fSp)g|@Gh4!21%_RcM!U8$-CkkmUMga-5LE)BKs9jJ3{~v%k zpH(+EZ&tRXYXo0Jg!-|zV5zba{Sdghiqy$@*+hJRPMS_WI=1Er6WkI^ew=9}{}%!& zYn-7sloK#VbNF~lc?$22prUne@6nWL9jIYP9EmnUlGHlo5gatqlwenCqSQp&Y}S3X z&!OhKc0m35FiE@>#DARx;$o(1br0x$Li?L<%oc!CWa`823`p@#@BwG{;KBgGsPI8R zb^FF+qL(zlqc`&0)hcXD}irR&c(#*?x^5{uzg1p>qZ z)^7sh5a=!r`?v~N!JDAdj=?MPIG(jj^yD=aD6fMVUt!s$uqcN4*-$we+EzRsrZPAZ z^xjN<13YT@nG2v$u7ccMm=rl?NKs6s(09Q~8;zx_GguN%p0J-fxZ6Odwg-1i`+KGJ zu|7!BZQs?Sl{0D)kD3Kg8Y4}J3|6EqAxBQQ_q z?An(p+W5Vk(RC8Jhp89LqUCtELxEoRWWEuC5|-&8BqZ9Mc%P}7pq&|6?S*Nt0p=MK z72?fI+hxAEnAo6Q8DZoPzuKU*PdHQHuUc9lO(kq~o)Q40Sj>-`#N4os1ZGwpB{wYo zMI>+Qq$IbObG-_#c;C2tO&w_OnM_HVD?sO#U4qU|1EOZi0ctkD9+osf0G=dHP9JmY zm?+)+A;227k~rhYOdEyK{fPfc;LXo%A7Xf@6nnBIFtd8daBuuVT%K5bP)lL))Y?}@3tGn}ZL^y~kFtd^ydxER^g%^{l14aHZOO`)m)UWAG|Erv#gY>!DAv?UcL?!;*xSX5>c?nigbLW%z}K zYFCHqlkeA%rt&TkT!Q2QWu0i>14fcGy3b5Tg(39H`Y|k3xhvUy4brC6Foae}5GR#s7RZxg5@zkTB+=s`{$zp_Ls0Z8_qsfRtuH64*^o&|{8Y@|KVlI5G`nQs7@ zkgs8`9f=Itf*6AumNf)2QLcg5>Jp#6sw%jfgVrSC%M}SgIhm5Hu@xtod2@Fn@35d= zGH4|xO~r?bv8l@&J(~D)_?($GgiTamzzljYKVQ95_C`E-;12U>(;RYfMv1ZC)QrZ& z|2NO3^_MEXI;brV+i+h;OqrqGk53wH4tL3JPF`|I0n@y?#bvrOG8M0IR$g+Y9oH?v z4UoSb{2G7ap>McYsZ*EZY0v_%9@+&6r)o2+6Qw}c&n2cz`9NlD>U-WcTnPJS(Lt%5 zn2|!!_;@xiza~I;Xd&2Mdg^~maGn6oZ;H9c2V}|3hgEkyInIl*mn6T|5qfrfk->@f zrO%GfZnA8i$(MI<9YoXCwSjHcy}{K1UE$n~)p~f!UeK2`7)a5gS4Z)?%Q; zDaJT$m=;=JGi_H6fRrsfwh#bjk<3thAjxOaiUAGE>7P_H97mwWg*9q2QrN6$cO#%;z3W!4jho*I?A7r}-h@U(?(2X}{w_k`IY- z2|+<2zs^Qe*$ou<=OFVosH*$f5ii0wM8jWsyFqV}v1{*(u_&YO+!5%bwm{e0HdW8` zT+|S!x^5HQI%RIXfY0<5`lcTzG79-mWQv%lxP5&zq?dlKb3BD=I!UC-IBS8FWwLmZ zi_;TU$V#-=33i6b{OrEJ_11Vc`zY5uZJ(J^HC6s?T{vVv9bToh5nSGWmnnw$#r2KU zyX-d?ufHUIEdehql^u5)p}5^}OYmXkQ{MotgcX4IZo}ljN}9}0%aZ~$j)3{<{-!;= z_BR|L^bW+r5&An5_EcYCuhy=w5H%dpP~)Ug*Bp7PQSaLZ75Sje3wWs!Bi?qBCU(E@ z2PqY5B$=^Mw!@wGQo<6zzM@cXl)XDyi!D825v%l_XXh_xft%I*Hw2X3!_p+JoMzSu z#?2MiXHd%O0h4*8{6X8o^$UE^76{MmyJ-fx&QfX?P-wG+UoK7v+QO{74wgz^No7ln z?2k>F=nMl6_W508G?V(=ULyLo7)n>%$9;@S>(lm!g{o9Zo)q);u$pP6JKDEcX*sn0 z#?nO~5Q>N#9?r>~-q7u%|DI0UDH;ndUm>s6LB8FKiT6OqAPHumCkyf2r%)X`G+kU4 z0IfiKtFs5}pctsezqcuNt}-Vs0s0=w_PhNtR*|(y&M+EIHm+BPtLY)Wimm08AT_8` z_r3f7-BFBAXM(;LPUoVNUBpDhOI}dW?|&oRn*Nk%kq^J4?J^0g>RJ{)WL^}Q2F|6s zb6LjVW+T%UU=OspycpK%f2(w?gr+GH3Jw356hLf$pZQx3feb&XIeh3BF|2^OQ-ZBKC7}3vJbw<_F z6fE7cST=M=e6CGwx}rhzqsz2VA$pRbf)KN?^K2_A=&KPh3rKvnPL)AX?}r(N$km;( zwH1V9>y9gop%)NMp%)f-8IsXf7F%)nKsmJGJ$i;&CKBRux{6+WDb0NndzKM9FeRDfi1Ddv%FC)}=Cr3s7>9vg`^vl~?{@kOx-i*WUgo6SYMW+}qyqWmX^9IQkvBV- zsyM|@l$L$dD!IH~VJBCY+8;EU=U}E=2y5MC!91!saAbA>~gwSkGuvRC3S1}}tIT4s%ViE@9z2%$>J z!WsVZM^M5jt_5!u{Z+QDp7^sVW;0(7EnlMz#=xGNfxy!|^q8Ftv7@Sn z>1LXt!bniD8PNmgS8e~aMtalz!WO-n)wgvmE3kf zpt1~1ch&B<&7(Enjn+JPru`7!{`=!k9Up`9EL@kDrJPkBz!ZDl?$XC^hf%}0evNvV z2Iv{o(47T7>BWHpPSLM1{*dXfb$Hu;O|}EYnOo>97sVp~VL-CBK3;ud{KvRRd#f%) ziGJxTFD6P7Oa7XlgiueJG`W?haP~HA%pzg+ed6PY?D#z_P7>xH2zSsy;M_J68VGrA zE??J^;I8xV$I5_b)|R}?Af$Y0Px)4eECpO$i6#1AeWAP}_*pYq1; z1IC5~i@N89qkJO4jN{wn#gND;FBjU}YV>-fv_lxbRZtTk-4Ys~x1e zeghIEZyWVY68zWmR*;wAn=4g(^n<@9$i+Vk2`H`Jk=){cvLgWa8Pku5s&Vp3v+OC) z4cps9R#z;JodY=4(jh$T{;Nl*MPeT|evjtO-@P4W0aT=71oqVAyV{{;WyZS0f;sPy z+I=V#h&AvxkZF}NVG5AzhmuTEvbXz`Af`rY zZCF&rOFZLRC&oDD%Qdwk8u7myFSI_=;BvF{tQ#vpa@^*gS&)Y=QfEe}pMbm`oyhB3 zkbn-dF#^mIEMc>W5&tPKHgplMZF=bU5r*`^s8LyZ?;%AkDly*q^%)dkCN8{0z`H~v zmTD1(b?890J!}r43C;AVHquyJ+`Dz*at*{d=sA>L+Y!dm+2!2~SRYdL;3opX@51go z^B6nIqRrCX8DY1Q(0J)MSzg<2E?Lm0v}>}sR}ryjd+F#-x*68c(OM}fI4^LZ;eeFY z0{us(NqJM@`5JU6_7l3ky?Jt?87>@2BzG$8``=GAtj31(Pllj5m=JEzM_M!lB)biVv!p$+j4)qG zI&-PeIil3)M_3q7y(v_QV2TM)KBshXDv(dRHyx49_Z|?wOYP2>vdaAn0>B*5{||C< zw5rPKzp+)?sP^kIK|}EE)*_lF=&*&5x3@T%adQL+f^GW5Cw5u*Y;r^yc+KBfy$Z}? zU~cf2m1#k!3f&K9cm{iw^-9KqI{p95h44FcQN)ry`uarX*Tcc93-u$wR^H~O!;C}o zkRZc)9Y}(SSD|elFVru9XU8;$|FZJ2Qks3s4JlHIfyuWcJMmN^6Mcy(UB0{ucltIb zFRtf2aHCVNH8F=>iMB>{H?Bb?bvSBC2u^z~v?L`km5ibQ{+VfWx+F=TS&Ou}TJi+O z7&)tejZcew2uy^T$(x*|PG`a^V;9RLV-^DR#z}^gbj%n@m3MrI>u}{XB%rw%AI(bx z{;|$0&?rJ~%wDoQ>||uoQpY%AiIp*3kmw6W`EGrx?~|17b>=JvIpx?C5gkm+#~8N~ z1@V5sS3k1B;DZA(Lk-_{N%#<3;go2#MlG-Tf${&R{K*`aU0lw(tqhJ&5eY-Y-J;5^ zgM9c$xqqT0nAB64g8Rwz-t(2RH5b-1vMLlUDN-xo{Qa9CRac|{3PI_bgO=ekC|^3B zz$)u|i3RMiuS{Dj#Rz=eWc|4RmgohdS`K>|BSc^p)}>|ZFah*J2VzX&qkx&OWCxejrhtoRa?0BhX;=int2x}{}aTVTc$ z`PhmmpJ((-QhUg!veo}nCc~bv-#j@Bao;EoI4-r-Ebg|hmaRHn`3&8hL;W$h?-HxN zsn2!xbIDWxre;GH2)MT?_nh&t{3l0%3-1x~MCo5*%S5Tczzp}$w3nY*C_q7+5IiFS zklGwV9PCO>SIGnFxPzDaWD5hcGQTXH0U+ZrV=hGm0k_VkY$O&G&-~xDt}CJAdKWHY zsW*??dJA)WhC};Z*OohyoB>ZM#*Lxi10lWN*0XYN?&|!+BNj9l*sr6+goP4HGi7A2 zWc)W|a_zkqpcd;bcWxfdHVTcfA{J?Of0%^%VPG%Ocrx0M!Ul=L zC)P3D#nv)tK|Vq?e%$%EZ=`0{3DYrpB&vPY%%-Rvi5eQtZRa=DXMqgVR3NqQMdFBM z;ja!?5U_|6Jp)R#uPbpQ2rc(c4Csdh#jkH21%RV9Bn~A=?U)-^95lT^#_ih zUo?1=fr?U(!S}U%fvNkvgcY(tyuHsv0S9)s$Nby(yEs-7p#d-rG03D{B*7VHPV-Lt zu`BUcZJ2f!R*qEU==&@#G8@A+M+&B0n)*!x-6t?Ouzn6hA}{5k4TprLNyp8iT|tNI zJq%F6sf5n(xL9WUy83LVDj|dp@wuzo2(`gp6p3|e-`tCJmZpoH>sposJG*4>_=66& zNy(4vlsxMLh#~&(bD2&chSs66UJ;7C(v9=AN?1`$_lm!&u*+rw@?Xj+G1O9n2p6?h z`RdY1xVIs1UFy=1h{C$_xk)r$HMG{$G9T=ceMG1_#A*OrMFe!+9jo?hne~-Ei@Mrb zO(}$>J*~Sv$SD-3(1qY*+dvB#ZZ8!agQT3dy(cmACC&uXyfsV$z9K0+J z2|}l8|AC8Q@|n#S{(J(B5?Uy=;zNp}aHcY;$dU{4&>>=OC8r%+*j(OOHlbocSgnwH~2O7z+wU5A})ro@L$uMqLZ}+>B`+cQ{5@>kh zYv)EHlm*X?6Z|ga%ML%QZj(otG?#^^V1F?P)77I*?m_R;6@uLctkR&WNzhoG9d>`e zb3_|f_D0pS%Oi2H^W*w8ny#BngIVfrVDyNu$z_1z*_X%Yyd{6hv_c87zSszxZ(I)Inv@ajg>QMCS63=7|DKbF}ps91xjF*6x)XA zbZUXD{blBV4f-CRxFNTzx5ypKo@~6Gho6)}YGrBw!8%t?awHn`?o*mbV0>Yp30aTl z;~fE}3Uxlc3B()J9@Dny6PYcU7gh^3n9I5Jyt=6Dh_X*5d}UHvKOGTNQ3D{=JU&4{ zaz>hb1fL22p%ePJiotjBTCso%<;+x(SD$_qbEBbA6+5#Gzf)2kQ0h=2Ac8KzIYTdz zkPS0aZq~}UZv(E}B+Gu$ByadQ+9=I*n(oheSTCkZoTm)FyY-yW_%2|o$@51TyBYB~ zb#q!1he4_Q)Nncl4*$dBq>w;b&c{Rq|Edv#dn2lv&jrMvAkZ9U%~rY&P+3{;Bi+ckqIDR) zVTRJp5dMUEb5q&fY#u3-d(MrA<#A?UI_PEz9#yB*5c866nWs;w^zkE07#o2sf8Sif z4ZuPeTeQ42?VatR@x+xFGj}Zj$DJ|ejR6KL^5)Vl^j#H6;zakAc0;z`|4Mg{A}C{J zhREoPW=cnj<%ig70sD$jc~7stooZ+->^p zF2|7e#DNfUroSyP|0(g(gd4L3W+e$l>h<_GM5D3ZHO2)y3{CB&c?4mMo!nt?R5@qFEXbLxUA>(6%oG&#q46;$ISHIIwWASZxMg z`r^K7c1UD4*J}027V}^WuswHD1ZpHu$QM)@IW?o;P7VQ;WqC{EWjmZQwn-j-^cYjr zi^vf70hZ*p5(oM3r=HgrC}jYx|5p+1e^=(r-PZYwjyv8~$xYT}A2CqY-H4EBA@bb- z?(NDrZp)fu-x3M-q^IHhNX|*RAhxA5*@Xq@>Oux{GP$^Bkmir>V1gtOSOP2`Ix*9y zLci7I`#Ff~z^d0{50)`&UPj$-kFhrn$g^4PYnDONWyTRAuZVo$Jt(H#PPNTT9Mt3m zQ|33|^GMj#B8NvuAH3H7fNO2Z%TkH(A$$|q1b#c#*delygj>qW1hs6Oe+mTOB^9f+ z`Z@h(NQbk#C{6^~-aV5rjN+Q7Re|oT3rxmHT3bMQu<*-H17}n&0{b;MTUT=U5{O+V z6ny5wqLi2}6GFR??#4n&h`}FX$CkY1sveK>NGM2vi1?sEKad8EHT8j#K2GQts!e)Q zN;wg>!i?MS06@ai-q_S^r4^~4HSdcBE=6>1V3E&lsrd))_bVPMeh&Pp9|pB)7r}B2 zEBdg%RIKfFdH+?j+isYP){Zy!%;cH0+>JD04e;;fgWwc?IZ`%C7^|LeHMXp~PM|3( z__R#UKbRfF5~+fAa&QNkPebE={eACCu$3V=P*wUa8a_oS@o-=WPm@IGb&gL;oV$G> zoBr>*kQi?ZoFX=|GLiP2Tmm{54Ng?AO?7qXz&cY8SPL@PE^i--1-&r(mo8A3i7lVC ze!aXXUw%k^0k{hWUf!9Gvz-oIFwdt8k)vAd1NUHdDK+=VEMuyIQ;nlLSo($qLV#vn zWB=sF!!3}%O0k~fGvi{!>a)Aoq*_0@xPSQs+27S2P^Nd)S}TF~yV*YKuL#?*d;uaF zIwkFmCGnt^_UX~7ety5-`Y&;6pSJmEm$^L+ZMJJZ#S#}X`VHPIAmUc1#GzTU+mB>^{8w3=~AJ%4ic3bNVAiDknhs>RMt-#`OgxVTCGjMKOtw!7iF z@s1-i*`o;&((q6m1Y<|sCM5|iV!%tk?h4c3Xr_MK2ryzMQF$~$*D&Fd-4|^Pp7>q( zi;@Sy-z-WE69vJr!Y#`CGur*i6G~&0{}3U1y)0FQ8oQzD`ZF3>hV~X?R;835)x2t_ zgt{M`L5@o${Hh5bF$o5M&~ei)S^E_bH}c@NKhx<*kB9ib8cg8r+u0RkS-_4R-6H(U z>|uN4xhmO?k6xji47Ob{ z*0#G0=vr-lWCNtWE7|u-jQZ))YTUCQqn-n|wj7Kq^gT8hie&%c&j+One)w1zSU^@l z=%!G9OqR>^UgjtzI*o`5Tt8ub)SlEbtD#nVDm1pGFQejZ^p@!~ItK&plREqi;-=!U zzU-(k{JIVJ@ltx2a5#90M&wH(BN+%Fq9j`yQ;jcU%~N!qZ`1hr;l^Qow3fs-V3P@8 zWDM!3JHCdW6Z5xnZ*LCMYivpCB)&Z2r?+3w8dVUQGDnDgoT&Hc9Bxy+;i0f-!|cu}xoN?vi6sQ@sK8;@Q?AZp5q*|&{9;G@HSEhZ&KJmhKK1a;J# zdceSv*$`o}pD6a7$j%U>Cb)mpH6IfDYmCqXZ6;40Ofz$sg5g>XfhEMX$4JH>=S@xJ zIh+n~D*eHB{TW?FvF@_c_6qT=ZhG#l3gEdUhg468$;S`Qy9<-lYra)PypTI=;)Q`k z@&HORkz@x+K_0KstV@P8Dm27}S!C0=m}Y(*8WPJpCvR3%5>y!|+{aLt z!@oyzaLjv3NfAI~z6g6eK&&W|u103x6-T{$6x!wyOkH#;7xSYa%{qEGLTA=cQqd8$ zdp{XGWf)^LRbi5M8d#(uv_m)b-UK4T1wxeSHVaK zsUP!z_Z_?ih_VBLeE}dsINbUNX>g%`jC`)81{2mk>kTf}c&X@VPMH}Fi z%M&o_9%=oc$lfbCGOx=? z_{YnCzozXo)Bx8w1i#c@uLK#;D>M`;zl)7%s`G?TSOT#;GjQQ-i5e^EA%f4t54Y5g zY7=bF!2mLx7?Bmfx2vuV!j5J}c)2%l{?y8^U3c`&_4~Ogsad8$zIVVIj9L=8CxXt4 zq%JlIDxDs;H0N+%IVu(k!gQ}lpid7yoO0T%OB%7+RDMh;xJ}15y*z)mVAsv{WV?}Z z;0tQHTM&l7ebbkrJ&+Kz-K9U>jEg7=^>~+7UO71sCFXf$2+2@nG2zi)CRy_9H zIsD!Uunp`%4^9?Df%Pe2)Ri;&&R`a76phYAFTKr^H~TQ)u!nM{s*U-g=a!T7;4 zYoSMAQWUHOT_a;LC5D+EGX3hC1Xr3{KfmnQG^F3KxP@ z7JR2EK!veXlWV$DQBw2Ls`cU9_fxeOnb{uN#@KDE2<_M3XR1m%^`i`UP@v1WlvZm{ z;3(shf!Vta{At{h$PomBy6jCVBj|^`oi}k~A#-#Qf*NWObLyz*N1d)gn*x!>DK8E` z;RID0`C`Na27l0CykE83e9gX^8^vo@M3U;+U!FxwJV`v%XEc3<4dht_p( zQ~ya|7aAY1*Ay@YIVeH>6&>MYEmC^zgNXBi3a?yM-JnIu*)nrq!MY}XNOopV>g5sI zY-!)%ZLb+l;dmMcmSwqNsDg&lSV)dPmep3NX0s_na-ta>Y;0wssLIrL^}Zp#s}OGC z%q%Z=u8FpSNYmv&3X7#x^1FBOH z<3YPapXc0dn~z$_@N5G0I+o-?}sHr#0--|zEtka z2}$Zq`RI-voU7^9ft@>x@Z0W0_HG=xJE)ZbvRMavt9+_~telhK0A2&Pz5O^}gf0E) zeqPyA9b88L(&L5Woy7DC*3oK{*;k7eGR+Ogf>q^cnFmWAO~D||2h;)_#qkIz;8E$;m1mMlVu9JiA% z!sWP`Gdv}QxOoY}JSZ09zR>jmnhnWeYrd>1Sc?%AaD%JN(PUd8nKG>7Gg?WnY_9{IFuX# z?fb_`MqMSla-hwvidFgk%xovyuH70ghh`xv(! zSpAfY4d7ZST+MG8lNN-KjQVo2Dzed-*6=q-MK;a4JW70K%f)zxXdN0+?xW}v+1^hO zRq{c#VX#2P8G@KhZP`ufmfL(KUK4N}j+@aSCDk{rdoJs&)?EfQ7i#e6SLPBAsGR%B zi0fa<4n=|Nur(j1w?@tutCi}Va<(?(LYK(tX}igNVY5$$cHQ;u6gq!7_N5xMC8xM? zn*S+KgiaVTqbVg8Uwhs_bemFRN-!Oy$SY;kb^L?2M2hc! zj2Yd6q|~7^Oz!YmtK_e!wmn9iW5dwkoK2b+*D!xO5Q6(Ir_J?9{tuEdAB< z;?aoG2-xKtPQUQl?jJ3?+V-(to%L#4sG|uC2~^|6{ZrOTZaf0K`ahN|4M**j0gLoZ z8Y!m5A?cMFGGvj`Cm5R(b5(RyyAmjx%E_>DLBwaofxi2;BI}{6FD3Pok$l6@z#{JV zoVxHEMKCxcERfH_g)>~Ya_?hp-j$$G@#&(xfsU)m+cC@C0m$HVugQdB=>+qeGa=$7 zG#{k2sU%eeXtmYoV(=HQ3+N~kkFm6Hs$j%~c@lj;00Rab#Q+2ZiOp>unU}sw`4d1P zN#nj$-EqfDnJR*3AsH1(^N=#!(uOi>fkhzmyape(z&Iq9gG#*=Ne55$5I{-FmO6sE z)!*3x3a%GI#^KX!Z_%$%M*VHMG4l~KuRVQz=pDFz)cM1$kW7zxJN8^cl_frFfk7n5=XT7l8wVVarQps&?@)g(q zIe6^4>n=>-8P`mLRK1~trAOA*HP|9LhehUNz z*uD64zN)IM^8+|hqCm9}i+y#6lP?R&J@$3LSA6I31b7)UAu9~>?%?^?2cJoF<`PS- zF-UEZabaa$D5x}E4cculx-Id=wzQ`bF<&(fgRwv2WpP8jQaX%#6l29bs&JYAF@;MO ziJ--ez~WI50SjwztF@Vj{aD(C$&I!eT%x!1s4fhAr(ONf$DiS{eEiMLlRtiPBthW8 zz*|x7UMRNqgY&~cjL`Tca<5%-f_*unW|BD1M}Kdx&$T2DH#H>>7nTY__Q_h@_Rv1lk7uj8iG9rXT^g3 z*1bu*A7Ve?2EImm!;C8G#dy#wqYspw-?wwgVk*jWW7^cmS@2nZhwhS<;NAGBH#V37 zf=Ru7ny}k97HlSy!POUKN@B>bhPUky;JpOy_Rtyy%y@#z8>W-Sg|E`BZmh2WonmQH z)aDb|Q5IBCYA19ZTUmg?T87EI;CcC5!m~d*+w%GFRkc%XYT)L| zs*b+nzv~G}wt@fg&o;cvB2VkyT;y5%nyDOiKCP$(`5gR>bYD&gjnZ?PfT7y>v?w@E&!KZ zepaj&2995N6iJPnJpt5xVrZZwXvkQ{E5hsW({jv9$vu5zs`6sH=XkHJH|ighGA*_8 zYXu|VJy60aIQPO6*`Sdh#vVf$!b#C2dLHBEC=1nRoM~3niws*Gfw+zTttHEJw(qe! z7Lj#<;7~= zP*j&=md?xd#Zw6~Ix--9(Mr?_1@2e3i)TH;AOQXc(YyVFiG}`7lq+Q|n_}M8Q%Qr zxiq8K(ta}Xqbpure^YziBLC^ouyV`nx)yM0yi>sU%-y9?Fa_93QZ6tGKE)Kza#$0r zK(jR_+ncXMrNTZ1HkRrPVEb?uFmX||APiV+^a8o_KGt#qq&gbGNe4jx^rU=5G*M{u z9+Kc@C(%iJsdFP@&x@H(H9~jko_RDG7USnoeczndz@Ux8%Tu=9PREt=zC+O2EY#wf z$f*TwUv$gz9Qi0dJqlE00y?hxWbo5ZWZvzXh9s>=T}u|v0T?jZaev6Eg=kVxO6n(Y z7v3N7^dG{(Vm?xntx=VU%kIpI3P0Lcw=blq&e*&yk2YA+GyQwqvHU&ac#7%UKbLaZ zRuQp81?=J##2J;(8hohBfWteJ{NRQ546RBfX^#&Www08&FGK-Ni92@2v|LlR%?^cm z&i{^71Z_d|1p?;TY;#NN7oOs>-<_|C)yB{bt40ecZ2BWJxh%=fm-4i$+)7sW{z^!o zCgt2N=2W`E>M*(8HW?^>_o@oh1I9&mzEDjm*siAs9IYvzVORyuu*Ao5(@MRhTlR(N zGA(ak?!!I>M=bpmKVAJL1w#8RAdL9)(<4So5LCqrd@Z;)9Vhplr{$;Lxj(kGHZHz6 z1|Y*tvY4BeRYv>GB(E1a7Id1aZrvm{6McwBn_$Vj)2YQpgX8qnIYe$gEhL8%PN&8o zc1QK$NIBV4#AnV(d<|v+%Nb{RmlwPLosjjX2Tp%&tvUbOuytzMQ+w1*>PJ1u+)+XN zu;(C7&0#@-^8Nls>(gsK`cC6RyJ-e%Cz^Ef;<}p3vQeiTgT{g+(uM=UTUDPjPN;y* z(|in9-in-UihuJqn)O}4^~2aYRU=_LB@2J_a3)h1 zm^zKd=Xm!ubMSdZKZ7~0+G81~AVZmaRD`6-*J$uKLZ&-jI^#9kQVv5h7Bt9bgQono z!tAjF&a!PxY<*RSz%D_D1kG-L(okovg+0>%K|KDV~Qo;EQ%bCveXd|d|!+At6IylL{jDiLp&9QFEcuX~Hf{=4{S!#tv&E#KJgez|h zqm;-qD-vAx4mn2^h$j~IqP1$!t?_818J%4}%cYvszWmmRYl(x2N?&k5E9?X?XS91riV!kz%OW^s$yLza>)AlkuxeB)b6S=#Z z_>BNMt45JSa|r|VMYr6^5PqM3hCjTl)2p-(F=;NnHH0PWpF(1+R<>wcIv(%TcpFY9w1m zEv2E~e(W(p3m8Gml@^VE&h;t$NqiK`<6H-BIMhjXbKoxN7`~tHLSRgDDZp7GT0a^+QCgJxWc9gQ zI2Y8QU>o_%n_GwLd68<)1XSh+wyUlm!J6a z5GM7Bm*dI%{#s_3Kjnlm)=qg@Um)xbOJO5XmDcUAWCn^da}m89mHS=rp`9OV>u@07 z1vxLNV@~i~k3Tk`(eKhoDruZliCDZp+IYDe`On4|bPJ3?@O(fK;t-%9#e24f^3Mqw z63fC`I85SJ);gmE0b+&Jfwv4DjkN1YSye1kQ5XZ$Yb=l%bEl zI3_TJmn~_}8c6TH6`hxydXx4Q;wK;iH~M7WO#C6lDGr6lskK3z)l-`Ynj=y=l!+#ly=q_j{VEu(Gg!`bN^BgJa)))3QP~_?`h117Cb9MR&G0rilJR>t zL-E@2`%4TsIBj0N04C?!hjRAN5*Bgz+nDi9IK3Yoh8?#@8pB+k?+-Bpf? zt;mlJ{bc`1TjXg;cnWV=_LtF`Yp^mIuk8u^&UIB%4biZniynvJ^T4C&ExXzSg9F%C z;#{zCHu9Tp_cd>=4UwN2uApy$^ex#lSlrs|coK0W_OKP8han~|j>X5X34y&~tw3$f z)wKNaQsZuNPP_cr*Wlu==tNw9hmSP{jaO?a2y@kL(Qiq(bmOV!@w`VQJQSO&vp{PG zMSZhbspW1;|Eq)bA2-Q1RZ=Hd*1bk8LuQ1Xj2cMf>n8m&nUwL%mCi^d)Npums5(g% zeXxV4cOt=@kl2B`_1d)EF!x4@_$Y(u>J%2Q!H^-PPl(6TC;a)0h}>65>z3rRpwamj z*4(YM&I5(7{pDa$(@*JQqA85o0EeCP^lUWEIPq9_Ahg98QjoB+dpFAKndQM%{id>1 zNf@zy(>{E;M-wQ@;knq<@`C!qzh(G&Ul=B2Jk{o0;{t%D;k&6zQ8r|?Vu?#mFhrh) zdx8BgScwmf-d!q+@V!hn6piQjur7W13by@w!KklNy$ivQYVLAK<2 z7wrH+K)%0E7GVuOlZfT1FN{F`%rLT;7p;-SJ~UHk{<@sY@`NsRN#GWIRN#}x(`X-r z`&yXN7AqnNoO_X9G`aw&exA$OewBN}Ee{+#J4Zy1*1bt7{&ox;c7;+!X@nSgugA~T zgqeI1UWKr#?lXfNF-=Po#laeOPe(^DADW{yTJ*s@^5xdZ^ONxv4?Nx^<7XS z&qo}l1p(c3JB+IqLVj0RvPzpYiwSf4M7B?di$Aatp{^|st}&Wo&S#d?O5Dc|c@pjC zBHtMl2GMm{vNJdkF1v!hBpG5{$#^cHAR zvBqYILY}rHewxuxg3Q^i7}ymvS|8y!Am}bgp1cuAXjk%-aBI5|df}eGRtf6vfRn7@ z%VDHXN<9h^c^kW}j4jLZpy=h=5j2Mb$InHOZHWF9>*&k8ibz(Qij&uvhc^xcY(u>B z9Atm)i7`~%N9W9dhd7jv8hooWu3%f$bm1DT&;TrJq%*ughq*R-buTtC=RHMpJIP9< zTJiPCdSv(Zjgs__So;R$-isc19-687Ty)?HAn(s!x!BJfZ$Sx+n>Oov(E9L7qn@2^ zi#nm=IX+rWjIrnF{xYI?JjZc?Rve-+&E(PCLep=5jA@qNH zuSa7~@6>Kc6eY>(7Nfwu%O1G^J3IN`p)rtSWBtQdIjm-NYc*rSQMP%xsk_=dx}XrD z9LwF$e;0XPX1Lm@QQr2(Jz71?_OU(nW+$tPTimXR_EaUm5!73saavBs7N;nGA$xGf zNViA*Q2U^kDDoMlEGohWRI$Q`S`qx|>Q1c=mDAMSMf#x1)`Z(_P!7!Y=TPDJ$_JE0 zp8nM@u22r=$tqA%+Q<7Htu-v#wbtWGU|MSh*06-W0am|X6))L9t2z<7R*9a^*B(!S z)zU;BD;Ha_5nlzg=Y5n@A91cbifR>nM2BxVP&};^HOFVY@gG(QbRYbkm?gbu< z58##e{d^cMOUmDFQucEnK`>lNDC#va&fa#mEy}1(EBLrylGQJfm$pJCo-iD5qkvp>E1@Kq7~(Na6E# zTF?C-HP%vFX_(QFNjfbAa`7V&sy8W%BHq543A198=g&e$W@q$C4!W9I;-nebF(7Y% zaIp((7bjO>#~LxMDHV+}drVY5B6tv!J1G6~@w8jNfxun$9j3D2P&3wXF-~3FbDCtF zFrnw0!$FoEG9;VqDbp&3F1>2j*KrU^fcXx2vDI}4)z8y#hXRponRlsmEHYOLP`pfZr}Z0;c&+tHy={ zRE7$F|7AuKhD{s)zJz;TYL537fTFDt05b?b?Na6 zt+g-iN`!j-sE%!Dw!mP$d_;9#qQ9i!k zA)xtGRJAs6g^EGxNL@(_RCKfYUpaVM?GsmPH*$M=!N+D1gR};MBURmtp;nZqXrGP= zwTUkOvk%k@+9Hr}fEF#8E`dadRlsf0N7yRAWRtTV>Hdp%K)Q7!IYwp@mWM%5C-0GS zzc370SdU*?>G&}_Tzd9g{0Gdt7G=Hb$}u$mn1p`p9Surj6v3evV~6Q8!3$eqE>MxB zIivnZNz#aSN`st*vCgb=mkkOL-Q5}0utL0Y0SN5v>k$*)+eP z#%u@RaBZ}d6l1j0ThkdsyTE=Hy9z<@Lvho8Yr0G3~57b z|8YNE>$iNWcxOxR;8g)_aF>62WP3j~M*qODBB2`og#DWl;Rj%d5*{81N4*3u zeL|@5qdj2w0(bCBb`iTPSv@h}^kwXX>tOhCJO?FhD1cslq@F7a@_IFm^DtDB5y>3c zgtP{~gg8olE4WV*+8*oHoSF}q#Md$Ux&80EAV@N&psLof&qe14J|`7OsoPu)SNzN6 zKm>xiH@_hUyc->_F>qIgE7hZ?W_d#0SA?O%lP9*! zw{NXl-p56*fqUS3l<58&CvSifdGV|^{cq&N@Di%o`#l;6)^t4M41^py$Am1~q(UQP z4RSyDf&p34)28p}Cal0Zm7FOp0*4P*Jv^nq+cjDah5|8*u0^3RBH$*S(-AEG?kyN} z(|_^2*zB|lI-9@r<%Wb z)~cd={}jS!_JW%o!tD`sbv9t-MjbfZCHaR5)sX8AmYguH*B#j4f?Y^}a8JqNf%;Sb z$oBYqtc1^nU==_MQ&^zXwR~`eRxfD;$ec)O|CbmRuNr^rg8(Di%3b&J(g}xH@>Y@w zh9?`j36Ofo>S&G0x9swFaMjNvhhKoB(B7}xvd!ziK{cQa(^HFzRDg)o+h8b|CDEfy zvqrFu&9_|O$y}{wQ}J_3>}JNbrRGSU!jbfNT86Yh0(UP-%5Z9vnb+x5gIN0WqewBl zL!}VMQFKUQJ<0IO9;2}wJMhn#&`jlZ`8p^l`Y7>EsScJ(@h9uc{rWzX>Q57!K4txz zcAh*Cl&T}7>_;|Gi939L^r;27z)S8*APHWb*WD8fK*`xBatLU{Jo^48K7<&m3)Z`f zTt3a)YKraiPBR_4%QIyz{lTuTHwm&5N`ZOR47YvJiQdzMSDXP6G`>}id3yT{K7*R` zw1-?^-YrOA^Qc{h>Q0HGW+KWY*){x_v=-y=<}sNnN{u8)0Ag~i6!h0%_+bvsk;RUV z{rpcE^0~a)z4AH0c(vuBXuWvJ&ZN`OvBHm9)vl3#9PeZLBuJShI|$;u=YrGPIg}=H z5Nd%h%cyg5R0xQc6M*4y@5jc=a|F&B>I5OfF@A#~0H$zde=$d&nH2o(8TGWmIdFA` zs{eo6->b^pLGuXc(#Dd9yHMPSlBo&)y~7OT%?~hzri^v#jdq|dDaKF%(ygupC!eCW z#A3O3O@%~+judEDM!znrcR`=<$>MS;4OhUD91a%v&-c^GNI4d$JEpj|{S6VXv(Qis z>%c%dpCl+esiR4R;;2(%JjI8d;G&;Fb0(CH$=g<#{|k|Vg}QNMC8}$*p->K9_h3YGO#pK6 z5LR`_rDXCUc!JoFYC+SJ;=y!&EqXPw91+bm5or076vz1~i?(ya=p}37&A$!+hBwZ~ zk;SoXUI(=d`Z+n=jCdPHk*7E~N6a9zMQYyRFu{NEgJFBag5la| z^GE1B<=2VluvX#8QCMTYBClRB;_X<7gjg$CcTm}UQG;SDUnZ#CJeeg(lq)_(-UbAg zn<|goW5QIaNQ%o2e8jk_k!%mHd0+8*ruiW5f{z{25Ag1Cuj1jn2sZS-G`k<_Z6t5J zmiFAi2zCN+6}-UiqqvL0%x#^0EBe+0>tR|~CA$;1{M(w931Hdp6ybqW2vH{acpjp~ zsgM3oE@aA)qLHcQ{gi@`B$ied*1>ppvxC-jd0_oPY%VCAr#?)|7E1XxXP$48sfE$G zy#XSwPrt_ua<6=0!VhatC47nw?_v}G!TcZD6}>_F{}~K^K>PXr8p}rMz3ek5`W7gz z#!^-j9~n~&J7d0kkYUL6+j8f)lqvp@AKu1Y6ohYC{j@y%VLNIYL|a{*KB$!;r`Au0 z_$_IJ2PJZTYpp^_(Y~B@y$~zngBghqHzyT}l%~G=kA+Fe>$1$JFan5v^~M`zi@v1s z+L4Mz7wt@8pBow3-LzO_SJ6nQ-8%>U@%AH{;&F$?NHlDp;>V~x>i$q_47jY>sEZ|Xa$&=5^q#Cv$?bN3 zum-?nS)o42(f)ZoM=fXTAObrR=e|S2D@d01CuPjGDJO+NK|Zf#YsKaF)rC-2FH-44 zva{6W0`uiIMqe$|y2=k}u=YLb_+5Yr!SrBysA{MojqDmS^RR^=1+nhl%sLP-xfocH z_h>8J*>Gbs@;+GuKh<&G$lOLEaqhz(g4!+LvGtl?%+6X{}}C&F7f zA1E^3*2fNNXG*$1wqYUF#s-&&DF9rXAHF5{@`-BA0kuSv+W7(ynlw@Kp@e)%TFaF= zD=2~|EduGLtZz|sp4l2SC zSdtF$;J!;<`|Gj)$BFgwX#StB!&A0+x#+T9eg5=`-W^gbD^_O5{*SPP-mam)GR=iQ zDI@6xq$iGe;{+GxO^ajH?3p!Otv(nu+wy`E#3U3VKD%|vVHvcN#>7gA>nL=0K zak^#kJaLM8#O(rQ-YjuE-Zh2}&yf@VFa&kl+T^ro(@58CVtOHzcff<UhXHl4#qpDaPjT9D7{;X#kI~PBqC_2RPM)epn_a)0V1s4kGkeJ1D`{W)h3J zqnQH3Vv95|Ue}9fZ?f19Q9qiEkyHaF)K8PwcMOY`l?j_@Rk3ys{k_HC%{lLnhX@|6 z`8mVkHl>%SEmgjLPMO;?Dl&IBxI8$;N*2FSu;>KB+*R-}V}fq=PcPcYtcszuO%}`a z0O1H9U_qV5^#=-ji|9@Dk;Ybg50*mtRQvMetWe zGu)0B0+S8t-2}FJH}@Ej6wcWYw|O$8^je3tN~enKbL@N^IZ+ZRXWEnBiAdVb3~#31 zwBlUfT+`_xu1R||!P3EKze@&!&ntV1na7(;p-SNW3=x@CQ7>>hJ=7XEH3-?`V6jQc z5E_vVaDR=lQGNajMU;~DORYP*W?X?<5+{HEN;a0I6JuK;1~ivn$SKV*m}89$lNLm1 zkRCPf*wkU5%*SE)-6X+>ln9&HXx;@utmCY4)QEJdpgV3pnY?RBYHvC`en_S(*6X_E zd{k%-4mI4Nhu;$ZzvWPBQ{DeZf)SxR8IpaPPRh*DE0|IJ@WE6(WLyo|6M5;P8~)fC z!@R`2Ch5}Mi(8$mVmQz0-@Z^3^ZuwfbaOQ@KFwF`h8=e_4pXs-e#?j+J6;&2b7vdg zxSdF06I#0)Zm-Iz@Q92u$|S!v3Z6C(3)#a!?hGR)_29V%^iS07y*X*ZZ@#^@9T1X! zI5h2W1{k;;^)9yn8pWq6AaT^7mh-H|KFGg2DZ@bsv&WM2%Ov3j!kmQ+_8~ zh|!L~zm>r&?O!YLE}=cXs#XX%^U)5!&zEbZvYF(5`8r2ND+Wn)wP%3{xSniQWFu;K zI(p7!`(68UY1Oa-buEE~HLisyM&#q(Zp@KrM{1t@h0A`1T@Ua7+fOa<3@FTninD~L2^wZSiB zzc=P5osj*EumdMI9c54siB+RxDX3Jz3aiJ(1=~V{ikVYmC7yVl@O0}uD&I#6c|EJI zZ5MKFtYJNa=Zd%u$YT@J-wS|4L>!@WJ=6J5_pV9Ej9|U%;(p-#HHI47W1h)1-l#ZQ zxXG}~TeJ%=joZQ#VWy#vBC48J?<>tyNZR&Jvc}$$kaKttaS`+#2I_|D1R{-2aZmQ!UY53M2Z*`5E8SHr&DVuIbM`dWWL zH@dIj19&>?{ntRA;y{t5SYircGOQMEP>rGzN;w{?>08iZ462OrT;P5>`|mFPk~4R{ zGoYPf$RtC|o_0=`mnWLD+9A~TWvz3P5RC>@k`khnoGIU~I#e3h7gSVrXb~tZ?<4l; zYns6XNW#)>Bu&{{&tOkvvCaU(xJ$Ng7~$DCzuJ679%!f#W+bZrz^Pl)jYo-2U;y5B8F=+kD z_}Us!_){^L{N}h4?_E|dHj(Pos{g7oJcMa`&oz==zB!`Ua8*Ck8^v4mR#$5^paCD@ z{F_mO9Ht5Y!(%J!GD(1mFAlA(7~1{x+oqPH2(Xbu67k}Wvh&Jdn%wTujfAKbZP4caQ|5 z&`pBj4e4q;b?#u5X+oqabG)kws*Gj;Y(1zU*a^lE$X~K+vp39e^Bq}*q{}{kfBN@0Bj?L@t|K+FTd7}b!g(@b% zZ8e*}f)mu5kn7|>&Ivp0Hf9K(4I!Nb(CJLmt>dh*;Zqo&m^E<(8iGaV7$AS)aMV)H|mrBCV9LUfhmx+hVn%?!k$2Iji_3?U+p%c2lT0;3xF} z#ZF&yfWX%ab7xqlAV_{tG8u>P#r=I@r}krdJ>{9F?`3A0(KZR)G8=sID%JCc{0T5$ zK?J6#vG7{oiR!=cGFfY)7C57Q%w{U%wX<{z1h@I&1~1JexZ?23SQp2$9oGm%<|oApuq_I*vV< z0z)}327ew6oR@*LF&ag(_mkqRz<65IZc6l(F)L42G z_ro3L;+b_p(^(<|dfp9AcSQS?=atLiRu@!D@>cN74J_d9eLsM{y&^#u2{~%Q@RH0^ z=XCq`ca37@#>lSR=`vKBf9NW^oJovvy5ZH9kqSzDPnGAgvkyOol=7f(OanCI!j5c5 zJWc2~xI>AQWaNs$iSr-KB?O!BHFYfESJJ1&Y5n~CHCoZoapy2U#)ODMwIidV#a;~r#`xtL?6%sVXE zKc*@PCK;Y9_7u5&D~vDnNp>@LMqmYTlFQ3OC+NrrlpsO!ApW#d(74zCu5flV0VcPs zdFpu`LXDI437r)Lj!sMBcGDnJE-3C405#&4Hw)AG@s$ls*(oY{vM$Y+Bwb970-#oX zwD{4XEKAqAO}w`r87*zGB+%$PG>F}JFl$@S=^PI7%?bI=v)`D?(V21czM9|K3-AB} zQw*uZ1zr6>M$t^>|95PF3WyVO?E}-Tvhv zz8^xu`uhc@lhj`G04m@(p;5&#}8o*9M`it!>>O$586jUI9#yx!!Nm;O~=G;LDy#jlfYMKQTy znEgnUM6{t7(b>WhEAg9mQ7TO0&8FbqdGdw-iBfqERm2M4+36%5R;#D@jXw_rD-sbX zhBI!PCTxeupyU35Pg)RUvzAv(0obX%6+4-ij#+|Bh;!nQpW#-$$&hnVwV!E7RJiVB zoC_&yNgIxBi@UExr)h$%N*gFgu=*#25cM6{6dl0|H9gXFn&9sUu*ceihUg_(copCf z#e}o%`5BOl|Br=&Fk#cL_XO0dvO8NBS}JHkjaw+dXH;Z4&rWZeR9$QPzUd^QGCsV0 ztDqVi(wx>_`2xB6K&>j$qc=#sEl2sBifs8x;vH76uG?Wh7Cw4%U*uNdL90*H! z6Y31OyZ58K{AJ(KY%*E&{%$M*-AhdQ3_s6QNt)kP58Eh$)6*lWeE73Auy$o_IQ_q% zA5wFCL+3F8#QxGHk(&$|Ef+85vR*RZNj&5UnQw=*ev33?;)f3LlS5OV=X2RYD!4|N zMUDNYfb#|~MkM%&AwBwbZA z74dMJV1kfQAGCNl+a>yj{>#uF|M6!7^IeSsV^P3_Oq z=8-DPWXX6k%O;MazLDiTDn?8A6UCQhL0Bzs6#hI}^H6K>huMS;5OBBoU3-0-y z;gIIG6bnhO?vUEy8dt}u2h*K=D8WVZ~j4oe;byE4NAth*_yls>C!X8Q32|-1A=|pTsR&326p-=!Xlit&6AXb9<=sX+r`w9y;A~P2j0*C-ovL!XkJWf99-D^8AG+*PeZZ>3Nm#mKEO@m z?2Z3cIf3x^iUXq{^%u?~#=BIW3+E-vAAw0zid>gy?FAYG5R(tp(xgGHifHc#t7$Zv z@;&1&1_)ex5Jun`yLi-@ll_meaRlh2z_K=9$Hy!V%#~0V-{L@%?I-2FFB9f<0nqZ>={5ghB27uqHJL> zC&R#TCK(ZsI4^WCVIYYn;GXO*&+icVdP9p5>^KSk<`o?i38Is%7ArqBCkCfZTJBf* z@2&xT^tj4}&m$=x&fPO&73Z?1y)yK7>hSEO{W*jpk%$ye0-3<0$*D1L31)-}24Ha_ zBG8Bg)|8<_K+urA<$xYUX{t(6?1!syzDhGQKp}^ki-joU;fW#Y6P}o4(IVzyAw4M+ za+3O~#$dL9kCXHv2ygUpF<2Q$vEk)E%eYtCM=;w#Pr`g7&2!OmW^C|8l~V7&IuUWnlDV zbtsA;@yX%Q3ku~$#B}55H&MplqX^v16eZ-Lhu)QFaCGdu*RD!i6uf4By6>v$ULf!Y z95b29V5;u$71uTB)Vu%cK!fs7oMpwdG-@DukS$5!#ri;W=v8=L#f;2Upzhc$RW=2n zX3!PjyZMmT=KxoRCMBCnpx3{l3}Iz)qn@y9S_qwY$kBH?W2gBfVV})!5;)=i&V_)^ zW!pGY&lc~rgV*@K5^RaL%+qjLxK~Q zct-EyQigYbV#j>K$r%$Cz`J|QWeqa#K!oQ8Jm}p}K>VHArZn4-Ig(LJ=f~+mN8tuv zIBheho?={s!9X&y35-gNQH~~mE-F&C-szz7?G^>HKO74_NTXc%LQJ!{NpYr3x{7dH z)%cbviF%GsM&M#C+n%xyK%JX2Wbh*BdkTExnGUF$)$^?)Nm$xW66d*EK;-doIS;zCjz}vV|%g59y0fO zaQf*Q8oAOQ7bWjlm6P#A+%lMzR!AcDQgm6holt02ZIR7Qqwbq9S2xAO3?c(3s3=cu z6eZ@{nyzhoY&~dRaof|ohW$`fomT5e>9VRZr|%&TNj1DmiUQN4U96da#IE*G z8h=nk&cNk_rZLM$@@qV{tdOD!XA(!y3=UAIp={A>B{PL&uayR#C5dRAML*l~c45)S za#%Vayu)sm-K{@Tx74C+3Q zB|FS92PH={yf)Edy|4t%m_njw9S=HM>D%49_~p{btD?OXii3}s9hqsCU|@KZHIl~| z#!qQfxb`II*y_3;Eg$+%M%cM1WXxQxS>nX-Lbb`HRC~(L6uNR^O=Ie3$W$Ua;ZM=S zxa8w-f5~+ec!5y1MWqB!i zw1yzmGY`re4UbtEdHGi=y|IdLA0V+e*2saQ5wDOPjH;=t`L&i;;CW;~xztO3J(a`^pfl0D-t$IKwI=g3b})`9yTsD_L^ zZwoURA$A?BY{(0f$ffzUp0sr$1A~4lDFa*Wj%CsIi;dAS<&VVKEeUA+3bSW!9Nrw* z=`Ow|wy8<4*=~MKxrmoDeAmjg#yr1r8m^BMxDOB*0r#D&YT!9)$Sp&g0Mx6TtpJZJ zRct=TF`@OF7_)jVWDG_~$Q2JXv71#c%T6Pft#hrcs}w*!%j0amI(lO5>wX7y2r*Q> z{EMjGky}a;hSp-6vljBL?iP#9hu&S~0uV7xb(_zUsZB(k{)uC}US;IhKRHNE~Bg z!Ftb1_)b6}z4ni4fTW%9-3TJuf7!Ei8f>7mAj68xnf$NZFUOL>)MFv&jTH4v$S)ny zR~Xv^DeK|_FgBL2oeHNxHcN|RTd!6~saHK$S(l_HmD`5oa zGN`)m(1GtSi2apR6xyGJL}6nS6Q9mjK$xzcM5Aelf!H>AUQ!zqhN0{D`63lD=&kos z?Ic?FF}NR}RnOW#87_y?a8>G}9gfEhdQ!gbTiIPh0J&B|RVbCuIF=ZM;Y=YvE%v|& z2iG3cO=P3Ce=WILDLi~jjGXpNjzjGtO_IbtW6Z?LNvwM%B(Y2-5o%uqN0lRk7V@!lJGC zUD32dAH1Q+bZX1EmT^^cUWcc7Ksx?})Lb_>wLJYYj|4)9bu#$Fc7;#T;8arn*Ksz4 zQ;!Un)<0j!U;YM&a*?18HQ!9pBztWw>Tr`g8kC@D0Ilh_mrsE3PoIv6j}vYzYtqt6 z0~Rk|zeB?!_I|7^Duo9?Dp^}o;p$@jZvHyDuvF6X+^Qt;SZ>wAHAiwl;%Ny_0~O7F zlr{@ipC@AS!mxm##BWCMy5mOi$n18q@7dXu7IY6O(a!zx8vzk?&7f&419pu2ck_-r z@>0stPpl5g@r>-4Hzr1Z{e~5DKjNcxs(JIx^aSboGHl}cT=?b?JZMTGf6=#ZoE5&m zlppkJL{ua@Jxg-HRUS5}jh(2s5!oP4!q*eB*xtf;Cm>c)$-kTmdj{kVA*!pxHg*`C zCaN@}Ru;`-ZJ|wddacvrvn;BSh*0%#GRJYboF(tsk z<`4GXo}+GK8TG>_;N)t5y4*)j4g+u9$|D0$6gCseLzD)`x#MH>3=EDFD{n}xAM3h#_ua&-(z%UmhunIq8NKe#&yrMb_`M9AgF- z@jSx2^W;=$#6e8C#Fju?Q}sSn4@!5zU%n4O&YUEk195T3xcyzvWI8-kJIE#Asud^c zNz56-X=+=85Gw#BAN2@7GNcXb59D*cKVvWXjH1Nr%%bbJDt-k6q)kqD^HjPvKvnvP z2TVx|;>1xEwjF9^(N`E!obR)gk*$|rBjR7%>@(TL#TV7|kBAM=ejuKXWy>iymDz79 zu)M7lRX{d;m#|FyG~)g?3=8Sor=P~;tRFpYn`kdJ4dIfZM72#Jyv5BUms`@}xp=eM zD9(u}eivo5(WZsbl>r8u4E@&FE=8$G;NoD;Gs@TvSp!~?*slIp3eJ@_|@uxm+3*!sg8TE2m=b6k-D2)+Csuv<+E=YIHu<4km5M-aV9Psq`C zm?UN}NYJ`v=MMn&;F*W?9-@E;_MB;2r5_l@>-cs;YCR9Z8GXQ+)MCqXe7-zRS0OHH zHT>Rd%NDLiCFX z9YL%BS4D!-5&8!oeJ+oVLwG~_VTiKA$?P$-%_fhZlImeQmLDms zhth;g*)c);^3t0lue%4O8-mc$RE!B|1#wClvdfLarJXG1O=m;Tt0?%V6s8=2su{%u-4E^p;Xq+U+f&|+Zh_q>>e7RV-W zEpmK74XXX@-cU>1oM6ac@ZF3c(&FyDv5tQBs|+g591ohtFH)Ti{uDBe zv-w~B5p56h06XrRQT{GaRbKG6;$Nx`>$ms25?Aj4vsVKm+tM%^j-T_8Cwr?(87m}r zrMba!7t7p*&sUtXOOO|4w?P1ru&*oTZJ!UEYu>b7u|5NZ%WEVl@Hg6S6eedXvy2Sb zm(ZSkqjwsE-?&`sV@%Pa1JK5rE0YF6WCO&}mT!Hc0kY2q0F>>VH}F}Sqb=D?^u2|j zCCgi?hNF>-tOdY@Q_;}cUZ2d0iWsC?>Bb!YZ^d68dGSUyC@jlFgVs5UhO6;Mv|jbn z+0d~)I9)tIWK38f_0mBQf&P63`vHv|XLJ0GjSI0BeQT`IEvN?)9~#AY8uEQ0JQpZF zo*7UyNMDK$Ij9xfST0s^^qYdI8k#kJkcpHrZkI^9g4V*qCm~5lD0|+ci>fP6BGvh~=$M&%ZH#Pq687Nlo0jEE$H$1k)bBS1<(>?SxwPym=TaHp z4>`*e@3ZpokZEogMp?T_$QYpatkSAN^m_x+>Unp^ET=YbEyyQ`V2>~xhaoWhk#<)_ zxABu0beV$B(<3hbkxYt}6UUJ@+5|nX z`!>IAg9f2KKkU~s>l|g{C%1{wJ$!zi87ZwMaPpKleaRzqoMIv>?FNbHg~XI$_d10q z(oT;5a$>{Wn;uKEk1%ZRuvfY7$)DdJ0kby5!KPPM`$-UM^^(d;Rp?vlhCQyj2My z7Dm$u`}MvJF*A6!xSIDE_bjcyTMj(ZE+2l`Ypsdqx%&g@Y+CBA?0#{y4QHACfn)%>v#hKl8Ut?pA$bCoAD+USry9xJbv*s!bph z3S5%@E;0%bDXr`Asw8(pxT*q7)3B73%cm+@OcD7!HoKv}aE%)2iQW8Q8Kr)^7p*@8 z2xSLKD`_dntQs>=vZ~=TXJnKuuS9>=_YKCcXEuHbH?KhT4kX5k4X#I1$r-IwALZf4 zsDH=m{wlY2@;u?GPmXVtF+7n&3teB~H1jIaA$h#_rx{9s^lqa;?6XuIETgUJnGKq! zdez~6Se_&?p~f4V;soA>=xD?;QUqH#XBquavm=?zYvw*qLNe+_z^W-E|IZdtOnp(=>%V|C#wq_mXQwV6l^+N>FU9P{!| zH#MFAM1?CsTKb%`~$!c!Gm|&Raw0|5sR~Q(-UHwWu`JmIN!nBDH4^T1d zdZ1;RY-E+yN2ZT^2h;)_6q%d&C`$WOCR7g0%`@el?(|vlRj4 zke%nw0{h~0i!*u^XNb{h#l1Nv6O)HCbMxwIiB-h)i9VD$lDwwX2a%YH!uehcf0}4C$g>Wzq5g)o$AUv{T!o zs;7e4@ir={)~QSgyyIqbfd?yJbr?6+L?_?^WWv&R`l_TkaF<>L(Q>HP zQhSSsLPd1ym(`0-i{7BmflVMQ=?5Vn-${CpOCwl<(0W*Vb;&(MAOC;`=O+8iJ;O1a zDVJWfn0t!iNb8x(if(QLD2?FI4IBtS0q9OAO>yF1^!!CxV|1*AMdeh$0}jT+xB*d& zH?qx?6a8EDrw(@`%_j_Mni{E&+$PB*=2X=1#6k~3DLDk7m)_~^QYC%gu`88O9-~@3 z!ENdQd{tfo?7BPMP8K*mnfSuhQD@1zgMJ*ok)2p~i3dPpaxPD2=ZZ@30ay{0Y77N! zm)aEr*~fR|OQ5DhP6tii3hFN5nfo5;xLa``h>vq$hyZxFRCZd_FW&1K z9{?6X6Tag@6B%Qt`ox;4W+)nmK{1_(tQAE`1{}Ue7*|FiS6;L-nqs(cr7jI&1)3TM zcxB5L3?4UInuRa1Vub|u`7CL$UP(+G8U!^~hrj-1U;_pS4-&FM@<%j+=g{~l42R@z z89EyZGgHjD4qC>j;^i?Xe-c})t@YOA`RW7#hi8+gQSh*0ICU@z%-#QB3{BIR9zY^VCT`9wzc0fvbh{T~C{ZOF*i5mn_=Py51@i!~!GH0U$V%?MzsUJk zl+hJ*&$Jqc9*HL}jQA|HVy+@~%`*_(MkrvNLb>I|%F=3Hct4QBzCEI)Utm;A_L zBw%I^_6-<_L8=4I`d}iA0lzgUm&uj9=LGHhRbTBH-_RDEkNz5&Q99qbE)VY9TS;G? zu`wPLfkZxb&3LDD?NH1lx2P#yV=%r}S2f!-i`!{snNi#rOu8l81R@yPOzPdh#vX0V zXJjN(#?gx`u^L?zT4K6$_Qcc6?L41Edr+YAEz|}DaVIlv^-2tZJNs2yoq@mQ5j*}s zHy1p_=~G3HdknIEC5sAt(feMFf(CYLgPdWg#FN8FAf+_O{OBPc-vSCFKV6IYF?2yB z{u!(EXSAYdut%}u9BwpHIujl!v8h+l1a6I5!P6s1^EZIS4nud|><Kh3sL$r~Qvk#FWMr>N}e+#giTXLKm_1CI8U4NMf(?y=uJu8;)(i9oNsOt)uH z=*#+H^kC^zJFGX$%?9QWV`>J9bWE!H!${C#jMY$z- zxV3HhJkpmf5MjY*`^ne?u+}75y4hJ(s?a=SqqrS!#miI z63x=e|GAfXN%l{^1)RRTct6sjRwgKe)l z!#(=0c_+*0b6lYhMcC59!w&pPkf(Gfe96fI4c;xEZCZi^bqqiBWnN3VZ|7L>KhCT# zDn_MdG65_FBxfg~&IyHM03DvflEClJmB6p+lxznes+AZesjKTM;*w|eE`+eh?Bu~Q zcT95kGCodrZEh6Mx3gawx3-~LzsA_Yq!88fbG{1HB5KoAEgk~ci)v8Q_!aW-tt7yB zZIsk;AJEe?+&6?hU+<8oeuxhF?RMEY4lDFEhz&`dl7kIP)-Auq9)Ln*&6JhFo)33& zgO4B)oA(QLT0j-wc|-61xP*sq!Xv6pOB}+7uq47B0FtH9KTrD!I8 z>k}f)6+5d~)6(%riSDqoQG434U>tIOF?-F@(ht2CqoX=#yMUQkIEd9*mzMe?2@v`R zwp_|s*avZ&=7%UOy*|j88cCaDuNGSX5H~!DnI{Jr;I-VW^Z{hc_*Hc2NF(7#{}XJzInJ)Qqitm6kC14?*gUP4aLoyzcuGh z$X#?ebV3oolz6@ zP*%lviz3zeCnoAn`kNdHVjVmBUJC;Q_tSDe)x`(&!zY+}q43xp)*(0(i7af9n!qQe z8I6$_R*gcqf??Sq2##MWelMX51AhQwK9<_0;mA}qeHV(S$?Eeyz^x-sxMoAd5f>^8 zuEKcd-J%Qh+-#OM2#I8%)u}bRfP7{W!1ovTWIv!~C{C0DcXF0jd&Md@%$F zfFuu7u(GkR7W4}6wVKm6hSY%IeMf`Y`n>V}6dPITUSL3RoEWY$+~)^K-{jG~PwXPy zBx7gM`rB0BiHpLjYpxM&7(EI0uF+|LA8cpm;dW$L7Z^|%t|13+PwZs)x0?~3aBAvG zPj&aE3CJCbEmb;MZlrVF{ONWI2va$T5$np94gYdlPF=mdnZ$k8l|lA)G<J69~{U8_L@!|F)M}Ks$EbjZZ%C z+{*449q&aTTP&STU}oUry}4}=q?`Xpie_3b=vYF205QBs#IjoDP*Vp9NGYL`)hOQu z`PpKkmDpo>n!0TwiLvBMcWG{w74XsO2u=l`NWx~pW`%{+k3AEfLbI{C z#w8v%2n8*0d-RiA+{6*qf)2a0f#n?Td2dQ+2)2k{O5^gNnjiQX1wx@h@04wB5t-Rs zwS7bIsb;g1LeV>A=Q>)c4XWOE`4dj6{L0-KXikMF!^w~1+9^7JS_&FdX}|RjAx$DI ztPl7<=dC!ag@k`UESFen*v4>5aCkZrVCR1xt^vJ4c_@mO@sw2)S+QW$-6(au5_R8d zB4FHrtbu?dEH6&)k|8oEd7R4UZnH0uZx&Vd7?I0!9cXi&vga3gl|1qvJ z4ZnO@R40}=s|3s&e_M?=WP3j=Er(uF6-0FZ342-qs5-lPe8TCC080ytBHQH+ES%fQ zT%(-=XXfMnSIN}GMlJ`jox&Gnkvhcae*k~iiQ8if7XP+9tjASugWTB;y^ODm!Ok-^ z%`0bK3sXAXR2@gTeb>#a_sHb#UK6L3e zRTg?9wz=4v0qN&9jj2WiO<@f6s4*?oY$Gg(OG9ohD|H>Z7%%Kw4FvR+HSb647!6g0 zL;UCVH0qsyRE>3K{v#P6tkRLb`O9H5-;>AlXV$0jI`V3MNAEwsW0v=j*5XVqF|v#@ zFbKLV$Ux~nck~uALDn_O(1;zoPI;t%dY2VNKs|l_a`06F+H#DJeNmYd9NY4-n3)|! zA_XaZGE2Cy#2u#j5maY9Pg4R2!EH99Y_mgHPZvz}V?rg%HIF&)IR-#`AY zFN4m9D`2J%cG+f>kAD|l77o$1bwOIn?Lw_adM|f*l52tbrN!Q7y^oK$YO3_W`dvl6 z#O10=#ZGcTfai10HAzr|FWD%51vuk?)z<0IMS2ul;=TlN;ZLNVD7ujwxG1y5X z&~r`(>x;0FoOY~=xv2^r$Mw+gSe3&1$th@O6oytKBNFTj5oNrY&Ktc!ILnx85?bqZ zSKJM3Sgjb8Y$_=IOMunB*WPyEqHkjv zR*t%Gdb!fh@XXpOcps>Ulem~A<7F6xILpKP&d?yEJIt%xt%n9BiahOVEybZY;E3TU zE=IvO{-_p|0=x^_2x2CIZ(j6*PPwt1?p*Qdifw|cH285M{? z>>7scheaH)T%zdmj?hIGi)kIKXiD(;-wwe7pd*tbAQc_2P*1XVZexuw3lOJcD zSdq_LSyl3bXYN?R-taySp$+b6_;u8qA_3fAu58|>8nYGZZWDLNW z2=&Sy=rxqLV<$pAC@%|wmWiOJWFKxM1!J4;v7yI^50F_lbyvP&*M2tt3v>Hn=|1t> zw*HOYO?)Swc;8~_6~xO+_<(}3*T5BblT9d>TRr)22ic6Q9I-D`TUJ$;63%G;t&E^m zfGI>NGDX_Oe*l+aHaXp^Hv;2hz3XuY&gABFb} zlqatht{a(0vU_zQW33!nVHu3(n)qw1xBC=@avIPnzz6apCXlUj zGznt5_${CYgHHthxMyB#cl1Br1ZN{9dTLUxChztQI_q<(tG?hH&$MP9I|WURqQS3CW% zH)8?Lcjqrk4=j6d43NAYH2Q2l=8PS$a1h?{J!Q=c$(ONqbfJdw!d?28rle-npuusU zk=;Tc{P}oxDxY5hp=bw>E_QYsPJpitl+LG7@gUv8LvC?+PGo8O;ayP*nm|RB^F>oF ziZO2?H*IYqztaezfk$|$fge%-d2F>&`W}8a;(A z!q10>8@}pdQzHu8()K5HMp(#8-s&lpQO(8CVu4U!2VNPI6L!@wR-y%QAtiHceSPnzKKLi5Y{rg^yh$((zXHG+ zI2R&l0MS);i~ID+w>%?r7?)Xq5$Kf?z!Ie_Ia_7j%krz>vfbG}m`uuC*hBB8R-7h+m%Dc{V2Z! zog2DH2@b8`smwgzDnI{vT5}-*b552adBCAq8DVw(djsQ1+A@MkB!^yo>R~LB|Bi_D zV1;=TSnPH_jpv8a>L~Osc{@1Ao3$P-!)~{Ul8e6X1{dYPA8q929db9ID_JHuHt)JG zy9vfY!3~r)inA5zqOxer?Cl9ZBQjybz@}t1iq7AuonsvT>=U?*B*}k0o#3Ruqa>I2 zivaI{GB41GdR3b8{0ktdBLY;p|I(~|*q4?#^jowu`OVOn+ZRXHaL5KQW6QgmUU9m! zeZY>qdAF^_xuj&qPY5sHXj!?PGZ3!OyBs4eMnjBMsd?jb#HH!Qr{S@caHrrn!n5r! ze*V3T>#l}xYntt7`wIXS9y(A?$zAb6sunYGUlSAgQ@06eDsOO}6| zWsVv=>K9D8!dbnq0l?VjW&O^6j&|>~`Y7`Nu3bV$05n0ENZ<{Q_PD-rCQXq)UUjK( zv5Qx>yFV%Z1iFYmc7m`(=3;y{KhW4o%t_z~9u|_Kz?xp|gXy5VZMIs(%Cn05B=-A~ z3ZC`$%R5xmhx3Q0AQy)^j}TO}$c-;EDq`GN7hA0MiRx1aPB?h!K>ndyV?9I`AH5bG zZ1%*pUcHkN>e)yLELM&K%!3D9lNS-nEUV9k+W&iPT-HtIrsnDvs?Y5u0?wYFcI8ivi5)Ir8c;w8mb2K01Cp$PrT6i@24lr7nR?#C{_UMja^*jTp5>tc}% zW6`l(aIM~2o&u;=5%Ynu=FicIDAu^9=DJ2pNZ(HQmIwXKEA`;s1wc-enOhFejf0>- zK^b*O4OTrW=?FcJQT1r+HXe`8h6VF%e~MXtQ%w@NEXMZmc0=@lag|1M2IbGnq)=Kg zon%}K?Da>~DjzI8S9{-Mx^xItYUzUAQLZzMi*tG3Us84g`o=vMAyK^g|FCYL^lBuT z0q?suzvg$JiT81?V?aUEOIw@0yMP*z& zEKVNKY^v}<`*7~^DiWFAx;4h>p^ZoX;)M%1GWjVd_z-we+F3qxIlRgyD{s?u>KB(Ub9p)SRTYhS~e?2Eb$JYh=NR z>Mz+Zl-jr>ZDRUUGyhfUbsS{1O|3wFS45HxZjg(QpdNo-s#6J#2`$Pv9%se03NIod z3BmLJMIm!0T>IOB55!5bBJ8Gd(KPe;n5V(9Dyy6T1bPbn$1s6}UP-llD8R>K{lZB3 z)bQrO-%MnD9c~Uo0u>$w7FeMZc;0rA{>D3%qn5~xQzBWmU;qw;_zpZq_3oh&v4snX z&URuQj5H!-q0M9dt*m8fKWQvvbW2FX#Xqp)-Gu@^7-{8_!0THy2zF9%aYa$xbD9^i zZ7*4K-^SV(GAJ0@3q;qja2+arG`4JYtdU{)^uTlrPm|@d94k^w{a#rU*2$u%52DmN zZm)R^+TO$AX|vf}=`_h6jVxC|Qc{D$g2%t3UysDm2Il9X{QXC6Edko%f?K&fUfs?T zk^_y1_I&oxRhCJEgv)Zez-#C?1&75Wk$~2PdwFmnmm<9k6{((9GQZ4 zoXyeEsEu7Oa87s_$LRE=oN$WKvK7`X*V4gwi6I+YP+3lRru^9$-XHEks0^zVi?LT9 zX*)m8OkI0e*SaNBKwbx36bb^-^z0JE;XCJ1;kayh*3E4ll?J*#8Loelf5xIp))vr` zng-S@JP@j~Qpbaa>Dhei6)v}!9gD+wuZa>n`)}{OesQZoF#}#1ebTEHYK^{Tp53Bc&+KYfF7UZxaKBsmxbion{dZ8VH+-JMqW4gML3((MY3+(#}nZ;HB6vOQAoxG8rUo ze-aUSVmw??pkjgCW^l=zGv|HkkObiCfB)<4Xk)i^cQ&5;`{1}K$O!Svn%R>hFXg*c ze*A-^K}3U?;5wFu+L(yNho>fP6lG0&Dah$u^F}UbTMh=YPB0BhtB2vx4 z7Gax@uES(tEYk-s(9!kNTS@ygEHw3@=Q4Eij!ATeM;6!zc=;^~-r+EDuSIJtD zi(E=kwVLgE8&3z-P?h+H=Eu_+Rz@gRO#1g0mCJ?AyZWriRr}$+MOJ)-xo#Rn@rA?=gr4KXbBO@E*So0SjS5PvOxZ*Fhw|sK$ryscL7ah6eh@f2dOmuR|+Z1 z5L1%a$qStAvIa0yklMkVJ78tpY3kD3{Z}Jn$%fB4LYPl8_aTZLu$5AEgpm4~w9fZ~)qT&~2fA;?xIu>i;z8XSQ|`+Mq$8NQ zK8nD8Y3fTQUfNz_dPupwkZSYk?c$eDJ_+}Y0=}52i|q>1O|_>-HMWA%m`tNW^6U`E z0hg&|Tsq8b7Wg)G{u=|>iOXG6nHyXHg;O;BTg0Mpi4x*rRU50diIIq(fN zJibe^aRT#e3l?`AY_$#>!qF9f<~j7W2N)xTvS?L3=6G^yst#yuy-U6gCn z={@6|&b<=%JlcAPljlX>TDVJ~0nlq3SCR~2KZ;m&drdGV!;6e^&A}Au>IiP*ucF?{ z?I8sLIfaTEji%@damDx zITlX}zqxomm;~1fxa&E3h$N9@am!>knEopNwYUm`D6dj`aRD!55L&}M6?(>p+cO|tSk#85+KXY{iuzv7dKoVVL02}f?)Z_2w zymkDq$3ZV^@tR9>WsZN_m|4`- zz}xOI>9E5`RbG|!1SG(`e z9PQ^zt2v;R_-26FKE@D)0B0(ss)%Rl>pe;LdO7boz%Q1il8RVERJvD?LqNsN*Zn5_ zg;ihs;pOxbj4P`?`<WLCPyEiO<^t-?UYQ?Y9>X@eLs5{gd(VMw{IYq zUoMG@MTBdvuc`Bn;7~M%(+x)M&WFbnV11Ai+B5*d&8KQ75IyxHQP15u#YPnSXE*xj zxf#pe*G?mz?v`yz%Rd?g>3t!_kVzaG=Hja&Q3-vzq z;+jeOz5e1hZo0H3!s)n>!p+E;01(@`ok!&d7Hfnd?KTzl%~btCuw1 zE6ZrbjNQSkyq!CyEm8#_EuBi;fLl!!&PWMhT~8rzj?jbV>JUVjb)Fhx2^nWc=wT|Z zfk|+q$Y~~1wdRK1L$DCM%zy;zi7cKmod|gG!W;77_XT8${fOEbpnH~0g4eooS-;2u zz(;uo_Ro;TAKu_r_Dv8Wz$5}?B+{lh8p8lP+M~vuAi&j8AHs49-Gi9uC2V7%_#$om zo-u%iftH7~$RR3dAM|Aq>>~+5jf8=)^8ZSq6wH%qYK44v$_Yu;oBJK1RGidPTUXC4|UhhymhQ8>ICzOqQ?` zu8NRCuVlP|F8fgXLwEZ)lx#C-;u&sN)xmdrDa+0PKhd$Ou;p{=!g3%!)(3^c<_2WO z_ZwK>6q8UIY!B<-&D!p(fh646RtAx%-NebSx=czEf8P1w0Wp+9uyrDV%;n3keS{yh zZ0EV5nbYX|-;4|KS=1O&07^wEHqQ4lQnAAC=t?h~@c%v-*~(lvnRN4i zH-~_dj-z4X3^JilWlj1qrp1(VD1}btl#n^yN)Q7p2+hTZ9@v?fBSCJAxx8y0nx1{? zU+H8waSJPiJIW=2oxj01y?D%sOzjX6$q!hJxBuBNxz?6Y(kRj3qU2{&oW#OJlU}B_ z$S8eAdo8XwZYbj2X~@lYJc4W-mfS-&6k_|y-2M?EsM)fVIJi@VZ#klBw)QP zryZK1X~J@#d(a{;Qb0+qQx^z%3CV5lnNa8_ECc^sRmMRr9O_ag$>J7$7QfAF;V9&?X%oVE z-`#p0guZ#MS`Y(E$BCBJ5njE?KH+h%wh(8J;6hz0;SV2D`cdLLwo_beU!k@KZ+caJ zE>4Np2W0fls2k^rL69g0wk^fn%ZPIYocIFGviw|*$9!0*9+;ipnZ`W>Nk_`h8D{#k zM8Lt)CJ0OW60S%#py-*ff4PVrjpPg@W%OWGQE>l?mBtY9p=<_k@YBC5i%x!-*EVD+ zW`~!DjKUv^maz}V|IxybYdKBQC-kIq!FB}NF>~PJ-_8y}kE{*S0MPFjsET1S?N@Dp za>i6sCFl62Dxo;@iJ)0Hu`h^ciW(5tAQd@ZhBa&a-%t3*-T(hMY zgl0>it!Dfc(zmA-7o~Q5v@AVGgFt6q2-s*yiE)#4iJ@>BDb56L+isp;_l(K3Q_{p` z!ftcyesQ@ISZP7#x}srerY1Hds($XXtsbKOx<5mH`a#)QF}(#MKChL=GwM;hvos=` z|2>iBF(O!3za!}wxW;^ivkf5T(eW{Bns3BEx5P#f3vwMh%oH9immr2Wlr`8M^UVoV zT%(EvQ`JKf7ixSMAWnEYQ;PCZs{T_2n5w(*VfgI~07x<2Pwnt&a$)k~b%qWhwfJ_S zh0RS;q_T_B=RVlBUaa3pn$2%#fb%<*NJ&Sw zbE%RR?f5{=9M#%$!$1?(+BEZtzhE1Go%^m^vPsS4r*mg$N=f+=40+EK#H#Z?h>EG!!%en zW{r|_g6I)WzLJY;Fg{>se%24Ewos~kC9t7 zSPQ?_fHV6xtJnZ(m&~Dr&S|6p{OT`vIr#O$S}37Wq=2t9E!DzYj!wm-k&D_$@v+LW zSQPzb4)emHy3xB@?e}lX({pNQwVf zsxBYt8O-_IOhK9_E%p6qD=4yBShf*kYk+v*%3zDBpepN3j!+nby*!XxeXe%!VT>P8 zHflFA(K(L52O4?TJ&L#%>ou=Qm4Hz>FpTBeO!OoP2Cb*>m&*D3GNPF%Z7vSNEIl-0 zwOx8`s9$tbHfR)rqtNQ;pWPa9tzz;-S6n*_@=)o2n#ij9naS&z5xJuDl&j<_q}X3E zhjY$<)jU&_mh_S3w-qrc`xcsq8QMDngot|9Fp+jitKhNE5^w(f_cZ&;l-D`wg%1?c zp{Xc0`q0$Hi9Xs_EZSaiFFlBl%&uk#A%^o1mv6K2yG{xuNx8%=&QAzo;2_C-xPga> zwTW^jl*_(q!HN3;6(IMn?g+b(N)D0xNYUNxgysTZ(T}`LFp62^^P$!(y9Bqp*L1ql zJ)ChpEEj+L+D(gWm4xtnT~3IkTJlHu_u222qj|9!Q@uLl@L5hA_f|V;?TbQA`r{0j z$j`lhav`*}MY7wkiy{Bkd)Qg)=m!cFVuZ4JdacC}*2P436WBZ=^(>Z4=QW)Ruu4q( zvkcg(pLp5uhPo!iu-K2;)V4{V$4tT@7Ma@ywDkq%#Myqx?(&KCXHL^+b$PV{z=Jj4 zDu*E9jtXw;m)Ngp(_b~tw;qpUBYAw^JRT?8kRtmR-z=(jw_}DtVzvMySkVa58bh)! z=|j?=cUma7wTcj>-{pZYX!`edvh`FFX#gB95D0{DF`hQ~R?=p$cp+4l7Ofuxu_AQnfHmBBWR` z_f+l$L)B4KxKd`u^D@<9f-fHYrznNZ6tS{v!fU`3nw3M70k+ar;}1}54z~v%w+>Zj zYD<43D_>o4{K!ee7n=!NUmO_yC}&l-woi=SnP=O`C&HR%ThR`c|Ar!}A=Fa9rAn~B zDx&jnaV~2Q?j+#{-g{AQ+Y1fAICY;XS`7u@9Q)?yF{;6beRTl!Z>tcsC|tXL?PF!+ z6_xK;MRGHNIdJg;(xS8PA0(zkrGZZfNvRC`U=rk=o91&>v$nL-t7EsRJo&Gzu?#Mb z^14&l%G(o*r7KwQr)hi+yy6?q*+U-UC@K^+BkHUKLfvdN&7=OUgFwX}>yuXax&t{H z}vB~%(%J3GGA0$ZA$QM^EXX%%UhmP(YYg1(idz=c$C)7%A=mauuj*M6Ix zB^Nh30aAs{tc8+VNYkZZSOcQ->OEW}UMkwP=Vq4WV6TF|=TGs;lW*k@VjOsm5Bdq?l$-i^IxH$qXz-3Jghl zAW=9;Wxx2Hwq@WY+KIu=gV^1_ivtt$g)0BWyVL(h4VSmBtmakjx?a)FfU%JKZ4@C? zjbo#d*jB%ccuAR~MiTe}5F82kMwSxi41f4m#f+o1FgBS8Dl$Z0U(maYHC+&l=7g{tHgjsLJw)Oltd*6C&}$tmveuo8gm~gJuAx2i#GE zXj=2;^~H7G7E>IPGD|wBrR#u7zoYN!OhfhkfcmAVMKctIUq|Uw*B!ltgoaSt+xJOi z@oA%k$wx*@i>V3j{BUzRbO5MJt;|Gw`YLeX$s3$;ygQsL8alw>Hf1jc=L&y|HGG+F3%A-4KwRqCN?{RSjm9tc^V{ z!2La@L~m~Tykd>1-O4*cxEu2VZW$fdCQMpT=X!%CJ7QfkCY~q5+2Wa60z6=C|LLY6 z$aUqigsDr#uB6&@{GQdoJ-}Fcutw0+m%k>c@uXSwf~YNn&&pE6_nKb#><;75@jkN-0ay%nN;vBZgjw?YkC z4A0Db{(<~N}9r$LSRgXUdsmAT-C|x>Kk|Bl+@$ViE+-i87i)JihrpJQG1nz z3D6=tb+T1B4zkYK@fod!9U}FoegFUf?%*{N00G diff --git a/data-raw/ab.md5 b/data-raw/ab.md5 index 66dcae4fb..4de5f3cd7 100644 --- a/data-raw/ab.md5 +++ b/data-raw/ab.md5 @@ -1 +1 @@ -5e69630cd8a73eaaf33145af0cf82601 +a5a28ebde6fc79e231c0a6bcfcd8818d diff --git a/data-raw/antimicrobials.dta b/data-raw/antimicrobials.dta index bed1ab784edf30ef74443471df589d366d4a231c..f66f307986d60eafa2587b68676372253570cd01 100644 GIT binary patch delta 7987 zcmZu$c|eX?)OViczDiU|+6!T9W63f!gr*Fkj3s-TRMJMa5(;CRkmikp?CaQlXv?{n@szu&pPbM7_wlI!+Yu1kX8d1i1E zn>L<(!V*2(v})7Nvvs>ptvY5d80$RmtzJ$32b~NRzwVX4O*@%tLjJO5!Tx<)^sgAH zb|~~tV$8rblg#}MBkKy`9N>`Kh zUyHzW36sGXw8{oky|r4Vs1?5|#(`^XOrfjF6w|N`i^25Ex+H*RrqY;&VET1qGAPZf zq3;US(X?py1Ta0{k_^zoJo;)|x+SzWr5(^!V|uO?zI&xvlG_Y*3Ycmi;#D&998BwT zOBEv?cQ9?u<3CpCTj36WuruWxFIJ#EE;$Nrro;K{!?rWdro7Wn72}=)D~j2v%>+~X zb8O?_MF;Xtha@m{zK{gQ!@G*{S0Zyii7unCg zSNY@fMOK)etJ;|!UMp6NS8h3*&J;`p)3BTT>Git~xb}or-SpztuL^XfQCon~iTZ_u z?`FDlUss{KIm*OG9I>D2>Ejy0_}6a^CXctg`ka?MFF>y6YI1&Ms13bkEUwf=z$1lP zSixeTgO=RJbC2<+z$4w$eJ3^c}tKgN)H;7l>@ z@KnJOUf@7+^`KP2@W$p@)hWdbepN8KDL5E2_Eo2ujrkDDc(FcwJBIo zRx2o0aAtcpV?9B7W6_TP55vu~*R+R1!16Q@#`V2N8jlZ*F&=-TQTL9}Pe7=7&R$>k z2}T(`zo`prG-Mm$&S_Vk5X0`o)6{v`wT9t2YW&kO|zQ^{TSx8D%<7cY(g zfs!VC~l;Wl@IasJeH^9n?y4% z)ya08#ISr4*qF*=rUT8LDCrrWGg%U1n_2~5(`gJJOf=hSnF`N!n2gMt8~MzU2AZV* z4eY)J($SWSL6{B}%m<={66j=VwOFp~lf@>>?Vg`3`7QCy0LpJiDOhp>M zP7bEwohZefk~YFK9bt8KV1+JeiY2W*EKMySPFY>0?30iIoNl-qHRO9ydtT- zx(9(OETdZwBp#2RRJk_pF|R}=&*g@h@=Rj3f=ZvuIqzPvyG3`D+GO{V!%?y;gLC>_ zg0za1*D?#&;NBnxtNDAG=uVpAKutg?Rg`traJ;wXN*y$XXRjwugTfwfphlMRcOx~g z$-l~`3TbnpzBUS{)n>f$Q1PG;JLRDQTd0czPr;t9iWMHdtk$M5CpLva9!gE@?V{DD zF|G=OvW7C6>)}pnYl&1=qD6NCSy5Z!jaE_s$VuO7gl$x}=D|?Nr0~9Oc zyBNy~H8|+U#*~~2sO-rUAiW{l)Kg)o4iQ7eUgcJr^BbVB3>}dGy3(z|5`jFK-L7m;uGo(SE^y?F5Q#j)+l8)FnSmBKHNjG zp|tI6i4yiIoU(uHmY!XwaeJj_DLK4avzmHsGMXf*Mdl4s{Tqch>!M?dgE4f41#LMZ zSG#520hg7udyP1NEBp?K$cGFEXLr>Ffoz zpxm#9F|9Ngx=<+DdT7S?=c^LSGdInS*wUS!<#)d#Lsy4x-&Fpr4o`^FoV}HksKy(G z0Zw=#!+6Fy=tS^LuKebA-b!3)rvRnBl5CW}X4LJx&Emf1PmUn z)TiJ6Qkq&q8M#+idHfIZs-be;y`fgN{ER+zRU0h2r`gazdzJZmR}D)NnXiF$RW|yk zDYDT*pbIW)s;0cJ+`TcLD#KWA3|{3#aSha$IslDo!bWj?8`UhDIK7E#Ln~UU*A&ob zNjH@@O1U?82#l!l*<(jq?W1x!=pE!M!A*&eJsCezxuh=WqFQ10Nv)Qg!qqmTn_3Za zsX|LXQJGvfKmG=@d#F~F-A!ef8U*kQsDWMA=&tll50z8h3XCse>?_J39qpy^KCi`X zNq<*57c5=3rUU(D?8kwV!y zrJt+C3f&wd{fUT@6C5goj2X*MN?pKi%XtfEvFZawaRglN4=y-rm8y|tg8D?qcT-dc z)7p=i$61qA-iJKcM0F?UB$ca6&6x~ARoj*fjeGyoWcCeh4C>uGW9!a>C$ZbsmQ_)*?P3 z@&AOh81UvswTn61J8x3&E9O7_wyItRr6pkD9oD!xyP0}S&1Ghj_o;6cXpQ4?bT`U8 zpzf~RDPcLPy9VBrmMgJnOLOxi7VRnxY&)(#*Od-tGU>o+nN}Umse7nEEz`k=_Fm?U zsNd}$zJijNr~m&n;9@=vBqW9XE1Zhc0Db%eV~OYQva9c&150oBs}kHU6|mV;;WfEY zt{1Bg2R$@y$AWIEk!qz{88c7Go^iisQLP)`-6+MAO71cu&>feYPk;A zy@*K%`r;Osv4lktOe0V4x4#s2U^RmqzW>IQcdhG!8qca?aP5{Di(P zn!te@RD0UxugQv1lOa(0nFH!DzfuS_Asm78yoW{12^A~kzwd8|ZnF1qmoVVsi z#`YS^N+@!=JJHgP8tXv<=@dyvoa1_WohcMh_}4+Cvx?0%JOGxL?IfB zW20X3T?DNQj6!{sObL$ogp5L@{a@;Q4A zaq@``#DnqfeMc&Z)L25_Bxw%BO$;wRCPrhN$J4I~JPQ)(c_IfU3o}fUCg)GpW*e|c zCdcP8i{rzVS(?~dcaElVv0>eIp|QOfyBlGJA-Tky@2 z2+hEcS8AR#2qluK#1D*M=uRflZv~SWw?&e8agDSy6PYCsidv^VR4``0Wa8%tklbD&$+ zh1!(dOlM~HR$^4zQfG|zRf_Q!t#!s|KgGAzIr&#t3U+1({z5rW`GlQxmhT+1U^5Wh zYwj7y#w$9*Jpnw3hlg=J$nCB3`I~z`Veb6kFl`EwW{>b<-!mbnKjX#l{Ak^VxC#7I z$LnJ`oF9iVXm~qLuTZDDbZew^>4e-G9#kBrb8Gc2;P@6?93PLCL;3VW6r06AlKJc3 z#>%h%n#M3ZiIXs#uGIQ>;~1Ytenb9|<^d5C6T`xj!}*FS;=hH`5!Y_knsEgEn5c8pTW0~2<1t(2LTZx4-({ihU@RX~o$5@LkexGwWH+6uhXT42r?WO>&eVD9 zc`s*(n$ML8bj)Te%@)Y?@Lj_R#-|;b{LJ{*i4sI zooxg!mo`T1(rwUVu5L?1vvn4TpNP9S&grWZuwH_bkfRHF5T|p8c73z-bkZS4>*8RY zH_h#@<%^Uf%wdW*pZq3mmkCltBX{Yx7I2HWx-)CHE9o~L;!#|CfoJpOlRaf0VM^d` zWpLIf*p_mylHpC?O5gTfWjD8=9oqx?ddS&u3g zx_DK(@tD?KkQ4oHNW)Jm`axGJx+&p(T3OJ7@98%@-~()-2sdbgfr{t|O>vGQlA#%v zE5Zw!qn9dTpam{b#UgH4+%+)++TdzU1cEm{(u4=JMGIZDf_9wVVisTC<>}%jbilnr z%ySgkTy}>ziBK4Yhnz$YuDjqY zK7w%Udlo^atyq%HNtZ!im2))!}CHbpdG>afU**IeVptIWk4 zUg9at!!r$evH4V^k=Skl3oxgpD2FdGr9oJKumlYB=C4k*5p!V?_4XEAtW!P` z78KZCv{K-!tF>(ODclf&Y}|K@%jdUh8B_!ehUcM-0@2E6`>2*(tE zcFW&iwC4gc&7Wi5jLZEwrY$%pK&*hR4$2Gqq=>|@$zfHg zdGOyu(edp1)T*Hzdf!J}(zxth{7jhm3TAeHk*h#1b{WK8aIy{Jyv@T?gT!P^3E_A? z2@xImvSnHbbAMvlU?%NbY(1FMEFZ@X78l?obsQpCvWtfC2admz_%3XlbD-gY&cnj@U_JB$>K0P!H!eJ zm+%ZvPGQ?6*gQ$3xRq9cTD=1A_}GYve*^vkPbM)>FUc#Jw>FfaMT$5Mf8f~^F$vya z*J)xPyv1eHIO*Oko6g(dPkc39+=2J_;|!LIa_p2U<^kZhsUj0p9FQhjf`(tDiMF8Q zp)|1-1cl8M%@w|sUp!m1SD`wdn#(e0fobzZU$DfB^O%_$IrBw-jc+LjEaV)jg+&WF zd~15WkOAhK)4;_d18lKqu_(bBOPH=J8O);{S}hSjgFO~65esowCcmGSDO&Rt@a{~J z4|Or|D=`Ng@%2~Y9Ja{f;R2%w<74}WSsa`jZOW1fGBp~r?Tun+{U$_El%9dI@%7GZWkZAb*MOySF1Kl(h?ILmz+4^Z(2Iyo$VaD z4|?wqN1-#l+#x0cbfKtSqO;0kzj?1{1Ksf2Ue?L(RBxZy#{aN_=k{}k);houxS1Hn z0Ni8}W1%Nn9}sEK3zr;Vy$-~m4=_1>(E6Zwz=yWq4+`!pgD{>%DFkEaH=>M%e$XKn zt^W8~uISDRzcg3$VTI>02Yi#u?1$jbhqXI?hQSfu9}cLKlhFCq!3> zqTmypZmj#Cz(9W9FL}xyyFt7?#Iv@5G0!`scnA8(H-ez8B+I_3wNy?y=nGpAilCL{xl+ahi@}&hpC{7cmw_y>sEo2GJz&(XLwgk@?ir>MA`Ip5Y)_><7_Cz1bU^3T}^+PrXo9Me@-czudLLP}dzy}1w6V6cBic6nzA^e&?ea6*` zHU85Q_G|}sDdo0hCygu>#Tx9QfZqlG6US~kS|*AB_Rz}LVkEHIzj-6Zz&`r?t?19K zJ?8w$6du6se~HzQgP*?VUg;a0^`0A{T)gm}sXvVN<=iqI!H(t3P9BaaXQz(gYkqP& z{%?|FBPLId4oj*c`NUE`!$A0U=?cSe+#w7WOWzxk_+ESp7-qmJECWMdI8FYFAyQ-g z-YETEU=C}|4U~PePC~R3f%VAaWIU~;WkZhF>niThj!L8xB}e8Gxgb< zd)T#s!I|}cSObF}+{d*I452Llnlb9jRg>}AcDOcMM1oYgC#Z+jV+cN z92FZ;Nvx<*6T8@r4UHO=DBmm>-Z$UJNwKtGtcbVEw8=jpYvYY3m&EQuH)kG z(<5TMPoRHbW1oPgE&Lm$EsXLU{>ZRXpBuHzqVEsI-?FyV8ICTuUS635P|MnTwV_#h zt#+}FSo>C3`mc4d7Di74>!XY$unyjk0@fEB6G7Coqlj&KGFV@4=2i9gB)}4|7HnJO z0REQz=n9rfiKVO=^hk&RJ1R3v1q8dkMUi}bE8|KkOE_%pp>=h-?E(ORmLoYjjdX`62K2%3jo?kOmDvP_RE8q^_LNW+9ts>- z6+CHDb$BXpNOf?dq*{!1tE-^Ab zGS+9p@bM!?#74$qUMTor!#d!L`SFme4Ieqd^3v>JEsReE>d;rwGlDr}-uetuaE}gT z{2VRz^F(L~@@GRB3+4_1i5=5LMS2ykxR11PA2|Z1>ms@+EZ$^9DcEC*;5x*pX)*LV zPPq_k^Q+u`ywzijV(bEo*S-LrqHjI*_L0IxE6-+ z!4amTe+qcujQX0Sqzrf zyAN}1P#j5ZJuMTQELo==Fw9$&qV;FHTd7gbN#($%lg!t_Gf>J&EG#4r8`rbf+F8nPr?2y&cokGfs zr$T&Z6AT*Y#v}M1)7uMg3ilA485=D-PgfwOpN)6%7EUy{ieR#PRT0kkMGeE5;(XPb z%?blD29pwNsC8RtSZ%e@Ry%w-PV=UD^~7^SY`4R_7{iN}2BPLl{#2T>IGmi^<`E@+l}V3Q`0qzC^Qn!513AVDPWvY@#UR*&d?Ak7;r5G$ z7v8=qbaIauEZN8CQ-U&c+~PCWn|vlSB_hX;IK0U~%cm=k?WeKFUNaTrWo8N|ra+ujF5{2DA zi%a^ywY+m36)5|x%EPT^Iox5Zo$2g(h4?P*y{O`Q z-$pSp#mwY`A~0U`;D&Pk#0@6$+HE22#h=B=Uhr6j`T_Zu)i@0%K39=_%4zIDX1;i3 zi05{c)|Sr+H2-fEiuZ3s(V2j}-z$TK?}R5+`G-x2mqpxEAm2if2^ju_8${SHkeP*A zbq9Du)g3jC#9OLcT62`}&L+EkTs6k{z8FgXiW;-pvZCgKUbA%v8tlnqD4@=j)RK=j z;^M1moHU;(v?l*4>;MB&z@1oV8LP03lT}IjWYksJa0F~y0ler~5AB5^oWYXa*PG7w)mVc{WB4|`0_6_ic~FLq3}Qa;@E}cE zYRq+^YhS44Wq~5@9^F|3Tl5xx|RHXcIiY5=Bs*9A}g-Ob8!6eNM<1)aWe5Pp63_iJ(o~2A|n5VHc zJI`X53ZhF>&;lk^6_pbOEMXAfL-m(3YEiYs+~Kd)p1vi+4LBL+{=ygUJQVwo_YBhqW`O)ra7fIzcS`q|Gx$hoX%+<{75WLF!mC z-0Yx+ol1r~oOKrd&LuAFFR!x;UBJ5QG&^*}jYs5VuXA$z;=${n8@2J$nX>L+c^U0W zgDdMyOwXbL^1z8ERM-DBFxX3%*uRSKps96rb}6LTV15HO2z@BZpN&9YRg7$`AKPg9%gT<`lFLVp844btI0!4@pyMFrS~wjFRj4A6QF+jf zAv&wk))3tZ>p2^x>25ghLNrik>W7Wi=b3mSoc(p2s&gZrI8GTH4Fpq_x=e{z!$`o? zHDY~?0-DuSC?TD!a~~K(a)#P1hMZ=zxA;C$FBYor7P4^|Pj%DO^9khtwfc^? zq3VTcVs6=yjaE!1=hVFugFK8~5yj$n$m`+QNDQ64!aE4&mHeFgXPcLBUJjnPl zdN=R6BAXeeahWPVD&;5==hE_D*fdVdV&1YYunuRPRL17pLX~w!k-9LOcM4A7CZ2sx zjZ=?twtRDlPoPJC<9xzZCv`Wf>xMyQ}}# zPq_W;E^DxfyU%q`>gHy!?X}3ZJt)M32Ux|~V7mGn$+Li|r- z{$Fe^uJ=97c?}M(XSh*n3nO1pL<6<0b1*xCqXG<1TH8k9i)myy5w>U76$_rUwUhcc zsfFQW8N9kI{nW+a_sCt!ai%^X#Nam=D{(z?@5!|3=^ulQ^WgNam(|YLW~B&G=NlJ$ zyFEok`ZQ#3<#|u?f(gdL44|Ij$|1sS7rCzQMHn3U9sPO7Q+*xi?w1B9O4eY5dtwwn zfh@Wm!>se6mA}17j8oIkd}+Agts&fQ9pVjsM>s^U5_l3`iDJ*nPF6nLiZLWrm~VW= zf;yeO7TLw}?J-j&70zW}#8IHK^9`k?ixe?`C-L&ei`DXvQyGvtPBu+t`b192#7v7? z_iJ&1^-1U5vBE;8xz{S5hhB^MCucB+==56lQk+sp1uq)5o{1D^O03-aL2Vb5&R)iE zQ4TdW zKcK7(+0L|Z?UtsshmF^zFm8{*t#=f^i0}MWJ)gMG@U#RkFlg^7g?q{Y4nAM~@G<0C z39_Ky7#UnAjt!^!4HaW=%Ke>lSKKUi`tnudnSpE1^5Sa`3>L|dJG@5Z6?IX%byo#& z*Y6DK)nm0OT{S$dw+2k$PWfCha=*Bhe|o`B>F8~hS@Exp>s9#J5aKE;L2Zn4mCd0J zZg!PPP#3FJkkz3ccCH|!9qJd~V9cJ3x7y35IIx3kgtgtI2l!(wFxyRbgFtky zD62pa`c;(v&4Fn#%NEcNf2=JlLw`I|TP}kE7+#0155zTf81o<;TvvY1Z8M`T z|2Y`*>dIAoJv6PJ41+MdQIDU6V~zT<8D9wvtuIqx1U{=TJHtq9;>XWM;dDRw1&qdP zesVZOVsHcbHALgZ267FI!3hmzYly+!4P_6AUG6V?LmYtvpxjM_AnV+2gx|TO8GHJdch1l86^LL zS$L?CJPEUDVPg&$%*FjpWJj2{ys3Q3J?2?c-e>_eY$mtZ!&i8tLb#=H*f*oQN9(hlty)y&G?#Q)4Hw_z=G?$$?fnB_UbN^VL4vwF1rF^%^q?x zq~rP?GLog=v8U{+!AcwuBG0heSMMY30lvisedRm!>nrUmsJMO^F(x4*cKCneycRq3 zll}N6VnshWoCO{~4qy^DV8lSCAp_S9WFNo70|VKQ?{V{g@fKAvpRQkaW zI4hJ4($=F9>qb)#{N;9LO)|llspSZX-Krp0XT-$W8^hB zzC4y^=HT2|X@OtRJx+cGzheJ5cKZaj8!NlONm@Ks&JmbAmfdon!2F-4;S=Oe0cXfH zL4`0Et4xwj;2aK^B-g`vd^btPvgD0Qlq&%)lb9^O74SQ*n<_`aA6RM{C(#v5oW|99 z72i$c%({-BO_$zq0|!lK19@05T~2^I7&n7`xl21{$U+nD)Dz;`*;- z7W|1r7Rp8N6dx^Q+t0E0A~^+K;ORviynKALh*^J0os+pP;SKsNkw@SyK3^gy^84*q zSSB}tLGvuKz5q$PzmZKeF!6CZD^w}`ZiVa#_W0Kdrr&|8uatdtaKywlay~d?;Tra} zG^A*WXPj@X}SD6 zIS(qL_xJJ?Uui!2o*nSSJ{#F9Z~Aqk%8g1mXR{o_*TQ+58G2Qmuti4m>;J7SECSWg ze=B=eoxa&BeF19F-fi-O#;<_Zo$`cw1)TO1(_EV>W^#^0eeAf0arseWV)CE?z1=Iz zYb@Fh2jmhK?eqgIeSx^|fNW5yQPG*f&Te)o&f)0Dn56L&B1)3D3F-&g-DWuOpgaW4 z$?cGg2WUabhh-~`Mf=3hGLY5!pPyOXT2sfPax<`8zc|ME*9My(mnm5AGpFCV<6Jo% zFepdPWKI4lhaY#sPdOZs&KUHIyboQ-<5$Uzuq!S*A@f48FwC zmt=QV?#xTF9xHd=CD!pstaF(yMq$Ux9Ii3=`(-Yi7#jb(>>*gRk6e)rSgl`Nkr}Mk zmaB3szkKM|HwxUJ7ezdKy?3o!AH zyu~8^pSyB$l|?17Ry{N#W?1Be`0 znfsDp8O?hj12q=-y^m#8_!_T1W&!$!V*ixK)j7Y>Go|V2G$UWm(plr-jZ9Yu`;~9m zDOiR1e{&>PQ_wrM1#9WadoCgt^C<;#2k>dV-bYSPR`Y$IxPN8Pm_lwmtm9+Ad{cE} z33eyOK0JwmJn9W(-H@cYJAQNA?m>n_N#k9vZWle8B#SSTJ zHh{gjxU889`_a1`kFu~^In#@kd{jBJKPH#u$;Zo?{aDjI%bPRNs~rE4QQk~oS@(1` zdqOrvx|$<(IEv@o%}#u6ThYT@$Je&B*V{}3$f2&4&95{T^WUoSq7&HF*Bk;T@dsZ9 za0-w6n)BcccB^Lk!dZ;1#yjWYqH1O+oTK~I%xb_oZePQk4;OH04My=B-mk%~T*QEy zrYBsY?lsM)0Dn;P+U5`gt`Pc}%_LlB9XYOolGlB?8$^fpVvbf<=jsh;FfPlLt0}L_>3=Uvu=Fm=RO5PN= zloprD$|9FclhjgMO)IS|O*6ABDJ{2*-|Gl`zTeOCef)lZe1D_Qx#!Mu=iWPKyYF*` zJqyk6SDOQeWMrg`j~Akmo8!sA*!KH62%!og6v*Z3ZyFmnHb1ta=Kj-)PuIWqw!cp+ zeRR4wziqeupbQTpQ8WFLveS~#HzB@HFTXfHO$k0BAN}hO46_dH!ahfcQ|o;(|XGRRo`6q3GtRZ+1%2nG%b5JuUBR_t+%}4So8Xu&Cf4) zH9a5GyuwLaw-@M1$?`wMEbn^ylAN=Pxw5+#muwwo{ zKi{%`wfRUZPBlGW`#{q&JWpmVAzBWogmwA(Vpa1I+1&s9f`aCClU}|`h?2sl=kIJ< z74^;QEgK9kYI;7Pd3#-F{`2-Ko7Xq$nl{k2Ou6~_qHpsCv&)*^(7Y;I)?1D^aqd4q z-?E*R;CK9iE4Yrop>P^hnBa#%*bss?Xp37AiD+~} zSKNj;^g>@n8`*7K`wEix!G{O&2&%9Ei?p5Hdil1JdK0@)kG(j65AX>N;|qL=<2Zp+ zID;SYGvxRA8!q88uHgm*8BGr(EC_%V!3agTjSw|91F1+ORyBnu?lPO44%gZ zyoi^v8Fko-H?b4Du?O$s06xIS_!OVvD8BM>_YF?sG=9K2oW}+Hjz4e(*YP(L%AX2Z zv-u$qHiV!J+Ts>OLYCD|=!)CW6Y=Pce&|1dyW8PF5{6+UMj;Iu7>fy*jC+u3M;Z?kjE!d8?@HXDTKCNqP zmm#M~oyAZ11r4}}KXDa*p%MSMwX8H(#*JD*Y`GylCACMU_D$?I9gC%L%UINPk6)wc zN3nh&p_7`HLE?Nuf_@0gTY9xsQ-<-9-o4f;YSKg=I^27n?~dlrXx=ibl_xGYuG+S{ zv2pjc8-HKEexvcv$O{)5FZ_MIvGH=h3zueGxO$=SMC0lEx5YNzxZZeS|LzlO|GIqR zTH}e`7j9hkMK*7*#M+c--tO~sx@`1hFp14aS56qh^Vtt;pY%B}YPhg%b2x;< z9y~oaQN)YQ)2q2}ux%F!j$PgnBC7JBO*klMXB}ch!KUy>CWs;C4&7=UB2J9^%r2j* z|I;iID!X6YuAS=J*&bE3%`D>oIu?;A;_9z`W8|MKA4Jp~Kj}vV+l!*B3$oJA!hq$z({UH%w`PB9iO6%%u5jAD^NiDv=+tf`g zsa4tTGySWA6O|$M+=hGOM0D+I6(Z`;`R&@k0SQW_Ry<&(vQe`Pbo;iOhjhPYUY)J< z7b&lqm8i-;4w(`v$DB;m={M^VM8Sm#y7)9MitGi})!Y-IHz_Nfo!fK}3nxCoQ({35uy&7_L~N z8lK_=i0r=AmUxlg?vOG<*nj(Rgh;UueImC)m_~?%35!EEijdj~O4RfTd>6GL@1`3P z)D5;O#s2w@jUu|fW}}V^pA*X|z9RF0&lKIddx0UkcFA&)Fru&CA%ZV+y6Pv?o1-?j z->f=pACGz1&Ih#H{a7t^lZg6o1)ow`{rWLebi>Sa5qyi?5?{Z$rc#MH>2#>k!g@#- z)v&3=l8{~X8CfE4T*qvYAU3xRSK`Ek>H{Lik(o#?yT@#dc64aa&JF6EP-_ZVV-|gX zdaiT0Q7yQ629JrT9Q$?=Jt-kkL_0F;EiuA2LXFD49;Zat7dW&bw}*|{u5aZ%z*lRD z6A33r{VtTmlB(a#9No!h9pr#1-Le&jFds}lz~{die29H}bfYe=a?;1yqHksK{pn`& z0nx`1cVvR#`YF2l&~oji+oQ;LAKiY7V%L7UJyL1V{O;)HJ84iiizr**6@5bG!`G^m zsAFv#)P(f?$@Qj?5{`Dlg$6S6$)4$^c!%S)ILcObk?W)wkp0uXI5lKsL16TTv+2g@ z+SDo$U2<8dafhDm$5DyZ_P_*D>0dAW9coNmpISB8aYY|5><+RBHQ@39O0oHvGBSE@ zzzBVm-Snd&y1w^>fC2UELYAvhm3p#*qhiYyQ?z620r{Oy>uQb{p+9UF@%DEYq#NQz zy){k@5oN*Q+r@zT?cY^tH|}UV^@`3RPVV|OT^C*Ziz6UjywdTcA-*zdNeLfq%gQE8 zRSxzk-+ z>bDfJoQ((Z1Xkc#yor5~U5RgT7P6;s0|uH#E5gwcJ&=eYkd68{OhqBe@hBESHsP|l zeqB$eY%htg@hcQsu-0e~d3o6nLopg-QGim+!=tFi3ao>?Je95J$B?b2Y#EI-7P1AD zjh}4rWMkJKV=x){2F}h*5_9kfR^Scn!hRgaah!o{jSNQWYjlDGBQOC@%s?4@Sc+$` z4Ikkc{(_OOAPlic#84l1qcH_VsKA3*faR#e2RM!2AgHne5spC^j&$4&H_B0oDy+r^ zypFf=E#3}rO ztI+$g(+GtfJ<%V@etiF_B&J|G%20{<(6AOSVLSHX6MT&`xP(Ro_;WT8h1<{vgE0zO zm;yKE;&EtLgAMr7pYQ(+iC=LUh5-7s=!7`*$1tQ}0$iAhDp2UfI=qVQ_z=f%3cuhQ z^nv6Tv_nVqzz~ds6NNtRX5(QjLJey1GPdI*9L0C|1y`UDVhTVTbV4i!A{nWegj|$h z9#-L5yo@c_jf40Mz7yR2jH@uxIcbGk&=+ZN!Hcbt2phvdOhXl(#A>X= zD|j0R@g+{-0Ue}JhTj4+&oS1`0@HAe;8`y(Sa02IX6~-{~3)-Oz5-=Ed zA`5pTA2U&fC0L7>um$yDeE%Pi_#EHiFNB6uNuWFWV;Js+3nf^9Wmt=sunq6v1ALCN zxPYtBx20l32i%I`7>it#;QqEF$kikk;RV#;AU?$j{EUmZ0ZTjCo;KfFR+`&VtF^<%=Xe;ugg{JE}mvDbCs42b(OmF3q2K!#9_Cy#8vDn8tTrSom&{D^cq^| zvWV}!o;-Jvr^M?n8d_fFq3fCCj8Nj-c}dSJiRDH1jk;22nJdXz;vFhdlAPY0gTl+g zU7Y8vQqoD47o{p0NzT#|o#zj&>&V4nGxU@m{}FmaxG?tA8A8O+GUpu65bfiU9q&4z zdoanB@6L01J#9p^yW%;am__eckN1?$!4pN}b-E71UgUZ}=-PW7$uTQ+(qsmg)+#X+a!jRxV@eO zO79X+Ua+G2i)4F=*W;C?z`BRZkd-;h#L$`L?&8rR$?K_bzM>mbT3+bM+azL2%gcnl z%qa}YeLCK1oTw_HB4Lg@uTpNwY8N`|Lb6?%%jZp!O{3{nT}+wlx)@XD&M7ZDqDwDx zd-BVF(Dg2J&$%Xe%P_mM&}r4@lzDR8oNqmc@c_q~=gDuC2m=PCMDVp?pGtIX@! zuZt?5Ge%8vl@xeO6nmNHs7lu+yP(kHbruaV*xYoQtQ?qYi9v4{z1_KmD^&;g9*fRi zk)-HtPNGV`3ALBO5-9v17M2KM%GF!KMW-_N8=`Na)4SN%E~&^gHmT5E>?{|y!kmEy zkJ;_t(E=|+x&7wNC#8WuC)Z@+J!n}tzb5ywRHIbg|EGhMLpnF_4+Sn)A zRroO#iLe#f)x2a^kt?_GaS@a3K4r2cKct9Sqo@+0$uAqbB)fYmLy|pS_gluKWKYHH zAC%T9&lyWo^79MJD^hkVol}b6R)(e&&vHL0(o;&voc_j+c`3`xwiLpA7mUd%UgxX` zpDsSdTNYtVDN6Cq9%x>lQdZzB;+ysq`iYaV?ov;&n}f~cVfO-EHF=zrr^MM?v8PnL zYnaLRH_Ykv><}5l+2(0 ztgyVZB7%f|w^`6zsGnWtDRmdSc(};*xGMaF>2{^xFi&ZNS-xnd$n=yJx$^>qQei1^ zmAQ+Dm3zMsdW(qTw2m}o4l6Hp=Y{+A9qugJuZtV*^rjiLuDXkPkkjRM5CF3d<+g7oQm;3b@<(gHe zHwOrlUHc<7QW>X(rbV_2_sh&5HM_{QL!UL;S)AuOqot&Ei+I4_*jmKRa^`GT#VY}= zMt2BQR_Se{`|5O!+T&?mO!JJLM!UKOXxq~4zQcjhqupQVlZ!{Yi`yA`jdpt)0<%YZ zie1H}$IX>gLghuHJ>Fo&#aBDpQ}LW)A6P04i^r!EQzOWmU+q&o9I7k# z7P|A?6-V@bLBfA%KwYZS>*TvjbrpGX4I!z&`P))8i}ID;p6WiM*qw9y=nQ;hQXW+m ze^FWHq3SD4b-Vp+6-HyaE7e`*^_lI?;#&mgNUZc%0)?&OHUDH+s>hqGGx>{vRl?Xw z_^mdXdI{5mrZ^toX>8?5)j3l=v#4(pm4|1SmO052X)^_9+tgMcmsaTV1}FnXa$1oy zZ?sRhC9R~)lUu+`yg5shq%^O)tg|U9&AZ(!7OTRpv-DC!)0X*XrO~dqZq?b+RHFzm zu`&NYMXR)EMgNwPm{u|SYjel6Ig1UE=@~X9A>CQr+K`b>#xJrcebSwChNz+GZ|ccm z{_}(_y{BHkMsG`h+Ng~1**e7*rzxgTVYp%ytwns1tE3`m3E4f}Rb1vS4b&_2Y3r;a zOl+xePjePKi_;5S#ZTy|N~~t97?SQTaz17oo9-@g6|FH+AVR!$BiTgEQ*>+e7P<^I zIyFq#yeUHYSPV^fdkc$w=3P-)xQZ;MF)YeF11&M>-o^9>4WfkJV(`>-FEx3JP3cYIg!~?rk*$(Rmu)oj z#`3~fbaCmky>IH332M$5nw;_ymq?Gza~9@vspu8y8BS`*wx*Ke-mVNMO>&puF~u3q zIpxRA85y(!B{Pk^GF)^1Qfo8ZIi6gqYa)xJy`=m&uK6p}}kl`tfwAeB>1gTF1hh}*78JT3- z;>Y!UGM(P*N^kCan)-4-Kcr3O%fT6$?xI=F9qMPX`L1G5zB|WD#~^c}zHg?xEKMj5 zW5CW1%}2i|TpexbC^B)D!7hD^10W_e+V!In9|V9VVfs7$noS9QA9!j|`-zaKSz>^z0)wE; z20F^UE@wM-D@HF`spMe&b7}&IoERwY2M34{Q&MKR*E2&fDASQKli0BkcIs9WFjMM=#6qOD)9)z3=@CH7@4`@U<5u)yp z<0tpvUQ|Plfb21Ft@AaBO9&(s)ER>z!$&hQADi$o&f+>+6Y=SRA((_xEW|pzjiYFQ zg&P zic&1VD!hcZ@CkmvC7206gd-kzAOm-!2#;VjHsE#0(8Z_tR>nI1gde3h8htSgli2gg55ZXZ}1ELfgA@iKNm zh8w=YZ;(-iDD+1XCZiM!@EmqvACBV^^byo02tzCeBMnYeU@BGDJ4;Y2AOLk(WS4jjan_yHH;*O58_J(1FJIH!$7 zDIUX9cm{RYj}y2EQ>P}PlC3__i+K1Z?pCnN4uX zEYQkeGf%ho+baCNxZP+?ROCk~)-usvv{$V0I>k6jv1V}I;y@J5`he)-e?@Pc9VmD8 zPu~3#SF(x1?=CGWH^d(Bnh0WGcs@rqNT*nK>8&000m3cxiSiQHQl_QmwpYe$g}KRb zLn3;Lv$E4_*{!p#5{l(g1g-R3>t^wR_1l|A9BS>XZ)@!?;!Ryt>oM(QZj_IJmbFv~ z^}8Yr^Mb`g!fytbZNi$%>wms^BnHbH!W11Dkfd0rE2=e&9a+hf^&%vof^V6K-(}S= zV5qR(ubQm8M7aE>2J#}hf!5>f#0j1J2!|5FD8Kc2L#ThHNGFz8Sb8%H+y1p*SXWK& zofzhER~Kc*>-koluf0NOdg=oZ}BU+}vbt8Q%dLkBbDqK7gAg9FjMql(pBKl(h z5c6LAaZDXv@cmDb! zj$7X35T?8}*LSM6z0jw$(-Moi=~a=bROvM zb8w)>3<FqT21_qyqf!-N zb%VVxD#1qz=?j-)4jy0|owe(web}uqtykI7y8UHiECqKo?S0Gcvs(G(7O^(*z;$1t z`N9YL+)tf(>BhOD`(m#>KDS$!n7{M#)BY$ds?LlU-mm*>XYRaQ(0DcP#>b7-h?BnnEErzD=N9cMvt$nJm``KvK33_J2c)5>xXGyJ~+NE z_Mv$7KTXg2|8b1ZvNPl5!N+hYgIQ*=$K{M6pLpyJ4!uK_L#L3r=Z9G`_t1Sm%zKWK2OGrlA0C%s>%};Xw&z;a*f=Hs-;HN<4-t?T{AZTS96%R$wJoVKtt{ z8a$76SdR^O6|doS&?McQrM!dXTX+Y1u@CR!J?zJa_y`~4Qyj(-d@gtB3lc|h3@30B zr*InI;|$K>Cp6$U{EmybgzNYVDh1d8Bjk)`3*@Y3!bidiIkUMHZy(i)Zm1 zZr1oLH((=P!X~_o*YG;(@CLR(&d=U~U3eQe+Xj z|J4Z9*7TFjP5XErO+YUsqCW=0fg#%F8IfA#a=UhUMr$Qc%UXV0Xc>=}V;1g31!ikc zE$`Q(iqzwnj|Er=IYnwQG(3f+Sca9_mE{AKO|6F7bGb_JB7UD}Z1XTLzvJn4WpjCyQnTWT}jSERnJ_ z%H9@j=XIkjegh!8Qw}5{g$B_$oWz|NjdWyUoNR3;k&qoJSqx3f z7RJo7M&kqW=QgsGJq}sEs+oAaE~e? zisi}hvN8*^F$Z(u!$WwC48MSU6UN}(^03WGjqxgwPEO z314u1iPQK2KjG+k?k?aWZcxS*15FI+%YKaY2@CuY2suSG z7;X3*TalIcUJiX$*da#2aY&y#yl(VjtxE)b~LN zFkkfhgp{1E`USqiNt^@KYb4dHi1~)Aid=Y5sft@7A7)#t zs#seHGDqZ7jITv5=ksJPx#;Js%T-?1w5dOpsAd%QeFffoO#Y+=`y;LT5RF zHvzrT4+Aj>gOP#}xC^Psz&K3c+)m*fPvtVm$$B0NR57lQrH2+!ct|weTKyy4+?;-> zRXqE)HO@Yb_;W*K^8~ZHLC=|#!Ayy22#n9oFYzJ|p4^f=W?Pk1)o%U?fIIi_u1KP2*^*TI}7wP%j!3Pksecg33Gk3crsva|awWSjjR&fzL#t1Mea+2}3B(|7^0Iop8`(9-=oLRvOfU*jas zf-apl>BT_bdD0i~uiZM8`d!Yvw;%w4ki9keTRi#uJK3JyiXP~Tevq^BZ-<LG5CA<#VoV|f9 z*ot@Y9**E=$j0gd8lj`?altIxd42;&6)3CpbLdDt)(M@_1)0c(6NM;3Ic7uF+z(?X z4&W$`LDq%xcV)kViEg3;q9E(JcnpB7!|p-`#`?IcKqVf)lURn8ScR4v>Uq-Z&Eo4Q#;#kAL>>_)IU%DMa(4eb_$++?a$xvzEW%S*id9&R zTD*fj*o%FTakFFi65rr7e#Z^`4Q5ITe*~a4W4T8S4oW-{WVT z$1h;!g9t(g$SMEv=#POIhIGg&|92x7(=h{b%Kuud!+IRX*EoeAa2`y$5O-lI*2>Z9 zt=I-Rz5h+@z(JftH%6ClMFM(3j!gGOKP2LI+<}p}6Zu$!TD*gO_!i&c9Dc$D$Ui9Y z8+>xAzZ}B8fxp2lHqjA%Fbrcc4syExWK4ye@;?i6aX%iwgLnjwp$d;5r=^of(&FL3zOkS87d%uPVfL8 z$9ycn5@=Y1T1HXCYb0LB7VN=6ypIp?CBDMfIDykRg9daZ7AMEud%=YjSc&s65`=4q z_DDp36rl>wU^fon2OoE5aT!;T8qCJPn`7{YS@{K*a240^Pk(cv;bwf4ROFnkwR{7lj z(`|cQ_?I1xTH=YjRS%umy45FC)t|^_WV5<;r{7debIA(Oa?W(?az6zG&SnKHJ*dD# znBPo$^-TA=qh~60b(ueg8cfyHbkGWadBpT284q=T{_?qET1Nc{?UM`r{cHHbo7Ht} z$hOv1Hg>gaTW40Dd*D9>;U5nb4+W1nWeYSbm7<$ndA98fJ?`$5vtsTGxw>;5bF3xF zqiv-R1@^mj^T|8Q?R(EX73%o&P4BY{JE_^5xj=8a{mbu%AFkOvU-3rS?JEgNgdWTm zY9$T37)*BL7q0DX;leLbgfx`YBrQ-nDd9El1xgow!dtUsf%1qlp(cExQedh!=(-AH z*P6!`Dy6~vc^fsI$()Stm=#iLLruUFN?)IKf+;Y*wS&-Q`!6bWy5+i%eP(?~!)Bea zUg-GPaA7^EH(8epeaMw`VLT+aq6=4y4t;<_FeOkIC)DLiNS|thu~O05MNn6R$`fWG zKl_-XD^Pfku2N?`U@)m8L;z1PEwEA;my3XG5ilZAj_c}1h>pThC3JShSfFPs^26Dd zL(x@;fO>@&voE3N%{ty3@?*8mXx0bR-W(_80b_whjjJ&%QhK(l;2A~jDs*hNz+|*5 z0i^9pX!m0^qZcWWQ5*Hf2E8s^gxJFMA+}>ib-Pd#^+C1rY^n_gV{Oe7io?MsfFvwsw!T?@!*B7~uc(2-=rbmGWlwkjpW#+Oy17_SJwuKbdhXk@ksQY(bc zA&g{fUTS8PlFVwW>G%}qtD>gzDdjfnA${aIyWU7%3(8h?B{e&qQtnWW)m(i_NmQz8 z5|%2tN`1|;rAm>H_sfrpZx~Fm2>s%u!Wg?8jKAG_h$qiAUiafw@UL>=x@legv%apdh28)T)BBuZtbOj>l zkZ9h~(K?43bj)b2;PHAMZ_cLHlZ4x4m0)ZxqIMC|b7MesPsc`K{ZS3IP7o%QLRqWh zB(gzkqR~X|wpJKr(Pc|SOL#^e@d#lp5I#;a4KodT)9pWG|NoVY^DhIGGSC<)xFD<9 zT%!z7!nXZfqdcK>SEqW}jZ#%~4J#v8my_*7$nIhHqB*-yox>~cQ-!_e`4viz8o7il zZ&|7It#PbW694^zu{tlTX6;I)%CMWa?WyU$N{N{GA<3_C3a9Zs&fypQ0XbZC1An6t ze(a||S|J!6AY z=!n}83po%o0E6K`3MOD83LzuP#qgjUGOGMA7NBY9g`A|ZA}^|6gbWyO!aLZ5{b(6O z`R`*TXLwvjgyk5Cj0#_e90HLS(K13The71fM>yI+4sXbd={WR)ypSG<;WE5?7e*lq z6EG2zAg`dOU@Gz;!@`RpFP7z>tXYd%Jcsp=!QU703O1wVVtF^|dhA2XMf3ZlKY&k$ zeh)*2e?P}De2tU%9`Z_>P#?vVTm>s^Ao?qVoHEiU!XX2|y^)B4Al55}AO&}W80O6h z&omZ-ke!TY%aE>5Xe0>P$w0nXh8nEEN^F3P?7n~(L0DVtz*``YEyKAt|I7_>%bP#e z|CHrn9Km-ug|qk(^6Fm(bAN`6=l+6UWoY0J5{=MtIWNPxGL$R--i-|B20=z~WdPTX zD8!-Xn$V-zMq{&j#UxEtA+1~-Z^OU4-F-0lj#0w26*LM^5ggh-{J&L z;u5Z)5yD83gpBxFAS1q3grOw}VkaGgj_8DLkTKue&>cMxi@`_+!Cv1#qP?SeAQfpy zhYb8?!-*Wopl=>r$VUO>-$^J$5sFcY*^mL3N<56mAj89tV?Gu@24I#zGY)Qw#K%ULPmy<;4^$)(@?8~`Hqv6;o)y_0w-}Aze9$GFX0c!5b|D1WO?!OPldJJ~U0H+92@_zQrkg zk00?9euj?dkRI~q1%7CaP_#kIAI2k-@s-eyM6m{Fx=apo$^4+#O zURDMhm5JNt)hR(b<$BE%Ta^2i#v1>vN?uLzR%MWKqvoZp$};70&CqR1j&gb1x^2ou zRk^-x#ZKi{-L|UT%JP_riF`;$Q0!&1F4AMT<5npjkT*GL;U70Y8O`CfW`3hd@#^qj V?~^b8|M5pd{R-HjraxEue*mF1Wkvu1 delta 21192 zcmcKC30zdw|M2m1@2spdY>FB(fNPlo?q)d(xTS)EORfws$S5#4fFhMcX@!-FU6o8N z%v>{5(ZtHaB{N$j+srJN7R?qhD=kx=&k^YV`}O-hujlo8Ue7c7zW3Z&?%d^^d(Qoy zGaRijA9&InFmTM6 z@u+Q@|88hpt_f(Ir!~%mHL&Sz3&y{y=T)v~}{WXot zUeWx4l3tCkTg!aEP@A^6uC(!my-h2uc*E`rx1MdBS2e9?dxp$D zLNxD?Ia3kx`^D0xJ*t}i?{B!)v~1GJck!6n`1qj5Wyrb z{QJlLUQTM<|Ns3Pns@x4E11=^2lJY~r}_1F{}0Q}o7JXy#f|&_pBwO7So2#O=gnWx zvuRKMcgxBDc>SNt&1(&6%5&k(PrT4n{`Ju#!_(~#zo4Dz_?)+xS4(g|yRZkZVjpU85Qp&&-or5*7o40=NSweI_zGw74bI~t zenLI2;CK9izt8}cLt%g!eh5SmLeUbf5dj-w&;hsOPQ;?SqRs6*F=8&s2jIoScm(Bm z5=*rD&fUFxNWF@E*pEXvf_HHY$MFeH;0t_(v-k$*aS=bE9#`-?{=i>ofJ$aFzzjbG zA_$>qsdAKBlZb!~G3bEK=z>^uM=$h6e+~3~&De^Uu@k#dgV*o|_Tv!V#!xc91AkZ$j4*^lmeIC|LOXQC?YI-M=#E~v zyDyXe7=S@Y!cg3cQ5cOhjK@SwK{_&#txf3C+gm|O!wRg#YCMPMu^yZ7BDP@%c3}@* z#Xi*HAP(alyoX~rj!*G9PT@4p;agn55BOOpG~=Cfdyb$INX8h9#RN>oG-SYu9Lz*M zW}!&ib?3d_ZKQT!7xq9_ko!=JgE)+%cpr867@y$_oW?nPhl}_Lm+>pE;V%f9Bzl

wjE2 z-QXQ?^Ty3@-n{f#L&MEC`Ot$+s}puhW2$K@*V2fx()x_;ywh$H+dq3|!a!b6U!V=> zb>!YyVclaEc3bd_%vcd8w$CVMT5sJh;_dr9b`e$fj#b!&=z2a@49(dZ{z!@#Xl~oN z$}VEXxQ}h}rP|-kBEGE4mF-$;?+&)0@~6c>@z;qqeMD^SpI?Ua(nCclBD!q;CJ}X} z|8{L<@3sLsN}T=1Vw>n|zwLaTcBpr%d1$)!t^J4+rA7AXt6o#IiGAXgT5VCE=hf|s z7T346azq=^xAUE4`uHthYKE2eT` zIN=jjzbuCnmENnsCr+faW+lRQd4f5~HfT|1jxgCp{DdVTPm7Q$yAm~Hf>p#ik{ZY2@#cHs}a!?Yhk4Hpz@zlbnbwQpZ95|m?5r1aH zFGA^AP=2{q6=meK=WQIb$(_>`yD-0#c!cfQ8@!!uee~%FHMVTx2kD|$S^k5uX7drz z(;oZL1Yr&r(G_(in(dybwl%tVS^(jk#bdiBP)~~(aVA^@pEk1>FA8niJ(0=@&3jL0 zZ>>SUT|`*}F6iRR7W`SRM4f0=r;ks0JF&_XQc$NxO}JFgnK{!n))Z&A?}(+GrRO=% zh<@o8583n~!|Vak8_&lYqpL=hi|B%@*L1OU&-dmCh}GBp<3*WYtq^_mqL(qGXSqJu zUa#XM+sQSw+Y0($F3#-xd8is)^;5Wi zoY>Z`)(}?~^;8aDZB3h?3>9Vl-%l6OZGFphM!P=vfpmS8SYsA-yQVIAYT)y?nxXZ# zn#KRoB)u@;IqzV#v8^(Zc_#8viusVui}jGrh&OQrvYGG|zC%6!fPrc+5UmgmS)=!c z9V0Og)8WQkJONofzo4VB^*RYzx5|3-H{67US}GhdkhhP$Fbrvs_2+cR`mz*{Vl_74 zW$eXAIFEYBT2Iz=L69|^tk7gdHV7jP9GGz=94JNwR$?8tp$7Z$9?s%NC`KV}Lp$`q z-57!tOu{TY2o0OD3ny?6SK!Af2}N6U_A=>%VMxPNOh*xxU?bkd`#6Q~@hd_op>5F- zJz&QOjK?$-VjdP^IaXr>cH%X>gX8d0fW-Hp#t;qgrDh62D@5T=^u|C8M=GWv2Su2N zr?3Vau^oGH2z5A#Z}20o!r)8Ihc;;M%lYq4Vj%9tcsMWvv+*#N;2CVdPP~qH@hQH> zC0v8*M{5Qx5Q96=9d@K59WzjjdDxEE{W$+`k@x_oP>;W0@@Fd%fez?~{uqjBaN_|y ziX~Wwm$4Uz@F7m(JTBup^Z{gQ+=)I&K#G^iBsh_eIaq)tcmdlWLq~^j3@7k4e!^cc z2GYnz8?;9p`e6vhVlt+~jk%bQ#aM~;@K!Ua#k=?vmtdf=5{%o>4tHW8M&dp=kcSd1 z!?So1yRaX1IEhQR2A!26jaF!nei(%*R?feRL=hgu<5-I=sKFte#AV!oDTtOTqR|a~ zk%+07fjL-!#aMxLcpY!!Lwt#g_#GAk8Lfjk|LsWJi9Q&F5tx81_x!@iN{(9lYN&`4#>xI6sI%9PYs=OhOKdQHF(BfwkC% zy*P;X@CnY~Diq?GfoP3(=!SksL<(FeYRUO8Be4k2U82Z!(>PT(AFz{KrC1lqTXRrr_^K^FmX*{hPq*{X-Ti zUSF$l6uPo=-6d{u+~p{6<~#ESxiaTw=3W!s2jx0_#5W#ymMhO);Bn;*DlT#hB`U%3 zmxy&`B|M_^DbBMkR0|zN&ICt+XOKuraCkDd2oEz?ewM?fq>w7k>!yrJa1<7}KUH=l zII|s@&LWR1*Xbu>bG1{$=CvH5GXx30&N@T5Fj`bYh!|AlD0N3`vxc|3ceDC1A8}4o7;0xwevz=A60EDYCAWKPoF3Tma=n0L_&cp&-JxX!VT(1F|fepaUWEA z6u7ej6uqBFv=w;Vc|sp5EQF>8vQWBI44PH!${#5bJnj<5W_5I7ajrXSqlhUiE)upP z$0@xsTjit1o_Zxr#Fx6V?w4z_*o3NWxHr(-UX3YoUKgW_Tp7hhAE+rsE_ZhES+z%z ztMpI78wcAQxei}lMv*(iRp80eu@4Wiqgn1uhv!dme~~-aUFyhxTOGr}bd*fj@sU~G zGMq(@J9A@<6^=ru&6S_y%5do9aVoy7Q=U|GzM`GYF;CG2iRs>Md7K9K0X3?)bc8;^ zS&-u?P;5o+<9hLzEJwOx-@Jtt8Ok?YWVWzPOxvqRiv9RX$GAKKZB7Bn2 z`H78eV^(pdD z#c5MYf;-n$n55I0MMbv)ckbLmw2;qW6wlq?mJu^ zgf*{)J}c3g=giDqC}I*_drj8Fd5TzJ6y+i;ah(@DbH+8`b81n8WWQ|j@c~&)VL&1 zQIIhyFUd1ESlcl&!uzONK}Jq0%5fJsdMLJ}lGhBgI8TEe9`~za%wSiRqhz_c<>2$m zpuxG0+3Q5?;9O^Kz2Yl&y7Sy6&g{XQl69_%iB+brKROQgCB^ITc}Vx*GnQ{XIe*mm5KPm>=Nn4DzY)7Gw&0W$#u{pbq(^;KD zE#o|PE12tXB^zV&ox?nO-Bu-jxV!L#Pw2g8efXFXq!kx914w>}s9aUzl2GOOqp&(b|sW$e=*q)a(&+^PI2h(ndP+ zvz)JMXOla(nc!y(6|u7&88v$Gh=0(?-~5$TI_t<@s`{taKBZ&ATx0u@&IUgd?WPb_ zH%COdGM`ivDdVp7`izmTOpiNX=v$2391uOy^{FnA=kr?|x{q|Z-wsG0>CSiN7arG^ zq(mxC?d6m<-s({f57*ZGQO-Q~U_;2Lqkh&=xjxE1oo$rsh+=b;($;&?q`35opC~JG zbM49<~R%cGDanP9x%)J-uH^nU%Ig5v3_aEMb1L!6~&tTzCnCq3`(vSx?H7C za>?As%pJ`jVvDK1a0!Dvm{ z<0rz2PzCi$an1ft--D@H$#mqUp%rKl1vK-5rloke81J$uJxI)vr%|b~CXz0)o0C$~J;k{X zsOm40k41T~~&$h%PMJEv#d%n6!IRTl)t381+7;NMQ)qGE$?x zSAFBhxQg2AIO(xAN9JKm;u!Z#*BQ}=qF$nlALB0EW44az8L0m&C~VAqx-qE^F3SbF zo~aJcb)^T>!^U1r{|Ii8dRy?AR9D_?$3p$b-Ljqe?rc|vhl)P+K3%U=S5dN1P8j@$ z2U%0M3cV(JrWQCl8iKv4~Xy-0DE^ovFpA**n6QR+r zti!@uupvMpo^>ryyP4KH;eCI5vB&9XEv&8>oe0vCO?B(^@$5#Oznp&N$BlAAYO%*X zS&dI~W12HU*D`H|At8;6#%z)9 z^kh(N9%#`c&FOhb?as8$*fPyzKDsJl^b`IEgLkUkF{`& zu;=EvGOq`OrKMY~Y5jdK3r{W;SDMS6<<57}-;I&0b?)i9a2dfdJJ)tB^1Bxe7vPx7V}=Q^fX z;?m~k9ux!T=FaA}xy4wWsk5z9u&I6LalgrW$J{}U9_Pvzo^dYEbXUHsts%)d&h2^3 zZ}|jDhKDQX#K~c`6UpSXWV0NZytVo9k2pAY7b23rGhLe-Ek&E_R$)t*V<{SL#g%S- z=0Ac<;p3n4wj`D#146x!fE46lHp=k~cH$^L!A~#}uZct-jK&Pihm7&;#s`qG9odT! z3K`Floev%wkH=7jy^x`mAIuybJym%GdLbDyZ1NDEK{YG92kkNbF=MOhOWaM*+zyoXb$#~%pdvep>`ajy(6WRNJuVmyx>cnhE7C+GYXu^1b$8}H#1WIRC7CdEA@Dt=ce-PTEFT5j}I4}zj zVL3MA6&%Gm`~oBQ zw=IVScVGauok;<0LO3&-{W_9 zx%U-TMBsMxMj}ST2@kx`uo17}Bb-MALZaAs^g<#=V=89iVLXK`IDnJ*5q}^cnhQ`g z=f4|?J{XS4C_p)?@Dgfp1gG&kd}Aojh=m<#$b<(EV+mHH8gJt>{0u`oK8IM`jp3Nw zt{Y!Sq8zKSy@_ak$S35ZDY!INtDpMqBtwHA_oQx*TZT!9R^&Sii3Vjf#+V)zs!y_V zERBYcQ{E6W_f?Jd_xz;+ksep$jP2SzaWR8!il{`xP;b@fg)z(v3<) zj$dDQZea^y$uJu%MQU`2v z%PijYfTH&qs9K8n^kiXKF9I#x=vel$37u7gF7fo-C9@Kt>YHq zyFvKAV6<2j#mg5dtRq4MD3$n*1NLBTgheSue_jJY~0kpa-zYBx^Nri0^ zeT45_s^txKrX_AuBK+PJfnH%*D>_*EtBTKZoh4M~FP;#(KJwnwCq?hKPgp$c!d=2Q zMIl5z)AE8)Og=`1mn~lie-w@xKYpWVyy`AFApw_X z3iKu-cH#bGh2^eWTi?cVif=lu(k!spl@QTESSk%+eq|zsFj{Wmt!&K1`X9}}Dy?O; z*V#i+9NMnzj@75L{Z(&Uh3gA!h=v?3)(-6UW3<#2Pv2-b{phuZ8QSQ)utDb= z{@``ir!uHJAr9P9YX%{@PVc+-3HhPR>NYQv>XKQ|mZ9eMqY%%&`HgvPCW zG+pBi+NM0O60LR0@2uk(XleOd3?akyBBWa9zDHFms|U?$s~E3#=s*Kn%k~TiyrMEN zL9EAC`P5EN--N4eTe8x&Xpb)Fj((7xltUp~+T$<PdkVT6FR9>YCydpPaiJH@|uNSuFc}w|K74H#Y|KT5#2QuE)_| zKDqhpEBjjBNPJ_N7UYeu-dOrduL~c4ec|B3JIB8|bfdWxZD5B|BEX?H#C22x+GmmHlb;-G|v6oX0`vu$phG<5 ze!XZ=m$0xEAK?ec-tS5)ZMsgVp7wCM;#0Yws`&$GN9K>Owk?R&|F=<3|37we9UC)V z9sv6FQwK1oKVK_mLync-!@dVDw5v*pmi$CZpNj{$dLD=7ej+@wL6vRs$FU7>;9b_V z;R_N!pnClia<_KV%sK!qaM69$Ig2_O|J%jrpr&Pq4wIQP8`F`48OTK*^5F*C#U+&P zKa}7>%!3z?;xR1LYL~@$D@i?#m3RiLuo`Qy4liImHeegJV+Z!227B=;YOx;&a1e*^ z7LMXwyoY0`!-x0?AIr+?6B3`|OMHbhIE!=m8s~8VKjRYWaT&kh5Bv#L(bnd)@cL6I z10V% z3>Bp01w6(fFWOaDi@z`4q&HwQw%|p)jP2Ngov6kh)ZjI|4mn!+4ZMk3?8gD^#Ed(X zy@TR;wmW*FAMWCM9~m^7)EK1V*0o=&&26c*S!oTE!;t^J-jmLOi|hU!Va23o zV-89%7o}R+%HDS_B((^Ou>=)ZhNrO-a>&psti~Gco0WHIG0%i5JGCCq-0PL2jo-z4 zkfV-2z%kU}LmbDa_zWlTIZomW$N|Y;;w$wrZE5Xn*{8$fsI8C`TY3EApN04*Ic3=BlRLSvG%kMWp@ zDUi(_Mj}s>O`I8QTFWA85Th(V|5IkT+C9n><$7VhZhV5&5-i0sRN@)d-a?imS%%hQ zBV@UG39`&ImzCG#hRebs3&tV5jiVr-cis0miBIr3zQ9*F1MfF-w=R(S5%su&-$Bjx z*}snH*HfpMIn(|eQ!A@%AsbP$pvXp(4YH9W8%Ukd1+gHy{82CFvbe}5l3i|OB8edw z2JZ+a$zT}wl|b2Unt(}|h78COBufrQ@M>^A2@hleD#87jhle0X)IG*VKEZqm8!wBF zhDxlI$6yVKwOEgh*aGi1Cfj8bW+#c=*o)WkrrgKQhKQjZ{np(QvJqAd+C4uxosZlvSAB;@ErGR9|vm?uGwM3jZfm_SSOwQt43itQS<&OZa`u@!HGOpk^`3(NV zO+6)!7`Xu^aDW<&fh2#Dl(9b9L$6pg(zm7!7_M1509W6^7jIZy-Z|8e;Fz{U{`$Q@XXbyg8a#VjP+OJ z4bHqgJZ(5WAxC9-`haIY#K$-R*%|N^I5Z(#R$5-*@W=t3_3YNPUrBI8%#qib%xGXq zM{c?5^)(tfB=Cm?A!q@zOG98A5^WKM_UMc|(HFz@;dyJtjG+$ zF(g}N#2GxDhXNE~Hs<01S>(%%l)nWmmE%cNkhz{>F1s!&v5F(!&~^=}=kPo>Kn^U?R>$c*y;ldGc&UbJjjAOvmlGnMg=9A3{1%^@Z@WY*Wad;X)mtt z5Ytkrx0En0sMO7?4ECYdxg;~Y$dgI`bCD<8Q&Kcd`*rX=z+6+IFonOMge8w2$GrnMkV&!64ueh^I7%Nl60J0JX z|1*CT2izrv1JKs_CkhWvfho(s?_oqq=ZQW}paja6i0w7_#q25i9&$j;1a z?80sw!dp0wi}(RQLk@CRD1|S{`h|+^RP1Hfo+ct7z5e6nGSi?%taBJ zFPQU5zlOK*DL%sme2<^dl0p>$8{~y57V-i$6yD)XMk5V#mn3#h~AID>C+5jQc6I~cFVWDRy< zH(tRW9L9I(K%Z_$bVDrS(H%V?`-c1BE(}Hnp22GDLoH6?OMHuq_yIpc_7(pg!1=#M z;t$A<<4D9}AW|?IauoYGOoZ%1o(0A=-Retzfcb+c!^4oH+ZW&wRAMb&z(&Y{?yul; zoWxf+O)y@ZA#o1h;ye5dIST#{bg;1Z=#1NO2V}=|f5_4BqmYbo$buV%n1ctf0FU5N zEW%=}#42pXOI{}1u@8sv77pWMe1cCQhthwAGxz~9R;~}|igYZ)a-4?}M1vOL=nmPb zorC#UjaP9HXK@bRUzl9MFe-?2JcwmjiCVmmNWzVsaXY#|j&_el9D1N9dSd|W7=#4K z&g~IM!(^o6C2YeE(6Q|mfkY{jk%IA$RSHXPG#DV^O_r??^p=ePZVu8`~&jwN0OYq!d-JKiSTxy?^FDQ-Qd`2d`D%epat% zRPvRE7pwbzyI0}9+td_2yRP2agg8+N`+_1yChsMUXb zA7tQndRJy^L6;se$hW**z2?#twmihyC8%t_FZ>5GLkwM6)DQjAXvHC=@L zSg)uPM975#)p$X*Y!?CkHo+6dp+0(B<>nx^ZUaTUs#F1~C*)vdiYi#yo_eVGz@ zn@utL=Lmg)PQ4%kQw;i8xrxT@mAfmHJ0=kT5si$Q?cxeu-B?@P^J89#J|JvskBd$zRuTNL z7@l3GSVgTh=&=fhRW?2Tk%Pb2(eQhoCJ7A_uUQyGTQP#xsOak?kZD4temAB#aJ(VI|+_|q(~QmzB$53 zRwjp<2~brCqq(wfIY+9XvdaqP4$Bc;yk#P9m;;0Hq-8(-Si5(5rv9rB)c&9!np6H~k6WPsU`UWZ@{$S*mVj zYT5TsCJF0e)61^(6pB}k8g_7#qFTvDI?GTI!1i0hbtVc$fW^k^XGCC`Vkr}0mQF-a zDunW;+Qw3=_VF(>sC9yJLlNP70&`?$C6A4MT4}{r&tx_sRv%bnw3M(_wIXnPQ$Dnu z5hj@(g^}XOg^hGb*E0X;uJ$Tnsnds9CJ2*0UHCt(a-`H8_RJ{XZ%Hwl^g{(};u>-4 zX(jx>UEBVj8H$x**ybLLv!u`AYkUKFpDTMM{($U}FzFiaXJzMu z?05);94{+78=@fZYrWl=#6u3C?T5h_j(d@c@tA=7FcFh56`3f(V#xc}HFy@!;d!jb zCdgpxOSlzmWiIbq-@uzVD5Jm4H?Z&U#8Jpt>xcLVALBEe#A$pDc~eVcghEVaLm(`$ zA`C6i5=75Lcl1U-^oJdZn2agNA^LkOwmP4MM?v&lJOvFhlDZr#AS0?o&~N<&d?WKs z*o^HUhI;D{sMIn)4B2!19^OYCK70&zT8v$ z!5;w#M_WX~hOX#=p6G>pFaUN8#2^gE1l)&-n1rctVmg}d@r&gs=GitW2t0z868A%m-nuoz3R0;?h8 zk>2Kzhm4`_!y7n&gE)k@@B!pN@;V&HNB9_@;8T1C`9}ag$4PvFukaIohK#k=<1%E( z^$KLz^*0#;{++}%`~ew%y#X124MHg7sC5~8ZG+ojLv!pkmUJ9?qA%`2bDU-^E9bB+Ib47D|;o7$+o_JqHnY*!Vr=ba5oqFMQJPvFbS z0HZQ?u>psHN0oU%uGP`O_D#U3TA(q5z7rChFjphj7tT&WD%t7Irw_RQX^T+u66 z_sn=h`B~jFe!sFZW=em)q!TFgg1SY7$1vehCZFJuBde=_d-&3#lJ7V3LqftxZU5)9 T@+1Fue_qlzmalF6)0O`VAqf8v diff --git a/data-raw/antimicrobials.parquet b/data-raw/antimicrobials.parquet index 3e1113357fdffa5c17cf56ff5a4b1969fcc15724..87cfc7f1828bbd31d5fe5231ea85181cc5bc54ff 100644 GIT binary patch delta 28987 zcmb@ucT`i&*C;#(&XIE<2}ww3(gH~Yq@xIkN`N4t3lR~qgb*YWk{AL4q5%a31O&fESu~FMw zMwvwOV%(W1^PLy7-!`22P>%`d0307(Y0{u!MDrst01!Rkj9o(m_=Fx1U{QELU;^d~ z!m(sDAPDnB1Eyn5XkZX#fd+vjlVCTCkOnj4UN?0U=qBQ>j6P0%9phApQXfSRErEItB%RH3_(5V%Yc$#1LZv zAM-&2f54rwSq9-9h+rJW-Ov;YJDhw$L(G00|!@-=Aibj%J+Ex7}q*B-nBqBG`LW z5Q#+qLE{-95Ez3{;sywF_<@G;;1ppce?SkHr~P`qoACjQ8DD%AcCVrBZd4qXk;8G2}CwFp^-DOe0b_7L6k!o zh>|*jDC5aE8WqiP2T?;FAWEJ9k2sw{Ibjf8jI*!P8@Ij-)IddS8R72uPAX@4- zLJMmK&=)_ z3_+?jAa>{{8XHYm5OpB7D;&tM;4t7gOVQXMY!HnN z=h))0;ldF(JxHX$V}l}C-XkpoXW*EDT1UMA4e;T;K{A0GjR5X6g2)GvoMK2Wq?r); zLy2f?EWaJT5lx-}ys*`s6+q~)5fz5>)j%kng9-!SUJ^JcY^?>tl1^M09*0bUwYR7+ zqFw`=)&Qa40&I8!gq^Q(Vc<+;{Rouqfo)e|zvc)k48cy}!Vm!#2Y8&K5sU-Xu3#SQ zy@v_|Imc1qRA@jVBrR}0`ga1(d@Gt&1^4QA;w^tcex@k_>5zOp%Q=@%C8+NJUDCT#}AiP^ID=vCLrxi-iZs zBm^0|X`@mkOVbrfm6UM8Gt~sk3KS_- zP4HRW46@ntnkS$3Oi6v^4R3<^LVurX( zp<-1aBu27Iku8;Bd{fvjlVnTzlQA+wp^_#`<-{q(5>==L3lK6RT_jId$e0$mQmQhu zV8C&5rE-2GGM1DpNmiHzlXA7GX2!@ot;WpKBLxkV&?vrcfFw~$(`nN%66z`{UkprH zML1KvV>7x7E0&^n`+&N@{TI&9SAp5@2rR}EX!ZQ#p zbcTCPcgaWEuA23c;Im66Lx z3p1s1GZ6`LRwP|$0HWOW2Xg~DrAaWkzBH*mX>a+l8Ukwa>-MQ zhQ)?_cTIwfahB2Ta2rvE#6~Jll_nJ=kk5h4I@@(YWD05{;`EmXk(mtFba;yt3)eV5 zK{IpfHWJ~uGF8RtAu3U|;zAg_ff7TWJtGy~FH!o1Yb2>yAuDo4jNtm8dZ0OC#2%Y~ zOU1H%KQJNelqod4bs!s4pi+6~u{JKty|_?j zOr+wb;n-ELN&+h<$)s`-tsLtBvJ0)G^c=C2z7@ALWW(hrXNsjsGKud2U19=5ks^Y( zq_^5arbtnU)e0Grj4IMu)9D<2zPAR7Lb`i0nM#6}I{m_Ohw!226rn!<9z!9MW~im~ zj|7cmr1P{>C#TD)XbbO^`^IB+3%W#Y0|rkVrmWWuphhG)Sb(Pz(_y zSgMU3aHJFulE}tWSS<(@q}PS8rZIvf=@PMw)`D3Bskz2QA9)FaSf44IapVLK1wpp^ zaKd`hYHSh?<&b_3XZe$Y6xlfuk%$H0TW!PHqu?z3loVNJHcKDyBc>vIaK2o{yoJa~ ze0i3X=)@=_C6uG5H;cOA8(ae{kymYHKv4NAxLlVUfU493uj%##&R6AVZ1?D6({0qL zqI7t(6tcPmGYZ31nxT+O3u=%nB)&RTDw>5#lZ&Jbh%1yLRs*&KWIruJMHv{G6fA<0 zp+gOpCX2F-=NKSQK=AAhNFFIzCdx84_v%qVBZ9gELhuu3#NT#^JG1iU@2XDKkTwZ0N^vjGw4?cA7VOCaTo;8!qk%+iV zI@MJyQKoV`wX3a-eLs--`qXeyhB&ji9#KO~ElTHo!pKypxzjVv&luq05;^xFnbii7 ztaW23Pe?9Q@F;?EM*G;>l;&rM(U`ySaH*UUg99nuMXP7SV)~IK&7|<0bV+#uvXB}9 zwYO8p&k`kFh~}lRDnSI@iUvdl z?SvsvH``++6n9c{9N7k>vhvD9@Cb?8+}IGigiF*?7M(uH0G>~_NKFgj*5E{l?VusC zjcLd`Y$l;7bR-%kihTsgY32W)QbYk&<-9+pz@_5NUqY5IGMb zDb=KUV~hf%yb@HDOP)ZLLOrUe|HGPq8B)~>sa!#Sr;kQTDa~Y%O`+gzmZV6jT1D|R zKt*zdja{bEDZYk80Mr+XY&t^13{hyHa7vzrY-#9w9UedO!OYop)cnN`IxAmwDJMb}n?C|bG5hDqMSWF5z&WD-gYRWco;;_0H~g#Ct-Xdp*%N49-^-D@dsGzEzN8T zG=|6x#1v1LDCuA5*XkM3P^6?8Isal*%3=n*?~^T}p@T7BBp2};Nzthi`MSCb#t1ER zuMtNVm!^y8)l5+}HCn2aq}%Sou`57ISxc36@oL~THamhPTRJ*o6oOB=K_~c}FkGsV z8PCRvOiC8hWi)glrJAh!FIb-;lI0%VsZWZQiE<~A*idh$=VVLeHUXj>OGDu57(&8r zyxp*J9Ln6ZY%CF1iIQ)t2^tEgbs(?q-xh1x29rU5Yv&6H)zF&4<7%+_z*jHEH9L0=$KNfc0B zlSMLUhbSRrB#jy)f@X*^o-iIohB);3D0@sepGh&I+)UdI2Gkg6jFrYB99f6QNOB)# zuVtG!8Z%g>#+3|4j5I}*lxZ%&5%NF){SVWOg1Sm{n_Rk%#h=Z zN>eCMY}MwED2O4v%daVf15lUPQUVANLnAY6L}KXq&?hoTF^V*)GXt|5QJya4C>8|O zE!~I0_XIH%BO@!8DMz&~1u3J(ilE8eScJ!lRMS@x)pwEn}{k!w}&y7akxIwiu8e4`V}LVtnR)U#cOyJ zHqk<@lECYpoOz)eOC)I6BuWhp9zK1U0k+qY<28VQSgTtM7&m9ixZNh4v9PSv<7pVN znUJ+&%1;{Il0+GY53n#(G+ByKu?yN#27fd2E->KqAml-=?9q}G~jWB zM81Tlh*BsL3aXINZyI2(@Y+2YO$74f7z33_jL(h6$RM5Gj5B#4o$|}XMG0s$4<)Fp zAtsBO5jPJypzmce?;>n-DVd{1?h*`;;}dz|KFu5`h=Y_y3xB2&nw{f3V|*Ar8V543 z4Z!&nNTIOEa7G_39JGY+8Vi`8NOGx6L>V&RuR%5gB_)*3?4kTNqH`$PXw zl89)wKq~sm+Cw{HK7r=E%h-ZOb~e6ZNU_5SXLu{kkJAwwTqu$?hSUC2QZkGvX#@fj zT((AL$ShnaNh&!^kU=tQ4>SU&Xe6OTD!zsnSXmm9oYNr_lT1j^$|qwns6=M|fWY!$ z$vtPF5p4uQUt2v$pRO2sf}DkjDv9!hX1>n|4ysxxC1z1}n_C&vfY33ONpWVvgY!)w zcqT5^0CiP3p4KO_>1zyF##lWGdK6;%3NvXsLbV-YVt4UWse)aTWCFRJnL>PsY1*UVY2;9a#+Qpdw4oDv!Cz6|U$OV;V z6qg|#);$nsKAnlwn#M_0^QCgB@l(A1Hy)=@+2$G|E~fF)B(6dQ4U?BSNU&XK!LoKr zfRYNM%4CsPD*t~+#D(@A|L2IBuRZT%q6y^*O!>y3-r}OUxNQ7oQ=@L5myZ{}pY+nIF!BU9F=PLvmx*cJM~62r z?rs_0u-x7E`i$=0ns{Y5=d6ns2|h%5gm}z{X}Ok0nT=>1@Y0>HvSd z0Hq(M2I$g~aF$L$Dyg8uMv_<=W4j#qUo>5g7HqcH;4IpD|A^96p&<^$%ph7wRX_(G zG771%Z$Lva^FSL`p+C+_MtSxj1!dHo3`ZUvuZtmUimuOc@vnL zGo!xv>CS}n8P4lNby1l60=l~P0MpH<0%pOJPDIzJaG8!90~k0YTjX@W@`AUGjSd}{ z7+SB;`DS8s5E*6Y26PQQfNqo%ykY*ux+r1{u#X5G5X;d^U zUn^bg$ItigjdjUC{+|1L_V4>sKM(wUPt|4p`FZX=eDlD$bMOED{RwAze@+|hZNtF+ zyn1)eLYKTBlArql+yA^8dpOVgu`az^mw87QUM;=l4c<%fqSw0%m-aG`8vgO!%<4>?9cL=E6urEX86;VwjvklF%d(mIHBB60!w| zISCNWP$HH<>`;b_C1T8ivy>!;rVHjhQ#c1vaSE9YQm`nH;_wg`rzCT3L)(;$+=Vo< zYz)Vtr;m*U791nkE3?A>!Z#cuVQ;#eNCdgW7&KRg-o+42q5d;~{R&s9PVyPJ0O3GHI%UCjPV$gW16PlucT2Lu*$cGr;L|Yd$PBRr1 ztH~716Xq@C{F`t*X#oVZF2Wa^J3?PT8x1lzZ%HtV;!gYqO7byO3Bzfi;1mNTCl^&J zBn+U0zPluX1(cFsAjO#uGRXU-ac~nVf=3nQ!Y@@U6;MYwFmcX!pmz8*vO=}M6z)DN z2`d7*&ibf2mz)TaBu#KNk`9;<5d4FtC3+y6Tt#%CDQdwS zaue)JQE|oqHQ5fR$T-L(kL4So;%rQh%mgZjnF25ELB1*Ct?lId;fqLO=;81uY01GH z!#QSVSS>13luUqtzeLLm_Asl%lNBm#7$g(1q+}SCBN-%#SRt=7)|Lgw+jJr-WEu%Z z=3+QeE;0>Gk@5H8<5Ogug=mVnEmDh4o#f|*&xa|%UUYssG7+6GAsS&lwdf9F1w;cl z4z)2%>8AfX8gmD#Mjx2*5+nlY&;#fpON&~xOQu@s(NP?v4gJy9O|?NXv=^sFAv?A7 z5PMoSQV7xo4)7tM7p@w3uMG=fu|9xw$O5UD^B7N;iU|P_vnE4_<~R=0IfEd*vtL^t z;-DePp=-yA$6;aah9f*wE+K|V@{zdh3N{r@aTP2A$;c{@!k+`=*nCtjl^8=n+=G!> zn++~ksQA4=UY~)>vq!oWDwp{HRb*iYad}P#76rdQDN?W+Tme~e9Vj|ij^s87HWmc~ zWR5ke&}18D;5bZ}(XB^{3?yZwVwr*~B`N%WN1&xKyu5NwFBM*4$td&b1ZtDT`p0n^ z!GDY^IEFykSUl3iPac6qp+Lze;YwFE zCTB>MFb65qL$Wb_>=jTtgg^?l#0eU>5W^gc%F zr_)IGP(afuMg|y@)q`iGWN>=Wj1=h#h^E)WhD=#~F0NK(6p^)OLv1z3fErG(R`R!x z0AHZK)(!J{LrY+OGM#{qVmdj-SZe^(L_kqJ6yNzIm}XV+25_}FC*nG9apP|&o%{@3 z4I}*LsM?jN0AiXku^dR@2Q77HIjWvdu%TmzbwR+H0_o%>PVmcaIwt1qhG|6&=MfHb zn#2lRk)*mGic!3T2uyOO%2<2(*HCpj|6GYZs#ZCSf!s?+SYQ$BDJoV-tRX;PfQe>g z6F$I|^9HDmE69-0*jImKbH>XE{>70fJ`3?g)mhk4kj2qOvqT&v%x}m!sC^c^qaz;{ zW@V|w(8pR!W%e05F)xw++q?mL-CRYsDWm`;_=m^Yur%mvo`2ks3Z~9C?9)5nr(jI> zTdMOd-%#`Y1Ga{?^y2rvmxey->^xm7+=dEtEg4$(aAN~H(3?W>hIK2<*Hj?jJP9B!AN>4xtSBE1Kp&_GY^PXF%KHWA&sSEkf=W$&mW_Bg zf+{D`jY}hvu+_iBR-(@U!lw9^Wt>&UVActQ=LGUy0LcEX!!6t3j#0nFA^>dkNa?N> zj7&B@?cR}vpGQSn_+)^dM)6C^RzKLu&s^t~xoB5((+IG)U0OBv< z{&rxs6|a;nrPqh9cY)*ejoKAn17!V2c4~J+;|~Bc^p<^0efSoge8<~X)Az(5Rs9P+ z^Y~`aQN!N@KgS%CKkcedt2TqAA6^Z-HgN-B*(91*S-iWry@CT5rpZ4fIl5td#+^~; zJyT(dRXb{)IRLi+Xh?Z$eoXcN$VOIwT>kiMfx#HL1yGI53V^>40P8nST&2+s+GK%t3<5Ya^Q!>Z zDQsCQ2?H*3A?H9!_(o6Zog?sU@{1=dd~u6Fxa^5J!(Rw+KB{&sLP@0x2cx(1%dMb2 zl*ZJDK`$B9Hs0JFy+adPj=gs z0GLiDAu~yUI%X7fFaU!$x)_qJGJ{;LZGP5Xp|K0wN&;Y@YrU(udvA^>82P0Mwi%hu zfP3lQIt6jJ7zY3qfYEiBadLht*deI)T4J8L05r`wEPrbb^6wrLU)f4VX8OZ%vm;I& zd;8CcjMtB^ojR_74(&H=^sV#D4Xh(ipZNF;RE(K%c5_a~%j-btu`WFt{N920 zhUbRfn`+k#?LZ2&p0DJgSl*uy_-*g^yPp;?^jR?y{}du?5B{`8bo-29#SK16MDG`I zor>uGa)h;ci0%(BM0eN`ArHU&IP1@QCu}Fu@F7O~?$tC6f^Z%Q|CqvVCrF+E$+_@> zgZ*)0McKH(HadK^vhImYs28+ib2=?d6Rs=Enquu!D`Qs-~ewV>@+{;Jog=|Qr zLWo~mtsmPWdVk*jf-`^XM$ExI1pCrw$3P6WF8THOy$gaZHH1f{1BMTudEKR>2{@mY zPj2RUT^;oxdbF%H{XDsaH{s2w$33I-S`~nDf#*%q>yNf5YhCD1>13gW`P5pA^|~3U zl|x$4@8bul!(Rby+vZ-tfg!zuJ{wYOU_* zE>1Pnyn8z7{K{`O)-QCIG#Cy)o!qBc`K#7?SXVP>_~+>qPz+c$qtF6->ZpEyn_{%i z#u#0mN~QGk{EKlGi;EUDP>uTo<`t9bSYGJLL8?`MV16-`WgCo^*weWELAAwsO zRVvM;pMSpClx3HKmN(G6`h)w5E$ZyD&^3d!$^BD7i4BXr0Nv;H>OuOP{;>QKHx~CYy3yV!r9Zs3WLzEh4!SAT zNZucDzQmg~<^{T?!6>UgvaiIiZp<*cZO~|Ge-tS7XW5U!>g*XS`lD@1gX-*!u^p+5 z)&0}_OG8)=T&!Nxz*yfOGp{tf&cO@YJ;>PFADdqq&2kLJ8ts|8`h~Tn!aBz|Y)>k4 zfB*FJrSYt>DcHUS=CS^`zS6|Hv02!GLFU>18DP~smeUHX+1~haf4t4A3j0O)OqTb#v+9x44RgAhbAu*-`saeOe3sj&Q5Wn@ zM?IToQ&w2#W<07j)s*r~;*_4U8j)v!KYqf@+iw0~*_I2Qxht-J zGxN7g#mnn><4RZbdYgyXN$tz)FN~{MaWmUI+HOH1XmlUn5PbWf`3&8(Wb(e|@h5`s zelVY_D=Q>7yL)v6-*+25UpIXx`DnA(yBRiZ`mA}b(Qj9+C*9V z+w&UBmcT`CD35z5=C!{ERu=-ZNrwH?{L0!t`df7d<~XgPp7*O+`8nH4(_@z#vSx@k zscGfEC#>$-ElyqY_QIr-E5ClT>a)u$Uh|PRxohQjZ|gz3B@Ju-y)gN~%AeWRAMBQP ztohEH@@nPp6V~7CG=pn?UzqY^<==1CfSr$5AOZdw{bIz&24@%8S6~G5ZqO4=3|%2E^nwDe=+z$@#q{oC3|&8 zrBA@rSH+escG>JTgO!smPW@4A{oO8~U4gIV1%&9Auzc9X>`ME!{EH#xC3ZRN3ijHN zwSoYFV+p5)y@9PwT^n&x;9D~0JG+*xsVZJOEg&?s#KDKtz+Ts|cKXH8gp#o|N^61l zX?i?8ELpJ7jnacO?MFNWooxPIrHXK%o@qJZ$y5_cbN2YaKv zR&p`Cro=Oc+rzF2(Mkg%no7pEaPP4(E~socZ96wJ zs@BE`yFx_{&TaLl85`)a$(pY4ItNzmu6tFRmc^<{Bkw!-)$jgRwT-Tm9~w<_3@mD3 zFn6eg6`?WH9K(tl$1!(*64r(aD;;BtnuN?fs_6$q<9Z!u741eKFt7O^Jq@X ziw-i3TUGJYu%u~DtBRV(8Ml9mw+TzGbkY_b5*lAo&2$S(>2=yvbXaYC{nJeUFsRjb z6dkEDzNt!x4qHGVO_HMr*Wc++m}4L-aXutD*0cUW(k!`wyc4Q8$?*^CANS8%YM>-s zE=o>NtNW7@R~x7VE?p8$i(B=J{=}^Y>Jpb5l9SQZuaai(H^}OAc_2BZtbW%&`>a7W z;o2`bT~YlhX->C6uE6z`VSQ!cn|fJ)MeR9NChPq`SqL0>F#A+6}txS6N4DmOrtIhj;U zxZ9>&s@OmmCqPDWYH27L!{`l6E2W6XbJeAz;j*UKn^Iw&1Y4ObFULV{zsdfI3 zvTffz^SM2E4KFZNzr4<8Trs!TzJ}kLYF@r0XIusMMo5hyQ0iD--!g6k_hxEMM61-d zeE0WpwcK09HPZqYgqAn@jBnuHZm5~wx*(x^PtN#*+&djLGc|!}3(EJkj6cD>J6JQj zH7&RN!1wXzx%co*qCi<`d9#mK2lu}HCP}NTru=Y@R}c3=$R=rEdQXy@q6!}5C(rxs3lKkD(N(K()q!H6@>6TXgm z@_h7?!-{Va=RQvOJE~8ES`>IH@yHAA-gk4x=3Q z_2+ed>)JmhT3yxVjJvLR@zifi`{z8X9;4i#>w~OG_3d9aTiw#;3a`HsP15XZ|M#@j zJ)_0R*Wc7lI@&(`(CVRfvHJSEr<2aKfBj|EXOvfX{R3-qTl+T)>*w0Ms_UObldrXZ z_p=@}TC(%{m%7Qf+kYflztJu^a((#e)N`Uo_gKx32#X zO?lh?`?U2pBhB;czv`y^+y3XF^)IdF%k@7`r~GdJ`)eDFuXHMaxj)(f%xZND^XU~j z3I3!8#HUsdEwHUXYy24vIx}kx3JW|cMm_MiXwc26HAI&MRN&@3b_2Sx7N*c+D)bY0 zP7PR5KD5_~JqF8o?jfTz*KEv%%Vj;##QB8iy|uBrwLGuKP$z&Ff|FUc!osp1Xzv6e zgfokKt8jCV(XxPPA^H(4M`6+49%%e#h8U!?Ty7Pe?lI8`6ort=Ssua_S9_o(l!lP^ zvAk}rc-S*~Ss=@X(pl#dwDMJj<;lQod&8kRxP*Z7R{epRB^`#pS^kV-wAaQqsHlT# zX&Y2k%;>dE3M%iQO|lJPl(2i*+k@71&}Z9*SCx$G<@N_{=`dPi8_g&U>b1A!*LN_s z*b1vkg}shR{CyqFGq&-JRmr_h+xbU3j33!1R;^O^y7cqUbeR0MoyRCE>~*sZZtF0$ zv`elktLoKwBn4mVFq>qT$|&F2J8paM?GE$VcCxDSBfVbz!H+sdFR@cHR$uD%ww*fA zVX?(dUA6jFuW!=Sw;h&e?6Mhap7;7~pZafy)g!ySsx@DFC-+bN-C_OPE}v0>-te~# z!8&a$*@aaVj2i(-A>>ZhBz7^Ql6@m+dkC}Bb~d}LN>e%RMsR;SfXS=Yf?8dZ!P=SDZja?(u%GSmtgoZad_|)%a=+wpt*M`QHI8Nv6QLj4~6L%wY zR>{~*4d=j@b?0N^>0#m$r*)je>h(P_2{B=5CC*1V$G@!ai%DD?mQmtzn{!HC{UK(~ zjj+WI|8bnFf2^JRBP`#+jo5V|XoJ31;O?-i?a~HwtvEMa!vY?BZs)j-_OX&f z;njqvgnRACM(^19pTf5hdJ2U~=O{H!wys5N}Z0q#49P^x^vsSB0h`ie9@|^`bW0JnDI)-^Sga3%B0T<|ahFX`Ixu`zyMw zU#rQhiTctw`Tp*oh1))9mp+L4)i~w*?!RcQPF22nG}`2E)}UKdORrj%5KU_0`84QZ zb+%Q7HPMWwfSC;jMRgukD;`8!GzI1~7-HK4s*260v73T6HW(FckEtq6nC8^PZ)q^W zb|h7m)l3`L6nwv7bkPn~)#?Y+{FxmqJC)fpWZ;9zN1vQ&M`K#DVmumnBKHt zdUI3UK+_!N-qPuZ7R2>7B}n$jnftq@pIk8GW7C|0JxiGf_2Vush^OsIlI&g0JQNz& zwP2?Eo|J*TTbV~n<8CZSn6_tuWZ!<~v97oWngz2K?vW4dJIg$wKcjy^V&xu{WPdmF zWax}n3uZU($r{-In0dN%#-{~ydiUf?4!mQY?V9mp!Q78~mJS^F!#uAauah>9ws)E2 zAjSA%XuN)!$bIh$rjEs()@AXuu%rm5(&^1kciJw-n}vys^2^(reb=}Dh_@M=T(Y;4 ze<*Z)r^a`t{a8uk-gRw<64qbIo#{3-l=m(Un+}ma%Yu_dv^JlR^F2+tbvQ`)^22Mw+||o!yj{*}VVG zz{xo#Z%St$O3Uiq|3Gp|Zt|{c_Q|wGANM~VIJMN|gZ`Y0Y1y;`{gTtGO+JOr=}OCS zKk#DU^j4EErE_ki`w7kj#pCo6yO@4&V zeU-MP`M~hN*~ccoO6Pt`TiSczhveKllRsT^f23(X9{4kG?vDvDn5QGlryYduCB;-H zY@WWX!2RH;7w4@^(N**4vSrf_LSNIxbkvo3=Cb7r4^m!Sm~4t0h-_trl?S2Y8EL8? zCUTS&H6Jv7adD0*NwZ4iAzRUV5PG5Vc&JBVUZC%w#je&YQ^VJy$!}I7%{JUiD@S`J3_!&EDMh7p9hb#941vKW+Bg)vg&fwSFyL`eqGs$e-IW z%8WHOdBvLw)}f$X9mZyMY00bKRPqjma67qXoIT0w->elK3g6Y~Wj5w@^42%nf=cwk(`uOe>^nj z#g(OIZU!kAolugeCMoV}*?srGl+N&t&YmfEu5P~Xxjdyeye7hPLEN>y_n}vOKYUZV zr~J;f)AuLn&VL%dx!h9~*M0RqbdiU`x9s!Gy3_se{>0_;KZb9;=9wFJ{mp&oFMki; z_SSRho$J5uPti?9B5KLwmc{ju9zf?A{-nrx+=@Fr77qfKr_v$}wnvOBjq7!K09|SA zh1Xu19nvG^mwSC{rv6OT*f{SjIZ_#XBeX^^QEKm8-*{x*o!t0@unegyc~{%Gjb1lX z6Cw^vCy;j!jN5YTW_CiB1+nE#)5q`0x_vMq?&gA7<$E&69~i!UJ|SLXlqN3UyKem9tUEmk39)Hu<@=6~ zKR$e?FCkHzmQlX{_V`m-cRwV|xtX@O{J_8C&kf%Nv*sDemX{x7dbMWVqs~f-m8~jo z9`DsYe9vZ9vR0-oKQ!IzO4fb1St&PVo5~ModR-sB?>{TmD1Aryk#$}-vmOM11!3vC zBaRm3-@g1nldvgmar!~$W1YwD2miBRQ~Ig&6VAtnjy<~kPwpng&-C-oCy3)ugCCY| zS~yYePj2B%7&!KD!>o)9`E_U1|M(#H(XP>%d*pYV(ZmUF);~J(Pu4T}qid&@O!#2@ z_|iYwc8Y;(r?*V_vi|X{e{#i&x7W^`neff{$@72mb}0V6cJ|Q(&9C)OzWlTFnd0}g zbH675lRorezMT^5K5yxbR`)R;E)y%s-4`Z#<0enp4-0oFncWv>dy}f4j(fP`nbNYm zb%{6Cq(A6kvE4#W_oXe~jOu=2A|AicX@6VG3F!09u_#-$&_jN?_k{WUXL5_xR~Gup z+drP5_B_jbxJFmSi_~DHwI=%Bd_iA@w)rs;loYKGZsd6Uu&T%Up!2N zlC9p~eZOVm%9o!uZ~Z4DZ~yi0EmQOcb+*)wRu}H?F*_N!a*)1d`z(#RY=5uM$*Fon zwp(^?QdjN2Q3S#k4Y|$UbyK}*_03G*sINo*vm1;ucdWj(&Np_^tLWKHv6*{T-#+R) znbiaYYM3S@p+pk1s#Vw!HpqiJzvz z z-`(cExS6+U&F9R?*S~)EpF3!@WXGB>>n7h^^doxitJo!b*8F?)toG%PIo5AhEjgqZ z?mhcp{!h8}yDOR{Cly~mo_+lC=Thqr21_q0zR}M0&;PaB`cv4_F2#5Eb1z=PPYhpH zExqB2hEI7l`+Z9D&GqllIT+mi*!K6Q2DkzJ^GFCV(9|M+`M4Y6cpmEj zqic2Z@~Lh*q34MZWNa;VI^Wbycfomb2Qsl%?^nK!8(Mmv7NQeYOZXMoyJ1b|nH@T_ zY7O!V+&(;S^EdO>mChp{DVRXjd*N?+LN{lg;g^CbRD2YVmHlaj4b5p;@CV%X0=ogN zwlR_|i~K+YT(H;JW4mpbdzZz1&`-MH)PNoD>wLCsc8|eQo}1~Ywmwt#a!C(qD{tI} zQMdcdlb5r=m!iqN6Mlru9r9eV+wkA|$+wUHh@bm$iKB9D6_f z^z6gkKeMdgzg}|o{a55%-dg)?b!usMJvbJa3#3vBnjyq|&$n{1bT8oS)*t z@*djcfDluH^OU`_a9t05PC)nuV*FF?^TI7XMoR;tP4)Rt?b${3J&dgZ!VUUSTOAXN z_8w%Oyf_0l5Z5_vF4Aa@95jA#aaOTGMxD#UqSFUWw))NeW>6qNt@K0J4CO&KI@V~s0YaYJby)4Cv)e1PS3b;SeaXjQ9xkbF*rgOy`kElOJ#hET55 z`S`6IbhB(~&FrB3Q#UbhLr*u2u{kI(u1MsH?g()1&xGiYN|`1?*UTaspcDV zm(Saq>e-2$%2s@Iv%P$&!PLY~EGt|6(LLaDhrQVtJIUU%^&dSnNtdrSm`$*o|E6r~ zN6%%Kd+g1p+DZL#>U+m+4ZgL(eEPEm$>sZc$Da+pXF6K)Ot!Q9Xs_4f%Li7D&e$P; zSbn;B!jH>OaEs+TloqQmHG4G+vPZ|dGXP2d;6CLtGjlK zWozDjoOH4Mo4xf*yCr+q41b*5-~Ow?`m3Gh&6+#>L4|;Ca_n&sj&JKxU7TfU^|sv;#A4~6tumA(WtSV z!Cob+bos=;*kS5mH=kX;x6O+y52b~j3#(dtn^`SQJP}GmkDTKXleXT`R;h|{r zuD}v|qx$WMRb_{!`F2eu9PH|MZmz026qC>uR^s4Uzw2Su=0mZ$T~UN%V10wdx}ArF zHC-^{5nJDsxNh&E=_k8p_;4DN*PUJ)?-913)47v#YG?JYwW65t)dG*1+-uJ_25B|Y zn27xXulw9b&taZrVN7JVz<1`Dx6ij+(&ofOy%S8nKj!!IZD>_NOf)4lV5U8Jpf0GY zBxagRXz+b|%Yhw*Rh2O@k)fe89Rk7LvUP`4aW}dWq+=DF{a4qWRLyu7I_Lh_B?AZ0 z^%r8|SLBNXPOIvh{nmGQ%yhgW>2%suuQ{BzzQ-dW^omsAyr=%?>Gk(KW-Yjq-sya* z{`jx;eIALWR~8CfuGF{qRS$a1Zn~1$>GDtgsl4hB9&@^`o9I5x7VpA_;af5wVjRQs<}61HIbjC0oNKF#_#6d-dhv* zc|p>(y^Z6KbML;Xne#bq*|mcXUhUlbPMcCb%eHH-9clEs%l${TN&Y$g;Au`bmN4t+$V1~E&Z&}=|1n^tvBYW)8-YQmA2h$HhME(_9t&HzqxR7WJk+P z+uhGMZ>~D5N{H;fG1KqLe8d?B?iK5AsC?Y#zqqw|lQttO^7?ll-uywvmK|F4`pBC( zzSHKv5^mX}(Pkcty!+i(H2+Q2mc!btJCXn7Ok6ns-K{OBw2Ou#pM0NKuv_Zme8K1_ ze*LMyZ`JOPep@>{a~!V^boy=D{W))Ik7sV^^&!EeJ@XedZ@p`@I3?Z8x(&iUWRZF_07#Q4gW#>scb{FH4odG~qA#p~Z3ro0@Z`Mr1B@aLud*MBum z`8wwBn{9tSYjk>mqkrIez^TP<v zMj$M)5+)TGEvJX{Q^`02m4Mj62H9@b=scT~v@x$ytTV(;GE@ddP&1a3CpaGL3(d4? z9japb54WhcmvPW}2LsURH&o=HrVC;Az@Ml5uir((sddu-M{8Fe)x_1lXIMpLsX$!n zf}(Mk5E3g|ErDQ(Fu`b|Mp412kwieP8W@*Q1*^E!iWmjA3hui_QA_=B2Sw}Js`azB zF0EB7imi6DzvoVn-ibZu_s_>Uw&Bj?-gkN4=Ute9xtSYhz%k=$#{Q2^bMs_a4+c++ z<1=uKC(AGaO&E7K4@b);>_L0|>CK#4M_DMXCEGmfj3HWvbbHyFJ@4cH@k{qNZqe;S z-zOp2f1bS(RdBaBz$an+JU+WsTkrMTqsFK=PK@<%4`94~I^fa5V9$nbQPBZWRgGm3 zfem8(y<&2D<*4U7jDhU3vGua_#JT@iBB^G?|Kcd;No9#a?Ay||XTpOogm(+x6+%54 z6d9?MMRZpRj|SayEbPs8@Nn;QTjD6~&F*eq^P&msyJz$h|JhF@Z17BLS?%ff_}1<< ztsOJ_uKYB6c zPkkrl#I(G_Fp+0cmVB^2wAD|;yzPB%e7D5LFs+|5+3((0eav6G)B0tlH}ib2|Lo_- z+x*SMMR~{r<^-Jx@m9q}2ki@B*iT`Om=@nJ{fKS!e3(ymoVvaItvvmSc1@4Q^;fuM zFP>Bq+WNN!anbFTeX_Kqy)@Eiz@QDw3igzA=#k} zs}_#>^_b(x%X?wjK8unWSu;Gz#^i=qr`QAXo1N@7FMRRjYEwvH^Qwe-@`An9<7D}G z#4swN=(_~-yS2?PFcn^2FIC!^f#)p4F1Pr)+^grdl*QIDp+(m(Z0dR7 zkZ<~w;-df7Yqn%`q?C))q4ZNqrRMY*>d_+jIzAs!v#RE@?AoZFH--FaITkhe5P zs&32ZE2Enp8#qr<+SYGcWlS44-F&s8U6X=Jb;oF3o*lOa@0=goeagj!$w8sb&&}_z z+;?&Dq~)Ql9?yTj@3V^^X9u-!>$@N>){S7QB(!a3&4A%e@(b^lbX0X7FsQIe!M3p* zyQXxGAMRGM;^37IVY7S^Qkq;|S*e#stnuMe2VE|_c18Nm7e36Sy!_So)th@?f1u4g z6NufIzK<8!6K6fUyp9R(r1H%hm@B{XX+S}z*zS3{#Z!Wq)}CAAG?qcjw=Lh;BX?^; zs%7x%pO$a#=ecd*0*k(+OTkuc?l%2ai(!YQVEZV~?Zc`pLrS+5>`c$yp7g*nwEU-n z-LpM+B>Py0o#?V+?~>ddV>?@o)s_{Xt@YeFL1P_$W!sAVyX?6;C#G6Q-27=p8B^1J zQf_?GopwVHRZr_Nbz}TUA|tb>$MpSYM?RS|wEV6zjK6wz)Qe+7k38QWHv5;eqyKgr zR^ic8HYd0`**j*~v7iI8dCKY(|GC3XwC@?7XQ&?2^!Tt-iUZ+GrZr|-|Iw^6TDtF( zPj-xz_Gx}*(58I_2vd7E>#DP(ygpl5HF3PcJ?h-V=@F~%C7Ao%F@8DID|;Q=eM0ox zEiUGbFD-8C%V-AQxU>?V=~tXfO`O|;*&yA&RkzbJ#J%F`9;cSgM^f6=!l zH*w~j(9yqD+xk7G#-Z>SiN+f5+OA)Gp6PJfgkm`o8mv~ zWlV^dZhnkMw(sO->b8DwVPof4z~1@&-)+|lTim;UnTj4+*W*XOYO?ZZ(0$ngV}hx5;HoP9efg^E3Fdx*g%_9KS8O$M%&^+R zYt@^2mQ|fg=WB~@H{J|-J3pnccJ+@5n|psDRk=uuo9=Hq4&ePVs5Ok)3eUg?YV$82HKVpF2U_p|>t?$dwIE zPfqBsJgi$X{Yr5g&(yfs8@i8Y2bBaAI9Kz6n9vTX8aDY-{szUyE}j(wj5h{3js$HA zFL;oUI(%@^E&Q^bb6d5xGnd!?{(N(k@3w&-HDoqOu5NiBPfrv6E0G$u#*ecMUh}(t zOMk<*!5b}xoxEYkc*FJ)_bfxdXqdfwj&jGCR$Yx}$)`l|C3|SRSU6<=u7aIu(;kla zuEo$p=L>c@FEPxOtGjF`t)qy8f1I{^=Hu<7|897#qT%#CIo)@p_%FP6qKkxCIBue; z)gQwu`%B3A4AZ`k@yw8~_BkMstjKsSeZ^;MetBe8y*>Qmk`<*Jm5)<(MZ>S|!t?LR zY1WZ{48L}2$bru`rlqCL7;*Fdkh0J3rDe?eW5n$P(+_;{S9fMk*PGupA-@JFYVzV4 zNq40~51qxYK!7|y^dqaUzYbq4_<8D9`-qVbM>YNY`qiJOANpqGli5wnzY8W0e%F7U ziXX)+|GNAKPlms|{nju0%D(t{R@lrtUBCV9QrVGTzX+RMyZzh0o|XOQ6=Z+a=r+?R zvw{hk^r7#}WG1B7(T1aBbKib++dHP$u_kL}xm_owFiFjhH~*?;UgXUbe|xhN_O_Cz z^EF9h0@pP=*?Gv*JmbwV%)yr@WlQ!hGAG<=@y*LqM3PCXO|71+Jl*%#a6I>K3h_2p z#z?1pvUuj$_8pB?@#ClDulaLqr}vF#25*{Dz$V}8YKlBN{FWSWy4PdIZ)cPJK3jP@ z;l8|xd~Bd%)y380mAhA+OPgL>^j%B4Ir7U@=cgU0UGsFcx$l!zU(Wiqb{*Slg37-I zlhdR0Q~$+3s=M+R7p0dLxAA=t7tdc>zN>U&*y0BXR{rwppG!Btmo_0b?C`}Uvr9{a z)x($HTJN`i%ln*#S$^Zn=Kj;R8NRR#DZ6oX_dF#tru#$V<-=bcIHKJ3!On*xYY%_j z@yILXp1Iv0r38L{?Nq;>%+fUz$AuMLKj)SG**f3H6XIvwxU%cO{@uQ1zw~DvEPKC6{_g_voaR-SWeNB(Hymm7}$W?HGXTOFm&G z2M0-S7qimB5%~){b#~0IyRyYkvZAr{=4Y(*(oQx%yIXt5bqy;Iy6+=dJ65tZLb~=_ zR{G;1mV9K@(PjYqULbb+$yc(ak+i&)mA-t0E5heDlgNdaZ%YmaN-yNPN!Py=F5t74 zANrqYEcr2BGUpv>`93%4wS|sJ@odanzYdiw|J_HD{kNxd#TIYrjbn}z@oaA*Yo(8* z##>r=vVru*(FTsm0r+svuZ|80Y&1FHjGN>NK9q8%f%HsOgO)vib?^zSJRBFUcuNj@ zNgthWAYEJCpymJ9y*R=W*e)RrQm2oemYzEGgJ3rawm9e}Ip!uUyxc%~?GpCh=INM` zz_xKb(Xb61T8@>xwJSt2=Sw%qhBK^m(_D7M^3-cuf~jA)2&^`qHu$#U0Z zHiz7|Ihmd8Oke*EE*L?zGNy#hly;zj+}0sN~Ma$Kb1=N`adzIi1A@zlcN=N zi!s9;c@x=fZdO@Y&ouU#TeK=Z#-fpPme_F4mZ6BT#M(H$NulLc;nX@_n=(0`Q;OG& z;fZQhgyU5@8*0ZbM!d~v6W^kX(5g*Y)EbV^$vBHHi{oP>#OoSfYl)R>^=A5L+{4*8 zwJMxbYvMVJF^kh1_!x@;uT=`{Q@3V!E+*=^%tZC;MY3j!*IEoRPOXz`%^6u*izZX6 z=i;@tjI2bpMy};!AyB>kIM|BoMp|I388SJwtM0mpM7{AJLG88-@(r}r(OSvy<_Im% zQIhK*kSa^7qJ%ML$jG5uJ<*ENkXOkQ^;T+)D5HZgrtn1i{kn_@JG{n=G}LAA9Ipx2 z>O==+au!oK{<&@n)2qbyLLts#&eEzm+CosysDulYP?X-ISA3%09Kos0GQfy7vm6^l zB&tocRq)y%)AH7EjyE|jPGMWN0kEv`3Hn%iOYCTXgACBsaeFEoWH-pLk0McR7Tu-Q z>lDC^f)l$}NubH;jWlHCfVYyvxwN5RNq7iy^Hx`gKt6awP23FW>~D$(g-ziEOZB+Y zWdPhNo2z>`eXNY5JwdF?8-Z0*rWk)ZUaPkPHZ&#?FfguT&MdZx-4G9hA{bmes5ikl zW|_#_I77?pAe#wsP`@9H4+HQ9oI}IXM9fWsmGA(q599<~U(23Af`=%{o5V_*GXO1v zLaR24y<_13EuDg+@k;Qnj?GMTd^v?}ZU?id%`UV7D$!eM$iQ_*vXQM`5@!^LLt-T~ zq1}x48G(HRAmA#D0h)12xL+BQDsx)i@o*~ZV>f^fKz*)n(1SK$Zr4K*7>HO6eJBwy z98?n_x>uJWCoUGj!IlBRaGu@_0qRiicrk_bM-0bC(ALM>ln@EV*6}XrfzI$0Z=jiq z=#4cK?iU9V>_ZqnQ$#utjqE{*YbUfQ1U=zrF=Sv+i4C!)ZO?9EfX-fUXfP6p)#y zSJ`Ms3Wn!9>1e=^7>@vNPzMtoO>(Wuv2+33Mx)C>G^t!|OZ;O4c3cC7V3!Va;87<7 z9+hCvfON2@1_q;zC>*AwH3AgCm}VQTO`Vns>@G$&;u#S`qXY^WiDZ;QZ~+oBr$=gG z1u-P^oOB_O-poT;N-zkEgpK!8YeI64;CQn_0-6X| zSd#ilRj8!ti{Jp70SCzPV$)(LQa9*a*AWdS1?W*BqEcdU-aw}sWP4KB8mS~~&mg5k zrdAEApuk7~$dQVZUK2K?DnnZaHX=!owl9Fqa}l&c&fr6qrrifKfxmcdXOVM^C;@b+ z49&FEq$ZBw%#OIZY%4p-1f+&X@}f@_!V!hHNt_AlK*FI$phzDeG@w{A$`B27m=jB& zDpVS_}X6s-yD zCKOd-b7i8iQ6}2ebRHmtq(j-rAtkA(coobD=Znlp(iAcdvW}V)6*vGK0E7}3RXcv9yE#lUN^VD*3LaCrQ(3z68wP9`xN04*)=$ezUp zIrgNn9zxObMMqt~D*LK7uMq#OwjK6DlvKmU9_Hx#(Hd0*2r2SJ= zLQ8-OZ$Jk~vlo0vIzTI(_{eqm*-SDqjbI_}zz#GB3D^KY6-qYJ0|YlfT?i`V&4M{w zza}@Djq0GGvvCgpbT-%%c|vV=d`MCb%2UcNgoObs8z3r9;DlN%BFsZ%*px@}pcdtD zA~M*}Kob|%NVO%ZxdroZb`p?0aYTJF{u;+9Wd1E4%-G0E0@)?ALtu+pL9?h+8KD{x zDG8_&!FkZQ!cHBG03(egozsNIR3XB)P`-i%=pYl=0#4;c<*%@xxY0#?SwO`2101hI zAUA{cm!Voh>U9+*QG|W)1$4#{Huzm;N9jfbh*%f~h^0va8=?k8Z;MurHWmOzN_!1R zg)U6UYfg^)5$iNpko-svCWXiAMx2B)2{rTrl+=RfNPXqv1(NJRG-$_YqY?5ze?h$; z!kf_t(8(2opaDRp!#^vOtVf9~#x4v^Xm5$;HUx*jvMAdU%p!YRi8ihWV~w_kz=SBm zRkVT-5Dj`Ab)z+L4p>MKxF!|SID+lubXAW)L(_^RL|cJi(V`L>WJ){YB3OqEm}q(? zWtSCYiLllZ97_ZMM%4zM&bPp(<7qDYc9|@P^<&lemU11r9aK)qK*dP}y$#7n$oVMq zG!YI=###%d5~?%NOol)KhJLg9MuXzYWn^eXI=p%>+G41x2Xf##cu;MULyo#!Sl0~_ z=-CB*g*pr^q%bL<6eBeojONn8gFIn$6htluk%Af7UEJA|dw67vH-=MYB2bpSex%{- z3E?5v$rdVWQKJc=)CekG6ORqvOfksvVuB#S1~j=q5f&#!G#Mz?n~tyxn4fM9@S5i^ zL=xi|0ff{dYJ?C6WCj8Y=*={~$vRw)Y@${XthZpalU|t!NuGC?{x& z5Hx{1XaPx38RP`Rlp-W35qucFAm6*JBUpt|26djD)Q;d^s%? zdF_(f5pb9vh?+71I|yQzq73DV3zcO8gjUiuisu(Pq)iM9{~cr;?-Ff5Iii@?hzn;h zfwK}4jap$HQlVp(r;in^X8&g{O`2I$+ImsT2~z62aY8FwMg$>C7f`iX7 zA)#9a=KumJ5*8G-pH^SQI~hul_Rq>YdSv2{OaTI97=rdyRFo6)Cby~xh0tM7?#D#N zh|-j<)dVld#nC6w3pxc+?Lp{~WH2xw;eY$hLxBZz^?x}fisK25^xorPKD+j@Ip>@WZ*Bf z*g^dk*qp)%On@8E5B(cm3v5mNhfW{mmN>Mrm)ZcT=V<;Rkxe*>atEovFy$l`w!i*C z1!=6noYaQcBsL4eiE}F%=K-T4p9xKwh8D(oDCRD2Ftl*54%eNei|$9@9x`YVNr+-x zCaMuJ_(epa9;1N;P4rxr!!MncjD?n>L67qqO%u-U(Y2l=qs2E00wh{kxxO}Y?u8<; zCJ$2rbZ%D*_TsKtyZ8&OF^OIHeT%5N<*Jj}Q{}w>$e-!Nwp0 zN=zZ92nfVAhl|afCPzFwYo5B2hfq5y#56KdEhWs*(d1AAMAY{n1u|AbcP7q^&=4a{ zG3Ptk1~#Ux;{+EEhNI%#SsalOl*qb-Y0)Wh1skz_9k&YEfep&_3`722;{O3AelM8- delta 28369 zcmcF~cUV(PwD0V&H|z~bNMb^h79cd~DuRj#Cf*!8Gb0YN|!#bdz=*u~!8aNm9J-S@})?>@e7)?PES_S7|NerxSeds6$@F>S*L zuE?E*vVKoy{bmbUJvuDF0N{^FiQyhK9>EVIOtEXIp8yNM{ruxF77$`{Q9mB$i2B7~ zHK;!iGe!M{Fze49<3w2W7zrKA4vvv%;7{bE{(Njb>K_0lgnaB1DiUA=V`TwoC>NUv zf+*1-nvfDdQU5rOE|eprz#nr*H9?5Aiv=1G0hiJIqG| zc$gP_VeBnFkuT8JR3R2>_AJyt8ouuzP0R(+4z{rId=Sl-qy9mdBOVYQi?}lb!e^rZ zAUePu(MRLLiFgn|ECmt7*8fb41#sk)vjPQdn6CrpL|8+KOf)J6ffWu6I1UFFz$NAi z;Dr6L0w_k25;s9KMMurqghmU9)gX?z3*xXE+%H0e9LN0wLb2m;hQwnaA|?Pn=8gK# zCSuUpT*?ICfoz1M;1grh*bB$&0T)Hd8ISr49A-GYh7ZCW2(YX%CWcZjFobJPY(#}z zVj~a|`%vLnolrnAfMe7T1_2a(5K8D%F2Gr*jEQan;lw8AjbIM83FUF&F7gB&C@+GO z1esox7l5S$o-`Kl9Kumv2nPo|q8sH2IDa%GEo*fh%8%ff0>0q&7(+$*BEl5TlM3dr z6HtD1{sBm^KadcA0N-IT%Abt|f&l5&vCUZw0vr-y<|`T?gexe-${+(*D?rFWA>l`% z0sfqKP>6>I2t^#24dAfRfN+ip8W75Pj0T7}Ud?zwj0o8VdH!lNAO^DrfkoF~nhOG@ z`$3?C59I$r1Nm4NEEq)tMOYIgl5WjIEi=w25J&|;;J`x#p-=|}Q5+vwatbooTT~E+ zg#tn2VGSE)I{ySA#BvZKCTvR2a&c47HZujtXP3EkIbLfN7>C0kw6! zj)n%p20|UW(NI3N91>0;%n3kfqY)m;k7XNy&~^$4EvnHRMjcIsXsAE71q~H&-a`WQ zBa9OPLPv5ysPwbuD{7(c1z}PZ2qOm3Fg|t&ggH!u8TgbgfKLqwYtMs849hp8VFK(Q zSa=O)1ZY?&XFeJh%@?9!v9QUo#?5%xoG7+4-1I##xr1=25ePS6<7jvU#{z_pn1gUZ zDH<*!yoezXUet|-&xWU39X^{whpeOl4Ugkf&jn5OVw>k)#84M58f?kQzY|>=9(P!}Jwqh?x$sd`wit8AT&P2zSA9 z$n&FNXQgN)v_L>4U;$B)6)K8@`ymo+fegnO75QPua8Xn=n}Lf2y!`wzyHg9R^-&R@ z^8ghEG>}nI1UxGd6ayl5MBM{K4zFSTL?}r71;Y7%p&}s%mJshy(QJYW0ywT9N>B%) z9L~TL0uvcTNlVbEP^=kdGSDaiG-px72#9K50-{Fx(WnT*l&AqwMaR*o=*tfwX$z z;4pmU5fs}E-!1w8%ei>;93h)GM)?4b5XHd7j4j#%Vx@&3)?hgSGgctB(a3kUpGXTB z0uU$QX#w~M;IRPf9?p7>JF$8+y|^LuAo|gnG*;K6gAgk;@0fqJtRi+GEjD^n2-~|j z>*<)J4vWUpW@(!m;ZV@j(xICB9~=OKxxNO)np~#QxC7`%CsHu1#vXoQB0A51eX-T- zXR=Kl5z3jjKfb+vXpYcV|NQZ*UH$No6+-+z_vIm@izn$zaRwya4Yz}0U39P#mI$4^Q zBz9;g=HSYVRQ6gVpSHkXoUV`y5-@!mNwPRmqEbp_5~LH;$7OOQI~5@_la%sIsSM*A z!Frh_Q_9i8C``Fhnj}plP9tWhTqOuZD9luGT9RDGGQ|~ArLid!wv#PQ<4@2WGG-$_ znqFfw#9#B)m}NQ}7_sw#gunubO=z)A<(@u1dBv)%_BXi+w;6_bJ(5 zk}P+x0tODYELzolO@#?tZGkMMn1l4@b%>`=|(d?0m^-*LgO}`sa{1fqorraIx$ z8Y!jXOnI85^*P%HF1Bj|Tn%U0vmch?bcv-jEk&A;8$&q6!}FL%y`w`5~H-T~kH~aYc%f(?gV?DtT)F)GdiV*PfXI6-S)f+CY{j%4PYE$T&FM zN4jWMB4UqC!PU}4*?~`3G^~}$x#b`elcUnK_U6lMwtMdd&TSVu@Z1luHV+F>B?>SF zs7gwI3aH2_Tqai9`r}xqrZ`|MY_EG4;emH1{OF{jPoS2$prfdLIbHaGuT2VPc2E6B+BR~F$*9yL3EKJz+=Cm zmg2|>_8-8rs>2BjpCZf$hX;&t6leRAdGgGxPyqr_mU%gDqYZoECnw7?GTFL-AL@tf z!})1SRv(f^=BF)_673k3tbk|dQG0$neB+xg7SAm;M+h2U35V;F1=Ofg_3RPDoWS|Y zEUVSJSd67AMVty1NiM62F{UzIrRnlCX>K`kjm%f2NX4UB&CCSKY zraAzsN3uk+n|%bzWhBlCBiL4+dQfGvRPuBaDnWy#sgjyu$qd*)hR;zf0+pvbF4x1V zfZY5Y89Ppsr>9Dj%o-W4WK^PRH^u`plx$l;IYz=wq-GBu89&witRZ) z5K_aSL?g$@AySptES4-3r;DilY4-sG&HJ zGHf(amTZ;>MbbC9|z}427 zOx;8n8{x~u39S*_WOfM%WxS^Waqd+@AE=t`u_CG+xjB|%2~yZAHw59K5|zma6}yB> zR8lsBF;Ne0Sf*G-53()Ci6E=f`ovC_KDWi-I2rqfN)si~5X^>3BZcgb8e2Bi<`Es+ z2&9b+iYb~VcUBX#fZRlnkvrKm6k4*hbZMH&N4jP<+YAwCma(nXkB-p7plMAfj*!D7 zsq)vlxjYbNQml{c1YuMeIsX$z1yXJbD$b@%p-G|jlsDXG8({i0m0X%8XSC^}VNz-V z1uFaNhM#1JzLivp9x6^lY_JA8gQ~Aj_(7{7&t&|ohv}noW#kaq7@kctea{|(O4d`m zm;u|v1eOe|s3&o05_TD0EzlOTW3boctaO#QD;$K=<=jUs%Bp^LCLS)6K;4%ZU^F~c zoD|uCL^8t_DtTgxbT1yROqkq_+#rW5r7Dv^f@umn3Rg0CdJR@oD$~UmL-vAjs}U;F zP77B_(j}1oND|A=ChAZMWR4Nc`=&|BE*L`_+g1aLQT*|>QL9T$;;UD%#5x6P?4jE5uPeh zFqDigXJ&*XO(jjwT7}W5{o|m@W2Wi|h!hry)5IK%9FZbPD|e{bfzX3>#$nHKX{wkp z$`o7BBBTmQs+9|lT?0}ojV2Xw#ZYmLk6=k=j*f*Cf=`WL5PXgcE>+4#o)H<;UZzVO zjz>tB4WzOA$DZyHjiuxWnK;{rYy+)yYF4H+&C-vWPE(ud16Ri$J>1gE4cmaja~C-i zi^rAXq@zCxItsgO#<4>*r9>r96<^>Epb<*qG%-8LMl{+WOPG-v(zFZ(kxO$;5_`###awC+ z8CgOTiQ&CN{RcPLNQOK_Z&YnV&IhtcoSk81sYesR%U3Znf|TPTN%no9NwqO_C>zHv zHqd7>Mbcz(LdNS}gmSrq@seUpMO`IUZ}e;j^~7W|Ypbt%nu9hb>Ov~V8I>kex08X& zL_$UMK_)ewN;m*j5k~F6frw6FT8a}Po?)CEM;6JKNS&FO^_a1AQJ@$PnpZ|Eg+CF9 zs5=Fwl%m_`AVl=E(Gt4nkf79cdP|PqU4i$kIB|>Y`K^nt_(VTY~)YB-=22uJ{Yn*U~N@+5afmq_vVp*e*{vS{34+d->=>ySLB}T|x zJX(@a)Iv}|5_=!C@&0sjv_zWNh3A@^>64vP;Tk?OAj4Zd2@|0bnMn z1)`@~=|K5Z`N%`$EM$}k)J1fY$>U(7%B50bE|p_qzJms$9bYopU*Wc)u5!mDU1AQy zSP%Jv6_6otNMt-Sl7=BPt56np0#A|3SytF6gm+cWk8Y#U(h&?xp$_U1JyagcOn=6B zL&60tYA)j_QMGgtH3*(Vq7IkJ5)4eq22?UFS}IGDQaj0Ly0pOzzD|uL8&l1bSTtQ| z45O)&C}gD!dJT5WXeq?uX;d%M{04|z7|D82xIK<=1KB1iWO%>J6BsrOxE@M)oEp41 zGobq4%EoBhn}8XjHltBr5NeMKJ@IrjTIo`aP#BDx`i+MH1>>XgWw+umI-VgD-|_`I zh!vV8WBnm#$(D&RDtj4-vHgSNmi7@YR0234gLtes&7_N*t2Cy%bdcD0K&;7GCQ@w_ zD^)I%rb!Jh;0+J(Sh>>b2^DcMnk`L`E8)Gf#TdkyS@n!(TR6qR0}8#uBr(Lc|J9rQ zVej$(^k$_K3K6^zW0hiKe(yIYXOl~$kN(gi05D2Iw0@5wkaUm`62K%HUuQ$LZtw;B z!@&L-t=}kdzx$O+#dYs54_3VO{$i=RF!|Az^w-`)ap?z-4&6(?e)Ov8`d;rL)AZ{n zjq1`55Uo$k@+0zSx}$v5rRLw=n_m!)-QI=F?0HY5q8!=9h@` zv>l!lmobb{z_?;$gFoeQC8VMzbg?Kt+AmnpW>xH4%k&HI^}us@Tuwyp6qNOt8<-+yRh@<0CUdkcFxbe2S@|1%s?kF>Z=YepDtTC5(e{}K-I+*}b8g189*c#6Dx z;s=L_4IHI`#GPJGf6esF`yzQfsblok?~lj+G5p0lTc)9_Jz92WAM+gUdop~n$a&VO zz#rXqFPHy*$VBJ?N8jEPKlLNGD1E+ZG0vl`4)p)(NwbO@7*b982;ugBOFtTh-+kIy zZ&n{i$lCuuzhFExZTaIzAZk>xh;3w(0NvDV=p-acF+MpF227A>G(n6lfxI#S`5Pp1 zgpf^FAZ8%ZVKts8NyJP!3UVU6gkX3vnNy1frG(X8TKB&;NVM6WF@Dj!H)~sgdLhK!?Fk}nl0yi)im&IVAL3jbi@9H zXrh9n#FHfoB$S|_nF`JoJW-m6?I33=Qf2Je483^4O*Ap(S|0g1hJI8ur65% zgV8FAHBeG;kU^Qi*FzICF&zpEC>(n_0UZ5UV`Hou zmC1`-A>n6e?gw}vRT^5LAp$h^fwPfTO>Uq$;-#q$^qFpnFM?6Fc63oHG7ViMAsS&m zCI32N4#by7acD4Ms5JExhPeY}qdSZ@3F3itgBS0E92ThYoa7c&_=muS8 z;AwIt{~}0hkf3Rql6f$@3@gLaveGdwTyS|Zwi=fw%Q!7S-kvxXQy^?GE_7BoT96oo z7v^lqPTvLz;{w zph{`c;{RY>P^AJMJ$WX-8&8KZMm41A*l#plfi1?<72?ZDARYSxvz!KT5i$zW34d}r z4E1qSFYBP`s(e$BZtz7HPgg17CplHoDOhH3Q4cXPf}qwiMY@P_QO}+N!#>oTx)_Vy zgQq8_b9&J9WN8>=QyVIA7zk|e!&S<3$t}%_5G(a+pn~126#RlQG8L%0Hp9r7G!O>< zQV9srQYj*XC_SJe{PI)bnOg+QRUCHXad?vW5?lp6<{hZYl~@B3=>|jwkaDbnsyz@@ zEh21C=_2e5Bpi1rmnMA<(zqR{Dizb_RKd_4r+X|)s8-elBlrM{Q9T0?Sdb!P@8F+< zQv7D=J5;4~Fow&Pim<_Q_DwWVE}=t$7$9^sJ(KVTuAB!zWiW{X1r0tDW3w`tPVkS6 zxyZ|qiKuEBb`&gwTDMHhNq`Z9G!AON465T;Kz^Ar5yG42YJJu&eJ9p2^8dPlfxT9? zJktnDfDbw!9T62|^ah(39oMIUkVX1~It$-T(X}w2iL5;T*SVEn&nM>XRLuDL&7W#! z{xC;}g!}5y0Oj>Nu0m%J-o~zC(`|@(j`q){g*2cylWLlyV+8cVyJrsSFo2eY3DDSt z(kX8!=eNGqcSFa+u>Ve^^C}Ih~7K<%RCshXRoi@2%U$W{O_ z97s(#s0-L=&Mmf)G8%%BmOJ7RhApU?RRT;GY{6-VQ+z6WhuV4=AW056d0#JA>WSAPHeUaMyen<7*048FBEp927nf`yh~ z4bU~2Ug%bHAzuxQJXJV2?_Wqqz$UMf1U>*x^Dk9KJ_!J()3Sf!$TU++B#-G`nj}ET zCjdBa1AtxRuIQ5taBVYeTJepMEUcO+gDXTRhHamQfWZN_eToBE`5QHf z9*(F5fH^sv=>V%s9p`l%X^g@|_V3gX$AXBu;O)UI7@2`Aoscd3ieS2rMXk!zn15ls#`upTpcMdPQ zc`)^dC&B`Q$oLaE_f9SU@aFZ8DGJbm3v3++b25IzNeS8szL@T8L?A2<4Ymi3qifO_HcM$C3O=~8iw`0}M4{u!%Y_?ydraD19pS{vn*c*?ti2ZQ5RYbkK*1+f?Hug42bH)<(^ zsBB9#4?Jr!t@KYx21_VCJ^7_&$rNrZDV=LE0f9b*AWm`Av~+qUtl+{P^;h1L_3 zn{Ds#wkpQSNnw`=Z+E+4-u9+(%Squ+37=-Wue_b_#;HjWs4myt9_QD%G5;b(+UW9| z?Tz?#3g+J=5l>g(?qJVvP&Y9vNKr|;q0J6n{N3-EJ4w-bx{>aVLHtHH)^1Wvy>3ji z<81yu1?vzg_LA-#_X#Qd15K>sq*+gO=QU5rWST*3i-`$23JXQZ1g0} zPL=!?g+aF!>bow5?Ys*+y2qgZaooanvKr@Od>lvEmT)W6dY#p0E*}SmkNo2Ea+Y#k zI`U6?84g>`+p{jC)#Yyf=}g0SR`c7|(cD~z`TsN-ejzP*s<*1y^(+6}JHtPug(x}K z-3ezedUg~Hc#Ti7PTjNNXsf56@4t%iaxHb*CCW+nDZ>Hxo5nA< zMh7>XshRRw`{D5T)lcML<9W81w$3Aa(}E`o%Z-<6ybN@nq?m4eveb8D8{6Af=h+_9 z&DLmM4o%_h7Wll!bnDu56}9`lw{PGu&8%*%s*HM*P72d`5oESEF{5c?|D&n%bzT*k z9Zp=J9GnHXVe`=H;!YF+_gCHiFA`;N|b98Qk!T zZ_~?VyYmV?{Ud&Jweew_*tV_G!6x?|C~q$7PGcU$y(R+I{2ge5Ik$NPb}Eh~4j}J3(2FRfM)K z*TG){_WtCP@$!gtD0-1by*FEO8(kN9&*dqs@%e#M;!EooA z;s|3$Uc(-v^13zArNyE-j>3jUuX1RUYKx<*9HSfd&Mx1#CgyN)?0{o@!@kUNXrL|> z&o-Wr)Udy@yk$-7jpDdD6J!ksPLxAy^|&~`YJ#fa;GOc*Yi5lW&mWkuvf3r-xQ*Zbh(zVJ~_#7Xf(b$L{;K)Gyhby;Y;PbrjTX5F8}7A zRvEq>op(MYlkWN?|4fpknBj;m-+u3G5j(*e=uZaiR*{_vwem?lndU4tnPLF zk$>)^;h)h3K$t^!(<(U6G}206NE5D!bki$non)l*VWFikuf%O!!G&ley>zjgu%K7% zHooAZ%1Hl%*jHFccegIMRAw|TJt0C^9O*ux;PMe8!w(4yh3iY)Cl*}kGa8?ss1R=K zb)Qyn^`nu+hr}G=Cc1}zK^xQ9Iz4HVur$&mq@aD0vE7HHYGE0Hh>|-ZsvHv~2g#e; zJ>rtDDXLtaNY0WgiHQlxotvsW5|gj1$y)>y7u%xyjXiHB-|O6(J8@~i^-kldQHx%6 zZf~8K70~_4c*e~|KRb6KlX3%k$R>VKDdesi?xdoCUMG`)n<=JUb-9yD0&WORf}^BP zT@9_1sse7xOu}wTr+4i}Cf5Y?tv3-xEf#h`)7%(vYrjeC&BgIu`*J5Y2lRKE#Hpi} z$hx4RJ{fTPmC5{@OICIrLOfdo?vTePM9J27L95*!FyJ&k`KD}JS4*yEZ@^vQ_{CAF z`@5hC9|-t2FDLb4>ZuLKzj+SY-YeX?)IY6b!%6Qc!?ySLY|Xfsc6Y<+tSRqoAGB@F z@|VBZ@XyI9Uu_=_Z(Vg!{(Zx_Z&QHXpc>zn>#xw=*y`9_x%<)LV^HV~1WW+`hjq;~4e!$kh2mFLSmxSueXn9dMYIJoKu1`;oe3{nUS@ z)6#}spWlAMdiite{l;m_hTaTrKU25-Gxg!fwADjz!H)CRncDh~9Htixy|dhLsV>t% z|A}<^#-aDVJKC(XZ1tZtPTxEv(Zkj}V1^v!qYu=T24`kxwS^bdVsxbs!rs$=?JMrJ%1`jNBqo%QM~`rjO8 zJ|Fs7z4N2GZgs!@59!P|L%+`N{A#U!uK%lX=I5c`gFAoLsXy!g8JYQe=uaL1%p9}_ zSoy*q!I)X1WjV|qQi3m~4e_zWnYlJSXss`+jWo}aT$VejNBgm_S)0}>OB!(LK5eTxa{S`+9KAd>Xl!>ye_Z?yWXSTAN0rc5tVr=)A8sf4X)xji&48 zmx9x4tdjCJ(ip*h!6}4$jqTIC9W-XKpD0B)vc@qf{~*nv!!IsHZ)uIo)BLkEBVGT5 z6mm(8M^eFcnn|$#;uK1Ajpx&X2Q*V%WN8q!i#;{^uU9>07yPq=^z(CQG}339#S4G+ z>S2AP*4L&`o6dIR6%5nZwY>U51G@EM-o{}%w>HS8$d=C8%iBE65Z4Opi#+LeFL*nK z$K}>W*c1oQ9US?)hM6_B(e=f#^a+dk2Zvd$wX<#3CDWbv@{bK0JgSYaU$>0z`htIU z*bu2(XtTb6?(P_HW!Q*amsG!gGhID#alrLqV{ToF&4yj{$$JC(hfTzFvic3j=u=(< zJQyCITc@zuc!lom82EhHw5Co~zpIj=#UuaWe%i!+~G8nNE*RQWvmv}M) zUj&(tSm)MnvMCK<2pk2rBQ`blv`wYaH-Zxc&h4CkY$}_t$17- zza>P~=rYi7INm_cnEeuK;Wp6oDx<#OqA~Gx>Pk)v*^39+F?@BE{G0-HPWe}>OBsV8+YBhv?Wfn zBs;Xp!LxnW0F#swm3lbzI5Fj!?foNLGo$3Aq2~y%{G36XZ3W|&I)+^t@nY|$ZQ53L zQ<)If)$Z+MH_Y5#e^XT(cB_5rJiAwA+mGB__BiZ*`?OVd@0dF--ORKKf7U*IyWPjK z9ep>m6T)A&`}||~mAUijP4&v!@K5bC?%Vw=+xhY4>c`=~+GqZ<1FUMaFUKkZ>+m(R zN6V|3eQOdTC>>lMdz@8c)0bBp!RqjvXHPD#nbcSCIKr&Mf0aFrRmnlwVg?0#h9PC*Q^?hZvqL_~0c@9qH4M+MmKNijF2wCOe#@cnMuhJ??(jnaL zFsXc3U*DF5sML8x_H(n#|5AE<-{~G zVlNiYW=%-U*uN>}uqgIg@tnyM7Jb@Z9do2K_GWQh%!DNw2byAz-H82HT|75qg8b8g z^D!qFvz`>kmrqE~IM@?&N;K^la<+L`Vi57c7G+S?-c=CSQV3WDQrQ+F)B?*!HizUr223I;}n@m7u zP8)AEPw$7giXD=)!KpOnu&}>f?Kj6EL~_7s^R2`2{Saljha`77ZHZ}-^>A4E(g;y#HplI==g5u1|B| z=T7sxQ7dHKuUmc8(fbz9IRNq8;m!Sb;~R86U&hIUx3SX+6|c6;JF;)tz(EKOl@)L9&O5Vj`L}})u`_Eb-kHq5v@g^65JZZl z6{B(UJNIRI9~#2`sjc|9Wq#kj>^X-ZY&=}?`R@FC`&MKfdW)UCQ1R7d!Bh3Vl~soz zh`dqpJ#N9PeXC9$`huN%T=8?uf{*)F4;+Gsa z5MDAWNplyH_vd;y>1elFRiaxLGWV~U(*&`mN2T_^3r+X0&1%xuzTj7hj~CnQ&#P*J zz*AJIJ6G(qKmTNtq4vduO0s&Zc+&oYfu`{WBxpy^i@k+^y>>J2zqs-a^y0a~LW;Xp z?4|X0=>7=;VUe@DZU3chcgC$vh!hrwx;w^R-hYR6F=38yU8=iF|K&4x47C!)!u1>6 zJz}qP-ZA!1lnOT-aQE!La_`RgwTVlG8@t@6#$J7O$LwNamhkV_?lbzYs(;?G&`Qb` zZlZYj#kP?L*#1dH!V+hXfc`eq0qeC%CBo8BkKovLrvc8zq$;5%)g!FGefof%mZU~l zw!uRb+aa8Tdr9^;x}JY4M6PsPiMt1 zkA()Ec>`|N$(K7T%_gdoHg}c{cqArwbyoRIOfl%HADC2^e5-TIyos{ST}K8ypCsS! z+`4L_!r=O)0Wa%C&pNklpQze=y>DP@;-c4`+y9xEY0&+2V0zu6Pn|pNPh7dV`{Tfj zCyRb{?))_|$Djwj>ua5Ybyb^9%G=z-yz7^kLg}jUnN(=dYjc-Zm%{2&*Up=?UK@~d zfDu5efl-cD4q)VvW&?6H;+3NV5UU)t5-_Vtvvc%v5RV+~JHWJBD>FwQkUX{o{F`EW zpf2mk-`Y3)wgiors%;L`R~^w5+z@REo+~}@SHsas6`yY`j1y|46F2O-HEHXzn~J!w zo6>0;c7K|*^YhJ|xCr&Q#r_-iL`qtl#^j|CpZFHWztG{pC-Ke#T*_L|+M|J^NfS1eIDA8bDg z(fo@o^G+|xbUrk4^q(uYzi(OaV@Zy46LAbed)=+#X|h7+W`|>!uiR0aY)xDt+vI#$ za0~){$E}jnvP$O`>9MXW15>vy`XQ@!K2mfHqW<8m(rKw|aJ1pr&0Tl>&M!_(Jo_wxQ#Sf^d?I$<`Yy5L^vR^{BZ z&I2dCj}IA;s^_XSX*V~VikYH*X+SzSe%ZCOyQ!y_9)I)v{@L-Fdh*AqXG)HbCO^17 zK08GIBK4o<O~ zXpm~UCPbl|*6MyjduY(yG;f`Pk#-^Sgzln8E~W+76eejGm!6;wJ(^)!sJGNAO?|24 z1Y^elLUDkK^NEfX)ahw&x>`?q*$q99$Gy_iTp+rcI&0|Fz3ms% zv%9l~`rA*<34FO& zz5T%Hj1w-mM^4SV`Z9a_p&uFNUG5O4#euJiw>M8)*5)$ca9VQpm7i}*`m%27UH&xb zl-GXX=)PtBZ|;gu%XYs$W_JALvIlSe%{{HKdvnF?tV-`uM?t=j#j-|X~~ z^b2tQ+*EJ{&eQSZLJmJ@K+mr z4$u1B`2Ys~q~Wg*_#C_a`QC$n*REI^{-(?4)T}SB9^AjUA}jpuYoD{Xzx;ggP-|sw z_&ds3P2gAEosXuiEOdSEaQ5=muO>U6tXR3pbyRS+J@A|3&S$69D=S?;NY8d%{Wf*y z(2teXt{;oe_6B|r-Z?UD)gISRjc0FN{T}zQJ$=<7{m++Y3{3fvvfy>gs^j`!p3S&_ z{72@3w;xuW)BlRid^F`};ez)QS6|it#+mu-_|M7(AJSKM>wo9Z95E#AviP)bb^qJ% z;&ZQd|2k&z<>l%JZ-3;TduR9iirV7a1oiW`KWol?-2J=X;>WbC*WJJVnfcZ5&(nv{ z1N_we`~J+I6@NZH{QX4ztNYKdnb1yRgTN*S>jCDz&@{3JNl7`B9%P0uZiH|K(fS-# z4{5$Hxe}Q?sQom@tVe6LFU^R=AH;2P;YaBmzRXHe%%E;ku5%A|*4Id#Ihs&S-j+M5 zN&D{k@r7FH)zo{r)0=d@pSQr#wbiugS^k@F1Fm%@TC$K4y(VN6;mNi8iqu&%-EZgc_*M0X zK31K*`PX;R&KGl6?LYKMy?y%aFW(m~c%@m@^7rRkGyYxvL$Tn^%~hxW{_<(Y!!JK_ z7Q7p``r_YTSu>w3|G8R!e}9`ibLh*@>IEM)t5bU@XSrUPqmQdix2;t*QSY`+ zE7bW=ZGLa<$|n8qtut|4tH#naFRzJaa>2h4A6H`)pJ#XIm-~f)Vcddkvp!EGgko>M?)dzp_&Q)1w(r|N7Nq@!LPgh=x7(wJF4UEzNm(l{D64zobG+ zFM9^B(1^}?%&RYC^;*s6t*@j{ejM<$(5%;bHE)vcR!Cha(LBgG`# zda-cB-ldZdU+Et_s6E1T((9T!RUa25PeRqu&h`a>Cq7|VsF8zUtd5r4Fu~U7clHlu^o#un~uuoIT`nb*(bGv_m9y4Cm|>mhV-@9PWr6aa{1MtiCj6 zG&rH%sgZNsrs7rU{LzpCfxEYDds5XT%_2tVF2UrJwgX99RT?=X?25qK+ioOj`w`7@ zM)-4q&q=#)NjpDk)Qkx2V6L}4A*q>E_7@}4Hkg0X-dIwnD*Kxu3J4Z>J2*(x4P>Or zBetVsj$p!)h688HPk79F(J}Ajge=LSkLBkWv$aFS#-svHv(x4)qqD89!6;1yr$x5; z`sf_LYbg%SyE#YqZ|)zBOSmR$bUw~G{%Z4s(Yb4`DI8p`a!xu`JRgm(y$0hqw>hU} z6>mo8UAUI%;5x+lXMe@#(fN`!A-}u)u~eZ!$Pahyhb-e z+l#VF>Ibo3Cyhq3+I4ALC9@?Vu5(?H`@~&W?p2z$BxZO1O?de4YBQ~}X-V4BsVVY^ z+SL(X<yGKxq!!th zu9hNC2!rFd%34xSb-_5%lU?_=ZB@0T-R(MEH08st2luwFY>|KOf&!o z*Dn@%%}jnAy=|Rlsb|>LZ(i)7U5>(dWX~-y87>(c49~J40`?Ig0DThw5=*C zJuU3|fVa=k5W2l4O0_ZU#+<34L-2D|V^qe$u>OIm^M+pLZEucRc0KIwoN1{;uP<#s z8MXXP*n@#-tA^g9J9a%gf`<25P5;a8z0-~>A2O}FpEgdfu=^m}as5Mis(!FK5pWe^upkbm;Tb9rtgpSRMY(c*fQwg^ zV&;?GKez2d{@yJ@hYjIc*^Hw77@7cQW_*zuM2z?r&I|ef+KVgQ+Q*RhrGMVgHNo8MFaY488%A`wew8DTtwtc;!PCIJr#V(vZN+Ygi4X3PpJYvwWF&!kyapkjcIG)X%V)(!Zhl>hy2+n%sHQtBcj zQfLh9C;6S^zpcCX45SMIEh~IBd zx;P;^D}QT^{d}hO__^tb4x+YET^P3$@a_LcUDpB^Q~LhTNpvA3O)in^AVqiA#b^do z&SaP{ZW|+`8JVaxHI|cGlA_J!U|n)2_pssT5}Rv6Hr6eFi?yhBvG}oT{r}&0MtRTJ zf1i)7&wI{!-{)^R_$XVZ!rLH56J4g;>pY@xp zt~>gkgV#|ewabjti^sit=vC;P7LX>(oY3S^lM92=f>xf+oYehM(`)Hzc-I-j44&8Q z#{P4m`@eIGpE9p`Ig{G$B)cRbUFXfT8rb9VwE9U~!dq0t4CH&=ds&|;Y}=B_KHvMP zy1~qQwS3+)seRs_UOM~TBOk^kyjsbZsn{@?=Nv6TjO17gTlRE;hj|s({NF` zT-yJ;jFFGqG`W~QfZ6Z9B&n#a533v`4{DUNyr^9VnKD9?-)QBbqV`?qCo+= zB<*%usY=TCSpS+Y>d^PLOO)lIN3NryV|eQbH50RZbF229BDAi<);wIkyq z5W0IBH)UdQ^E+kd!U|4vQkpO>koFAx6yVUypwUt|lX zufoP5=X+e8qe|Km+~T>0Ki~7`)2bPV4z~C`>3lEdUH#-UZP&kKQhWazcs1qPvX*al zFZ`-%+SQp4Jbd0?UfAc&fvdA#Ec5xN(uw)-Y$^Y-RxaZ*xu2tN_MH0ja~(TPmen(4 z&m(^6?cCoz=i2;^j;XHNr~R8;%1#R_+E_p3X?QEw@6rdzH#J)QRNgVdo#C0>O`ZpK zD7skOGbgm$+_ZGZfUslkOQvtx+~VbqfqnjR&z{?EOKbO?gUF_tN$uLTS1KbX3|+SN zb-RuVWyG*eLs#rhYVQ}TjAU*#5{^CI+I3E+!4sN!tiCjHTkytCoMDv5_jev|>&7yw zX*oZweX8lutK20jh2SW6`&Tb_@=>$@^2l{)zeDDpHzciR<4ujW?ob5gsh2nuZf@n- zNy%jlU6Eh5HDE<2Ese}`+54RvobVWgKq2`vcfldPe$~f={I)8cy`v7WDGx? ze`8O=iq2!JGDe(ubz@(ur{8$D#UsxK-8_)J!Y|f;v9@IT&4am~{&C#mQ8)5$9^TKd z@Q;sQJi7dqggIGzZ^9zun8&`t(JKq~Che?CRAz3T-8-r(|S~nZ@73>k#xX;3~l9vCdI4Hg`GRF zge}zh)Y4v%hXv)VxID2#xb~9f2Yf6#HJ0~Jyj>h430_^2If>b^x@2nF!L`q(=zCYJ zzRJ7^&aKT&4sScEG;>DC7PeJf#OP)};h}9ks^W&!>Q}ZUEHp2=#K0VBc9Y2t-4mZ> z9Q)^;p9>{n2ePuJ#0KBJeQjmf;XPUL@rifuK9F=fT9P%D|K{M`@)s++ov6w(&HD51 z|1i8)_tS1m5*8Sn-*@QHooVuWLVD!dhm!M0&arrBc2FFFG;-rXRcG~Q>DpLwrl;Hy$erN z#+hc`t62ZvlTIgJEHZujxbuehR~DXpz0)+S(zxO8`%b6cT{O*py=%iiXF8mE&pw#_ zu6V=8x93lNeE$c})N92!;;pCkvQwFkxom^Q*oy@LnH%fjZJtf9?@xo( z-Aw5}dOuHC*t>FL1Kzo)mFu*0W`FDY^Ewu_{*)E5eH%$>`at=FMk|iUrD3IuqUKL% zytTW+H)2|bX7?t~ed%ZY4AT~mscb`#)pfRe=6JsGqb3(e4hUZFo)xEg)a>@H0o|~h zX}-?;*X{#*-Yi{WF4DDpb7Wwjx1~#Y$BC_K<0A$2a?;oVD%RcaFOlIU#7-ntSa!^m=wNYHrYSa+bVD#L$)3mv5KH`bHm(82-cc75nDL z`o;E$nbMd5#p)lGr{X$t?lqt zMO+kf&tt>;vfui=za7PYByYE#+^=@eA#){VxlDJyV}FmlYYQAwH@bb(kw{wo)6%sx zJtApS<2^eRT{B8E4N04M@2VXG`?_Aw&N#HWTpcl9i{~9&saY)SJAKC3(XOF5TE`@npWPZ5(;F=kWZMo;LAfZXVne zy2miK^XR+JZx);h-8+3<=dlPF>(7o|WBRZU~OyM}wabL>Sy3FfsBTiJrnr4>&J?`DP5hwrLYMNCw^Xm^!Mx6TlR}=pa zWdGn*$Vy(Mvi%-7G=Epf^h=oQc|4|0w_B$hq$SL6-+R34h+AivBLQi_yMJ*@Jo019 zj{$soxZgwfWk-sneF8Iv?SANa@W@#v;pO7--nyn&SDg#};bj)=>iyfu^Sz!-TRIEx z{Ql77f=u!%d(oJQZGD0X5{-zBd_GIEWo`9M~laO z3|jT0-;=;)M=wvR19cK6g>2WB7$+ruU;bfI_w&5=O5(P}byeT$d;g}rI`c{5hJQZj z`#FueHm?q|v2Og+@U}fmGscB%ZeI0tV0h2#IqO5Vc8-4*sq6XEn)@N!dsRJ)YCfuT z@zg_`ef({!zlZDy_kXTl){NO2_GYJgogsSPni~!F%y_eFyj$wXV$01#dk^n1WmSx+ zu>5@d_rqQH@otqdb!Xlx>hi;ZrT74Hhtao-C(Ss>KB&}(_qua^ec0h$@l{5`7_C1A zw+FHU3w}LK$$Hhj<|HZXE4kEJx}%M-Ov#3}$HK|4Bv-mfj}4Jt@BIINIg>=F6~Rgy z;`Y~BtR!D8eYKI5=8h72M6g51>iYVU%zDy$2UzL#U2KkjJK;nG8`Suri)772NoKHg zc{wY+U%-0fqn|>pNVcyB9(n90*;H4$_a!TR{v21VpMxAjF1%_k$@h>RpN9`~yd@X# zu|B-a1(vK&EmxEcanjT7M$+7W?SDv{@&y)&U72DP;|5`)IH7BXFr1E>$ z#thTcuL(Q7NqKK!nTq|^p?miN_b4{hpgxZb(#qc*GL+915-7{nPAft=YCjK4#m zU@)hF(v+f68bu(^5Ut^x{>+?(x6@v(3su1~^uwG1>d9#})R8KUE*J-X7F=cu;^fKz zN*D;HCWi(Rr6>h0oLn0kRlUX&t%){rg;`~Z4xu&(3^(ZDHjdU1Yn+8MMB{gj*0`=n z!LupY=kr0jJT>@Jk}=%|kh3z z=e<3i6@ z06Db>f)7|j#)8mlIzaI()(nUeSXz`x5ZxhUb7Y%Py9|SkkaIPhxyF?>iQAeTNJdGi z$(NtfC1*jwkSm0jGg%Lz@*CEfM*z`Lr8ZgM6|*QH)Fu=LwYcEOOn_%Jtu#CZ*-75A z=wJXka1^1)3ba>=7Z8vzh;NP1q+aTRL{*KXHj5TFTd^vPUBEWs;VgXs;*dU?#5a5+ z1EB1q2!J-wF^?#ctKl;v0hV1-wMrm1vsD5kb(RZ>c^xv6OqjEP^^obYzX)}jpQCd_oVZQ~nT`Mk0R{H~Fw4bmU?EeY5R^UP*1u{Q} zXf@L72z51yK(k#$kX&R>1Z+O!4MZy=fK}r}vI%IA@pA#Tu?`r53lVLsMhPNS!Y=s% ztN@mt1_3c7Xp{&TRsovBq{*B?bOC1NlA|Fg(Yk~o{&K!fm?O`B?y4JKmd$ww+>0Q zh&cOogn~tne5t2%E3q|F6kU8!o5639hd-w?-arV1A^_=vewaWHX-q-IjLEj4h#q1i zQVuCQTYYNL(F)moYS7vtk)$v#kQY6yH-T${ABy-USb|1JCt7T7)%LR%22wEy!`Ir^ zYg7zGq(xLQssWV(p4*Sw1iT$o3g!uovU4)P0CyN^cR&bIqKrc6eAa^peWeQufDJux zj(u_>v@;qBgRmyb3)XH#2?{{3S(6+psoKtP3XmOR2wfARc#@Um`VjEiAdb#ZR)cbg zSsDhUf+<1tk>SLo2hdX^atOr~Q9=T4pg|TODkumXPOc_rMhfE=uwJBIXi?+z02AFq z;Ao@=v`A)JW&#wH1zI-(FvQKjutbuM2(vK@0r+a<#sr=wy`Ey5dYS9LZdQ zdKoe>sDhTh7XlK>DkC&n>~{;2F8~A(QR{@t>H?xPG~Kp25DFp@(0f=z3yA>HR8tFG zNNA~1HI24P-7txDbk+xwDjFrT(#96miH*)PHot=+3a!n67Kt%qz!!A~^;4zM)7n|H zE@&*uyr^`;LJE`_x|Tr;BoZ_ZC>^wRL<A`D4%1UAS7Y|y z_>4Xh#0!FuI29Lj2n^Wi=^ScP21S`iTBEfjAcN#wDEvhojO0oPkGQy^|I_3C8mwR+ z&{$|qt>HQcE1;nj(O~O-q{(gcxuwvPwp$y>34K#RVUXm+aIrojic91K*oec{GFmqR zLqbmNIyquzP$$vIfutmo-J{XX(KgdX3N2GvCtlPz5{$rAxE-XNwgjn>5Cb7cD}!Q! zEFeOx)qR9l(c;1tq{4#-qbH**2VC*$0CC+^!^h}Sse%AONH>5ghkqJ6FA#g7(-aGe z!_kq@&&$a3Mhro80ix6fPR$AbI}05L33|u@H&V}$I*Yn)=YDWL*ppHM*KMsEk_H7Q z68Z{YlFrAZ#%KW*rCB70Igl_5@G2{br?H0a5K|WFFjx%AS&RkXz@1pae*hsRZPOaq zgMQPsmxzhN4VH%V_&LK66KVs#@U;O0FWRhx;$UiG$E!mK8z4@|X5m6amV!r++v$9R zzd@tqUp$L5K-8(CkLU}4TFIO@8P`!rBo~nN2!%DPgg-J_Po7j+n4b2L*+lvt7(x$} z&?rJR7E46njv7a151->1hoD01fG%V*@!=$VY=f!l`>kU)Ywssw=TOxM0saMe7H|`~ zD1bB~7Eta)69GIAHj613r2r{Dq(7lNu8;Hq;|v9NLeSDVoPZAjrm-P~$N2Qqn9eq( zv*HjT#gPdBwI7K~BU%`>sO^M7NY2E%BH7MRgkxefYfPpM1!s^pCZJ}`9WW(Ug`!YO z37iOp8LXrhSgUYg87paF;b@#7TCEcS!iPdZRK}#RKC#w$5p0K^jasI0w zTYdpw1QuXO?Lpv+5fJ#6Uf6F2*Adb8PiaJtYRlPy9*O{;;tYm%iHwLXYCGs*7LI;_ zIu)MfkR77UVmblG)zM%ugR$87g{(&anH12DB_ld~Jkz2UrzLCarpKC4xC9!I(YUDL zAV4R*un6eZQ~*3ecUm&?Hz*v&?ivN%D-cW){Ml&+ZSAL-u4JrBh&9?%St{FDa9hSY zdD5v0#S4`YjL9~`ATA)~J=rb`kl`t|2j!*W5V;<)DGC>eq=gIV5`%oM0WGMGQ_`Ii zmTkZ*5u#EAgByIoEJfUlJdD_&Qj+aZWw3BEhn1)~(M-yAO*GktK!gy|^?)!~&|>TO zrY0%jJ`7RG067Z-WTjoWlS{PoZDP?OXgiuv#F{PPCS(LL@A!1gzxMpFiQYEj;Xl84 zLR^FC`{$(i=^#382p-^KQ7qXGveA6ecdSp{ X+T^7~nGms-9pW6K!B@87|6=!l>f&wJ diff --git a/data-raw/antimicrobials.rds b/data-raw/antimicrobials.rds index df1ef553596d1635163d21e298c7f68d8e4d1572..8fb42a592ed521d0ac233b467267d904d0bd90d8 100644 GIT binary patch literal 43628 zcmV(nK=Qx+H+ooF0004LBHlIv03iVu0001VFXf}-uZyZLT>vZsd>Q$l_#!w{t0WW~ z`4%D=@FG&D0g{n6nqR2BgC5ilVKPfZ<^D9_$sfV{^K*jIC%%-FG>J)E-fE8A=Q;Kg)X^FbdT=u_oh;YYW_fAlE&X zl9&8&OA(wLl)0<@8TN6qo6(e|RzAu#%Q(?Abq1rd7}~R)e>FGvxTomlp5kph$s6C1 zn0P_(#sHwxYg`Yu>Qf$fo`pjIvwCG7!t~+dI8&YXPlPa!*UpKS^d1qINv;eQ`I-7>`D^= zn$_(3!+$Xta^WhA#v=>~NfD zrfuj3TY`8FGEPB)xYAg@s*!8@W^b10kPubFREvmbdDP;@NhI?~wX~<{+Lls~;FG&~ zU(Kwwr2xf?V?QN>!8XwJWH%X?VsPO;6GVJ@vKTt;xc^N7YN^PEQvN ztfh$it%E)yIoUOM8bT&{@nc(2!`n{Ja{m9I*hOY z+FTan1+AxOsE(qZq4@9xuRLGd?da{0JMAy zCu=8$x7b}cwvmeqb33yrP^sM|>+aWtjASuaijbx?I^l5*&3D5PL`; z7Ity1bOUHT-d)ka<;22|hvytozd~~l$f2a^74Qmb_$!<1o1@Tqgklrqo*HU&@x8B= zE{?OMJrl9CfV0LSDiR^PD{R<`*&&u4FhXaH>H}3BomwP|3~tMhM;*Yrbd0Bhy(xSO z!7-B&63i^OVzP(G7ylzBuRQCIigLq`Zgo^j7|z(3;_jY*db6%Uh%k)DsVz)j^oKxk_xk!@Fizv1`eFg7*GJwG^sMO>+FVVdx7R!1ZfFC zfERfd(`YPK=JD7Jhf3Yn+q3E&9M9AY39N7$^@VpU!Py?bdn?RbH&+jyv($|T5t(n& zyKUBVmeu-u#GKGOBJzAt!}w0+Q#0)M{)p|-8mb37;e+6o0%^kSHL{o(v0dVi>cmbU zpda*r$41>5uoL>7)q9UW>xC(oilpv*W%Rc@^|5}*0=e}$#QxJDikUM{dEG;)*HJl4 z8{pN>3N4U3+zRb-Ntj1t{$iuKzJ4YLw4Ysymm!pzGX`=#w~k5ssy$=?C&e?Un2F_1 zzk|i;@_U4xN0)Amk?_nRZdU5MWO_wAbEX2U|8wIygsMW0IloFOACn?3BrX{5eOS+A zQbo4UTGb!}iIUV#94j$$4G3F~4xiXF#(LR2D92Ey3t1GI8vzbJ8171DwBx^$=SmJ-Oo-R` zILs_!Le=BWxG?}jLxEb*NtV_vVh{(ccUq+Q2B`b`PAaB}RNIh`%=UQSysVLV4ZPOk zZp?3a`}nb>Z4B5wK5N&sYLz`7%n-3pivr1JhFp6S+UNI>ui7KSg&|ThpJZOExdLE{ z{K8ay_)4)>9tLS>=m9aSgWNGoPrM;ty`lV_!qs^Z#;~7=x78JC!#_|c8J`C9I19-k zywYIN*yYD4q4(xs&Zl_W2ymOedY((SdOL))1#voKbduHR$xfUZ4`GKGtCiPf^JJ`z zoC#Z+Xyz0}4dXZ=rx9SjvxO_c1e^6ESHCW9G|$>ye3O0(fP<73*OhW@ENu&cFNCV+ zzlRBB;^JjvuwZ))5(8>5EopyzMkp>k!6L+UW!V)?aLE-nX0ES1C!(05hf)I`5r;@` zdHHe)93yA4T(7W6YaOM^!KZKd>4mb2g-s6@lXy#K|EuszQDCL=J^#ltxbtF?^3m{O zJ^y`s;v5)%Owx{m4HiKDQLwez~ z8$5Y%uILeTu9(;0$REi?mYgy;)Ks;|rqWb)EKC1vgi4nkt_Scy(t;GSzH;|&RQW2Ub_ZO4aPFvsSER09I*sS(#U5$xo^+P|N!6?r#rT%rrYtcD zBRkxn2IW+%PcvCSN&&VtSx_Lioo-1s9D7_^n`7NcSfd6oii-vppk87cyTb%%@Vzz6 z5Lb1@nH(n`5xQdKXyK564ZmtnpWZ?DMmO^u3Pr$eymERuM#)A9)}xPh9@Pu*&^7pr z>VB>X!ayXXzxvS$KDyTu{>h%`YW$jQ()sGAt&5r^k=#-RlGyShiMcH-fNsN6i0^i=akQ4 zK|9a|@A2sfsyxTe6|VHmm7~^(WRY}Vf{GUwn&u2WM>`NM<(pj!qJ4GE`}G0DLo0Y? z034k;(Q}7w)0V9yl&Bb7!52LLe3ZZSly*xc*%n#v{Q|+eM@j<6P-ADj`45cJ_*6^A zm)F%ttL=KujVjFesZl>TYGKiJvM@0?9pliR+K1HqQ5c@80Z5cI#N_ ztdf(IU`scs?D5Ted2s(pWt|z|rz+LA$sUhsdRBSK*SdY+VQCZXN)HD>?uh!=u!iEk z_mhM)xYNJFZ5Ru^89%OFFNK>igphvd!&L`U$gDH9j)#qbFc#XmXlfIV%E@CvqgzI`~6RzHNDFlVGoJdwKU-7y^ilypZecOZX6?rVwf&6}6ZXD1Th)4p@pjS6< z?>tM^AI)$octhy?)>Da9vG|I)dm1b@^Oqa}Qn4Czh}Oe}8Xji1t0;RKJ(m`lVcbxp zdoi!nE-lfx))(%oZYvlrnG>pN0rEzBDehB=WS0;;<-rD&SH_DMnFHb6=J`=_4 zrcX;qU(ms3enD7vOkCy$0Ab&0%nQE%$MHAQK(|0@f1__st7xrUAiC>~k6z6xO59l4qSZ37&x1inq(Pg|+_6)yW+p zq=&Al*6BoT05dKXk9)dxk`W34)m78LpQav_2{S~;zsD*{T~O`WabolHz99Y^E?5+w zYC<+VJzau}_$5T6KJWhX_wTN-8_FrQ|8qY7-t3(|j8i>^GHcvP`3rRLh*u`feOc5M zOx4JL>lj2rSYilP9KO1*I=Kh*)!GL@-&~Qnh?-puK5d zuw2c7j*V&n_>e8Uws~8Gg@KgsitOh0o=o2pe-f(&jt)In=>UD9-D$D`;XUmw6#pWH%a!b*ueP3&EuUusY|r^baICEcU-fy? z>Z06d0&y|uu{6=Qr_;oGZQmnF?UKBTtmv6tt#5lUPB?X<1FqDy0*Ri0H}sCXB3rxG z2E>VlF;!vRyJkLviLI&gk#cylo%4t2Nk6s8^mfSvjji(r3Gk_uZoYiOzSD6?nX68>m>$J*soI1=~2U^jpXVfli;*X1{km ztfNP(KMPL}LydnHLQv&0y;#1pcZw~e_*Eh~HXhbNvHW0Xi6r2Z*GDiDM^FJ4AUxe( z6sK-WZlB^hv8H0Ij;0{YYPd}Sr-BcKsgj-QT@_#LaKaYAIyI70?;Q`)d~GnWu1=fl zxnfW8v3FHka*pw1XUk0OT~7$+sl>fa)}Iaig9*tu4<&N|j08t!?&UsR(?{fHSBgCh z-rz74Jpn{fAQ||*|G-zj0!g^B%9rB`gxN83d=r_!SKFqt;A!9VgXNqk@$0tkeP8Et zql30TMIR>LEB31Qhb9U}faGf2Re@I#+X#jPags`|k&_nVrCTvZQyS*jby?iUTt( zVLET*LMivw$BewtuBHkjdnT_v%N$_JC`1UJBFFxvj!7<&%>lR^2{rw=X{*+YuW0Cf zO%dVDXm*mCd7mT2mQ51E?qer}Kf+pdPpl+zQ1FiA(jlPuaU8)eU&jx8hsS|9ViirbBj5VvwhlYiUv#*8|e1ovkVPbQk0a~2x0QOp11H@nPx%Pnuw>>*iP&o_wX z8#ZfOHdwG{`|9y+1bGnl?n~f8xxTpiLQDUT`}j_A@s7%%*q!9cvK0`S*@u59&SO85 z#U`4G8SPbe(7{~)h2UA>{2EoWgwb4cdxroN(Qb z(W3#I`ca%mYmnG`6i;Q5L}mhEV0+uvD1AR{{#KYBh$(wWMf_qeN8qWV&^(s)fpSju z+nE4t?WWiWuE=tSA={qjJK`yC$GusMX`bZ$N4*>82X&5!P)C4!x|#Vk%b>2trPQ&D z#(ADz^OoKpVfD=7QpWIgA&lh_?ZYy+JwL1={Q>l2mdx( zyttR5iT)!S_y%xorR zA^c}O@+v7C@OMY1Jiq#BC?6QKY(5AZe((@AK%4g?iy%FuT1uj-h4E+3(wbcNi zB|T}11*2o1%&^3N1mJ}|iVL^l3lh1DYiJboo*9!umatRpJah$8hzOYA^#D7#=Fg@# zJH8rH#SLO+vLE@3RY{R6_Z29O2E{tyahzKD*9rG(;nP>l ziVBWljfJhs^V9dJd?pu!>D-KPPI6evh*v7$P zU--HOcYXXP1keOkO@Fbhm#?Hwah7Hi@y5sB`HxOryQffVQ+cI=S1uRYWLj+@EmBKu zfn%{YEHr%=s%X&AW-G~*z$8rCO$D5Ehqx8tgFXo&)cbrc6fH!!5Vb0(P7TdeVThii z&0N+2#%QUmC$*sK=38#MA-BLLVfro(&od=w!WalG_r1eGsVxR=6&e2OGN;=t7e2=0 z=`|ffW#P*8A3dV&1raz(?hA}&Zjg)km^arMC^4myWnSqle=q|L4HfXhkmj%A7GW(r zs993KJ-QGLaJF@zNcakLDIjRj4~=kNoBF}|u-AeTvY}T_)0`YH z5Zl7M`YK%%xp3Zd1^wfKwpK-yE)Y`@@n|vgb}-2gYE=L#%+D`=m7;OZ`;szKZ>07U zJCV!ZKM%@Qsz@};j*>`BOiYEfK|{b5joO>{8WuvQpyfzhrL@s=Gyd@Sr`!9_j%p^_ zW`AwqBbZ-II(<-(6?VCiFb9&z&J@j_62#oEl7-X~2;%aO*$y#U31yuDAGC5<^j$Z> z^JuyLznNS@;in*UazAPeMDiLy zt7z7Jw@LlGY09fJl+R$Hp7?d@pG!^lX=o4G$Z{%FCjS-puwn{t|+RO9$?ok{18AQCrVv;-F zmfd-K)|-TNYu^qgSjg@mvE@{HsveuVr^|sXd?#yEf@OS-a0K@oq~_`Z>@M||O?cSK8)-Y%H~W{vtZWM) z`8(mMJaA)$vw8J{ykNYkp1o)C7^Dx>?E{MbMErPZn zSl@-mH9DB2vWf6ghbgSIX4e8>a&XS$E+pyRbdd5X&MmP9D`SKlFaw3bkI!b4v3s%U zs5=+Y9K5cY9JH|$`Gqi-eOHgb?&nfZ+ESQYcVR-jGj9S5s|pd18yagl82)eQmmkbA zcbC?CWP3m;@`h5eVcfv&{J2Y}t>$iAC$~pQJp2d(Z?S7}>2@-Rp-r1`T*rkCq&PRh z*v(I5Q%IgJ^Oic#-Wxh?k}$Mz`N*OlVQOGgB&lZkG9GT;8q`b+`#sCRILL=Tka2L7N8!R{b8)U}X z7T)YK=aRU69vs=7*ttpAjiA?MYWD(pftwMoRXJS%p6>!@sr{!0Lq#^&C1++QD&h}I zash21z7EbfJ{fp7>OcdfC&-JsAQyEEjP}C1pin3-IYaN;s9J{5iH(mbA zJix^JY$8*wGYnpnTA?au^R%jkE^psC8MCYQKVVXikt%q)HR6W%>tC~C4Sl0lVYY;R^ z=JI+{)*djq97a3-14cFX({@H@gf_k-NzVDXZhM!R1bZM)U$oer?)8Dwcj%|g%@00w0r-5o0jfnqG9Vq zqoohz@7=PvYSeNvg%~E7Ygolb59nhZCz3}cguf(;bM56?1l7K_)-LG{SYTJP^TV$` zHygp60|nucD+%pQVd^*H=iDGYfJ&I0tj8u@WfQK(*J-7)rJD1$pzf9LwX8go=y+zjv^OB2*^Tf+W z6(`h@=^eYVp#OHI<~u|F%A_lepbN6p5GKe`5=6E1F?Wfk)MI_?da$kSt()MSKPH3* z#ovsqM@?{D`nA(Y9aH!L-4E_JvLTaYAw-#21fXoL-6z*0OZKP3{S0fdNu~^d_8mBr zdQ6ZB@7H~Uv8Vv$Y`0S*koOVZqIt}k{|2M9^0nh2Phb- zN)@~tXUBEpyz?qF>>7QndR$jwdP&2Y-$=-eQPSIq*o9@w2S`CgA*M@{<7!e=I{L3z z`qpJhoS4C!9X@A&3B?RDA?9Q+Sd(68L|`os|EVWQ8DVegfUTJLO7E-QRODrILjsp!jgzi=fCL%$+c z{~t4&j2bfUg;cCHcIj1*8nSLr3aKsS*QhF3i>yx=GcDBN6-KrKweFCn>y|B$W zmpJ6ECu6>yb$eDd8jxtsrt%ood*VZgC9W75rV!|cm4joh9y}b_K{YqJjfqCL9gT}? zcQfdD4-{5tfDO^|$zI6aVE>Kg2W^pznFrAWf38SvrLj~iVivJx9gzy`a)&Lmk z3E@6^L7?$nZT>|>-eNWj&!1?jYK$c!RrTI%pGC4jGwa^H;f(M#B*B2ExKsUam1(UU zEtw)bY!)qrY<8f*EIn+w6g4AprbbM`;5kq;UTO4)N(0T;3eK|w<~_N3os{7jnklI` z1YK~Eyr&heF+rLH0m-83I=yu5l+Lo z{&O+&7pR&3DUjMH^IijB0#P^tf6#^1_}Ao|G!}T~^g_a}W({esJ9Hue zrdpwXNE2rY<@KBgTO1nHY70+)J>5V{?YZ;Wt)^O1WSw}DzQGuGcGJ(YehZmc4M6{Jc(8=gV)61$uadG$;C+J#COluNjx+F?DSK-s;>=8yfA0+mew#@(6NjqP_6ggYzTx7emo95M#)XRBBg~{6%OfBg6yWXLVCK6yWNhGiY6!*)i3c!Ib;pXy&VM}llyV`z5_aU|#b*NC5JMw#oI$S|&ovym1GWch zY&>3kdmR_Z&`ue~wE6SwBAC7frX5F9ghbek0@B_b9t~RE<|HVB4W-x&EJLnMY);yZ z#Q0=a&+d$TvgB#)UAvm{%Jxv?l)1q@ERdbVF}EN-5|En1g?Koj9?t0rjkVOXh4Ep| z958}=nFj?CDHd0#7V^jAWF{)=O2J8n6`_>r_Q^Ssb<^o2_M!gJeqV8?TX3Dn#E%)# zKyNttwuKVm7WwBCXj2wOs4bC<#{&SWt}a59lydT{a|~dY25Lr%Mwfmx{<6VEc_$^=d(*V6K@~MLt23?$4{xAxe%ug zyyoQ<0+6=ST)%{50Y(OGoW=rnrOdMedeU!aL#154jOH#c_aZ1UHWLO-|Z zV8;`bHIH|Vq2ZE>iY$7$&EaV^dCX2eM2sp?{Pe@Yh1Ars@25flO+I=`Cy*wAcJ0pnYWv!c7#iK;s*G<6voObFU>b4PLNwJ`wPjS%7j|_gW%#_@%nK-UCPQ@#rm&7su6{XMx-cq7|SM zjF98w7vzi!Wt16=%xNFg!!C!8;-m!5zwMaI`l)s*0^5caVG$}jv5ahjKICsa((GFWd6!L4Q8rd!~E4O?0F%N>3*3mFl`vp`FVP}S8z50-rstH>vo zIMZDZ^nLg&V2sgAQ-$<4Y3q1c<_{dx5AejeO7g`5N(aLz{go*g5ziReYD7RPFpL5H zyzV)uSy3gV&AkF_)c07${prX?-G0?GAy$pq#p_k3W%5=j^ziA{-kj!S#R`y#G(SY2fT@PUtL`cp8ccil^=;+(UDs6V4E)I`DKceeXtd7qQxpRc zVddN9(?n(WIH9GmUbnd_9#4HAJ1&!#nYzz=@E$Uo9+~qEjac5Evd$%`@`*{62x`vi zH;H=u4evl?Y63dw^o0Kv>qQ5Kf%f|y->||Zxt4;Ugv1UOtjX_1TFOfPd>MpKX zw8-3W#g3jJ)^jcJIK|wmRNMD|Np4k+;)V-iWnyRlgioZ7n@HW0G%~l7fwDP8L)w|t zZ1>Sb6NN=BqCy!MOE=aSqvb^zLnk`##DY}J z4;DNx8CxiYcjio)C?II|WfKdSJNc%IS4IJDM68J=c_fVE4*uNaPTLslhTX})^B*nR zsTIL!Qfb2HALwOJvd_L1s7I<`JI`NiI;?jy5@Z7=@F7=aE(UP8y780mLT?&Yf68o7 zC0m6*8*K%O#p9lQy|IjE-2k8m3Jxe36^?w1{hcHs^AC>I<>`wuAcqMZjrQ6;LXN0Z zJ8;hQONm0cdZ@e4(JGGqy%5i``0oFm1gC@F4%J)Xvce`gHKyGiuzg8T64ERRU8~rN z&5)JXZ2ghZqeq`JF9cTu`zaYTRQC}PY|C2`5*+Oug=1JWGzfIoc0nG%wXS0n=a}yV zVaXH4E{E^DzjXwMLQRei)EWI>c%HDD^-U&QDA+;qUp9jxFn-bi#F|CH2nZ38BWC=K8eH5~loqJgmbrCeiF#_DS~>{9cB8m}pNNeCO5)fDpS$E` zr`8{huYPlNzkHbzK_7vH&zE|R;oK<`8e>#~^mO3T$$?JQ5f?HW$WrzmV51>rY$+Z) zVaCux_X}ZCf1Wg@;z2T90b`agbr^H5JF0QX)KESUa?zo>-7*Ocn{vkr1PYN;#DI~*Zi^N0 zFV1(CE)3EloL4mPbk0X$Kd$|2+MrAkq;;BDPz`#9+RSmU@R^mW*8{8_u8%mGv#LWy zgm67ERATekVL0ugp3+-2ZF6G;sTwmCM&~7H5Om>bR~Tv4_ag|SgLvA?MHKk97^=wi z_+C4ch*LQ|&D@5=Ut$c|sSo0gE{dC#E^l(f@=0T$J;A6_!rcb*fV|3j^8PB`)vs;M zWDk{Nv~%f$L*cC4q;a{&ZgrNGkqMGYgf%EF=nNgLcmUr5abn05z|6mReoh?<#wGGe znfyY&RLbt-Sek0l5Ul}GdDsE{EkXAZUB1HejhinZV_&+n2xLYy1Sck zXhtqH-gd})apD={;y2=GhgYo*eTBZJ%-y-mhl2Q5qtt$?kREV`##|ru>O1StIWn}K-23~YCH8)~a6DtaWcKpYJoNFE;+o@j70i$sI8kKUL zp?u z9uapc8KWn#YC|MFf6~vSh(yLp+jG)UB>qk%E*{Tx!GPRyQAM``QDU79fu55C*N?Qe zndzihKG$Yu6s_m%#ano54NFA^TJ8AwV@2x6naSpg78=7kE`@wn0@kEq)brW2q^^=z zH0^5LvbP`Zb$C(PF+@}@K=oH*)aZHvUIGABtGLmQCs{1qYLkODAH-DnbG3#tR^_faR0+24@~lIi^9OUDE?5}b8~F>qbj6p*v#mT0%V{|c z`)*lZNhMTBG_xr@vvGPs@vXUkfB*y;wke-li+2(0O)rJWRW=4`I-+$JyPD^jJ#qI$ z$b-^f`G{HQpg{zb%50Y|6!GQ+tGpSRlcLG-DI&I?Q=2$}9w1lR;97Eya0#Y+MKR{W zbF3a18qt+2EX_uwZeF5xXg^Ank`vF5dod9?wUDw%oIOK`1pFffq4);Ex$&Pi?MJhQ z(TD+Jrpo~&@Iur)$CMLVXZsb~Tj(h6FTE{CVP%%#h|$$f2uI#)((~IiJ&YN*)EU>*k}JXOQ; zGRShmZup^^pnnwV008%+RLDJC3_jb4z|em;jZTp-CF(&IrSNJ7Wl@|u!ICE~f7#I& z*oXsy9prh=aFoM6Z2yrgiV-Y3W<$Su;~w5`#mlEbdTu)BzlQ?eVa8?&+M8RKNGzxa zituS(s+7Y4GxA1zMf$urmVx;tvtHGi%$py)(J*z}$-7X});+HAn$f~Yx`MMX0HfYv zUiT#vv~&&%hel-h08jo}Zqj%qfv7#6zW!;)+4iT z3TKAs`!2aDUt~^bbAE~<7MaL>2@>efj?)H!{G$g#PuvFMSL^h$?G-~kj%@VQrtdIg zr9($t(^LNV@0uVHPphP-SdakUi?ej}7Oqo5r+hMLEeM-$Y<~%i_JTl`>vxy{XAhXD zyl06*2m6WZeJEZvmSyU2tMqxMAm2+wDg`4 z5^?i6iFqYJ8)*A7%yt!0pOf~gS2NmNR=`-i^1zy8XCghi5lW|GVdGq_RG>9vH(Q(y zj3f-?7kYt^kraA|ow8y+xh{}uAO*KTzqndK`+~x%-$PbRXsfdzXA~u&6QJY2Pdh#% zw>z^Cs=%Asjsb(hYnW`FR0MZ1xu0!fW&joQ@eCziBgd|#({bOpf9}IvkZK7nvz{j- zjCXMkxHmAYE*NTA0>4&?wLJms8)F_ug4CXp(B9>fHKosn!NUE)xcniosP&iSjxkuNfJQ_GB1ug2;<(*8H8nPqZKLcO)o z*DZ_>u$z`Mo8qSPD^(~rE;{Kle+fD{S(-!ssXZ8mZXZz$R(YP;riNqEh1)^QKlw27 z-C<-oP;!a1BuoWyykyxz0zPs7#M40jZ!$?|~c4Gfcnbr$IaY(*|i^-xo zTJJ92HVJBtT+RcAX3=R}Z>UWKb+AK{L$nOlvMMNF*;hji@OR0F4_;amCY)VkfG7Oz5UDT6vig!Ggvfop5)_yc{Dr*Xv*f|e z7@)N#00ASqArhMEkWw^}LXEd4<;EF!kO-usJ1w$~`8@TZqFm(7v`XN!X^G2O%try|$t@V9oSU!>p9lqAZZgk4|KPnB!qo7_;w< zM-YjC|K6<3v-yUD0{5F2$O^~FG={}3igMIeAK^!=b;TBSC?ks2v(!vF2@LrF|A%-I z#0&>1B9N$UvHcC8xqs%cM!vx{N@Kw`84rqpdjP&C064^rdZSmWnLq)a$P=;;W#HIq z=P)=EcB}>kT0&_BKn$EWn?;rOxi^XcUhUY;dj~R`RV;rb`&rlVvcR_921QsF2^4R= zu^eK{PL!#>ao)mTrHoalRxk%4ma5P zC9(4q+@eU3b^)f(K>-~G37pn}0%*h|SOM(vcUqz!$ z(wTnk=7K&GnqNJHW|SbkuoxOCnF^|Tvr}ffuKGDjA1k`~IMEZPgXRDBwJK`foB}_(bdIy2RrO)yuSHZG- zy7W1QaQL@YQ`nud?;VWHnGd&gugd5uDXjWA)|3!s!-CtU0pqC3dCQ?&cO|W)^8={B z$&@)JL!^?)t1q#)?YsTQ#^624Q08!l2e1BKm;hC^w(5d9g+LEWXPn6ZoPk8vurXmK zf!`PH^2Wkf2GZfJ-(OtCDpEhVYFRlWvQDgeNQFm&&1Sv#oEK~VUn>y@o*P-8z>5$b zEZ=k}!k~}va1M2Gd(KhNi*{vImt{YBqr0 zOc?Nj-&MJTQzmzi>&E=ak{?iWV=!-EV$9EgXfp*H@b)-Do##;dCHfASAPmaZ+sVlR z8y>$#5rJ*qKglI=jI0RO134B3f-B(Aj&OYEn$zZ5&ZtT6RyvYrjf(w z5{`{E&8CtFQ?!&FLT#u7BT*jPs&6Rwcmsdl6ZHx;f^KUR_Ibm~1WdM@ojA{n?l4d;4gb!w| z8a?zU4Xb|1xE%(*v`RXY9u8LlhrD+bUYanB-+kB_Z$9D|w#zg|3b9*EFF1|wiUQF5 zCVS(?iqBYUzauctnOTo=u(heE76B9x`0L#%K_3$A$mYhkaS)_k7LNP&-oxg1EZ?Nh zI>p!`qW?OSP90>Tx2V8>946(g0uSEdr(6ekBDvxLhWqN6DdM^Z7IA_&(4@ELBnB&J ziKpJ3m7R-Y=H(Y+o=YF=UBVn`06Woa30^)7hWptQe6QVXsaK-heRN2Wp#`|R+E+NLxTo`auN?8t|2RF@(d%eD;Qf^*gFJ0>? z!FK@lgvyR|qz1{u%*gcfYlfv1WAe)QulH?Jcn=MYi!}vX!d1AEjvN9)RJ!eHGB9&< z+w(0nIU$5+26~n3-2qKWN$bH=`s_~FUb2Yu*WNzbZD!Q*6@jxTdRvTH2|E9Dwx)8W zvf88|6Em)OM1FJyM$pI+M2{6<5$0`m4oVA^s?pneHU2^9SLv`n$p(|7MoblPiiLBZ4sP_wZ?>0ALSRMpU}XEnz@}6TO+A(>>wV~b1XrY$<#>>X z5XfA5OFlf$rTdDaHq4b$qU~tiy(4OC8aO`DqSf!2u#x=Bf4juT!L~rF2c&*0LQ^!; z)Qck{cDNDi2P#F1nc{Wvu`Z;3zgwqd!%3&KOExLyxUO#b?8tFi0q!W83dyugOiEXC z*zX`%Y0T}j&`*WYEtpWbR`J$C0&aQxg}_$#;JL;16i$={>RpLtIXowmXD4 zXkZ#=U{i)4iKRMk%$K@>$2Nd2=|*s`;#jX);RHd_#WGA{0{IP(R|VAh2OXXF*T5fpmG~0PhVNtez*r56Z}jt@hSq z)qMiRx5P#erIPy>-azRaDK)zmQ563igy zoL0~KvDjJHfi>1&%I#8>Y}MR^^4J^9ZkyN(c<@2Pj(8AlQ-UwrEuvP_@SN+UKz<%kXVX@Vna|qzNGIG(8G1H89tKSbn6a&6t0{m#&X+|Gf7iPDi&J0cuj4m|cyv zN3flK8M_8G-a}ugr5C_uCe;;mwt4<38RsT}CTqN-5Z=S7>y&UI5Es0Kb~3;3LD!3R zR2wp$?*=sG^fun04dx-kSG3>jFjeloA>2kqS_UY!cAGlTCbmDQDRDx)Nh;f-=25Ct zZsE*N`q8;oZ1@{;6hX*SYJ47fQ3HiA$E1E3X?w0s$(&9Y1*)%g3o+#bg&1-D`~DQM zOvxx8cNpq|KoA#){_T3c{K$%M<>n4&n^#*?%bvzIEz^-jTkHc$S_lEFQo1v8_BN9O z8V{dO<26_5rYhwTj@fXlGU)vzdI0;m;%U}f!9(50yA)_e`P&H29k|Of;urq0Ap)tn zl@tkML6^EoR(;m69e#!X)#s3>6y^{(0vlP&=Q}WSU#j=mY*aB@rj!S%fK*|4=&z-T zevHCYT;?DwKN7(iV(39#Gg(?Qm4%%7w^;w9iCRVt5!kD2;lYR(KoMWUb(9{Q`yQ52 zkk#M!MC+A3k)IDZu<*ND_Dd{~b-8jVTkk&eSOGqXV!Jt@M9m{}41^dqn?FVMe8gC$ z`-xpr5_hTSeteuas00wMjmiQIkc?QI-M-nwt8xRl;@-+#4~pN1XN zhrpi-3Ums(-m#sFgkWz863r9=dxbCvs|IK1^iy9V?fni$Vg#rVHjM@ctbmH3InI@e41Q5QcJqUnm%C;0Vo>*Iab!>-25KHF4L?l7Z8~L$OAb-`N4XNLAhMHYZ`mz)R06@)1nXoq0 z1!mMJ>IO1i8-e^Q2fH~*^DS)Dx}OvKDWIN)Q;;KCAgB5Rj5@wd;2S7K6j_4C1yIc}qfEt7@^u_Gfs0E(Y2W@`;5 zViZh|y$!LK;En&MiBPXD?7nqqB^W$CFD~m~Zf9Y&%V>85*cTqr7S^bKFbMcqkQ0vn z29B$WsT+f7DV0KINzPTuw4?@>qxp;{MsSt5f46Nsfw~(YmxnLapFdf}Bvd3T;S2MO z0>lGo>;?xdPtdGyoj*?}Pq19%XEWX(9E!qT-5_(+r`!>wXOU~K4z7T{+MXMhqWGj- zQo0QVdAYWgf3fj~jUW?ztI0dY{}`o5UKBFC2w_lqUGDop@>xSIyVJJxkh+H_%x!PV zOJjy&jaD}k``~Rx^A2EneMkMf&h_IK4;l=zp&=njWDSQ4EgQisuegE6G5aJb+c<;M zr2&vpq0_t2&?szAS7GgUif?9uKtb`3<_wmc5+5a(2Yn^T*XffXtGya$1>9xD=u*#U z+jXilR4q4;&y%qdt60vNjBRjcgzz+Ds`VpC^3tt3UYxQy4xKWneCaBIRKPbJ<)2Y0 zP!|A&R=`Wt!UwymICO7)=7nqhw|GUmU%z~>tdQy%3H3Lzi9|*&cgEgd!N6R~M@a_N z5_|-6@MB*u9cY(DBt{D$>ggkGm37!^6DsMQB3=ZUYgo#JIk*iucyNRa?j3epd=Xo~ zvhZ0Rh>5r~_1xEIh`YJn_Z0JqD3VI!{?f&Q?JT?ova@B41Z7Op{{|9j~dzEaKDlONGg$#+7;b8 zcC@f|$ub=@zod0?&XDv@3q;=JQA<)0`bpUe?c$?SZRtgi`}4`(wN-2m{=go2oT&G zmBEI^VE>n$>;BOM$-y=dM5j}zj%5xhMSeDnO<{TGv}(*B0`RruAB^13gSy~f z?6TI&*X#`dHydD+IC~A5qVdPW2g8wC%a$e&%NU=CKpt4KMBGa{y%Q6x%9!7#y$*2I zTnfRm_XkYLdI5}c*$9j}rnSfX0m0PYCMzWcOlQkWLeEYjshCx?3R>5SkS_Pv+g+=N zf#*7G$Wx4!(<~oHQ->Mo0%Sw6$qEW>XwcO%(gxm|a=a9+VI8t>Urec)$OY+d6nB`F za{}7Pwpn8f{g%PK#9bDUtD|3~(g!4s~2HwRHodXkSfB3jXtb?k60+pzq7i(|uVS}8<&VD7o}*cos>Hh1c!X#MFN(~02B;dSa&baL zSOlF<+>8_45C%%5Kbq%=ur4TQj~)$=>ADk1q{t*g`;nvVYyBCuAtIyxg;ea6cI~df zGwxDF8;%|4CO?jK!x1M)y+03(b0IK0&M|z{Ke^u^5E?e;=c9Fa$j<1W>O83@**51db1wjl-IH+9hiTR?}Pe z3jdKPpCA=g1nU0b)sW-iYi?5F+k&PGzX5;VBiaFXw4SnFf>MQxavvFIfmC8Oo2?Hy z!g!JxK#Y~~MHKj_%?$cQav0J;BEC@AH8larSwG=Kb$0XoFc zHR&NqrF`>b2&5_*nfBc9lY*9c!@W~U3tWXMRJnT8swAmG`mu3Lj(m98oGJbL)SMMg8RrE%Z&Atc# z1JCSt;QW3>5;ottn|fF_0J<_6qWC`$x0g~C3(V_Uj-~v^>z1+IU%(WU>uL!>d*Z`r z4LZ#bs|Av*w~vB~*J2={Tju!cE3o**G2moVX-`oGErmEDf-Am$h`f3*<)ajkIrxLS z)!?azb0>nWJGxYn0>vFHIRWaL`Wh182CqR`z) zBv)2YloE;B>(VIM@3XM!na$~C?q1`Kuh9K}KRPq&gaC`~N_k|xVOcCB<_i5wbH%ph za9+l4SO7eI;>v?cxhwzo$4zSmi7e8*BJqGwP5le2f`E`!sH11ZhFRup(@F;=3~gPc zSG6TlJG7mMfs2*j>=m2vrNF#?38}ITBsWTaDE1xX3)dEBoD+Xq3izH=mNSs6E@8=^ zio!_O*JAdHDffL6_-Rtg+6Chus{0~2xrmn2vtI{THt5S4L&2JWl(M)gzEb2?#0=31 z6%YR9Ts3jU5Yo4^xE6YW>ac>G-X@ESS~{X^fnyADtB_;{*2JbpW5onIeGOH?3|K~9 ztHc1ayw`86Cs>s)E`U(i>Ar8Q&iO1ABS^QW?J(P%y#u)$sT4u}FAeIj2)vjWka;ly zqE!!@0{zv%DD~cgHr~ASIDVx72^_aup`GJmk;Xaz#~9{|6F1( zXQ^~;Ps38&AFC3rGq@(~bZ_kk4{!uONei3cj9)b>Z;tMabnJQp}!MA>t z_R^-XKpZ#1(SszQGEAC)AQr2KXL)qq!2+oU`=ubtif^h`I*-U4B6-?B@zWb2S{{BA zRZo(l@g?m>-wK%_96}5=;JOk<~{MV_31j8tgc<|VrGzMm9^EQ^1S=DvGVSi*AhIcJ_zK@C1 zo@4#elv=FPOvtZn$k6rh9U(=s()d0!69M0dV_4Mcr1d1&QP{7fq0@9t^!T(pwEh#^ zk%vGP?4i`+Cy3a20|>4KD40A6(*i~n$YKpcV^-Dp48r42^!l5oQjJIBz`Lfp&qfzz7j6C7ptLU{=;G$tRwZw&e9r4Y47wJi` z8|J8A?uP3%8nKbw^<}G5n6v@YIit#Cfi!=hK>QeW-u_Gw2CzX8TF`K5ZeE)c#8jYN z;hgGFJUVx2Z+JMDs~V%i!rKU$3mBWu!_*h&=^eCM;e~{Q4ABB9Ao7Kd@ryz0R))P( z%kp|!sC!po?!|F+;xL_z*O&LD_fq8`Y>~9tV|bX5BM6Yn*a@WryS#Co;UnAUBSYW_ zO>g825RTkQ?&;PSHty7tbgA4NXdd?@xp}H7zb$(f?0haP1FvHG9muWh*DBPECT(Sc zT*PY5-y$)axBE0rkY%fX%9r)>NRAn0V(<>nB@5Cnv7r_?nUwmraO{33@f7)sur$xA8`8iOiplgibj*oqgW9THGL17MHR)>90!k%{5tF4=aL z0wojc`?91*e2~zKCt3@PzlDF{tH9x39Y=G_UBp4w4tUNnLx;GsLTa_ zVLV@*5OH>Fx=7>SL)7T#@E#4fW?t{+q!KHvAewbo zGL#rn>r3xdLMV%yyz#~`*URy#RIVXBXH)Y8@Xn6h(V zrtlB(#0Za}E4kd4B`1%XY){^dImX#KpnP(cOA{L_2spvM9A^i zfSQ)#i^;l9P7BZ~s@75PlgA=W@ozz#rRI5ixj@KWDux;g*ga-fR!K z|3|#qzmc&x0f==wAJSxH?BY%B?uwL8Ie&;i7dBrH)f78U=dc=bv&cJ0AAU;Q)V*Z- z>cu{mJDTdl6X41isbvo)Rl_R(3YI)G$Crcnm>~>Lh#0hZe7na|W*et}kkromUdtez z7LiM2l7=;iYDS8YQRzh66YPQd~X-z>KKT_IvWRC5&%A1F=aH_#13b9(?#Wq90h1 z@!wzy>sEjf@!wE~i-E9E5IcB&ac%C}b0%jnSOH68761DocaS1@wU z%;22$921@3l;_tI&|6?xw%j$6f@l&=`I}1_nqMa%%l|p&>o3{tA;ItcJV#7LyV%?D zCr7~%LF$e9e*<8or?`G@idc%zBweWZBdWkqPK!gUF9FW+n1q-!R5O|AL+(o_H{d?- zUH0^EhxU@F_(J%$?p$LV{0~i=b}ZsS2A;?G`K-W*twIs4@%e;CfHR~6rrzs7HXqj1 zu-g>WxpyqAq42%HJ@Y3Z55^$0)#M}a z{4Q?rNQ-#7c?L;J84vv82Nkgkm_8sD*8r{8Kh_@56e127aq@#e3+g!R(5%%XjIZjE zWtVQr^k##*V<_#J`8CF_8v2pv(y&I4KPduK(}9Hpt~{?p{&IIE-`Ff0MI(wQxl8`U z(JfqDKg?77WVDJ9FcQD(?0*@K@cTeWPW;zmxv7+nsqe_YI9kYF%j(?<*ZJvk7gQ$T~f4S8DPT38JCf zzv{evNYPC!`v`j9-|F4R<9NxOz&vZR0o_S(JPDbPf}&A8^=;uvQrnsa#DG)QXD0?M zrvQVRnqg#urrV`+n8+!)7!{Jw>=f=Y*gJ z50VF1!CDWI>3DWk!>2fRQ@j(pm z^BhoCPsxdtYFtz6UDyg3T!x$4Uj4CEfdHQ|JBF>qxuVZfuqs{pHP(cc$P+|YJs&^W zEw-GBq$((u;@2@g&U0#K0tLm0Vg2-Pi$GQl>na7#o>@1hvk%ft!_Tx49;ex@8AwtTj`o)UBf&gZe_{dwLlO%c4=lqJ)#T#U zZdT+`uX|10<~H|P@b}t5pPKO}`0PSTJ*>ybt4|~wUHp9ARLL+;ur56w*#p5sRo)zG z(F$YJdkb{^qRLn;h&eClRHKv7Q_lp>jqZe7<_Ek@_M!AKdVWFC+G9RjQop)jc5?e# z;7Us9?Gv^~4?asAb<{lQmINeOF_0$ZY@O7aAaDTZLZ<(|D~_5iESTu8?#<))jTu(p zmBtVMv9!2XRQZ@m5SdnRDI~+u9M5Y9(@TPBVGljImzJWh*qS__bGWIc6BxR@=(fD{ zjHUsAD4!ZX&wf79bd3_cP>6vvTT@Zb$6Bo_$e%v zFXg8;OeZtyy5TxElK0Lx>PHmc47X7f)R244IlmnDd>( zY@B0`mawYiAt^xmbrR}BQY7LXD4enuM_l)Z(J?*cfJSIm@(+yf=OCm6QXdx<3URpv zYQonT0(CwCxm;bsxYAz*zgftS1zW_H{q~4k7y~^W{ zTAD>=RzYZElc2&>Qcf$}7ti*2%>#8?WXJ{qSqOfKOj0wiEX?fX!yEo{_EwRz#in3M z`Hg}e7Wye1ks$LVWB2UGfU|3S^MF}pA~8r31dJAjEE+mNPF&vJgnq(BeC2Zlc7(aX zna+Bc&ncou%c-f_l;{Y}Y1N*EJo1j?VWsLR8I>{&!lI*Zu-_Zm~wr+z87`pC?YjM=S%Jr%N6_xx^Km8yaHkt8$=9h zx)aSl(lyN&1Z_jOb*740fAJD)!}~Rl2p2hnJo};1V3FN!vL&Twn#O|F4FB=iAGK0q z1S#$d?KNiC4-+G}fv6UP$IuAWA;_?5v;WZI;YueVY$YX#@ebV6FN9{D1n!!Tt@ z_g|C2h_=PK^5@(CVDjHS-fNilymH(eRmb(k#uZ15CeG^3+FuRteO61{Nq^qgOZZyH zs(Xx%934Nxr*xMY546R&m$cy0sck2#0BLFW1?Y$oFag0;b8TWBOXM0@S; zHnzDc2{k`LOPOa7jsowHmz=b3E94=Cx62yKTI&OCD8pl>dTqu}oOL*XXAX|>XP=SF zK6&xxUKFg?%^&u7CWK@3vrN;!JLD<-hP^zd#I9jj3B+NR2ahLTBTrU2EKu6^9w;@z zBSC%rM&gqQ1fB6jW7ZZ)?Jx+<_G1=|RxlIZYvu<=G!F`9ct z>H6U@ipdN>G6*KitAr|$8qHY(SUcbA&H=PFkrSweB+nX*;Fmw2@}a|0wh$V6r0~bp z#EMgiIgyv}$k0X`DFpcpKCpBSt_fdnMaB^OOZat0UqRR)&QaB|g%hN5t**OX3}UhB zfNB=$vU=J7Eq&vpIBj>==*7d5dfOk-jFPvmRsLrZIbWY{(UQMATWHxj#JEY4yU>68 zLNwK2CXq1cgki+@`Bhg7*`CVr*-9;@cjT=&03(h5Z4VjRW(>OG(rAF3)&GqHcj(#nt zv?8naeN9R(5viPb@`ljqlUKvx6BOi(xD|#+|Kb!^B|KntP%hERXn^sRyFA!ov9r-3H^i@cN3teCPRSxd<4}eo^>4yDc~Jo zN>Sn~h~~k43CYvDmg9orSV9w@fOY3SXgnF~+0*9TZcP>1>p}IRKPI_$r=T zVg%a>a>pQ>guD<1P;BoTZfX~M#hMzALaQp7n7j=Z>8EGP4_Cue^@q({8`e;1T*`-) z7B-$#$5~8WZ#WpxMdrxTR=Nm{zA8Kn()Zl=oU2sAb}F$eQJIVnkQ7H`*n9e_J{)sJz{@gu}va!M$MfSZ;074{E-zr z8FA8QSb4&?us3a-;XYUYSeTiaYB*y>F+EA=kl9@Mg(<*rb*K40!F>J*VU0E@eQv-a zpmcLsbX#MeP!IzM;(U~)zvPvz5Af81o6FdbRGL_T6bB^}aHyO%Y}&cs37w!kIT)|f zy@W7^z4C)d)={DTqV|h6?~iaDN&u0iaGZtsu9>WnZe|nuL{CGEJehGJb5k;- ziXxo<>>hKf(rGDo3M!=|4OnWm(^}rKeO;Zyx+(HqsrnA*bh)ID9n$5fO_WbEZ$~kg z`V8?rr4Y&%rrSWAj}Jnbj9tAh9b6P~jH=l8O8w(V4Ds`*&huq#SOXPJEp?+6hNP@OiUCQ7XtEVpjJh9ds~4D| z2I+ksiAs5*LBqbJIDPU1H1t>fq7tAoB%OJGJ^2m; zB!)Lv+PRN7fHpsR0^+Wy%#YPx|EL@9+jSY-(t%pf!8pw%UUE&1l|s0GzTC~;rQK7t z#2EVu+Ms;O9zJ4@wi9N{y`3!?=zCmA3yR(VJUYbun-mCn8VH5^Vbkp(@o4ch$(o_e zsUPvdnU)P~lx8B~AU=o9K%lg}P@4iLnf{@X@}M|oaDMriURR|+c@m-khs$J?y#_-9 zu(DTC5oVdsKrn@uy~JgGiFM?TTBW3$fp~N5!r7N478TK=HBOW&qUMHln?9asxDinR zwJqpkmPV?6(;*b(WkNnfx7W?mrDuK=;et+|^xPOu7%g;3bUp(&>I1!HA7EH;Zw4@p zv%oW?B(`R0QC zGqBwZQF|bz3LJTW<*sJ3-{Oj7b;DNsPRQ(gLT0&#;FwRu5-_aeiOXst_E;~<^@>@t zTuO2bPuQu86OT z8F&Ok1Wd-_F}1ce=lTtq*#re`mWY?Qpslx0(|?-Up~?u?siB~dqBC5m92y}P z3f5US`OS0y8`?+t0K9X5^=e8mHy?E!*@ei--Yk=1NRdg0&c9U584W70*G#}sX;Q8yZV@GQU~me{a> z@fv=it>ao1xOgkhH%Qw7uSgES=Xj^hnpc6`%R|>~F=%%E2tD7DJm-Wqk2#f#`3)MP50d5j-IP$Po}3cV>i6G%`z2#K~-r78|X=t0p{7Q17@B z?~4D?G-K5Kxc85m|E!<|*3*J2zUGUM?k z+wUPQ9MUv@p+gz=-%A95zipv1B!&zGW#bq%#4seTp)$(HoZBdiSzZ`2aGCYRT-!&k z{sAw*sT=FaBh%o#X0uvzj%yAplI@Q5ILS ztmC>DcimN1SdN~jjqCXzHavJ@&T}wh{+(e5jci`oB zdtua3^KlLG1h)|&+PIkv0Nco0urPC5`=zA^doIdeM3jx~_?Fr|@ECzJn}TIbw0Zi9 zvRWsx9|F}#E_1*;uJ>3lkxaqT07uYy$}17bos}7`&3Xt1xv=uvvfak2G0Ub_T4VLe!sxeK2C2IG2MJJfE@xKWsFCtrU&mDKL>R~v zBV1{v=OhXKkv94V?YBcrmJC6ldmwG4Z6DqaIQ<$-Sfe7WEw6@6mT+mOaPZ7GXEq0~ zgWe>}u#WyRcY#@0!4B7DYP}0G-hT#+3j75ZwTOX*l+zUHRX(GHL~p^CXBsy-O+~Ke z8DXY0`l0M<Tw0$s@j3H8$&4(1E!4?isuE_iiO{33Y+DfU2Qe;6tyEm#xV5wkKNyNOE+q zy1Sd#n(_d(pdc3Y{6~)i^oj*rUqqDpbnHMl42V1*Eq3N5-F z4I8%eUQ2q>{zE6d{Wbh00$De|^HjkkX=ikJlDRu?%i{qr$#;PWV##6)TB=Q>^oNN! zP%?$}&0s2)$^oVmQZ{}O1RzO*0=7}2G0l6&wjVP?UcgubK)B%iwYfdhY(+7*L#afP zRf)2Og8%x!VO4S7js+_GK#^uK6)4w4?fF+}+++fnNLFJK+>VZNiA`zuUffz)NBPH^ znrb7FXlBM!N7olGHrHj{|E2ac|9!uN*AyurV#o0hsM&81bL3M{fX(Hwe#GF!U=0p1 zmo}6w+3i%Nl8m~|eOL-=yRmAw2P_I09bS2BFmU@on67jL& zwMRjay1}-xwsKfg=FD8gI`l%lBm>JfK^q9w6_nLvi2K*9`_&Rw`{~XQOK-s3XFQ9} zeGrdRL<)8>n=L;zI$#r+@^zVo4+0wx+`(#fQ?HHDek2rb_3h*U!{iG!d1)lP(R`DZ^uT| zYQh#WCN2i@>>|Ap&2cpg{6@=`YMg=fN4f1EWJmg%K=5Ej0jX(hAb1pcnYv{e1tQ&b ztO=w90YpEw8x#+ulNx#ck~QNaIsP+{WhN>8Q(Yo`n0WHB;HSWVLgSJ+96L5?6&SYvl1u$w>?$e1$g4z zmmACNb|IXs|4HA{6j>h>Ce1}XZ~APrTzpzAt0KML)j?X#9Byvm1oNYlC?=QC_wPv!{s!w}jnCs3uWGan&_FQ3W z5Kb7#L&muW?Dbnu2*U3~D9IIc+9bnAm(sjMRF!qcsc#r!;!&Xa6R!|_uwOJ{CbTKl za6xhaFS#NfMKahMRY}=tAb93R!J%MTeI$j6+S`*RH-$fOA$639aIul#YRWs!MtEaE z2(@F`V(3FonqCLg|BDf;K5K=S6 zN1v?xJoBAdn_svYi-*#;j>L8F_T7+L8ON`vKX?(kX&?zdEZ)Lr$E^9i18o)t%EOe-=ZD9di12Szpr{F_g)^VfLF^ zuKI}aIoo$tY_CAp9)moQ_TUTk#Ep{>_m#J;fL+UZRoL5RPN~JB)5)i8&0qUe+T~bS z!^l*6yj6O|v(jlO3G@iX=MU1q=kSC>3|Gy>dZFR=$OckU3LG_7%M7b@1I9+}kE@ji zzGhM%{LeH&qu)h*9Uv@<^?x!`*_Y;14*Tq?Y$y=0j-Rx~}dHitMFWG$n{SX=XsOk=W} z^4O6rbRh_8h{lHHLZ?Z-*?~PX%)p{dJPxs z>@)pVni#VKDt4Q`7Ll)PU*lbtg@AC9uN6&Cx0$~~Bkt(|xoqjBB|A)zYC&%U#f+Fx z_#5~-AHGWBJudaHSX;M~%wQ>oljKf}3y5UdMPjy{*cLDi08iXdllIU;#N&4pa&DqP znNFc@9yImJU}~n{tR-!|84R0fbCf!Cbloe`s%((d6nXa?mlbQ}Ya)0O5j5h}?^Mp# zvDCxe)m6={Dn{T%RyAO`-(0{R%8&lf6nrAAm{$~9(1G!c3n&jBC2X@C1Y&s6MT5}) zN3TpUdPir==5SIQqt*x58+QZ6dS~$*3-fC*+cYdBz$SvPj-zzdKxxynl`bU%__>*q zliX0izMkj@i^~@JzVDw&E{(5h0sQha9LS&lJpR*BspI%R?Tn9aF;?DIp7kV3r=|kA zUmvS#FyGyr?QtNf^vE;vSl?Pw!g- zEnloE#lI`#vs@8|BB$|;t6OkZZRCPz1Eqf`w~a(UR*R-i7YlmbX2uTQ>1LAT}K`y7Wb>{ z%~REY50e#7C#gma6W@;t7Tl)UZO>HJ*uDjmz+0#aT;e!LUDA!wqiQH!l!Sj>FpYAf z(MeI@gMC!(##d;Cgbd?Br41PUX$!hW^LM`_tu-W?iLIciD@`T*_8w>#14}3p2;1I&F>hXj?SAP zW()Zp3d!j<(H%7yBMsG%JC`!LHprN4D#NmPBMBQ(2N5vh?Ks=ZEb6oe%tAfcUF!K) z6XnhZq^aO<-I1xr?g4{3r$Ewt+|8MUbs6;jn9j=ghX_rQ)m<&G{-arM!^@v4Yr@?q z@ZZQKXLWWuG;nga>=ae$^B${^mKebGmkjozb+@jFD#!}@-x+b9d^&ggnJsqZ_xN)T zAjry8cMI2b#n4SNg1H5!HGrs*iYw5Wg!MI0x!p$ zl%{t%@+F=&;Fl*fM^%E}w^}%gZB3>U{&TAH*+3H@s_2@u4n8I69#8Ku(aF-Kf8{c* z1u_!XR$&9OK4~RcM2mN2f1r-<7RjUeRznbbv$}l2RS?R_HYDv<_5}*mz1&BaOg6D& z7*5Iz{D9$zX+6<|@x4*;_ID00v<~G2_G`*=LZ@=;l|&;c(ACc8;5Gm=0$@lflJh8r zg{&bOYRl6ntPaTqoW1v%hnMC$_o|`$DdL7lQn}ZX5fTrRGi#rL)zstbTn<`N+c&y0 zYSDmtlT&Z}FsV%=AK^nvc4e#q4tomCFu=<71bf#*wDg_3DC>>Qt#oYTh1gT8usv^R zhmKvVpj3zU>_ z0VT4?enXFvK4GDm2fd^9ONdmOxvn8id#hkCGbhb&G3eUU?cO&$7E)<+WJ9E~$= zYkjakk{2BTg(D_J;wyNZQ6S;GxJnfK+%^CcA+Hg|I`01h%YW>-8a#_I zwyoF6jI7cuQ;vMlVV7V5P=S zHJV~ZkR1aKG`Pka0p`$x~D7Y@fzh-*ZJXQy+{klx~^esp?n6R|NsKLIBy*wtZrNFyuDW<@#z zA8ry`^W;zBy`6r7ik$X1jHvZi?a@z+O{Vso&v_SPG&E4M{IQO4fX$g_D}U$c!bU$Q zkJgBaVZs;jok`{%!jGjaYx!@zU_|d&Y+l2ysNRSj*7ZJ}L|_IMK)QcJ`>+~sUamB0 zUOqDzZ#YI~PtKNONd=w&8YI=;qRpD|n|F`OuS!ic=FHqND)*gmX~ibgk}p!5chbq! z7~&T4|CRv0bu&T)nsSFs!2kSSMpemq2uL-LD(%2=kF>CkuH#kPrn*f5?!jW>|E0vWTVDXZIJ}n`AYSKaa=TNx-!2#w0%0Uyx3^un{1@AUv1GHa<}*ch2!$zQ zs;unqM+SiEepv>;{p1OCcJI%QO5bITB==_ur5%g8AC^>jHG@C4`*D=k zX(dCoMtHbLX8Y!L(M^6!0sprzb1^XI<0_sA9KS=a&}I)0K>?@?gjRMTe7X&dKCU&O z>#&1>d{i_xhDVoDXJWYly!=!u?>hMZ5>YLMgQWbHipa~VUy)(r+KPOC4z<+Sf!q_k zHPWC~X#*J4HZQ#s&3syBk+GQ6B(>HBP2D4yf;2qJh^R~1s$N=MZU5{y-9h%vK`=SU zsqtU}0TE$q$)Lf}83f7g@?DRG^F*gy>zrJP!QAQ0n6m-4>y?}~5iGZqT=E@6J6{hB zgA>&T5a-qV6+*KTjS4qGC~kbgjJlg{%pwLa#jwS9Y-bHkp0Fm*HTzI>A{6uE*GEQ| zAwXYdu1h{|r#qH_{wor7g)e5wt=7X!*rkJ4;5azXi5EGfZ1S{9WIu{=mZ;46*9GR! z#g*vprjJE6BQ}~(UF}c1^$t4>sDdX>uQPT%G$C7=IO63nrUg4XFqGSGYsk_LFWLhS()=h1uHPJ$Wn@sU|BxieoZsFrI-lu$x2V^-_ zxC!OPpd@<6#0qjV;|r~9@isH z*jr(&YtZ$?yqT@)_{}bCn@b^w7-}w$jhP(%QPm9@jAKPhnk9RIQZ(G4FmjMW|Tu_`UyTaRM3{5WA^ zuJ_3Flse9kQ^>`Zn9u%tL;TPbyUX&qcg?^YnQ7HF`T1^uN1BY84S4#R+xz!kJ5A0s zN3!Ydk`Z_acaLegHf8(2k(cdxSb?Ma6*k?rB^{jFxEh~xE4*T2<~_Yc>gaVlzHv#%_w zEv)jIURHP^;`8^Nz8uuIF1j8Dhzb=F_o2Ydl(Ah1OpiU7ZO)hcg1N89-g{2n&-7K0 z?ntVQM&51kM?+ZEEK(SXA78$G)*{PLxw;EjU{lpjU7^UOTttvOYtEm5^sdJ8on-*9 zgvglBGV{ER;r_7d8sRn6=GQ5h+h(&QvxL-V1A&gTak=lg5gxD_LpsK6L_ydnaDRLr z#P5nr3wg^41({I-efGJ=)FNVONRJlZM%WQHkrtd3TT3im#5Edg5B|p3iOK#))CVQO zynG4oAmn~EA>LXgcqBS3R-5( zE>Y|N#aZLNO{kNQ$e+Qr-#M_v>3^%uS-Q|&E1>DeP!4`Qb)ipZW^b%xB!L+9w0w17 z*^%cr007W8rQ2Mwd4GF*<75_MR*D9TD$5MB#<3-iYO?;@$V95PmPCtW0ajV8G5mH*i7+lvo^kbhE0GQ#9b|ysq_9&#}w7r_KY?uoN2UcvY4+CTj3i zkH|VKTlhgOTI?bfXAXVW%UpKaEbZ+=!}&TXl)V+swtn?CHAiefW^VgsBR9HaTPn^}AM|tMM7ptrI)uRX+Zx;E%;mG1jtB}0z zM*5Tjp?C3X)t{83B7?n%DjceQ8b2j4QlHxjP+OtJVWp5)Q&$oxJn9;6DTO_wn%N-} zfrEyQ$p$h-`<_KHheHF=vq00E!CU%6j-F`k@>`fiWOp@#c5bf;@*^&j8yh{?cTfDGys7j`@fUdi0O%rAWHqt!>+7Hz1z(=QX6_88 z0#R3YdvYI#ZVy5M78qt8i`6kF4X*l(!@;VQ*pA!lb%3~TBLaRZyvVU zSrZnQPP#-tY%-A%@RK(H2IiajN^=I?Z6HD$S_d}@$#OY#^*rxub($(h#{GYNfpxXu zs$}Bfc#Mf+@9Y>5(gQTMiWzyPNn^)l#N;r1Gu9nEW*P3;@?2X5Vc!lMw4ctjb`3oWq|8l(7+vw>)d!b#{KaN;~p15K)hKrk zv*f3Ot=m)D9%YLiJ1ydY>A#8+vBjD=3ClImgPqUojG%iL#5<>6iwwZkOd08Pb z-$*gOB3i^iXcd-D{!um5c*j7>ZxKq-tsD4BnV=FU>!R-(UJM^16H^TI8^BU*g@aCV zcp32>iU-Qs^2?=E3E7F-b-4z8&@%~_0-Ek8<9D&H8HS(7C?fEP?~P1GlTNseezj9D zwYkkhs_n8(jDBBQZjle zw$Lk_+Hr|nV>xx{qC%(0K*Ey|=QEK+mvr?Da4jx!QOS&tndx-+hu#FyAREP!`7&Dg zKgktuZ0FuO7T8+%*7_9qiH4)y3KL-J&@SnH^MQSr0p5zBHZXfj`PRl^ZllHfoKGZj z@wqkA3Ul#^%9uz+%u;W}I2go&4M==lomiiJ4qvLWAVXoO=^jVWV$3UKU8MsO9;#WN zH*!>?lLwmXraC;iUmcMpv6TxdN3YZ8Cvzz6b60HCf`CjYUEX`gWS&tp<+zVNU)-+M zQkW}kR*jV0z2_X(4dN*-4bQ#?dvb=I!2oh80h8T&aLj7ov3|2+JCM!-VJt|5xX->A zU)!vte&phGfTEW37$I6&$X~j}(NVIqfKcbJ=)Ed7C7jd!e%`W%4Vpx=41N=Y^SB8P z19xkc$Ex?qg9HROBZ@ zshrIhuGf0bdqc(&wi~g#rs!p#pH)dNmfBh6eX04(8pIDIRZLtV)R+_yN>i!4tA*cK zR}K2iD5bY{)m~WJ+ZUyi> zDo?mZ;ZA4@^jdZmto8)|A>tAe>^&PPjOo#ML;Gk(?T1ix!=0kfpjp6~Bbi#HE=34i z8YBF9GVwU8j+Th4$QG0dLEBBtwL;c~Hg2Pb2oq#VUl|B2z3nmNH3So+{9VIACo;+f zcKIe~i1Ht(g6*Bf8v2M9B0|3s^d^x&GC+UtVkm&)9Wn*-aPRPrcqYGHW}zSOwiL*w zoq%#8BTB#)#35a85L2n!S8r+?0~Zq=RYhO+F;mn)C>_Yg4cf8~)=?>CwXl-&YLvLg z3s%3K(4XzJ4K_uMJ}{(6D%4tji~zWP@m{Z{JZ4f8mo^p4uiGDqX%fmjpTTCfedL4o zzce~vDg~gQw_}(uSmjYqZ*@8Fmw2UXA7losGxs+3RvmY7>NCtpV^&Lc)~0BSt8JM| z)Qq>BieYNi6sNsi!W@)LjH$RmzV7x3mk0f(`y1DPjUK$?9w(aEH~?5=vwLhiAFgzH z?v*pWbp?Mc4>wQ?BZpkmn{C(98R1F3S2t5Uh8!g zXxB43d>$|sA{3Xr_MAL-#IEWXV&t9&zWIgQ4`kH(NAp%5vhnhus~vie`ivb;CIHty z&)A4-sHg4p99KRRM(>Wur~Jf}dKq+_09*fC+xK%S0R+URB`&`o7@DWXhF0W<3O4lDglSF_n<~&qJ2hCNK20|FuMsY5=YB>UR(!L7V@`OUh#VG1SuPo zSv*kW{?{|0j=?t%tu;j7jF^x;N^+BF!?RE#gp501__*iXw zl*J(OCMS#Hgi8-W3``3wc_6l?}5z04){!Fm0>xJy04bzHxdR-mHu z9bAZs914g~Z)e4M-xL&etFb23SOB28Uvm;>(>X_shOwe77B^%zTg6p$cu=9iY)>4s zT+-4Qu1MjkvGa}3uH|W#7k)?GJt1HJ&=$!bo}*M08)M_KfSs?cq@~IPMTh*BBC+3V z)a0+;n^LVR?se^d1b*%O5H!TcL=JdU-bKV3X3F|`O)XCjwB~lC%EfR~L=V_P=oO|U zMi8#^B$pVk$5U20<8qfy2-5>e1R=>!pGj z*ZjEf|C`Iy8{<6RJ<`f0`W|Ggrq?bhE=qEZs*phpCP5Gh$kZi>83k&?sI(Z2o11Q4 z39>?q2$AEuY!>C}I+=QZK-UB=b{&9>T-`V~7UgkmJ0!)Vp#_8TxadwHX_i4E>kb;< z?e{)~g^Tz5v10213>nvm@Fgm;=t>(Ww;h@64`U()OFMnP4;^V5f`` zp0(lhEf=-^iz|s30#Gz%X;4^aa5r-?aE7lO)n;^1useLo>_aEuvE#{Ajy%cRCXg4g zeN`c17yR(jUa=olshO3<=-IQjRra7T9g`pt^fbQvm*!0yauesM7!$2XsR?-V}*saOE z`|T_b*>7PKRrG?=Y&=#!WJaaTQ&bYC5vqd3i_6H2_qznljf%i*;Kcarx+Li+IrC@s z4CeR@_SB!u3@I+_Dtj>lV^Gl7jc=a!38*d7b&FZ}p8|S6Ye*f0_s`4yT&5bV|As`uaenyihi-?EbU20(aZB)C9yu54H8GuaV7OaBa#2KVtLH?U?1TOn-$ zjh&r*>DEGFOKmaszb73{TPdp9(NrZI~|*rNJ^bDAmOmZ#EkFvT4y_ePhF3T3~F(K+0fQkn{@Y zeTZUjgFc8Fsb}a#JOG12o-h>I!yHZoQk|G&Db2n6M@RGfvHCs;enaHq)2DH;<}60$ z;8!UNB*AA?{7jCz)LwOGWA`A?;vxr}V+NKympPKg51hiRfP)25hf@GX3c<`2d(Z$c zX6(1Q0I%ApQj$aS;`C%Kj`i;hm1m6$o9d~HAt?o3i0KaVKFv@}M%Dk<^uIm4a$WI! z39vUG)dTICQbZU4{0PCZL*mYt1HB-SAkWdMzBlV0FAp&qoXtK3z=7#I86ho6zEDPi z%I#@Mf()5e)jvDizuYZhUNhh&KA5fbhC~81wIeX_<{jWmi)4XTSt2f3^g}<+N1u3= z{R$$zht@q&vNbl^!|e%p!m-xdVBH`&#Y`G4f%r|)$bU3Hb(j9MwJ~#Wjk#|z*gjjZT<$`V^Zi)#vvk!(&1mUgfdorOa186IgV>uVJq%hOiIAZ$S)atT&O z)3Ou`RxkQKk)rBhH z-z~8l4P%rOpBxQ*1T<51-yU^WozEP;7b?)P<8>==jS+2)7U=-Vuj!TO1X4`LkTR+$ zPp_^L37*3eZlAv$*|mxUfxQK#(ZZKMZY4CfFB#LTGIK06@?Vl&P*q`5A|D6O`2jzk z0TbKmabWOiSV`Y>Y{{S+#y|b5zs4 zE`PMi6gRY5`qbo)#uDIbtw#I50R|dvgAIARL6Pakrr2vqBJzdDU@9@>nbET@jG4g2 z&gJP+Z;t*niLim1Ld-wm8MLQg4e9@E!|sd?iV)#*2M)b2Re&nAfGhJ!Mw={;MjZEv zp7K;qpq*v?a|2CIU8QGUKD96Ozjr(1>4f_1I`t&P=AuMP&+X-jU6nH)EbE;nmv(X1 zpDTucSTGC8N`*8=CG2c5YYiPCG3TARR$MO0o#zS1e(4o@rJb>@uS(pj`L}u%bfc5m z4N}ZN+_x&X4p6M(nLIiuho&xBUT3WcASkayEkoEy1pM~dX8IS=0lIG@GF+t8(Ib|- zm>?_w?Ovfic59*Gjq^{*_a>HO7GY)AUDUhw1*h}Tjz5^NyY4kgMk2seWhao$RuD3Z zTq9KzuKOIy<{R*R?W;`d8w>kueGFgy>lfTv=ff6RhvyTPQS=kEvoCO?IlYk?+uP zn<(Tv>T~kiP+KGi(Ja4Ucm4{40X*TfUhDuWYg%eC3r^I zIE|d*h`JWz=$Pr^k-n8uph+BE0JFdyl!^hkxryc|1DmAKOCgqI0=BC;^!q~68rXW+ z6RSh62#A=+v+6lHB9gkouxGttOFa8JrdP)8q`uGyD8Br>m)#w9E?MA=DEB|!zWz$#QWz}{1Y>>( z1%c1bmT(j5R%v>W3zjJ8vWu3MNX+7DZ2Or^?&2SAzts0!75)FQXX6>27NOYmu=d%& z{{LkzAx}_zro1_(lp74U6;ywQXh8uh!6rAyURNsp3W%Te9Q}jEBj?#7r|*lDh0a<% zHh+w|xv?=2Ui?=NUH=Ibpn_MH-o$0)BH^BF(Sxu~Ok*Qih`%C6jpQ_|EiKz>|9SO> zE}8f&KmbEcg0|k<>BT#`bkJZ(gspm7NyGM|%H^Y8BxW^vXc4!OtICn|=AGrfZ*U=& zuR3V7RqCuzRXtniu1@MejP5jV)L~Kl?ooSF6^Ul7uspsTcvm-B!JY@9Woy*`v8UXo zeDv7T`F5l^8!UNrR3$S8MWDc+I%(OAP%W*s$+oz9xg>uwO)j;uS-Bm&de@kgDL<el{(I!FUS?faznn~$tSbT4 z+dIK;$(cwg@OqnM;8y>E_7QPI7x}FW#ri0{POilcRXL4?&dW|l+y7t6@4vH%Ogg*j zmWLJKkPWmh3tyWO{`0GSWH1{}_#ro26H=jtY}!jQD3v_B9}df|DffH`DDgajJ1)F? zr^%g3Eb*+$39~hLwT++@kfofy-5CMq7zkj<1BJ5`@ax;ShERU=9srsxAI63z>C*Qmgvk^>IJ<=30M&|kf(ljL~JWZ{1cQs zb@zdu?j<9{?onS(S<|6XK+e- zCTeXR{Tp>pZN9M&m8Rt{RKh2=B}_na&=Hrxje%g`K}zlV{*FxQJU_QC#<9MsF^H+W z642VuR8%ysx#44$8!r2yLA?X;;lj53Q5L>VxV@TY(^7;;31dnD<1&NT7hqN=>q!^} zVPDf%Ay{bluN!k-HQwBMv;pJ#=+F>X-)gH-#OK}-C`m-G16gF zgGDkDxt4t0C+PaS3~*md=BTwCrd=ZAUDcRieqT5BWhV)ej>4;Rxdi8>t>f2HjYBw* zRQ#GF7VI#?OLyIPwK#He*?Y${w^}{X;F0*$DVKrBm6h)4BuOq`3C#I@vjJS z2NaRe^o`^pFB-(d#5t^E;O>N3x~Z6 z0ay8_=Es*Hw^qDo3_MwRDD6c}BcX!V?vs0x%sT+%JI`OvE=6jR%>eKS?4$v$%eiCA zB4LuS2P!*k@25m>4@nV$KRi-}#f$eZ76Tt%Xxd@PL1 z|MD9_RE+A$*nr{7BL0~F9W3+Tfw4PAOUP=q#XvK;brzm2)u+{*|hY5LTGPWt#jrFy$L#v;gOk{#%t6HpeFS-Dr~hERP-c$Uo`2}KI^1Bf*H1zCkX!}S(w26q1dSy6n*DwxTS=f zgbdLYpO!={)|i$>u7n4{*}+e#smMtzBUm3&($quSx0ZtHA3!!tJim0Ios|o~TR%{P z3geF`-2A3Wi;_T#_~k01OW-|@dln^#uC=t2^%+1R2SsyL9C1@l>4LqC{KCfdL9${V z+$P_joSadoi&iqkEc4qV4(-Ki$_D^Oc$#KD=ai-F#L>o4PQCKV!0^ngm0YF}=G%fU ze@I5A^@~>Y6C!8xCkC7g!0zZd34K3U$ydDjktq7)rnUME$Sn-V~0Ad9XSZAB|7l*-EkUtBGE1$D&!5)#7~^okOm+9FLnGE%*5&9B5E=7 z=Ck7^K1^C{a1JYAuc>ZVnwNx3Jf+L3|Bti(k9hquPIGLj3n*j$oF9D*HCXdbGvCNy zYH1K$8_~eS?hliS#~k&f5+YVmOmkz{M;Jmh?=;RPRY{_Woh89`smeFDS99~(uq?}Z zZ`;nprm+9oLB*SS3=z@OgECj&8%=qTUdXbCX^@G?Y&ixs`!?$`7vX){l~c+?!EYcw zy}PA}cw@W$x3zEM<$!S|hZwhb!pEKcYCp^tHpf7M2GvEZpLHUQG8md8{xtA7I#^BB zA49Vrseqz8)Xh3HQ=q6w-6{ww0TpY+KM1@3&rSXM#Py+yN)GRBIVUeDj~ikln+J4h zBT2x3`*wNJyb+vS5tY>qZZW@4Vb@@UbOU0xxk6N+*03A^08t;f5&!|m)B=p( U4)Fc+5I!&sivj=u00045TBdTU0RR91 literal 43436 zcmV(jK=!}=H+ooF0004LBHlIv03iVu0001VFXf}-s<5eUT>vZsd>Q$l_#!w{t0WW~ z`4%D=@FG&D0g{n6nqR2BgC5ilVKPfZ<^D9_$shyN*6kJ%rH^ksPHyG=`*Ka~FNE&O|C`evYZw%=auEb~Q(rsFXz4 zA;F}X6i+kM74v5;{#ReL>uE-+65xM~Yd*@0M`r-o@pBeMw(7-{1s38E9R4Rx)^*0a z{b)qf;6`NXxg4wdIEbiBkKkS#eqOGy+S9*48PT)0#&f4i`qdIQRZNCGxx9EP3h}O* z?s={{SZr*4@gcyLYROZ`5uNdW^$nxj8Y& zXpJ2n5oVLgd(;)&Pf4DzDL7ko7Ni^3rKn$mL_u{*~MEw|Oyd0g4B@ir5<(YzGq(ZwPs#-M4k`Ko$aKVGa8l zpE;xuRJVhRD1sT;5g6c0rmBMSQJZ^0~eoBoM$bECq%Pf7lKj)k8RfL1jv%| zeL&ZBjdj1te4QUKJU|8#V{5?z;I#Ql81whhB{j5R_3;1E6Tb-)&Vx zY86)x`kn+MJJd9aYJ_kRTVi+aSLvYtPn|_^i~TU-7Az zW4{ANt=(CZmM_i@(0Rp)tW?6=y(&RG-7B=LH@n#Cp!-a^Lu^eqm0Bf^5H@ezc($7f zmA{s?hgg@c%1}=9F)^27aI)rx?kU_h&b(xU)rbJx#RS?nVf!cPIxbWA5ZY594dQ!h z818$dcC>Ljt$#?DvMHUh_^;z(RZH{Gn7S6%!gT%M?V)jH=}T4GX0o_2Mi4Ss!PBq% z`!QuU93DijZ6 z^U}_64r;TzGe*oy`~%txthx2(VP63o7CnOaxjgL`ozc{yOxhv=U4(L9GJL)YO1%+a zP0Z1e$w^S!1iW~4x_BeoQbED7xJm1U&HP2(gPk8%VBX|TyXyF2nDbsBvo(XcWzTuj z$Q-l1;iMPy>nJg9(qE~$#Kv-;;ceYF{?8m`p`Lx&0u>fLaiJp)NuAE)8 z={`%qMcrG?S5+nlM%O|Tw3{y_51%4NBuE3ByDd6HO#yKRf93rBNEz+OieA7%t+b&5r#&XCHA5Kf7^4 zJ%}Oe@TziBJb7_88S>PZ8bKuYhzbb4stn5lN$-S8jf<1cr|;|-502!@(63d+q}Tv9 zCVgbe^caIhVBfwxHtuKlM@(wA#am-8fh&3qfOs!-v)S?>HMspJn&?-jwn7`gt*}0U z8MP#(I?oS0zO_7)Ryi+7mWbn#x>g7N^?s~*{o+pBk6#vp;;e1pTQW@f2T{-y66P6E zzI&hLR^QIzKKS>rcan%HdK!KDx6BWjgmaM6KlrQ<$w&{hgcGuCw}=QRCi=*SlJtT? zh6NbWtH_0BewE2Z4tREx|9f-v(3Bor5LEuw9*O381$0y4p)X`^L|B(zv@t^89IS)y z>Pq@`_)e<(_qm=!6&gkkTTSSTE{x@yy}!Zs+;93AyUZXElwQ`DGulXseZn#L%gICsMU+4)7|k*+C%$#jJ7IIfB4#1uII37iK`XF~s{ zpv!?ne4uT^2Ltu(wbM+@&@HGVflzXr{Saa=6412Cj;@5|91>*e{Z|cb^X^j9vCI_! zqmP@Y-mv5c^0=q&E`+k6KsMjx+5bJVRp6}1)pl4HTE|HqZz3hFh@MW;Oixe_z9U5> zY3yiRU8FH&85(&zzEfrrjdqlRMM0o`W##;FgNh(z(+HJ4vDROVWAjQlG(ISLyAXYa zP2=om*`?+6Fa7_ZmcV7g&iWbXMj@ z+Zx2qNRy`}hH(FZLVx7z{h6z%_{bLFgo9wH#rBLP`G5_U;im5by1nccMd z&E5KU1VHV+5Qc_u_DX3FA+jSVyyU@buza_jY7%7fz^SUu_zan2pWUG<#}M>dFJ$SM zH;u>Sk8NUFTHdjeRz`8W&lfA75{2TW1p?v72BPYo-I^k)i_k_z_)3b4PAWDFg0jmB zw`W|P!-Kt+Sj0qQEf$0~z0-0-+>okP&ax5{!*(W+SDqYINfmx8Aak`=T`S&28A~Vi z`bRHJ)%MFBIU6Zt6c0PB-MCdMKDm%P`<@=2AR|!;WmD8J2NLh35jeuvAWYnn34gsF z4U8b?9;~@?uey>OOc*O%9rRh?#6o~g$p1wr5_$qd^8dW1D`FD%$^1z!*glMnbIufes3-ZX4@ z1reJ+FL-fMBk`WepUS!T!oW#3_zWCxWrygb^vJK!jh)_-vum%*cbuqG5@>>z2o|l` zly`akSkQsjm;vlMgTQSvXrQ77?diWzYBo=udad;E=GPxS@+@G*nS`BWMN$IeYs3rh z(E=09g_!`$sa&*~FnoKUWj5I5T+K+s@T7Fb9u5|&Ka{PuihzheO3Nj!29w&9Z3NX) z#@u;dTIR-fbDJNju=TlCgA5lQX-=vLk&O;ND}lKea+8cxl$ZM~&3=<&UTA+1;^|Hz z=Fo(er3@3oYZ#7^RYL|ccKy?tlM-~tv?{L?&EPQu2l70=-to>^tX1-gE_eq9^>0{k zP(`5SHK+s(sWVcN0$fLnmeFF0-6et~h{Z2}g7k9Ta3ICIP{+3(816o?qR&m|k^DRp z@x0HQxErzN1jUkCzHt#yK+{?iqCEg>pu* zs8ys2C?nPVQ?;2EjS^!}kz0q-WPrKxO07QvjGd8hCWpnW`0W!cm8>}oT=uA-P2*NF z0o97fjXabouXiQRWeM)ZawgpQ#jVKG z5Hf`b7B6Nwe;==lTju<0<5G<-5*c>kEdPiCR*#e!egJP9tE+lx)A-}Z1cgu`RPY8ri<|xVS&Jm)a_A^ekq#Iz9RK52T zRWE~=d1jA+Q7Z7nYACmXjG-ODSC7J+Cn;RRjyTXXw{BcZ4G5AQ3-3m*T^=3mW^I6J zYD(VkfA@>7GAvt|&2|cTH$Cfreq@^yUz##m-Vcsgu(A9}g{AqfrNUz9Sl8o^N|8>< zhkVThlAZXNfSJl z;fRf(HSYG$&>u3~-4If8S9JtC=B`=x&e}gDm5lnY_A32w%^<)a(`>80skJ+hWu-W{>kH;#0`%)I!*=;UZ$ zY~wd>LI_|H*k15?#UG(VdBk8{=`PIsb3L3exn-JWrxe5kwG&fKVxQMlF8Tg3(Jk|l zNRns+lPkQrK#Dj|F>DfT2+vv|k`(;@^?R$u!c3B{=(%IUl;}6{(a{YyYW=V9 z-#&vrMj(b$5~m0g;0rZ9XbYem7ML@`!B1t?Ly8Qe+Qo&oyG__G(oAUJ{GH^CjP+mr zbk(}eENDZBt9QJ-)PQMM5@}TX&{@1}D~2pR2(~^kA`sLF->Ued(p)nWKrPx)m*>NX zZX89afomWuQ?RdI0^sgLA+DK-rx^}}EkDJZT<}U`M4~3qY1_OIYoO9jLK!S+gMHO4 zf9sA6<9C0MW7eTDWsr=Gp=+WU_i*PGT!KS%fl)WTw-E|=gq_A&q zCr1$gKjeHVIv!QXE(OSFgPEN|Z)kc(u$rAbZ64gqRo8hWXjPqjR8O;%b6k}Ck;)-! zncjYfRhsu6x5+&*5wM?znEHHt2Ew{hbmXYaN68&`>BN{2&X(j3mp#M~%)2wL&l5TZzs3@9SrP^{1NliS5ifPUkQ=BYp>lg}8w) zmL`9No`&sm3~QYcZx@#Uxt4sX%j%5&dF6k+0|xV`eZ+F^t0aYXL*~XJ$sSVfmaJR$ zwHC}y&GwY%YCW!cEMbi=1Hn6@{=5Mb2fO~V=_m`aH5*Ue_Ghri*xlLPF!HI5c^xXh zklv)Kkx*AQE4yI&B*7^m%o3FEf&)m^`z%R ztgnCmm(&Gr$zbjstVY*pUWs_H-G)^*v4OKWzE*agmSptGZMHvBMos2@!2V-;-QLve zN)*vIS|pg}YAe9~c|tcQu?p?6MfSqEfVukwf_x$(o<=F`yolfs@?5^zFM_*uZ|_73 zx@8X*m=@oLMMJ;dtB)sRR{2N`jJflK?4>cFiWQoI{KeFUX0_)aN|dKZlnCE>(R}vk zoO5aN1qTnkFF}9j!;?>UqSef4qL8%4qk)dCL)Shibh03C`J1b(GJ~7(`Jln4j!L@E z&QJ45-T@Y8k2Q{ymv>SKs}ZOLq@;&?)bzq(LxE6zf|HA6$18Ad-r)rX54c26rn{fm#P)PWQ; z&zqQ$5mQ85`D*UUPocyV@V7C*&I&)N5 zZJ(H;J;J8dKP9_dGDz9!%nU-UwYNtVm=Wkd;x^dg;(E5@$vsNQ2viVdvNUA?IMGl|EDxXaC4m&auCO9mkXO@}M+@RK=Zwu76md$irTCQ<(w z)~5ppf934(VUhOE{Vtm(YufmYTBu!1Z}%1IB4#NV7`yf6ajmQnF+9zISr%U zu923Vyf6q}ko&t>3!*hcne-x~z}g}$vv_ne4Gc{e3IUWv?Y`<+RDcc)(|;6ZV|GvZ zs0VA5><|oHWDA6PL}8U^iTRl!*dhCm1cCEHeq}jOuvgn!wm{tC@kiOZBa`&+&7@$l z?kQDfvW*lg*9B3gx`y?=Il&oaH%52pKv&W`Xnue7(*%11>-F1r9Qph~clJjO2ku<- z6gKJa_x)VyI^)JWN^;+7G4q|Tn$>JS0tmC4s`<&ItlhGNdJejj2r3^9TO!idm~H`uKsdsV-8cj$6TyG zeJ*bIqFth*#=;UV-(Ham96C*HraFs#htI(V)3v$J(mUE1_|$5W`u>t_A@QA7l7N>x z3L$nShT((L&%DMd-}vs1bFP3}?kga&Z;qx~1Jpn5HEh1)ti^YX@TpI^V75BR6lx`i ztUi@b=kc`P>+_@$#r5Umb+VWZv@o$4L4w=w_Wa8iX?(5-PMdOO4{TIB&@Fu@Mr4*? zKs{#;ts(vyz>T!5C80R`=Tk2Rf=-$Xn+3nI%t__)55O8x5gFbgUrcSFA zXHJz->7fJ$gC7cwk!XG4b zg7rH(f(9<}of$w@>Gj2p%^bZIPhDAJE6xGN$Fgn26LyW~eBO+j>XASiOS10u7D}qV zM42r7Sim>alM^))&X(}~g?_Gmee4%}WQTa{B+b?AhdPfXzn1pPq^ZetX4il>Kp|YV zIW6qWqp1OF@-se^u}p}PW7Y?a+Gihp+c}Ijyus{Z(2~_3JBvzB%>ay%CxjI^6R~xo zo7DrdY>S%}1)q2DV3}bhm-@P{<0*#Yv z9pvn0(ke^Ko0@e!u^=Qny7e!AZeo=IU5$>{N7i^cd9_gL@O&dpXPTKgjgR8^$uUtB zM_{2FP(qYy7cz`MbwD1zg^P>YWggrSo@e2NNIN_^4!reMPKjpoyWJ7NWOrPH^Ilxb zqWDZ;5Kw_wM|T{$R|nh+Y~%n&v*IYr>AjWl0WB&oDJsc$%8RBAabA{U#rm3_!gv&E z6?9Ql>06o)sjX?Ei{>R;NK(kN5tbwneVFd9S?hM9A4k&vzu1gD&)1RBWckQ1)R*7o z(kcDlKO^8D=Z`hihrM|PzA|3kLkHXeOYetgWd4_Sqb&rdb9=CyXpjow7O2W${h#K= zGHa=y>+bSvmL9>=z8q@7F*^s`%W1zMW;T%=1Vw;MznVrk4P*S*yz0Z%(sM2HkC^$u zZY(p;Zno=b1PJc1q*cnzqdk(=z)8tg(Y3}+&9KZAZ^ur9D0Iw$WITc%pN=mMDA(XsLD{Y6eG8^p!6;g;(m=T^Z zm@=y3{{_#c?Nt!)0H*bLMlwv9zDBH?&h5DB7Uv(eTMiawk+8|>JA1SF*TztY^i-9A zDlN1=qiM0t8fi}rhK zLw?z%i8e8VLTs^7<1Vn=yXl0XNpRuvg#rK@u(WJWXbZ?s#sJyoqUe-hR>Y4K7*OQ8 z1-WPb3X4q&mRb!)46#)tKyEC}$ai{4$^(j}bm^$(t$pLBL)~DG6;Ec4rogoGVas6U z1dZlkTsj<}@0GhNhUqObW1s2jl{GP8sc}H~@|Ee7e563$)AMe2L9a^hV72n{$6H|j z=c2HUhwzxSP?$1CgD8DL_Q3EAD_V6LCulKc1lNIc95p$IQF_FT2<43yTpZ_KiBozR ziQ44W8I6_rte|aAYzJtTga6oM2lIZ|a0IFs?bT-$-mwkO%Ms%GBu-M4iIbA~jVwBw zAFy*Yh5#l8eIf!HyyXje_s>I-@BJ5k~r!ze~Lt$$?PXF$$snXzDg* zOY}|RIaB^Kk;IppL|M1!LUf-)7+||2Wq5hPeymHZaanr%WK6h^BHFd5a-h@w=2H2A zbwOsLzlo^*6kuE8C;nqkSx2J&zW+e(JQD@4Fesk2m3V+rq#z>`usce$&w{{S#wcS2 zp9YoYx7ig=c6X+Pn5gPqZvf0;@(wbH3*lm62R-Vx3ri|P{-SNlJSi|PgovtF$ znImju2uf2D%8WckX9A=kO(nN+5#IhZPP6}_k-KGF_!(D82AhcJw1__}&0!Ne5|vD9Gh??5P8RqqI%}s? z^r?+JIrT643Qy`Ygu_nx1|u8$^Dw7dtv!J#XP$D#CsBZci=+FP)mX)SKKB z29CNbGpRZJ?Vgf&~($|XfMkkJ`Ul3qeVR#K6I+=*II$Z>bEDrXXbCR)R23jzTM3O}gX1Rr z<3ROW{U4+*J5@sSShoQdn+g}l{8hDDff;hU6B?j;)9wvn!*Z|ey@}#$U%V877e$^38tg3uH&fGw>22$YRnh>bvz zMFTic-3rx9pu*C51ATj-)UOwQZ^(LYE@mBHci?#zxT3O8a;c%ve(Mjc;0{d|7I^v` zVr$-LIPC5c*~f4*(`Jhp1HV~qjpwk&*v%qyo}+T_nijfEKi*yU4EZYHf5ym#L?Qii zvy@a|Vk#&kK!l-N$Z;_v3#6{Pt~Dq>VhUXebz>cjRy67k>ol5SO>7?$e#6!6oU2+r zuLboLC<9yJ2|Luu8LaWDn&-N6&jYV50|gzc9(JR6dnMDI^-uvYjzg^Trn4^R-y6jm zfC&!X3Nv>AO*>DX=mjR))o7?l$ur1charfckvRVhXR5&E}bYRagT)FrW4;7O$7-^8HZtQPM{h-vV>}# z-DfOpEw|O)A~p$ZWX(jvp3>oSsoh zt+c_WVKKSIOmxH6Y1Fog9s}GKCj82}cd;!R1%g_dmrE6JzAPW^9=T=<@75D~G8!~2 zwp@Z|R2Ra^+m;b6?53z>9@e^u+siOBwk*vjfSDGBZI$+caJKPBK}mbl8so(h3mT_e za;{&eMU3%PJ|*FrYr0^W)Z?86ZW{-}RHvbW4UY@<*b(nXiSMI}*O{AYE?jb?O%%LZ zbg|8d8vyb69l3t^21gd8>u0*3tVl!!l|?7tdOEs7TxXXKT<)xofD4`^57nABWES#~ zj}B|pBG9hrnZCD*(>ZAXF`8m;fjywezo;?WD0p{VK+Twu)@^+|5PJ08^h9`Mkh>Hv zX9DpX3Ql=*!0VoUa@roxWthe_BYG>H0en#7n$Pa%96P86$w`gLz~qTc zI+Bd(cBO(QaI1}#6MiC#Wra=-NsFi8caU_OU%Ks70K>pxyLhqJcFp5GYgLF_Xp*f) z&wfvyN@p$Pqgk)#Z#SdCtisUC-h@&ny2&_t8tuM(r;eSNNfgbF`!ayqX8D z+^Wi-qA0{ByL=m|ub|P#p~gOI2u0)UqJlql@&4uqjqrXLOm5b^^+Kh8`?|1!Cc@2C zvt&}sF&000f>f;C9x26mL@mM3hQ}DiaBpMRp0#_UzPkVwSH7v&r_`lcQ%d}=7XT~|7uTou%NcwIGb^c_1Dz2-Nt)$|nPrNj-CSZG!+m-nzh9W1U) zn*q8B#c?t`>?!sD(u`lws2P+`Y1b5!fV(vIhw17p_f2dz|56lRf@t(L47DrJgUh4n zQlUbRsU5W(ZOS3rkhogy>>s3QSu%Mm7Z>XBlp9D2_uuZlq1NDBa;mz<(lVK*+DzuI zx;z)d{{~GCVTNI^dh4m#B|xz8ZgQt)EYXpi*ExQ0B=aeoVtqx4+W5BC#(x=icW7mN z^S91M$PSmA(D@t2g(ynlpdWiM^1FW1c$pp;4anD;+rmhSX zYRTFI_A?q{$_W@2M@1;krtb5+AO9Hg4Q_O)7VJ*CoTz}$?ummftyE@IUWV41+*&=j z9&+iD<{qq+^mzN3G4;m*=FOdWmT6+PllYEDw6ZVea}$kqc2e>_v)6mhePo#g4T7et z&aYSGJ&#uh$2~uHbDYjkbaYM zz1Ffr%uQ9Wk!RUzb(`yuLygd7f>KrWph^{7kdX&?+1M2-K?i4p^a2J4X)q2+L-_=( zQ2*XD?k}5!(QUhnOr@`WC%pXd>$E?O)>Szt+tQeX7OClHj^bH0Jl7GtJIhh?XAh$k z&DWkiy76_i!23t^G18lkToE{a5bo4ephSKs(GDp7pACW=H4xlqr9`v(r6O_M?D8N9&sPI^t94Ldcs%&PdCHSOj>^Eg1<(ym2v6L>P@e7?pS0 z_4gG6_Kzi*TJ_qb8b-R1>0&w$ON{y;BX0PCTn|4eA>EAL#7suk z*A$|@$_Y;AZDDC8o=UaBDW^3z#kbAK8ueb*ko?a67)ly-b`U3(5Q>T^jd=mI4X{g@ z`4jg46G=3`gfsN8Kdou1BV9E5M=icV_-oOE5+De|xohzDdMGUkj5<6Rjo&pmYSeuI zsIWZg?2C0mb>mq!VFwUlU){iafY$1;c(DT3)??2QU(1LF+U3|9D@oICvL~)K|Qdk`9 zEbG~UWjp;Q=RsMu8n4(5kMl6W@3`mqR&)aGyKe2A_;GT{5y3x)tTS?d;UEF{JF|IC zg9o~aXfx0wg~L~|Y{L%ZV~KSG3B9%%^W-{gBQ>6Os!j~1cTnc8HfNK(7lR%8w>CKJ zy95cIJC!X3JL*Bu_HNRt{oL8&RVzXiz&X!5p%1|n3P4i6f>fFS0_Ul*nQ3KXPXZ)@ zWvuH;&FIokL-$h&#A7121TGm3I? zfn@?Bl@^r;Ii|5!br8!KknyR;+i(c8Za7z(!QABD;YGFz&!l7jEj5kSY!2u zz)>K=e&P-3MokvSWh;QYTc9#ErhoUSomfM$o4G2bOI?UQc9Sg+4nopA9^9H4?)U;{ z;@Udq?qtLSde=}N`Jo5oCO6Lu7==x4n^GLIAs&$p@{k8eBe#!b{OYn62U#G&J7PyW z?Qec!R^N*kB`Nld1u*wK%sD7)nV}bJhJ4~|*y6}q(?7>i2Wy>5s{uj&Q9=#t6tR*N z9n`0uz1(Kk($+>6-s(sqY-e+Ejr}kGS$8yc@^$#1`EYQUTzTvxIbbcMZ_%7Vsu}{U zgglKl(Q`N4o|Vf3i&{TNuN7&Y|lxWfud!eAy;PFoA$h3NPWkNFuq4~KQb%vdg z{w*c1%US-ZiC(MqF|Gzi>aKy$+F@X;*e+8aRH8)O@l`7lf((M?*ePvTIvfZ1E z&RU&AciIsv>g?_sp5fxaBil#j^4YUqX#8zy7h(+TEuQakNVy&Te6}dytchOD8(%G( z(_Zyn<~U?Yxg?zQH6lOo#!l9&&dVEri6}XxoHl5E;(E?hNl?TLw}LEP!CGpLfGSMI zU&jKYi(rmyQb5Ld?dC4?sph1W%rGRN^Izts~k3%-%>1D=l9u?ia|uGxv^md>y{9jJ3c~M1L`;fpC*WIj(itN2rAD3zWb{0YoG` zE-Yb#BV2$pxKh%NLN?)D5X`siSB@aA2>%JJ_1-kqXqvbtJ&9yK4OUNsu-hV$p_hj% zP8qI?C}Y=sYC?wFT4WD*r(GBAf1~Y!4Cx7|6w@DJ?e!bx4oa@{WZ2DXE*x2_GnAd* zj8aHnkM_&Rl`^_NeoRR(`=rKer*@E(4Gai&MZKSdxN590hYNN*Exf5F*(HxXBQAtu zTz_G**5ga+)tg@6!~7qeuKO-kOAyD}II%4ocF@P(B~_AZ!~}vAbyWu|!X1AS07W;| z1VW_KY;$yNDR_c)yP#eGXI<=mnpd59+IOR%{n!XachuL}H|$J8UD6q>b4V2el)z>( zkc9@d2%CR}ffFL*IQ*HBr&RrPKgGqmUzj2Wkn5|6O>?pgQF}Ri6(SUB2^;@>9XrUr zc0!paF=ZyUF&%5oSna!rE-(N(7{|@w`j&K}Uxpa%Fi0nA>mr2`btzbmJ129mS6MLK zRO)r&0CCevXap^(Cg)|LXv8dYCa)cRJaB*-@$nE3lcwE~LRjl6uQA>o1cIGLTl>Aq zy>z(_mCvwQ2HA~f3V-n|c14B&M{M&gj2?}ear@)Jgt?}a&UcRAx;l1ezRf1pQJ0YBs0gC9Xn)*D);d)j&v=ex zE&z0^y(qAAQ_m;kuKh>md^L|;VweV)26iTjOROo>SY$;@8mv)7V)1B;?Bt*x2Y<~u zdosyr%dTd9R(iXBQY^ng1_;^X3kbK=F|{Br8>d0hr}yC1NGvzEg6kg?74?Xvm)U9i z+_fIKeXAA^(<^4O{+-1jBOfAh>BNTIL6)?TjRDGy>&oU&6j<;<%d?5|MJOVXHXA;% z8`Pi(p*ufD?2q+Yp zuj{ZoANe-x=7YpKg*J)I+(Ts))d3x6mf`E^ruc*iY#L$elsU5Ik5JkRHyKc_RQu56 zzv`CbpFNMEiw`$*U#te_U#zES`y!(R1ZUx=C-m15Hh2X`7w*aXq4*`VZn11L6~%0# zrAwI@40kv5(Rzr~vqy9Rr+133eA>S;fXqWy0F2>l)q4#&TiVW1+s@zE)coB3{g=fK zPgzg6!Ms?(4^SjzK&M{)pBdO@tcya6;ry$N_qR)%e*XQnT-l`4e1=yj8(iz@pBNahZkTrR`Y+~8rXQ+M* z2pUNaCLiNKZt)>YCDJnfnPm2vGlOv>kmfC^lIgq4EU4Y4Ji8QGZKe+x%$zlB9GUa< zB~sm-6-HQ$<&0S^l%P#HM(S_%M<<;59~1-I zb+MmeAuK;}f1+5MI7i(~n9DeulKyVkDB&R4-x0${#SSNYJmK4oW=jWq|9w^jZQwT?Sw(+{k@#J19 zu?gI-=BJlDiOFmy{-rtI`l%tpP7TVaQXQXS($f>cUC%sIi$P*bC}1HJYAR`y+^R{J zEV#mx11B;#2XbxTo`-dYnv-t-X&>$H$Wjw~B;XWXRgJK6f`hR*gFul9$6m0nTwE)T zc_2$fY@S(4c6wBm43Ubra)?9X98n&)`ns?L68nGCcrrcW+Wc?+KEokVu`vS_`SsOQ zQP^i)i_wDRU|cc&BMgen*X1h$&M|ExF|&G&E;bz`&Uo1v7w=YJxE9 zEV2iKoa+{IvGPBjFzfjKa91L1aKF0U< zy~m-ETLlY<`#FII0PY)Neo=E6J-**6k`$~g!&GXcla*eZ;kf?C-aoPizW8Zl9tfw^ zEk+6Ym@qvD^V1Qly=;vn2vV6Zp;P= zI-}Chz}=26rUU1~BnwzuXhw7R?6#BQPHg-Fah~mQp}>Og^+Sw3v%_E|`D`6H)t9+F z`U6fGjB!fMdk(1qQM-*D{)tN!3xgChcvs^{f>xjKo#S%>>2K8=o^R%WwWk0UaTnSLQY|dG@L8E$k{vlYS<~29 zT!_SZE=XT-Yx5xXpmWSkqzv(Um18a8{i z?A+gt2F%W@xFly4D2fpB0%a3zCXv#w3@G%wDG6HK0n->wP)R2bbtb^70+F10RmJ@( z{#zUHck_sNR11u!z$k(bfx4d$h#nP>buuAwVni$xxM8Fe5g%!Z#3x}>m`BE57i~XB zzz8mJQc^+(^;bq5M*gNy^}!+CxY+fDkO9A-rZydmaAuBL0MVwR516bMf|gzVD%+V3 zbYLAUrq@oku{Ikl#VuQ!aLj=u(1d|Kikub7uL|ul66nfmU_#(}=Mqo(P2u1hgWE5$)x#HnIcmAT7#BB#q*jHXPS3J4xeH!W}Ua@g90Hem`>&W zBCE@uGLh*i(?XMovvvR_=-HuC8rA6hrA+`%p`R#{u;r1uqy>%Bv=c|}@{QN{9-|f8 zL)Q%lgj>G+ZfqfuX_itCOIiBqu^?T>#7%t1hfNUhh)6562${qluEH6m zks!12HW?I+f3VMOf$HS%#JXJ_3CCVM*0@!E_8CTsx4CcMBm5i>2#o>bDC0TVmP+sd zOz`Ur`ViLQFck=N?X4aP*{XTJIyrk7UXT}(CLkZ^jd}&NO%Aj&qy(s7CxQ3pW$j)n zi189BI0x#me~obk+;S$#Eas!8_%+V`$ZGnlx>W zC<#14NpE@~3Cemn*L>NJwQ_T_zD&+XF8b|GJQ?X;H)ZCT-MFiyn_H9_J zV~4%hdIjtFPAyMS!#gaLwZugAH_FD&i;=P#5D|~&1f<42jbYe7%9KLSl?<{)bb+)z z^GP?$DR%~BdQ4L=+?1wy<(uEQ%ps6kkf4Gu#S^3 z{*zRS%G)&Ng$L)B{RvoYx8{~lJRnUGwN_iINVZTw|iHQZ8ccB8VA}#&>dhc!C#E9Q4#zd}Ee7B;GC#FJ8!DB>nkK@4)G=kJ>b9AA@(fSF_Kx z8o5I7xHJ9T42SGZ$N4dNDxjQMxUE<2O zJnqm*R!2xsZ@2&WJB;cP0dNOe<@jw+o&^V%W(nMBC~8EDj+E=Kn|v*>sp1W;V*X|67nf60`oN!Y1ECS0``UE5 zrz13DFAZZoS4Mp*>fLtnq~o{HXj2Xg$rGWH{jSyHo6f35%J-StVH^n7eYd3NuA(Nt zf~#Nu1VP$`ii=Po*#b(CB8<-H+blSGx6H*Wn;!9yY586ae;Xya<#!9TPqcO^1li;^ zIBqxu_)STw_B;$Id}=XF5G$QP2&smz%F2u6pSq-lJdW37DmB;}@52n4<0-0k1EpqS ztdlFRBxH|VRsAwJj|exXPQ!}uT;i)@1RuPq<>VyFyx6))tEq$&cP2`o#SgzC_J$}& z{&owu6DwGoHiS`UZq?inF7BAbdBic=aHc*UaNgR6LgkJ=y|}jRdSc3&4X`1;4!Gp^ z|0)Mh_VEDRIFyzYG%pe9!Si46-h-K0X!XTi@8E;rPFc`c>X~3~Mw0H#2XQD+z!$%P zQI_Mp7ha9zQW2NRklZ7WEs)VV>*8$aMxy1$W$367K*H2Bx$0GFyE<62T{&CK<=sqZ zEm-7*ge3`{Eks=+@su zx=FgHs!uJ4=?Fq4xN9{A^axRAV|=zLv}TJQ;r!E3EX%KY9wH44Pd$v&n$5tP`ST(i zuj`VqhB(7&!c5xnGkEInUG|jrq3DRgtm}tvWaW&DQc}UHN)L|=sf4+P5SXsKA|t0# z;tZv5+T%}V)*P^SfcB^cvW`il76oicQ4Lm5WLOE}Sgl~&Kpa=TRL)XzWFnX~YWW{Y zj6mwSFxDf_sAe3wArH5ffgxzLHc6!_7E7`+ZF@2daloP!S3kxdL~WEZ$MWzBVt~;4 znV3711Qpofu>(WbWu6roiZ(eV`F+&%86l)NCMHp?{R%{LM<8%y?L+(1G1*z_YD=x~ z9+d%nvx6rqS?y2TPgrhUWuEA@|GziTuP z>zF;7@&GD)P=JVSja3!M0e__aYu%b>pzw^8yOf|PA%m-i0Jbw8iyW1s{$*HN)_7AJ zrwv?p_FSlX#c{~xSdY*us=RUd3#*XZ_(>JDI)J(>G_VT{aJk_3Lz(qNTl-Dx(tWY6 zVw*^znU$l|RtE%0twv{_+;j$CAgQ#f4YKOwsfI34{3#YU730jw(I{7P?T{NvF;I2` zQG|o3*G+`{Xx=C(4-tOXC*56Z$07du9n!mWZ>K_q(fcZhEEYM56N}4P)emJRUeFyQ zQrcZ?HNzt&vJ5>lhW1=n+2$EgUt$i)@n2I$nO!yEGhxnS_Sp^;ssa-_y96TLFrV7J z7=+sMOonB12vj-KCBjw*Te+6UZcto0=W{}L82<42flib0C$SqDZ--MTRR1PlSGW;A zmj0q$RTUs#wP1o_@=C=Am*T*QD_6lB2u&jh4}nzD!1CgCfbl)k?=4$fQ>~psxyRAT zV|RO?YQ}RNy9{X}3C@wgK;QGDVwn1TM>&GCm62S%=B=L4IIX)Se&%bl_Xav zdGRU=fZLf;GBnaze*SaLr z%{6`^q&=$qK{ay7{y7~q^~;<^SeH{7oxgJSO_>gVsO{ce?hD3kT~5u}qqs-JD}v?- z5Jjgcl$=b5@%K4G!qP_Dr(r8}|FBiIjlua@CdvFs6L8Z-5LNGM#g7hQ%J^=tM@a4d zN)utu_~?icusF}c0PrD0*B@9C-IQ~J-%>_jb;0gBMa~r$X#P~rd0wxB2Xbp^F&OL| zvqx*??8#^lC4>AMkXWvmYER8@03|@$zt2?^`o7}_L#w4k`R6AXpN1lvM6s?~JKg25twch|2Mz{HX2r_pZc%FD z^l#PiJR}dZw?y2Q1aLaoYdOeLHNQw|yl0v2!#6`)yhfq@?Toq&BN9^$broelEr?7q zyjDx05H=29E}y(O{)dxB@Q5Uw1Ot4bA2&!5F8m3AeEQ4>b>`m3t|`hE6DQy_6p##h zs!zT(3w3W%N!R|qAG(Cq^TdMtQ!}D5n>V)K3 z0BTP(+V_@U)AazD>kbgc&$S#0MY=OgP@Lk2OJSqN^n7CkdUtNPCW~`1@z$a`)~&YT zblfAoiU(oNKyJ4-@{IFsBJ-vR4Kz`~sOxw0AdtUUakf4MQYlZK42)NSK2Lz)v~O*K zCLwVU)V&hrk#AS%A;ZYZ?OF|$Qg|-u^pPp^!WkGVG)=7_mIm?ecLc#)e`DRu^{21Q z)8i~zZOB5Sw39C4zJ7*9zATB-(o4f(vgJ{mj1UXx@qk>%;bjb$%oQ^#f4ls}>XoU( z3k@Sj1)^k{4|nYv!6@a>VT10h#EezRb)t5G$|!21QY?ka1|7FQDkxX8P#s;avLETk zH6fEbe@{lSH)z#UstYk&b9|xGgjss2OA*OLvwStnsX4TPnY%9MuZ`F&w)i3s@@PZw z80S5K@tIxK8=wyqj4#vf&Jubvg4DwQ#eQs2f}?Sg#O8J{nm<)JjzGn1@znwF-(3B> zFq2@OXG45N?5n9X@4{9Qi>E?ON<=|P5@cB1R8Tu@5#YeqvSsQ$-_H(|{`Mv9o zXsYGA_=~du@Vwx#+@e+TeAEb+Qvol@BN27V%O}kk_CJD<-ebF1!doUN$t6hKLX3*Z zNNL+9M7Fjz`dcxmXOm)VfCeB}p+!H-bK4RXHTayRTtr+A*DEqTj$MQK$Q!?{DXYeW z@t+nLnz07i4(DSU9(t|p8`r|=-A>hRGt2oM3BY?Rgv>>zkvmoq-Xh$e1HC7?fJB-2 zp^5JLii(NYfjt3$=|H1mNq5VVGhb_rx*W>SY;!4!^0x?SC6%!7Su2Z=9utZn4JVz}I#~wC2F=oB;R}&mg>Xo&qctj5w;jou6 zwQ2A`c%?mfsoFK^d~tqtQp1^?3U!CP!-Kbo1`ZVHbMaoMm-CN0`EK`Fzcde>SR{(p zXBCUAW?b4ooJ{SjrdlN2-fm7JXeu#+I)PC!A?Ca}Cj@ zsgNjQ1((!{D%R4BR=xw z`w!Qz3w z{PD(Oz?%2bHOdW^RpFJa9iWyh)c4nQC4?xc$H=noU*l&wg3=!^mNh0$Wmwgxg5{dXahZhHH`0s=Q zK0M6QEa2&~(h*ukqIWVy2x^-!&iB>Sqz$U0P;!a)yM8pfk4o?Edg|B4O*iNfVb@f((OqrorY4FT}K} znl$e_bPQqJS@;{5RN;N26hLM0p|pZ3VHWbf@aqD;!b<(=Jb6{O_EotRm7*yOuI${U zZ9N829d!A7i~y$+#;OXNPKlf(5^MbtSmCdp>-_MQnI?V#U1lFLC{!zzrGx$_53R}w51l|&UbAA+g z`*85jYK2+(6uQ@>`lHgVU4(zS{XZsN~ko5u>*Q58zG6@M6U(gBU?7m`Q82j9xUB}{aGcdylmH|iFlQ?v78bD9Dh8U#`^0>LvYvBH z${raNe{u z7|G2^R8+>b+eiHn2JOd!i~Xe_q-!&9LF4TM1eOyuusbC?qa}R@t!ygiA*e?(u)`(E zNo}k7qG%mTY{N2vbNr(C4s6 zli6}}s`+e~^`|iZm6IDIP3UKe4S8tyh+|N*vMTC+YUY94ojAK^2(e-~CqPvK#V2^z zYDKA#o!u#7PorwtN28A0add%R{bWP4mk6crF6`K&GI`@h`>0j!m9i9zxnvQnnsgH9 z1L8)vW~e;Kj}Jl1%SOiQ`&qc)-eh07V=FqMqbvDP+q119Mei6GQ{GJ;zev=rN_T7- z)oXV`f0vMrCJ%(!scH=I^?~RCrjZGk-4bq$!tfzp?DA)!IF*U>z3WgCrxJA878iP>D(UFpUxSTH@%vK#p-MzDEh&mFQ8@F7ag z^9gH!K-nGH&oz+Oz^$cQPwPi)7eRIN7oXC96k}kU0~J|Gid*kL-laO@o~tZ|KmcEQ z_#H?2RJgE7ojDje*Nr)>VW}IJ{a+UB>6YCPU|nx^=ypmTl4x#VG};e%mD*o!V_G-= zhxe54do&j}eV;X@m@vkv^eWKoM;>qNHa26yrSQ$%`2822K z3!5lLqhs8fmacxU3Th>F=W7rz#a{{_Xb(9kCWuUs=jwt-w`?mMDW{#Bzx=1*VJosI zPdVP9l-NrY!PWVweSNsHw!t93V8arkZ|~ZGJMQed6$fQvgT3xC+lfP1;Y$%+SFLGTch?#v=Q6`$kD{ zx1E`#3TLDSn|R_Q0THQ@eCF&CV+xhwmo9hC<9UVvWyg}sAQISy2d)@@@Jn7&!t76Q z|L>i3W1-QSyjJKi$!}()`Fm`wHp*?p7nRKGy3S>n|11Cvb@l>mE}BgWe{zWc8kD+J zng2viCGC2d2alA$5B~=OT`e#0CGEFM=^94J6DUef5c=OobE%D{jWlZ)JH-kdpWkqc zhEFZ#iGC{D*Ed4Uy5!51s#+?oLxk{|S$_y*vd@l@@EojW2ASjk$$xCUn=JrcE~|Xc z9mP!C4%c+B4XNjO5YZZnjA9vR`-4dt$_Qere}p-ptfugWaO&%6Je!3b_y#P6Gh(!y zhf8g5EAma+)!s=+cW8dPhWAg1IOD9-=&3ypbVORd5LCEIiF{_=Vy>s=7%+;5oYczE z9M3u2xOUS*C<;jYwUXk573(~?&F>y*MsFO}QslgRTJ|VKqmV5e1t=x(6M7R}l{8<> z>bJ7FBW_FzypzwoKecZw#qR#jf?WEHxR|{eo5xn`EHE&CxByz+YT&67M`cl7>)noU zoIzQqJ7N(fY=Z0^qY#tcf%QYsB`kz>;PSJ%rt=E` zu?eF0uGAwbN>WAwT64w88V5${Qt$z$JgdGoyzgeHj)nZK-i|62d zSCK2}f%rkp3)uqWwK1WZDRBgCz9S{`1RAC*_R{Q6Tm1pe&h`mmPvFfah>+%|eY16# zBCM$CQvvvo$`fL|?t&-tv&WoAQQ*NH)GO39jR?MdDnlbk#Dtt7FE+b(mY0E2g z=!(Dm*a*Y;7iD8Kbg%nJD7=GMPWk&5Z!m{;8fADpLunz-17K*Mv!$bf$9P&9 z7rI3nr&%E{E(5Qrvu&9l>}ddGVQw~Aw*^-bJ+5EM07XI7*yWv2L6G@7`Wmfzg;Ms*TuT_=RMstZ38pLy4%CX6TVTBA|BjV(vu_-vW2SM8)6cd5q58CQKL zk;ELY7+(leiz}EVU6L35ZIT3#hhy&&1mi|W8kumLqT^PgYBVZ9lrI`fMfL$y8NYgy zZLBrWlu^D8c0obGZ@R(VEEIfoV~Z1%TH<=N)^O+i%Oi>3QT=joQ%%emWxE!!tA-fp{joMJx4Iu-(*w@v{ zgOX#>bO1Vt>Dt9!xZ^FnFVJ~83TAGD1BMx^n?CV63J<$K*$5d*pou7V&UZwF!wPk` z^O=M0ub5nkT~MPN=o)g@G)l%USUy zDLraPBMD=mG9d*52O~`54e>%kC@ibWWl{Y)a4KNO6kzpu;0{kI7`4p)u!AmV&F_#U ziUoR$)~bEAh?MTo+9(-r6!#;viXE}~)o{V8m*r;nFtydiTnqs>EHK5ic!Vq?B6P?m4|TY*~rxcdOj#cl1m7^tkO$i_^uD}jYsyI!1lh2Y}a<1*z1!y zINud#N4K!N-!rTpPE`x)@7exZe?6VZk@)E+!#m^RaoDvkc54dPW@DZ>3+(Pl_ofh^ zoC)vVee_PpLyt4oq=$j{UBbEP1!*rI2e?DoJrk8m2G)I|@W+K&hTdX(kA)}tX#Hr4 zLemLjqt&(qLWzcTLP?`X9Za3>eh}U1z*zmN-Nso3iUXVbYA@lAk#cV8g5XxG=6AhB zBI)z~m-QlgN__V&J-hbrl-n5e<&B`2ECn?Mb=FHaIzlD@`o1*n zIN&&g7>t18-Lm5F;#y+7Iw=|%TccE0S806`MQMH_Z<}+fv4cQ(NiWS$4rovs{UCGJ zN2TD+NtTZ{X>xt=mC~66Ml0OTrC&V=fJxwd`4Bzsads`3?A(v+ec8SeCJm}#!NkR| zg0@;dTuG)+v}QemqHgFy+V{-c8e!o_H*rWD&0?2tVQeya$_;oIpMRdWG+LOgv}Sb2 zO`o{hmW2%1irv)?z}0*y3Y&fCh;L!Hl!E`%o-jV@oiav@kMhhxlX}x1{tT%!Hs+=i zQx*#ov5HmRhH_AdLaVo-<`6MwxN{*Y`|w^NVHE3W$(ehZ5mh}2OnJ>qP?-^Xrf`BkyM381}D`wZCWuQ4M5{!X1wr0Uh4)5m~__*F9135nJ#k zd><1pcjo=eWyv(w8sv&-!Ggk<4@*C(EReDcJIL4_6y_w^PQK zAfwoFK6U&A)q-#<#e{{7S!b0yg;+R58HeK->YHW^QFyLXN$f3#J!$_zb72dzI;(hx zU(ykgtv5KtTQsA&%!wiK&!W5IQ7JRNoj}B2Eutm(YC&3;_M@cT{c;-PO~G?l9w4<~ zhf`!P9@WZ{c+CbMfI7-*uN20fHsTbgx@3z=Pgk+a&NKu=9yos0Q+}rcA7$Yp|Is8$ z@}CTdP?m*o8=gLirbVOtYb&r3S^CYB-Y1y)XEFf1(;e`mTDb*y^5GQWR609U6^dwV zE#59CClR3uS+Nd3UqBDpuFnFLv)Z)4M5pd8aC8B-4F=wp3+?7DS6&r35^t65*z5zE z%|lSPd^r}8X&D0=S<5b=M9noT<6^zDvB(1%RVVvG6C?1XcMhjHWWRbqLT^VqnCAs8!o0HRm{oNQYonb56^CB|Zl>mk`m*NdqbX0v#G({0!c4uSosc}=QYk^j z?7}RcOsTdZ>52j>SSF0JsXvC*1&i|BO0R07t?UF>h}4QMANJilTf})}&g8edXL28J zR6u4LKc5L6Ca{Ld`1b*k?lHRoomZADFu%_|vbq~lPg>B;+R@!`d`OtAGWASS-dKwO zx+2N7;}svO`ET{m-`iR^)IbXET&Hd5j|v48I=|<8&JAw9v4eCYAk?YsZLR zltuIl1mK%G(dSTk;@YHN59?{9S`7F~<0bdL@Y_{%O{@Ezr)CQL{V((u_o?!a_~P(;bGasQ_u# zg-J?B4WAXbxHmzHPu{v&Dj3#mddc%HamWClSNpx=k#&VnA-2II`tcbNBmpY_KdbT4 z-0y0)|1fSkau$(tBY9ZtL$~1;tYecllFFg{+)4c^w+FJ-@y#2%>eVN@ zSk{|?ljQ3pgg4YP;>pe2_0lFdNejGZ<2ZuI0zj#4ip)^XM_ zMm$0>s~T(%NjjP3NzL`w_Ok$a>`Ig4u#_dH{JCdtkxPJ~Pno}>M-fJwTD(n(z`*tk z@_nc7W!{FeA-`nO(3_fmw>Np=IsL&!K&F}*=~wyRvXUOwb=qL%A^<}{P@dA-muo;y zLYEWyN-bG7H{`?~n9#i$TahH^ibbe=h>tHhL>JRf7U!<8o z`EO%V#g>O9rYU*f>)AiCl=}u5xs?2Ii)@6U3Yk@Ml?_M=IFytKt>0&hyu9mo8hU}h z5fn6@+d-2FqU5asSxt;s)YPqLfVbu^;U(jMUJFXFpk*BL>ZXQ_rrf;ymmOm;D6;Wf z4z!2jY-Q9mx|`l5_-#OM zeLN9`mXhLoWb))`8Vov>1Qy3)JEJw0n!7KQ;gQ51M2vD~z1bTySq)qLPsgwFSlU5x z9zw7+l3iv2hESqrEkx?Hk%u}VYmd4EC)lSQDaCEw`i>EcC%GqW?F?jV#8uTQhXs&IL^FlU`gkh#*{=)n zlQ_p<9e5R@Q(3|m+vOTUX19!RKng8U!Fx#O!{Szq+S3vwVe+!usoG-?%;Sz0w zGY4(*Ny>j3`e`;y=X~|3tUkWDCmfsVj|5r$E?Y62mpWV-cJm6_%7lw}xJON#@aA@! zZ>2aTh+)oZ4cirCvGoiBk#;Dbk44l$J=%gpOKCrf&@<8aMHp8H$QY*ICIYozkN+8U zVvEJeiJ>U(c%4Q4%CpV|pfG5ZQu~5z{{Q33tEkv2>mpmOe}nAr>u@$w22iEx&^3tQ z^}yr*eyy_Pp%|2vs~uuYkaZbP7w>!L;3**V7#e3GI@valF?a0GX5Gh~lHV-j&Rr02 zHBY-cE+>w~mPcyvKrL?NPPv3b0!Ul+{!rJ)mdEMcQ%?UuK$LisI-A}dn=2Lut47c*iuM^=wh=9cMLvC|8@J^DgM;%9WSOE79SXnHxole=sS&A?6<Ne$T1~;@h}_93jS(OFo9NnxwT64@+!E6 zBYW?KDq5y}Jq))|qx$;@MfVq6llPCvhRpNKfA4F+K29G*e*mu^#bt zWY!j-_Hdb;X0zX_Ule}`jQ0J#I(vzR&$%zH4|c;FOn0|UWN8Jb78#suB$5--d7u;=CO8#GPm=+K{ywK~G0R>Ki zZK#ou(mPLe`3v~lIE*;mjH^)4@e=};K&UvB^$g8R7FoWEbpxIgh~E;YU*2u2G|=sm zvBgGJ&rcMU!nmJ{l@_3}e6I!xb`}uO`jcu=k%p^2ZdqtgTc{D^iwR=QENcX@bRFAN6Y@{p+nxR;qab= zf}|uJRg)jBH<>hr-Y1$hDAc@vUG{4pP+|tku_@al1b#PUJ$r;0_;KH!Sy^JvZLJHn z5Qo_I!GeVyG~a>bRJ!=*n`S-HRa0Zj0qqr52PI@+6UGx$W80Ft0vc;{;>H~iglE3v zX3v^$k<|;OiR@51hF&+<9s`L{pOuZ=zoO+@uzeYt6 z8Cb|7(zFL5jpy%HxIQ8?>UM?betZ7oL}UJ%01U6rk71$wDfA+3v*QgtQkx?bP zpGH(}5B%sTRKcGXMOuWxb1OYMvu!Z@tNl`4U)s@>l9L}8X@8l!p-UzUV#EhpN_izj zq@S2us&t1wyr~<0(SG7ttYjFx?we^>NIdmk;zY$ptfe3Bqi5I+v`FCfOxS{NQ9$46 zt5x+<&^$z z*=jlqh|_~6+4O<(sdU@>tfs#DIU`Ogg%yWctl7DEXdJ!^zpwu`tYoO`-j)5L!yxp3bB83ZMgwBqVx%q)E)*j;Y+O^@Ayw85==sl-*vC@Q>~0; zcy_a030B)z%oK)uDFQkm)(!IY9HW#V;%iVLGLMJ5r|~IeM7pF^ay`Wvb_Z+UuS#G-=gPU1RRP0p(e)}R<_9>IA@AeWviFRaX~ z-+axb(oE%cfWPu52+k=C6r6O~xW^f!a(AVgbFO}E#Vc(r^gBh!Cd%)~WAkpUM7P?n ztemb8EPC^^x;KM(h>PTw8apkQ2TDn=zZi=@6!n4*meanr0c!K$Q@7l9ue>9uT%E~4 z;(EKUXhspA6Qki#-#ex7FO(wXmD`H3E5w!_uzNUTqZ6Od z-KCrOq$|LMJ7W%*zdztFv!3?K;`9QPTIlGZuYZWO!y%}gxQ>-?;Hjuku~}f5QFkWD z+`XGrNBZb54oRfy-%CMsrc^LvxzZH9v#XP#YKG>VYakzE3iG-{;-!>sCKD=A;lSPG zbcpo%@HfXB)rt0vxSvfd>20Uod!1hK6Iwqd%>Hw*rYpE1ys*fuAvH=oPHyLlGQUr1 z(9GO-HU0#?UK5G4AxUQ7T}@ICRFIE!lzJ90&3neZ45xz)~=scEcr6` zbbHp|;3ss_qFKNhn_D{7{j!*|NfjIZUeWWX@>{_wswtO(pK4=8dysGsz zGC}LiT6L$rA@S4prCZ^-5U%wk7zRQAakN=yA9>T!PNer8>tfCsud5aN_k4uPVuje| zVAAd7{YfB?&M*!d2!duptYX80TA<)mckpn2%Fb-@KD0oi#lE`>Qi-9x4dO+8s4qZm zU`CEKk~v=ob!S~{CDz_+etoCum7e0c{7UJ*9+Uji1ZbvkJ)c7)Z+r@Px#M+wCN)y9 zDDh8+iY1>r^hK?0mos

    dL30u_S6IOE5~yh8eiN4B0FBs-@PNK=9dDDtg71gdtk z_Hj5e>TtvtfxT*VVoZBe$F!4Zu{8D&wUAiXZmF*3a%d@!48ZXb& z8Cr7085{$Xatac(o-%op^!~H!h>O3w14uiMklJD=T}MgU7h58iMC_ zH%9?o+}*IFpvyhgNj;Rxh;j(pi~0164|YLJh}waS%LFO3C-0=l%ID-*um&P(N0wSw z27v5uZ8gTh#{DYX1NxicIn(C^-sYr~s@EeK*^)LGc;tm!wA)8dD^-62uz&R&MDBJ^bQ!Zr+S_381=|1~%UAI+XQ3lqo1zn=w)<5i_ z%QV#tNGNkBxMUaRpEJxFybRx%5)6%q>iSw0D3480#rHWPu{1#46$aD^wklWRk?BB2 zAu)_YRw{SgJvr%TV2*q-yd_HTAs@0&Wa6ZRdLq#$1!vhO*CCvpn8w(FV&`@`#A&l^ z9eX1Pz7b5NX*xqe6xWm~#`$lrEdekWgBWk^Z&YEN>q_0dk!E_LHr-e04izSV7=cxC z?kUVK@-3IAp9b(gVOFTlPr%H1`FB`7;XB7eAng_o-8XkBdhiWz=*5?zTq{Z|4HO`& zp4F=XY=8}3L~SLw6J}}|0sT1tA?#BLQN{Ap(zrTWak1gJ9T#PfHDU8Q;08FX&lFMm z3ZDp`voN}Pcm(l;mloT0@agS}8kyfutE}6=ZqDH(y8cZsq%|3_vR6Z*_M0#QFy>OV{LL=OrN^f8zqUjznZvWLKC2an4+j3c&0;&L} zIzXQ+&1z^YcU^SY>7ARB2=aA{g_9fUv&}1<`kswrQV5;$BAT; zHIdL;TSJ{7DUrnk2|JNf*;*h5Pscr|jqWDm7NKNu{Fue30*^Z1s2mUCFpiweERp6@e}V?KW#KuF7c3hF0zn1Zz1}w;OrDcxj2e&cKwk~M zfwq9(Hhh|ryc!Q&K~na5i1nMW$`JW!-~iq4Gml)Il6OiK^b{?Yw|pJgk=&qq%=;`{ zkbS#B7O$BSFtkj=AmYszqC_(kN>rDHhYT)phomzcT@pz+@R}rDOe66?D!RYhZREr6 zRi7q1_j?#KNn=l@6B9%LyC^rPESQ8a6X*Xy==?~O$3svwOk0zda$ET$69kYY^9}?$ zTt`!ClF;DYxi#tzGtdGDVG)!#o_~6s5Oght!fd`t!-$3*ecQ|DJ49%M_`u5GrQ z6uZF$B2YL_4!L{c>A}U`2W(o)sEw7mT`xa?bd*l#r<*ku4*nf0at8Yn{_glTQcZjd zg{r7aWk2L>BO*_*`K{G~8|Z?Lu(h4czToqJi4E5q{;I-*YMvZs~{o__G*Juiz*LvxMb+<(GnHINsd()e_4oe`{fto<;NDX zTk;n(ROQxDqGjDr4z1&D1D4R5F01h+6VrFn5!KheLj1ykB41W}}`n1f`Ycy`C{UkdWw+F_<%P;uY z@+Xx1=2X9|*x~&YNf(E-ZY*)x=zO;hEL#rk1Y`<;ZNaw!pvHz4Qy^|<2L<=>!RH)( zjumdHgVxMB?<2Nwg zBUJKhkF*k$?RJ2DO{RD)wn2jc;(<()#YMS4Xhpynw~VzT)8b7bi{QP9j5wr`fl(qy zWbV(4gF&KoAf74GJs3zut3^SvTDU^(^4AY)wvVvvFC=xYws$168%6lmE5MDa)It#cqO?Asl- zBev^fD2HK%iG}?93oP_c0oI0F#jD$M?HA2O6<))Ez@#%fdNq_m)CGUQkngsCv8OuQeY(aK9tr3I9$i+E4 z*i|*y7O9jRlUJ(TV)RGU`l}zr5TPF18^xDgFp=CO#PGLU7;TU9vB>(5qXU}~!d~9a zhM~K*ye`Sqk4-tF1E9%5Zpxa*U}2#kEwK8iufItC_`Wth?2ITjn!=IVf5fzaWXZ7H zWEw>k;Nj;5=YZSFq;oljdW!&^h|{c*%ZO^zFtr)Cn-N2r$4nZ4&i8uRv_=(x@AV5Y z+{+&2L2Ql<)A63ZzRxnYC~QBCeG4Ac*l8^vGy5ibdaPA*hfcFG$1!;?sy>P|3}|W% zu~H@!3Hitzd$il4|1AL9qxBSf0(H7gwWU3k{_o@xDEx_xT`c1>6VEIQf-D*3xYx!l z4d=oyr96KqO;{QQ!T>oPY`as z{E;yNU&F=0*Zkk0kjlaJ9Bm1!UCcAylj`!WCe$HA1CcMwOr-gini4JJSCPq8;SQs{ zL0BOMWz;src`WVnp)>6DDpdICXF^%-k|jFYyTrq9$<-|xJi*pGB*%mppv-Y}`&`6{ZUcoVQ_K*fS2Pr^si zlpVXF4WZ-+wL)#S>EcdQ1ZrSdzaNn*s(xK$AiYr)5nv8DA7-$>JVB``g=T8mD&wrb zzOhmrRsAFm>AAB&aFAR?=jIem`@=GFC!OUhh-MupNo`7B zPnp`W7J!*0KA(9a%8DA3g>QZ$-157pTz2Jn7|5A2p6x}2UJ)|cT^C8S`-I!{m^k4~ z@_VCZRy|H5{?d^VB?;T>nn0K<_uNWpDOwOGfAwZB zW91@T5%{QoVPlb#1YuR%)C#%p4m&{C8zvWiHfac$jf+RUZ5XRw(2pQr{d%{y5t$mQ zt~ad|s(#jjfV;>2= zc_A!`*N+DLeMm)Jkv=DkG#O~oTZMrW5)pt6re8WF7W1?Ltb(GwPqU%vBPO5P_vJd; z)?+YaxEO3v@A&GbpD$UufTW{gRrUR!>= zMG$SIo`pbAW@|cve6o<|`TMGJxS^Qd`ulTGwIU80dti?>Lt&d`$6eCQ^v^js+-n&M zvJ$@MON|n^X_0=KQ*Yxfz@6yAa-}_)xT6_&M4B$>LFt1iH=!k?aG&sl6`kmYudZQ< z1xH?S#kp-squdE%dwP)n2^oJ4VHSl}xIuJ`q9_OatknDB`(hGLmH-I8BB3coZ%WL< zaknL`fyb^rlWbPy`n^t7XqapcjBBhFs*Q@%7@XR2!g1r~v-3LDXOv`np=O2fUV4-U zqKi#|#D*3R9^Z!g-Vl$i%o~P73=0@)heO7cZ&pG&;Uny&9pDI?^OTjDca*`a-I-wO zZ?}_$^S+Ml^4%1gjv}&t7ysxU+H4*(!9ptoP|33byzL0Y2G%=&FPDEN``p+F3fG2g zc@jKZn~l>{mJwpL++jf42FFzU&ul_IK-Q;R!UT6IeU*~0PP~AV%)*Lc; zIIqlF7Djqs{qCY!T0+KA{xqu+kw_f-Lp4UnqK-6nEW4d(ZyyrBnJYF$h}ffY3K7fY zJ5{Qz2m8`KiL7I3emfEAtdFeHi;ORxHE6JegTWhHObP57fk2pl#!0f$y&sseBg%tOrxmJfb#My`NI zH`td0?hY>GPnV1~f_>d%8sQ%4^~6_MSYZ)GoZ}W`4vNskljtbNReefP!Ww&2T}AHi zr(0Xv^im=VA6tpm{jG)G)^g0JAQbf4hkWq^iqw_RQ1?0Vh z@=N4gStdM-7z;~^nX--nwYwif4iifE5{dJxTb7#+AE#(P8W)VJrsR8XCbwa2(HF6c zw2w`ggYor*w3bI);ls%U$XRgw3rDcX>`Oe(k`c2KtHMs1JvD?5H!}Y_#LZ^@faj`b zC9BeEbHGp){;a5ke-5dWy<(h&N*eJ$I0UT}rXtlvFJ`;%w3eJ-3O>kIeNJrKL^I~f zrTD+#eCMY?{=rn205ET3jL#ocd$ic{mLiQb)CFxnrU0E&UDjZ?_Z{)|YDRxrV*USn z-MM{U_chRf)^r}mB#-o-@J?xlsMmnbS^{(lyy;L&l1dYyn${a8~* zg^p0+#9A3gSgN7TFG&C95~UF-cYJJ;`v~ycn05<@bCoRLctAHq2I{HCLmCn8;i?ZH zJj|+0BQMbQ#7PAnRvCWWMCNu2CUI~54eAZ2)Bh1~3M^fd(Zg>dBXtK z%8D>`$+g<+7u^vgTu5`z`H5qN0a+7S0X%GL{P=5o_~ zLIl&Hoy(AD4)QB6U3%TvUdOgGt{HHSDR9z@v#u5 zgJfPnm;}fp5(){>Ua8!Ag<`( z7Gj6YY3z@PDTm%i5o=0eftC>vPKlm(An-gHLMGTR$=#Kkk=3|py7^A#`OTXdI`!>Y z8$7=y9E(Q5B~do3Q_lJu^vz9{iX$cfs%wD&-=IHo0O^618<00#GM8M)iAZasbwFXZ zYE`PD;cttE2A#F8NboE{HIu#yNgc??W;vj9dt#ZL{P+Bc>6;kWoMDdacX}w?=4Blk z8S6bT1%AbsXC{`}>WPJ)T}`xjO$0w?z$3<-&y5`T?UD#L(S zSV@XwSsL&&CYPYi^kPqD3!M4CUNH8VLNc?4RgT@s&>cUv6m=OH5lN&#$~+y{cQGf4%{AP;9TzaK zT8sZLm!`0g{5?8iG?yDBx6W|b0o~lQMoO3Uc~|X zP)+!uniu%{OVQnir8gXJmN_*6GIRMsFSr!_`AXBJ>hxqhS8_j&1}0i5<@f8W&;Ibg z|A>_II_jo3`4h?4@(Sj%!1Ij)<7m)f>S_hgMS9uSxF*3EhZt z(WU!B(pUYKAPHi0WtFme{Q{`58E7C9T8!~ldYWgJdXlhw`y5`c9`~Q}Hl4*zu%G6$ z!We^r50NxvIhvS~O?ee<=jlQy(1U>zBB#cTVUC4h-Fv(XIFrj%cTV7Tm(sw5OdqmZ z{q*%WubFhVIAa0w&8Uh!2x55g5W#2>5hsH1S+(;t$BuL&{rRD=9VE!l329m zE+&#wCNHJ|3^4fQ1LJ-K3L!Xi;4?_~!_blJd5N*f&@jRep--%D6Fpks@QXaG8;8vG zjPkF1!f3dNZsFuLA62ApnZZVx6np0$ z`km1);MN{=HZ5`xa8vRYJfL;!G@=E{q#>W&MxqgQN72ouDtw^XBi?2a!N&Dz#B!AXew7*pI`+w!hIS z8VA=b=BO1-YXu3y#L;K(VxJD{8`Yk4#Uz5SN_jK57bNL)cpHReX9-BGhNi{xh&RGY z5h%x5O`C)dC2jw-69`DeNF&hCJ1VG9gIw)*LR$VRM-<@S7Fk1!UF$kqtuftD<#Mi^ z!of+rPZ=<1!ut62+Xn=+l1D4kN0*!ys}40F^)BmQ4iEIKl4ONQRn?$BTjQU4<4%`K zN`ce_U**uTB$ryfH__^s)zyIHa3LGFC(WIOt4`FsHnp5WJXZM-Ovvw0PuEf)^%a}f zLa8NtVeS~92o=!Jms;Xa_a|BgWNxdSUfQ$#DB8ize6%m1<8%g0(2zd)ruzpn7dAP^ z8DsQdIJ}$H?JfQy%P#FNk*!Y1K?^0!+jx>4{?8V+%tw47E`;)-Y&fDMROwp86THyB zVQfILP<-ZgHz|6KQRDfhwY>ik=d5wdA1Ox)kSTP&yTeHfAfS{o-Y#x<5oY$m8ty-x z{+Du=QU`?CZNOEmAV_$aiKWgF)0?YLFCgVlcGCg*vc4);0zfs|RS?T}2{h zjo(C4-QFD{^xNvLGJhSj8j_634PP9Dso;pEmRQHDnl{ar_JZbUMf;|?qG%Ttn?`gl zj0Y8Y`w=vAPDtL2hA6P4 zJ&VM7JUPUG`4SH&os;`!KWNsXi4r@@z!p6`?G&S9nCr;!9S7GzK3zrYvD4_=lgMLDFZ$`L!uXpmST zaop|`V^XR=SnIVb1pTuxTb|O?nlw=Nq*V8d*AX;u*j>v)o_2bc?wc8>l-divFt5K! z21tMVm8opn&)(Ym*1KnqrS^%_Y5C+-3D%L@jX&+iSSnja#erS<-N;3^z0*D|Tb`c7 z3(?SLBuN=S#$&=-Q{=3v{%R2jJdazc`kKFgu&Y^WHaXh)CFDRWK=3|<^Q-xsl1HR8 zZUL$>O~{R;-TJqc0^ra)EZ>l7ubQWgC{v`&OelaQ0Zcy4(!$Sl>QLinDhM-!4 z*Nt)sNirr;zL9F2yPRKW2QA|9wW7KX=0W_TY{wXqzR}% z_1~P0V@!l@@lt5k$ht#^QLe&r!ZULai{*#Q^{#(9!&VDwsHjTxt$PS0-3)Vo$M214vRX#R#`@aejF;xA(ZI{? z{eLMkQ%Pl*n8FWlG%h=x4WjT#3Y>{0tIdtQ-$*0+&n2PzgwN(U>}N-LMZ!xYo9sMj z6{qeO@r*0egu;W^8X8p*iwzm*MOOjn09SYmhcZG>4M7yhZ4kaXJQ~!F2tL72HB#UG ztVFOOIt{-3x}T(*?!*+5!F#v?+lXhZ&N(XKNOiz=qHr36bsa5Z09}Tn&c=GtzFTtN z1q^9Zaa|Fxxotun=#ojkKc(~l`Wh6=0%RHD=yP#>o-@@q=@udty@;En3=JcR`f`4R zYPut5KCjelbrTn2#$deZ{MxNB?VS@z#Kx0!(eDK7Im!C&geMZ9XZ%S*Dc-K2u96jg zUw)2#J1+7Nq=fRTq&cvDT(0S?VDmrqB9tT^vke=b*;VlT0csyz9HzOe*Ji)0b3I%(;Y7QG~#z0qC zAa){rGS7!xWljKbs%D&V-uMW@Xh( z8m2dGvb^fNUKu{bv!i0ruSyFm>?ts_bLq605ucr|w#E>y1vkqtS^H)gm`Bq5b)EMg zhir3`aBdN&ib>4rn#}?E#j!7w2$EVwPc%SKz1!sYeLUMU+`;t}vRrL^M5R8}ZC0jg zP$E=c4>UX)UH_+x!U4fQGPN4hz_c3lf?D|G5O5{BZk1<-zd-6o`73Sp5de2Gz_>n% zHM!?(H$^al(!a5Yr}qWM=ucjgGiZr$hyowm1zH2667Qkopfg18_t<0+Qu z!bbU@_M6D$Bqw7*@}CQ&DK0hF_ITTG_uR{r1oL3}SF2ZHhOQt5JT^>JuUv^=rGQ(K z%+wZbqip+MGO^2j;?=XAQ`hcRcZH3#b`Kl0K3Kp)jFe%z0H{#~KYyVX6ZLz%qZ;Ay zXhUzrt2e;60%FAcX;uWI?c~;;V0fE3i$bX!vmI6zm8+YF z$(#)rO$;aoNjrW!ttz5-NkQ|=YRnc#QwXFG-Vq7|w+aqTz##>r^F0O6S6Bvwj!b`` za#;y`KXQW_@;$ zZ6Z7OYSS5+vz7ni3UXb&*C*-dJ%G47QD-mQFzzhRw_Zz)b>3t+7qO;F3eTefZ`@Zc z!kDu6CdC(N41dhew%}WblFzVL5gS6}IF#iwApj;7G2yrWt})f0(ab1~f|XR-gD1He4S*hV)-_{vgICg4YR=e6>M@sx8_3L z^R#642S*K+9MjPrpX^^;fV_)sbq(4Y>vrcKTTZrbf}^$CiO-EROMxAOmSp< zBEBuer|U=%t>O{*`<&!>o5I^hq3QqUa7*V=2*H24t%VJTi`cql)p%rG;~bIxm(%(L z&V?&9@eX!UAO$hZSuj%!p7@n1#=C9C^GtQa6|%NG$*$NJqZlz{+8q^zCKys@KZc#i zM4Gjoxt4&NBrkUWEr*(<{8rKX%rP^iucGIph2=#c_`)AXtSshE)u@X@UsYf)uF?-Z zzwPV5J_KUdb=co50uc1}%o(A3X@nk4=pSr_t5_>_+*H7ZF!C=kkEjas3Y8{Cytw41=5{~?QO}gMs1%> z*E9N%1_V$@HtpWW#H6>33lyqVU`2VLNrZ>V7%%_*yr4yTipOcqSuY=B9vTBRz(L8l zcVm-K$y(7x*IGZUN-R%h>j%TJUz2J~3fML4kfqIZriW7WR4Wg87;A`VR@jmGexg)J znbISJzrZ=|qp^kCT)abtWx{L1o#y~Bf4ytvAixxTywa-iJnI9CHj*15-*;;bYhG{* zd9ZrIh-D~yr6TBWW`|Yy#uN2Q6Vw638avp$_FydEzvLZgeAXRgfERQczTtP+04t<6Y(vW(SK)HCYYWH;*> z7*o-);O0~UlQCPzBv|$;)sR84?@W<*S{py zzFqb8$Mvf(^FE^{LiJMK#XN{y<1`df6o6h=ad&gNI3Bv8fA5sAZQFhFI&H{aB*$z8 zB8T$>HQ&RCg02i=-PN#<+v6(Fnh;#k|n2m5c}~ z<+jjiqGfa;JTr0Pxvwo5h-}w>rYZi=NYAr=-)WUuSi>Mxu6?G48MPlXWj|a`2RWHp zEtYcJ@gBdy*j;eIU}y(%k2l~zv{`HHvG_z)$+)iSXTK_33AN;Xe9+_i+}NkidEMoG zmRmuQMCm9#(g80WS&f=U>FSD<7iUn{Tx*NnON^Ds1lb<9gvJiE@LKtpriotwLW~~p z;{I$wB+i!7{bgTSL@rP#qelU<@YFo}njR2z&Vjg9oY*(GMxdgXAH%gkyG3)p;=!sN zt$Xoo+N9f9=L)!3K3TQA2QIYh|DvB#oDDE410R5*-fu1vW(WPdcguTI=!4_M*-77b z0#U0EUw#n^4JNYgJ2oh#sByT5Si(tke30TIH$IoAk#82v?D(|Ab5%!(6w zZsU2xTBc6c44bXy*tibrA4FdUB$h>QbObOxmmoiBk>QSV)4!s+xpK-|59!A@LG-n#al=I@TKfG#QKhg%jR3{CZhLA$^aP|fT;G-W0{%J$Q6PIM4W0b2c zp0q@woJCJrm?8ok;CCGevvS%ez3~r>Ma(pOTcZGGnVf_%DVg#vkf{QVCm;*#2+ zW?r9?K52$KSFD$J-$ggNp+h~_f3I)Bxl7%oiIHUp#VtL$p(-O-Lw|7iAiYVcvR}<< z2k3B5QbX|&FfhW9o7Zlg=@!Lk7O8hec$N?k?}#9r%dSUYnPK0`)H^MHGd4|dJ23zk zNum?><>ef+?l}wwa_VFs*8z>AY#;KsegF=yybzR7doVnfr>7z#V__b$qbB?B)9TJV+ zHK4n8!gNeBNK$v$5nPuyB+#Wnx;Piea@_I4^%D55_&f%^wuUzo-7G!qaBLa;MNiub zZ)D8|vyxCpQ&$-&>R34w>aE+^KjXkvV$K#8BJ*4JD?ykKsMe2=`=O;XZSQiMdMYES zMO{$;GO52~Ef;i73?$AKQdLGVQ0Q9Nm=C$)fNu~he z;cYYx?V4>GzX9hw?tr20Y1dq*WZV#@z^QVEY5%p3Tqjhn13Pkz!#JUsZL|^i-1h`6 zqHRCES)<&Z;nd4Y*acRR>ne@R!n39e4IP!{=$JB2p4vB)oSgzw_=;}d6yD4Zt4X|_ zyFvE=J)1k2GV(pYJ3wlXrtqs+L1kV@m<7?f$QfbLNFO@{g$U;a%729};vQcFoll3% zlO9x7#bs^HG9wu@CJpN?bQ0p{@RJtJgKq9Wc?;D~+$O0&kG|D4Jt-cpGBe#QbK$0S z^4>Gmwa;cVA&n+-Z!oVIc9+3xfF+MtEbwy7KjB>d;0553yvd8C_MF-~y=kN6a%q5W z*Dm9%Afy_-Hc<)2HQJ55icK4W*YAsxHKs#a$t-kQ**ZP{Tkxxw`=rZ7H^f--s>3kz zwzT+Il4yPuwgxmix_i^iR#m%XxM9e~@KPsyxQO2~=^BUdFlAdSpSL*i&g@67_Yc+C z_%qEz@lXxO&ISvT&Z^B#CY)nfbwwWCE8HRxHn*f?-@!p$PB=MyuF(2YaO&CbWYqF? zZNrv9;k#7TVX2rvwv{4VHrgL>}x04c#8P(Bo(MfBH<{^l|1Qvd0;9 z%f0U7=IYxEcVJJuqcD|?o!mQ~c?M)YCp00pY@=U&90%N|(r z#0U>94Gx#nRAkQN-|BMBSB+K1J`~zX4OZr&r*@A)hZmaq=&8`HHZNM2{t%Ba z;DO-aOlcEwN#(?$OM7m{fSL%F0iWr8uSxh|_tGHPqZtSpG3a!aJp#<}(papbk?D*G zU1z75HFX!{!=f!`M(6DT5|qS__%d4ipPYziC?kfJWKoS53bnxVTbiPLiy63yIDsqm z;E0_{&uM7ZN_h|_8k#H7o;at(0nGbo=kV4Y$u;h%yr&;Nv^s>YZ(%Co6oMhQNk)9b zpA1%LnpT2H9pQFA`?=6)sBB6ZHfjkHG3cpe0YHwEXqqmTsjJjB5Z*4=pJU>UxBuL^ zKs=1J4heg`!sZobZKWzqz~^ZRn5k~gTI##eSR!A9PVjSPXx z`o_!LlKs;Bc4kBf!Pemtg7bWg-08#7!pE?ACt1ftebOO~3!-bAOgn`;_>{7we*iB- z#%{Afbrg*El+QQ?3~HsNQ4{&15w+RyI;9vJ5^@i=kceSzN^_IubEzcX?1db_C({Wi zgFtY|c29+S`D<27`L`Mt>jQ~3U|Z^q4%DrP=Cd=6(t)vSw-T)!G5(AKup$u2Lp!j3 z4|0SNe!>9$dx%SpCChE(#NB>!oVCAnFYl~qBCm;?L#%yzK64`CMMpJ|7F$7I1+ciY zl(4+o4F;z7 zRG5w!L_}W3XKhPrG3GWwV{A~?3_-=5aas@k01Aq7D?05E41A$(wG?_H|_4$Zw6Zc$jBdKH$wQDdcYR~jn}jYg*jwZ*#y6Z zoq2|r=uAa2*aW4xQR~M8`dU*R6qo$jQA1r;V4J1;9?;x-LqVM1p(M20faeQkuMXVa zLwYOKb-fkHAOYisnoesnz_ODCx?By{){LW++?qj2-R-PMocGAPux~`h>hYhtTut>* zZ{I76cCC4&cGulC^`zY< zsZk4Y#^9LHET=CsnQ`GoceI3o$s0nr9kPx|FcovS)<#620=3iUR$uJYqlCfTTiae+ zNMuCUh+@m!i%<{;xgOfT0tJp=HSRPGjT_j3ePhmrs&xuuHOJtbo{J$0jP_+IHsjA` zeks`?romT&uw_1Y96+p2YYCD9tFO%G-?@~Ld}8<@X|!-dwtJOTIKkb$heLyf_=TmD znNSJU%lHA|@^czSTwJoYyDP_}x(){54TCe}V`R$0lH*@lf_a_8jgr`AH1iNLWmcwn z{FtKGHE-+q8Z7D9GD4=LVe12!?YfWk>@do-{Uq2ITc2BJM3eqcW}LjmdM*8X!43|* zzt%^=oc@WaQwl;h&Z#8hLk!EBTX0bQ{gCz4w%nNrB7M2JO*em#95QAOS>;~m=lS91 z7s&{wM_{}ljc@$jRVcc$Zp>ebd&N%fr0Qk~1Fj(!jb)3hp~53rI9`1wTH50BqO5JI z(ISE9ce~lkJ?fqL2{BNqkz|ktdLz%teHQ=K;w6mfJ)#3uJ~TexNws66Qi7%Dy>=FC z&e2d_5=jK+x$Uv7*vPS5VfElr5%#JEKn7gMh2~9*QeED`B`3g?RE*J&bG%X9M=zbu z^}SDt9iP_9aCSg-tDp!9V0X+GhltVmH1jsH_ZYV{SqMm!fV@JXNO}_^GQeVT=C8~7 z0K-B=_93~l7BrV(2e2(p=c8eAhr#`RNzQjS<<0y|d=jb^w~%TfBz^u}N7K@EECX`s z#!ROmBl20}%vSz`<~qS2|K5>99f}3w6=`wLfMd{e(#0p1p3@25w0IQ(vr@qy)2AD| z@m$*juRVz|xw{LQ)?Je@$9Rt?{D$V40?pk}9hHZd>Iv!#a#nb$kk$ISC{(u~`cMko zQ6IRRS$xKK(4nZ{;5S(2To!*X@Q{FjM9Fv*_)+~l{yq)mG0yW)+3wg|{j?=s7UT}C zw*X9_z#|hLfJ2U=J@;S5s0zUXo~uK9=QEypOgIKww`=;~BP>BnCeKV>KR4~>I;V*q z1Vvfd&BvxGZy(FxDy*d~@=MDQ)In0aAt0VLZ-nzpA!Y-|i8 zXmZKdA#h^*6DUJqI{k{Fv$fK9;hy;kfBzJvq+WV9Vi}5FxG-fXh#!(K=*%FusMS`L z%jLgXZv8=D)IDSG^iCm30Ye(M`DKE4PHUc%4!HchBg7mI^HzWcpQbM8P*FF1uB+JJ zu{M+9$oI?-vZB`34HSogGVN*5>t92QqNs8Bt_A{Sw|zM|X7|vF+Eloo;SVVvR?^84 zNi|rB=`6uLYzKun@X8mgtXJ~&h23AMS9bT*`F$u#V^H9~s^ia* zyRVmWhLZ_4IyzG|2d}iNNXfLLE63+-{v-_00*0^Mn08X5(rq~J^Z0k%kosZp>3>wR`{G1H?NCG`kYj_WI zrCwV9^Hkj#;6J7uC+VlD@ZgFr@tx8zb74{KyeN5Xx>!{fV>}_G)Fm!=;u?E--ymF* zjNLb?Kb?Xbs45auGDL?F)~0|`?^@xh3D8j&-{)SWQmp^z__mwCL^guE4BH8CM@F!} za{dH$o+_4}l&!_LgaYmKf3`Rt{~CzPp|HB0*PQ~0l@FHwOa4ks&YUvyS4ueZd0myy zz5YM^Xu0jr9ayaQPZcK6B7!b&6 zU=f$ajeB~@Q$=;nGO3vpp93Vq@>@Ln>jg;*y*En{`??Rp<6={vwhC$z?l1BE&SzHN zNf>S*^O1M3!p)}Bl^@JwYf^CaJcCH{YwqlAa#0x@w?0d`Ih!KJ3$IfI3vYTWzAHAwcN_Q%z>>l>ZlN6l_$t(_siAa z{79CuxcWCy>ThCFS!n3Ce9R(E`xElCOxXcZ{mL$`)l1EsC`Zhd!0g(9(QhT*WXEmx zqiw(KrAwv-dM~sqJBT@XkbT$e#zc)_3V~QKwna?^o|PLe6tH)6y*rYhNlOdxB)ao+6Yri=~JsjUuIbU4znBVe)T?1O&C`-11~a$hi_H~!HK2g

    `tPKh0C ztoTb|?QvQ5HtKW+7ySS&l#m3BK*Nnt*cP=(h(k`*A?>w~_K;<`cDyxjZ#usP+9pI$ zYwTfSdnY=e!456^&Uj{44C12PK`Y1MT&4BQta&f$hYM)ece zf6ewog<7Bs`8tnV_;RBK zR%BM;FH|9V0-49m!#a%2KIM+e3QMnHc9AK*4v|x*4puj@SBd=LQ=)E*Au#G3vFFv? z!R?hfVGYK68ptGRn1c&V`1jtu*E?Xk197u%KHG4!j@KAZ$K z9?jzlgj07%z5V~ngNj&jW9?&Be?$EfO&%*8YBFPpR6rf^kV$CIp~vQXbKbxD)r-Vv zsa-21lWKf%dVcz@>Yh%iaR+EGov6Xm3M2|shyhDv?aN*DM1Hx*Lq%yv$H@DR0zgtx z^%K4VvgR~&0?;GWfh*CaqAFGaY+DUc4P!T1iP~JN-Hdl^xD0nz(H9zC_W;kj0`S^P z1W%!JNgH09{^vfB(G7u<;$%8TUVF_EeJ~uP69jbWZo9fr!&}^UR@r-C!6+Q;&bMID zeqX^%mlUkawu2g?cwhDS;U6h*mgwW3hzQ?^6aG`HBD}Az;Y2W=>OrOo_8Ej4oqd}K zpjN4mvX0%$KY>VE99~2&>=^8p5{U&C9DTp(<6|b>?7?9}zE8OwWpK~1(K{C-7q6Bq zx+8tdi(uwGj6so{CWI?2ug?RSrqfD0kN;SU6v^EHX}=%q^5;Q!##_iP2!8@$Dm^Bw zQ>*d-zZJmagWgmgV)~gm>w`O0uE~_*;^f7EnFy<5d5=gT+Mqs3j@G}5&I_K zACK$)t9K4I`3pnY9E(p%kvyOBM@C!?CZ}t)i#pExDg8;6iyaiuxZ+}J? zq<(Jo$pfwg%b}hlYoXZs*c-}@d0nRmU1YU5K;xU%K}8Aw7iSC;5c zm*buBa>~|HxwGB_!H)&NTsH6AR#r?qLibp%mVa1A5LL-`ngN^J4|5Eqxn#^7yMoik zClEc!E&9C24P8=0no+iWA+74hke4{MgajoYR5!bDhofcDRGrUbi#J&N;>7Or$^Quj zt6Z^`#9$doqHn9&Gw*fytK||nP(>fC=szK2E2lM0D+GUFle#}$BFAD14A13+i}a4S z#YpY(74e0A8JKY~*Ks(ip+oXmf*l;mzFpqoD3e3dV7=-2f3CyNfxb2z5tdwQ6J^dB z5J_kZ;vPfnuF^{1>+wK@1j?TKeEJ10hrrn(Tr;7gbB2?E71FWna0`2TAJ?hZcrE&` z>9iLs!tC4oQSh!b7F9v;tZ6$Uo#YOd5_Qe#kIjyVjW`Sv#!+^fdf?_*=vm);k^or4 z9#)*LKwi`zJ}7}g=~C3}oa&(H@ww)Q0X(@u76^GIfaKw*pC^66 zSY^c?#mdLa4`8dFw)@$?H3Omzk67)VmM+AoQJzBn%(rh5oDs0G2}0p{^=`;ckdk#9 zb@unBO$-{4FdYq{ma7jD@FB05LNSS+S)?RBG)H;G?e*`*HD(@dcyOx@#FA4~i-|d{ zQyk=`zozxHWplQJHJK(Y^tcRb2q{mXK782}y{B5b0oOq~M!aq+n!fXli9(X=Q9QvCw8>1Ixy>?q-bdHh(pH zkT*GZ4!e4QtDkPLf`WomYF<@kPC;s3W^!guPG+7$adJ^Ake8RPP?B0)GWm6`)nvP6 zY~25VN}zJv@0GLGF>b!IbbZhCZZ<|WW>Z6j$r~*tC&yK?ZNF{Am?Fre8$8|7g;AUZ zWW@9s7e=Sa@s+H?|B^M7lGBQlm2?!8(()?|l{6I~W^Gq-W9;i?|NGC`#}lY^=VeA^ zh}Hva%(j#D^4PXZUt#=lefnu$W^pDnh0Tf+Lm4L@uw>odx0Y$5#q{|H8Kt&6K4X%p z0C~;I&(R0$HNV81%#_TE%w&bcsn_NqXML@S8Ik%2+`<_kA$N3-uW(tZOrRnpoGIMReaFBT_7buie168k~q#HT+hV^Z6`K#EmY32c0bb0paKkkpc* r#N^6kVA4v3>PH0C^uo1_s?+!7FbY5dy(GC3$&M<1Ixy>?q-ZHHh(pH zkT;ok7U$-3%h&cy_l{u{oIK~FfIzZ_pQDa~l9z#@i;JnDlIG-%mXed>D%rLlHepN= zlrU5P0_W7U{EEzy%shqSFcL5`ZEOm`-2V&ZM#Z0|&DyRUkYRt z+Ww}W`LqB~MtS?C1T&cvB$f=MQt*iHtqZQC|Fm?RV1ws~UPwr$(^XWskW_qXo1R-M(o z`mElls$Ki3XIIZoLKVzHASjO{1ioGI*%Eqph{?grC@cKThU*zyn4bIUHJ~r@eBWT2QkTsg-*!KC8QOnq zP}aNy%R_CBCuhJZ+5z`HPL*xPkx$ZE)Yk`pklQ?y1Ydy3)O<6sk}$p1al;Qn;%h%K zMmb3dDnSlrF9J(H4Y>r%=Q(r2tx5W#?JXdL-Y4GG>lZ5&o$H1JqQt5QnR_lK>6GWQ z6`076EJ$Q>V%ln7LJ)XMUkJ3Hee?{q1%XB=;Rs`^5G%}c+xU~&-@Z4*Cq8#KTp`K0 z#kN?msW~}@O&{1}^{|YMPLa~XAhmP#Re0hU7wBbH2b;Cx!2ZYB8bd9u0@pa~-4?+H zy~i&lLlLycrEhREwyub`C|lqR7LD6DM(&$l_FN;{_7h|6g3pLD;;?WYrX_Zi;9y|7 z5MW^cN5!C5DD3~yF*Xc5#DA3i748D&KQ~w?wg02_QB)ehep{rP4(>g!#;biKF^js2 zetztbakp54R#Q`PRlcBI15#AxCnDJbabfh$v9@yr7&zMIra-WBlQ=FoaTgkri^bc+ zmG=AibiUiY3d?i#+S|Q$OU7z@%lEorH$|)Sw`cnIhu2~0L+!QGWsl~e5;ygid+qd) zSM9fq_P2Q;!|}SZoj&;P%gp-O`!oH$W%IN4`TBXneJ}a?yT*AiEsyH_D7p1!b)$Rx zI;&t?wphwh>v_}Vv!s^Qdp6}ug%LuSTPs~cZ-JZZ0_L(3nrSe#b=K|kvt9jpA#WM^ zq&n+k#)WwE9a8dxC@<&Kbr)KzWTVBAXR8&UHHQzZ)?8MMtQl8$?Hh6C>87-}a-4WU zba6k}hE!888=GxwuUW>wA1|-gSzQT2uS4R+)35WgUSyyEotd4FSIClM3BqEd5mA>v zA6O#3F)2w8z5h^~jEY~!K=g`K@gT!~*{wK#GgpLQ-kfdDS9!nJrfYe3#5bDMUh5_; zz8MFqAMD@f`QEJn?f1u8D&_gzIx1Y{lW$!O4$_W?LIFb(aqo3Qc6ss&kur#+b zRcCG?(H~*zbxK=jZuja9!?maEHC^_BR-zVp_6a(sabP(w>*2Hb<-6qh1yXHWaIMF$GV!`OJ)hEoJ>dJV zUTcls*Xz19K5GfbHhV{%;KH|iGs7niT{pKh|m)v+(lzbjTH?Xt%pvEaFlHZ_t8rtPOeSq$NZJK=N9UO@r!#p_6Q$oi(hq? zjjmdAAq3=s`6J)ug+2Dn0O#%yL}0$BT)TlfBe{F^?Mo@cxmqHUx(4t1?6LEyt}M&& zFU50ldBnErQ=<15=SpGk!9pq`pJpONj7IT*mFG!@jWzMrwqg8z$M*~kJ^S$b^zU(= zc2{3`3R4xqlXwj>Q4j_=kF$LQN!PiYIe5%l9OrkIA&t&LidW*k6GJr8H3PJjGM|>i zyL^H#q>K}+n`&0%mv%0EhG};*EfV4v{?N5+&Z_7{xPKQ*A&4b|ump9?O8HpTX*u;`sC z@<#h)qqBm2e#c6OPTsd=_FmRXkEc?;sbRY6_50;+yW1Z>QRRDb{cB;cW=zW67vpSu zTuDQvGylh`97TR^*IHo6*}b7J)hm7*WXRXR>>)dL%EY27?)hum<6P*JT3$Gxz{z%k73!J zyzE;;5Z4>lGwz&RD}k`n82<--I!=g3$g}oK6y^)#qh4#q_Rap&m-wUYyVj%Y<(I@? zodcJ8ifjCSIu)nqH;s;dDVslZ2?)BgIj9+*Rcc}&F=RFNAgk)4v-mQZ-ds7O0w={BcXYn2-k-+O9rq@SX5pN=S!C zpJm<7pEvTvuv0o}+m-)Y_`W{f1C=+B&CtiaDV@G8XcfOD7%gzbrIp-Ar}1nR36%&_ zMbzcVe-(XE5IF^Rq>J|+E1RstDI)IznUC8-cCkX^1MDY$^^{%zBJv? zU-qR8zqC5&&qAs1p7A^G30j%C1;nV3y@J0`?iI+;4f#Uh<2TC^yzR*2{b=RztNSK} zP;r-qY>J&f;S@sll~YO*o}I6vEipg8=Sh*DyzAx0OY?l5wRu{?%cEG#=#=4>$rZ1d|Uu!6pZ(e|CfUCJMV@P~ahSdV?mev>Ew z5yW@;5(sCJ+9gVo?4p<}(N$LnOpJZ_IPESHv3;;*h3%~8?B0v)^`S4;li0}RO8(>; zMZYZ`tgjlznukZg{ciPIcFR2>+vOFvv1{Fz~8n5dZ0Jf{3M4g3H|| zoub0u>6t^+S%+EfM~vhng4s*B*2gk6-yj=cX^4bLB5I?2==S3x#(GiF?abEKpN75L zi)FM@;r6nk@;E$)Lqy6*HC=5SU_95Q;UO&cF#pl4!ezgw84oAb(%#gDw&Xa@e_hSO zKbHcH1nX-f`@oX9-2(Z;^7gt}@Li3=yld1QXWMcW2W9LezHRo9G@n7GXb(Lo&O9R=wP=j*-%kvIirU7yQuto#AgXH3J zsW7}~j0k595O50%nK=4mmo*(1xP!A4;`$-uN@p?s%P2o_^y=0Ih86D=#z~G!HE(4N z^Fh)DFv}##3o5SvjcFeF-E)^|OFm^FRgkUv+p2NuWN!$+(9{O(v6o2bl1Wj}gB#)3 zxx;}wMgSiT1EQYMcIN#Uzan*b=_I>lQ_Tojz#cSA! z1oX0ijn}@AnLe4@VQ$zYcR1WZ#(LxtxMtxPo9 z#2`M{w`F(CA`5^W+XrK(=Pvn#WrB9!T-ULQ`*x&?mBh@(EwtDHmv2F=68p!{FQ8`j zavY0ML0MYc&#eNrtV>e#VyLEDckZj6nHp&2aSGT>F43!daZM%;RGNjf@tOfv?M*5z zP1IW2gltbw{u{BUZZen{B*1Xs@l}3j;Rcll;K8@@i^DCeo%BYkYp_ z8d}`>Lc3stDFPtkqgY_4bJqt7n{fv}5N`O*rO?*;C{QW(cjRUN!BueRLxO)jq6>)) zZ`9N(9U@4sIypbhNa>c+oEwG>?8Ec)9I;doeG!PPK_<|0RC7!+PLsD*OQ09@D+4EM zID(1?5~0z)&iL~pnTGrnb{MA&X+P%QMF>=e1iPs_9)?*eX@fojq2psF&PLofAo7l~ zMOqU^+@ml=>ijIaR4H?*piRH|6`2r!%c$MiR^fZ|pvZ_wP+1yVTA4Qv-tMr}O>>1h25TqkjiH)P4jycd1_&OMq~Z|?@pskyU< z+Gr@AlZy7+lUT1uB3MsoVbK)K z15{A2PPz(Bx3NZ1`-V10JeqN&wu;!lQ6@R(_6Mk~S%}`U-yx6fZrVm`yKZjH{Xi~&}ySUf>dfrVG>cWQ| zE>~p}8%z;$?83`*fVFT?RLd>rYr=7d?{y zPo4relfTsse-Bw8;q3?N$kQlJ#r&zbu<{Qat}sWbg^Q#}lz8u?83$4n=l$a~;m0fd z_u0Fy)ve2uW9N@WT}!>D>Gxi}=X`DC=@Env5X3EvtN6Ce2gR~1R@*TmqaVlCMg4j0 zNibyl2HcZ6{>h@jnm%h1TZnPjKvqeUgFH3Xb@_cTAL8^kpaWH@`&-tea@V!_=405! zOZ;n5Wdbx0u@kz;W$s@piIn)m$@5z&4<-2>Wm1BJ@1;Ca+cz^i(G;^Z2y;um72iN5 z){``kPo2zGnvP%M**{`m8+RQ0;@qw#07mb$m^~hE&{=tI4Q9Uv={;Xb-hM}}{V}Cm zc1Pe&8rc&tHWjGMgCvrKf}lWSH!g;H*LbmvupzX^ImYR6HO_RPbNa#5N%A zFI_5l<7D}&@)Zg{aT7vYCImHI`zdDj>%vEG>!{6y+|=uz=>B@bD(^XJnw zE840m!IdSf12HevoD759gZY_gvvvJ$eeMDjiDGK!2KYT8F$mR*p| z6o1&AU0XoD9zcK5V#2atHA6TFj@F-~QC86~a~7;QTwXWX5=4id$cUb3TWt(gr|UY8 zHW0$4exn*&!w-RA!RH6Z5&5BC7cWwt_S=0f{0n!~e&eVFz?11JsjfFXn`}gg>1X=V zFxowvotj7ZENdMB6JJW$N`8wA-5sYtIYf&4&Gg?jpcl$F;mx4uucu@AbH+pSJ9Y(K z@Fui<=%hAa;IJ{y*w=msT`1z>^`W8Q7eeYQ)zTepp^Avr)S64$nAE1%s)S=4~cXLWgW zByhXjhVvBQc4XJ|?N!jWC36Zm%JuSwy6q))4G;~CKEoP2nkXc)(YClLLw2HbnuO^! zrfoBn=ZjjSr54UI|1#r0B#T^8mc`}OJCp^m^Xp#8$xkos$;2&eP&|oFw0&ktbNhWt zK8q_I{#N^Vm3Vy48y7K_$f|Z-yqL_34+nl1 z*pJYphSQ!l(v2V%-eQsp?8_gS5|J<_%fc|aVqKE*!~8Wo>fpYaaVnuQch~bspfKC zzRy_UY<)ptCHBS6WY4HvL`C8NQ#wcEj`OCw)_(&QKqq%_FOoIhn8acvfT>u6;-0P`VgDR`vNNe9TA}rf8`V^5~}6{#*+4JUZ02 zim4;~fkyZ6t^b^kRM!}bZ!1KkC)gAhH1hnFPu*l@((pCqyU|HTY31mHCb=oQyZ8|y z4nsrp(7gD$w5xLC_g+Eg04|L<(j5-;$gYqrh5B*++ML)|6Q>UX<;OREPsZbnYR8$M zRXTzGrerTV-SmrYoF~ZYEAyM$;@r#_$Je*o2YC(aGq0za)4#-YG*8ban0q!A55HKX zs_5R_3xM(Z@6RXeN=@eKVDAjZlcQk5Kc>OG3VhGZH`v*SEv!P`Cd-*b>*w%bK)!Jl zfh51gkh|%V{iWnx2p|#mf#q~b4Zc%VBIgkDBC8BsYYX)s`h4+w9+*BBntEP=A*sC0 zV`Lpq)p)@D2Q51dRvhdG&%3xQ{_M|pUE^;)S~7foM0!aNQ<=G(Ync4x;S=T&6;}6n zrL#%;4*O_A2u1x8UeR?utiuGw_0L9W|Bd!+Kq8_Z3?%G1jjstC8$1N9%a!j5rog`G zE~FnD>2)e(zd=x;Wrgex%WkiIeJjl<(efS4blRXjy%xbU(S1|M<~*gAw%&lBp1bmF zNLND-tlE^D8DwAE66G5l8E_N*%k9jvA%B{W{YOGB72W(0E>-Cam_ydK+%oklWF@#c zfaRf^uEh$5xZs5cRe(byO)HEqA%#Zo@*QRvo%p=p>d#ul`vc^k>h>l+&VAxd3!RxM zL?{!bk6fh=nl>`bT{*zVzQkk|$<77iFhlsj}t)g9cmE?cHp0LtSWI`tm%+7=|D z%JZ$?XPiap$`*|ObT!kl)#<5Tf#A@!cpD0$j89a)7|TAd)^hAPrM zYn|**x$rChaE7OxX8w%iL>Q1q0j&MzTxOs;sl*==yt`&tyW& z3H!zC+<30+oIpR{0z{|R%SpZvdHTiH;`0VPi?JyIR7`6;s6q=f?YqBW)p08M1Y67U zCuJO30oUOU0Br$EhRK>H`0G0KUBgE%1B>tpsgG0-n}8z^(2Dp=*np_w*Pxz5nkj(4 z>mLM|k@dzL!FHduEp$25QZ2dLN~Crx(2H2=cQG$X0FthkCyY_)?h+C(mkY}DEU&`G zvR%$qm5on(IUsGW;}Z&EkFM)w9lEa1H*ne=5ONvTVG`w$$&~iO6ip*t+h2tyg@Dsxr|qY_JRXRe z{y6r@2TIsvmJ{4AhNgR4a8?`fSA9n3whm_CqniesYr2pcN%~D@9EHK1iibv@i;J9_ z$ctN0)~}wLXwsTnisv8w?B}`VDu&((nqKl7hM&ET3vt|Itm=2o&NJ^F?Pwev3TE~* zXLwyj&sQjROCYfYlH!k2xc4VcE}d~Gu)rm;fOPF+Ml%&|k=5^CV^di0cSmjyQ^OC>j2{Vk*4~I`m_Z`dbd7@_#b$HGSLBHoPKfs2lK5oTiBIN z@wWr#Eb#xX04FhVZIF5daX{(mwlOn^>N_u(0Au;yp;cIc(#f!69>f=%$6%o3A&+ZD z5?LmygK)uBs&E zJQuME-Qm&DYcmKsM{9naHkp@;35dc zcU_C$IaWfJX{&4=ve#*8wGq_lFlv{F=M8E(%F>{nqzNx`MP}X=203X^LN~;J)sRN9 z9o-7RV!*oj8XbS?@8jeo{woz}c>8CHxll;mWuQg_R@ zKj#F_^zr)tFdUm2r3@!kU6I{7A0Wk=pL<$@|HdyW1~*+zN=SUK&>FBPYv(NzvzgnI zTDtB+2>hv`yZLCyft!=^e_1H}vEJD(LS;l%_cHVAOI3!y+lN_*{oO+TQS19y1SZ8T ztkPa}5A7VA@WQx+;)sm7F;Qg;l)a;yQvI-2!7aUT&VR9M0-@oyQE;NV;J7dNbuX?R zae74o#5V&R%a83e%Xhd%zU0ORTZ^2b=OYhdOASfz=hecl-WcfG|h zaB#P|i`t*;`=+I_Jgg89pA&z@qh=L((N!hNO`+xC>gkwlmRlERk_1 z9f@@>wtrOhl&A;NIGFJ6Z(JJpLaLymf~`)#?SbcJn?Ybu?&zD?@@K;AA^Jwn&`D)R zGbN!yM_f|B>|%B7{5zXUS(K~a7Nv3^^)Zn^KS%j@OrAZ_EI(0vJAyRG;UJ4i?W9Nd zp^*KfpOq}YBMGl-{K{AB)NePXAdN&JBz5}ry$AF3@5QV7ox_{TT#YnZ+Ffi<<-|~c z^Zf{TW)zs<2Wn%@2^$g3QFXGnFeUKDe4<18X^9<(H@vgX)(1CI6&Q8yQF1>~C|vP1 z;)}4*mr#)`w zZ?tnv*)A03gE{9>zu|p*Qj-7PDC|LoV0LZgg_tGapY}z!%L?9Y1f8-fs4C*u$1+r+8 zR@EPZDsJKjV%vRw6_x(_=52vRcJ=%GUH2jaBOe=UGIREHN0UYOh>zpq)`20xFRm}orL2ztXj9FVC@yyC?w`@;~w&yBLG^48Ay z0zvELRyJj??Jb_qXXOiTF93kwxQ1SOGYt!(wlk=QO5G3j{dSjUad#^1T<9g>mU13n z;gt||NU`m5qMpz%<@{v9JCH-uBvaOb#08%da7e#P!`MQmQI;m$0vZf+vsotv$N2B! zvw+>8!r}$#1*fYr&Zeur?i5V0@wm+}=>1yuWJ5u*eA{mXNLjz6V|qmwTZQVACUdZP zp!QwrcS8_CU|MRSW!r}%V~5ay;i`@j5D--DqN}KK(5V zKE+e~dmSutFY=ncX~G4PY~AQ7-jy% z0mE4D)^`~Q)Z*`Fsch4VP(GNqeLFRBaUQf8a~=&^JG4plHx`0Or{ZZhT!*nM$VB)dM^ZOI#tOH67!fk$r8F6%ay{`z`-K9z#C(1rc{UF+{RIsl+6{eMJP!(EkJWE!&K2 zzM=MOTcQmHwzer_J$nMrhmLo%s0HeR8H$iR z6LPrz&v}KYat@zg^#!Y&1rN2L>y$@3IW3m4XBk0D+=7tnkiawE z;x(PM(wN%2n83(IcRZqC)e7~`hGXLV?{_sQKCP(VZZiAMA2OSfr`WUwuD~*ID~1(; zu-#&hu&F@^Cdr^&U28!NpL0b9%~OTj_`gcGTk zsxl(QxguxU);uL<&Wp7(LM@qXC=}_GIt8R8?uYG*wND&^(CvX~Skc-)qOw(I-D_gi zr%cW6Q_t@?VT${$^J1{lN1at9wh{~|fGT=^SES=?F-aClw!KOGjWZ~$H20m1aQh_@}a zwPGVBvos0AQJGL*dD_GFsC|C7qKov9ytR8V2QdGQ-4lonb?{Rat9jWFX1L!3D8zd? zzss0u`iyjK-lTq)aqGjPtQ8>({f>&SR7-vP(DO~W(L(!<$RKe%@N;0>LI}0ep`$T- zVae5M>Z+^DymJ4~{*d{InVYac{pO0` zx$<@w~;RWB2sw>pSU09Zv3l^5Yy@$5Hf^RT{r{N zOrfS`yHK=QV&J_k@765hqZG;JnqTgN*%^I_%7~YES$iSkk9Rn{U4UcI zoRujqAO+AaT_0~n=BeWYH505uym~+8KTf*JT#sjF1$e|~$?J-ii21PpWWmB0FB!lk z2->1%pW)@Axq<$$DCtEJ|KNmc$_tlwf#@Zruq}&JTPfM|+HIJT*Pc6It)jh<$o{T9y*QUFkY>gcTpc`&Px+!&=C_80C zKjFD%&_0!}MVxUh!W!LGj!)mKJ5DGk8PodDu&}|k(xQafUSlK1Uv^y|FAx}Wq+@;j zO2#psUqy5kZM@i*ynEC#C~j8BxMmwSf@J5nWII~m9*uEn+Z=0fw&yDyy-aEzj0tFC zumTtA>0+UNRXGBSm+W4D+#=8Ch#H2pZ*UR)e{jHUsN6to#Z#aE;c%oVlXbM;j=Tsf zROS)RI^e=42>bwci}jmgv6LcQ13HePJPjfqBU#a`#JW+IL5Fd1dP?mB1Otpp)KozU zPz7c-JX8;2^u&hxLXtM|vKT7DVUzVP1gZ8jP{stTF}y%9$Xe6M^Nhg$W9l>TdCh-1 zr@c3@)S=LK_|yrm_j1H(4%q);6Xvw^$8DXtYQ}k5ft6#L-qNm#_Rvi`{X7sRR6tCK zq%piC*eHG}$b_a>DeN0aNytMgEbk!{Pn@P~_X%2xmYyN!SMXltM8#Nl$R%nwOoY|2 z)p-pSpcTMbJM4Doq;=C9u(<8rS&}{Ogg71rw^Q3|3^0yhOUbs%ut*qdvLPS@_@TXJ z7JJYn+^p4Eahh;o&*Xk!gD)r8C|4v!zK7&>OWB(k))<> zU_yOYf)d;m+2yKC&igd;H*IEAFXM)lK_XrfXr?}^EzwhIJ`9d9BX~J@+zzZkzQ&&)r{khXFX+b+Sh4E&q z>lvC}C$I0t3sd?Dp^xQ4)TzTd$8b4NFM!$YFz1}5`QN;iEj=W?pVy5LG;vFjQ*2PG z8Dp#!>tC>;Y5_i>E3JqZm$H3BQyQ;U!1?j7htx&tx4UQ0#gVu-&<5v;zH%jrCTnGi z7Uy?RM&p8S>$I^;9<8ABj2epSw@HmS7V{v-W=Z2xx!8WcrN_bYPyy)hDY&9>`EZJW!iAbdwK%B3`-N-Uqldw5};DXt03 zD13iee&j|>v&?t(J+-4FGu(b*u&c6mpVCeVt%A{o5^`upId%OePX3$1a_6aQT^mHC zlhYg-D;9R5c+lyI!G6KKbHv|1{GNmWWCWbH`eRsL92$d^T>5*YQ1Uts>wUuG$ptiB3os?Pkl42a_%t=%UWqN3ye^gcZ2a==hMK6|t zY*J^93k#egsz;VqfD=1Bc&tlyk|!LUnDL+Sanb+(662H+=;~;~0WlSfGwskNM^PFH z`KlfT`rYD621O6-{NR1YI4~3Ve_eae?L@EpJO5uD01CWvag`Sn{;tVWB8rLRrd-MS zG$L53j_m%7S88_Hf2c)E?PPM=Gj~#z)@iDUBK^o?E-QL`fg-wdsTIM~QiK~1Iey+8 zUI)Z|%e|Viw#%X^L#E+K7PL%;%}3g2Hiv|~-B;VfZ~1EL{0?PcmQ#L)@Q8}9SEB=W zru}zSKtej#keFQ1X_@a7DAR}r%Lq@>-;@O_e{wLqBSt|_<_KS)d)cx(+kCGIHD3_pw-fd1c5Tklk>8J!7mU(r>>>>~OFw{Q*C8E;V zhmPs;)flmbcN21D=L;!e(13qjs-|Yy{9m)K=i5)F z)(G3nVgGqBz>LckyGSSVPBtb@Xf1*s^T`pGX9lSrr6u%Q025>Epe-lr->M(026 z=zqbcgOwiqsG6zgT9$H;BsV098W%!LpP>Ur-xFcF;5@b2m+gA{%EZ_40@-SDs$bo7 zm45Ev^WsbMe5_xGYOLjdzB}&xji((ueI0Jxdb&|ZddZKM3bA|z$1zv#l$cxWAM6np zr4<>^Uzj`5Lr*tkgf9yb-O-7C2Yg~2^r=@p7_v6b%R7-%m)Gr_FM)im&Nm} zr#xdkB8~43Ag;)G+UGRv&2FQ|n9lXYbKpWXbOH%om&1M%)yt7VT%V{H6K0C3N*wgT zQRE_I`YJaTFa>?oI{3wBH47kM32-PR{I#%j6!oHhi=E9eN#*}pNN|F+qlnYVCxrOik z1Cjedlgw$G_WZe|A>R=b*4@ij`n+cvQJF^&d3l)Pnl9OtQ<6YViVXsYEf{9B8(#ZV ziR)$%su(d&IZ5hnLQ&PZaP`D#QB#iWm!uEQ&Lw7UcZ*L7bR0{@yMvq*u~mi^J8nr8 zR<^!zC(^N9Xc4?hZ%?u6LTiq z8*$pqjE|uN7SbTWg%)&PHhaJP1BJ$^ecF=7t}KS)r0uXvoe)n6h(DRI`@%S=y^Ya6 z`QqGtSG|%yF({girZ{Enj_o~e!zm+|JN07v!@3>&PV22}30&tyruXvE)-D$$)l=-( zNQ;k~WW-;U%M6-r^{W0vfWIk)^fZrkwqwEGy|ka$P&x4bV-^3DPsccNFCN||i$Z^6 z=jS-l&!wuyQ%^RyvU}<&S%(+CcqgMQ3TJO&{&VNZ+2sY(ii2=zx*Jg(VE`;r$o8zPdpbv@eF ziKw+O=($76G>xvCpQzZvXHHVRlvVZk8RS5N9B2O)2)*ma0vXfTmKiW=6f_h^B(Tyy zBU~RvtYcR zqi8gs9ZcL=vOtXO>&*O!mv48A11|_?!&4n$E%Nd?BM?mU&)L-XLTCITtOVk{rOYw# zwn4zhf##w?3~Qb4aJjrrnmVb~vvJT^5#u7W2h~E&{~jeTTa-(x&vobFBA&lm#c~>P zL0F4JB{st!Oi;3O> zyL!w+8+M7p6e2BitD34$M`RF@;tJdzYH6<}pmcXF9cR%U(UhbbIo+H^ck^ynqGhUo zZ0<(AlMZ~ts+8(@Y*!>yBsu|@Xgr^t&(lM=@y7)zn$!1-1!Ab&IC}h?izUh-Y5Yv{ zKW$aneZrVFj3rY+mKPWpxFs3NpV-2Cy%lQP&sqMpK;ttK%qB@(XGeuhxd4mn!V?T5|}b_N2EEOqfA?S9WhSupmlhDHsr$BVQLJIa71 z!o^BNw@I~|c9uBGV^*9eGOkN>c=!YR^GUeZqei-IA3(9&({Dd2<1@-?wF}`Hlntpb zS6l;H=NAYIo(pt#oWJh6cn8SBB9mt5{G|7^N#^SuH*j`++4b!JV|eLrM8oK)d?};u zh~?;{ju;S9X%AOr=$SdlKD++|x8SM7Y;KRh5a}mO)3tRbO0onn)H`0>J_2I|2wH&l z`Tn#_#v%>kXt<A^Dg}?A;Vi)uc`)QQl?|qgXt`ukBUOONAOE(y5rAe<{$Eg2&A)?uvXE1Ui|=@8{mxRYKX=+ZZ9+3&wOJPd zy)E^f8_{G~?vXp~fay9&isAlWlZysUsV8^xF8lv#o&HmcW5|uZ8l+$8&mzjyoCGb9 zDh$)j)2}Num{lwh48BH*_eC06^`yw)XYNw*=mN?GU@#NVF`(~}N3@7`G2>+*-XRb9 zNV52Iljx*L)(H*}GN(k0I!mDhCpHY>E3ti}_yXlv0zv%!kr)f?0np_CBHuDiK$N_9 zR8DoW5rv@Pyy9#oJMb>DP3T7-uJ==p{+ee+-h~h%BR#OPU_WnZippO%z^rR&3qIdo z0sj*iKo(|OA0A=rOn9j2URoim3+r?Yjvct#WURRA6MzI$)Q>Wi;l+$1&mDXhRp3fc ze10d+VPZLay4qZ~P`?*-oMyb^2D+n~s(7ZxYS>wC&^S-vNaeZKNw(nr&blc^Z9|LI z5QVTJWp)O?{0LdM-BAm?o_=PYeq6nS+&Ml2{%%`=^%|1z! z9zp+vTt8_##4AC|{To)pS(_rq78S52F_avjmx}Ro#BZj)c@liYv%`TV^kG-qC|@2- zE>%dCNskjTw(&cA=`g%{FK)9|Iud&YGW%uid&C9#si~fGdNUt+SLQ9ZBaKhmvT==duZ&7re{u!~O|Pi^ zm)A(qA^{U6*&NZJE9Fp~PPlbc&%=kHfe!!fG4h#@zz2em!c}bvvg2XNitL;-qMDxv zdW~@jE(XSVyC@=m?<7G)n9lKv@!)XLFgy%XTu)4rfcX&*O}PLp4m1ZlB7MHln~J@^*@u1_zp49D(|cBmSt&V*w{qw#=9nxi0~K=5cA85XGi6{X&}Ip3%X z7vEoX+e!lUT zBI^`4 z4$cy^M`;Q+x(B3xxG|@*(>{C_+F%pCH9Z$}jziInT$v3aYMbGA;^_RGSMZJ(o8a3r ziI1;Mc(F5{XFcR@Tdd&WNCC2)OPWj)i`Of~M#BaNYN>-$b^L^-QU-p8YKikyqePxs zfZh;fZCnnX&Ym_;8<5y^oW`e)as|5*u*Jc(vdwfd75gv5mtILdg{-s!fqltY^W98|}H1uhVCg$=5WcP&2`+U^{W*z7W z<4|M^+Fm^2)|I1=yVktr4gS$axP!|Hv{C35rvJ%uLkc(=?Uq^GN{_(%V(>qv?5E<{#@^DlfdjEm`DjjDV6g+rSYrAfOZh zs|v7#G9X5?Ignc|N;S7sb>`TtkAhc|CHz%MpJA3@KwkQ&l=QI=9}?luq5H@#U4$)D zb6n`yI&N!a8R7_CpPFFTTpo7QCNA0X;hWCdP6l2!-Su%vB8^)gWTOeUHx<|OpBdp% zJ_*@+lqpnOQW4TvV+!KRc))29l5%!CYX*^-Uf9=SJjB4tD}z72B`PSuri*j$4z87`WD*VUx_q*Qw+-<+TYOdD7B5qU&J_t!B^m~ikb)#!H zmZ^LxC|5)EkkNrfE#edUA0G=29-$9AQe6kNJD=Ah<*48ZF@j9P_eXDOl!DR;dF<99 zakX9T5vRejhQTz0+`ze1ZhRx}rlagGh4u#dLS>|>Y`4w4v5m6sZcz`-3DUBNez)DN zdUI_i8Vxliu>eR6f}t#880>QSNr@Z8C_3xmemrs^$cMo> z%;$JcjXrxDUM5boD~~yG^^S;LVWsVsyzZ%!v00~mh8`L464#738_6X zeOi6|NPuc9_{dQe*uF8SsWQQ|Q9m+qPaAOrfhZ%z4s^{>wc2Q9X0#=d?96PsmS#~j zSZ`C*3rS*@?PbNM|M>`!W`~As2e7;Xnf}HmwFGxB;CzRm zjtzRD`s(6p1Y1~&L;1QJO&?lIk|4|4{mKGmUtzF|%!$cSkFBq?~=!)U`722f)TUF42xT%(K4l;NyO0+ z!0Y46Pq8(Cu1+T~Rn5UM?6fHm6WXk@USHL|q+BRnO$}SD@U+Ij@1=%v6__4dS4Oeb zoUf6yK58dzri=pp*DihJ*WkVr!&@n8mZt4+^``hR%>B>Ul>d*ccMJ|B?6!sDOfX3% zwrwX9+qOBeCU!cuZBK05w#|ucCzCJlx#ygFtG=q;wX2>#{bzSS8*8miI_7HXe~T=m zs0Zc{w}Rb0cn9tFXPV3O!?a2LmQ4@q*@6eQVFXAhm{qGrjB>BZ8fHu+EBMGWrz@9_ zOip6hP3{WRex0|M-uBln%N7C;DK@F4rd&l&s-Gk>UP8GiJDy9)mDcyC_l9Zv1;i7O zR=HfIw@K}%c#K_eguYk!#`1%3c%v)7r>q+FBDRwdop*^_s&{=~r`2}@C;H?eFYMx_ zHwTOkXY12rUyoRc9^7Z{Avc)1}?Y; zKy(tn^&E6H;lNTh!S+_w5R$so69T?%uK;b&3q!pp?B{V3d(>Xs#$e38;3Ivt!x<9? z*R)$kSnDhD;i+_LIX|A`L$PsHSK$8~Fc?-Te_g)D;J+4+6p9cdVS=h>=z5Zb-f`@1 zZB{HhDP6yN7G=R!t=)Jf!w+lM4*bV%oVLP??~)-zUXhVbq#xtEegO=lk0zMU_Q5VO zemR5l5s@Bn!{5H-OVgkoo@C!?GJxauqZ@7n-_r^fJvN4X1ek!OaH3-+NG}KXEmr7 z?1w&amyRW)JaQgZ(vjRu7L&q%@(ljbM-9M-5OkcnT6CleEMY zn>BU-ct0MiO6n$CcB)`F=PVMPJK_0G9e34tPcykwH8;GTI3?L}xZfG*Y_q<#eid*u z|HRYc8hv}q0^Bv6dqQX*h*SO!2T~e82G#@~ zR`0Z;;*pBz{VlL!l}J!1XM>iS{0WO@9a0nuNPffGcyFuC$fscAcq}xTB9MWmwfqRt zwE3wZLDA!0Lm88q0MW&X*D>xMBj*QXYZ~fhE>!U_=)jRa^?}-{XJokkv5x9casgpv z&7g-zu~wow=^La;#P(nXu;J&Xj^^zPT{z0LqE>aqb2}LppKT>kEH%{`5f|QgHv;+q z&e=Rour4oe+}@v-37pr-$YJ?1u!mVTFR9h1L#s=}iMbBuTwNe~&6C=9Ey)u;;G^dp zvAMSb{$t?4qZF4wANZE&ZIm58w_k%O{J`#=k8*=-C!PAwau>7}@Y-;zRkLg`+VXBa zM$;>=y|YO$au1!?$E(wa!ohp%26|0EtLS29A%FXio%>gbnGCxj0clIY_7n&}AG`JR zhJ3!RSEhM$e~y`F|D5{)Pka0fD%TS^!|-i;qGESqRj=;xJE_&SLEF_{514$pp5hzD z*dsB7^Q1-=G%^UD1W3bwrODi-aB>=UzF5$-0&lD5h!hH`_OTw9BXZ0&c|hm)D|m|3 zaOCwyW$=vYJw#j6!`}K=9@El~P#4Rdb{^Xq&N|JsCl(zxG>%BzUEIz+19JYua6S&C zX0|npsXDh3buF6ef*J4SJn_a$J@Nb%{+Y+pjVd@ad~wN*M*(bh#+ViwA-j}V=DcI> zsyp#LtLU74tKf-A9_D5*dmt9b<3RpOhk8H-C~!F`zcr}L09 zo3^^;_B=uqI+NsPQ9yZ4AKcX$iBnj;Mg)_#k=GMW3@m}eXd{wZ^QJ~uLU$Z6x=8%t zIL1_H%zNi$w%n?~v?&w-+X091MI;5`iv@Y6;{OcXhN|)C0b5Bi1*C%n1WOdrqXrde zE8oh*)??m`wEOIbCmeJR^quH}H(M-oHlF_?#tM4hZbUHH?s$o6CgS|8Vf1SG%}bV% zzp!ipQo7m_;XOKd!@*?LAEVl_PeboVLGuo7AG7)#TbZtYhMfB5ezu<>+DXrNp(Uu9 zwTdDAtb-tiOMhLF0el|C+GRWcs~Ls?Df*oyte;_0i7#|0VFx3PAEejG!2Yb}T;Gnl zG5qJ7&v%P&Mz0mH$o;7Dx(Hg@eD{buA;-5)iVqmN;NkN)Evcp4Z#;HRKHG63tYtc7 zUhdX@{}$Wsn*!@|5I{nfA9CLoqD;EhT{U^`TwA|*dFuz|a6sL}`eXC!>u`qn?ODfy zZ0V;i?fT^-IdJMQt$T!D-84O1Uc86$PBt8|c@v`SqJMS&m90}dIX)g_fk!ECWBJIo zmPgapp7SZ>DC;tJl(kDg>{9B}-<_uNs!=XpLfowrmA(d|%PfZ@)lBhS)epaSZ8VJt zcvthN4_`G>1COa8sJiy$FE@nE|<2Gxw_)j~+n66ux~1m$Wqk9Yl-_`kvnJ1zG3em-O#p8FOSc6Pt)2h z79G^DoJz;9Bpb}VZr<*4up0B#o*Crj@7Q-*$69^ zG4g9GjKZ)c*`3+bTp+jiYf}Z~!z`JDtXNyS%9(syRv{^~_b1mZ;I+0~?{5m&i*d)u z`1jl!Ru0=fAA#6)v=jXZ=F+fjafE%0SFsB66taHvFkG%zrz%UqbV>K~RhvN{cEtdF z(}jk=2c%#y#UUUg<0wSyg2$d|=BLL7VB*l3#BCcNysfZ_y^*JDbk`x?cmMv}GBDio zYV~?1RjmoVDRmdCw!!W|gIjnP+<+=d6q`?3!*EZ@UM(Ky&I_xvr?`TR+ZgBz_BSj$ zV~*5CxBZV13rC81>K(ChZ$xhQ0Of?OkFaKqNIT zZ4%W&qDug56hne>6XV-@3*@=ULbZRthG@i|k}F13c-Pq%B{JIgGW^!2bNZy=+KaZ} zcE+X#Pg7;ZRc^BaZBrNYs0pKSW6SvfF^P-K=wGefvTktlHp(!XIDO+m83=CD6sw8~yqU5G!aKXYkjjV=^JZgS$}stCCfJkKJkSgDb@KHT zmpxu7u0?Sx^FU#XgGnEtRES=u7SaNYazsU}yLg1#R|dmjX8o=q-iA7PLh2%wMG5Wu zqrFVa6?{EQ8n_1Q@H;>9`w?^&UX4f!6_mQ*$N<{B{TQ;$N>>bo`%59U-HQw?oA1s7zNGju0?FvOH`%vj z^{BOr|Dxl5mZh(w2cwe#?HP!+*7%lx$BPKH^K?b8_?v?DZyQtg(|pELQR^2I8PG6C zNwvVSXI|;aZse9fL~|+I^kRN;|-bATPJBcWe$lr#sx?j!wFQlw?8`!eM&5 zW(r39@hyIN7RFq}v9sH55m#1`x1@ag=w&oy>*-3X3={6gAt%WINVCzgmnv!26?V&f zN)c-OK4TaSX!&$(=^NBe&A9me_O~M%_O~nkj3H-m#BN;&(7&vWBa_uWhxFD>6ojce z1sr^P)T>eG5rpLr1LybGniD|iMkJk<06>KZUJbrQ`RzdeY5LPv6gY(MGff8*`~wln zWAIj>G#P_~^s^5hh+IB0KJ-N=P1S##R;SFqN-dl|IA!GM_+khwRWn%R1)a4kHI~p5 zs7i5bj4f~#{CQ1PB@jONJhwgFUOFZyXMSNSUcV_U=QVtrE%J4l<|h8m?3C`7JlzJp zbRhQ8!zKk$3*fGNpU2yP3pii!bIDg60|cN#AT1*WpoZ4~iVz=C$sH9dL!ki~xEzGS z!)sLqycetza~K?AB+6yFJlGMK*^en7XuDph3&eJz-tQnoc1YNSDtZTc2slQNclXCE z^LsqS-06{Tj$G*&M?px25eW{AYjr*J#Dt@0grUe0?4#Zh@tej#F@UlQgQS}RIN_F*jl5UWcp+FzGK6n=`)aW$HTuY1K62U z{RgBO0}-IpV~EPLo+hn@k)*<7cm{WWr{}(nAg8n2Yd_$p9S84XJ>d7Vobm?GfB6%S zn7qO#OsW5MyVjk%zk$q01S8#1@XsfzHtFH4P3gl(S&9C6lTCT`Wxw9+ERT z^_onb`}TXh>O!z(B|n_fo{Pf6?3zmfJLX@i=-p|RkHS=aF!DEOXMHC_V{Nk;8XR?X zRjUsW+t&mJo5ztA+?zr2oL>)R>op7+24CKOA4Q_hb6~yhb0BzSU#u!b2RqPy4U?p1 zh}~vfE}X3a>HqgJdsvw7#@P<($uG*f7C?+iM)kB9tgRqpA4`D~J8|vH_~KNnCzyru z3bgx%6_oTuB6wv9txS|x(EsI?pjLo{nifP0r^CKmjV6g@Krftx@OODehcq&D(oldI zIpMJBno)n^&T=n{PU{MM1qD_TO%xUKt5MmL?YKIr%xSnTM4&WEh@-e%6r$yvQdi@W zk?bW?*zq*}y}ss_HWt?AsrcXSDVwb(I+1%;m3XIGt50FW?L~c!mPV# zq+B3PO1y{RorF_1^A5$~R`;@srA(Y}D(@7k71@ju%JKc-JFG=tNq~Db&JVsz0j>uP z0|L;A8{a>A*JHSV3L-~9mI)^X@r1MZ2+kzK9oTrFmjTxDpB4;|SI;yhu=K)nm&hv$k#KYOH?LD0#iw69IsxgEE?wZJ7{Nt}G>F z1B}^QF)Xwc8&Nrg<0N4+7gX5U5Xp5mMX+0~E>dQfg;~ZFE?OxowUUL3%rcPnpXmI5 zJF+G_(2|jN&O5~=5W!IQCG`Fl6%DO{Zg{%_R;0hsc&ob8u;eYG0u6CZ3Vb_w*f!|) zfn;4vmuOvTaS=^Yw=v>gN5!18ag3qi?ZD*sovI`fFPl%@6t79Lb8!15S{QT3WE_E# zNgVa1)&=xNY78m52%n@m^x^78>h!27e2&23Y7KY>);V>{%FE2A@^Sir(@`=--xDuI zmB_!zrWJ}jOEg^%6VVkUtmt;rjyD77z%X5^IJ^0=LMpo<{fWKFaq;B1gg6Vy_et9P z%47o5<6SBl#S*;Nuq#VZ2KdG(i!vb#@ibO|GPh=ZcF|h8X4k7Vqit+x9%=h2-xyP6B<+AvW*LDjJ_IL0TFn^53q0Q6%3lU1FfjMF(K2w=5=SejFX0FSEQS z^PlpZ=onG$m|4^8GbH?rCMMM2#d1fiexmHyGH?=-5c zC4`usmQ-oK?aFm}fBFs(e)YQxtyS^H`+xX^K=E?XWkOvgT!6MZF;x*L9{sd{h!MMM z5GR)OB#mznU%~k6|07nObfdo&!m15>O9rVpu-+A(g|EnbKhmN|EqrC33MygJ2oW9E zs_<}xAd)$Uz~r#sb)huv7l|RMJUpLSr!|(<{0MNC#$8vE_I?9E@BKNbtp0d4g-xM_ z>?aEHUadRRsT)+*#AIvPC51%lsHJboBl<}YPI@F9x9>$6pNS}1pM@w2{*BMb@2?dL z1VJeyPgqJDNd(H*|Eq7ksi~y7Ue&C$SsZ=iW6w;C$#Se*zGc?k%x-j9Qe>9tsB7hN zyvd6eB0Pmw6r~=3P96j&Xo{t~!+~_j#TSUru2ZP_XQznV>+JB-wi)PHonc z_!?D%zRz0w@?(R%D~`l`H+50Zj>>10+vLP*W&aD4pBz7l8Bs}vV=Rg;@aZos3Osx3 z10APi+KU5!^MVF(&>Cx2@NEi8fX2=Fx~p?Te7AI+b`_uzYh`BJWny8Mrzko1Q^NmW z!Rida>idrbz2M(wWRBR{napX_{jj^1>i3%YVCdJ?^m=PfH)?aU<39*%4qgklr3{hY zhNPnFVTI=0)-1j$T6dS(m2v$m=0CI+uuSe}bkT-!HDOYm)oWB@a?dU${yLp|o566u zH|aPR5H15g2qnJgA`cj^Hr^kGUrhPyDesKxnG=vu#O$T1aO;U28eIDsccSP|Ut z4|?&!-@4YxASL;d;&~FiZ=X^A&?PQMJWkzDhAXC7fI~D}n@kt}FYbWYOKgV~l8-23 z3g>3MWlk!9wzE_b<yA=>x-~L{| z0ao>zdvVNdsmfasg3y%y?(SAT#1L8P(0P!%STbdMXQ{}Sm&EOYXVm@XB`eOeSZ#54Z{>~~(tT#VUv5hf^&4oRF<*o(G`uAz@M)PqHoh>2ee1LOz@$P95 zCG>As3)Lg%ysv@i2FCFFxmDBnu2rn+!@L21$MzZA8avOy$JR3y!Fgo+7dMBCBl08b z(o)>^XY|`|&aasUndncK5ge}#bXPW@y<07kJ^o1ij+J)em+fI(>p?_;0=cRl3J>$; zsFBhi35k69wbL}E+-nl2Ur~E34OV<2;FBStiz?3js>-e31rYpjyi^u zdkGH@s_N7GC81bx72I?jC%Fy$e7}jOILb7=K6*{{Zy%D!-sk++r~eIi%UsaA@7JwqF)w!v;4Cun=|t{2&dK1L3*?07?k~;>MwhqIjXkH z&f-iXE(`L5`T^`zSYl&3$k#R3nFmDqj+_0P8sTduY5S7W4S1&dCU~ zGM z{KV{jH^0Y)MTBTxjuO0i+lyJ3`u)VbPmyB%uflIQlgjO(q{Rer`}ZV&ALx+P&otfK zjBa@$dc7C~062k`gr4peQjkb7K|zD!L-H}~8QI0D$;m`~v3ezsT>Zq2)?MKKB?pd{pj+Daw9J!=}GAvj@EVOWT z;+@fx&G_`P1zk4SpV~mR8MC2Tt8zbYYq1F<$$H{sfR*Ncm;-_@>S(arD8iVKbKgZq z5e8RD>2s*(w?C8tk3w&#=7S$xeR1^4{EQY-WG;BNMpt7yp@Eg$9FK|BXO23zEq3()dTKr0#p|Wsj$fm;FVQ;doY2b zTHRv0M`)h0-oH6MOjZqpS^!bR5bfC9moO~7xy8Hb1?0cRY|k6$)=@DNqF}`j_jL+A z&10QJdQBxj1{LGE1MP0zqe>{>!LbSyVQRemfYgKOLj&Uilfo}p`j+~P~ znmheherb}E7K7^zULPbD3mJ{NwZ9guYyZJ`@%>e2( zin3Mhb>uegCw0?t!TSxg@z%@IvX3`QkaRX!Bq;8p=?%Vi#6-b$ri(_RrRdg4;e|D^ z`mmiM{Ov|O?a!D{vZEjACL2J`M;x;!kGS+fGDEZrNmvs}ub?lLW!|349Ew=K036xj zJsh7mlQ!d^lp?5{SoT@e5Sa9L1-UoATUlE&qX_h|$soHWrpQ0vv};ifX|k&n`yYCa2kybbiCL(6h zjP0=)#y+6HKTa6H#eNG@B#cbrlf*5u#f$+1ZufJaIBFEqzsnnE@Qp&q-f`BAY*k?{ z2YP7(3XkaP1@4tTq32}s=s(wZ;I3*;N zpu(dp7#ThV$k3mmck_T*@F-eC87gRfTpXKx^@_m=b_TV<`yOcJ^Kv}Di~O50hjcpd z-1*;EIjf(eonR?jWNh91vz3YrEwpS?45;$uEght?;>UKY1c46%&rr!(F!PF2;Wvqb zB3%{4ETmRyg`9A6yYS-lCN{S!0Xz642l`DXJ3kwKMI#_s)mjg<>X~2yo`#A~op$gj z++815Q%dhxAR0IBoRi$b!JpX(F^l$@6jSUN>0lxZ&MjY;j|b${n4NKH5&G^}S-~Q; zWp!o3zgUev9NOotf4JK}Y8o$G`>Df;bJvw$pT8vyfnhomx~S8Au2(<-7YP_6lkQ_B zL~%jWLORfNBuybx_ur<(5a?6>P~C6|Z@7f0anQMYnJ z)$Y#|CVOF|&}U+Q~GG#edl94$*8&*f%bV54fKJ-c5PF%4w>!{G~{@8 zEJvcmObM-N;)h?M96=m}5T2kBLUc3pqx@`H2Jhx_l(*}Wr{XrtEE&Proy#{hF4+5%sNF73fg*|9=y1u7Q29C*ZX!vAj zIvzi;81G9eF&|ftm#st9dMG`$3r3bnv7itG2dKXWu2X7}bKUeQtVyqCiis`RtBN&gm2eMWtVF1Znk%UH*`a|1F$KSkTiz|>wchA{5_ z8!H8-ihlghY)spizlxEz2ZmRmJD~KSwK$N+XN)(>2HtN?T0d~gl{mXZ`v|CV@ze_KWL(tUK4hu79JiT>9A6VMXI>XcMiwZRup2mHCaGAhsE zMyoLUMH`~#w}Qi_LMP#)zJyvC&I)JXz8rv9ODD~&Kq$c}@pva*f1sB?v(tm4eRWv`4f zE-$>0ZFasj+el&KvGANA`Y_qpUVCO;_2z*pg69m_(53Mfk2<3f9I)a{xwm4RJeEG3 zQ|KHkp#>ebKT90PqgBJZE3SwhC*^{hyMh;`*Lc-VisVuZZW9m~5XKKMN&i5mDuI-@ z@2o;NM2fM-TVqNOfmIJ;8jvL2^cR_-YcHEnF4 z(PjD;-=MESuMh=tlJE@-(^~OZ?vY#M!D_67I@3a3a6}02#T8-5EKGzA##6-#0;~nw zc|M{|=&FAiZ|RzRO{xD)!)OL{7Z52=RW|Ldf;TQE_yXzkdpbloa$1A+N(K zBCe*-L+MzjfMpbzk=3&149|J-=`Q-({3Qm0ZIG1dCV}ys}l*=kCnKATUn0R!-PyU0q!}vTm-XJPqEt1TE1$` zW*{ido2-O4F8A?LJEp}2e=2(-nkW`t;XY9KneX!!SpDK|A8^V4Akm1=t4R~xwyw^e zXi%3Y^?VSiQn!J?L5H!jHiEjZDARx62`XiT1?A3UndWPJbej_GgkjS@G?rID!2Qj}t?qNFE|p zCK&!hTt)z;vo11dVbv{o0+_WK8fYPS2fYbXlm6%M#NyfxMo%=8a{WNMS^FBMwqx`f zrnJc57;&Q?gSnM3^=CHV?#Poz#$P1H?pKrcrU^1dB@npCvzN0LE>L_87Mtz%lS5w(!Dj)^)AN7MaRLg#yaIwzBALa<;B@ zw-vg#d+UlggBZ*KiL7hr<5cAyX;+V_a~PB~gFHVE5?_O-HdI5%;2}siHZAl1Ci`Sd z)qJW{QE63ZAJ8%PN@3Yv%ioh?p{2W|b)NKn$5`V}ZW837N zgl#ADFy7kz(lPd>{r#L(7TRui`UlUtZM3%)W*H%v%U}%t^m?B%n7xt#l`VemQ zCkWWea%4*#nRIORTKaj=4X-Bkpsk17V{dtGJ94gaw%%6C)!x_-i(QCyK5eFIW~WyK zc1OjUg|SccJ+;v?8|_Or!Byu6^@gXO$Sxi)h_;f<-hy}%ssy-t`O#TyH=l>+t*%P{ zFk?3#Rgpm?phxh*-`magUJc8Ns<1-@vdOf8r1S``*Oe9LgbG`2vu4Ic-Yj?JSbvN z*zz5lcxj%}~lwe#JdE zA$Ev|JEMT|&l-a_vZo$1v+%)5?g_?0h%Q`80pEvPUe8+Bf73DJ&jQ1&0nt z(h~Zyy@Vs!BAS-v?ULrksT3zp3wwenEvZxzW^ekd`k=97Z$IO3I=;hOK5b4bP70MW zKq_qQ#_4hYTESKBdhVw||*hiyVnlbtWQ5 zNM}GdRz}G@7)#?TQECAaf9h%p^RpvkbYNBCRX-EDkD%kkc}lAH@#RIzy^YFckOa8! z=_T>jfH_ZMX&kP}VXe)i)n1YEW2+T2nceu2Ngf7fPC(I2EUy< z@!vW9oKT(nB}pcm?9@gs&83?_mc**5B>BHCt8z3R;p=4S__MFVIsJ45PLT_NeF|kf zW6fXE#16==pw*(y>9SvMKd;zH%vwVxi%&v$DiZm}-ecKz3H!F?ynM9QIjp6BIw82t zF&*Ru66lnjFGbzTBSDq|eGWJ4%?|rEv@vdo_Ex|IT}*C@Ya3#hip1>B3*}e*Uuklxt{MgzfsRZnD5z0& zkx1GBrEw@~CM+D%os6Gqf<>~kyr}M2m}!5C!JKcKz*jT+&}tgfWCh6~sYeP0AXo1N zAQOQ9VORYh=-W$|h@LcB%u7``FA}Uh8w=25m8sR6at6mzP30WSC^tul^+vXLqWV$* zc{#m>>*4#S$3BDMKem3q0%E3}kI)ysO`t?#3e`Y?_I5X^tt1cfFNNR_8l0Xf#E}1Ea^gg*O^2U9_h&e!9&5z(m#JIJY3kL}WrQeM zVDctN1DO+$q#lcVtTBmwW9AKo=+~7nnyW1QhsoY<%zX__D+KQvSJi0dk%}jWgSUy)CUE)V#bgF+q8=aXl-S>h?(`&`(bfx{EW-KC9@PG+1MT~_2J38B8@;@dYJV>6G29)Z;D~^&-dylP(2V9Y)}&ntXnivP8frNu;)pl1Lp;+#3I zuTBQB{THov&2!o|D&>Nqm@au(U#h(+XowvjBR#@?ifnxQs-U6dCHq%3pr3eUz#4nG z-t?!0?yM@|jISIMP~IvJ&;6Y}*&o3I!!SkKk?IW) zS-KTWE6L18VHAZey~|Y|Np4@*8&A{=Ar#0}ltoSPzsC(01Zg=V=^WfSo2~HNiX@hM z6%5#nWdI{X_OOQY3WjGaT}NHTRtmuZ%fv<)kJhpMt~!OH*i^X`tL``=jxmCh~d5@2Qa9fio6*K%ah z^PRXDre$&R)~!AxG{z)CunXlA&&~-0Th4XtqD`YIu&Dt21^hL* z5LNyK*8gf^xm{ZKt~QtKYuO*mpi{58+sj>%yC^wcRIR2D@$=u~1g@eHHG5R^6HhUG z66NVev4rbQ14eSqec!#1;LE;=PdNr#K= zO?KY>g{r_}x)(dT*%NeUq#Td$aPRq%`0mleIM~c}JzaL5?911UsTaG((k8ADY?G+J zOZ4jvrg(q87U>{xVy?H@sr~`Zfe_v}B?cg41eY*dfEx?-Usqqj5yjx~_CNe{W&+h&9LNXe~ z!)|!oGtD`kl+GCp`A3j5*@R~2bD^HyN0(i?d|l9tygxX{SeaKLGzi`X*Vl_s-EpRz ziA~r%dPVt%K_NA*%h85^>vqz?W*e>f+K2SUht-oU3L1Bkn*aTkfkm8#kxOW>Nx9pL z0HE8i;a6Nywo41}em5;Tr1bjpz{<|zOj}t{+Ymi8j}`B%jF=CH)&crQvL`s!-A57B z%kd!;eYCAI$8xYrRaDaTMFh-naa338d|m%Io+}5DfpyQyAjv_crCf!-j7X9H;FrEm zDWu?bnNykGQe(|!x=0%A!F2iF!9RI(YydX*W~jE*)nuz;MQ{5N|iUR7V#Jr3ioSmf}4Tbh3<;;JzH3_dM?k0}cF- zU;@aGCZ3X$ald*Kxfy1o{-?%Qmp~N6IxgWW2Yl%=kEaf{Y1Z0?j-k0*Y-wc~T0oWw zcY8=PF&9W??fsUS=Zqx_m4HzGd4nicQs6A9v;6RJ!#ozx-9z7@(-m;BKE`uGYM1Tg zrW=pxrzdW6Iy$*SKoDaKm4?Rdeg`|Q_*_Yb2%133TcHFqh4nV)#cr@DIn&*j&If@H zbzP^HGM-)~a9KdlrV^nHYWb_D2*7{3;F_0oIetMtJ9%%Cj(J-1gpa8&Y_i0rE|5Nl zMt$7GmBjLHUngjO>F+Xu;NwE*n>HT((sKSV`?fhj;xvxlYz;ow8@lg%RE;r_rzN{l+A_3b7ritR1ZxO8TXlxl|zc7c9v4oMeV&wCzlVHS@9?|@4 z##s3|hhq*7xY2WCVL!~OnDC&G6^|XDYyBQ-#M-)LqhKmL(!ydc@*XieR2WdpE}*fvL+Z`(C|1^lfr@znSAQv42@-TBqyvzpS!Pa>geQNwo(SQ67eTV&4 z_4zY6(6i@oeFK7yT1h}sD4>fa-+te2v1am|{bsiN+ADY$9QRaY$f|qg>phEo@EQ{> zWe{tip0erBbo}&pQT5|A+^?X6en5C9Ml6`a?w3>I`|QZ|VHEsyU0EPDT~wm7H{z@c zaL<~&g4mtSkNJa-n|R_4Pd;GWkOv=umM&Iizrqu_YYX)~ys{#?0|wu@+vhj9_riq= zj*tX6CoGHfR0Fy!Hlu%4z%vSiJF@h?+pAR;H;dHJ(xfZflCF@hl9`5!0^McXEnmoK zngSAp>@hFo&{JCl`!M&Lhj{fc5<{5*kWqbCr`QUewBu383|?}4IfC*<>FVev*hj?i z&RcVyxP*SGnlPSK3XW|1l)Z!*Egg4!sy_|!UcHQ<-cH6Trdm2)OUNue(`mPVgnZ{Z z&k-(;G|Og$D27(@JG15N6=Bj7K048KYjVTIl0(x&8pK~y6gVwV?jLb9wvmqms0ogI zg1cfqNC#rGQjJFB_{md(?fsX~nOfN*XEC^F`>?n;22gF>nZEnt#}+Gbk`c|I4KP8~ z`;iVP*+)(#2TaJ$7AvK?9p7$*ZKQ&2^kLyM)}TglGz4*JnFA4dqzv?7IiPs7K5Hj|9aeuVI;A zxGzTS-wOT-nLoMv1Bl;o2a&D9b#3{tI*8Oh%(|MmuG~zE!lxXz+=crYUe;V^j1Q@p z(x_nBPlB+VoqIA6H19`2cjN|y-}IuV(io!yjE{dSXbPG z_08M?eQ~1j@|9FikUN5lB*R1O6gLSEADYxT5`*-RiBoUCcbTo}O24_qhx>Bqiu&4E zbp5PAGStV%c5?~|xxqFzQ^ncz{x+prxF81Oul3tA&F(5UhKjtUi)Dn?^1fI`z2umk z5W+&U6ke2hE#BTKY_`RKG%k*;@XcAVf>2llxWeu`XrI_)d^*0bb#a|6amDzzx;Na%$f*mDU*gS4tlj5# zK!42({#2(m=31N~n*&913^cnCx2FpU6r1N>B=0J}l(UF3X?US|{m>oU1T>~!kb!|O z)r|OiDY;^D^uY~nqn9Gjb-BfDa)2rqrd39rS)1MkAWqjnQ^fx+oQ@b^T%o=4V|W@y5LrEs0ino&PabJNx*ylER$7Od9B(6cnXgQ?CwbB>_+KXU^U&(A71OSl!uimeOR!8)7BlCSyoG%G@j zIzczcb=MeTU6NY!DMN%H{!s5Feqj$oR!YTi{%QdR{avmCF7ps@Sc>8n&*eu^ic-S> zVW{k@q=Ph-Kb%1-gu)dL=$=r3UGE_-zwOb-$0O9|Ubu!88vPgpU9V<=QeDnV{j}|~F zbT~kEyb-3}AA4zIZg~a4rj>PA2bH7Oqw`nOH0}I>hpw~>w|Be`sx+H@uTjhGl#0iX zljE2D|NnPM4fLqs-acFutP%uP3veLGweCuo#S}MHI7E(EAO7K3-+x2Tc%R0IL`%Gq zmO1z`c{A#&ARHY+=c8@s3iPSN+ke>JiBJzCuraNX(FL* zAEq;u7q09^oTA>5e<{UHRI4juUX?MJmvP@g@6)P7vuhYg>YrzuaoVQgEba?zy7y_4 zGfYl;m|#9#u46REY)cV%Wq0AFH;;an?ky6go?rH`GcSX+U8)t=F6;JZE1NkZJyFat z^nhf34?SF~n<)Y+4u6msW_1NRzYZOralBu#m!m#=tvE5r*l)O@4y67ihALD7vB>Sq z@$?G^jy;iv>J3?ctXecqPXk{_j(0ng zw!>T8fc=-rDjEh3vYRC*9gDxv*U{6M2668`c_qQ>)K#-FZ97G(x?TJyM7&MsRd9jH zjPTaK{LIVWV^wqdrMo^J>8z7%Yxqyy;Ii!pTK^)aSL54vP< zPm-zBZ(0H<1e4maZd@oX*J~2g2h#z||C3$JQ%We3F$R5-xolDZzGW{k<3SVQ>uEb+ z_3b1YQ54M#F6g4aKIvMpwShF$SS+%nFuTl#6!Zya3QFv^c|Wd48!{KBpB(*>$V17) zw$soryB{Q>%iBgy_uep7cVsP7SGdVBthOKSVpZ1mso@qJaP8pRsvdrPmmUR_!JW1S zcxd1{)AFl|Hyn2*Gua~vwHO-NOI=O!<7S`_UN|Mt^UQu8`kbSyzW~Mx=R9yG{ ztf=UIpy@}Bp~KDEERh#xcYh^pLt4F&XEE{;@d{OKE;cx(3DQN(c zyDC%(mHKD<&bJ#{OmNG3L>$~C*XaKv>ztz_efD)9+qP|MV%xTDW0Fo!Y&(-oY-i$$ zZA@(2_Ra6?yZ1Tg-nHK9T5t6~y?XUqRbAib`8;X8F<4(=fQvD2MU3s2FxX*G{R~k^ z8+!R~P=6NJ#6o42V;$%9?q(l;a7@2z=Pv4`&>IbZTf^H31d6)e-TjCKd}{6QOwU$v z4la2PPXvv2I|(nkz+2Ny)8ipfz`(9el7{FW^%i>~`y*00Khpi)5#w-4uH=_GEx&JZMUJs_5hU{_ zYA+b99ITo(Rlb}(EK$E#Eh26_*r?f(A^XRa+qDEVN?7LUKaPzywafqKh`3Ab&A@6xrI|R-_O>^G+|fYWN6d#!-EHr3 z+{X1SgVVB9SFI6H9-$C{XMk9Uzk?~isEq_!bHttIdQL~K`9`UtXpt+6U-xcZUJ#9)j(v>;gZ`>%nokXkq0_MaFpC!=u!Z?l;yJL$8O4oR! z)tv}Wvh(=OhYs`K#WI=>s)PpoLL8o9ezu3gae8j6M&$S)`-`Y5dTY zgh^z5f1s+7QwuYIuWRp`FVL2Ss3lVUPh-$n|6-XbB;}f~w@sV@K#4X`xBs2r{ z>JJ};#*B*LqqIv%&3-!)R3zlWj@6Pnu>^?W#bYx%mf|*J=!v_BvNF9ZXp@qyAolH{ zd&u z^SAECI;u%ZlMEqfzSG_(io;ML9F#MSu&@K+Kn7Ug>JZtGwFZ_ z^_3ZRonC(}8=KjE9Zu-X?O7-qPzWcWk`Er8j$B!m7ge}>gGRa}guvI(>^J8gHr`AUXy{K#Z0ZhE-K~wO~`+FgFQC?M&f|jR`~mSC-L1lrBaBJXZi7T9ZJX z!=5vxkgC{}J8ADD!C?~ku&4YkJoCq($|gO&jX)3h8x~4_UStU+bZ5VK4_=MdipP6N z$o~D`5gc+cu|^^+PPH}@zh`i=N>nklztcdJ9tV{*;dsuBzzEZxpkVrx84h%SAlt-; zmU1VzdUJ~bnn?mei6pjKLMm{OmN1eK64Lw6W3>hOWMqFJD4ClafRUhYqa9YHFez&t zF;OZQU{4tYnzw1=AnSJ;^a$cuqe7B?dzjcc6P_j8q4h-Qe#L{`KqIF}FO$WPE*A$D z%Jz3&Zv!^_(pzfAgWTFQRY+_wArt@80gNNiMa;G^g>;`Cf5~BpGi>^E-2N<->sLE_ zx_GY#d1?~XNzZuAZ+14~NP49($QPcageyKpgPik-0Fz0hiFc0x8&MG>;k8YlT|-~M zqk)IaUKzqPbHcXfMo>9xCyye{!5j8I4?Afng@dfaOj5+8I`^3@It7ULsqxzb09#0_ z*Uw0+l}MPOSec$H2h#k)i+srEv;6*FyfbRdH5k7p+6TscniYXry@Qvnw`oAL36U48 zGo-^{DHOB%CG6-XW{OYWtPSlz0Vtc&I&FLhEJPwV=tGEe)1>qz?&JcG#BTIYYXK`b zsoW5Xr0m3ILjS2o=rO;BpWM|0adTHT-mJqC-fr2}loKmd4JcPHlcJ4xn3*oHVcS zFHACwA%T4XK6U-Dy#H5x6TS{dBhSa@UBq?gxaJEfzF6wY<)cNz3+##^M{sYaUgwLA zbuFESa$aX=LueIO02$!C?^I^}OYsWzdeV9IQM;-E`D1YM zqZ6XcxGx-B40Z{T(ztoIX-)-o^7ff{Qqrprv<=_2bn$*dXxvPE+kr+hdd<3VZtEEH z^m|ai=6GMf->D*bMTA2Gy9`S-sWcp6R`FunQt zI3gi#6oI%XdX+|>{Lp>;{2q7Z`7=corZsa?k+K2fcM?Fc(R}*#2Dz^!UyWcdm2U53sL=%;<#;?VA+1Rh+vX$*{WKlllC5h<-XlYh-C z|IieJ)&2Q3A59Vpmy(9@7;XlzxmB~>Ol?_j$G*Q@?FBkCKaUd8F?>$~oW4z;@a4`d z!BRqSCZqgy=KF!CD5We0D}wm10cBC;zGWC&9%1Fa^b~>2pzpzT9Mts~sQ%9p{BEw< z_Xi}843HNHq`bN?lv40#_^|e>qcAVrdV$%_ZMPxHk={hIs8eFFp$L>Xu3vH(Z^uBq zPy$#}*0EOoy^I!5r2eveMPaun48c#{8!d&P zD@g@e8tS|LyA%&`HDXF%z(R=&N$X;u9_1yV`X+%0=v@-2q(yz`2IuE62OVDpWDMo> ziuFyy58<)%bG8JCD00Q|ViAggEsZb#-R+QYwkaL^d%ihJ03y z2Tf=`7m3OloLrj~liB|s>uvF--JXVvGs?NXDo=`$&8Y2one#K7Lu=w4w>J6ruY?^S zL?$OAO|IG{F^4tsGC>9n4Oxa_Pq`-z{-wY44suTtB%e z4Qn~BX;&qY<#w{npX~4`?8l#INQ$Ar;Yl<$eh6VP7v&&=Ggbog!{*N0PMZBGzidG9 zu+^I&gu}}4>s4r+43Iy)O(Vb7FDHoy%m3$4q3*lkj>B#GHrV#c$BvEn-C1z*#&^6+RY|fw%TN-q7PW}vE{E5_V_*?1Q{N1h z_PA+ABLZlG9W`KBLMQlC0m;r08`Bk7yNwS=cRM)}NIUCAwovJ)GszFLQS0QoMqwy* z_5B-zNgG_L9z7)xh7e@OJCzWgKCvbpxr?fr&wu%9=Sa*!9o2<5jy9?Z1ItZ#DUeN{ zq3TP~q>ur$N1F%FNLQP#GE>+C4-&X>9$waze!i1wEame*!>n%JlF4Jr1IB+|DBQWH zaX+8pKMp*!`bykR|B7)K3EtzaU$DNK5DO!x<@2GCpw7KvR2=*ZQW?XeeSJ`&6GoBP zt(#-oS#=p{@N7<`QJGhcl1!axQ-~)cS)O2Ch^GJuQz|&VvZ3fHNr1?eMEi~>b7jMU zFBk)LWz%mG%Z)w0EYed_hc88*L9K+~S>Wkkc%(2)tM_{8o^KhQL z-9hh4OMYi@6=%^7S$3MUW>LBx){J`wbB4>Q(MCfv8sI8e7#rrF8?xfGegCqs)MFwNjCO*% zkZ=@h=leOk6Ki^k*V*L+?fMi0itVo#-JG%cTo2xGk&Wk;%y8ei*$e2i z$K`f72s2Et|HAF-te&~QqZ_%@TW1z^kN>PQPr#GID!X=%Qg3p}GV9s`R*kWT0_x23 z@#Lt=>w*;q(YSc`rE;CKgtoXAFwZUz=J_s2hIk?pS!Ji@f|f_1cn5`$cn3X)XY7>$ z=$|}$IR7-IFak3o*YTM^V(#8^RFO4;_B7At^LJEq0>gOtnI1%g2i%}x_kFL&Kqb$} zw%S|6`3|$`bV#IKpKcR|<*vcRcRT*o4^E;jAZye%>j#_ZxdrwfYKGA4*3L+eRlT0& zmn%NvYNwm7m%ZTXA7Os*5Zb#40M(G6klEbmPw5FFAtm;G>MSMLcU>z&lioIVXd~=! z@*NnzVK0)*Rld`DQ45a}dpFg9%L}KQc89Xq5{GI&n9jSr^1CX;HMNX_<7dlZ1nRVb zQ@Q=6-TOa|zlfc-ELs6Hw;uyfNhd=u>AZr=`>XAlE8Ax*g@|SN9M7E^fP(iPo5+*a z(4v4Ssl$Wm^2wg@F%~z97Unzg?K9-Kzo>iyslSS~`tTt`bXS@bVocnLOz3CNVl&X# z@2gD_!0$lr1|@%A^Dia;*X(&tG0C3+ggUYrH~ra_<^Qf~5wGuKMhVE#6ftt|W9r?` z`eKsqE(m>WE$nc2KAZx+WH9v@^0#o0Z0dNWm)uoihW(2k4aaUizv(Vm3DC+Zj-*Pn zoNrL@WN*qxbp$VI8E`C&dwU>)zVTIv!J;c0@D7LtXgOW{G>rpwb+%5JoeCvzAk%=O z3+4SmLG&e-r%?ECw|-OvDZZQ)OWVlW{*xWW)nl)6? z!cA8p6%RwijNG2DgA7NY{*A>Rv(UohM)%0LYN~Dqy~sEDQRmOta;c2U?HkD|XWkd@ zV@^_I<6!Sbc>k1=0a?Ng8QlW7LR4y;Q8Pm;jL42XspiK&teRj}?eP~Ms>U6u{2Pf4 zzDEq|6^o5sTcs8tq-_&b@PNe=t8KAQ29-U|JE|?yZMLu^EMdws)hA&rR{I< zl-KT;3ft+0*hFwoxehszL0)2Iuf?(&y}Yn{Ev)cm)PoP;){7g0V~(Ap!QVFHXFbw^ zo3OKYzB?BgM-KIyXYBV)9(%Q)vEp?}3jP>Edm)w!-K#T~ zCYlO;-vtGn5jQx$5|6uY;3kI2?8Nb_-R#v;=WZRDS_)UMP*hcWQ>_roS$~10-ml#o za~;+sAEnRTd1FT?CAg_RH0R0)|Gkk()8{cM%=#rS#u|v>V#p`rrU%=yuwx@RF|rJ41XSw0O3w^Mj@Ywt|-&ujt}(o5&?`=1N^Z zlhDE4AG|_vx(1bz+~)vbYgh;Qqi}XahS~41mrVo7W@~V2A9>=kh`S0EYbXHiU?`Nb zh8t|QpdK6K3p&y7;a%qE$hKX`&Kq(w_`<{91XfZ0DWGt6z3OkDQD)Yfw?qq~ooXAb zK@2~(V(Da9yv^rQ1oS7EAu2}_9_twB6?)bRyPM@R2XalOzFnHwjyjUqMSY(#+tmd2 zZ(|AU4f!C|KK|)fC(lxoXX5}Gkkhz7-MpueRH&A)b?WLvlJ_Qmb*`ThhNG>V4G@@P zd!Kg+*=8zMRy=c(Ib2O;$V+xRW z_1>y~AEUWrYs4JlP^~j+Sh_f%!aaJVsN|Y-vUFODDBSE*I}^eP#cl>1J=RiKB8sKL zxf!DbENhj0dH5y!fF}Q(yW0J?X@4_Ks5bz-D(j2*{roU69w7V0Ek`jRJYBR}Zq*DbQ?;Ps=G)G*EsN3hn>P(Vd`cp(4uETLd0XUj-%H zkwk!)SS)AF&QZlc^0bYyk$ml8x^!)lzp}RrN5Qt{%j#Z9M%oY=e5;wTjE6lUyh~>C zo8rrS?S>v=2Q70JQUE%LM(^MVz)s|DHITNHd{v|fgOAvACe65T20E-2pZPN+{{e*D z9O?Cp`z7j%l9f?XB+7+|yOza|FGx#6;laXIh&$WGUMJARKsW$dM9;i^txKHhgpKJ( zv0&^q_=28*wHa$Fihn^fwk=?>)_V8`sY4kl{sqExS^rem{I` zf0q-#R3&XhfxbnGfG|*r$@Ds=9`N2NQ7|Tn&$7udGl4Iz{6` zm9wclR}E!IC(vmN zeb@vFc~@IvF7Oc-JQ7^z71&E;KZwyrKE=o&8I%eG_tgTPVRsR`&w@j80Twt)LtRj; zQ{MDbXkx^D9i#wOy&Cj9*|Wi*rR@RCUFFoOyE5K2S|H>2xKGqfEbFX}pEkzCjWVz? zBBSWM^F>QY{2`IjZpR+0wK~h=BVPzOXGF++X(*tv+%biPb8zP^L7JDf?yq%tud#h5 z8$VfXw^FD=#BFXs#f?k>d!k5D`Yj<_i6Zef!o2A=!W{sjSi+F}HgLAWreO%(F+4Ts z;^$*~pCk~k_d@mgQ8wSzg>C!!5#b_UWOaS{nfi}7a3ODQyYi-yD@SQ5^Qfk3N(nGV;klmxUN|5{o~dCAS@)Zo!TR zsBQaE&;TO&kI^32_yjkL=(P-GJY|%?;eqa4lX!7&p%C|cb$zNa(5ZHf2FstGV}Vz(WqVdWS}0!9DaGzEGGT@tZt zVc=-()0{+ixYjiLxzIKho&NGgB`XwUAw40abW6L9`O z3pFI}x5ZCCivt(PF<(P8lm3~65~frV7T<^i$qo#`m`RclC9C|#vf$ZbG}$agDI03+ zccwoN|0@8?4iRN3xw)8&{KKYF%L8D3-8(nRDtng1h=-*2c-b52c&!Dv1-fK0blE5J z1Nt0CnMT-6J=q41Q9sksap9ZuDVLj0PgZ<9-gCu7xNSYmx-Mn^Qgb3@?INa^&eR;C zE1r3q0g|f3np1oSvxZ?#09`sa+L)yf%VqH%Z zYHqZ(xk-rkBF&lzE#u^(99?qpr@zxR1N<-UMg)a8B2E3YFXriy%kva`v;;+7AQrC# zBEN~>uxP*z2jHc$`N1-pq`?VF(6CHWz+ zvOR5*6ax5Kr(o1yfHI$t3?em>lr`AG#BV@#Fkdy;BL%B=bZO`-htb`imKMkAJV+x8~Fz+8+pt1_6*MbFBS2F<8s!6<6Oe(zv3bY=tPRjAX19a0P2~Op|TC2>X~(e z)wvTV*%?0?zwCDrKYesV_T5JpGELQbwW#dslPgC^E=!*>GYSIn8>wzPdj&w8`6}4{ z-XSD=;0`Dv*XAVTQa5?SsaZYXfVM6{rtwEG-nF@Wi(j7Bz&JZne{QC@B=E-4;rCLp z*9y_3q#v85o!;j-2l&i{nKul+bG$XoDwc&k4_xgC4{%XRUWj)wA|CUqC;Jp<4Uj11 ztgmhp8g%&$9pL_S5Ve$3Vl63#INX!~zflhiEyCKqd2E(DE z{v;e^J^hkar+jr~E70{M^u=XJe{tzTGIw=x9{AQm;FOIK0ytfNzk;g%N;T&ySW3a~ z?nv{P<9mI1I(@YV9oDVz2m2Q1tjIrdej)_=$v!kS1Mat%%bf-7W5-5b5N=Pj^|KYL z)c~TKbMzdnNE1IPDTqe=>06{SDoZ46mYi}N)}H5#Qi8+JNvLj*K}iu~0&Pn|=a_^^ zNp>M@Pe{)KU)ay0kFIZKXlS%7`dBEQQ-i+a=lYK;>&)*$wY~Qsv1X zHjz%wCv!;7Q|Ff~iYIw+)-NK#nqnDoUMoV?Z48Aqp9b`DM(x0?M+xJdo(BKWgk-U; zDwrmY7R3_%u!QRW+E7>}d~+oqo1>$xoPg(sdT-9zsm~DhrUKp0fC#pl13EXk=$&9m zQLfZ!Evi5soKkz#^n4pa5VTF7d}I3k_TLlJNj7>af$=eJ6o8#biY=swI!B}^o>~)7 zjeLS)xiC4g5nOazV}YakV}>18a;muR$bR<*^2}G-`H#SZqTq1fo_uq;24eI08MVnl zMsS7|nq`hmx(^pV`xI2V&*09Q(YR_A!(VpOoz`pV>Vc#_M+ZA|a(3`e-aTPUc;2fF zAYkKVrKZU!8kAAEvI~>Y*L)7>_22=}xGsHjuz$^|4#V!A46{@yLH&tEcRMa$mA8TG zT~I2x%=mMR zCM-c>X7cVdPOI4-6Sw{qD%}gP%vp1}=x-h4&)hf@5R9sVhhop%;bz9U#>GO29bD1r zf_|PK)oJdYA71KTJ0NGQ5Kva32f5x9bZmFg*iSx%`z6{hKcdkAqmp9a2-(r*B=zUXSiz^|PL zqGSG=(teynX>N{2U%CEzPdv|L0`sfB;_`)Io$A27f4%+b&AU>i*JCL(K$Jc-%s2n`RjqIQ*LPU!Sz#UL_&(ZWVa*hys-*uw=HjM(^IluBNJ z@kPajtEk>`VMq+To(D{iD^*7&+1d7u2xL2-O05sKjc7noY5xQ|=1E?T9_E)n4pfKK z)P{+X*e2)cnXkV>W7OxP@9jPY+A=Ha+sMTy29x<5y=({C+Pr4Z`uZIb5REYQP53|5EdnqBwq;xFJq;tYD5+0zy&-fh!l?^Z`1oCk&WH3!|`!kS+%U!)AMl zJ68m20Om*x(ouXjdr(?A5<)7taJSvb{*p?C_b*Ez?hs8O6*f)K5_0o}Tgs ze+T!a7%C`D?AXOnIED(VYZ%71W^DLz?33XoaK!MpQ65buh1oT;x}EkVXDh`*!Gq?p zaP2sc6&bTUdmeBrsUoICm`q!)A!2w=OS6OZb4{q6`cx8>^rR{!hm^L&N~>zSB5S^A zfK}`k)!^@#MKeDMg9t8RW-=8u2X`+*o3ff4yYJ^O1o>^>riBpN{ItxGnRMxtMRa%z zVt2ij_quuJ{c8i}AwA#xFr&{Bw=>I8ekYm&G6({^`CI_c*d@IEq1ofu>jv}vVVQCM zhCPbpXj~L^Tj%9V=~R;4+eH%J>OH)pv;+hSPSHopO4y>Cs$=ByR;+{4%v zC<>l>87J+_yhlaZqCtVnSU!CoG~ZX0!|u2gKdA8muM_WF+vTiv+kXs&Z#3fMjCa2? z0aP+rOa8^?-~)Nl^Y6S)ZWS~U4r_d#9YV`vNdI{BsP1=2Xg;G;$9&5-mUO47q%{H%YZ<_G{GT(#k zcsA%!9~B%n83Wp+zbQ-D`P8!*NXbVL01jcAA!OAXIRf9Zu#e^foWW@SN`$`|Y?|*! zPUG4tC-Np3(QgG;jVFV)+NpnJQfM2>*bG|gxN5BS60B5geE+L@>vRhBPFDSsk>Q(? zWr}hW8;6gKFHV#`BU|ljU=fgu#Gv}9zA;?0P}Cn<&M*jG9}^s{q!JA!9ay-dLYl`PyF)Sw0}Ro_&3FoP4v-#3543=QcC2{{@$rPnN~v$B zt5j_YvHX;wwl=?YFGjGJqmKqiK_6TBf2pQ#oYwM7Tr`=ps<;<8l2@GnS5D4$2WVei z8_QP#@9aS4>|o^VA%Gk*V0T3ROXJ-%QG;!0ZOL0b`wy$b0Y=vO;V41cP<&GQG_mM@ zqq}{>edC_ue_WQg)k0eann}A~z_ty*J>|wd^%WC?ndadAW`9d(iVHaV?u(VV{%3Ub zsgjjGfN%E&?SEVixZF4_OcmGHQ}FD&bXAylWXY`oY^JM$R(ir)sU11oM)&k5AQ!@; zeKs7r8>5v+z{Y&&*+?S!!xCdYAxO0UaWy>C5&*8yDw-Z^V0Fc8N*Ti8`2W{vies5d#c_K$MDI|9v?xJwZ0x$<3lk zz<)my-!FY-;^C46u!6Fg!&%QwB4}5Ouz^pMBYF$@QWH zP{7=$0?__Mzha(m<5%0Z2IDaM=6Rx$+=3y_ZPVAWxMrEL;TGZ&v*A0Lb^csA%wPUn z<-fTFRc~m!^a97}?NSYCYyd5PxFg{PMj6>oU<{UKckIduQ%RJHXWH&jDU0*PEjXXu zU~-N?(pnvvxKxP1HUm$yZl#1=2EVqTr3-;@ifZ*jJFl{Yu#)=EwZiRFcnVxQ~yG z+}Ii2CRqrzdW0B(A^?C|qFn=DAM2NIN=M6rwkq0J&xv4;qaF_gh8o*yobJ(iV~=bXE%!)##L38Bod!)-A&aG`1t?fJ?@1n=iPPLy{x-tf zywpKr+u5$W#$ zj7uIubdgX&=<-HmFFr<+LZ113M1P9tQmJ4TF>bh}7vuh`zIsZ+jW)lVaI9oM2s2{P z%-&%c60MqL1%OIPCt57kh|UQ;!~Z1!@o?rNqJUMCzD&c_D~J5KHG^|a2W*5J1nQu)jwWG_*0I$GwqB(cldPD*}F5C9849VJgaGXK8+agN$bZJ&j-lo~Q! zgL~c5n~g3sK8O#Qs;#lNnxY`v2UU@NK_5$uB2-LatqH302XqGm?it*HJ-0)Y!Zu0_{_0PS#}vOGjP}3HtF#0Ey0d* zAb$Cw1zxl!wZ=OT$VW9M{CEe9=}rfvt+@VYl78OYYOThX7~O!LII6Pe?p_dBnD4D2 z9=9)9gY9=bi!Bz)!5RKu^#kfsL7MMN*Fj-pOmUM#&6*3K{_@I9uVx|n`k@`2%lvAl z25#g)_%;Yc)>lf8H4d+{7XG-1KSW-N@rb#qz(pz*Sr7VMD%W-W=tS?Ndj zawz#-qBRVFic+DaU&05XP~won!YeK(q!~YT>0-^RE?TP$HK;)z%yn=&(1@T-vgS&fBVBxm+(h@hl1Z051g`E3(kR1592T(qP z2eD@i+Gc>^mD~SjY(YE$DtcD)74g)mU_EeP1nD-4%~gw40Ty({KX^3vvDgXe@(|)VE;P}e&hCo)`JaQ~^9A`s_tyx z{@oBjDN#$XN0+$esY3|5?Ok=l{JV*ta1UOXRz=L*D-JpK`LHTBOkWRY*Kf%7!#a8* z2=!km!7s!*%hKF0QePDDc8*{e@X;^|JSw$kj{6kyo-^vHwtR$cVP?Sg5VhI4%8j{BZ-D zA5U2s#~7CAg8_V|+^JYP#kyp7R~ny8(mM=K>l4t5Tx6a0vm5Jh`Zv)puAPDn$I?-_NP>?#BYYRptmCRC<|*b4719V4*U>7n<>-b zs{*zwe2tYY7V^=dbrcA>5iKLf7g$<3Yf-xcjLgu&gfal!9ppvj1T*=fwejrhpZvqU7C7Y`vwzm#)xTNZi4DGSmPpIS$o{!v64(sGI=-|p(bf}ZQtPA0G|4r?J4kMXLR zxuOnq0P}i>r6gemm{Z>eG#A_HU!rd^)$5onR4~;@#t7Rj%#X zaNWzQ=zdi18~dls0u>a<#+_qsWGDShY0FVhhFywWG5ghw!Y({<6ns`ilq>jF? zX(108MKP`>ok9%@sP_H3ER|wir;pitL!G~_1$r9}LCu8}SKj=2a6J_IOlKD1Qi~tF zH>qgdnLfLxCNPITtXrzS37tEfLm%?)&4%{R8d)1BcN@coPVfmGJZK?&98n1-9%_81 z0-)a|%af??KjB-P(X8}HFJV;9A`w1=2d-Jo90M{ae|DO?PpW;VWdJ%;^yd2XVu%IT zo!wJ1tfkdD1Ng8en`#3_w8BEvi2Xnw_6O59H;W$hW&Q(;5qb_Tg4$}H%FFK3PgnBp zL|R4(E3n8exkn$MU+ROa`(6#O&vHx^r|v`#KC<^ekUo?HX<-K4`fvxyb|AQ)M8c|F zTz7YssSxvm=ju%McfBDb%KoVVnjv7$5|6N#%_%>~De2uYh7BK`-7-{l`w)oh&eKk> zB@E$e;HhVvm%Y;@Ea6=O9;K7k+p9|pT}PJ=7fLi%!8G9Zz}jVyz`P6)km&Dk9AVX2 zKs>`@ks`|`91JeR%F{vC7ZBF)AojNst%u}AoUhy#kFz6~bffBk8u$@KNb2A8 z-%EA`yCPJv5Kg+_HF&H9}{!t9(s2hU!F8w=C!b0S_)P6XF5(}dEf_ue0N z@v&t0#U6fs&!{?CN&Y8e=(DT$Ovug%x4*y=VC<|NN6TN45mh%y*T@~Y?d;v8V4NHI zMfc~@AojZ5%#lp)RGYqF_=$v_%z6z~)*|a4&q!4DBu@b?jJ_yWZxOp86CF>A_DUp| zJizHJzawTtth)WOl8KvyCidOZV5JP5wqfx_pke{h8Z$J0PAg?=oI;sf)pJx ze_ik7z)V&PPrVCk!BL-P=FmTP>41tqK^JU0+V(L7_;5oJbVh&W;3QNKykFBxZbewP zZcUBH;Oct|FqsH~iJ~m6UhOx(Y2viA?yZiG)5G-6PrFtZZ!FvM z4JrP`C=wRL-3A~Cw8Zc#%R{-2M&q3w-{3IL1!SY!;zU=Uda!-{H9FdMniw)!13abZ ze%jlm!|DN4U9KoGp}zu>gM^e_uGBo`(=`a*)H8u<0qRFe9|3k=@Pmoz-2Af{4bF5E zy=5HmN{f2w|8F7_r9C)WE*V!z#0C~c-um<`@z$eYnA!Wys?ZmrQRXadyT=9t(M9D!O&vk!bf?gqU6e;#!I39}xM3IzRt<;Q4wtRtKglk7o5J~Xx~2p~1r zKy@Q+L~V)%C2CW7J)>95_xrxf*Oy%l=H+rIL-Wmg`%!-t^n7<=9a9lLJcWoC(8flu zZUMM{y{fL-Q$gSY>(ZYWig8yW=`9-)U)XBA*43PZ~pcWbs#kA_D0q70|)^Rl}PGLf(xefJVX7)75E8;Rr_lH(2wJOl?$z1 zXwqbMjH$G5&^eJ&b}?~f#4?x99UtE%Ec)@|c-V+#{p*gw7kuQa>n;}tt0?Ap{F;YR z)VuQ~(=3Aqgjdh00`Q`7Ba1xa0Qf1hWZ0$^lYG7qc^XXS3qI*LC(EvRwBm;&A=;6r zy)6vi8y0`nh`2yO=N`-toJxh<))v%wZ>A9HcXpOzU^su4KUB!Q<7jxKO;$VJz7rXT zbV6sp-(pcE8JIvJf{~wi415|lK+wg1cY;p5JU8ZY#6oax2n=asnmCaF0v-x~#!}Yv zGtN)RVk|w@`k+W!;RYvopu8N2;JoMJ1kWr(oAe`<{p9=c$IsoD%)2h6OX~K?JfVfM zoKJx7xw@e&c&(bGAaD{jz)*$s?tDGP_wU7Z*#(?~+^5?x@UB4Zj5yiCsFP4%m`Kta zTNrc6JPv~U3h50JgRPbQ7+`;cHR0*8s?76Z6J_ z&{vlnN~z^|^Ccg0owxKsfUzVC1O|gZp@9u|x@6fsUL4E}Y3O0j1ISwkOAsW@OUA1= zlGxwY-`(Id4Ai$H--(!-J{YM~jiIb@br+Fc*PvY%X8kjVv;d4}6P+X~`5 zOV?uxj*qXQqC++6x=WWiqg&c^P3!>c_OdVh_oiA{r1tINXO*6eUeheolNR5G z5>g`6j;aa?+4DJLd#0siX2-D(h$1*XMlhPpwKB7 zN?-D%tX=z?WM&c2o<^UiVuuRNh6_t6V{649jy?&2o+ysRnwK6}xA{rZpX8Ql*x{Za zP7K{&3*%EWy59COR59Or1)&+}s^RIeyP=uLc)sb*v)UKMorYKKT@f?@UQJl(u^zN2 z(6Y#vSgp$!833zN5v8Nh5r!8FP?_YEaOP>*a(3-A{rH<{nu_*2SlJF- z=olVe2%BQ>y^qjO*!qnhm?!9ZFNRK!zm_rQCsuz@588wxjZF~G#6w~*4n1py{XWY1 z8bg2elis-pvn6|eUCJI)*IvSOS*WvpS=MZqC#ZycRVPz-87Gd~u{!?*zz7Q^hW314 zfgl(#zP2LuLu?o_EI#TPhIe`3{VKp&YNG_6zKUx{!Os~QABDi0iDz2h`B&?fu-nb{ zGz$3~UV1_eCrg2`F1VVua~sL_C9`8$MR;_fOe`)(K5nBWg@U<(IDWlo{>jnR489`~I{dd?@C=*6w7F0S^haCzZC$#+e z?au@vPP)n5vYM&p&}1g(V92V6%zR;Jc!xUZZM0;eUk5~IhJiTAk3=`VdMLA$eG24f zq73X_nAuRkEe@D|Q$#Qm8x$C{+y6t>J4W{v1z(`C(Z*`jIF0QzwvDE-ZQjPV-S8LN zwr$(ClfL}D-g|4!xwFo>U+(>IG<(mUf63ba~VGOqSQWcdeu^+Cbagq|}*=SR>`AapDu+U&>0 zLOmu0f-?@RVoa2iwYdi-9HJSYZOsM&pDojN-rFos4@vqKm;=xazDJrh*`R_-6n0)n zz0NzJKjGJ#0UgYRh~h}`8fh<^uy{@dvmH{ollJ$sME6}HVzkU(>F8lj;~pUpbSM?@ zDG`DWlR2S8^nw1Jo$Ppi-rlo~!L@Ru`8lRsqKa5m-g6_Cre~N(VD3WIe-27?aO-GV zd*rKM3QX4F=lsjMBa&Ia00n?T`hML2azD9rM=O7CN{F0mT?IzI5K@f{NCGfUI64hAP=Cj`&H z6^Mma+eaWJ^9fDw74-~mmp18{xe!kG$9E@5>|{lVnlT)bIo2RttV(#8B0tM8@RF^t z7pP)}z>Fk!DMYPAGMty*a$QQcGU(N0Mp^My>@=Nt+Y?DZ)@WYS$7E=QV$NcR0446$ z`UltMfJ28f!{>zFzO!iK`SX`)cTasdCoWEyoE$LCq~$u*xnV+EQUDG4N}jM(MCS)` zNa5K!;a3k6+F}@1^T?J_H$1cc?so{}jY6$ds!G-N@@| zDg{5XH+=O+7G2lPgp00dqe!9Wm(6we)td&??O9NmGMe!DmhjI;59_b5K;Gwa^3;5O zQ|eVtKRD61tf)v7tx5zB8pYS`^Z2y}hflhpyR4HO9UmxnDb=cwJvvzng=4Vf#QV$u zi9rraC556uh94n>gkM}>S=1S+u5u^_y<){p*j5K7D!KDZU`@%woZ!af15PgA92_fR zp`cQ&|H7AzE{OqxZp3^R*cs!C`-ftt*wJKOoq{MJnIUNdov?-=(UpXK zm)E*a>%eqGMK`4wN4$;N=%i&a#e_I(|A#LP=LA6(ITJfH`p51tkh2Tpa=_Z|b=1ee z?{ol}VYKUcid!3t+?AsZ=1XHj`^&~ld=m+BGAqLp-3s*KP(Qdb zlpQ!hIuVXih=&Pe%+I~&k{T9wG)c=#u5hwtTq^r@B7B}nBAEjmOi@VSM+%8p=CuN# z-R$9&isNh%!Sr5TaJz#qj4;AB{xLZ{MUv+g6#4hdz}FFP2iy#5u6Tvv)POkT5(QH; z#4x+q47Iv2fbK6dMQlIN+DKYm-Fe$Du^3(GY^9(fQweW0o@yy{CNFimZV91zTx@TS4%cvJV?-8)1(DOwCxzaM=ZB^1p(s()^^wgmW+!$W|tTm_C~(ne$ykm-swF6U}`1 z5^Ag*RuE~1T6GBBAD+UiQ9Xe#Eb4Y~Sv)Rvtb7{DC}M9fCh_X(^}|h|nk{IuV<){j zsSmb_z7=!|3!i^#Fjy1=GYn}B}ZzfeHK@bNpt~CHxzMQ}{PWu}&t_JN(JuuHlJ!PcXfbosW&x!@-gv*Iz7c#cO~R zI%!}^?QVJVHk^H(ny-=)=5irr`e>7|Yq-YsL61xmVN|MeCDak#p0MAToUF z+_cWo5Mf(70|>A?3S>RnjIxVamu%=!NaD`D3iEO+j5h&Yh&O1l!2J8 z)T!NUg4k?^z}E4Ve$mZ+NUN-0_%j$V^DBO~+RqSiCX#yXbnw!KiiW)-x0V?5+D(>x zxSI3vAf{K^2~(Nd}YY04{@=iXoz6q@hEJQ!qkQa}|iSe}_c; z6d^3u)Q!jG_EHFTkjb?ne zq#;85%k}D|4a~xm8pgB1So<;5W5ap?KZT|v3M-Mk+Xe7`7ZtL@QQObOi7Gi#_I~!= zi$b!g(4eGVR^N$sl;;wrLA%wmd>XDS+HbjBuH^D>`w+*1I`xDDF@Fc`YlJIMc7;8{ z;Weh|G>{<*+AjXx_d2?EFc7{yvE;{Nh+y$@z3>{gH)c`yyRK6xr+mxM2 zL6R)*hispOeG&y6+{B6C@NvAUP}DHSotg$*1SbLA zwq0F-3)ShMCQOg_7ta^C7-)N_u2hvps6PFwYfRi1n#XIOLNIosKQ#(ZBae_^*0?Wv zP=ChNAGgE02)Znka&eF=s$F0+4Fb-7p!k`s)KOResUss6&wnjTfqDobSk0M&+IFNl zG~xjsW011A$oz*%jyEde6SF=g*+D47e+c86JtdUbZZH>?J=|+Ms5!)OyvGv>QzId2 zZ-XnQHz5pl&k^{nRHcx$13u>KD^3c{^k0=(`?0oNi|Q5>%f^yb44oWXu)HB$bW>XB z@8svjj=yBY1xlu;Yu~*Wp;@prte?uPyNv@~Y|V-EWlo-^#(!&jYl}q?r$CZ~bThBa zi{y{8*4+Apup?_*n9s7huW}^;7ENNtp@nO?X!kY}7~Tl?P);>x@dqVzj(?;eFR?HW zhprG!61eK3h9>1?tf6wkjRWY1chC_5Gg%h0wx{^j6*~A=bFqBIv`Flam`sxmjP=j^ zcOYhd#UGD$+H01k!z|MkL`vm{9_$Y7a(Z`jPyM(pL)TmRc~Pl@-on~&pY!mU)|CKZ zA#@aYSxz!m&4>UBEVQ(kp?z_`=I>$~Qp&vc9KAEsESlVDM&<@wk-yRk@;cKC4tJ}K z^yI?D1m0UgPAK`ZoH6X%f-3=#=J7y3#b_vWHwBr|3nE)MV$?MB`4MJ z0|&6a3vl9J9$+Dzo?v6Jq4Cee_C3CR@UUo<1QHo`#Mc=Y{5#Hw2yzl<57>V5RW!ac3h>c(NDl?PY62N z^!t$-NV4wTm>`f8MQr6CYxBq6zRAv0s*KEnxOnN$J#%MRr=~EWKSP{4k&(Ts2H5DG ztnq{Lm?3S!#pFA4uN3ndQ;F<}K{=77<K&?hMhol#nDdf$`4)>?qc0Ge4?q zFbZ1u`BgIagCj`_QIkHjn6|qki7akzGq+cSd|uB+n=hJ{-a6_y;_WSL4dr6~gw|36*<&lO zv?E9kyaWFOBYfgrYm57!_R^A#oJ@w0KaGQ)mE2u!6PJ8#>KmTOFku%FG1!I@rv-Z( zNa3#zEcp%ZPYT0339LY_mM%zHMT_;L2mkR&*rvi-?#B;m>hHQH+8K5Y{qUyRGVE|* zl4<6mD#jN92*n0k$6VFFp8|rm*Ab{CZJi0kckM-muXH6XdE@6fBM*&8&a&*PJbSt? zhP{^fQc+te3I1mQ9=4S-T>o*-Z(SMB#Z`N>0LCR69JnN+W}lw(;P-&ed+sR9I1^bo zSPCtZs8SwzCXwS3=sWfj=%bD-N_Q3Nh^y2Q@34pNaD=9Bf=I5-y8r60N#!8r*C7Bn zvZMqR7^MWEtRki9cx%gxyf*)PX7MJ<{Uw7f(URS3J;K|A&QJwv+)omBJHwUmMh!Au5Sgem~Li?Z?Y_*hjS zURAeDuD(X7)P|h6neHXp_uuWiEX1BXL4Qi^pwo7+CR0ZEw(1gK^ zJFDA<)yuhtWl424bzUmt@U#xQmb;5xRusu-Q^@*kRleWK{P;%TX7M!nPn;FOHlF@^ z(Mu9roCt!cgoc{dl=Dvitb^*O0JtLec{y4A?}Y>?(NKl&#qb}g6yO8d?yOZ37S24| z06^(&K(Oq@9aZ)!Gt9v*{+-8L?X%A>ls02;l>SlR5ooWDxQN^`aE5-89H~Zgf`|<= z@|N1^{;HI2xc{ztfut$%4X>wW;L7(qsbtF!B&!kdDr(rSIOH81$ti8IgdA*SUw-C* zuJ3tY%!Wfgm`P2_G!(3*c1nORqhEr7xfu+7z14Nr`@V`Z@;7Oa@<+iYn%h}KQg##V zE_|yvx+>~Ey`1~LQRH^}u0(Z>M@WLM^5bf?@V-muooa2Qr_&F|ye)g$0|q~ zcednE+%{N3MNFjg-&6`^y_#fB+6u86(&Hq~1}`tV^?5l!IRv&-5(dGN;xqamscjf=fSLEmVEmbw6d989{&cv>+K)cRFzW) z?-vpzrPB{MC?k%_Qa_zGHbMzllF{8LAM@<-ka67^3$RTNP9}E6WB9y_!dwnnqnW;? zI}CIld;Lv3BOP(Qg7ZaTSu{}xW==Q?54RrfUJ!VMt0_%UGaMeesQ=6D_2!O}t_|$6 zG0{i-roAi(9m_Q*dMOSpD1;ww7Ff$DwP(c*{&1t92;CodN};JaXlqU>vF^!l?u9PM zklssh49%Eu4V7`RSI#P&QEq9NsY=Aj0+d<1nqG`i;L*K%M&?ZcuCR8l>=EiiWv>00 zsRUu6;YGhH*^+I%{c;q2{HSs|LDqt;zneZy$lJ3{Um&1U{cDxeYQrU;`8Md zWLt1Djpj-~eOLahOro=4rO%cD*C?o_i(x~e8^Tyf(39c-XUI*YFLU@kf;#wr21ZCC zjtv5sYQGFb^mO{X4)g6Ae5=$z>jCft zTv!E@aPW~a2r8DD(Br_>F*ZaTcO2R3wT=B1;lA`z19iQ`Qi@BsAn(FyTFrmnTb-WL zOF5aaM@7OVqTZ2RvcpoZ{8Ehg9slF$169Q`;|Lh^6&Iwwtcg+rF11 zRSfV@KsU$W2&GVKczHWH(3`Py2m+;9LFm7Io=a=EKhLFpWf9jpJiW@uk`Qhy=lY># z;7u>(*MGrke0k2ru!jEro6+?ws+baKIqwwnkdt#TI75`!?FuZ-t;ElBr5El@9oQp@xVg6{Zq>8Q5-0;cqd<8cGq}D{_FO zOod4nArRRG8(^)kNyn0mVKWUStD&yDwm!o8z@j}IaY6GEKS&|i$8xZU1` z#khtKjOTxK<{VA(^~8m}FeYe9rfaAe`!PiST{sDi{+tEfoCO|SiD($f%;CQ9Q=0Pr zE=XzUzM8a=acSvD}rWYoKCn7rH&9aj--+8`(h?MVHXQI;xuX#szlOyJ_p)c^zc; z5?r5ewGA;h0)q-+rx&{j%{Y(QF9n2_&X?xTl_R%88?a6!bq7FYh8sK4n|cR|=Z*J( zu^{X`pPO=+#F^JoCFH>EFR7EuqSgmeY}?nIptH+E9|Z0OvSjw(r5rmJJBhj#oVlM>dxp*@_mR;u>Q~f4{Rr$Tmkf$8*DaZs-bF zO^7SYD8-I)=J{sLwn-%0V}0+!4Orie z?W5erY=PC6suX`(NX&qRSy}&G&m`5|Mg76M_r7)7sj6R4%tq^c{mRjz+!xlror@bB z{<$-Sz|S?s6iL$>&H>!X@D^W3Fw}lvpbj55Ii?2wH6h!34qvqvOS0z_8bC?=6dCL~ zHQzg3mW!(movIR$pz^Il_TK9-o-lYYsN;{X(;19=X0#sYuET|$H6f5mw`a6&z$nE0 zfG_N4?Y8RVxi5b~AbXWln2X;#5PWKS6I9OxC!9+B%1d1M+6>T5Y^gmo*PCKsJI1LF zj!8Dg^~RX-^z0)%&i}_*$FdNYCkMo{w>C89F(~1ya-`COon^ArHD1*{%4Bur6h!W;v82CC-`WjS1Rf*ma&!)u@HOFdHl3y$ zlnRYvn*hcQzCViNQ}c1zJIVG1|>NxR5*dvhLoySr|QsG68eoYbB3x zV1oK{0kWmnS8R@OF@kV07LB{{{A`J|0bZo&ipqBpw9^Gd9*9Etj+ktT8t}!!A8C_! zUkCrsq!rD#5yOimah|g`*JZ4?+J~b3%=)It>V@l-q&jT~3rpyxu?ma3P|n^d!{SX@ z-_2h4+tV(FL7F1q2tKM8HY2Lbz&vtytpWdJ9H*17HDA{Q=pO`4#%N5dMcB?;ls3j( zBV+f8pP}>5Ge4~D9w&PwUV_~RsEQ`KZp$$I6yoml@jX_C@~=Nh+b^hsTbPLlI~WRx z`tz7bCLW8A7Kne;B9N^wyIlq>Xqc1eCDng_J|uGR*lkx%H#s8`oV}$`iwl>sOo6SZ z6_0d?1`K!T#gbX!u9(%LFH`k3D?u11(uO-4zIS&nW~VR+1g|ox5Cf~Gf+i(Flx<)* zB`<_Ps0kvBwb^OvMGI#0I!Lc`Pqh-kwrU1gggfvFOXy0GPaF+* zP{J+{_&)A0i`Er|2kJI^7MbVgc!9qt&)kvw;UBQK>}8*EdWDE^u6gzScn#C&i!zcG zwm~US5MdYA-bU@SvEx#vup4za~v#(J4a%H+Mhk8=^F2m%KBvV^~Uiyhujm3V(bma8!0f_!-NgOJ` z-acTkPJ@cNR%FCgur=MJ$Z}_IAMBM^&g=RFS-Y1~9f^1`Ev4iEV37)eavhWi#1hyO&T0L29enk5J zfg1kz+|6edL3Bz*Fx+CU0BKM@OC;c{=Wibh`gyAcDGIG@)xJ~OH2MZHpkIyDQju_j_8bm zsWdkB3vaCdZdr4V?C{j?+RIz*gD?Hb{A&|FhNw)R2fxVE?L@c~#Q92X*}B;HTu!4_$Gxc4T<&A)p+!(6 ztmb|Dp!m@}q0QIZrn+qN4V&OjOfhq&N^JvER$ZNo33TEv5@9lDw;VBI{sEP7Fqz@| zX!cRZ3V8a3@XG~Wz$Yl5=SZ&19z_VN-raGrrSYmrK4##xuVrwngAR>RRBti8{GJi` z!9iQ-cK_?T4WP5Tl&;_<5;HD|*30O|HUuN`^?g$ePH4M=Bp8#+xc#I1_cjDe{#IU6 zk@&iC`Cu{BivJy|Q$P1tMvO0utppZfy>@>^-L}a6>?M9J;a$=%omBL^dc}&itVCD-W5QoPX_NIU=FfHuq7GAw>ZvqRW(9RVtguAU`M-W^cf&j(qtz zaAG6(Z`f?dRFxFCc+qwjoHR>_%{8lYWmNdV%4G>-xPY+omDHUSe0X7Qt_yq6>9#~J zcPDk*_IUjflUDOy6N4{d%U)BZb1eO4D)JxhagE-?AG5ZS6^^y`&Ga(4y!C#|G`2`f zim1bc4MUUR2DWm|KDR0j!acx|(Ot7AnbH0W{{!yqpu=BQ44k65_qo50k1c}UwjOZV zQkYesux?F-6K))OQd(mz5x0{#tM zA6+%$iwzif1AMY1YyS)*`lQ%qvT*q_?4%cM;^TY2FLa|m-8iE|dvk!F;*LZbxBLjG z64$|DoY=_dW`6Oq_*DE_USS`hgBTYepn1YDOlwyw$Wkz!%uV?Q#CH zJod8RRxtCdJpjgT{q?AIvLhbnf+bTep_ZDDI5`23WKcG&65V|!!P zix3sNo};Qnuy7lcC)&8qhs#((7+~ON+r|FsJGuCk41aBJ{;S*xRrj>CUG`A0ioMkP zzUtJ^-;aaL8F-obInw$P-xgPz?aG7kXv{Q~VoElB1#=0N-X(zf%JZcRcrk?lPl9y< z?Ad}k<`mo*RsC=_IaR?0e%>O_s)r31ziGS3WMp+YI_9l8QvZI7Slcn9JNd4UBkAZv(ZYZ~SIhp;_UN(JOg`3dtR(aK{6ZvG9NUfIvxlGFH^sTdh-$!=UV34JxF$bYN-G)@O2!em?CqX z5&rD0qy&w)14N-Qy~cPUBp_cL2fPp?|7s#K99R6xBW{Gs;W`Qf94$xiVsY2&U{4wx z*016y>pd~)2uLl5Sx8wG5jb+x-#b7s@1xY;5@d z>d~}un>N>`LuE@bvj>5gDMPzorEI6)-TgT^ys-8$@Zt|v!gE*IFAouF5i5Qez4oC+ z-?3J?hS;IQXH#*0r!O!Hs>|TyU7ql+wmZ=`GU7rmg#Mm}V z(-F380Dr!81D9x7(*0QE1Jz*Rfz>@%1b?wnlqKEW ze0xMuTkXo8sd=FBj|t?j0Fo8jf^l#O%pP4S2e?yDU!H{7d#uXAwQ4=^KE%r+4c?IS zbXu#6bb`Hz%mxg_!WmB7Vnz&;*-Z>Qi^0+j*t_9&ehC!||NO|Da$yBqtBmX?$^Gd~ zAwZ_ov+6G`en9_)pw6z>sh($r%My3MbPaXD>@Os)^M1gt`oX}=oFNE(CA`{G5T8Lg zbxf=xMW{RC$U_L9+^Yq~kcuL>X0?UHi)&moZmuSWck>(WGVv9Q6S}TgsiAOr0F3v{ ze%f!17wcw!ntu}C^BeLpqHfxAgFTzv=28gZ5X6Ky*^=f|T=T2SN6sZVSgl&q}B zj0z6j1A>O%?MJ#Lo}Ajt7388Ywh5^jK#ihtTI@;(rPi^?6*u3rl7Gf6tB?~aakv-T zbbaxYK760tmNTc>K?~{JOyaCyw-}z~_b8(qStw64W}n|rwMA}HXI&7q9C1{Q5?{_c z&)+>;*foeA)qpPBoTy^4di$ZAv40l#mH9y8py;F`e)1th6bBoSMo;$r6QNX zyf+s)Q{3F9-$-n^vuvw#_SIoYw)cL=!~gR09MoKi?3)V2Fe&aJQd_vzsMZ4jb9SXX z1kikuLT{!9UUtRjyLcsPzf3*3$S|^d*5WxYXPTPre_T|~2iMQ%8yat?xj=SKDM+i7v1N{H{El4(BmT) z8GjZyWyT&I(wTUni5^HPSjPlrR&+bjXOa`NMU{O1j%$cyRa{^e#)rdIlX!EnF?{|` zZOE89?025Rx9P3MVz?;z=6bUI1vI%(>b-=No_;BroPs`#87Ube7LIJw_5^z)Qgpcz zhI_}f^z!VAY7w=0P7o_6XtiDA$stXewb=OSz$=lgroT-K^YM>B7bf5z%xV`E2xZFOR<)=_ zEGDB<0@N(Rc^ekHXHS49-&T}s=^=xqYkuvlIAA>?vl#MEXoVlByhErob2%j;r;IC%CXzrgMCwnvr)GlrXQ4?D3ydQ3kp6}z7rqpR z*($f*WOT_%R;`p5w`Fm7q;NbFnBzin%WAiou)U*v=ys>z{#fo!|MLhFo(B5Wc>l6a ziwZKpai9qz0RjK%w+%3Rhm@Ei%sK%g$j#d%qqIbio& zD#t6iD_JMH?PBUbukep9DGev@e`NusY=KT?GvK=iEZD+b&_ij6z6=i zSv7XgkWxxG1;znHW2Ez(<(TMqmJ~B3LmNO@CO{)3tAYtz){{hL9rAgfbvGCLS_o(S z5fGAK53#F5o9eBv)w&BSMe%m?RF~?;HvY0NH%$ARfWsMR7H-$CYgapQth!fxNE+$y z-&HKOGxcuv%PEG0StRr^WT{H@B?}{Zz=IHn#b%tdlqPg2!0j1gS9|BSvB@@;NzDqL zaP+^m&fLs&7_>lLU8qGEISOu4MZ$+H1(1HcL!O@Sjt}a+ZZpN@ij3Z!kjhok@7$dn zT+QZ%lGITI*%=tvr5lU4f2?s{DXleI5rO-x@Z@I3u;I*T%Aw48s2l#DDS>_VF0-I^M zTKg;70`whj3M)i3cd%tJ&&SEzpB1?5SRjHSuvjvTJ&54ny|o=TXn+w+EmO5@NS=%t zIQfhq)4@FFR1fXG;zrR75B%ld#BWfL1yaIN(jR%_izQUW_{J zCGw=H2w0-JWfU3<8=WtU36eqg0B}@k3s5h8m`^edM|h6;6)8z8T?R;TQQHch9@^2j z&%5{mVG?~@e&L+rc3(kKnD!+q(*~*~LrMi80m3a#Xj%vl7iC8VI6TC5z$T^i`ZTE1 z!xHB~D)}bH^`1_LCIJak)qaWU`n!SqeMwnjSw$D5h2~Ftq_uL6*!RJ2IvRODtW9}) z>qmssKGxRh%wr*Y=<~ z+|mp!wAfMWQ~(vuCz6rEt74)3sh&p9eYCUrp%yxvpY5cN1nE zrt~$A|LiATh=9Ygfu>!73C-1i|1xUDGA<1Ij_Lo~#l=IdOcqoM8w+4}K1}=2t1ykl zZ#hE&!gX2Fq@S(tv~LtmAO*#kP*W=UYw`Qzs_g})U}JN`bV} zUo0^C5Su>eX>x6=$_y0P&MCH=^>M|_atBVJ*mnsf>i4PCH%o<=-^Ra#1Pl%aV*N?# zi`BaxtIA7Iq!7QBgQ+yPwyi)I2@b6^{cZk=&C0RkH6WTX$$2vm1+V2PM)-@|P9Vw; zs$AT-q)a-H!HWQ?1CCK4AC*HH2M!I8x?}7Hi-ibMI3Z_F`lwqB8&Xn>Ff$f)Z90|! zJhw)ekAtI-X97luNSgz-Sz^oB0jqq(L9vm@$OL@++eE1UPf}6-WAT<3OY^I{X*l3J%Nx^uLYHQKw^0CET3$nne~9A!EU9dJ zzc8UGr;LFzIP1@#fPrl~_pwkTFQrdY?GF$ee{J+#-R{jO#GWi6o7R)V)O%NT;iwFI zt@tEyj+eUVm9-9Vg?oPj3Qx%vE%+S}6PcOsvSGJBm=e=$1sqC9la52+{4C|P~U$4_tk=Te)XW(C(nMaZ*|Q|t?7 zR#5nZLtK=Bd0g&k-u)jC8uE<^bi6-%hLp?VQb?AH@(ZM_#-u3>fSqI84*9+1Oe)OM zf`~~tq2ar!CE(sG%q=9UBCw(m!MClp7u`7bLE^)1IC*^iEfVw2kQ;@x4o22}j9o{LAK*Xnqv%)kG<025njp$K5yi ziTRIqad!Xl>2HTEO^Lt6?@?{8gA`w8|4zKZhk+{Z@fu4|3Ahp{|+6ZBznGUXA=qcnh9mRduq8~ys$H%ko)R`GG z>lMx-FK5(z-o?~>K#>njgTNT+9VqM=R!msL9g`s=w8b`ysOq7)1+~KurZz20Nef zn99vA`O_BiL|z~_6f7Pf>mT(R-JoqXFKAq`z_fDOlpo=D>#B0tw(}+ri*XKrt9YnL(_XD(j!y5x?t!ic}y$u~rt`D8wSae(c zu@Cl4YsA{u6Q9D`Cp;FPH7htrzowfXE4MKuFE2}@5GD}tO0dJFAIlWO6u_ShfLlR$ zp{`mU!#4@wRtRZs42^ITNIXOVW(b+yZXxBUs?Fa2CHWS6AK3x-+p?x*1}U?igYTs?pUJ?y;2haC@`w&zvX+bp8#7?qlR zoXrp)f4h@NWt&Se+NodY3(adRo*=6H3WQTBt|)LGZ{;sgy>7R8GHOm#Ln9o+xX?}7 zMvYOAnoHkf)&}f`!SmxFCCI;>Kr!WY^;&{K!ojLOac2^+VmZ-BR^0|`?@_Zk(TIF0 z`0h(7i`=^@=jK5|OOMZjktok-LUpF%5VRe~f|PuV+&fIT!;(Zpyu`n$>b4}bp>hDX zesxinf1t~`cy=o0&T^zz`6!rfC4~Z&NB~E}^+m;jm%NeGZBBkfv0AyB0+}i{vU~I!zllis20yeV0UYyea1aUcaB24 zl_0FzNM22X7N46t9zWzmG29Xaja-&1u5rFwdfM4fotParM;}tFl$4QJv)83I>|5@@ zv_u2YRjI~p9licLH*rGe7VZm`iHqI*mX;O9;ijX$H((+s>o;9oV#}mp{6!yZw2|Tu zxehvJ*G+kLH(P)u!r~EK^QyZ=CqG~NiD`>Puri03t;$z|bsqc@n+}Magr0O_)wG9p zul3Q*vc1gUhgrIp>#@r1U&T?g&sfw;=DM4gRC7jH_Nlbq~ds%xm3r6bn%Qvci;N*!fr~4I!BK$Aj=@3cv!BOpPtBxl31V~1a&lsI~5ig0x7RYh8tiBUDdQH2-CGP>xZv>FNH-f zA-R^0DXauOQuiuj!evwB3Eq%&{WllD+b{Plp3xH7uo2vzbc3T}1cNa6CmL?w?F8o& zxmRq4PEVxT>RYzVdYVN5VN3Q^}OzMW(!1W7Ur6CprR6P`Ipf; zg0=rd8}h?peTcpFU0&e&4HSC6=xY$|mAXX@NCZPXDqUfp&x-_EwEh_j8Uels1qeIy zHjme+kQ&KU@>c?ml>$0vm}!Oml9emY%6|k+T;CCN4_mPFpN!)ki*Mp(i2H;a;`+x=>>4al1m?^jl%&lFXM7pA=N0~WhZxH zI2acp=~;d4hD}%DMnkWt1b_{+3XLJD=<&gWEieYLQx?h5`r7PD3t}!+$l+o<3AuSe zhY}cv>Jr~N6=bqv{Hu8UxWrgLNlA=Tpy>nxFiuX6p2;D~TD?6?+jb`(Amv zlBY08m!g+8GKEzvb4;78=0M8 z?-YF;PvlNk-Or>4I_U7{Lv?*kgE03lRn!{?dDgi&-@3-YR&P3>UPgaPwf5q*PU#3| zkLnh`Ra~ZNW%}aDwgoCLf5w<`1k_I`?ojf$w(2!b$KMgI*2Q#JwX(mdLGzzpB+T?z znP!^QuW(lM?)eXw-A&TQmwP7hj&5B;)}jXKws#{h3KtUqTgAe+Vg)Y3Qo+g>=E%(( z-ak}+B8)#R*opIHxqQi+K?T+Er#zlbC4zi<(}P{}D=12(%cS0lGTl{PCFPHGj9VV= zq&H(ceks=mIy$L(YT1Ag3Dw9Y7S>rvu_J{Xrm4t4+N50TXbyd%`U$ym@WcVsFPX8V z0pF*|DhRa!ZgQq#n49Nt$BKyh3Gj^Cw`p!!bjYmrT*E80jaJ7JveFL&i)PbdH=*=^ z0H|Rp+hG0{jwt!Er_{2e6s=+Q&seo3__X&&a)%4|8zgHacwi8I35y%3Nh$NjCW@QW z-F8I z82Vw#f?poZomH0R6Lm_$r{F88@5v^&xRKL*Lhec9u7bxxEI@r?R_(~+LYU}C>F zBj?Gi1G)T}J>OON!tSU2kVJ@i+(X7I%)2bjKgWw@4zGhVe7Ug>>;Qb~nwfahO}oOi zi{aZVFA&=GXJa~4Aw9^D>dTl=83T@G`olA&`jSjkWKNj9?GaTB(CLH+mNlM}3e|E? zU4x$z4<~57FY0=b%La}$d$pX_-RI${JxD9jp z21>QZ;o6-H3l>U>8Ij}vPg&Oi)MT@@6RLC!MXHL15#^BmsS7WJaq zh4G0@w~FGwGtl1q{gr0=7n~q}QL3y33do_9fzo+E&5y&F2X~^GD-pw(Mwch}Ai(!0~%YIiwYTp_45BqGw(c>W#} zI2JK5atwTo4h(9)uc&JMRkyF<^lkj7*Z+OEPGt_FUcgat@t0p{|1D(MBcVR>KG9nhb zhVNQv41#&|WE5`RZ&!U!@5*L-b>pPqPttf7D#7x?Jw3s@{qWmV9gqthVDFciVR|TL zQq%YZ(fkb=ng%OMmGU_Si1uw16QmJRTeIvXo8AiejPS5KA&Y*jHI$OklrKtX>UCmM z2np|HOwjemMI!JYQRvgLyM*^hP%msPQaGW$VvY&T+_bO|JWhhX&)SVLP!N2Ol00UQ zt#_wm9xx$;-BcK0o>^@qr_$TX`OP~1rt`VM+U@%*)0UkWzi9840rf{_w%jZ32n((M z0MfLy8e}9ZAW~$rhu4=9I+PURQAR+}A(A)pOuEjEH0*S6LOWJ*2 zx!Wf#cg|giG)DP8;>^@h!XlR-ssrt3n5z#)HR8iT1=PCI&{!)jacmV)Rf$5KnCP@zq{YIkUR8yKH`-$wbG-FtgL{CSdZ?&cYO_DNVOavC5?|Z>$8y zP~F%Q(J>9*1JWd8>dUDZBJ92x5WRBH{_?|TMT{R zR-$#_77c6o5wxn0oz%cMN>Ekt0f;7~Ut%cut1#y00}W-QLuN7M^H~y`fnuJCMMIevv+$y60H|FG!QP`!+3pgs3 ztT40XARF@OGDi%eU;DtEX%|SY+NK*^U z-g)*j(063mhbPZBV9f$_Q~J0N6vxfMZ*VAO$k4s{=VKu%I*F%z{F7LTrbJ?U8jmyi z9~n^8iU*`9%_o$>c}HM;=D(<-QhO1+55&c}fPIQLGB_|#KIN+L!AdbM;HN)Rx!3MG z=n8gYziUe$pY-?((Ne^y(q7GI7T-p~Q_u0hLPLft!XwUCQ+iEg-dLJ&BZOO3QiXR0 zpMyY|=L<)A3CZSrDG^mV-R!A`r+{tur&>XKlMGqL-2n-U3O%l~7em`ttDZCO&p9rW z9IpT4iGd!or%!5Zb^d-D4=CfxJ^lDH!caL!MX_-vo12ZU4e`VU$p$OM2WZy1rw?2J z(MD-X^NIe+?si#vBVrJy#*_Hcih9B_C;`&MQxvyq@&X-+9G*ueKciL%(I?dLq0S4f zF^R+7W4;}+F9WRthPHD|^4CvAqeb%ynRyG1@B0Ty4hxXpO;e{JfA_q|MzkpS?K4Fc zhKGt&Nv5#5+yPi}7mJ#Kjn2A50n?foO9w?~`SQ}3?R+l9mfBpk-}>T?PU=FdWVthr zkYXF0{KyswGLAs;aKKYto~QL_QCXtUB`__etE*fJqBV%vX$sbif&CHDJt^ zMUkO-Jm8Dd;jI$c;g|fa*NY~%p(RdqiDku!wvUT?R4WKxf>(viGnp5C{r()EQeEQh zMeo4VO%5EcGcJ)4ADK8#n?hcMst~RRhb<@xXV5cH8N;3lAGFhy@ubW* zxK3N7GRwl(oL-kRRNI3DrRLAB3+h6md_`|sUr;h3$h@v++{YFBHyZABQL;gguPb_| z-hbi8+2f%Lu?~s)XNKM#WcqnH z59BM*-H$&g^i-Z|=s}p+9vAFr0llq4Yu#pI@MOWv;gm<-I0FuVulL&k-8T-)qBQDg z9IIXC#Fy8K1;y*_L&WJpxnKFQkg;-h>#359uRn@6)EfEcn2nQ&B+i25)=Zg>&(I|~ zlPlvD1|bDHiYWG(%sqrx?X<~by_q-USS0h}Zu@}#M$m6Ry}P~S5*;}rJ=h;;m+ zO%xs`Poye~_|_t;l+sZX2&l1rLadU`Vj8Vnjt>`|fn_R3e;zw3V27HGs7R} zw9ZqtOWU>T+m}=@71fmfQ^BNkdVceJ!{8*?w@x@2J09!i(I5#^NLCF49A2mx4$)BfZ1(pF4v>$_d;|7Id(eTGHa&X-Q#LZH_e9>vzEL znjhV%ry9)2?A*?ukztcv{sX-O+v7D0)@+T2dRhOhqX57Mjwei1398_gonbRwz?8D0 zy2za;6=XTIUn%E!lj0h0(A{|jR%QwnZ0mTxqiePdrl+kY7s)HEh5x{ z#4~;@ux{e2-|l2)bnQ|Qjt`YdcM;zm)$VN9{2I|kB?euuJPVXlYtUa?Wp=KTz+Co& z#(#IHU*(7PP+duE0k2z;r9-j==7)J1={+CC2TS8M2GivSZ_>9N9-!C87jr}$>I}OM zr#~~}i-&r}A0?UM9I8=LU1UFdMnPre!q;i2Ng`^h@Se>Nu*m+hei{t3Uh!>75@A-$ z_1gEO=6Z9R1=jpQ%LxA31xiwTUv$t0)$`W$$3C@BgI-|E`w(r&`tU7XTnahPYDa4- z=`zl-K%w~XLr?7?Sw+d!%H5I5J>q8H*BcWBSyB~kkUrjlAJ5mtY#1y}((W8cvL!aA|aJGx$l^2ndhkrb2<`M3w=22 zitTKUkXd{q!MZ`BY;m8p5@ zX|%b!IbnA02)Fdq7QXjtYafNbfe*!b=w=qU$2j_YpiE_-c#zElpf9BoYq76xIcmJ| z(yw2%Mc-_*MZCqsqw0F(eBNm5qmGVop{FDkdoY!8!FF^Pd0A#V!I-TdD%YRkIO*)_ zZm~+UxFaq)_GXlZ{dV>2`vXLCdv&ml&=)m2_at@vV|-D*P|~+%)fR;}I&@`)2fV@* zTYcs?|z4dA~jyGp)Os(4F&a4puM)BaUpRz=wR7folz~OK0M}&Say6 zJai_og)x~}q*K_7jWAuf7MIX6*a$p1b!-9r8)V$TaZCwmI?BH#ul>&qoVsSZUFA{-Q;Kp6xptD@RgE`rDk{>K_&?6bKqY ze}1(Fdf_|fUc_LMJ#%j}-`=(T@@4_a{qO(ga2Vs8ROM;S$Y)RelHkPknj9x%BZC^y zqy{9Y5&St5omXME{~gYlFb!OCP85mhDgNLIWxQ#bzv#)8frF0$&C2rGKd>zdTuji3PNj6YCm$Zt{Tr$;Q5RS3Kd&sS6 z)F{9OktF=*(GybnlgAG;=jKkhrKK}g%m}D4 z=oJ^-)vVJ)e@{WQd$u|PS7eokQAfzm`j8?gWj4C%ZI!hy`IpDa;s3x$*SdaDUSJYD zRpQ!rqc#avV@S{cBz900ETXhsAQ}6jS-Wtxj$DUXzD7rH_AHVzECNyG?AN>+PhTZ3 zcGg?qqbbT|8j7Dp#UIYp&XK3H2l{IgIv&;DMJx||{`Y`}jR|BxioqxkV5pqW0~ z#+h>bM!q+r_tTWjdDe$GP#z>&|8skqje53}N)em!^HQD)LD@b6fjgmFSXot`QT;58 zSJ7BJ1inNwkDx*u z$jUQ+O#G(t@b6+i@fF|jpxGdbzv==a78LX_2^Fv+BNAXayGhgFpZHEhzH~1qN)p1~ zday-pU~(e(Auo0Q(qn zb<{y6!ydh{2-d!QOt>*2C?qUCyJYif9Va28Wq0e|{M2y>`&{(CQE)#*``%XNmN2-x zNT;ZiMf#nKRK}S=5{bWZC6+ z1Eh23D(^=wki;?nn|F%* z6em;?m~pjBKA*FS?GN-tN`?-CNypvPCGs)7_BFcEZMFNJr%rj!(`n&=36_`cu}8Kz*)R{l5eeyZ~{bJb|Dj3^F&g4E6f`l5-2 zt4{$df1gtL??VbDlPfSkUB;R4rrzuE>-SN(nL$6tC?GGY->Y!u>KNIk;N5+RaQ7y@ zv9-UkaPRwP|MO!0vbox8y7*J6W(3fpRzgHO$|x#0?GO1xo$h9nK3>`@1p73zYt6 eAm6`dXz&4LY5z6j|Ba#(`GAkeboqb;Gyexi&Ny}e delta 72146 zcmZ6y1yEeg)-{Z~g#f`JI0^3V?(XjHZU-kg1a}DT?(Xgm!QI{M<9TlV_tyVb&D5Nl zs_Aoj_1>%3UcIMq9%6nP0#Qy990Cml1_lNs?w3V1A|WXF=VvV)sN266aiw5~|9lab z2u=d%%J$Hq^>>cUJe1=p3Zz<-Sh)S}6N(sUT+zw4e~WA2c)U;S9{AOEwd6SQcDKHs zc#~oATh~qpTRVq~m;!V>GR8wOr*WPrBc~6#0Mard81Ae)*InB|vf2J}I|A|>$s>tF zUEyC9GaUbXOwSI;elLu#9I2K&Xz*8uEK3Z)`#6g)d7xCae-{Ki0)cNa-mk+zG%vmt zf<-5gZhEF{KIrHhs=)&*kiyq_{|PM81O!ib)!cUWJXam0?gs1HhQmMAAGiQjmTs%O zVlgspKj?h^W;~}}caz2wtzC8y?Ufj{Y&kw8ig=qpKF)E*!}gVVJ>OlR)VZQU9=p2m zo}$FL8T|`a70vM^A9_+_A}fj~U*lfzQxz91^2-(7$GA-EE5;pxoFp`ih)LQe1tfU82< zo#AM*kAHA1MVq0myvAC%@rq0;&$1d{R6vomC;K4;(bZ1`Mrb{LMnler3L~JW7p_b7 z@$|uEJ>nYe-cDO`2D}Ns9>4EtcWA4W8hAeF0#7dlx<2CX*ESnQtI8@WtFN8!4r33% z6Y&1R`vH_4hrD@bvR-7ryL{*Z&9PB|{x@x#Fl0@Oac!BTa;i2DVL%~x+`cGp? zE$>!R!xji2H^Bo$joiwG97Qo7*YQe?qw@$~}^qDGY6<%DIPLM6U z*Ct_kjPcl&$0XOZJ;1AVRmHi1V#|}Sw`Q-k5c~aRbCQ6GO|v6sc)2E5sWU19W^y55B)$y+<;OWBkqxpw#%H^?kM&-u|?YC`Sn*frxQBOCagm?K} z0670>o$OrQPz8L-!{?o=$Nld5bq^1 zP~f<|80-99W95TM4&?d7Ju2(^4OIkyYdcY`{1DEnA$z&_C@baNm|v>;c%LLSp{W}F zxJ$yVAozIsaD92-=H1{G@Ju|uf_`dRO1!KEY%M5M_!^l$+No4No;v(~yDg)C454qB zq-iO>e^q_2s6gVB4w}>oDpR)z1L)B{cyEz%itpw%MrY?*j4Y`!hCCcPW|V-}0p-60 zjq~?S)ALUg^L~_nUU^Fs&Udu1PH-E9b3JF7RZHEB)*TIty4&{>OBGf6?{`N#pz+T! zmrpR44Jow#YMJRgb`wV-{~`1qz9L}f=%!sRSWKg^h`P$>>_XYzFM$^n>0@p zFq}hEqpob4--PugF@p)&5HZ-2YJ#``uRe2{4zQDYInel z`d-YkAk;HqNP6vrr5aOBxnoFgZI7m_a|5^DJ`ZiUb~PALjAiXAF1#^NbvA@o1asl! zvRoh?&YkZJMbNaQfHcxz?k8<_v#J~fdEeCdr*48yUF8nU2W?lSUq8THM=^ZFD_Rv< zPI-M}_oq}tm2PgTatc59Gh&M3!6f8+FxjNvWLUY)c}y8?TT%qjfA^7LqjDKBIuQAE zbq0~?MnCdq6aRwi=+g#FM>=F_pg`uFWWKLQQxzMpNUqy01&%Zv-WO2Y0V!Yb;Y$ZHh)jwT*j$Y0i=j|Wm4R)UP z@h&*X#Sj}oD3B5pYT+GI& zR_~zjz^Lk`6~OxZ20PJ`O%=P5;CtuWqutgs#{%4eHSdU*s%eY&V9KFZuwqJrr~ZO- z-Ki=0Pt|1`_l?b|E`)ZG{I?y`rJq)% zgC)gR)or{ac{bB&nTIXo)n(V(4%siI7g-2Zb`v6mOvtP^JF9m4cHu2s7}cw9KiBNS ziy(b)MTdvo!XMAh!D|Da(NY?QTuH62AO6;jE5GfEeB%Xz4!m6Z7m;mtU(dtB;bmJl zvhH18^gggt$l*_-n|EQ1kefaRc*nZ3D!z3JzXlUD-e{IYuRhdF+Sby9_{W|be5Mb7 z)#9z|^WT<%@yl#Fq$quP+=OKBF`SX2#rn$fO!zh+`-NF$*w{mBTO8C#mJTCBSevSP z0Q_F_eiw)j2|*ZS`a)x2s=CYUGE!lo2UVKsB*?%}>9s$&_Rr-=B>bo;uEJ-ZL*Fzzd= z9JTy5m+A0i*<3Qh~h z)r3a^R$)l)^mXxtG-vLE)FC@LiLaUN&d|zgH(35MT+|%q?ho1u1}ALWN&pLqc?{nw z;_qKgX{iP_UOL{>($dver9KhVH?uF!^}4F3GK@ZNO6Zd-`l-Nx>dnrm+wmXn`c2mx z_)6fvaki5(sxfmV(?eqk%wNd}P{a5w%gT~d@Z0W#|kPj2{7Qpd1u@5x&_H?o2qbnZ`h@P-!O88WFNtE-B1?ZCs@icn5{C za-47BZh$*xn(xKeJ?HDaTcPeU0v2danTM9^dyx0;)O9YPRn>^M{+`FuV1R`+q3*$d{IQs+QoN*z{hvW z@*Au-V|!QT#WMTHSu(wK4QGtp#jjVJsUW0K?MoBwVf-@31TZo`>J)Q$Ts!hI)S;jS7vXI6{X0DXB8Fo`iX3_L9Jx8&>KtTbbHCUS5m!1MS zp(W4R>soRO&wIWV4zt|3S&6MW#ftjS|OT@6!> zDxR?Kb4LUX3Z_^i0%qSNO()t$QM*GQSQlpnTF;+MbrSanEoyzY_)uuzvY?#OT?vb* z0q@2`U3gRJCU<1RwqlF3?i6qNdwlXy(g~YO*CxkI32LL$>sG`^GY5x>h9BO2XeMDS zFLfckmrdc3CoW8FZSFGt2#^R|Az}BF_zPwC9j9(Z-fTL9P zT0%%WF_wgiJD1$BgpB-B*sHH1u8QZ6g@^jo8_;z{VCG1yv5&*KWgGL=F zT@Q}KZ#w#Bzp+a=uq#s{BH=JurpxL^8p(JPLYv-$HUXh`N zLowgJ_gwSImO`z_Q^H_y`@Lq8-&Ukdsa!OiWF2hN*`(IiG@`46&vN{nvKfEoA&11v zMhzRE16A@@Wv^()Tg5=66@wy!;K3>0LA!Rk67qKh`QO=Tj_?U;O-s@W(gje13@K(>W!-q-w=L1T0HJ@44(HqHoXSVot>h&#KNT^QLoq|rr!!HHA z9ihV|Scxh+>Y2KlnHy@E8)41QSbtQfP|8&LBLNjbK{0eh5Db~SM>mNzO07|sZuSNi zKlvCEk`{6WYGfI+u2V;8JC#^eNg6@QaikA8YWUhajplK1 zp$c5>Xe6G?voDDc?ne}$l4%lHiZAuLyZH@zuIwo6?QN=f_W_=8!haD1Ra#@mO4?_) z-+;BqbAJ^f)IGU<{(4;W7rK63((u!y<1e^w6y9T*MiM8tQ6!4TNy9t=5G8T%#76oF z@hMPA$M?{PeR6im0mSGoKXGk;Qq}t!w|gSYR0rRZCk1efTDWG--x{DrIoDLD@=U_5 zs5Cy5gcQVO;AJO{Y;;q~jO?5v@zob!kpoW4e<{PAqiCrzq!(uV5k;eJ8>_CmOtzXG zJ>Bvea(`Wb@|e{xE8vJFD7YYKNk}B~3!9F`OjTOciWQHZ)p#izO+^?3wm=y&r@J~e z0WP-X?Hzq%Ea??E|ID17o3i<`Nz@PWjXIjl8*EK*F}r0rDtdS#p(1!s%o&WJD8MXB z9s^kH3`a+*#0ELEUQJ@IQ}uzLGbLpiqA$h2u>ad8f zPB113Lph07e?wJZ#anp{44O)k@~73IV;8MRVMqnALhket8p{%)wO0mWU~ zS<$=Tyy9Meu?4U})R*82AS}tnC_;(9=~%2_-KSdnE5ba#36whh%rl8ap#;)7WL5X3 zT7GB>A#brS986Kz&Jn!#d;~eOzkW!p4;{C(huk3|Yd4LZAtMpN`+{55jk1bD@Td)( z7j=YB)!-pguTIPH^7X2NGch4fxoCA@MqA)!Mm1;S2p3Gx{w#sjQ9NTkJB+p9q6dM^ z?e4YoIg_(it3>@l^pnbF0TwWZeLWMU;CVIbyNTVSKv$1am^QMTVvpF`1q?50&Q=eo@!ypMfi5Q{$5n0S?mkD& zitcgN+6(v4mj-F$FIM~*2rutYbO+oZZp@a~mNwV_VE0^bUb$YJb3ug&(@=Mj6Y6^r z=mQXm{p3ZlvsP$)@K}S1o;Q8WQRcqOvk{`2iFNZQuiwC`mu+`66RHw|VVUZM%oL{X zxqh8VE5qn+ps{=jUaCJSvf^wayvNfzT6C5)to(#-J_%7KMQO}n2A2E!H+p*}y1LfK z18-f~Qn3s~4x94yPUu-$%b$FS(Xe%#0zlGs0cqxjYV1Hg*|x^BQAru3UPFWhhI@pMDe~gAMZb~|AYFvmfHFWpzj_HIs1{5 zfa~t3VUYVc*O5VfrxyR35>(Ej95#$92c0B0s)^AFn|P44ZZrvNbyHKJspo%k{X~fT z_3yi!Ekij`M}E-%Mm@c_?qw4ym6wu-CQ$6_lvAc>{z2`|&9ql-H^W|>E>lMN%DpNVt9 zZKLSl>rMT_J`Cl2vWnY;B6ZyJ+(T2m~`?}TL4Zi;hmypi3&^SBKzy|-!MJ&6m3;tnN?b%_YjesO~ zx7EA{yd#LI5l;kcxsJ_(EWTVLAWd{c!k*|_bWVx3b= zQ=~qky*~Gs_$dB;42nAUEnpWW4vF;aXZn0jBJU>8Mv*4Ysn+Qq#IQ+huh9ZGqIONC zD1k+eBKU+HY#l{@=hv`&L0g}m-R3_9%y&6dKvlQwZCtkZq#4KEuNCPU#!TEh%Ua{4 zlM8P2=!tArI^AzLg(uJ>Oiuwf2&ykD^1R{8>-8Y3#a{_%Gnwb>jCy9-O)z8z6EP~_ zZ@?_Lg<+=Lu5ZS5=q802*NENxm%#I-G;c85n94%&@%OZ&0E*XMF?n z?DL#8FDM)Y#geuRnQYCwuA>iaHC&wyT%FZiop<|0K|0ZB9#m2fveYzZ;(2s%+h`)w zlsh$jnUb@KH@G(FT(!E8?OHEDceTGOpfd?a#jX);Z%*~|Ok-^E=gXQY`;u+q{#gN} zOC49IiWjlS(gc;HX9JVW-Jv^dp-1ZI8$~x34{0xH@;*4|tQX-Qm~Vkyj4Qn_+%!kE zRhtAJx>cyX{$Ep)9*Iq>sOXmrcj=NW`!lS{(=0T_L$lZKN*fn56#+QU(nCLDN>$Dw!Ip*DA@uWcJ#~g>u!#L(&(M%oA-|MDiFn;B>IEpu8 z!_>SxrF&2LyjZLmTGy?68UIW5cdgyo2M-nl`9aMyk<|w(t6lYFvovaCD4uJbVbL2x zxzUS9i%)Kr4dx?HdbM#s_=kl5le@g%`fj0-*3}^Zd0VUP7l})f*IP8c19M~W02b<- zbnro=&>`zem0hO2e#gdks_{i@&$pwA-R5t!E$@Tv=LV0=*GWm3*MuAE3G+mYG*=zJ z>oQk-t1B16c)ikiJ<XTk>S*Zsl%vf&Y021e1#o)cj3zg+gWVUFte9L#ux2+ebkjHPT6)NUk zjhl6!%=>PXo@l++QIsaAZSF27jQ>lCr-RIAaYf?vD3f<&)~Dr68b>u@a?gfR)#v$P2)+hfjKbDJ)jYA+W=Ycc_Z|q zeo?2opqiw88)hr9z1-|5S7GPavho~I-<2GbbTgfHRp)8*-Rl^oO%Gwv&8GLNbgjI* zGI`?vCmfD*TRSsTlb>t73SS(zR60X6y^+|S>`Il_Zm4B?-94V}*)7kvXv88KCI@Ra zI4#^+c?NlwK)QWiPXRIwvdqiv<(ExZCR20V$GG;y+De_>@}EJ*9hMnnQ!H(3NJ*H~ zd>*4+z?UTmIfhciFrp3WQ+s1~pEF6eDT3%<>UNv)@9ykG9-9-Uh}$;xQNCWr@!$H^ zi(}DbO9&8JU%cRF=gDl(%MG`23p{)bu)hjeGBWS=*A5CfoCEaqSbc`N?Q*vS8N#3& z{ayRlY0(ot!)3KukXyB%baFuChwnvk;`W9(9ze+$0B`C zGfP$DjiKS(i|g4dk49Y~+)H!VkI1wv#5-_!MM5ds??B6#S*L+r7bJPsYTa3 zUZbNYf9%d{YBWrdC$ulb+Ns{X&2G|OX-;0s^Z%Slx2&O+wg;>)4p++^$P`cV7kgg+ zUT={dQGurNWuRVWb)Cpr-?^BQ`GLVSfBmWvDL=l#4#3OY&8EysOcCdTo?yS+T(p>z z%E|oJ_VYuMO_I&j=%8K5zvZe-Q&|er9T8MkwX@n#!PL_sSdS@V5RRz%-bsz>)sk*@P zdodV~Y)RL2rllW#!^~ir&X9!%5~G@?Ps?1m3mCkGnY#~`lnCPT0=1Fq++j_$PrBkT zr4nbFI=0hi43zUMh;{jV9jhrek|a)zr0=5Z$J9&y4Xw%7_%*kP{?Y?!m#`I?;G=kt zPc{?1r;j@*!cC$7x{1nN+qhv{NgObwLv}@=YRcVvB7NalLRFe9V>-dnr2UzREHM*D zz3ATIuzOJ+BOjWF`gVI8^5o@~v*=j!n)h?`#&YxqXY^)OkERUkw#uYy+hb8fjqx&p ziK}PRy-;cd^`|3vh(mpui-gsWNm`Q6QY zeE{E1%ib_?!GLCK>p6{}Q^|=ZW5Fsf05n8nNpRJf_Ud_vSz(x-wqly}zY`JYY+{vH zu$<*P0(rYtq`9EfrqF;ys`n2JSd(U9L@WC`Yrnb!kr^b9Lpr_bj!w&V3JBC0I0KaT z3Jo#QixXHYW8|)`>qCMf&)daYEo` zMzw1JT+iQKRhGHMA@q9Jj3OOf|Em0ol)M7Iv2LxMscdL0 za3r$lNAb=#B|^hZ$V}er=WfN(p)etW;PCRhMRIl6iIu;DW6D94=6?2vabB!wrpa$X+IY~D=#=Q&O*BdrT>l^(x>G3>Wp)0=p6_K{1#SJ#)` zrOv8<{z-}8T&Zh;V-g#IJ$QR{zY65&5L6JtY_H3Y{<8Y{=|{y{9wfl9z}md~!1tue z&HNR~WcgejbNkb+Vo464f#jC>R<-cCNaaOBR)GY;@`q84xm3+os%cRy!>f&bN(N4&WMWN!JXi|qCmIk;k;vhsg>yV2+nnrbUJ?Fh!$3EM48_tGLoC)mI&y> z&0;+4Zu1q+y!Al^hedO<+0OXm&P93qXzG9M@5txwx2z+}3w+Qnoj?Ky^^1nX)HN&W z0+Sr0K`wn&YHKXLx{g%EF31zqA-YGq|5T!@hpp*^^=q+$d0_BFpIL`TckkUz#TP~$ z2_9n*3+a=68ZQ?Vj~gX|iOPzK88*h);)vjR`@<-p>b(H6UoccBXJGw^ZCl*fxmx>* zAD$=Z0LBuhWxzg<8+ey?zxr$6H{-R&21nj&bQ+$d{ZR@!14O>=<-a#!T1eki^r-V| z3&N+HxchMC6X-CwBc}#YnK|d&f#FHuLM?Ey{*tNB6$A%!S+W}_-TH}mCh*nfUYNEU zp1LXJGc?(-SPeBBtzP`MDB$Hj$0+BSI>N=7@E=~9$@w({bQRs=dT`siQ`wqteaQ9b z>ud{OiJhd72cK&_QG8kw{*5(4M)A<)H1ci@gylJSGim61e))}o6?4{H2*UXD<2gPRWk*L%$k;wjQ{Z7D8uzk%N%Cu8kc}L>~2=%@>r`dRa1}vM` z^;jQ|0(4m8%WtqRK&Yx|h1+d?ng#E`74keAy{=m8q)yLuP=s|m7I)|F|4ZV2knG9UQ2&R<6AQvA^}(ubyPY*3~Tfw zXYO`eq(9WnOTc>)64DnduoX4ux+-1tVAIBMdXa&Z0)e z0BvN%>}Y4#mndnpm0zpX3t$!8LbEQ`gR|C^LZ0w9j5S)$9gRs~(~C9d<@gUfkcy%L zCEhOIWmh@-OpXfrENnAO3TcV)^4FEwqwTrlS5x zoTzh-{+?vv8&%N!f-EeX-`-$zAo*v3L#2Q?a>y)1p2s+rwtaHJdiGLvGmY_NK|8mJ zFF2X@%sXb(i>2huZ1te6OJQrtnl2kX^2=-MN46cfY1cZ;L!+^(4)}Tiej) zev};SeenX-0wSFI0&DjBKM+hK+2JWZmE&j!;vnuhvi(@lNId>S?3Wg#2#UXe`7awg zqFjQbst`LtB=Gk4GQ{tw5-^M50h?%@#^PIgKX1tQo6s_h%Y+B23zX;Javh`U4@gd@i< zxj3g3zf7z_n1tZ|SSRJ;;q444Oj`aXm~OM@t%7t}W(BJpiTi$7ptP=Os`*GCL&+$S zhXs(z@rIk|7h?R?rN`mP5a~sa9GVtg} zVOfJvU71Ue)g+l_eTwwLo)Vd^^6g8bJ7i_Qko`b|N4$FB3iEBE#KdlwXRD_hf6!O1 z0Zv=E;h2;FUZjgNUqvH;$ze(T`x83a@QHH0=xjb|MuE$qRp%s~1Dns!gtE)BI=f9C z?|yF;)_MG0lL?-Uk!YE7hdoV-D7K8&`=Dp-u61e4x&ygVv+-s5CIfhmh^BtVd(YJqp?Ndo2QhqqiP1d*}9~{pFw$n%t{pj>s_`Dq1 zUc)O!zKq`;@LTpLGfe?O-GRuS$AgJ;lmQvWA_q}vh63C%?sFntFvJjMp`1RvJA+O_ zI8F3v)sZW1cq9YR_7dOZL>SH%!bcElisqnN$u%_Wmxj0MO!&aUQ=|X!Lwglji?^tl zv+OF+y_bHj2d10!j0frH^BoI9P)Os2N+|SBEgP+(=hD~|v5K~&VCSbjcgJNqUgjOd z+Z4PW0-yuhwslY@UesI)IU>(BFK7W)oM=k0L&cTCo<7RBHBOcR7%d*nA;OEF`@F{0 zLh+d^o8&whQ}GHR&px!DFNCtSLf~l65VD*r;ta|fya2X%^)G^4T!=RaQCKd&?VPWz zB4X6X%JxJuS=$Pg>saFT2pf?zietW{LEx6Ez}z$Qu$<*UDq8aZv$&-se#Yz?i{vS~ zr2>=sOR%?PgZi98yr1APMaXo8nK1kGC$|%~m!6v?e!eSsWamz9gv#J12sChF#ExztdLnxjGvG5Zov8tQ z$hz>Dob~i+qKI5!9J#>qo04gw2{sL~pGeiV+G4Q5MkjyvY+qsK2{$Tu?Gm_488P4j z>`=O@53%~FjThkTOH?$7PfS+6f3GW2WfILfdqZ_$UNGp3%8B0EbClj0Uy(Y`Lg{y|v0?26$JU!av@ByT;82yLbYlE3OLapi+=M|_Squ4BsSRYd6jjO?b{aZzJ6s$ zJr(t{UPJXX$!)BDui#jHV`gLih%}*GR`VJBv}mbcSi+V=Q?2buz-m`NiWc)i)r1qH zHKbF;1R8Ua-28YsU;t5;OwY!j`0Q`>6ddpuVJvVGId4b);^utE$XY8; zcp-WzQ}4#QlmDK#u%w1(igJ74S5MuMmzNlktm<;o5q6jg>Wn9DBDDB*H&p* zrSI33{GMj-c1&C%co61Re4d;U2--on5>sV9El`~RBrZ&881yb~v2@HNr}3H>1XU!M zRD}^)=|j}8hpqL-T}#FrHeDL5(ROE-FsG?P5Mukk2mCv=$!IThDs>TIq#e2el;IdM z5yrcskQCwt`)<~9$9%CKPjl4PVTwA>_+%)_08_U!JMjqyEz}*m>2R$HSmxS39Y!s+ zDZnkCfFN#-tq2(gCsMH@bB~<6=284V`SUj%?j}ZrCg?pF5qh9AaL(cVn0}MOxLKp~ z%*>GVg&u}Mwwa^eq27KYHZ!Po*8L@FuI56F`X$PVh}Sz@VRlTaopH%+3Xk$YZux$T zj8@NyeP$*doki_Z?Z4G4K)H79PrifC9jQJiTRHW$6r>-sbCq{*c*!@br^6HS=@_Z0)`L!;139rg5SCuAt^MM%`S0ZAVw$V8CzHp z2MOpgjS%QDGoQZ&;+IolI=*CRH^qohTZpu6{QO9D-`ntoMGdP^XI%KvY_BZqFz5+h zAF2rk4n(^%Td8>Y&u-t^9qaVyIb$xY(tiz3`2W?BGUi8;Hg_I2#(u*D8sTedf7Hz} z`}N&QfUlk`D%y$5J2^s}QVwB-dukU{xSW%-?p9Y$HlG$@hYhS6w9I+Fi%S-+_44)m z|I7k6ns>~HN5ipgljowfYTFbPz#AtiCBS9yT^(~QYfukEb?-BIuZ+Gy|DS#c7YRvS z2Ic6We%!9By%3ci6zBl=6D0^-XqG4okP&)2B|D5LxPAM0NYqc$DuP_l;Q#!dB@^DL zpF0M?r1sx+Q)$2dw;hKF?W}8*^HzNH3zn zNa>ZI-~B8h%y#gp!qtn82U)3C2dP&@iP)Xv(Fa)?SYai0YO_tK&`q!-sb|fsQbfo( z!J-Xu0u(ktG@Mmc!oy;HHC7xyYgB7@A47K^oJnT$2+uM~6Z_2QMGc)eIbkY;Sdkre z7J7Qkjp>lqhi%gPADp4(YOi!R`jE*DZeJVAX4au`eP`bX%q#EMC4o&0% zHs}C12wH9SDDPcaK{`<(PdcXz7Bw@yhPEBO;dXJ?q&|F4;#-H>w`OyLv=ESf42YqB zP>lfTFAg0q0&ZngsHL0!>y81D2Y=YbqxVUuV6Mb}{t(aGVJ!LS1mKn5~of9tH}}MjXi)Nrbuf~iKxwJ z5__90++&EbGUOLphXeOE%g@RiurlNTQsz z=uO7sxk**OBTYl(cA_y_{mklyR9nUQ&X>LxxfT0zL?pEfuK_pOOI3?ig+bh8xs(*6 zssFRb#~UXVfZRlZNN2D&jz{5DcqB0h1JQv(;sRBZ=d12x1) z2c)=0VZ3$cR}K0H$|cvaLs;lBYu;RPR0Vc%xN&5;2#QCIYS34Ae{WD{UHosSNP)j6 z;a-ZX+8l{g5&a>LRMWfkseioV`+RS$fNSf18nSnFjISF_$$>~Bp`DkIdF%Z_Q?xV( zOnio+?I!jq5#*mrX!oTcu^~xeBkzrDnXqyrmmFhv_)`$tj~CBNGK{u`Q%4ffIr!nh zTsPoA;oIbkL6D7Umf&Ygs7W1)z>|}pX8Wr)7czvB&>;o{XBA9tBXZJv_R7=)R)CD{ z(lC3wK6#vcWuG3*!o9~uqQF`)lzZ?UHOi-f;XF!SSjIcL8BR?tBvux!iFx}DriqCx zjU9(spG~)`;6I_Kuy}aOawK0LC|qrGcfwzk=SYN7*xLnCq~F$0euhcs>7H4oOrH|u zjizB55DF>$NfAg3XYAh_b|X+U8L$i_5m3@j9am(F&TXaV z=J!et3-#PfCwoI(ly}uemb>nVmHzHSa~ZPOMe_@whKHtp&J6X)6(E}~i|tMrFvlv~ zp$KZmG~(J$niH4jXYPL!$Hw%wA?4;ts>)7YN4FxnYVJawRa9)~^PNz}e3CBRO_CDc z8`Jz6_el@!8Ws*Rnk0-oM6re7oGRaXU3*c>i@~3a?b-)bXX4 zXNE319IAZZ_g(?th#-67D7a1YUjc;vZxYxasO;tjb-UsoV|4mgEwmb?p+e1B2zuje zdjPneTFNU0iD|X0a;f8Mu+c)80tf zxbXEcQ{w__N~FP0KEv{?C0junHdRQ^YUGmPhJwGxv=@NCs<#|eqmjJuxS#uB#vxuV zSuJjEO@2`LfJ2Y4BKwvH1Gb32Ac}}VQJv7#3vmH#s!DdN7(z+#gsjn2{V$c0IWvyb zTTIKI?X*ry`h`A(L2s!U*qxiVce(3Sw_$awGt{_^dD&Q>yv*5)ACjlc#Lf&+oc|n} zCjE103dktD$tCY$Bv4y#*?~J2a(ATF3>}xdY$UXtb&PUryDES;g-@7(Y|dXfaGoa7(WE&P)nI|(vS;meCOt1^}8H1LwW6$6gJil#qp-esw?Yd+VwgtcAL z)Nh2+)+5Blxkp%-Z|e_sw%wQE9%a6u2GOqo$Jd(&LdOw-woYK-v-k96rq5N--ohdt zn{VGDE2&>+^v$$7*s%D}*+fB7%V6|o)Tw3|d$r1Vm9lE0{7d6oE#JXh@+nqF-BR6u z8{7&UtydH(O_?y(Uj%S=O}Lim$eJluu^QkOJjN0hcm~|>(~)@9 z4JwxytLhS`VyoHgCH*WA2?(stzQG?Hoq$QU=)rT2UsMl&je@WlTC?j3fp}dhtoXB!3r%*xEkVZfdIiLc_6) z-jm=*_Vw287xaZts@97d)GVNc-$#6eOZI1!E~*;4z&9rLL@-`Dr=R)x1d)3yXH{^C z%5N-;MVhd|f%1-WsZ2~Es4AA)1uhBJT|6*1#N7QT_8=b8`(x^OA|LM>_j$`~?qxxq zw?C1Y8y+R&x*!-y8Y0Jss45v(BU87gQky47`lM#M1iCP89QmJ98sPssdXWBXNG{-R zNvoMUCg`+GDQD)52yh#-^2=C`fSzMwgHIc;<&~no5BZcQM@A$r|HpB!(H@fZV%kbE zX~LJ3RtLF7E~i)jA>T6P+OCK<&csxWYxSjWf@G$cEOfs&_lx{I^ojH&R#_71Jy6n1 zOiB6XuL# z{S7CK(@&cmtPx2dru3U%rg~u4ILNuMTsi6kQIoiDJG9O=K6nnTlz06B427QbY5s0E zsq?sJ2)>YvI>&u!e1nlu(=!7vboG3C)SR4=Qmj?44R*c|0yG#~d z@?#OF$8>6WsA>b)Vgnd!16X66$5tTZ8z_8@-h4C;H@pM{^>uC+qA1s4np@QbON9UL z;%zE?CJozT<@iU5%4M*dIUUf<+CC@T^E5Us7w?}mDvR@klk`othIShRn;t-^bVvKx z-;>GxYrU>LDwX@4N)MW(sf^p?tf(a}x*GR-{p43Fd_i{x2m6OxDg5+=VRg~6%FDD# zMa>G=dLPS?d9^w8U>~)Tix_8i_B25#;qGH%c4YTyvz;L?+YLRv*RFv_(Ap!IeR>|t zdRX!rvjkrpjxhW;-lEF{xgt$lc1InX_CXO$FTy13$xWU*+urb z+Ng?5Syu>&IKg%i-jvb0Be@nGvN;e52vkJ#)kj}AQ?E{E^7X^`U;qvx; zrGUBO!g@fj>h~2Qz?1_s#(~u`Ozm-0f^`+Y|DxChi|NUO&EEtYA*PROGp*NDoxK^I z^}I#4RX}k|#EXaAIK=aJ{p>hQSWgPgB(l}L8)@}Ac$VLY6Hh7_^=Tkh-u#Zl8n8$) zZ!JG#j)zkz_1aN#)&T^*q@31x?I}rTfFJ&1X7SxA%kZvVPB0?B{q+^H_ExANpS*^e zJJ#Ass9~C()$EVm4(Qh#{ja>oDQpeHX9k=EveV;?UsC%guB2R|tWR-Qmr@4dlJb2F zvcd#?8r$DSR5n*sHV0HTT@)N;)o8G)aN(!k9;GK8P)QKlA@Ts$9rsyZ)SfP2pKP?4 zE=QQds^;Rg=%IC7)nko}l$|)fS5foa!hE%Pww6wnwlpgoamWh8x!U$^a`@u9$2y~p z`BIbIR>@l>6F$=(yE4DK4jh?o`QWeX`#M83CSshrAM)yUFn`<<6ryF{(bm488|ay_ zz+Ck;5tdB26DpwZimHYLdZg!6{kVJ3c_gY@GBGK?8DdBu3rh0#kh4?+eOOFayazHK z`?R_!r=`_YE$H@oFc%~xhV}MK(mKw=B5jUbQ|UTVr@>pK)hR`|A~8oYnOejm?Lu+Y zD{DoKwZ7WM;&(xA4yf;wT^Mr;3Ov0pJS6=1TLEt|TqB?j=0Al4>mCUDBd}bz;m0l6 zdqEg&v(hOJcoJM(^B%NFBISg+?XcpD!rY6=J~km4j@I>swu|<~?XpD-?;wvqlEF~=U9 zT8i$370M5_Bl5!w=c5{hoa*D5avmhC0k6K|9&4gpx`Spb@kYyPF(Gl?Rr7156=cOK zEhoUh(6qHWB9*6gwG^#Yhth@C?jdlT!$D9`GzD$$+w>*x`$(-JirT8nGB}0urQC5) zW)gU~l`MpdjZYRgMjK^bXdhJvl8H>QUt~TwjwJMK;oLA(?0?AkKcs%`&AvIANE=HK z`O4Zw3>gltbLdMvgy>s%bKb zG~RM}>G$sLk{y62mYHh$c8Zs3V*AV@lQjBujFe60a8Gmzn#o*yRL zxjn(ra5y|89rn!=_;)+8Kxr&DzP%f-pzJi}Tr?R@8KqTKK~;BZ50qt1XEqKC)s93k zGs7_mC_2^H;}wC2NCH{>41Fl;_N*INmW&^7zx$@F{&n{YrIAYcV_B(+*MxF7q-xe@ z)A&u9s9L{Mpz;!mioT#4dWaBlLG(d6X|28ry{|eXyq(WNDSWsPFpT%6#`=M+r}Fst zH$E*rBy?QI=_~hF@&hadNGx{eC8s&!=v=|4}L91)1i{k^`CsL*sRReqrN~@y$ zs+>e3dVb!+1JE-z@LcaI6mTzvs;5lK2>ci16eBExKqE%$)w0S~>mf=1PAG@T<)ai*}Mp}5>>m2%{I zpQ?;Ox_HvuwoD4@QrU>a1k+w>ZXBB<=|O64a2rZbI7Hmc#HSyHMrld^kE^$giX&{+ zc5!znxVr?%KyV2b9D=(Og1a~F?gS6+?h@SHVQ_bM%g4L-clJK#tTi*es(bmcm00l(qDNNOgq-3GC-dar+moTTrkRbs>5NjdGy;`8tY<@NtP+ zS6kAF5j=dsV|t`)f1wwEp6VOhFec&>w3NVN%=B9gyv{j88%4H%F~%tpvZxgZ`5Lac zY!E8r-&|YKCGSR^G)~kmtDXUw$we&(Cy8UnCjX8#?f&sHyZU5si^uF|bz9#5i9loX zb%vEHzdd`5p-tv@6bsQK5rgQaS-O&-UWsh4<(4cP0D6}%o`so6mA|jNl2Hb=bEBF> ziEM*r-I+2bv_a%Eb&zpc<9ai7%QCgzgpYcOf7bFY`Vr0y!@DR8c`hKk;K7JgeFv!I zf-(KGovVkLg6`AEAY$p8b_*z?&OBi~&2c%GX?KE|-SWHibul9SBj5zghW!|xIe8ZT)5?b%9|6t1m8|sn8gqq%59D-%e%z?vJPxG*;PbcW0UC%@z z%}4#07^DCZQZbJSGfGAXRBb;Z0(!ny@`}4<8>$NOHn<7jqN)7!+ybLK9sN(1)M$4G0SIsDwjoYn_o9JHE5=i_mesU z=a;!|@8`I$6rU*VplF|}Q?9<$-BWcm6O5qlRfvFycHyI2<}%+!`yW@=T&w8I&PaZG z0&yaAt%v0%DNf5Gv?0V&)P%#vMnp|v)~nweNq@e147b~-rw&+$e$t1`Viot5$f6WZ zN5stO#3z*zyIwk?sQsSBXN0IfeU^yQsTm;f)zl| zI7y@OJC4d|zb)sK^q5F9=GEYDIdla-bkyQDC!ZD&Ssb6CPzjeI~xs0_)m&jeU(2S9@uUMfh6K;+Ceyt$bT{S)>NQZ4teBNBOoL3b- zhqLwK^nz11D}trMhf&uQ{9&D8vB=%;bAIH06#h@i!(`mN+7cjDJG-fo7C%%@OocEl zr|hDUgTY)2GhI!^srulybO=WQv=O)Fa(Ap~8Ggh`nnQ95oSKlzY4RxOf`wC=F9+Pg`1kH@E3$u?On;da)Iy0*fV{hBL+o z-u|qu+E7=~nwaBY!P^O;*EIg=t+_Gn?HN?3zX6x@0xDj`uTxjHWp{GJALh>TIdw~B z`E#KeGWjC6J~!W}VOqWdB-utcTk4Jq-ryK$zMc7h_B{x~Z|oKAn+dzu68aiVzIpB^{`bv74^sZJN#o>|U-c^9>wET5 z195lX|7LHM4j&rqA{5<3f7mvR?s?mg+mt2EW|+P!RwSzF$>hFOip5x-btHf51ai() zYIF|(4&vy<<}*JoD+5w{^}uyj3R9zrCY^(*fkk4W;YF0RbaxY*r)~0oqPEl!&OLt6 zzVbYFiuJ$Z@+&3%s}Z6p_NlrdtR9}KD?M78*}Cru@|~%2GU?zvC->|%Yx5Gmyorlp zsU~P*m>HdPqG~@_FSQDhXg|1*8lJ`~TTguktSsf8JWb}x^**mib)xz{SVOeiLT`E# zK?v;~WM6_I)E+b;UX*Q1Hf0dL$oAIogcmsLt699*XWJt4oF8gNm%WP38!bhZ-492x z`uL+9C)lxdHh13Onkw0Zex4E1X%-zRq`&)dELO^WZlv!p{YGnM?WWr=)47f1R@)~8 zU_2Z~p)Z$ewy^rP#AwrjnM<9ce}a)lO2-8Cdk!4fEA67q*G@M=tQ>zl^^(#-r1q$y zd0XQpc_E}luVW?iBUO83+g?^&n|Xe2j*-E9{WOEocT10q)w`=;ji#l|e~Z2uQhe>C zbdPTheLYLmoI1?+!d#~6vl0J|t5jnI@S1KAezR2d(C%7Rfc5GIRy$DqX!nYjU8k^Sx&F+4YMNm>l}9!-2W&qG9AAH3Uc3el&)6=)mr3?v@1UZ+o|z z(X3iXG}1^i(=j>S2J@Vq$Vv7msV37LTmgzXNZ(E{cWeM8RR4nJ8fxJE!@3_q@#G91 z@{Ht{@beF{w$F}p8LPAExUd4yL(xy$FmUX zKg%kPBUz+-rs&2tRp~AHwxjNt=Uf*VZJQJzyQCJX0CS#V&ek~R_&1GjBUk9Y8Nm5itIY=Uk*-6UtQrxt%_C+5}pG&&&9%fMH6 zcdBg5rL74B56LLNTLu2)S1a}#m$oDl1K;UwnU?PH@vGc;J_Q|=AJL>uX|mRPt#UJ$ zL?hY(eDyNrF`m@2lWl{rf&=sV)A}iv)n9ll5g}pwum!kj>~~wuWW<4-je|N5=Z#w+SI}#ZSIGH`s6;Y>7cPHP zVkDJO<93MNKojt{S3EG3or*J!VW#>C>dLxP`1Pn$cxiyefQ<^kB_8;$MVwOFX7S@z zHwB%|4yIl`(YDlEqA18%U1C2MY`|AbUvrUBswdOhMm%9X>Cn>gYn1G}yJg?2@kZsK zkz~?8e!(69P05z=2>j#JD?L2Z_C{tK{2DL&L`)}Um@~Ft7jCq18ywpiPDKWPrIDZV zDOfb<>Llxy%CF2766^d9Qc$%8h?%ijP22vgD1@b~wnF(~hvJ*hEJRp@q4N6@E%w5- zdZ({$tF2dXu}ZN7x8b+^c|0BbppJyMZ&?jbS0f?NMfEL&q`7#mpS=oBqoF6j@?rXX z6J|gro>9F8L*6F!o*&7_y(T4 zlZsTh7Nv@kECB5|;=KTVKPh?l}9 zTC@+gL;@tu&%#x%ol=3Ntqv&(X!Zju8d_V4VO%tK}+UH8lf){G}{}DeG&qvA2-b(501!wK)HNbKN{$) zgjR5-&fO*RMS|tAC$Eb=40Nq_(RF~lZx}CwerxP&-5u;h@+1~?p9)@yOzbprdJs(P z%Do*9CF5b_8}Vqrjd5Kb30tD+!_LRW2#ZTEVfYER*g&cZ%ZHx3-t)O3gDilhJuDjt zcAtPLh}>(A2d^azro$r1ZrPZdjB}WZhb$8=wh3g49z41|gL+fHusOP6+(sj$=@HXSct;v=^s#m700z4X9|)FiNukr%jSXf!QOr&R;GjDOeN}&$@N2+!MtQzT zuSPspggL))*Hqe?=)Sq9+CDOAEDBMb$g5Xp=-jrQ@%^Xq@V^a=6SP}eXf@NT^mR+2 zYH^+|hE4-ro;3nZZa3@`IEjV%wyaH}cccZ>iJ{h6-S3Yuv$~HkAbdf;@gM~Q$1Ut7 zoky6uk6q9eJ-(_i?F(&}i1})USk1;|Vp$r9{@eRmgJObL&bAm2eoid!(|`^noQ-H28@AhLr@-EAh^4V?65o?+ z%MY^_p)^#D3Uk*llUVw2#h#t>CvlX8+h&GXMwMcw%id#{Y??C7kmWY@96i{>&y)-j zzaSVy!!zGSsy{#GSvLPXWe)g?X;`T(YQ*(-44E1G($7>UWm^y8kWIM+W^;O)QJS9E zI6NGHu+yRB`RrWtjdAlUY39^ARd;&p+w=1E`==wiJ#$; zEV5U{u;#Q*oUzS@p*BAfa5{(yI$}Of{-W>vkB-hMz67Mim9muP-(8;k9f&pD{zFLS z8j*JXX(C2Y+Oer!c+|A1=bK^H#4b|nuyjwr10*>x^ZB&3{0~ux93VM? zwsL}17;mK5oYYq>>}9vCkIOdtXU$2k$^t5hRy3gL5Wa3)PSwCs1$PN*1*Xv# z)NS?eN4IbZtwEAOh*+}U;7{r`d>`ckQBKS0w*NRXWH@9EgcY*+?MFm-QX#XZR>8AXP z8sQH+3GD7($(9WT=c#gn@KZ1)XY>_d45n0^#DwC+ZtlxE0yvAux zq3su#5iA^&iG+*qh}0Ka=I|OA@s(MC2%n@myuqr5k&~zq7owhXru|;zpj+JUWqf&O z$F<`*9u6Wn2E6*aGZpDpM)iYlboguf?U8AR;801BW@*Q01S)af z>cbM9xKw7QWW`o2-9^Glv;1L#R{ZciE0u416v3&q9EmQe-=P~3plu|f9^C4I8>Df) zt^mJlnb>Qp-^)Ljb-rFvdy=}rxAfL(BtEsh)lS@4*L2LH-`x_6d7DXPb>YR+RR`@F zZiHrR{B!%lEWs`REG6{4$kQCj3W?HBPK3IeAruA#8)wkyFU6yXfv8y!eZr>2imDA8 zSHmrzrKXvSkLd)?+Y@ix4w@MSYKfsm^;D^a)45sLYLf)#L--1WRSz_w9RlGB>`Xh$ zIM3o8Sih(67tq}1Bx^o>dhjmF167Tn*DjMQSgM(-lcHVlaqTJnJfCyRE=LKFJl@Lu|M|cs{Vf4BV4s7F2fsj*&O#e)oXm=cKP&tSLjHiE=+xvux zm}Eq-%!O4wM_|kq0{s@Rc$p{rmmsjhUz!(7?7DB$QEfE1h7+}4TLGLa(!G12Fd#Il zt^aa2j>D>n^m_;KrPdVOViH7G$8Kp?CS6MAW}N9L*1PXQU*AH4WNi~7nhwsjYXs*` z5!taLW9pxDyOu`oKZWrDwO_WvlE@pa83T;?w4IZUJS~J*g?!9@{3&dI4kXHS-B0$) z{D!0JaDH>vX%RlSDtZ-PP;BfnS?y-P+*GRSSu}duuR4D`i~d*h{Td4nVWiBp<-I)D z&7@t=?PdX)sGe*k=gkgOPllHBHgzxv$Jr*6En$d3V}lcu@#*SA&Mq`;65PK~pKcfg zNB_^iS4{t{v#P4fV_0pzrrFluN^5{=tSM6!=dP;OP3t~WU<_IzK_#VjM(oouI67@5 zdvFdkB~HbTyXRuEIyebDl&d@+>OU+|EEvy=4RC0AD8FdF~Wh zRdd>~=?PkXh$dZE%1FNM9^P-+jg(Idg*zR^&ObH}Uog4=EQHq7!{`S`YKOzCV^of# z_>#G@ly5W$94FFL%6~$olNCIUOMYZtiaHra?QpW6@CQO?hQ!V*J(jJ{su%wt^`cm{ zW8O0XhW+M<)ivH8O**_(_u_PLK2yaz=kE=$gx=pk(`|d@`S&lXgI?mRni74oGxtc} ze`V0rU2K&?+cccs7Wzgjhg&+nh_$rQ!6H7ftc1iCL`nYprrRi{;LTh7mlVfCq)ICX zcpkd(%Jmf=2LHZv^tjWIGPf& z^(k;>K|Xdro+vg9;m<}^#8T72Hpg*+Ncd=Z%)h#!@9?|?6lI_*^$r$20&P3atUu3V z7gy_csQa-o<50#N9(iy5StzjC_U385Z;xK_T(#|9saO(GF~t} zNjO#VAWNV&P%oTgXO~R)*9qJ#&hAF&2oxMnI^9fKu^k;1y?x6yyOM$hWfa+AuB>_o zf?UZcs(xa&eeV_B3>(Hq@OST#1Pe7|_x^3B{(xMzgbj-J2WHTwT% zFSfhh<&^kSMA>maE;f1h%mS0P-!E-HB5gnI zcW$FwWiH9C!-8T6ziAn&I*>M(qCqH+#_Md%#vOm@E&hz%*dOK!tEPjVBnjIEy-j_l z)rjm}a-yUl0twukMuqm;sTO+O+C-=FNsnF)<;1D-i4oQ5UEm=q08iMn^#MVfhNs(~ zzh%;;$@Ssd-)3>*&r%btiJGAP!hB6f)%A6ExM0I~j-;L}D^(LLIz?N-mI?h;VdXp` z4VYMzG>V`C@AQF&Xil*s{?{JjW2K6Htw9tmtoGFn~;bgzZ2 zqd%D*HHyiaB!T7b(yjw)#KXGB1XWJ7(V!91Eo2A|u|J{=u7`}9GJ1l+a{G|qve6JA zMXr^2LsVfol-}y8C5;ZF3#p}1t8Es{|srNBq9tf5KiZfYhJnYy+Z0~g{?vETzZBC zt#>@)?|mhM*bd##@`z83oyzxkX*+HedgAx-09^!eMfMQtm)|?0Y*)%;3nbbE;y08! z;vihVp+d^8PWC%&j32Q12bo%_UO7k@_8136lPC!?7OIR;g;Y0|S$dt_2484ZyAJPi z%O4lx>0EO8Yffm!t9&jN7u7pV%8qI6&ROUif-#lrKLHJq!FxG1F8GXltYBpV+~t22 zfaC4fL6>o4dnH4FoMgB!7vqZi(-czNDDhoM=shh^YM~u)fOOld_`PYy`2}z39-GEY zqoES#&vf-~_y@_xA)PoD4)s1yB`NG{A$W(~Sd&3a=>+3MOk}63%{T*sT(LyXLDtPM zi6=WQh-WGg^};;-+hKy@PmH#sr7`~^K#lnt-sh!PveQ3mk|bRFq1-980tNc~1fE;f zZ!hhptDakdmp}stzFcT8o+g(l7PBp!`I_eIFP#SOth?p*$wnzp*MM(`W$hlkf+pIC zv&bFQ2GCfO(Xyr1Bpl_ zl-QohahzSNRA`y+eK0JcKioq46b2;WlQnAUEoy31&41R^{K&^6sFe9v@d(ZY?&psL16WLBqW-&b zqW*m-A9VfP5MCyAtvFp+p(LGQdb8*-3qrhWh{I$XL9|u35T*8I%updJfU#T;xs(k7 zRXUecDX+{G-ap4FSs4z;?$g(EzHysO6Zg#_kNiHtWY;W&PJJokTKwSB4}%cnjSb&F zPGfoFmG^-b8{uRz$%*$@ov+VTPt{t4%D`m{6F8n0Q2l-Undg#E4`_H{@SsDsL^hRQr(F!S%zh$h@+CFpgzcGP*hShaM^nW&K z4178awx7RuAfolrwYu_4?l(>+6|tJ7Qq0Iv@(w$2Giu(82*Kn{1VTFCec_v7zS$h+ zrSvYz_})dyi0~^ig=(_DR(Xt3;#IUW<7EYpYkJsWaUqT_g}WFMYO4mbS@q%_-y!L} zt^Zf9tgfp%RHh&)kW%*@hP=Gz_cCYKl!E5YRJXP`y-qidzLP`kvGf;a@U~(X#9uqx zN1f;H9uxyG(+EFMs@Qjl=$K?=r8!cMo}Xru4cj8plAj;}oR9`IeRHGGnRasfxiflM}=1IL%butrcfs-RytW5Yc3aNCT`Y#h>xQh61*y{E(k#k>2 zZS=O}<{J%Wtrc$&*{%q++tSdnjqTVOT@6 zX;?@1ZLdgew$L%lgHagVi;-2!;H>4&pCdZbNeC%9keykHRIiynAt>betA!{wZBUUh zqBoeH`@9~A2wE1^^WAN88=ESD<&?9(Wq)n<3Fnw6PgrP2mw?wKPN9#nb)4yRNl79+ z6>%hJi_!FEHtgH4K8YQu(M=vX9?X_IA#eOi(g%vcs~OLO1!Lq&39k6*Yh*}|=cdO`BjRpudQ)vSsE|Je4wMs)2d!uxlkADb@!A5G; zQA!7x1oTX5}LQTUY5Vt^^|uMY^8XeWgx2#Eew5kqEzC=NyFIj8bNuE9Hh_s!r;0m z2C)2Uc3YZ#M{^)ZVc%%PoV-5EiB;~Mc*zM)9WPl)D1U=VXCzQaFZb!P$gXxBO@me| z^No#!8|H@%Tq^X%0OMdR;rrjpeVZw0Cy)5VMiFNho=#1+mh52%Ay!Z`r`l?iwY*DC zddSd6!M8xL><^P->=eZN$%?tAf@YmU8*p6lMIKi+@LnzFsUJVcwHC~-wCn=e$B`Hk z!GPne-;CH%jGs}fLN`9|W|1CM*FXIapPBrxA`9KznTA%PnQS&SvTJ+JU%L<5Nhn$) z>n$Y9oaU9$%jxjMlj_u;uGyOzMcKG<{ToSbD*V&5k4lvo9+(opuW<-~J^dxk7AZPh zEA&jH&sQ|TI2XC*vdWI$4*n}T*$FBZXcRd+Ya+Ej)h8E54Z_|JnL1yvr^;NPR1$2} zzZ%%OT~;-?z@;z?kX+Pu*$FE4k#AWv{uByNP>J53zt>wgCp>}gN1%EOam&(e$r>By z=V(fJJ~Y8W5#Hf3mGoO*pi|5F%%~D6AuQ#K+WU^%75UhG~^|OK53m)vSwjhyH zaU=ex>s#T{?6ggW#zK;;?z;lsk{OuxGHS%gE)lpKY1F^Qbv$IEv%QViYs3?dTE5qu90Cp^mztrb#4c{kdXbZRK(Ey|BVgcUs-gngASPvqQwOUi<=GJJ zCq-(1Rq6s~It9*cz%8G5QmT+$4c0TPX*5dDPC={6OT&C%TqH~Pxq%lb>bpgn1((os zY$3a(6L^UtF@IA(Mqs!Q;!-~RebfbNVQC)bMnqgTb_q*ZO0>^B+0k|8a69;R!G#@5 zIAyG5-$Vn-#2Y8|S9w}i{x;{kx4CP6bAd3JNt_$O8)X==Ogpuaf} z%aW)twm`E?8sNp6`6gE5PZqGA$@w*PXxy=ezck}kAC9Tum1PoblLyy@+r*{zPEIwY zVr|6`7F8ML{y=GA`6Puw0YC!e_F>&Eims=%zDy!zvqbY%V&I+!Auv?uK~&RpbA9Lk zA?-Kkn&i=mbbpfDL^mn^#S7)~B+dv);^1!TANFe*)V~p7F+o^Ts40?OR0`8cI@J`6 zBpoB!o!EsDuH-^nyxv(8h(S7LxA(yUAJZR7NKo9w*(w@FsCLiWUE&0Q(TN;RBweQn zyHCHxR85lJFP%&RXCysqo$+{a$@*v5xU#stHP={HN0aqo)fp%56`i1EUBAoY>f`;T zVq*lbIQp4w}~f8 z;R(V7;p~d7pyEZiHf3~Ydn5JDmv}CzAi_R5I3#SuvfaxNK{G2#`wQ|&e>ZCEof2o_ z8`1|Z@%u4fv|%D|CTiLZB<|Ici`7nC4S%w-aVRxGl4nBy4?V&D+Jqn!)JrO&i&* zSN7?n=-tFYkKJPuKyr6>fIamO8fUWTnoHzk z);fKo``nHu{h6k?7IR8el#kr>XEwSbT>Nc)F77RzQX?a zOA*G^A0*KJig0C@{3SJ6ZXEu_p+Au!UeMdgj0hr9mG`ig2P@z$Ee#DUSF!tWf_RZG z*&#e3R;}~dfs_`!uNT4$w1&6Dcy9R?@H+_lEN8%8w_9*2qYWWDwo{^R-0 z>f_MEmi}GVNF_|V@TJ%wJrvWSEMC-i-&$z+DCDg6qA^+be;aGhS9FowQ_j*F%T&ySrcii-^{~S za>*t+!|~M;|L{F3X1|H+AtcyW+h=L0sl&-Ky5E?XP8mJjMuFF9%wdbh=91~-m{ps( z8Lqh@)n=X5mmVs?g6ii23&+Z)XvdvCth>9lMs*OB#keZRzG{ga8%@JeK|V;~reu8fHE{#zabNen;ZMG~4N3pupU_D*Kvik{ zGs)fh_eMMSxGh}BH8;M^A9KFS8D`_YCa%}`st(o$xQ>mnFIuCef*;C^W|e{n(LWEa znwocCive0r&t~y)JzS4aZEv6Pp6m(eman4RHwbIj{gAnoUlU?PYKB78xBmp=g=RB{ zYaBt?$ZL{a$PVqy*(x|pA5sruGnL8RC05<-^a3~KR(4SO=O2DqV zXeNs(+9gJBzsQAwB3!cq>9^!v2Fo??8xfG?+BS5l_QONCh+gy{O;C6qin~w1s#qn0 zGY;l((U>0X5`9`1d6lKr%I~2bmE9a#$B|MCdYI3bb0o*d^Wq7!lL5Bjxa^jJ--{_t z=Bffki1f$r?+ylS2xBi=A!{a~=QGO6b2s60O?1ItNV_cHsO&O5X9K zv~s!wvp|x#VIDGB@9xQ>3qLASF#3t=IW)1!G)_cK4#!Ptn1k)G>k+V5C3M^M9CbCq z+5Vh)aFmtn$Qko7CuOzz54yp2qPR<%l;O`m!Mgm(ECjD(whlPQ?0Kv;VLhq#W)LB^ zg6ynlr)=reuABiqpcb$b4v^}t)EF==+-eIB{?k|vmalv+H+hw_r&Ax2gXC6~X9-N- z9%iV%RI0M86l{{%;?E4hF9NmmG;H;sA}jS0c_$l%+qAPsCGEQ!eN{lS+u_;^BKF8! z`e77Xb2)$)!{2ai;Fy%1)vM}b>5?=lwff$qv!_5_PR2N!YjKZz0#ptbe4Y1rgati~ zo}3*u5Q~X@G@%_HA6pDSUM%tg3(Zmokn<&|#q!p|&b*6a0SEVXT>FI4?+z72q_rF) z+E7CLYk7plsxJ*sFhh%(b#gl;hkiYc{7mrmxF4l;9y7B}`%p}@=Rpd`?k}`BZ6$L@oSX4sx|-gIbmIPV z=3YUDE#m8U$z&rE1yB3ELVAlShZlJvb~o*xoB;);PpPw5A7l5@On3pVcC#lx+hOXw z&!ABS7=2=IWl5Z6MkH?S15Fl(ne-L}w?^@r94$CndU)Yi}Js;7|P=$>$BX&j+dJ}Qh z=D1eeHT{dK@*|a$aljM(c|LW>Wbp6q0(vMkms=}_41Fd*Ly63 zP!n&1xqa%t^q%ilxjViP3Y4)onS z#?_v%f7{Mp_S{MxaY*W8NCkX?o3helId1=HlKdxI7)g{ldpG99!P*#1 zAgP#V|b>6MstZ+~t!Z#c4NA)ym%ruEmAD*hmCewC^%Nn7h! zd>OH(;94YH^g~tzc)s>)pi;r!(sz}%EibWCxYGQ2q2bMKlzX(nTYI(Z#V_h1V7crk z&!&ai(^eC3{8h_;nu4)0^Lg*Zf;{9ctS8HIl=!rloAZn07E?u0Tvmw~nD^7l!n7T) zSgp;mh!aHscMccg5(dYhIbj!fLX1UR`S0VB_*1Rq#QGEkYK-JeV70KX^DT(62E!HF8;_bRvV&d;2l#10Xu92oc5ITDXp@ z+2M~(SV&_94|-xO`#G&GlYUBLG#*=t9-lxT5nW@l!m;#0y&=xOa?oF0Pvl^{`C3X& zhY)LUFu=y~vD`WXF9v^^KYt_e!MO!rlNYhUPb3qHjE16as9%FI<@tw7Q94H5nTwCt z?8~x$ih{2{tt2l_f%*d*8G?7f^r*(Slkt57ew^&AdD8|nhIc~m69~?UtYIguS=@RO znhx+wLHMJt)!y1ibeV_a320R^SQJwyLvjKwgs)FEj+{e4dG&O=14?^B$vzH|MiICWTRXQ7+ z4T&(&B>-x8exSnuZ62!!O+^T4#))~+@TmLec&P7{syVpu)^by+Icz8b7Y6BR0M^QmLS`$A*Zf520p^~+=HPXnPJ;beKE`|JUhQpY@dG55^#Ls zF!}ZpJGq)0TE;J_v@a*L8DHfMPg1nupK2+r&gUAyI;pSIu+;X;86ejq;)p4>5#oK7>2(mlA}&hK^IyK z;e|ppJ{L~?%_6WsLqHpQf7bk4gQ4sQfrcmAOa+lb2VW$;V~1s1V|?&ybSr;DzBfv$g2SW+cXMBVZ;hRlw*AIQZDaw- zXI4!&&;egn)LYDUP8}bemxMyp2o;13H8Mz-K71K^5oyDxKQZnfX(FibN8=PBZH2@M z^C3wII9U=PaVy{Bgx%Vo7aYDUML?r0hcN`7-cmYzxV>3eW5#LsB6#QaQfB;d6qB7! z##bRbgmh;NQo(}K^}#V@Cz66<#uY!bT2@$t@dg-SYlKq{&IL4f23Emc|tMep0@2OF-3^m_7x=jvh64nZQYB`zEy|@%lH6Bu4w$Js1F5GR? z9?Xs-5YjtCtB)e8ZQDmLkO}M`EMNcjlJOI?U8JHt4k*tdkOa!9d|ToY|G%3hG{6F0 ze)N(pbzvw2S`KTgZtO{HGGj!7Orl0gLIUH1?5*tKSvz%jRU<>@hmGd8KBnp^6r`kW zQ%}|V07)DEH<3vAP#67x#)ZVJ-Y(DfD2!KhIEDQbZ4@^D#LAiNx{guy&iOG-&NVQr z#J?`Xb$#kTSTxCPD&X@SrO?s5i)5#te@=f%5ik^cTgLwr5fJMC=bN2R3Z#m7@klPbdG}fwZ6UnDqmeLirsDQ(d3 zeELXxdJoN1#r&;+xvu=V^(6ygpF_U{M!2U__+ckR{ex)uV(`dzvDp&Dsst^vKNpi9 z0phfh{xVkX`jLN5yg&_lLyq$qFykZXHIy71A0_tpLV9-^xAu?iE0!^~S+)gYd7_+` z+T@aH&PUV5atM;tp8egFIf)UeV0yrOr|)s+jFbB+yp#yNgik3P5R%1ysl$akh*NN# z>LCHd+JaN`NVTB4j z%y#-^Xg~Mhdx?}6Zw2`nX4c%4U2n&TmO<`u)(QB_&7fNQGplADlud_jzuXkEG~(j zU772|f!siohq z(!=5hwWapqi?Jhrmex8!yUo?zzT4V%NzP&ga@^sv*9U6lv9|r+eS`lVY$}Jw7dGGa z#;Ol$z*B88IXW7Ed^kQwhPW7gCD#TRoy*=i$aW2hPtQe=UROPaJ;qK1Jho=gk%lRZ zU(K_4{i;i_5z=`fUqmrLPxSq;Tg)EqVPaglc}q!pR?t3hmazT-I&A+A%6v}g8~hOh z`)#Nt@tum+BHS4AE!|S) zF-48coRPp#`9T3Uc-Ipy{dE#Q5;u{~N|xs1Q^<+C*n?VG+^~L@Ujh5Sx4GA-ad?}o z2+}u3st%Z}<@?nexQsyx(G8!&yRc%8=M^L@z~tYk3K+-AimG!#66Iki7~*+M{hPv4 zO0M4PVH)b%K@gXRHJI%wyx&Zd#}1I~`AhPemr_eqDyE>q(<^%CE^+LJi$DwJtBx8= z^sVfew>)iFtUmamiQD%Uc8kmoVUGHzrEn;Tq0Famsak$A*qIST#6ad=_d0yjuT((Z zZBIoX`ng~HR=NN}SwC0^zcUgzL`)0TSdZ{tYTpjV#YJmRokPWPIzFVSF9GCY!&5M# zsB?;PXVT=PL&&A2Ea2G&6h~r_u#Ur)@-B~{1f;0R=XzVGXvx0V%p$C<(+wyI2pb7x zlgww|<*hVXD|?L&`TTpDCBuK-I{WM5HVI=WK!k9zEUaP6i*OQLRd}{! zvK#Ky90XHYVS4Me2}vB~w>18|t8&?BJ47*CEUnK2j- zHjgoLwOrTSRAuAJm=HXETWm@~Sv3z(U0#IBc`V)t3Y-Pfs>PQi{26RXdj>FD)Bdx@ zX9fEBYxyC*vVqEk+@TG|BQ#h|@YWWP@Ke`FD1Py`cz1FhQhM6@Ei8@X2aFw-$a?MM zpVjvpx%yYuaFdi7Z>SmICjgvdQtnpM&Yqwl^b1!WJs?79_Q5JN(_HMdeZl-m>S!U| z{9ptx1Sm-b)mMvL>Xdvs+#29Up;|hB9#H!1d*7Z)f(y*YAnir+lYaI8GPR<<|MQ8t zIm^7~&OnP+=K`6IKRxmw?!^vo%=kza)uBsy3N<#BgxorW&pY|D^%S$=`cB6-;Dnz@ z=U{o0cM@)~<}bpsmQ>83oj+B~Ama0FFIP1)6aXzexg#87+vGtFmeFz{>vrd_@NQt4 z%8brh#zrn$?sMah#WS;PVcg;H|c&( zp*P37@Cv=4^om#(HQ3I<;l|^rSSB?KMJO4FaXg1FUCeJ;@UH^wNVOhfHlOIBaltq? zTma7$ezT3qq};TRWHZkk`A^Mygbgflp2MzvQjQ<~4o+n&fASj5^ZiJNp4&%8bgpF4 zwihnpB5~t$>+o;i{xaf)1lv@69{WFRon=rQ?bfxCFeJFUTX1I}xNC5S;0}Yk4g`0% z;O_43?ry=I;1-;Z=bZDN`mAcC_EdHM=<2&`&${=zR-;HJkuksr+9O(9P{dDH*N9$7 za?1rkGcU{pd?a7jJ(TU_=dy}HP;8F#JjL;{ps9NpGrm^XyyRO-twhklpYE}Qsv z$7W*Se(pRX8mE^;wmD0x{Y+aII}V5SuEp4wb}!Xnu6_XLr;@r?&#P`-Q3}TY!8`1^ z9~;Mj5F&1xN${wHLHHQ>4{&_tbqgpx&fGvyO z7u(CJQfx#7t4B8u(R^D)+Xi*MY=(3@lqn{7h&$M0QM4IimHzcz^l2WW=U)H;Z7gjM6# z+G3qCaQre(+EApY6EjHMX4=3iHOgtDO+C+F%cIf;&p4W+tAPZ%@0*iBt$oYf35&D- z){e;9Ji`R4ZT5lTy-klq&t! zK?iD2v89#-tNVw~TwYnpd#s@jtj{X?6g&^>3mq@1(+tn25TYeItTNy9c^{QtpdMJC z&<5hbvtMhwbTPQ<(+CP^`z2-H1li!u*G$$8{pL^##axS)8&kc-Ou~l@jpV z&sQ9t;hQ<%@eN`5ehmF#^iTwrPYwbxX2C*|4u7bTMkEPrif^d(}$Dp8=yQR6Czo(`6))dTLZvK`8 z)|f8!8x2mb4gS*6nvlGjA5mf*eV3`i#Ody+$2S9b_J;OHV?xDtm)|A)%6709+iB01 zgaFkW??08CA zm~c0U&C?#rZH9?GYFaN!cl(zUk>%mRa@K>pb>Jit)K04e%aaBD$g0dDz*yWbF9%Z^ zjA{SXJ{UbCo+GECBc`B7OEy>61 zW2=mKExS#VpJub=^E)k+T2|#3_-zLd){hhCQ##VXLf}SE7?U%nK19?D&UJllg~g}# zfhh>RmBF59phLoT74;yJLNJ;(Pk6YdE+xY=3rWvpuGMJ6rYD(nW zIj(bN_(WV7@=AN0nx$ilF%xI(mL&Fxn?L# zVnt+jzk5{?U_n2n!X&?+HcHSVzfuhNgng|gafXcfVjp_5Cw(|ZcbgJNQ5k;7D9EZq z9|6laRc>^Fj1lUUMfmJt4{o$orr4orMCfkAzuH8j>dz{X-CL^<^-2SxJ`V=JJ0ctH zbj~AB9*2o_%GL}w(O^9S2go)HHTLj@#inuGdZNWU@r%(PA;(;a@4U>EzkZy{>#t8L zw3l`+{r4&F9_?nPlo4;B&c`t_d-6+^*F}HO9{*FWd2xUrfO?4k0AIAAO-QqppPLQ8 zpL^|xl1A{l8ngE+L*rIGDtKe5k_xaJ&W85q2ih^}T#&D3?if5nyDlS5xh|VJ7c;j` z*UteZb|709-OZDpj^oP`1x6mkm+PE6ZK)+7FJd=Xm0=Hq-`Wswn#29*%-H}yw?Yqj zg*Qf~J1~BdnhXsdVvPHVT<1iNudO3>cPGl^B25W@-wIxld3ude!O3^j<2m0?U8I?$ zv!CVH>@qLYhs8c7(hJ-G!6kh41YZG`O8iB34tJ5b;8<%*Ga9H~BVG-OLoN+R(F7}} zj+JoR8>y`|FSP0lhMT@P4)vG8C7z|0<-)bSHLz2fR~jeO=0Rk4)>&jXaWVa4derb8 z4Eden2~V@mon{o9^^-)W?E7%jG4UhtmHZy|>yhq$@;p~K(rttn(tF!m#tMnd z9+(A-BrPH@b{|WgX^jb4e9HVSjra9gT>d>%cPX`keT;2Y8_#ECanb&9K6kTiiv3!o zAL!C|iVwPf?ws%eOP9&xI6*8t5g5C@25(ePCoet<5#*EWm}hD%8mFDm=>7Q?AINZ= zuTCoYvy$YEsY|z`ZLF#5ZPNpbCDyN+gZ;IynHrFAY^0) z*7H@VKIr!Y>Mu1xwlOqCiVyHMy}yB+IB~MuAcH-0HeYmj#Gyi)a&TCj`ex+(KjM6< z>JVFf=8(`ESNAf+_3aMdZ;GaE*`d;S{JIb1NK($_e62qK{tS*(v>#SKdX!}X_)owg zD8Gpsh&8+VRAEiWU%A^QGitOrg1;bxv2@tZuc1R7#d4^&Xyp+oU)y@O978I&#|}|s z0#VCgfVR+n6KjIZgnq{O>MkArV6!rZW%b9gv1gOVYd~ECB8U+VDlPnHcaR7GNZ=qn zm3~>kxg~?7-0~K@Q6-&SP2ejq%VJbJe?2tXoMvJrw>kmHwBV%U#iWw#Dl?&*T3zVe zhy8KgAhS0v@#62lxEt@H*R3{4U4*e)bR#zH{mD$zELtotZV}P1ot8)yTqwMtjT^|! zMDtzY-02fDv|;$&Sk|F_esEEeZt7C0Q|g84lce9shuai`D}Q)xmalD(sZtl?Lbx8G zO5e&q8JUn&$^rU19uK(bs-k zf<;&47YW`;P-l@6F^2*=>a%(C?hsiV7qwb6c|;S2Qdn4Viq=csCuj)v%awg4+fJ-y z2!+fYU)K%wJGGIKySn)_zTb5i`h`ztKhttF)RDe=WGf$()XlUSgDsA+_KzRU;ZNL&-;oHR@n+1x2WSi71_1h4V`4U)Rri<*Am|4(IoW~;q+pn`aYzv z83bk>-xm2~zTLq1h9%*BhGq)Q`U!qh|vCdflPWh=BB-AdPPxI=WuVXKdw1y za6OXtEw@mtq0?s!)J>P18%MQqYKQk_pJH_i^MhI2z!Oc+_noB+(ZvS*#C!H-QP}CQ z-Pw_}nGt}A_RGEhX^B4X#4o5x&qynUsqVBE<6Xchy?q3G4-2)^G@kmyrkHpCOlf+b zkLC*v1^9g))MDf1X!a48Ta4z#LZcj`uW#7AxYb8u1iKh{1(jJ$Um^ytq6^8h_G}h9jL2P6gjMj8FFqkh%tzl#Wwu4hl3ppZoaa|)+Ar*R4ldPiaUn_8I zVwI*0@ooQUq&7k+$!jK4+1U@BPf1#uEL07kNF;6QHu-IR7r!+8)`g8& zWcxY2h62HKaOLKBKt<>u$ym;GGdld$?5$}4OdV4IDS9?!EV3usa$7SCVphO;{_H&& za0mwp_Ot!)&(`-mJyBtkTfBZ7`kh!cDEW)#k>nxDjm2o(${pfwc*0}9p2R5FHQIE4 zFozG7ZT|f?K;%~k!ZTL)PwJzfx^^ZOZoR*9T#{gsTJ_XY-g8Jd%ev+yj5TL*lOqtq zX5Ltz5e!S>x+|WseTl_gM8?@x;*map(HEj!+Vr?0`Z2c~%`J!6;wPcS&3DWH85pte zCKca@M|e1c7pm!>u})|5s&jWgLKMe?{kd-LI!SD7!iCbqV!}SEp+y2cI%fFDxC>^F z6uGGQ3X#+c%lSf0p0Q1;T}AVEaS80r7ATYS(*~uMgp-!kR>f8wse7TCAP&0*1g)tO zo)?VqZ0pz#jnJ$ydn4BAodhsGBh(tnj9NhxZ)m@8ASB7v=iMn$w^u4y)RjK3p7ti||a+IF7YNebiZk13Bg zF6ea9W!~n6ai}%)AAB*xD-8mQEKHjgtvV!Wi=jIdnv&FK7_Y1H6B8>&o5BmkuBdLR-MZXzCE=)Z&Tjlg$7(z;%xt(qV6~Vr`Z;|d_62v%g zvC+Gjvk4(uQx$JJsXzaJG{I#{h@>EvF*R_+rvhjhzZ&uH14?6m!lFwD)#?Jfz932- z7s-fokVZ_=8hPpbqt>MnP_?xW3Zy`}P8Kc>sj{II8w87qR?n?D;pkShEt~*cIe)d{ ztn;8$aNEZ3C<-jCMyQFT&6FBe#tyC65e0o96e}-zKgrM(;&C75A$Xt&e*5yoA`GVV z{ha@Z${mczETn*mrnezVEJ>0t%Av<@CDg={GPu`GEydR?x6W?QVE7I>i$_&%9=P&( zB}OgN@L6orwr;-%B_^yupD>mUa&a0^9R&2{NJpv;n)`264_TgrsE=p{UA_&WkErZo zx+L)n&KfDiJ&aJB&lDcqO@rW-*qK!IJ*Xm?lx;3+q53Y-y33gEge$=lc1O@$p+*#Y z`-s2Y)Yu51K5`@=6pZ8vAax1xGOcoVqY#cS9 zJXYXp-LZQo?=>)zYmo%S<|+;>n;$k!#FK53Hoqb57QxoVe{qP=MgAskI;?1`fZjp$?`n>8 zC?uGGjeTb*(r%74B(2iZ!gcMpYs%K;&)*?PHpR6P2o!Tko9od0E3_xQlb)(qlS1TJ zToDJ5!Lbuy0I+tYTfEL%pWK!iK?5QBDiu{~nhMHY^dyqK+0EfHb$oFJw4h1WKFk(& zc}xBBaW7+S*NE!T^oAGi2A-B-n>6I)?d7g2wTk-6AD5GV*Jz;H{zG6dN??Gzf+Xsw zZKjh@Tz-xrD?WO0_A2Yr#ISc&KVl5qlgyt`(Aog@^JJY%&9V&|w{!ULY$Z(c>26rT zdbmO}g};i#-Z2eksqm@k6nfT>0mdoNfj`Xh(q^yQ}6JUi|>N!Q)h2w%xv@e7_S|^ z`LJ4LTWB|;G(AE0drZM1yLFQt$sJ8k{jPAzWS_QcC`Ph4E}JOFrgucdoO+~8+RXj8 zvN`i;cYyyFfSZ$AFcejGsnd1vY31r~FwY~A|K8R#SwR-!w>8mH3=IUwPg1<6b+D2r zr^nN$r2ZYGIbkrbGLgOCH8IQh_V*41XOF8eVLO`Rqiq`^V>#Q3nmK7lC1O6iBnRv0 zR>8s`)e_>g!p-LLx-&Rc&mJxphbr-pK9#TTgZA=^-F#xK)226L>ns@PY}p(S}lldT9IgL>#P{7;c2e`)C&Veo$c6~#XB7jIER9T%T^p4Ij~Ysp-eu|m zAxcZk*Ek<(WKLLzxG#yGYb>Mrfz+ATB32f6X9Q(Q4LRW7rnRFb(3qm)m_iN2EpD7dox!^~#Ipqb z@3;8WNo|p9lBkYYSLsZG`#p35om+%q)wKKt%n8wFa{N`|mFYKg?$s%vO`b=-!z#g$ zF_6-CxbPFoN&*B~8k!(GSo_Pz1%ec%2TcW>hbN%<;#e78)$9LJ#pQz$vvnb#P-=$g zIe@)syqHWe)8eq}vt`-oA z1oLU?Jgi(7vmkzfV!gZLo?Lu$aCx|TO?ThwHVAI0*s^Wl=!3-wmibxFyJN)FsK7$) zl#DJldbUs@Of>}bBM%tIh}J2zK}tzhanNj3LWN#h@Bs(FP7ec&0ERZ<3?B5Cyeh)) zISJ+xRU`w!P=ra_qce{9geq`xR0|8WL3zpJm6;deN~RarKt~l^bCQB-$;6UNlDunc zngBkPqz&M3XEQRmg6q_k$wq~#a^Akwl2-LZ^Q_s@V?nv5xD`WA8uxo6k_%@8_AH-R zzOKoG2=&0j9AI@QI$ac!N3gSNHG4C84)visk^C!C-)bs{NOAetcG# zCv+l?;oYf~u-0AN&TDcb`22(3SQcUSDL+AsI;95pQ6|)?m$*VG`y~oQvM>Q$MfOpg z$O~STpesIbfRWKs6PHCKV3iKF%<5Y6!kRqJrZ0~fZa@QN$f}YzIq`TnHGO|L6-N<5 zy^H_5+uaMfnS&{Y@7+k|Zu%WU{O7s=9NJN%ycg!{@?~!d)?M5mhkfC4T$}5p=pD5s z-w&nI#N~|VhAqC?vUeX0utg(WjYA`F?>;j=?q}~R5P zV%qlKMR4CaBFAlPa{YYd`z?20D*p}>uH1UMg}ny%qU-`*iIV!;4N@j~ne!W=MJ#!k zzpKxr{==5~-$nww^g4gO?)WXrj-QNpJ?ENqX;`jz*RbOZ-ENg&jv+8ir&tJp`DL0f zmNCxL`t)~h0-vMKN<|z$>t27#Q7X(hc*Gl`gav!sT3sO!t=>ezu`(5xM>BlAQ5ZZ5;eik zk*>%RA^=}dkp@^9vx<<${KAI7U(+{9J5W3x+iF7DBm&)TN>V8yFDh<#eam9EQ|sLv zY8@1(Qz0N5@D3==6#H)JqC%X}=cC*niC|>dOBdDe=nN1Pii9^|Tj;gd$f5z(w#m%|e$Eh>;-m zQHPFiOdHxVKWV<^M|*tHJf&eNC-yv-97*`9?yGM~*CBLLsr?qQ~u?Ls5VEe#nRhO?8IU0E*?#_H;@@*gR z;6}{m8qDU5dC#vAJkxQZniEO39!;w?0X-s2SEB5?EgBBpPBJ1d(w#d9bv?`3bT|7y zg#x~|KRRcce??hjlAgmfTUO6bg&D5CeyzM~iO>Zmjc(BO*^=Ud1@!jMF0+y6qoU5O zI+}-rvFo$DF=2k1!_L-tBDgzLwTL<67W`>ch_Xu)VQ}Pmt-gNG`Bz4AZoPL5?LTYd>iF>p0MM{KSRFX;FWl?0WSpkqc>( zM4<3w60IKNe+XbbRh&hl_S+NL;%XY-@5 zuc=_ZY&w1V`k8m@3#=;DxO&5gfu#j39Vk1QAqm3?2gi2ON0>=z++Th5CnL z&X|xqpWVa=FpM#MOD^kq+vIj7DNqbz>m}{G+YQ}c9hcrGKOP;L0B^Cz(0vgmM$nbWP84%QB9SR(Gd`S{k|ThQia_Y)CNrZ^RW%bztf@E9M;* zaWJaWA=F9WHg%i~WC$2Kyio3)3 zgmp*`v5apkMo6!fXx(V62q%ww7*lR9;>Fq!>+-hLV_%a%%7?A z-MFQgA#hGpnQh=_WxcsV1id3RcT)cEWwy}##3|ofNnPFiXXXHO3CNHu1!KO&l~I7oRRi~ z#HR9r$@ifX1>U(FAzj9Q zEE{V^VXEvB&g)+xTW1~$9uJKO)Sih0t+_bww>N{|{*o5qC$`sYHc^(w;|0sQLQ`4Z z(me&B^K58jL*wyU3f)}y)h=@uH;Le;bcdfc3cs_Y@wYj@snY-D$VU!-O`4a;VVo(< zOZS=!=fzS(90s(sj{*BYP4&fCe_J3YiVW8d<+4ueL>Op*!TY+M*ChB_*scTU`SNy% zo8;gw5ej7GRNvDgs(8L^nm%~zFMmYn`Uz}AkZq%uVa>-?vg7Gea~c@e4(|-2&-F)n zuJ431;74l5Egg{J6ZbHJwB%U=sQsFhe?|_CBiX!vDf%Pb30HTi(iK+f$MY-qKyYr! z+P*Kq zftJSP*MA^Gl8S_1C;KVN_8JBe<0Q9yV$ZtJl8v2})OA`rjS6T69XhchXz1^Uj*l?@ z_I(*RP-zkj^mRwa!ZtBPrWh4h>mFo58iX}YBEl<7n;g3Oc-Po-Ec{`tNj#`1yaK1G z%^g!;?d5K+Nzvu)RW|5I3&1)TPIP{xxu%=FBNk553}>WZSUQPjQ3 zrRQVP7rvu%lY|P;4j;Wrn@9vZ0@i~%N5UQgRvyu+kMfBra(&~5EY$hzaaXp~-1lLb z7?r(b?!wU}C|)k?)(AV2%A?wA$sdokIq>IwT(t>uRe8N9Oe1d<2>8cvDkt}4vg;a; z;s?aCbrf8>|A%KHuAP7k(GsUz)4ieirZ85s#lqia{62wx-?{)w?wh*^_^p|73E0>% zb9k@nPBMkJ9vPo&hv@sX1*nW2$WsDsV&V&uCabRh+cW`$EzeWb)%uVUTC(9QG#n4gb#4>|%Xv+3r7*9Mc}`#%nk86>GX z-DiI%b$Z*#th7Yh6PlL`IrLjE-K~&hAz#0yfG)O3`or_eb(JTAR1y@expr@H%zcL$OBi z$6+;hObJp9K_VuJoOk|i5a5N=P^g%K1o4^>iF754tXPOPEidA_w;W%js*oLPW{OZ~ zJ9smf%EG9GACR?5^5WzX0pDn^eS#%HHM*d*ruglk?5lg#Ade1!c;UO5PgBFoe@&Y% zN{8v->OBY!dCm0HE67;d`5)#9?QVtxPbA0&9^O)oJNa|k+~{=j)*9}XeWP>78XtWC z2(pa`jnbxVV+7!yl76h#Qo5Ct`3l)u<+R`AQl_aUAL*Ir^tj|BZjFL|m9t1eTBQ5h5t03!% zPv3t)G6U~%3l^|Y&Lmhd-r1P;Zw{rg=BLhk^l-XlEtqY6n!qI+`M?GI`#@@|FN%X` zId=`n*H|(2qL5Nr!f~a(-GSrP{#DX+?Z=t)C3ASc}&7}9vvf3w_8 z2ocPt3K1x2qXf@m^^;~0^^@*%fRK*J@uG8;uA`LM3-AdBC&{$4Uwh#S4^0;Dv+H8! zSfwaT_@~TUZNNoGoyJE;vt<_C46Q^zNlrN2Zdr?fJ(5`q)t z7aKka?`g|$h$zWTR7xKzag@p4FpAuu>ZpvFwDFSA3*lnY$5DM{hv-4zZisVados#K z_`Yq~s1`^w7?(aW(=L*vjt*}^tfKwPd+Fpb*K^6yRR%13d->1!8@qeF3NyLHXK>rP ztjdRJz0vuA3rqnp>tdS4?Lo&iKFyC>45vD#KX6dU6$}2#r!*@&!wgc-HfdD`4oZ24 zC8zfyw}gO|ZR^#KSQWTyc~N-*0i6~R-NWpRyWhV zSTjWnk1^!tJuBNXJidjB3Q+|DmY(&Ylu{C-Ia4scH z!$wb>`Yx3EPf^LnY>FbLn5orUsY0s+w|invV%>H(VWSu|Qt7OxgcAi^r@e%}G(`}t z)wkdvtxNjw6A4f`(w7nQ@yT$L*j0>Xr8Fq)XJK9nQFAmXNm?RI!_i&p`@94cjpoF- z8E1&Y;1p0@B)MDmLt^cy7H8HSn0)zEY&*}-@Lg!rwmdd=c5lKAR>U}bv-x2WR1m#j z3P}e|RQmU*(P*@pAHPB-DapnlUF$<eS zo7Pnw|C?Cy8{G#D+Q$%+=j{oZPv8sXqX=gS`O*@=g9If=8D;GIPUIZ1Jb2sI>8Gp+ zpV=4uf4yATUW@N6N0)|2VT585;xO#KWJ~BaJ|1+Qu%75fZvR$1&o7?}Q*(4(yK@B& zANuoxV*gZrmfUQkA3oG}z4ARxSoc15a?s{wT`k(Q&T#(k2;|t`%8*x_rtao%QTB8M zZPZNBFgCG9$l#{onkxEYgB#E?(sLyzj!?PB@cT<8v5?Xk8JyQKeB-Pc37zYfBrWEBJ>ZZ^C`+57!lcGD_{B zZ`~O)Mrb-D6rZIU`pox7IlOh3tT%ay)jeW&|0X3$Y~xftFgfJGx4Bpwh5ZXC8rd7E zL~xM;rjmZonvd!0@0(+St5(WGr`WuM-OW(Fp5Zx*PgL~faG2FX3;U@rJ_i~vEUfW^hx@%eTN(G+Ls#t=Ek6BnmDTN`_vXC*))46r1pu@1Ct$~NK5%u1vLVf+kW(>TvJ6~*>W(mU0YG4i zCKMVAVSYv+!*)|FZl54+SVkua{~m#E!<=HL8A#7(IIX6?&jAR_s4py)oyCI=92rXN zrl_!2el5pOm(_9<*Gi^mSU>itg(p~Z{nvW`pXH9ehzMIgW?2XR0bZ=DoG%OQAR)BH z(l9j1v{t8*Ld0(~ZZ)FJ3_+k9AgDUC^-*>6rwO=A$CEo$QBya|gW^imY3g%Wt2aB4 z_C~Ux)Ay&@!@29L2 zaQXpQJH^0)-Yo|cBL*Rr;n>|M3OMDeF((doVn>N1%h<+Ou!=wscNTK^BI_kW-G4S6 z7j1-gGUgGKm`hEM+%`B*y08Yfbv==1MjTuj%Sc9~*dzUe4?OALbpbf8stwQyg8 z5i_8+5vHpLBR8$BTmJhz+XwsG>2M+x&;Yc!@K-)!feGQw-tUE`TxR`*_r%ZLo{U2M zelO93BsVBPk_bwVY4CEiS<5L*H7t6p8IM%{oBv0`Dqq-jxxz@pFejKg-?RZ~Qx^7g z5Ni4#Z(kamIO-Px=>d(HiCO;}_n>96A-m&0_F~YV-s0EuI#J!Fm{C~6-2xs~~U&V;J_1&{B`2!d!$LCOw4hG?yZ zJn98x|NA%Ywd7`NiW*E1{!BffDKc~hGn5H1-KtM&?VUoe`FPdU(I43#@~B~GDwOEP zRynC8h;kW@pCeMAmGxuuQ7CH8i|;+OX|jes&=&vh*%}N?r2j$)?`YdsJYy2odsKlD z)3m;MxJ7~71rS|)if?}!#T$?CE_wSskA}zcLcsdLv*N9Wcj|{O`Pzp*YuC-rylc{n zj{v<0*+=Ywn-Y_4NYIvpAATjdMaaGPOdzP;r_Tj1&FIF7u`wXg!RdWdwzj00-^52& zOY+&nbs2p46x$v9l*dSg^vU)~@Un1f|GLec92awK3$bq*NUyP6t`7Zdj{>9pfXfO^*V>SF&iquoFo6}E81r~ zkWP_#dzJJ?7C|=(fr3H*aDP+vbVYO4>OU+az8ha4wx}J{4CSTj_ye*t^ERMdAb%CC z2ed#p31VP)!ZPF@9qJ4rgOwa>=C^}DU}Jw&RD_B1^L=>TY{_FR9jJ|+4Oy_>D zJWP!Nda~`CC4dAZI@nT7XD`aezkitRv24b1w*JeLK4$lUQK4?DL`x-buCsV-INJ{9 z$+q9GHTPK5RKE{)w{hcu19XqH7yldlE#c_KB~T7-Ya)d`KPK=Ov^9W^s5r&P4Hi7p z%S)ER*>2rjRK1;P2t20&G#BaTjAp&(5$9A0K+e-fNoWo5b`%-02^!q)vU_p(^r=yP zozaz)%b9tsQwfP6>~&6n*@9{6?rh}K)6=_)t0={9r@w4bI`KOq2Y8d%&inyGl+c$r z1^ax~XBKG0OIpb_k9^v0&bOQMswI9C% z4gggB^SS36E%oY!HlZYxJT1vb4%-mK=_Vlt-W~+$SP{IX$~9cdTFDgnGWcl$7kn+_ z@|70*0=dCZk{DzWsln0*F1TP!U)fGF7YdWH{V}f%J%TlO%b8L475J~ok5JyANNzYP z1`7e);OY^#wDtj!1TVzU#l7uPgdKY-{c$!Pf;Eia~&$k6GV!faQGpxUqQ?| z)T6AMWpR!Cg>7Dt!F%cRddS)Xn86-Z{M#gHJkgIXi3{ltiTZZ-EXZK&rTCUqiGw62 zq}nkIL{@vfy;zn8Y_WQHGPa3;+Zps@0_?yHx52@O3=G3D`aW#v=^xc3e+6)3m5tFo zYB91LMXEpJZ%^?WT-PzBl*|Dl;qloS3q^K8@MVV}XALgZCFn8kC2`tU8>^}R2A!Pc zXLd+av1geMqx5JT*v@hGv_OqZk}8(%2oT5Ewzs&DA|y zhTI5~z$gzhSoq~J8}63;g`5r;e7#ZrZ!1X136r$J<3y}DAV`NvJgQx|U8QxCaF{{Q z)!jvR&u#>6li!$hBv38Dwuu@A@fyTzvi3Q@fpS>`umM8>x)`nbvzMZ*(?RyfY{*27{jHX9$YoCaPLL8DpIzV;g?}m(@ETWvRq zI5nawY|&5}elL{PAppw%wl1VICbIUB>&<|dQ%tUvHU{XiHUC!f1Y>f;dOIP<`V%x; zc^Ky9rij2~{>Viio@AV+nz^-Lt8+3`VZ0dInwNqZ-8Trs`L8f#5mb0y4)9jBm`EgZ zgpPW_PdUt*KdJKQ8-jtojw{>ccW^XxM!fy(1mEzsLQSS%^PuoP0Qw&vX}41Wz;gmU zi=_HH2E;C7D=RAKd$Bg5&7JI{s(&^iUZwX}>e+bHT!MB&W?Ft(*Z34%n?7@00>W^J zg6-ZPUc{z`Mu+_D;!$6~`i0{40Of5G+! z6eyd9TS^hF-9Xy9x^t85LGw?+HU^R~o|cns)8D2n@ywY$Z`AfKuVHV>z1C0t$444f zOR0AZR^oj~7-vyRR@qqZ<|t!y-_Y;33we!R!+#BlUGB02cT6w1!E7JzuYuz6eeFJC zN=SaQi6T8dq^?ZKy5E6FyxfEp9mmbQ z&q*dar#E2%FR%$`d!N#lV1yg%>zg!a;i&OpXf9Uev-LOE!{vJ!4s#-hMDU~6=wtZO zV6GF0c($(~MNjODH==FF7lBH`kt77EdpG?M#x(bs_#e)XZ=_&3CcV@&7VGK~Gk@8R z<7%3<=Jjm(koDGoy4fKQAoW6>P)R1D^c_f{loMb24xmsv)SCrnzGnYY5JZ|@+HRMx zJwDgB;Wg-HIX?bmYGr6k6>+knuQCP5^O!SGX|!*v)WdjJ%-rR~7d~1+5uOS{@c;%) zr$wT8KnF}4frUDzJmgI>!@7ySaM4+q@+9fLsr)usi%30*<8;(!jb8&%=a`9n={Tm& z;avAxt|J9!B0k=L4*D`DyxgQ6>TuV3)t|-iR26T6#al;B+qVW@ZDX^ud z9Bw5e9Z2~AeESPG`@-lUlL_$l7)vcKnh&OxLVEtaU~)wMiSY2`Xoo`s3B9XM2A*aw zcU9?`)7S7-CdLJ$`OF{OZKWgko+vl>d|Ri{+9}_+f_!MznQzRSCq&M9@f{9VVt8yD zFKofSLyz|qnJ#~*x#>z!o;s~%_-Oym zsJI5YsK4_Y3qGMLyu(@qBv`{@#{{Ep40=NYSIB!1+o8dbVjiH0jFWO9necTq3jqY5 z?L2~Ee;Pl$<>*IC=F%BH=j6nyKyjD9L^om^U=xE%jWf~?Hcj~wNS4~n>vc_ZKij%* zf31OsZy>=rVu)Y-;X)fncOWkqa}Oz$PvkU+@|DZR9G(FtWfQf9CMC?CJevpA>rLN4 zW}D3u3C~8aN4upJ*VnN>B$NTrBTA;~XCs=o=Wok`rt0cb!@Cb?31j-DJ5SqI`#H^4 zV4ggTij+#m))Dn^_iDiCy_`*rq8de&rI%kGO-%iM1?T_6lC@XqEn3cbLyFKGS zPwN_72hMT1t{$_A#fiE?DgU!Zsea&WBDYNp5&BKJ$O(g$VA>l@UYD#M)j$fzNaF~{E(K#}t-p0H<)RVJEa1S@x za+?6>Ct&eh7NYYLbn%>---xZit&wyK*WWyQLFh~k(#WQVvwh8O*-hh5U@&RQ+5USF zYP;=_=iiGr`d`nkkLcB_w0a%>gp0K$4QQn@nH!aY{DT4``;#_B#Nh;fhVq_b39$`4 z4ejq5a#l`FR$U}toM5wV_Eq0@N)eTr+g+7}aOaS18XA4Vih`s{izmcnY*7wKo9!fKP>?3>d^g(Uq9{&(4lm~d~M&Ayh5 zRmpz64bgb7d3%>N?m(&dhXl=l7frf$UiXqjj*E&4VX8L(fb+a-8{y_KT6V~!LolOk zb_Fdw*=E>A5B6?yqv7?#%+|n=Rb^X~K9_C#i#T~deMMVB^7`KNw{k3US2FFgLS?+_ zB3!}w>Jt$e_&FvLbXYjn*zdD07lY#C{Z6Ra zexJmsd`0=)yR`{HM0RKTRey-E*U4*^6rJ`L6;l{Q&lx>9HF+29A{;Jg2#|;zxS9`y zhB8^F_ESJMwv-O=Irl+d!aD=Af+_Z1`v{YHR36-+z{=hz-hotVKb8wq_FwHbAGoYvQsSvU5<#1&4A<|{$*0p&jA(mAYO`^Q(|nJMx_sA#MW_lMr@%P zko$9BT3NA=BN}Cls1G0Z+u>B|+7tC2%5{v$aNqIgZ;v5uZ?D;+Hlu;6Nk84@&e#2# zMUdE$!QZBN_XKZZpeII%gM+S8Yr7HnO#E=4cCk`&V2Xk%US1=oTMM=3D1s1v%_3+y z{wlmp{Z;6sGPie6x(%C_Zy~LhZ}AIhFdo|CEY71P$wjK`EYC%1vs+);?RujU>tSuW zOvin)kF~lPvOu|RXqIu)@=THZM*sNj#H&oI1Pp*(o<0#%#yGm!z~WJ06nf^d$`NVX5MTDbSJra%vbgcM)j8&)UTW|I@A!M#x+fC4l1KovGgq1mzuD&UX^x*4Yf>B}zYJqPg(mVVIA~!5lhI>P-W?E!yg$28)&g5fA zBxE(uGEJy*`5nyO+e7|0jItH&7lh#7MZb?!FW-mpGem5V*N-l`-;dR=+P`7Qx^7bj zPjdS5n@_zlCqy70o2VeLV^XKZS(G`#HOalpbQCs_MT+1|k&A2cIT6-q^lcnjark{? z+eQo69*cw13L?gkaDEo^9||EW@ZOo;LACtFBg_A6z-B0#ps$C|5gO|BcG#7PxEcci zA5#K>$@2Qoi}43C7%9qfZNf@ts=R0On{H*SLy-wyIHEc8!Gc<7fIT(!+4 zmbyynE-fDPC^pLD2CD?~5Yep^8|#>>DadIFXdZ*5vRxJF z>bhb9L?GYqQq*2_$BJ*Ff&*H-aWo@x6hRL^K;XR5`~tRZ`FL{aOnFF%7jrktKf|2+ zi>L|A7kS@>Y&Yn3be||5)=}xa4;$!A(i;=Ys?G*KSW>pJMz@bY4>_QT_9AD8tkrn8%jn@Sm^WFMa&-XiD>+CMyAM{ zh(Z>TH_bS*8FrtL}F84e;?0JKn|6W$a1qA z^f*coBn9=yNgODVK4s3gAc41!vgn+<7{tKtWX37qur!vh8yk6H^hN$R1%X2fAXr3k zE$6{ZxPk-XHJ3?ZDmjC(*npZ;xXhmL1-%pyi#d|G|=}8W@sw- z!6>Qin^0We@L$S1R1t|reux>mtY8g^U5CBrb8;oyVa{+dTqWBUJP6qGZvQp>uNf)E zU7{`vjzUbWIDIh@MX|$esX%t$6jKts%X#c6Rol=t>kOcwer3B7`N!2A=8Rhdrr_;v zG(THu8;F1(r2WcLT74JcB9cPN(}suu$r3x2{V=U`Pn8iQF`C z@7mfZpuFD2KxIA2oYxRd{ioCRsg9-MqI0$1(g@&rxxL;o2<1#=HaSjQ6vkfrz&e;g zhLt(zz%oqMZuftK2W##u1lo0aNPY&!^n>9;!lHaSSeFEY;WrTBAM*VU&##*Ovv^}* zcKZBVW#s$09Jc4@*Q?K|95mNhpW7>~)ZgSiOzLyEx*8Z%I4)eK*Uq&5fB|91(7=e* zZlHyv_BmT@r@NymkYskPk1TAk_alWOwB|lWbt>+o*znxcd>4xt>=3Ju?O7(~c(>ay z>TMr)Zr!b9!0^c|;t9;I>U(Qbin9WGmUDU9MHUSm%#S#szgGquawQF{BaZusbTF1y z^3e+P%Ia>;de1CVQ81Ehtc2kzP^%|x831;|_EihH%`u3_F1%qKPQo_|f?ot|qXb{v zgLFlSmKy6amzQ=^p?^vjo`e%^dfXf%Ah0iB64cv1wiws_m$J`45#e8& z;acqUoa3KVSeTg5?wlCm5suLCrm27KW%c)SLx#(JI!K~mz;#84b41~bpjtnwaRcQ_ zlpPB5rIB@XGG80Mt6H)mBik*Jmz|rV~brZerWO4 zQ-)z)!WygUD4xUaHa$Vyv{;-;*8{xnRhRq$a$>qwOXiyQMaFeOzfa*dsGJ((Y_;E2 z|Cs7s%B<%78JlTooz9G210Po}=C4G^7;Ns=@RGWrV(kz<;YjuOx_=BDTv_9Wvnb;) zK5y%1$bAQOW6+Y2MEc?Ga$EjMlwQtgGq=4`PPK)sGAu8*1lRG@+*^f{0tPtOoR8R! zpS`zla>Bo3Tg&xzB<-b(bREl-#Se;gO36Q+!5V_9uy>@Q@kjdN*hSo-T*D!_W8huO zAsi26?Dn9~lhJ!;GJvJshQUMmK||%S!9!%o60nIaLfd_T15{%Gal5 zy5dY*V_jD39WLY7t5y=t#swj((eY8)ymUXR>WS%=;8qnT&~Nh(wd6h5>$zl=e%*I( zONs_TSLzE4xn1khXLJ@YuslZi-I?;%p}Kczq?YWu2c{;^4}*&mm>)zO&K?gAZi0u~ zcy~N>rNQK3aXk+g?j_E^vgv+MfEsmcc#j+~j!ZYIgFL#Y~wE` z){_od>l*9!kq@IUWGhi}@*jnKOtZIcb1cMA`2ffux2)JbmHvf zcJu{(-9(k@V$ic+EYT1jRWtCi5)GaIs2HNHI^O2UC_f($nFG&uL=opf&^KltjV4z} zm1DH?Q9k2$iWE=D6wsw*DqpNi`{+XDF9TpTQ}P$<=_Ux8(cFgYhwEG>)6uLs(WS!} z1vqc}$|nlI22L!gKA{8^Ml83d#*ZjI;*21E(t!AHQWTvoqiXwDJ5SV9JH4lkx`vHj78sZc(mxB8i`VYg!X zf!>u{;4eU%gW1n{_+vgzRC;ff%F-skkU3cT^afnD zq%C1UJl?*tMmcLy$j93tV|;h#$BseipKIo$Ic#Tw?2Hnq)vY}bBj>$U2XmXgY-ULI zkLSm^>_wKC`x64B8AB}H7>Y3e{)vdkb22Xl%n3M62Vrthm;t5VLOpoqU1+4xKy_Qr1Dv{K5!h5Z)g1X#BV! zQV+*I*DLKk=tNg9oHA3Z>xgBT<&PWf5UYunDs5@C6GIvN?J)H+&Hbu2>Md4Z64;h8 zWnVgs5t4k7rB3E=lh@h4x+0g`4vlF8bH+S*m6+z(R8PVeC&WUBBg7!)BKoL5LjAV^ zTr;eS^?|o^h(CNF;{l_Ib%Y=m6HK2ZAT~Ljh#C-wAnK@KOBN2%YFx)?tfuC5SD|~= z@^z4fL(JTy;SI(%Go$&0aPmk3CEpYzXg3W24>v&|i{XxQ zAK%Nl^)wdlgAL#K-2M45Xrh^2ELHo;1yF8IJoDa2y!_3k2tB{o{iJ~H#sDZ6@O}St zpb0#>Rrf)zY$sSdu%9^QUbh4zQ<4?Dt=cLiQvI9Y`d09VQ1joy{^Z!i)Ziz4dfIuc zzxszm{vBitnNBH0TsB_@m_Afe%yCQjR{<=OU?fB2ViBVRE1|uE|g&0tt&Egb$cSpS?o%=gT z^y|ax+R{g++`CZ7OX?-UW2jR}~}QWaJE!itfhP8+ElKYd4y9qFvps!kWAY3O-? zooMKH(drso1sgizB2xLo7YxcQd&mA4j6`rSp@g5~NNPYkZ@#bDhMk{Q1#dNmMpM@SbH5Dll z={&YZX-_cVxV+Q_3;XBN&0#ZHelEZ5^3BXxjaS$reK=^{U65(=%^yoXxiFO#@0H2TAk8q#j|o3kJwcPn zTI7o!x;$Qt@}C?k;oS^hx+YmuJAQaiA|Gq44NHz>3YSW^48iKYxQA)t35=!4QM~P> ztR5PVF1_vw7S00NzQOW%=_ngR3^4SnIT%Qqv>a-6qtUixn%`&-GlMe)9TP=1*2z{2 z3*AfcrT2;u=1kUSfo&9`#6}Vok1XzP8bxw%I_Qo~%&I|G%0cY7Bp7BJCTe9FLA2u9 zBF|5f+$G_CVoKM2kL^FAfc28DjIH>GKeN=g)XnjXcEt1k3g0|JO--fn9LQJ;GkF`w z_dU_Ai}rGzgkQ~ah_me%ZXVM_(2TN27sqPljv(Qd4C)LVZVZP`Rmxmh>~~c`3IFik z$-*m(ScHyoWVE)!$?@aPE&nd9KPiB+L zo|Q}L>0Hi*6rVRl>K*_OqpkJ0Q5$vWL2*Of`eMJ63f$-GMbx%=aAB}MO=rGuC`D-9 zx#Y4({hsM}KIxqmgP?yoD2d9`FPsNiz`}_T?MqncRv#$@)TFLuS)rP}Tvgx2%>%k? zu(9GaA=kmXzsi4`F~UgV$RAN7)&-(i{!~3usPVyj%=f@T@9w(a{yL%Ev>I1N7`S~a zO5)({Pd<6{Rp&Krxrb%T`Sp_kWd<^*@nA89l29=ULPtG<)OnM(=5ZpK`yN1#t+(~m z>=82Cr@wrOl0BlUEp40{Q-%8=ZZ=6&WNam%R=#{22fGTv2sfsRUWlz|J8#Rk6@O=; zRs-xMJrHOR&1i^Z{y750 z-jK?TF=$eh@wbXiul_{JgSg=&QJjSnDbkmq74-JME_vwIOV+3Gu}yknKJ4l=_hLFL zw*IHqt(EK6xvvTXr1N};f0MweR1osy%)yh&Ab%8_A}z?aWLo2}zA|MPx3$fv1p#4h zD?`oQ45{*)$lu;XN;K;KL2r2h63_W1H5d0XDBfDf)(JN7_J7J~WlNwVQ)?}`o*CNEa zi_U&YjhCq9b>@dR*#q~{p_b$!3^YTr55pe|Cf-B;$P=vAFpdhPpgFVxD)Bt#aU>b! z90V=`W=T$XQ#lnU^)~-RRexEf^Uwi^VYa4v6IGOxNL3UQi#;u&Qedw2xS1MrgCjcz zJwXwsbfUbKk#~D)k5*)p9)~lrcz?%+pf%NLTYuc&>%``2d@Cog)#1 z=pldFk4&Rx;zNSozBE`DpGKL_BOlR>=TOu`f(!ZUABsxPiL*X|KmWqQW1kcIM;4$;mIoy%_-V!>k{EDinQk3=R4am*xs#d3Bq3&!5k0fI-ys-3rQY#@-{y$?Hf zZYE9Cy^H%aoHR#NiE?X`?MsQ0?6Hrm(jBW)u%Tzn@c1MJcuvDniwK7o`;-;&qI4`x zF&t9krT#M7`REpBGl5>lK;cQD1hSi`E)#hvB(Sppa?3>DAjcFM@{Uvao;BLtI>2vm z^fOfaD810DfQOv3U_Dv|D+rYVyn@%5=wCgW*2keLsK9pW)+%V69=_)G_jU zqpx%K0mQ;OU#zaZ0h?NOcIRvt{j~zxT*@S7ySRIEJap#&vBgTsW8f(c4j)pnGOplWC#!RMP=^od5Cj{ z4%nTRB|VIb{22Y=2gd3oPBQqrCTtj=lNG*XQc5=-#wi|qL|#y~p)Wp=BGlK1^p4T{ zJ17+%D&QB^FdP)0Yfi}JU+X21@J!Yz@OEdavzP^n?pt zI>N$FJh@CqCfnh@Mr`PXpAAN9lL3~jC|VyIw)V-eF+S1}R`I%5)=sOKj39_C%wPm@ z6CaJpl#aA_9crd%oX!f+USmp5X(+am!MbByq4QDBR8x)M*M5RWz1w7s(*8)wX|}G~a@79X zUKf`;jdnt;XE}Vl$23q3-Hbe1ZZjMRGQcz!)oSg9Ve=IHoGgbVF_qsQkG^OWF~aL_ zki@6{8-8`>VHN)|AMtJ2^V>mx|Eb?t&Kbt8h8Ccv z!u1iTgrX^uWw~TR9Mkk8mqkQ7uGOafL4doL z&gObMW^k&|*6L(Z33lo&+n#bx0%`MxE$pPP4t5L>DEMN^(Mhb|&zVpz>%QB&9|fMs z$}nj^9Q-mRA!N$U{B3}cn*%pAh83P?TB`QRZI^8-7_^vL+u&%!J!|wl*x#?=MyPkN z`(f>C)WeJ9z=7YMvwolT*1z=yV#m}Cl&$VtD*Q@+V@yl%NeO!Ab9wa7Dh}2RW!_M}u!K_y_1TYK*tXGiv=h6#@*v2^ zw9+|LN+JQ1m~kh%uWK$UXeDk`YDk#3oO>dlIMdh;&wRRRHZkF$CTNPlc7!pkz6zS* zJH$|CyqUml%qVjTEP<;zw`w*h_ah&1=e6bWBC_Z8u$P3>6ny(xmWQxPpNFu}NMcA1 zFQY|44<2v#3w-Y`=a8s|%?jkPvC_d7m&Yxwv^|&basCw?c5z-pXvAk^)-sL9aBan< zw6O#+CG5&}KhuKB?-yC%6`IR@tWe|56ybRpkEretKyeoG&m_5D0R8vI_OIrYzU;1$ zcUt;RTIJ>V#hh^cy6Hr0d`~y9X1|tUnauI@6OukgJmStf=06QfGyOktAgAC?TkkG6 z%J#<*qg{@Qp)OwNoZk^x#!>a%lC2tNhp0-qs<_>u7xhm$Kt-r!PO+zbFDhN1Gz-%q z3sdfhk44?C$zCSv4{WGz6diF57S^vWdneUWzvaXBz8?A{Ur1Iy62B1tUoEi@%^=Zm zui3p5!)|(~Zr>wmvdqfCLzL!$iYh^o66KhqpErIc|6eoYhz!MuOawU{vA4rm@%`P` z3xrz*VRWy$aQCkjQc{$jMqDuP8Iv* zZlK#2dGt?ZE|Xkg5cZ$22IFYS1w!3Le$1O(5&K&_(x|L(*$;{zu58KsN1$xe%+j3n_Jq5mW7tR|SAzCW|BNFp zs4t1@1S$|)y)2J#HXhVX3#o%qAhMD@W$^C?D2|$WTx%eaRA_)0n^Ce)sM6;twAJdX zluCN-ZcOiEu7Jnj4!vg=x*LtvR!qFUU%83e$Dr0`;_o(f)6>3fIwHZ5QQdGZVUk^l z@UToWWKQXV)qtSdG~HRb%Z|1$z_VXwNT1)>5E%ubd2%dUI;<{(L|axIKs$Km*!CNe`o+7~OT>qnx;q+qa*A8!v0IY<~w{f%R@Yt571Pe@eDtjx_N0+)pXw@`S znbG-R@XY`Ni+$T;xZ90(yX)h&(p&X}^}Nb8Ogo`J$-#mypn^6AAdbAi9}TYKVomCN z+d#|oUuA(3*3@Au^k7~@@|h&VOTHvgE16Yz?iy^*p&|f9Nqkv?Gf{wRw!>sw%1tY? zQp2~|jdADKhXTDmOuD&Mxrt3K_rElCt5UsZxB02Tj(Lws2D!`8aXvDYJ&tSO6^j4X zCvI^omR%ndQYym>g3j?hr?C58_wB8yG~;&S9OE#l%?Ip#gBV(y4C@n^G;2C%T?+gB;?7=?mzL~geag3#rXa25ed+P8 zV)7Y-1qowFZ_lgXOLlsXF7{|L7kJ*2dvW^o?ouVv-97_G#k5BJnds%#NHu-E7T#?) zmE&78wca*eEA(p(?E;}9Mo+NuznQztS9W!}b{&AkMi;H&jgrZ3z!FhD2gd^qnIyfjF433rf&7s|{)`DXA3x-K$+m0%h_11olCRi$am=9N~$9)=gCjv3rlJW zm1S1=;ZU?zEcW8^t?2AK>Wik$nrYf+<}!pOU{7G24)>b^8r6`x| z>^@!WF6HtwXL#lFC$d+j;DndFz!8qF!*_t84N4=C;0e~=9K$}5f*Uh;qcYoal?cab zpq{z78_FgO%DLg_&XI!#7bgAwfxn1sR6jPiVI>}!isi!P?YO?b&}+Y9iD2uQWW+@; z+0by-M-4u%_TZ=#^ZM$07_39LaMrF;4w?+L9+4mQ%=ZbrwZq`Xx$38v@4G&w!lFQg z1IxU5MfbhNW-ms=h#|&M^WQxWQT?a1iya~_e93d!4|#X~_GgPv{ol$3gUp;VyC7es z8@UB+kX&?2Pp2Bfpgbq$-XsY&OA_XhR2I99v}l#ey~yQ)O#RE>%60hU`A7E(x^c?j zDxS@;;Pk`SsErnqR0~aiw-LmU-R=M@Lj`~{y+l+BF*kusUg+1;YN>FdMH?ip1l#&G zOEpT$Dbc#`pm;X;mJ3e3qI1qras%_bO?)oLPzm>P)U|4}kMLj9v^8*)daFZhd2vCL zRh3iRdsV9jw$imgs~>{LltGH*xPJ~7dXB3{%5l(6DX)y&tOa-Keg@%Zsspr&)l>sJ zjL=P~SukFvitpfPZ2vBCvjigF-is^8*Xg0mg0PaNPy@3}8II!HNHQ1Rg6-3LUI@Aj zTGb}H%{ij{VM?6e{Vm`?0kITa9>I16B%d-aXRO?GlKB+5JZN|R21LY~!%~@QTyV@kHit5I? zBxZi?4`uqLg1FQKT-@LUtNnC9h=>t>SMyKyhEFFR<&$?EBQQ#>r`M&yM#pKVsiQ!x z%b9Ts;kd5|?9d9unlJqz#Xt9Ip<&%;_a-^m;7}YqIsPhk>b5+u7-;$TesU38-n&t- zeQYwFwfSjX+WT?B5wP!f*2&W=jnB?y1fh%ozf!VRA!7T!Fj5(^)h+J6Mf*`s zW#1j8H4~5421e^|L>}jQs2Ucnl1#M(@a7L$eZ0svHHs*&DN1}1OkbwhbZ&5|Tvoq( zb6la<6wpG#`M(OshljI7=-}{Dz#`cED4Ly}Z#OL2>cel$9zgJJH+c7SaB8W>98NkR zV`OPTo@fk|{W?$MCnPx=l#Hg#Q9*RGvkH#4iE^pc2lIU+jsF5c8`Jl3le-cf&AH0c zB^eB()Y5%_gYQ9Ow`_8LVYC!QgCZLQuX@wx4(|1IWO9ZwACHUsB~1jbT#wCGk0I^> zTBF&OThFh=Yk*P=Kj$409v#SC<(v0(`^-`0Td~7rB4ls<^qpkoT^OVvY%QzEygrn> ze8)d;Qhs1vDpnI-e@1HNpP*IYks{}O=6_u2>8-Z^+mrsAqLib!_WNTYy8kUeY{!Rr zdJ$*Gne|q-p>P&$eFt97Yt1s)@;Vt0m>W{r73_Th{On%x1esVkGmk1<*UjqEwO#pk(N;G{q+ERsV;u!?fTp+j-w=( z)i1UA^?DDhV21~4CI4ML!p!$bpJK5P25MrEuYo6*wc?JufyYT`3;y@EZR531yrHkf zuM1Rr@F=>}XZr>5G;&yp!pL1Qp4X!KtiFB}asoP9l8HP$q8iYUxVwI)!EHz3th`9W zQ`q!9>W6w$zHJv^Unj&{z;^UWt92z;wMHBPue?^$J>5XI(_ad+21}PJ1 zm9;`J0vLaYaO+=PdyeAY!V&4aOCIhDuj?8Jx7s_+vbqA}Dq`(2d&Xo7KP>WlsL>W< zG{~XTb`|i+XsC&(%`MK5OtYfzNCn4uhIN=m8rS?F^;U`KToF%kj&uY$buX@6t`|IH zVa&UZotGm&ZO+8E>h

    D=|%;f|iwvS>nHoFu!24{yt;2PCC+IdR;wMb@k$Wt}$Qn>64*~kKyEJ?LV3~g_{9mWMv&~I7u&)l z)&=+Bsl=#E%7&_Dun8+#thzOstUEF$b)7!L3)9zP>Fz}zqXK@$8wGmWrV<{ z2Wv1HyLBSETd)^r^2+vx^Z1^w2u$R~@93 z7~gA>j1Svp6a}B&k~KrE)8becupg9Bk0hS!xmWvIF_!DZcB^#s@I4E1t$gPX#rtc+G($mWsGR2by_%wKJ@H_G z1sZ_2aIW3jpy}*2H*D)Q$3UJK?jv8>wwm7)*tzcAz4qHAQsE4>{+&rQ1@%+4uN50zyA@Su?{2Cz zz)+P|y!P%aT`9gWrzjb&I8!Aa{NIy)1}lI#V~@DDXJG4C+xNgj8W@~?>J=p!z>uLg z^oMgZm9uFLNhxfxF7KZ3$rD(u;JGBdJ!5R|)SCDhKwEdk51D{MwaPI{&73^oW6?b#_7XfxEd5PQ=rolbaQxl-GgF8`dYxQ3OdBpxRJbvNg?^7CIBx4&t za>Mi7L<4L$i@u|jr@5}HPMF-({Hoe3#1fslw!>b=+_9_nw zcbRLZ65P$_g_z|G%|75SZB>d!A+rzt3>7ObokmTSw~x=M?LAwu^OOQ>4~o?JW_sS0 zRmQn*rE`jT@)mMI6Y{_(J8)#|&gueO{c+GCfR`c?EPFsft_@nu&rAY!w>E(qmSk!_ zUAj50GQU*NKsXf5?)NKM$~?Re;jVk?V`aXcLD+=oeISTEW&&0&zLUr#c>A>HZlEx?U(pZ0F1eOo0KDKCGuV}A){nF z)2t@x>n{bSDi^Ijo8>lhzI(*$bcK#iP|y+HFj6tneWL-SDcQW$!@v|TcMg$)Km zT6$6Q&RO6CP|h9emyO>c`-%5-k6zeptFYV;zu;|(;au$8cTN@LZ^ncfg*EwNM|jq& zIT;MjnP#|XZ0DvERj3J*W6z8kB}pu|f%@`5w-=xhE`lW&DpF1kML%^UbpN&f6qdoE1ubevbC8~b2E+1|6oGwh=AdO;x+#Hb`&`vuxC5dkO#;u&<@T{nqD|m+4~2oh zUWx6{y9^DR{HuD*_0&pUp4a7K^D)eF^z?dHmmstBHqd-M>zOo{orPKInOZmM!A%4? z<@nHmsI?hsQE-$#ukIUNCW5ipA8DOAH@eq6@$UgA@$aL^MwuIGEFxD{MMIzL5)OT+ z8@|+gF~_u%v2gq#L^R2Prv!{8~2@6V~9 z?}h@cIsQK2k=P0}6cPb#_Bzu#7qLwutCQt`vtg(#4sy84-MK^aG^;&4*Ilz8t34_7 zJtd? z9SF229Wb9A9B*>TUsK%k>T;I0hOAKXl0YeccU8&5`^ooyF|uv2K1f}nRzKDvI4%{S z+_0Hi%`jaV@>j8>n{iMcA_ON>^f!s`WrYADwUfYBRK$6CQi{L2cKZhX*I8Twr%#Eb z%e0Xbfrq?#m+Qr)&==zuzp=jtA2BR)f%{s%*S=$bNt^aKpW>A3_JFTTv-k~Ntdp~(Ls~AC{d+pJRVze&|l3(64&dz=tGCH zrvUlXt{fiJbt)Tj#qEREc2E}5)U=2Hk3n(Rs|)M+FJu zx2;}(-6D3Xd>Lq2iihHX;*0?_(JWjATvKJZBW#!8EG3Q6FVhg+E;3O{OD3Q0>-uIK zOc8#>bZgD^6Jx1krnMyXpR#mPp^#JoacURqe!W}B0;zL6;#2N+CX;?8Xa7l~oM*sZ^qEuWs*OzSt9xeB)eqi{ zsHBJbH-X1313e#yo1jV9S~$=H4mvv!Dk4u%*So6iWRO1gO6+24%fIF zq+6Q=`>Qmei8!Sf+c3@L`*l!Fi0Y8)&*18I`0Q!QXP&U$h{kG7sp?_JkVJnsj+UT^ zz+0;6f&GNT5Z(FpxJYbFC+59TjXlca3v7mK8oxJ3468s!r`9FO?W#J)&xIkc0$ zDKv_JUO{rJ48wp?nBpJpQet$SH>K$LW|dg;!x5Li7V;x{lg;|!@xbQ8#t2E;g8#C_ zpL6)w1+gAUj7~+zW#TSGL;PPzOyIwvnABo%#`+YkKMCl@+#g0Z5=18qnef6r4 zd~bffOLxzT!#p`&0VtI{z4VK&0qU`vls&AZ>*86%)bB^ zqq+M;gGNaWx^UbRMGnme$`)D-!M_|D2`{npD)|ezZaT@Z2Vo0N{H6XZWe!ASfHKC! zU`$8FU^vaqi7@bJb8W0!I4wBa{rP_!BO{uLI0~{UjcJB;xuSCj6hRyb=92I}P`d_P zJ+(azEkI3@&PpKb<pkc?u{3+>7e~Z=@Uo13Q(8e*6-a1bELP;Qml()I>2B2s)+sn zDf=p-8wiQ}X5##4&nZhi03`^sXJm+Az1p3w|@mLlfu?mno^3Z}s|bvi+z5StSr|HlC4M8codql(^b#jnyt8fvZM zE=!6e3g(9CKY|J``n`(z^Pei1g4`3-*0iIJwhkG7^-v<{g2#)2D+p{E(BkXegTru(^ z$fEdz7`Aa((!@;j=aI2z_ZFZz4c@eQ9z+GsL zD1H>J{a99!ps;sL*2g5uoWU*A$~fbu;|P?0f&B=d27Q1I=R~5|?V$vZ7zq0Z=zoxx zW@xmAr8-45@n#j0mTuIsKI^PufiENohmmsQrNUOtqq&?e@A2UJP`i>uVpyQXp&D$g z2!Jr3qLIuFyJ*-zq=*ODx4Hz0dO9Sep!6d~6vbx;+J|~BpR-tn&fW}n)8lx=%X^49 zuIf9ZpxqnmE=cM6__+sb<3QLP!SCk%0m#ts5_oi2^0C@1Z71BE=l?G~Eorz>7L0-hftClVOK-gzF^N;|uU|URVi-;?k9m}ycggv^tH}AuQtxTpYPLxE z;T{q&pO|bkHajqN5o#m3dKq>>I>NxuN4Me(7b!H2l(=pjs?b`0zDA;bV#a2cNnki& z#v^kutaIEc6~3&&zuV+J=Z&GGTc~6r{|Pwv3_r6D_WnTlY%B+K=BMvaiu(<*Af=ENrK=> z3N0oI`zn_F4{Y=hoPshOJ@Xxh)IOe1;o)8P z;;cBuF@^TEksCnK+P;knOO^p%PrRG1Qnz2xeV(jXUG0g>p2`Lyg za$+=N#anF0K3%RB)QN*8&f_XzCg{%5?O5xk1_ko0-h9J)@a*XVW$+1=gGW)@NTxOJ z{-G-1`3bC28qjUO<}4n`xd(BsxZD-=KC9q2-Y7>k< z=xHGGWjyGstT)pW>W2+}eNawR)h}Kf77-Oz4j$7&V<^n=xm|}1NRc9tMjzWy!r;EZ zcfKEzC)qZ)n<%FtpaVJ7{O0NpQni@%d!5{(N-to}Apwe{ z)0}*}-UGi+x_9nrEnC z(*g-$3f;)rJ|%3tg%utRJxYR)f|r%mx0^GOD3IG;@<6D4g=Tuy=qud+p8`d@SE^6HE}L@ItO_u zTq;5M7(XLNj@w;REy<9ztR!=8tlB)SVje(b4n0VpHiBIdJFMlqV`+tQkl(?{QJSA_ z$UU35>+mh=aBcl%0w$S0I7hu2=W|C+RYbN4QKTH(GpZr+?PCR9y&%E=@G$(Odhhc&jC0kQD|s4USd&(RqpmN8t%>}UHX~4>>(x+#oGh)Bd7@GMO(#fjIq8g^#|xCZeT&B`}e0G!w8bMN7D3<#%*-cPYLq;E3%HDR;W+^kF z5WuQ~l;u{x-I-XzcZquWo$ivn3PhldnPn9l5tiv6R3&ayt=)%^PG%$~FLq@5GDJWF z1yUBff0~`Vkbth6H=|X@TylT)*LBSHIRb>a8xdCrc;701*s3cu&|lAsRG8nZ;nvHa zpY1N51qT?q2_+67DMD%ssTlKG!uDoLN2C*U2Hb6E`8XTb<|6~3F27h^)Dg5n}MH(tZ;|HY%;H&^K`d+iV@-b8SsI#WU zN4lt$z40{z_5@ZhPK32{X)9h(5%MDLV8lc#JLwzmuY;Smov8ud1Pwhk`V?~CMTLK= zZ>a{}HjNofzD0@+iqH#cO-mmV-T zA~ne+Z8W5!Le76J3z8CZ3DoRq)c>}&EE?_&^sG`iM|?3jT`P-wXJVu9II$lM?c*J4 z@-7{^5GIdeu+PAo`I1^TBfuJ`m+Fj$+i2uA+{EHS0MJ%mXVlx8X=@7%t1d_SwH47u z^P6IHD>-OYn1JPqxzju+@9~49+S3VsbWJpll>w)&Kb$KPOC*udmi-{muObVMGbZ!4 z`jZVC`Tt!d!YQeOZ+Qs6BGo~aU&c6j%Y{3V7G%~>DpirmDguZ3J0ULb$ZaZ2WY_G~ zlNgYAc(5ads$Xz^co2D~fAwVENX+#PfK6E0qO|*voPLeXdVq7n!1NSx$ftxb*QDSY zU}5IH52~FU7L$`zxkO_yUPn6~fRXl^@(E=IF_U9@I>qgAc!-u%-;yP1L|i>tt+3}) zvVS^varYF9_>W_)`2K%YBmrL~Nw%wQu=7M`xcNV%8(A2qLzd&%notHDRXmR{p<{@s z-y=5hdOYoBRQiHrk#wJ7nEAaSUczeU4mdp;)Sd3TX~|iBZ)t3%Mszn$a5h0i{le!g zM%m7u&K8$-=%a$bj1qAOQ4e5kBmwx=YDVmX8%-32V1}(D>~O=SxB;U-EUhSo;ftIt zeaSzdG>o#oU#wahx3b3mxsT9*)gT`3SIc^_yF`qlEp@JtIuWUjrugzJS}oSOZ0Pybl)|7q*Gqv3Aa_O7}JqO(M|SZu85o#?B@ zB8Xn1MA#_73ahM$-lHbbqeqBNw1_Ct5+PRaLDW^Fyq@QIzxVsj`QABm&NXMw+`r%a zF=x))bI*NUj>EXtXGFJF^-L5~AE@UxT>P4AGLg?Z#y2c`_#jQ&`o3ZoNM1sZn`Dld zKRbghnW^@J!IMLu4&0p=X>csl9%1VASOO`=*2N!T_opp)v*w@jK1+)C=5}A)HTW`2vT?*p+EdO*E*#Out{UA2P%6t;U)x{`w4E=26`C(|cmm!V=eg?m%^r zATy}6DvH_f3>rSLr`ET11w&LxszG#+VGH-rOL){bjCc0S&*Z!GD&+iqp)f4uzA3V1yBH)d;&)c*y`|Ac)w=#yNx9YlLEajs! zVl-(IdJ2>;0G1J?79_1_xthusxA-^AZJ+Aq56^+_8LWGcio!YdC`LX@{1#zpm)4ip z1}g9=kt&`oobQcNFgDt>^9!3lAP~@B9O$o(SrZ-! zbJz;SobU&Yex^>-eex)}_d5O22$wZ9D4GF3$Uo?13kG|ixXQCC#fhAYLuiH*uo?!v zy}Mxo+H3?&ak)P>(GRwzFrI}595OuCu|=QngzxsUMT5Ns+~jYm^Kp0(?>Huy-hG8O zI8F4=%Q*Q3Z3@abZNLF_7(cRdOKWU_D^=sJCU;;`Td|<* zSf=n7_3Rf-E_8c%7dm*H+7Yn9r*s<;{f8Y;VnGAU!#Gf(V`bLit6f^3ESaMOJr~Gu z<|rH8Men)kP9FP+KCC(Y!*Fq4@w$DQ*!k8|{gRhHi6d0VYD;pKA%LiExePy_wl7rF~_>uEEmbD*k>-`a%v9 z5WnSDAF4i2!qZY;_>zaE^V`SP<7W(Yp&jFpc=?sd4AFb|pKtclAnzkmm?}b;>8};L zn+T;7XRdD_s@$0dNOFU2_2mNKc-UOo25rwb{oukLy;1iVzWSz69*!Kj(W+%Cq#_}4 z(9DV-#f(e&pv#`y`Bg&CAFokNfV4UWmQAQ(@u@u>qS#SC!YBWzgy`2O3h z7XOiFBgFn@-nC*<3!-k@+E=9I8QEgsl_Lz?gW-a%Y=j_a95%2u_9}?fkGJ9jv!F7g z+e|oUIt^v$*rk%B{ie+J<^?P>QXNuY=6GYWAR$Yz6;c|xW+k2;1t$nh1nFWx;rDex z;SsLl(d*!sygpaVqLiKlSw-Fr` zLQh&)A~UWC658X(dw%-!mb~;mGib*ZpNyDGf$Fquc|$@Fhs zcm;hqSAHuaP z&J0gbC7f2S%B0LwPF{nF?6(y}h?%xQ7hVzUejyK9X?}3X46@h~O5AhA!vOf*)s6be z?_$pxKERxOw2)>E>q`7BWuJG6$^e>}pI%m9+N+8@-(8E24rtz zCVRP;URL7S=OkG56N!E56$=G}fVb@R)7E$IOSqHPF?ttQ>libJsE zC3PFHGfuyl*K~}Ki8TV-1c$s@3IU;sHFDSUksXRcEz1QwKh zA8g5*y8*p_0-^4g#k1QU)aW(x?!Z3WSs8nC>GAIPcVffb*5><4l-jB`CsfUaS)1gu zzn^Ncj+h=I=0`BqcSE%JZcmy7x?DToO3M9%>$WB27coie<9FwZTO^2Mi^kdU!#n-< zwL&P>53DTqh*>qs+59uhuTA^@50V=Opv5sJxHsqTB_*=4WEA0Pqzp~QX^#|^3t-=+ znqaxf~&OzHYZ{_ z*aVC-C~xp2jiz04fk_Na#3r_DK*nySD*Xr~eLOD_&ZX(C!}l^kTa|_2{3sH)DL;C8 zPYtX|SRGz?)Y5abb4`pDs}Fw zM8`bhu;s^0bS)BJN&IHN3N^{|^<1TC%fwu7C}{I9o^EYTHs#~8bK^Rq1fK{2o;9*+E7~`zy9!Tf$>>zNO-x`G z``%}wlcZW0b%>N@=ZWMYbij`yH4onQ+Io{&VqZnf~zgk`$L>I11r9UV2jDyNM6F6QY* zt9*BER=WxVlgWlMoNu1u1tlnQ0~0U!*hzbKRPO8Jdo$(Rjr?6J?GzdMXQMmwDShoT z407^vS>-e-U=fARSZtdo*JDjXM(BOLAPXY}$(37RmnsztRRn<3j0qh)j>bqB5pA`h zS?Bt09~o}gzAbb4h_AXbm2)&UX42_{Ofc~rElY8RGnc+)iWV*FYO^1%$B1*sL*1D! zl5pzJ#}kWk!#F1dZWx_EE>-6 z%-7iIDf55^xv1!&j$o1{)4mt-*o#il;5K=uKnopQ`;wlAdWJrZk5VMwMsvT&jXXJq z{v7W+lWrlElZ+w>AahPk$NYnuux3pbM}bE-#h$-}PLGAtGHLV>4#eN)db|_dSZP4_ zSZak>MHF>XP%7arjI7yVBmC~j+x^`cn)B;Ac`04-F@fE2ypjSDr3{fqfwb|_1DoYT z1sHO@rx2LD__0?=GGIb;*wo2=R3z5CqL`QFMnZ$l~jm?xFhd^qL4>KLCSlV0f@lN`19 zagg+)mp|3uoU!2DwN|VlecnL8U#CJ&wa^jzTu}y01oWc#CV7VwtvCP6AZyjE?-wbF z$*DosFT+MwDeDAyn-tdPG*SkWt(>*B>1lo!FHv!&p(F#zoNLo{8-DU|JegUh9@|oF zgPs<9A(6LXes@HitI|=cXtIA``JJkZNQx^Ntvq4uevwm0dLqQ{DrO$x)WIM2JtiNc z^2ID`I*b$x>D;rZw|q~vFvFwu0ZG(jE20V7)n&K$|H{9V zML#*puiCRIY;p$pUb!Zxc|pttos-k_sjXEMa}MougzWk=ZHjVEO)&pPS=>34QaHXq z_|c{B>QS0rn)ywz2Gx+7I9z#0lSs2>j_JbzE)*JLJylZWY|UN!EiZj5^L-%Iv`#%f z;-}3=-9N<0F`^{w_5rcRCL?a4e=da>Oq)Ds%iF8R zLKt;tWK^-+7{UA#ClnZQ%_7^>XF0^h0@K6r;xOE4i*<@zl2uKd>R3~WMU^))hAl$Mwe-K8xz(0TL>Em z;0P0sB@c3bygpCL8nc8(q#}wEy#P-Az*MB!N}pQYd@m+7tmpFZ4*Z^P1&HHERHras z)Hrjq6C(RYu|wzGs$(2$M%Ip38{Bs#I^(SmC~1C+kcLEhW%1=aN-S9`&_zy{Z2#d- zto%U)_i0=13vKX7UapM@|wanpOgD% zew1d@mL+(7xkpNqzgE;88~~4a$4fl%REH80J^;nkA_qI`t=tcO8_oESyldM=d=KvI zxuf0W4-sS<=3QCLEUaD1EM&CKGLoKXZx8Z0c;AIc;f+&nQlj6|LZgyR_MXiQ=6uY^ zbS9D1mPr&}Q6BS=)sp=$0npS4-(q_3;m$CTfm2RZM4=ht6+R2|0cNL#$=61@cLOs7 zNo|Y20SEuzDlea0wF-PdKhxVfaJ6=&e0ODg?Uh$g2wndf0lMMpka}eKxNa_*$`g=h z6^yi873gp9EL#M71S)lsPo_#W6i<)KnG>j>&Hb#};B`1|(oo7rxw}nOn?uIp7%OI{ z_Q2W!KlKAvkj3@4P82wy3^;w+=<^Asr|TRU>9-QgoZ>&i-YIVPU!7^L15b$87<6O3 zTEpA_ylZYsQ98n0dKw}~K>?M&(gGQP0B$-GfFS}%z(hz70D(Y&loxImwp+Nm4FCXu zAOHX;uJM0LVQ6}g0FagNdQ5t@08sJo#4FSbPhqF)Zg9af3;?a{@daf6evsem&O0iA>9cIlqU&=0Iz@bFLWs_x&QzG diff --git a/data-raw/eucast_rules.tsv b/data-raw/eucast_rules.tsv index aa76c8160..506da21f1 100644 --- a/data-raw/eucast_rules.tsv +++ b/data-raw/eucast_rules.tsv @@ -226,109 +226,140 @@ genus is Bacillus NOR R fluoroquinolones R Bacillus Breakpoints 11 added in 11 order is Enterobacterales AMP S AMX S Enterobacterales (Order) Breakpoints 12 order is Enterobacterales AMP I AMX I Enterobacterales (Order) Breakpoints 12 order is Enterobacterales AMP R AMX R Enterobacterales (Order) Breakpoints 12 -genus is Staphylococcus PEN, FOX S betalactams_with_inhibitor S Staphylococcus Breakpoints 12 -genus is Staphylococcus PEN, FOX R, S OXA, FLC S Staphylococcus Breakpoints 12 -genus is Staphylococcus FOX R betalactams R Staphylococcus Breakpoints 12 -genus_species is Staphylococcus saprophyticus AMP S AMX, AMC, PIP, TZP S Staphylococcus Breakpoints 12 -genus is Staphylococcus FOX S carbapenems, cephalosporins_except_CAZ S Staphylococcus Breakpoints 12 -genus is Staphylococcus FOX I carbapenems, cephalosporins_except_CAZ I Staphylococcus Breakpoints 12 -genus is Staphylococcus FOX R carbapenems, cephalosporins_except_CAZ R Staphylococcus Breakpoints 12 -genus is Staphylococcus NOR S MFX S Staphylococcus Breakpoints 12 -genus is Staphylococcus NOR S CIP, LVX I Staphylococcus Breakpoints 12 -genus is Staphylococcus NOR R MFX, CIP, LVX R Staphylococcus Breakpoints 12 +order is Enterobacterales LEX S CZO I Enterobacterales (Order) Breakpoints 12 +order is Enterobacterales CFR S CZO I Enterobacterales (Order) Breakpoints 12 +genus is Salmonella PEF-S S CIP S Enterobacterales (Order) Breakpoints 12 +genus is Salmonella PEF-S I CIP I Enterobacterales (Order) Breakpoints 12 +genus is Salmonella PEF-S R CIP R Enterobacterales (Order) Breakpoints 12 +genus_species is Yersinia enterocolitica TCY S DOX S Enterobacterales (Order) Breakpoints 12 +genus_species is Yersinia enterocolitica TCY I DOX I Enterobacterales (Order) Breakpoints 12 +genus_species is Yersinia enterocolitica TCY R DOX R Enterobacterales (Order) Breakpoints 12 +genus_species is Staphylococcus aureus FOX-S R penicillins R Staphylococcus Breakpoints 12 See last sentence: Isolates that test resistant to cefoxitin are resistant to all penicillins +genus_species is Staphylococcus aureus PEN, FOX-S S, S penicillins S Staphylococcus Breakpoints 12 +genus_species is Staphylococcus aureus PEN, FOX-S R, S betalactams_with_inhibitor, isoxazolylpenicillins, NAF S Staphylococcus Breakpoints 12 +genus is Staphylococcus FOX-S R PEN, PHN, AMP, AMX, PIP, TIC R Staphylococcus Breakpoints 12 +genus_species is Staphylococcus saprophyticus AMP S AMP, SAM, AMX, AMC, PIP, TZP S Staphylococcus Breakpoints 12 +genus is Staphylococcus FOX-S S BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP S Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus is Staphylococcus FOX-S I BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP I Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus is Staphylococcus FOX-S R BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP R Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S R PEN, PHN, AMP, AMX, PIP, TIC R Staphylococcus Breakpoints 12 +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S S BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP S Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S I BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP I Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S R BPR, CAC, CAT, CCL, CCP, CCV, CCX, CDC, CDR, CEB, CEC, CED, CEM, CEP, CEQ, CFA, CFM, CFM1, CFP, CFR, CFS, CFZ, CHE, CID, CMX, CMZ, CND, CPA, CPC, CPD, CPI, CPL, CPM, CPO, CPR, CPT, CPX, CRD, CRO, CSE, CSL, CSU, CTC, CTF, CTL, CTS, CTT, CTX, CTZ, CXA, CXM, CZD, CZL, CZO, CZP, CZX, DIT, DIX, DIZ, FDC, FEP, FNC, FOV, FOX, FOX-S, FPT, FPZ, HAP, LOR, LTM, MAN, RID, TIO, ZOP R Staphylococcus Breakpoints 12 sort(c(cephalosporins()[!cephalosporins() %in% as.ab(c("cefalexin", "ceftazidim", "ceftazidim/avibactam", "ceftibuten", "ceftolozan/tazobactam"))])) +genus_species is Staphylococcus aureus FOX-S S CPT S Staphylococcus Breakpoints 12 +genus_species is Staphylococcus aureus FOX-S S BPR S Staphylococcus Breakpoints 12 +genus is Staphylococcus FOX-S S carbapenems S Staphylococcus Breakpoints 12 +genus is Staphylococcus FOX-S I carbapenems I Staphylococcus Breakpoints 12 +genus is Staphylococcus FOX-S R carbapenems R Staphylococcus Breakpoints 12 +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S S carbapenems S Staphylococcus Breakpoints 12 Not explicitly mentioned in guidelines in this section, but previous section about these 3 species do mention OXA as preferred method +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S I carbapenems I Staphylococcus Breakpoints 12 Not explicitly mentioned in guidelines in this section, but previous section about these 3 species do mention OXA as preferred method +genus_species one_of Staphylococcus pseudintermedius, Staphylococcus schleiferi, Staphylococcus coagulans OXA-S R carbapenems R Staphylococcus Breakpoints 12 Not explicitly mentioned in guidelines in this section, but previous section about these 3 species do mention OXA as preferred method +genus is Staphylococcus NOR-S S MFX S Staphylococcus Breakpoints 12 +genus is Staphylococcus NOR-S S CIP, LVX I Staphylococcus Breakpoints 12 +genus_species is Staphylococcus aureus VAN S DAL, ORI S Staphylococcus Breakpoints 12 +genus_species is Staphylococcus aureus FOX-S, VAN R, S TLV S Staphylococcus Breakpoints 12 MRSA isolates are in this file safely denoted as FOX resistant genus is Staphylococcus ERY S AZM, CLR, RXT S Staphylococcus Breakpoints 12 -genus is Staphylococcus ERY R AZM, CLR, RXT R Staphylococcus Breakpoints 12 -genus is Staphylococcus TCY S DOX, MNO S Staphylococcus Breakpoints 12 -genus is Staphylococcus TCY R DOX, MNO R Staphylococcus Breakpoints 12 -genus is Enterococcus AMP S AMX, AMC, PIP, TZP S Enterococcus Breakpoints 12 -genus is Enterococcus AMP I AMX, AMC, PIP, TZP I Enterococcus Breakpoints 12 -genus is Enterococcus AMP R AMX, AMC, PIP, TZP R Enterococcus Breakpoints 12 -genus is Enterococcus NOR S CIP, LVX S Enterococcus Breakpoints 12 -genus is Enterococcus NOR I CIP, LVX I Enterococcus Breakpoints 12 -genus is Enterococcus NOR R CIP, LVX R Enterococcus Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN S aminopenicillins, ureidopenicillins, cephalosporins_except_CAZ, carbapenems, FLC, AMC S Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN I aminopenicillins, ureidopenicillins, cephalosporins_except_CAZ, carbapenems, FLC, AMC I Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN R aminopenicillins, ureidopenicillins, cephalosporins_except_CAZ, carbapenems, FLC, AMC R Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR S MFX S Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR S LVX I Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR R MFX, LVX R Streptococcus groups A, B, C, G Breakpoints 12 +genus is Staphylococcus TCY-S S DOX, MNO S Staphylococcus Breakpoints 12 +genus is Enterococcus AMP S AMP, SAM, AMX, AMC, PIP, TZP S Enterococcus Breakpoints 12 +genus is Enterococcus AMP I AMP, SAM, AMX, AMC, PIP, TZP I Enterococcus Breakpoints 12 +genus is Enterococcus AMP R AMP, SAM, AMX, AMC, PIP, TZP R Enterococcus Breakpoints 12 +genus is Enterococcus NOR-S S CIP, LVX S Enterococcus Breakpoints 12 +genus is Enterococcus NOR-S I CIP, LVX I Enterococcus Breakpoints 12 +genus is Enterococcus NOR-S R CIP, LVX R Enterococcus Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group C, Streptococcus Group G PEN S penicillins S Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group C, Streptococcus Group G PEN I penicillins I Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group C, Streptococcus Group G PEN R penicillins R Streptococcus groups A, B, C, G Breakpoints 12 +genus_species is Streptococcus Group B PEN S AMC, AMP, AMX, APL, APX, AXS, AZD, AZL, BAM, BNB, BNP, CIC, CLM, CRB, CRN, EPC, HET, LEN, MEC, MEZ, MSU, MTM, NAF, PEN, PHE, PIP, PIS, PME, PNM, PNO, PRB, PRC, PRP, PSU, PVM, SAM, SBC, SLT6, SRX, TAL, TCC, TEM, TIC, TZP S Streptococcus groups A, B, C, G Breakpoints 12 penicillins()[!penicillins() %in% c("PHN", isoxazolylpenicillins())] +genus_species is Streptococcus Group B PEN I AMC, AMP, AMX, APL, APX, AXS, AZD, AZL, BAM, BNB, BNP, CIC, CLM, CRB, CRN, EPC, HET, LEN, MEC, MEZ, MSU, MTM, NAF, PEN, PHE, PIP, PIS, PME, PNM, PNO, PRB, PRC, PRP, PSU, PVM, SAM, SBC, SLT6, SRX, TAL, TCC, TEM, TIC, TZP I Streptococcus groups A, B, C, G Breakpoints 12 penicillins()[!penicillins() %in% c("PHN", isoxazolylpenicillins())] +genus_species is Streptococcus Group B PEN R AMC, AMP, AMX, APL, APX, AXS, AZD, AZL, BAM, BNB, BNP, CIC, CLM, CRB, CRN, EPC, HET, LEN, MEC, MEZ, MSU, MTM, NAF, PEN, PHE, PIP, PIS, PME, PNM, PNO, PRB, PRC, PRP, PSU, PVM, SAM, SBC, SLT6, SRX, TAL, TCC, TEM, TIC, TZP R Streptococcus groups A, B, C, G Breakpoints 12 penicillins()[!penicillins() %in% c("PHN", isoxazolylpenicillins())] +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN S cephalosporins S Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN I cephalosporins I Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN R cephalosporins R Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN S carbapenems S Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN I carbapenems I Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G PEN R carbapenems R Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR-S S MFX S Streptococcus groups A, B, C, G Breakpoints 12 does not explicitly state that it is for other fluoroquinolones +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR-S S LVX I Streptococcus groups A, B, C, G Breakpoints 12 does not explicitly state that it is for other fluoroquinolones +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR-S R MFX, LVX R Streptococcus groups A, B, C, G Breakpoints 12 does not explicitly state that it is for other fluoroquinolones +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G VAN S DAL, ORI S Streptococcus groups A, B, C, G Breakpoints 12 genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G ERY S AZM, CLR, RXT S Streptococcus groups A, B, C, G Breakpoints 12 genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G ERY I AZM, CLR, RXT I Streptococcus groups A, B, C, G Breakpoints 12 genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G ERY R AZM, CLR, RXT R Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G TCY S DOX, MNO S Streptococcus groups A, B, C, G Breakpoints 12 -genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G TCY R DOX, MNO R Streptococcus groups A, B, C, G Breakpoints 12 -genus_species is Streptococcus pneumoniae PEN S AMP, AMX, AMC, PIP, TZP S Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae AMP S AMX, AMC, PIP, TZP S Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae AMP I AMX, AMC, PIP, TZP I Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae AMP R AMX, AMC, PIP, TZP R Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae NOR S MFX S Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae NOR S LVX I Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae NOR R MFX, LVX R Streptococcus pneumoniae Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G TCY-S S DOX, MNO S Streptococcus groups A, B, C, G Breakpoints 12 +genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G TCY-S R DOX, MNO R Streptococcus groups A, B, C, G Breakpoints 12 +genus_species is Streptococcus pneumoniae OXA-S S AMC, AMP, AMX, CPD, CPT, CRO, CTX, CXM, DOR, ETP, FEP, IMR, IPM, MEM, MEV, OXA, PEN, PHN, PIP, SAM, TZP S Streptococcus pneumoniae Breakpoints 12 x <- unique(clinical_breakpoints$ab[which(clinical_breakpoints$guideline == "EUCAST 2022" & clinical_breakpoints$mo == as.mo("S. pneumoniae") & clinical_breakpoints$ab != as.ab("cefaclor"))]); sort(c(x[x %in% betalactams()], "SAM", "PIP", "TZP", "PHN", "IMR", "MEV")) +genus_species is Streptococcus pneumoniae PEN S AMC, AMP, AMX, CPD, CPT, CRO, CTX, CXM, DOR, ETP, FEP, IMR, IPM, MEM, MEV, OXA, PEN, PHN, PIP, SAM, TZP S Streptococcus pneumoniae Breakpoints 12 x <- unique(clinical_breakpoints$ab[which(clinical_breakpoints$guideline == "EUCAST 2022" & clinical_breakpoints$mo == as.mo("S. pneumoniae") & clinical_breakpoints$ab != as.ab("cefaclor"))]); sort(c(x[x %in% betalactams()], "SAM", "PIP", "TZP", "PHN", "IMR", "MEV")) +genus_species is Streptococcus pneumoniae OXA-S S CEC I Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae PEN S CEC I Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae OXA-S R PEN, PHN R Streptococcus pneumoniae Breakpoints 12 from flowchart: when OXA < 20 or PEN > 0.06 +genus_species is Streptococcus pneumoniae PEN R PHN R Streptococcus pneumoniae Breakpoints 12 from flowchart: when OXA < 20 or PEN > 0.06 +genus_species is Streptococcus pneumoniae AMP S AMX, AMC, SAM, PIP, TZP S Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae AMP I AMX, AMC, SAM, PIP, TZP I Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae AMP R AMX, AMC, SAM, PIP, TZP R Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae NOR-S S MFX S Streptococcus pneumoniae Breakpoints 12 does not explicitly state that it is for other fluoroquinolones +genus_species is Streptococcus pneumoniae NOR-S S LVX I Streptococcus pneumoniae Breakpoints 12 does not explicitly state that it is for other fluoroquinolones +genus_species is Streptococcus pneumoniae NOR-S R MFX, LVX R Streptococcus pneumoniae Breakpoints 12 does not explicitly state that it is for other fluoroquinolones genus_species is Streptococcus pneumoniae ERY S AZM, CLR, RXT S Streptococcus pneumoniae Breakpoints 12 genus_species is Streptococcus pneumoniae ERY I AZM, CLR, RXT I Streptococcus pneumoniae Breakpoints 12 genus_species is Streptococcus pneumoniae ERY R AZM, CLR, RXT R Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae TCY S DOX, MNO S Streptococcus pneumoniae Breakpoints 12 -genus_species is Streptococcus pneumoniae TCY R DOX, MNO R Streptococcus pneumoniae Breakpoints 12 -genus_species like ^Streptococcus (anginosus|australis|bovis|constellatus|cristatus|equinus|gallolyticus|gordonii|infantarius|infantis|intermedius|mitis|mutans|oligofermentans|oralis|parasanguinis|peroris|pseudopneumoniae|salivarius|sanguinis|sinensis|sobrinus|thermophilus|vestibularis|viridans)$ PEN S AMP, AMX, AMC, PIP, TZP S Viridans group streptococci Breakpoints 12 -genus_species like ^Streptococcus (anginosus|australis|bovis|constellatus|cristatus|equinus|gallolyticus|gordonii|infantarius|infantis|intermedius|mitis|mutans|oligofermentans|oralis|parasanguinis|peroris|pseudopneumoniae|salivarius|sanguinis|sinensis|sobrinus|thermophilus|vestibularis|viridans)$ AMP S AMX, AMC, PIP, TZP S Viridans group streptococci Breakpoints 12 -genus_species like ^Streptococcus (anginosus|australis|bovis|constellatus|cristatus|equinus|gallolyticus|gordonii|infantarius|infantis|intermedius|mitis|mutans|oligofermentans|oralis|parasanguinis|peroris|pseudopneumoniae|salivarius|sanguinis|sinensis|sobrinus|thermophilus|vestibularis|viridans)$ AMP I AMX, AMC, PIP, TZP I Viridans group streptococci Breakpoints 12 -genus_species like ^Streptococcus (anginosus|australis|bovis|constellatus|cristatus|equinus|gallolyticus|gordonii|infantarius|infantis|intermedius|mitis|mutans|oligofermentans|oralis|parasanguinis|peroris|pseudopneumoniae|salivarius|sanguinis|sinensis|sobrinus|thermophilus|vestibularis|viridans)$ AMP R AMX, AMC, PIP, TZP R Viridans group streptococci Breakpoints 12 -genus_species is Haemophilus influenzae AMP S AMX, PIP S Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae AMP I AMX, PIP I Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae AMP R AMX, PIP R Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae PEN S AMP, AMX, AMC, PIP, TZP S Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae AMC S TZP S Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae AMC I TZP I Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae AMC R TZP R Haemophilus influenzae Breakpoints 12 -genus_species is Haemophilus influenzae NAL S CIP, LVX, MFX, OFX S Haemophilus influenzae Breakpoints 12 +genus_species is Streptococcus pneumoniae TCY-S S DOX, MNO S Streptococcus pneumoniae Breakpoints 12 +genus_species is Streptococcus pneumoniae TCY-S R DOX, MNO R Streptococcus pneumoniae Breakpoints 12 +genus_species one_of Streptococcus milleri, Streptococcus acidominimus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus criceti, Streptococcus cristatus, Streptococcus downei, Streptococcus equinus, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus ratti, Streptococcus salivarius, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus uberis, Streptococcus vestibularis PEN-S S AMC, AMP, AMX, CPD, CPT, CRO, CTX, CXM, DOR, ETP, FEP, IMR, IPM, MEM, MEV, OXA, PEN, PIP, SAM, TZP S Viridans group streptococci Breakpoints 12 paste("Streptococcus", mo_species(microorganisms.groups$mo[which(microorganisms.groups$mo_group == "B_STRPT_VIRI")]), collapse = ", ") +genus_species one_of Streptococcus milleri, Streptococcus acidominimus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus criceti, Streptococcus cristatus, Streptococcus downei, Streptococcus equinus, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus ratti, Streptococcus salivarius, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus uberis, Streptococcus vestibularis PEN-S R AMC, AMP, AMX, CPD, CPT, CRO, CTX, CXM, DOR, ETP, FEP, IMR, IPM, MEM, MEV, OXA, PEN, PIP, SAM, TZP R Viridans group streptococci Breakpoints 12 paste("Streptococcus", mo_species(microorganisms.groups$mo[which(microorganisms.groups$mo_group == "B_STRPT_VIRI")]), collapse = ", ") +genus_species one_of Streptococcus milleri, Streptococcus acidominimus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus criceti, Streptococcus cristatus, Streptococcus downei, Streptococcus equinus, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus ratti, Streptococcus salivarius, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus uberis, Streptococcus vestibularis AMP S AMX, AMC, SAM, PIP, TZP S Viridans group streptococci Breakpoints 12 paste("Streptococcus", mo_species(microorganisms.groups$mo[which(microorganisms.groups$mo_group == "B_STRPT_VIRI")]), collapse = ", ") +genus_species one_of Streptococcus milleri, Streptococcus acidominimus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus criceti, Streptococcus cristatus, Streptococcus downei, Streptococcus equinus, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus ratti, Streptococcus salivarius, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus uberis, Streptococcus vestibularis AMP I AMX, AMC, SAM, PIP, TZP I Viridans group streptococci Breakpoints 12 paste("Streptococcus", mo_species(microorganisms.groups$mo[which(microorganisms.groups$mo_group == "B_STRPT_VIRI")]), collapse = ", ") +genus_species one_of Streptococcus milleri, Streptococcus acidominimus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus anginosus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus constellatus, Streptococcus criceti, Streptococcus cristatus, Streptococcus downei, Streptococcus equinus, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus ratti, Streptococcus salivarius, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus suis, Streptococcus uberis, Streptococcus vestibularis AMP R AMX, AMC, SAM, PIP, TZP R Viridans group streptococci Breakpoints 12 paste("Streptococcus", mo_species(microorganisms.groups$mo[which(microorganisms.groups$mo_group == "B_STRPT_VIRI")]), collapse = ", ") +genus_species is Haemophilus influenzae PEN-S S AMC, AMP, AMX, CFM, CPD, CPT, CRO, CTB, CTX, CXM, CZT, DOR, ETP, FEP, IMR, IPM, MEM, MEV, PEN, SAM, TZP S Haemophilus influenzae Breakpoints 12 x <- c(unique(clinical_breakpoints$ab[which(clinical_breakpoints$guideline == "EUCAST 2022" & clinical_breakpoints$mo == as.mo("H. influenzae"))]), "IMR", "MEV"); sort(x[x %in% betalactams()]) +genus_species is Haemophilus influenzae PEN-S, BTL-S R, R AMP, AMX, PIP R Haemophilus influenzae Breakpoints 12 +genus_species is Haemophilus influenzae AMC S SAM S Haemophilus influenzae Breakpoints 12 +genus_species is Haemophilus influenzae AMC I SAM I Haemophilus influenzae Breakpoints 12 +genus_species is Haemophilus influenzae AMC R SAM R Haemophilus influenzae Breakpoints 12 +genus_species is Haemophilus influenzae NAL-S S CIP, LVX, MFX, OFX S Haemophilus influenzae Breakpoints 12 +genus_species is Haemophilus influenzae NAL-S R CIP, LVX, MFX, OFX R Haemophilus influenzae Breakpoints 12 genus_species is Haemophilus influenzae TCY S DOX, MNO S Haemophilus influenzae Breakpoints 12 genus_species is Haemophilus influenzae TCY R DOX, MNO R Haemophilus influenzae Breakpoints 12 -genus_species is Moraxella catarrhalis NOR S CIP, LVX, MFX, OFX S Streptococcus pneumoniae Breakpoints 12 -genus_species is Moraxella catarrhalis NOR R CIP, LVX, MFX, OFX R Streptococcus pneumoniae Breakpoints 12 +genus_species is Moraxella catarrhalis BTL-S R AMP, AMX, APL, APX, AZD, AZL, BAM, BNB, BNP, CIC, CLM, CLO, CRB, CRN, DIC, EPC, FLC, HET, LEN, MEC, MET, MEZ, MTM, NAF, OXA, PEN, PHE, PHN, PIP, PME, PNM, PRB, PRC, PRP, PVM, SBC, SLT6, SRX, TAL, TEM, TIC R Moraxella catarrhalis Breakpoints 12 penicillins()[!penicillins() %in% betalactams_with_inhibitor()] genus_species is Moraxella catarrhalis AMC S TZP S Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis AMC I TZP I Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis AMC R TZP R Moraxella catarrhalis Breakpoints 12 -genus_species is Moraxella catarrhalis NAL S CIP, LVX, MFX, OFX S Moraxella catarrhalis Breakpoints 12 +genus_species is Moraxella catarrhalis NAL-S S CIP, LVX, MFX, OFX S Moraxella catarrhalis Breakpoints 12 +genus_species is Moraxella catarrhalis NAL-S R CIP, LVX, MFX, OFX R Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis ERY S AZM, CLR, RXT S Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis ERY I AZM, CLR, RXT I Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis ERY R AZM, CLR, RXT R Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis TCY S DOX, MNO S Moraxella catarrhalis Breakpoints 12 genus_species is Moraxella catarrhalis TCY R DOX, MNO R Moraxella catarrhalis Breakpoints 12 +genus_species is Neisseria gonorrhoeae BTL-S R AMP, AMX R Neisseria gonorrhoeae Breakpoints 12 +genus_species is Neisseria gonorrhoeae BTL-S, PEN S, S AMP, AMX S Neisseria gonorrhoeae Breakpoints 12 +genus_species is Neisseria gonorrhoeae BTL-S, PEN S, I AMP, AMX I Neisseria gonorrhoeae Breakpoints 12 +genus_species is Neisseria gonorrhoeae BTL-S, PEN S, R AMP, AMX R Neisseria gonorrhoeae Breakpoints 12 +genus_species is Neisseria meningitidis TCY-S S MNO S Neisseria meningitidis Breakpoints 12 +genus_species is Neisseria meningitidis TCY-S I MNO I Neisseria meningitidis Breakpoints 12 +genus_species is Neisseria meningitidis TCY-S R MNO R Neisseria meningitidis Breakpoints 12 genus_species is Pasteurella multocida PEN S AMP, AMX S Pasteurella multocida Breakpoints 12 genus_species is Pasteurella multocida PEN I AMP, AMX I Pasteurella multocida Breakpoints 12 genus_species is Pasteurella multocida PEN R AMP, AMX R Pasteurella multocida Breakpoints 12 -genus_species is Pasteurella multocida NOR S CIP, LVX S Streptococcus pneumoniae Breakpoints 12 -genus_species is Pasteurella multocida NOR R CIP, LVX R Streptococcus pneumoniae Breakpoints 12 -genus_species is Campylobacter coli ERY S AZM, CLR S Campylobacter coli Breakpoints 12 -genus_species is Campylobacter coli ERY I AZM, CLR I Campylobacter coli Breakpoints 12 -genus_species is Campylobacter coli ERY R AZM, CLR R Campylobacter coli Breakpoints 12 -genus_species is Campylobacter coli TCY S DOX S Campylobacter coli Breakpoints 12 -genus_species is Campylobacter coli TCY I DOX I Campylobacter coli Breakpoints 12 -genus_species is Campylobacter coli TCY R DOX R Campylobacter coli Breakpoints 12 -genus_species is Campylobacter jejuni ERY S AZM, CLR S Campylobacter jejuni Breakpoints 12 -genus_species is Campylobacter jejuni ERY I AZM, CLR I Campylobacter jejuni Breakpoints 12 -genus_species is Campylobacter jejuni ERY R AZM, CLR R Campylobacter jejuni Breakpoints 12 -genus_species is Campylobacter jejuni TCY S DOX S Campylobacter jejuni Breakpoints 12 -genus_species is Campylobacter jejuni TCY I DOX I Campylobacter jejuni Breakpoints 12 -genus_species is Campylobacter jejuni TCY R DOX R Campylobacter jejuni Breakpoints 12 -genus_species is Aerococcus sanguinicola AMP S AMX S Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola AMP I AMX I Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola AMP R AMX R Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola NOR S fluoroquinolones S Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola NOR I fluoroquinolones I Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola NOR R fluoroquinolones R Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola CIP S LVX S Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola CIP I LVX I Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus sanguinicola CIP R LVX R Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae AMP S AMX S Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus urinae AMP I AMX I Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus urinae AMP R AMX R Aerococcus sanguinicola Breakpoints 12 -genus_species is Aerococcus urinae NOR S fluoroquinolones S Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae NOR I fluoroquinolones I Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae NOR R fluoroquinolones R Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae CIP S LVX S Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae CIP I LVX I Aerococcus urinae Breakpoints 12 -genus_species is Aerococcus urinae CIP R LVX R Aerococcus urinae Breakpoints 12 +genus_species is Pasteurella multocida NAL-S S CIP, LVX S Pasteurella multocida Breakpoints 12 +genus_species is Pasteurella multocida NAL-S R CIP, LVX R Pasteurella multocida Breakpoints 12 +genus_species is Pasteurella multocida TCY-S S DOX S Neisseria meningitidis Breakpoints 12 +genus_species is Pasteurella multocida TCY-S I DOX I Neisseria meningitidis Breakpoints 12 +genus_species is Pasteurella multocida TCY-S R DOX R Neisseria meningitidis Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni ERY S AZM, CLR S Campylobacter coli/jejuni Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni ERY I AZM, CLR I Campylobacter coli/jejuni Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni ERY R AZM, CLR R Campylobacter coli/jejuni Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni TCY S DOX S Campylobacter coli/jejuni Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni TCY I DOX I Campylobacter coli/jejuni Breakpoints 12 +genus_species one_of Campylobacter coli, Campylobacter jejuni TCY R DOX R Campylobacter coli/jejuni Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae AMP S AMX S Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae AMP I AMX I Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae AMP R AMX R Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae CIP S LVX S Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae CIP I LVX I Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae CIP R LVX R Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae NOR-S S fluoroquinolones S Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae NOR-S I fluoroquinolones I Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Aerococcus sanguinicola, Aerococcus urinae NOR-S R fluoroquinolones R Aerococcus sanguinicola/urinae Breakpoints 12 +genus_species is Kingella kingae BTL-S R PEN, AMP, AMX R Kingella kingae Breakpoints 12 genus_species is Kingella kingae PEN S AMP, AMX S Kingella kingae Breakpoints 12 genus_species is Kingella kingae PEN I AMP, AMX I Kingella kingae Breakpoints 12 genus_species is Kingella kingae PEN R AMP, AMX R Kingella kingae Breakpoints 12 @@ -337,19 +368,19 @@ genus_species is Kingella kingae ERY I AZM, CLR I Kingella kingae Breakpoints 12 genus_species is Kingella kingae ERY R AZM, CLR R Kingella kingae Breakpoints 12 genus_species is Kingella kingae TCY S DOX S Kingella kingae Breakpoints 12 genus_species is Kingella kingae TCY R DOX R Kingella kingae Breakpoints 12 -genus is Vibrio PEF S CIP, LVX S Vibrio spp. Breakpoints 12 -genus is Vibrio PEF I CIP, LVX I Vibrio spp. Breakpoints 12 -genus is Vibrio PEF R CIP, LVX R Vibrio spp. Breakpoints 12 +genus is Vibrio PEF-S S CIP, LVX S Vibrio spp. Breakpoints 12 +genus is Vibrio PEF-S I CIP, LVX I Vibrio spp. Breakpoints 12 +genus is Vibrio PEF-S R CIP, LVX R Vibrio spp. Breakpoints 12 genus is Vibrio ERY S AZM S Vibrio spp. Breakpoints 12 genus is Vibrio ERY I AZM I Vibrio spp. Breakpoints 12 genus is Vibrio ERY R AZM R Vibrio spp. Breakpoints 12 -genus is Vibrio TCY S DOX S Vibrio spp. Breakpoints 12 -genus is Vibrio TCY I DOX I Vibrio spp. Breakpoints 12 -genus is Vibrio TCY R DOX R Vibrio spp. Breakpoints 12 -genus is Bacillus NOR S CIP, LVX S Bacillus Breakpoints 12 -genus is Bacillus NOR R CIP, LVX R Bacillus Breakpoints 12 -genus_species is Burkholderia pseudomallei TCY S DOX I Burkholderia pseudomallei Breakpoints 12 -genus_species is Burkholderia pseudomallei TCY R DOX R Burkholderia pseudomallei Breakpoints 12 +genus is Vibrio TCY-S S DOX S Vibrio spp. Breakpoints 12 +genus is Vibrio TCY-S I DOX I Vibrio spp. Breakpoints 12 +genus is Vibrio TCY-S R DOX R Vibrio spp. Breakpoints 12 +genus is Bacillus NOR-S S CIP, LVX I Bacillus Breakpoints 12 +genus is Bacillus NOR-S R CIP, LVX R Bacillus Breakpoints 12 +genus_species is Burkholderia pseudomallei TCY-S S DOX I Burkholderia pseudomallei Breakpoints 12 +genus_species is Burkholderia pseudomallei TCY-S R DOX R Burkholderia pseudomallei Breakpoints 12 order is Enterobacterales PEN, glycopeptides_except_lipo, FUS, macrolides, LIN, streptogramins, RIF, DAP, LNZ R Table 01: Intrinsic resistance in Enterobacterales (at the time: Enterobacteriaceae) Expert Rules 3.1 fullname like ^Citrobacter (koseri|amalonaticus|sedlakii|farmeri|rodentium) aminopenicillins, TIC R Table 01: Intrinsic resistance in Enterobacterales (at the time: Enterobacteriaceae) Expert Rules 3.1 fullname like ^Citrobacter (freundii|braakii|murliniae|werkmanii|youngae) aminopenicillins, AMC, CZO, FOX R Table 01: Intrinsic resistance in Enterobacterales (at the time: Enterobacteriaceae) Expert Rules 3.1 @@ -498,9 +529,7 @@ fullname like ^(Serratia|Providencia|Morganella morganii) TGC R Expert Rules o genus is Salmonella cephalosporins_2nd R Expert Rules on Salmonella Expert Rules 3.2 genus is Salmonella aminoglycosides R Expert Rules on Salmonella Expert Rules 3.2 genus is Salmonella PEF R CIP R Expert Rules on Salmonella Expert Rules 3.2 -genus_species is Staphylococcus aureus FOX1 R betalactams R Expert Rules on Staphylococcus Expert Rules 3.2 genus_species is Staphylococcus aureus FOX R betalactams R Expert Rules on Staphylococcus Expert Rules 3.2 -genus_species is Staphylococcus aureus FOX1 S betalactams_with_inhibitor S Expert Rules on Staphylococcus Expert Rules 3.2 genus_species is Staphylococcus aureus FOX S betalactams_with_inhibitor S Expert Rules on Staphylococcus Expert Rules 3.2 genus_species one_of Staphylococcus aureus, Staphylococcus lugdunensis PEN R AMP, AMX, AZL, BAM, CRB, CRN, EPC, HET, MEC, MEZ, MTM, PIP, PME, PVM, SBC, TAL, TEM, TIC R Expert Rules on Staphylococcus Expert Rules 3.2 all penicillins without beta-lactamse inhibitor genus is Staphylococcus ERY, CLI S macrolides, lincosamides S Expert Rules on Staphylococcus Expert Rules 3.2 @@ -618,9 +647,7 @@ fullname like ^(Serratia|Providencia|Morganella morganii) TGC R Expert Rules o genus is Salmonella cephalosporins_2nd R Expert Rules on Salmonella Expert Rules 3.3 genus is Salmonella aminoglycosides R Expert Rules on Salmonella Expert Rules 3.3 genus is Salmonella PEF R CIP R Expert Rules on Salmonella Expert Rules 3.3 -genus_species is Staphylococcus aureus FOX1 R betalactams R Expert Rules on Staphylococcus Expert Rules 3.3 genus_species is Staphylococcus aureus FOX R betalactams R Expert Rules on Staphylococcus Expert Rules 3.3 -genus_species is Staphylococcus aureus FOX1 S betalactams_with_inhibitor S Expert Rules on Staphylococcus Expert Rules 3.3 genus_species is Staphylococcus aureus FOX S betalactams_with_inhibitor S Expert Rules on Staphylococcus Expert Rules 3.3 genus_species one_of Staphylococcus aureus, Staphylococcus lugdunensis PEN R AMP, AMX, AZL, BAM, CRB, CRN, EPC, HET, MEC, MEZ, MTM, PIP, PME, PVM, SBC, TAL, TEM, TIC R Expert Rules on Staphylococcus Expert Rules 3.3 all penicillins without beta-lactamse inhibitor genus is Staphylococcus ERY, CLI S macrolides, lincosamides S Expert Rules on Staphylococcus Expert Rules 3.3 diff --git a/data-raw/gpt_training_text_v2.1.1.9192.txt b/data-raw/gpt_training_text_v2.1.1.9193.txt similarity index 93% rename from data-raw/gpt_training_text_v2.1.1.9192.txt rename to data-raw/gpt_training_text_v2.1.1.9193.txt index 6a941fc54..171265de0 100644 --- a/data-raw/gpt_training_text_v2.1.1.9192.txt +++ b/data-raw/gpt_training_text_v2.1.1.9193.txt @@ -1,6 +1,6 @@ This knowledge base contains all context you must know about the AMR package for R. You are a GPT trained to be an assistant for the AMR package in R. You are an incredible R specialist, especially trained in this package and in the tidyverse. -First and foremost, you are trained on version 2.1.1.9192. Remember this whenever someone asks which AMR package version you’re at. +First and foremost, you are trained on version 2.1.1.9193. Remember this whenever someone asks which AMR package version you’re at. Below are the contents of the file, the file, and all the files (documentation) in the package. Every file content is split using 100 hypens. ---------------------------------------------------------------------------------------------------- @@ -732,7 +732,7 @@ THE PART HEREAFTER CONTAINS CONTENTS FROM FILE 'man/AMR-deprecated.Rd': \alias{ab_selector} \title{Deprecated Functions} \format{ -An object of class \code{tbl_df} (inherits from \code{tbl}, \code{data.frame}) with 488 rows and 14 columns. +An object of class \code{tbl_df} (inherits from \code{tbl}, \code{data.frame}) with 494 rows and 14 columns. } \usage{ ab_class(...) @@ -2278,31 +2278,31 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c \item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin (AMX) and ampicillin (AMP) \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine (AMO), amphotericin B (AMB), amphotericin B-high (AMH), anidulafungin (ANI), butoconazole (BUT), caspofungin (CAS), ciclopirox (CIX), clotrimazole (CTR), econazole (ECO), fluconazole (FLU), flucytosine (FCT), fosfluconazole (FFL), griseofulvin (GRI), hachimycin (HCH), ibrexafungerp (IBX), isavuconazole (ISV), isoconazole (ISO), itraconazole (ITR), ketoconazole (KET), manogepix (MGX), micafungin (MIF), miconazole (MCZ), nystatin (NYS), oteseconazole (OTE), pimaricin (PMR), posaconazole (POS), rezafungin (RZF), ribociclib (RBC), sulconazole (SUC), terbinafine (TRB), terconazole (TRC), and voriconazole (VOR) \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid (AMA), calcium aminosalicylate (CLA), capreomycin (CAP), clofazimine (CLF), delamanid (DLM), enviomycin (ENV), ethambutol (ETH), ethambutol/isoniazid (ETI), ethionamide (ETI1), isoniazid (INH), isoniazid/sulfamethoxazole/trimethoprim/pyridoxine (IST), morinamide (MRN), p-aminosalicylic acid (PAS), pretomanid (PMD), protionamide (PTH), pyrazinamide (PZA), rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), rifapentine (RFP), simvastatin/fenofibrate (SMF), sodium aminosalicylate (SDA), streptomycin/isoniazid (STI), terizidone (TRZ), thioacetazone (TAT), thioacetazone/isoniazid (THI1), tiocarlide (TCR), and viomycin (VIO) -\item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), biapenem (BIA), carbenicillin (CRB), carindacillin (CRN), carumonam (CAR), cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening (FOX1), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), doripenem (DOR), epicillin (EPC), ertapenem (ETP), flucloxacillin (FLC), hetacillin (HET), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), latamoxef (LTM), lenampicillin (LEN), loracarbef (LOR), mecillinam (MEC), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), panipenem (PAN), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), tebipenem (TBP), temocillin (TEM), ticarcillin (TIC), ticarcillin/clavulanic acid (TCC), and tigemonam (TMN) +\item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), biapenem (BIA), carbenicillin (CRB), carindacillin (CRN), carumonam (CAR), cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), doripenem (DOR), epicillin (EPC), ertapenem (ETP), flucloxacillin (FLC), hetacillin (HET), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), latamoxef (LTM), lenampicillin (LEN), loracarbef (LOR), mecillinam (MEC), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), panipenem (PAN), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), tebipenem (TBP), temocillin (TEM), ticarcillin (TIC), ticarcillin/clavulanic acid (TCC), and tigemonam (TMN) \item \code{\link[=betalactams_with_inhibitor]{betalactams_with_inhibitor()}} can select: \cr amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin/sulbactam (SAM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefoperazone/sulbactam (CSL), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefpodoxime/clavulanic acid (CDC), ceftaroline/avibactam (CPA), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), ceftolozane/tazobactam (CZT), ceftriaxone/beta-lactamase inhibitor (CEB), imipenem/relebactam (IMR), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), mezlocillin/sulbactam (MSU), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), and ticarcillin/clavulanic acid (TCC) \item \code{\link[=carbapenems]{carbapenems()}} can select: \cr biapenem (BIA), doripenem (DOR), ertapenem (ETP), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), panipenem (PAN), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), and tebipenem (TBP) -\item \code{\link[=cephalosporins]{cephalosporins()}} can select: \cr cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening (FOX1), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), latamoxef (LTM), and loracarbef (LOR) +\item \code{\link[=cephalosporins]{cephalosporins()}} can select: \cr cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), latamoxef (LTM), and loracarbef (LOR) \item \code{\link[=cephalosporins_1st]{cephalosporins_1st()}} can select: \cr cefacetrile (CAC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefroxadine (CRD), ceftezole (CTL), and cephradine (CED) -\item \code{\link[=cephalosporins_2nd]{cephalosporins_2nd()}} can select: \cr cefaclor (CEC), cefamandole (MAN), cefmetazole (CMZ), cefonicid (CID), ceforanide (CND), cefotetan (CTT), cefotiam (CTF), cefoxitin (FOX), cefoxitin screening (FOX1), cefprozil (CPR), cefuroxime (CXM), cefuroxime axetil (CXA), and loracarbef (LOR) +\item \code{\link[=cephalosporins_2nd]{cephalosporins_2nd()}} can select: \cr cefaclor (CEC), cefamandole (MAN), cefmetazole (CMZ), cefonicid (CID), ceforanide (CND), cefotetan (CTT), cefotiam (CTF), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefprozil (CPR), cefuroxime (CXM), cefuroxime axetil (CXA), and loracarbef (LOR) \item \code{\link[=cephalosporins_3rd]{cephalosporins_3rd()}} can select: \cr cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefetamet (CAT), cefetamet pivoxil (CPI), cefixime (CFM), cefmenoxime (CMX), cefodizime (DIZ), cefoperazone (CFP), cefoperazone/sulbactam (CSL), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotiam hexetil (CHE), cefovecin (FOV), cefpimizole (CFZ), cefpiramide (CPM), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefsulodin (CFS), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), and latamoxef (LTM) \item \code{\link[=cephalosporins_4th]{cephalosporins_4th()}} can select: \cr cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetecol (CCL), cefoselis (CSE), cefozopran (ZOP), cefpirome (CPO), and cefquinome (CEQ) \item \code{\link[=cephalosporins_5th]{cephalosporins_5th()}} can select: \cr ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), and ceftolozane/tazobactam (CZT) -\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), ofloxacin (OFX), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) +\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin (AVO), bleomycin (BLM), dalbavancin (DAL), norvancomycin (NVA), oritavancin (ORI), ramoplanin (RAM), teicoplanin (TEC), teicoplanin-macromethod (TCM), telavancin (TLV), vancomycin (VAN), and vancomycin-macromethod (VAM) -\item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), and oxacillin (OXA) +\item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), oxacillin (OXA), and oxacillin screening test (OXA-S) \item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin (CLI), lincomycin (LIN), and pirlimycin (PRL) \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin (DAL), oritavancin (ORI), and telavancin (TLV) \item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), dirithromycin (DIR), erythromycin (ERY), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1) \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), carumonam (CAR), and tigemonam (TMN) \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin (FUR), furazolidone (FRZ), nifurtoinol (NFR), nitrofurantoin (NIT), and nitrofurazone (NIZ) \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid (CDZ), cycloserine (CYC), linezolid (LNZ), tedizolid (TZD), and thiacetazone (THA) -\item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC) +\item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC) \item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol (CHL), florfenicol (FLR), and thiamphenicol (THI) \item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin (COL), polymyxin B (PLB), and polymyxin B/polysorbate 80 (POP) -\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), ofloxacin (OFX), orbifloxacin (ORB), oxolinic acid (OXO), pazufloxacin (PAZ), pefloxacin (PEF), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) +\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), and rifapentine (RFP) \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr pristinamycin (PRI) and quinupristin/dalfopristin (QDA) -\item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline (CTO), chlortetracycline (CTE), clomocycline (CLM1), demeclocycline (DEM), doxycycline (DOX), eravacycline (ERV), lymecycline (LYM), metacycline (MTC), minocycline (MNO), omadacycline (OMC), oxytetracycline (OXY), penimepicycline (PNM1), rolitetracycline (RLT), sarecycline (SRC), tetracycline (TCY), and tigecycline (TGC) +\item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline (CTO), chlortetracycline (CTE), clomocycline (CLM1), demeclocycline (DEM), doxycycline (DOX), eravacycline (ERV), lymecycline (LYM), metacycline (MTC), minocycline (MNO), omadacycline (OMC), oxytetracycline (OXY), penimepicycline (PNM1), rolitetracycline (RLT), sarecycline (SRC), tetracycline (TCY), tetracycline screening test (TCY-S), and tigecycline (TGC) \item \code{\link[=trimethoprims]{trimethoprims()}} can select: \cr brodimoprim (BDP), sulfadiazine (SDI), sulfadiazine/tetroxoprim (SLT), sulfadiazine/trimethoprim (SLT1), sulfadimethoxine (SUD), sulfadimidine (SDM), sulfadimidine/trimethoprim (SLT2), sulfafurazole (SLF), sulfaisodimidine (SLF1), sulfalene (SLF2), sulfamazone (SZO), sulfamerazine (SLF3), sulfamerazine/trimethoprim (SLT3), sulfamethizole (SLF4), sulfamethoxazole (SMX), sulfamethoxypyridazine (SLF5), sulfametomidine (SLF6), sulfametoxydiazine (SLF7), sulfametrole/trimethoprim (SLT4), sulfamoxole (SLF8), sulfamoxole/trimethoprim (SLT5), sulfanilamide (SLF9), sulfaperin (SLF10), sulfaphenazole (SLF11), sulfapyridine (SLF12), sulfathiazole (SUT), sulfathiourea (SLF13), trimethoprim (TMP), and trimethoprim/sulfamethoxazole (SXT) \item \code{\link[=ureidopenicillins]{ureidopenicillins()}} can select: \cr azlocillin (AZL), mezlocillin (MEZ), piperacillin (PIP), and piperacillin/tazobactam (TZP) } @@ -2498,9 +2498,9 @@ THE PART HEREAFTER CONTAINS CONTENTS FROM FILE 'man/antimicrobials.Rd': \name{antimicrobials} \alias{antimicrobials} \alias{antivirals} -\title{Data Sets with 608 Antimicrobial Drugs} +\title{Data Sets with 614 Antimicrobial Drugs} \format{ -\subsection{For the \link{antimicrobials} data set: a \link[tibble:tibble]{tibble} with 488 observations and 14 variables:}{ +\subsection{For the \link{antimicrobials} data set: a \link[tibble:tibble]{tibble} with 494 observations and 14 variables:}{ \itemize{ \item \code{ab}\cr antimcrobial ID as used in this package (such as \code{AMC}), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. \emph{\strong{This is a unique identifier.}} \item \code{cid}\cr Compound ID as found in PubChem. \emph{\strong{This is a unique identifier.}} @@ -4498,34 +4498,34 @@ These 34 antimicrobial groups are allowed in the rules (case-insensitive) and ca \item aminopenicillins\cr(amoxicillin and ampicillin) \item antifungals\cr(amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole) \item antimycobacterials\cr(4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, simvastatin/fenofibrate, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin) -\item betalactams\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam) +\item betalactams\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam) \item betalactams_with_inhibitor\cr(amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin/sulbactam, aztreonam/avibactam, aztreonam/nacubactam, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefoperazone/sulbactam, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefpodoxime/clavulanic acid, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, ceftolozane/tazobactam, ceftriaxone/beta-lactamase inhibitor, imipenem/relebactam, meropenem/nacubactam, meropenem/vaborbactam, mezlocillin/sulbactam, penicillin/novobiocin, penicillin/sulbactam, piperacillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid) \item carbapenems\cr(biapenem, doripenem, ertapenem, imipenem, imipenem/EDTA, imipenem/relebactam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, panipenem, razupenem, ritipenem, ritipenem acoxil, and tebipenem) -\item cephalosporins\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) +\item cephalosporins\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) \item cephalosporins_1st\cr(cefacetrile, cefadroxil, cefalexin, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazedone, cefazolin, cefroxadine, ceftezole, and cephradine) -\item cephalosporins_2nd\cr(cefaclor, cefamandole, cefmetazole, cefonicid, ceforanide, cefotetan, cefotiam, cefoxitin, cefoxitin screening, cefprozil, cefuroxime, cefuroxime axetil, and loracarbef) +\item cephalosporins_2nd\cr(cefaclor, cefamandole, cefmetazole, cefonicid, ceforanide, cefotetan, cefotiam, cefoxitin, cefoxitin screening test, cefprozil, cefuroxime, cefuroxime axetil, and loracarbef) \item cephalosporins_3rd\cr(cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefetamet, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoperazone, cefoperazone/sulbactam, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotiam hexetil, cefovecin, cefpimizole, cefpiramide, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefsulodin, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, and latamoxef) \item cephalosporins_4th\cr(cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetecol, cefoselis, cefozopran, cefpirome, and cefquinome) \item cephalosporins_5th\cr(ceftaroline, ceftaroline/avibactam, ceftobiprole, ceftobiprole medocaril, and ceftolozane/tazobactam) -\item cephalosporins_except_caz\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) -\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, ofloxacin, orbifloxacin, pazufloxacin, pefloxacin, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) +\item cephalosporins_except_caz\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) +\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) \item glycopeptides\cr(avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, and vancomycin-macromethod) \item glycopeptides_except_lipo\cr(avoparcin, bleomycin, norvancomycin, ramoplanin, teicoplanin, teicoplanin-macromethod, vancomycin, and vancomycin-macromethod) -\item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, and oxacillin) +\item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test) \item lincosamides\cr(clindamycin, lincomycin, and pirlimycin) \item lipoglycopeptides\cr(dalbavancin, oritavancin, and telavancin) \item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin) \item monobactams\cr(aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam) \item nitrofurans\cr(furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone) \item oxazolidinones\cr(cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone) -\item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid) +\item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid) \item phenicols\cr(chloramphenicol, florfenicol, and thiamphenicol) \item polymyxins\cr(colistin, polymyxin B, and polymyxin B/polysorbate 80) -\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, ofloxacin, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) +\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) \item rifamycins\cr(rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine) \item streptogramins\cr(pristinamycin and quinupristin/dalfopristin) -\item tetracyclines\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, and tigecycline) -\item tetracyclines_except_tgc\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, and tetracycline) +\item tetracyclines\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, tetracycline screening test, and tigecycline) +\item tetracyclines_except_tgc\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, and tetracycline screening test) \item trimethoprims\cr(brodimoprim, sulfadiazine, sulfadiazine/tetroxoprim, sulfadiazine/trimethoprim, sulfadimethoxine, sulfadimidine, sulfadimidine/trimethoprim, sulfafurazole, sulfaisodimidine, sulfalene, sulfamazone, sulfamerazine, sulfamerazine/trimethoprim, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfametomidine, sulfametoxydiazine, sulfametrole/trimethoprim, sulfamoxole, sulfamoxole/trimethoprim, sulfanilamide, sulfaperin, sulfaphenazole, sulfapyridine, sulfathiazole, sulfathiourea, trimethoprim, and trimethoprim/sulfamethoxazole) \item ureidopenicillins\cr(azlocillin, mezlocillin, piperacillin, and piperacillin/tazobactam) } @@ -4702,7 +4702,7 @@ To define antimicrobials column names, leave as it is to determine it automatica The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically: -Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) +Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) } \section{Reference Data Publicly Available}{ @@ -6386,7 +6386,7 @@ To define antimicrobials column names, leave as it is to determine it automatica The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically: -Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) +Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) } \section{Interpretation of SIR}{ diff --git a/data-raw/reproduction_of_antimicrobials.R b/data-raw/reproduction_of_antimicrobials.R index 918ee425e..1bb058cf4 100644 --- a/data-raw/reproduction_of_antimicrobials.R +++ b/data-raw/reproduction_of_antimicrobials.R @@ -777,14 +777,110 @@ antimicrobials[which(antimicrobials$ab == "EFF"), "abbreviations"][[1]] <- list( # add clindamycin inducible screening clin <- antimicrobials |> filter(ab == "FOX1") |> - mutate(ab = as.character("CLI1"), + mutate(ab = as.character("CLI-S"), name = "Clindamycin inducible screening", group = "Macrolides/lincosamides") antimicrobials <- antimicrobials |> mutate(ab = as.character(ab)) |> bind_rows(clin) class(antimicrobials$ab) <- c("ab", "character") -antimicrobials[which(antimicrobials$ab == "CLI1"), "abbreviations"][[1]] <- list(c("clindamycin inducible", "clinda inducible", "clin inducible")) +antimicrobials[which(antimicrobials$ab == "CLI-S"), "abbreviations"][[1]] <- list(c("clindamycin inducible", "clinda inducible", "clin inducible")) + +# add all screenings +antimicrobials <- antimicrobials |> + bind_rows( + antimicrobials |> + filter(ab == "PEN") |> + mutate(ab = "PEN-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("pen screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))), + antimicrobials |> + filter(ab == "OXA") |> + mutate(ab = "OXA-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("oxa screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))), + antimicrobials |> + filter(ab == "PEF") |> + mutate(ab = "PEF-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("pef screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))), + antimicrobials |> + filter(ab == "NAL") |> + mutate(ab = "NAL-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("nal screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))), + antimicrobials |> + filter(ab == "NOR") |> + mutate(ab = "NOR-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("nor screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))), + antimicrobials |> + filter(ab == "TCY") |> + mutate(ab = "TCY-S", + name = paste(name, "screening test"), + cid = NA, + atc = list(character(0)), + atc_group1 = NA_character_, + atc_group2 = NA_character_, + abbreviations = list(c("tcy screen")), + synonyms = list(character(0)), + oral_ddd = NA_real_, + oral_units = NA_character_, + iv_ddd = NA_real_, + iv_units = NA_character_, + loinc = list(character(0))) + ) + # add pretomanid antimicrobials <- antimicrobials %>% @@ -918,6 +1014,8 @@ antimicrobials <- dplyr::arrange(antimicrobials, name) # make all abbreviations and synonyms lower case, unique and alphabetically sorted ---- for (i in 1:nrow(antimicrobials)) { + atc <- as.character(sort(unique(toupper(antimicrobials[i, "atc", drop = TRUE][[1]])))) + atc <- atc[atc != "" & atc %unlike% ":"] abb <- as.character(sort(unique(tolower(antimicrobials[i, "abbreviations", drop = TRUE][[1]])))) abb <- abb[abb != "" & abb %unlike% ":"] syn <- as.character(sort(unique(tolower(unname(unlist(antimicrobials[i, "synonyms", drop = TRUE])))))) @@ -934,6 +1032,7 @@ for (i in 1:nrow(antimicrobials)) { # special cases if (antimicrobials$ab[i] == "VAN") syn <- syn[syn %unlike% "^tei?ch?o"] if (antimicrobials$ab[i] == "CLR") syn <- syn[syn %unlike% "^ery"] + antimicrobials[i, "atc"][[1]] <- ifelse(length(atc) == 0, list(NA_character_), list(atc)) antimicrobials[i, "abbreviations"][[1]] <- ifelse(length(abb) == 0, list(""), list(abb)) antimicrobials[i, "synonyms"][[1]] <- ifelse(length(syn) == 0, list(""), list(syn)) if ("loinc" %in% colnames(antimicrobials)) { diff --git a/data-raw/reproduction_of_clinical_breakpoints.R b/data-raw/reproduction_of_clinical_breakpoints.R index 06b01f9d4..3e85f9151 100644 --- a/data-raw/reproduction_of_clinical_breakpoints.R +++ b/data-raw/reproduction_of_clinical_breakpoints.R @@ -222,7 +222,7 @@ unknown <- breakpoints %>% breakpoints %>% filter(code %in% unknown) %>% count(GUIDELINES, YEAR, ORGANISM_CODE, BREAKPOINT_TYPE, sort = TRUE) -# 2024-06-14: these codes are currently: clu, kma, fso, tyi. No clue (are not in MO list of WHONET), and they are only ECOFFs, so remove them: +# 2025-03-11: these codes are currently: clu, kma, fso, tyi. No clue (are not in MO list of WHONET), and they are only ECOFFs, so remove them: breakpoints <- breakpoints %>% filter(!is.na(mo)) @@ -235,7 +235,7 @@ breakpoints %>% filter(!WHONET_ABX_CODE %in% whonet_antibiotics$WHONET_ABX_CODE) %>% pull(WHONET_ABX_CODE) %>% unique() -# they are at the moment all old codes that have the right replacements in `antimicrobials`, so we can use as.ab() +# they are at the moment all old codes ("CFC", "ROX", "FIX") that have the right replacements in `antimicrobials`, so we can use as.ab() ## Build new breakpoints table ---- @@ -290,25 +290,36 @@ breakpoints_new[which(breakpoints_new$method == "DISK"), "breakpoint_R"] <- as.d # regarding animal breakpoints, CLSI has adults and foals for horses, but only for amikacin - only keep adult horses breakpoints_new %>% filter(host %like% "foal") %>% - View() + count(guideline, host) breakpoints_new <- breakpoints_new %>% filter(host %unlike% "foal") %>% mutate(host = ifelse(host %like% "horse", "horse", host)) # FIXES FOR WHONET ERRORS ---- +m <- unique(as.double(as.mic(levels(as.mic(1))))) # WHONET has no >1024 but instead uses 1025, 513, etc, so as.mic() cannot be used to clean. # instead, clean based on MIC factor levels -m <- unique(as.double(as.mic(levels(as.mic(1))))) +breakpoints_new[which(breakpoints_new$breakpoint_R == 129), "breakpoint_R"] <- m[which(m == 128) + 1] +breakpoints_new[which(breakpoints_new$breakpoint_R == 257), "breakpoint_R"] <- m[which(m == 256) + 1] +breakpoints_new[which(breakpoints_new$breakpoint_R == 513), "breakpoint_R"] <- m[which(m == 512) + 1] +breakpoints_new[which(breakpoints_new$breakpoint_R == 1025), "breakpoint_R"] <- m[which(m == 1024) + 1] + +# a lot of R breakpoints are missing, though none of the S breakpoints are missing: +anyNA(breakpoints_new$breakpoint_S) + +breakpoints_new %>% + filter(is.na(breakpoint_R)) %>% + count(guideline, host) |> + pivot_wider(names_from = host, + values_from = n, + values_fill = list(n = 0)) |> + View() + breakpoints_new[which(breakpoints_new$method == "MIC" & - is.na(breakpoints_new$breakpoint_S)), "breakpoint_S"] <- min(m) -breakpoints_new[which(breakpoints_new$method == "MIC" & - is.na(breakpoints_new$breakpoint_R)), "breakpoint_R"] <- max(m) + is.na(breakpoints_new$breakpoint_R)), "breakpoint_R"] <- max(m) # raise these one higher valid MIC factor level: -breakpoints_new[which(breakpoints_new$breakpoint_R == 129), "breakpoint_R"] <- 128 -breakpoints_new[which(breakpoints_new$breakpoint_R == 257), "breakpoint_R"] <- 256 -breakpoints_new[which(breakpoints_new$breakpoint_R == 513), "breakpoint_R"] <- 512 -breakpoints_new[which(breakpoints_new$breakpoint_R == 1025), "breakpoint_R"] <- 1024 + # fix streptococci in WHONET table of EUCAST: Strep A, B, C and G must only include these groups and not all streptococci: breakpoints_new$mo[breakpoints_new$mo == "B_STRPT" & breakpoints_new$ref_tbl %like% "^strep.* a.* b.*c.*g"] <- as.mo("B_STRPT_ABCG") diff --git a/data-raw/wisca.xlsx b/data-raw/wisca.xlsx index 8eb444716ce11164e287694e9f4bbef8ce6452c8..9ebeb52173a52135def9447f9500a6de567063fb 100644 GIT binary patch delta 3143 zcmZ8jc{tRK79K;s27@$~#-44)79wOH!i)@AMk8V@S&OV8hG9?=&Cg6|BKsDVH8M36 zr4q)H>`B%s>nDB0?cRU7_ntq_bIx<#f6nuq_kGVjr?+;GN4X)w=>CaJFbK2=nSJVWpxexVeZ^IRic$Y8<7 zm>B)zCl;&gn|7pyt&en)N>xIoN>)`pIGv10i4Qc@RK{yvK$k5QCqC9S zlfJAyp=p>TU_Sbdt1h_~)6u9E7?1_ZZ!8s<6}T?M6^9&^n4j^sJ~FU(?kSx3{ru7n z@NiZVx5p#0<6+5b>Y9lYvYt{J_{ZRitkiwgGaVrpmX5nRzwlpDcJ_3#_dcOTh@s7T zYYgYFsx7v`KNf>RX43WrfdTA?a47fC{=>&^Hi17|DI%rKW&6%}ozaC>@R5?B{T7k@ zm!CKwW_lV9w0?4)*Zf$>87(|C2T-TK1FYl1w z?wl%J{k#0!9JG7z%}Qa~>-`8rDXAao7iGjGmCg=~&5w7UUW8fMcX56s3QtB9Fzo{G zFj&{NTkbB*N1HFiUFCQt5~Z>;){bH3`G+g{l#gI#lf{Z-m)VsI?<2o3j^_0`O7MU2 zZ`lSiocVK-_nFZ*KNgkHW{ofajRjNhgU02&5y#rLa9!!WV)wCyZs?__b*bvI01q*tRWL}63hc_O1$092?8M?z*}BbVzR6c zkch&KXBO8vIoFh@1$n2w;^`iW!aiGm7R{FTshKFvV4m{c>)rdJ3G6Z+Cad|&IRSv) zEo%_erOcnE|8qTlN*rLGAIW)$gU-!?QYY+85^~u&7w-utLbLmG=?@=XK8b;PB>5;h zscGvuBGvM`To|S0!%WNz>k(q3^ci#IJpVU$vX?H1RabMR<;{viGL2B$L+`!zE-AQ% zm!lJSv099&Mx#2PjC9mcr<7q17sb!+on-)Ss4`AkKulm8zG`gT^C`2%BZfi>@^$hx zmml^WN!jlG205elO8 z*4m7ts>|Ph)u_Dr$0zcP8=@)dsgj#m(KJm*P(nnFMpD8LCnUW!MrGDWX{g=0@PzEQ zr>aD*$Dwssvu>PmEE^{BY8yL9XFJa19wb~(ktixmeY(@)a>G2w+8{IJwI3s#SXvNi zufdsBy{~|I)@gsv7a}}9wC#1)U|hFpm(Qy;toVDVft!)vR|0qH7cktTZZ~*#uq5}i`BpFz$2YDSN8;H9->TogT$UT>lPCO&t z)3#fGVouUvcfU8};8AFD6Tkv!vsdFNuk*q%6Yg0bUX0~a2pd_c6wyab0gpm_?>{Lq z5qUH9A})C&gFNO{r&1X6`X)(tHMm|`{6bAQE!9F~lFQ_7=b&wM3? z@GR!w$<><^u7>i+0?HCeU`4Dc$59EVDlKca)>22`!YYz{R=J~tzl~2Q?J-|{pUeX+ z)y%8V11fTGTcF{pz@x*&lD%5}h2ILj$qfQQfA4lJ_(XU_Ot5db`nAi!rOrK9eoHn( zbkRhxUB%U_wOJOK{^juDei05fn86ZKIQsc`cEs_D#TU_to@NrvT}b+DnBH}|ZipVH z&b4DeZa5X0H@kM6nf?|6HDVH63@_48z1a6BCn2_!Gg*aUPT;}Yo6hZbTk>iMk30wS; zeX%U<@-e^degZ-MW|zAfRq+CUQS;{%SS7ULG^*D4A`9;^DR;hzdXCBfxp_DXt1PaB zF6>Vzbsd9bPZLvN-3fw>nW<&n79g#e{Kjrlvs%Hr1(#zS3BobWmF_f|0esSOzLUqMc&12e}quIh##!JkvFz zqnF8Z7w0;ssK`{Suar|=;FlCo!EXIyff7hbd3Fn|^8KR#SuGLGZ)^VG+D&9EqNAi1fP@6@a) zNnqk0kelPW)qof1ujv&uUnCAcpp97~zoA@2dbrvzt3?#2m1XhfOM($uv+4{!|| z@Q@ba$(dTsqZN=yha%*sxndBdna%FX=D{-g2418ziC%0?2LfJotA{j(VlL6xEcxpG{ zjlW7$M`eBTI@4DSYDwe^jF-x39rXSF?!>2$`hWXkUvEycZKJF2Qm?=-SKc*=Qc^iF zuHw7MVWh$t>mCr!@bivl1ZSNr&>8Bd2AAXUC>n3X-Ew&zJ*A%6glfTKga?9}ge1X~ zK7^N063I#)@+!FdU97D^<{>Y>@{}V|YoQ|a0w&!|2jq9x6JdyZhZ4$~*>YGvy@QQ~ z*3dWb;2TUkw8+{|KeENGrGZ@ac@`n2f)7he^6dXQy@A+!z9IS_v%MyDl=Dzq6=l)4 zAzN0PgUGAbaHN|O5EXW#=aTkR+xEDnSwp55lsh7v^kiGD?w zu$!HUG6M3BhIgMKW8F{eX>QyqqYR?Zxy5k4eBX~QNR^}I+U@?%q-K4wzPwWOdHpkS zLGQS{UvA4(LL_7-Lu(ozjKnWXsv`~hC1=vJ|01d~9k6O$nf)i?v}tKu)e3asyL#0=y9 z4*xVE%$ZY0S2)Yrgz@VPHcg&W>`ES-=N7Pc!Gv!n?+m2BB3LU9$ak3+ckl+XS&ZIO zf7u&9YKZY;Y|>O#Ez^51KU?PwGaH+7htCuQQ6d<9K+Dd00K*h-QGCbF%Y^Tv58VPt zc_nQ-m+`9{A1#AL?_a)!4zuI#ZjcEI_t>}nq}w1UAI$k*|2A0(%asBFfq?rEIADns zl=$=LfIwouh5k>p@B$xr;eake8C)d*cq0@P|KAk;U`e8XECN_V2uu7S4hRJMgZo|O zz=3ImDOgkjkVV>oVUj=?Qc>bR7x0^B`M)ja$p65VrGZAI5x83x*hC)ZE|UNE@Lz$> ByCwht delta 3743 zcmZ8kbx_oe)?Qc^q(izE1Qu8t;YE7sUP4kjmyQb(3j7oh7Ni$Yx)BMbOF+7%B$jw3 z7Ad7f>A1dk<{Q6z&mU*bocQOQndf=Vh<>(l4VI9&+?wqKjSm8yV%7*50c-swQQENl zhFiOHc`OB|5H-I$zh}B#1@@W72F%+r1)I4yd9M#xdAvxgZOf=y{n7hr=y(V3=|+G_ z`nDmXK%=&pYyl&2`i@nFTAa^~6+u{h6%M{tYI?6TTIxpt$#Gc=Y&YN(C4aj)F z3zwPu(5bQoKBN{)6xAaN_-1~`lQT+XmCPJ2b!q!=A^qhesl&={y(pd`n_8|0@x$1) zQ9d&Jpu15g?<$;J8fN{2K$A{-PxKXwqiS<$t4{n6#Y)hOM|@%AKy#Jum6qudy+Am` z@#m;3S=HA(g#WwW(FA@! z@#`Xt`B|x!%zM3DrJB5W5zdv5=Uh%u_Z%Oa@mT$XwT=uV4;X#QaD8Km#^gJB6Dt6Ki57^EM8$ug<+5n#e#FX85Nqm9e-&g+^u zh!#Fshg{MJ3iMBRKI-zB+C^4aiCC)X|J??S>~v;n!L$k(u?`qE$Y1hr6oHyJUzSUK zAeOJBJ*Z)NzhKpM_sl+qJVfPg=v`Uzi26p1t2H}2pQdBaR!cQZ`- z(7vX;{#ok2yT2r?W3N&!6uurFMZPjh+7ydbe zKlO<1IRSFk76by_-u}nsnCy8+ijsxWr4gBHl3W|b&HN=2!Ds|LeyFr}a?&`g>gzx& zbZZcR@;}OTjJ8}!YGPX&kn6PR$8o3eMIW3fbj{b&^m|1mRr7@#&jt=o*e+3812I7F z50#e#0h-cWD2JYN(3^=ei60A$3)h^&V#BF~6|s4&nGg z$#Y7269W`ElSLJ3^%r^$aRH>L$rqc=bvz=Z%@LKi*dg>&Zd{?>S1tkY*;neNc6O-Dns>UMfrjJmLw_&`}$ehO>9}-I^HF_{ziis*%%ADeQ>p@&_ zQWNo3CEFCIE(fR7e~Z z(MSiMUo0u=on@3`BQfoR2XE;*Lf-4}k9HhUk{21q8eXe2 zd%)BV-2-RiV#|xON|nJ20wCLhFw8*zNTZwJ1{rxFaD}QF+&>0twq6-Bwz?)cw5K-f z=!08PIna@Nb#$O;!RMEb{5AB_gOevPK4rZlETE&bTh|4u}O1eBz07f+5GWxBlu zxSQ`WY?kSYNr+npUsK^PP|CJ@I~>KhvYmiVSov<{1>GybH;OsxCGXDnQ|lXPXTG>* zBc}DI)ZI?Vl^b5QJbO$cPa)H4-#_`ITq{h&GH5Y+$rMQBi^{oHFpNRVAe%DHWx{Sa z9KjYyRp}Cjg&%rHKy?`9gNCxOxJmcX7W*Gk5g?ZZcAmhXdF+?{KE+_XQk_RBLQ+97 z{j|`*eAnTodotfI#@N&RsQ48U6&JP12LIw7nj0j1L?6nvt;l~9E`KX(ZMBsmMZ9^} zCjjZ_!#u%YBiEKCLVqrSj;Mr2GHgP>Fr0EksIIxr`3ArEX{vw?Lyr~<^+#%HtPtZj z#4Nv=de9Qz+ci27ImwbR+?O3c;V6>S>ng_n={-)4-8X6Fi~x@nSl*+L!U)as_=hQSx6Dd zt|kY0as#)CWx6}1M`dj1cOLOrJe|bc1ww7$T6i*$t>&G9P=I>`Rnx>x=W*^qXh5RR z{Y03t8%zz&63E5{r^yr-BRkT2Z+R>>9gR-&<#$D+jB&VaTukB|VYgMGikvu1F@QBU z-c`Lp$R7^aIdPb%lS#}@PPGT?yuCW*;E{f?H& zQe(TT7ppCs7%PLEviWIUp94=79nbV7YsG}6GNyJIknI(d!V!5qy6vGz{S&%j7mv*x zJn{^x&UVueZcpi)8s#nvHl_9gOWOpg&qUd2aY}&QrN@Bv5`=iA8lrIZDD(E~cb5Ufs7_p6AU@aF2TBe31@!&&S`pD1>KCv;0n1w!P1Ln;obon-@k z#UtTv$A_C|7_5R{6tnH-aIZdF)yk?M?x#lCQA*Y$JHspQMbXP4+RvBoN+rJyT6ty3azII=BF-y^Mf16!Oqmhn9A<{HoajCF6h)>l= zE5o1pzL2z-@vAps&OWY*@a)%wg?PB=3Lv;E?Jvr->iDb_-BB*~eXLV?c;Ll9o&br0Cu%&y>{81UFLc%Y3Ri#CA3&(oj^^PBNr0&ht(rTHe z?hYuc)=TXB7XNT%Z|5m)fC(-=j=LFydyo3$d`sJjGFN4sLrvFgu=UqD6@!o4ltO1O z!#j@SO>6=Qy-r2OMOHEgIx0U;OC(mDHnMOJ@|KQ0(9*ab@3Ft|6iYtn?4%`jcryz zDRv^qW9+QwZP)^t=M=l3FJC#E&3Mof|fV4#s!NJ^i|pc8#ea zrNcz?Qq-?=YJvaXKPSP1!~-yqJVGpgBs2)b_?xT$SRH1RM-5+^3PS_qf&DL~|7oN7 zJ@tPCkI9G8vHpQ55Qz3q-|r}p1yjRJk12t{@!i=mlQ4aJ6coeB3uFDy{qaDctl!8+ a{a+(toES%5d3*+LOcC!r!XL1IivI?jwa?=K diff --git a/data-raw/wisca_params.xlsx b/data-raw/wisca_params.xlsx index f94158dccb22478c945235c905e9c8232eb5575d..55e249c2f7fa1241eae18198e65862be08f9af57 100644 GIT binary patch delta 8018 zcmZ8`byQSg_wLZ$-Q`dtFo1+~DcvQ5q;yD1!_Xit0}L^gh=9@|J#-`8A~A?49g-4v z{C;=c@3-#x}I=}N&? zZ-MyDbg3c_BK>93D!ZcyP(@(n=kVY4nDMP?y|NNT^qG(I1vABc1v&QLJW+7PGR5?# z?j`q^j@YyQYyd8)vTWfB=N9-Kbybq4GHpq?5cf2I&7hF}{!s`Cw7F92RMBLF7PK7k zY_n{dGtHzVlREuUv9Tx1JZXrBh~wG1mXRE24XN6*}R zpunSm5-_Q1c2cu<0Ry<`!g0o{qAp81f!;4r}+P@og0fP_x-49m?)uHPaI3)j}7Y`K$JExAh)dpt!nB1hQU2vcD9 zkLXELCZocZ+L`;|o)_t+_=Au5W*hwmKGw2I^@WzBBKC5j)zZ4uADf2#pIG*OrMS8- zEI#YJ2@fS|rwXz6r#$9{tP^GKWtt8<;p@wK9N1v~{B*LGxJtut2t0XxAWb)h$vf1k zzfa>~t1HkKoWU(n3X;T>-`D5#kQDn)*&-%tklZ^7{L1xf6!}hEeQ@|g7?Ehq8>{|9 z&~soO!w;SZeA^|-_CeWuBA7lGbwdh)C?=uo7oPx8Y5*WJ0X9a&2F>`EvH~WLJp!Gx zaIVABx-k`_joU$URY7&T7oG=_RJIgD74A9~=ijCMNZn$L?CBzSmI^%X8B!bCWZ%w6 zhtIq;At1ODJ}I&l*_s#USnqOwPK0t+{+yIm9~q5Mgnc{z>;JjLNZJBGPezcbqh_Pk zNsRfGklg5ReJr7=H?#s(RyHs@mmW)`h4N(~3<9LtB%)UFWD|LG9O3!!({B$}P7YFVd_#y-EH=_33v7To7v) z7GXO8qN4j7?s7C*8<^NUU6O`#O*ZliU1aQ=hlX#6e*7dIrNpux%wPx$S6$6YGh*b5 zvGAAZ-Y}~E;ZY7n;L?pIG>k(fB+_tigrDzN31Wn(oG8}ZZ~MSU2ES*iZkHPM^j}*`QqT^OmN1dOYHLq9eloELXUDEs5&@-__JHg<-$4u&9 z@MXeDdZ$7@)v-oDHBbt}DHua`OWv$RV<+y*d15UBOH#7 zxQ`+^yP>)|)&x4IM?Pb}x8Io3Jf$LxwJC3VYA3dAR~NXGx(>a&I2byEvsuZ7-rf~H zgkAo%T02_n`g>m^)D;T7t10v+J6gZH**fn^K|dXvA5PDAptqOT-!5y`!-DU|;tFFg z3+2K(uW!A5MyqR}4|nGt4_AMVPx{!f0B(i!c)~gN5<{u%@WS{Vpq^|gMA9=sI;4g;&)?TLBQJQox15RWSsLo z`i7yuif?{4Dm8&4)?^8&wAd3zl+F(Ufqy8cs4C<6Zj{EH73q*{VL>tl{&AZjGNgYu zZKB<7y^oxJK48yoGEQOrvAy{9O^3o8dbM|P{cuzvQI<)LPemL7?&+`3eu1x3tNW5O zfy3$MBhI|x{hF|Lpo$H_B*uKh{hadkSLYaSo5&0zDlKrLdh%&J=eG8GV^QvD@X(WO zif5x(pZMf2^}>80#V@nF-|nktTfaBcq8-H>7iDF(!O`lWLLz971;&U|hfXK2pn&{< z*2^>62nt?g5P7g9p5EERQr`o53aCxwEfLkYNa9GZyg`U_1Pm{(+0fgB)fr>`O1@3L z3{OUO?JwUo8M{{Ga+HTYiP`urn8a7~GS7r@I zdv?x*clb^M)S>()@kTRsy}0$zky)Lkv@8oZHzIZxCO!Ofy93vCyYe+mjm0ckfc;+Q z7DLRksH#8qt{;PZGBTZ<*Vf|Ffp;PyaJ zy_VC*&h5PM=H7OA$#}5BiAeF(Z0?~2 zL3Q%lqhzHhPnfU|sx_yf4mC{-Lf9bYhC(Ch4952KNF{AqjKQzo(VS;8Kbj+$C8D%VL**h z&K0c`yjVg!yjXJ^y|4so&}M{&fs%lswo9GxsWnmS3*AFi^>G!9*jJh&$JO3L4G(8( z%_R0yITKuhk$_jB;2RUW!zrLo!y@FdiddE{hn=7U+uy9Z&bZ_w%1tgDuHg;Ywc|Yh zR$ockl=e8UE~q?NS>N>)fGwDBt2&x1!K&jY*_wx|?1D@C+!4DG$k=r`b}`lo50)PK z`F$8hsb_S8AbH04HEZ(O>mmSl=GY!bcR3-UX7jK4t0T&uK3s~&Zn)Vgx}R7^wJm>Q z2GrqZZ7^5ZvQmr4K){RA*Zm#vR#pDIU}`yOxc>Km8t8VhAc>6IRCjM|Al-o;>#5R3 zc%0#1jpVB=4-uf-+59G9{!zuMHD7+Jpo{nr3dBwz3rz z>!;d3%{k&?VfwR(C46GW~J~zoiq&KGiEn%>?1&SaTw`^W3OuP|5@Fcrs&)6+mQkbqDEw zI@&S}Xv?slqt_BRO!OVg@~=73Sdu(6e7t}&q0}E88NtPgy(oxOSl-Fit`n(~Jr;et zo#zE4Sb*0KOj)ziWAsY=xd0`b{v+h?JmUF&c=a|H8TV~CMr5J{k*uB{jcu$GZu;8SPS}0(j%WoYZ zy-KYY66awZbFSA6T!>nIwh-mI4Ge%6v6#h+>?u{E26CMoRn@uU4G?>*KU&v3wJ#0` z_liX{D}$*o@>-KByqaX7eih66G?zvW7QDtGU-(vfF27GYyb8+X4(9!aDTT9+wR*{| zJa(|W1(rjkTta7+duNuJ@?Xd!aj7q}pB8!C;cK|;&onQ)3Q#Ly8S+Mxl(Gof=u#)p zN}0*S!M5&l43O$fE4JjWyQf~fN}F^)@0#?|v0`G@!%YMi2L<(^d7TSN9N3^3r6oPV z)7}i_X(gV$vKUN{D-wZXfS=VU@43kFC=E2oniQEyv|XpU=ujhe7~?R&lmDJ&Ld`M{ z^$O3`nuD&JFI?qz#_d3^_0Qu%?oApSz=?Mi=HQQ6po=PPQwJITre-A(lZKq-9OWK~ zXT9YL4cRJ+DZmlR0-w=jc>m!$$g-oKpdeGF;V8Xv+10+DD34{P+6_FNos5`-(@Nry zgG_NvoP{h58}Z1U(SErQRBWfify^2AI>ZS{WRmRiH<&pMy*CC#ELUvj5YMT8ovC?o zIF@=}gV9e+)t&HZ#ou{(ze#-l8AX;Pop`p*zB$cAC@u_QXxd_Y12zs#GXCB*o%&)Rcp~^_ugxV_0oURWE4G7T8_^& zDrY$YXDXaG6)Uoz^`%}A=CM!+83~lK z*O+_Nz1#6OAE|GbU+T1{DoG^oAuDx7S>Juf@9t^WXONp1IggRfrz=h>1T<0*<3>aZwfK%mhl zn&W8Ccl8P6djr9RYARmYiH0{3&jH;pnLbq2E>r9%tr*~*?$UgYy?95sLo#VsKr_+l z3!IR}hgl1jynYE{Yx8x#fT+uj;tHL`kO0{l>Rjzx##7mu1*^-g%r^^Of@C{KX65Ju@v&NSU6hVuGh z2HW6}jlX0;YM*l#wEr@$5R z<^4#8@POO3dCqJ@HGY&_?8K5Cx@8gOS#`2j8bQYNq_#fd+07$2Nt&i7wPMzRgk<*^ zr8pbUz~MrruX5fzF2<&2Q^z?Lu#btFDAvSrtZ7;nwEH{^RV71Z%ZW$R{^PlCD#_s@Z2BmSd*+Mp*hkx3tk`ywZ-1K1Mq;^q&g@Kss2wDwV4 zwNOfNL|li{v!0MT+N1zAGDC%F2?hwqS|a3D9qIb}Dj9Nf@+aKH;kHim%%LWeL}8iz zq&K!PYk6sc$lwp9o}IPJ4Y#t`NvUfNWY}{t9`zlf;0o>cf4jOB>r!3Mff^8X)Dm0J zNe+0B$$3jApO)B__!Ux3e)J5j-y)L#SHEXiV_wGG?KIRD$Du2yv0n}i4G?E9{P#22Dw)&jlX3;xvRP*z_LHW!Q+#_10;!Io61w zVlIHF7?S+_4ovPGhyUh!rM%7ZkQ(dtE@b zUdCI5_yAXmS8c^_8W|LB9zq-c3E+^n*bAB0uWNI@i7R3u+UC43Ac+aQhXzK`BM^brY9MN{i98KPjEqh!55xA_HR%7(*5c7cw=!S3F~*maU*%dD z1CCR;CQe=cS`@(oeO<-%8nV}MRUVA5_Qmbp>! zlwa;RrO})kZJu7x0bU2#Cm9cAIf~TQli$ud zRyJoueE%s0WIHm`l(Xo)>`=VoXF|Qix6+WicNSfsJK)NUnL5_`X|}mKW{O&kdV%6E zc?~QSgl-1Y*5vC)^D%|Mfo_u50oNL6@{d5QFe7O!(7_Pwp4gTD#rNhp$cyz;XXdN} z{8-k5961^*Nq7EIYAIk-^B+7&Z!_ei(({n0zW*N|%FWL@G=CJtgqH>iy2bl&c=I&} z6#r-3AoTp8mwF*W_93?XR^}VblnUcJY{-Y3gKw!jLh{Iv8#X}04Q(|(^rDx-ffx$_ zP{juTNYDo<0d7J*zJYG`K7s-6Zv7?}uHV4ap=|r|_?_+dP6%L+pK~rFp*i29s80Sb zi1^*UVeehv{jQ@?KT3ZV*TvqfIJLI)l!CMF7WVdXHp2$7*wXbAGiqA2s-GKI%cp zv6MT#J{uUOoBF{vUT*}xG9~BsiUU(EyDDH$U%vTmr;*WLE4DShZ~iz*MZA4kt#l+8 zYkrXJ9kJN`3%v5_IAzFQgAevt<0m7V3BaQ9vmTKf#Nk|i+aqZXD8}ixwA-okNFJob zO|lx7=`2gbW}mtduQPu}1%wfwo4m;s+z#JW{OC8z*lw(DB>SFa)B2n8Z=B4`goJ zP+LDZZi^UTd;ew$Yl-6J!g}BPkCLdaR}!4|BbRW5`-h@@Xj^(bbF98W>S$Nu`H0}_0h<_f6E;VxT<=k{h%B;JD`!j`Onz-E1ZAPUe}1fyQ|X zUPtyx9+b=|@$zlTNmZu|>Gpd#A!IR$i5tqL)jggEo0H9R9$fe)PLNU-j`D$|<>t+M zi42zA)8#fmAqp*jjs4xqw1_CS3?CZ4szKc*0rMf%MM(;YE?;eL?}F}~+gfz698q6+ zCVnAeC!QdL5T3qbR*z>Y=mJdTag85X#JWO1D15qiGVuyv@I7+V4GXLv2mt^3)!c;d zMAoVsRp-xeQvfRnMv5}R-ik65#_2HL^w`SeTE#i@Np7$rPu!1Rt{+)4Xv!fNxOp8< z$v-Pc$C}_%5XvI~+~{|4(>$+pSZcAV z(@imj6ie7Vl7DmK;2-wK3`Bd(wX{(;OE!E{34N%xr#0>neUP2!yp-<#hx+zRh7;kFaXzi*M6=MQchYY9|ZC~Nb`xiPu1N*nz0 z4(ZOiuA5CHhN+x<)yYmI*nvZa>BqM-j$1NiUB|t3PvecbW6h?_m&N;GMY^cN`jW@v zcrSPT#i?CZL^E=Zh?^c}_8pU!z{`E@u0sw`LALwt;;)S@)c?GR`%CI)Z99j^dSOj5 zsI!-~lB?pg)MXsqTKdg5gpt6C5^OA%_#0*R39^e;uHlN|J%h|)g-2$--*0_DO~CF9 z0WfPILg81~yG9Y~4-~KxuczNNp5mFBykYm@cRXKReBkk|YpwX!IZCPd{Ld-ed315_ zf6jZc0D7<&TqH1G?mL1*kEtLUbT7;R7Q_R>dZbMSE9YT>DxYCxi{4)a@3fnL&&MXS z?0)glP6Oqof|-^xnzLH=W9Q7Fkv-y#(a#JJ0pHUop#R=vp-IZ2BzBAWN(M7xR-Jxj z9}u}xH^c5#s`p$kuF!!E;vW9<0&egQnq&{)#gzV!|2+z9okm#4o73gN#bT}uf z`iFKbTd!3Pz|8R$6l)eGqADaTKIz8DRh;!q1>(7A=0yx@{FsVEvLqqhi_b6EoU{%j z=)O1=+guvqx6Knqxn+xlw!xz|$7nE!49F6?_ z@~EL?yi;h38#G5f9nMZhEu`|%&+t#1<<+Yn3}YGAfyLGdE?}oDODkYUQeg4sGdiGC zUc?DPJtrG(*x39fNmx9DEIp^2Vw9vgCTqM+x3dqph4%%EnG$*$4t&9#ZQnw1WACBD zQ@YVve>)clB4<`6rOXh^#-)C!rEPoy6>NlI@QIqkt7rKRrvw5d_J5a*1l4}}RFtqn zFDO57G`3@GK0j&XW6G?Ti_hvqGEOU%>43$U0VZHYh)V>7xA8ZE<>T2>)KvI#qG8x% zZ*eDc>NGFKzv&bAcj)ZopHG-qcQEluG#?BK4dXZm`#UQHRI9I^%jvGYA1XV?Eaf0j zm3teav1rE}2g_cAK6xi}k>~I|LI!xo}9sYYY5y2*j7-6Mga+oie5tEf2mIekg|No`NfAN<*uxT(G z^MBP906=#R|JNl5f)NWVV6Hxf=?IH4|G#j@{r_>x0|ofYuq+2Gf-JR2=g0GW z-}OE3_0Es^F>}u~XU^RBoHM5zJY-wDfQ9>BqJlFP4F%;Ax`{;%G1r3&0fN`F?}@Wv z^ItLXy!n#i4n&Hi6Ta^kkuS-KmZ*!XV-6y_j$apYox+{5PklDGbKh$pBZu45_fqM2 z8#TcGO2TlS={B8F!1`S_26{r34UYqeHy_UFjvU^*ZQ05I5_^4PB0=H$1pm>-!_sGu zDVQxgMPW!{?5GD3!8UDp)+~~{)4Z{gk*1VB@YPmflThL9i||4!{8VJ!ul+RM7F1y~ z5$rQJ7M|rV8H=hL8upC)JVV~bsC{N?oB6al2_t;j0vSM80r?B5gTkgTZG!cbA0$oU z@_QQIO(6-VjXuKOZL* zY7MqBFw!p78`qLdBUK0SS*{NU+CS*e3L4yKs3$yYIAWzr+T}j#HK@5-3oEZ|Fj4yu zE%rrGQ$<>OoWS+-Md=i{C~IriM6z}%^TyC^)~bMtRx_dcdfkMY=$Oa|XS;i-KJw>b zLL1twN=eoV#ArfQLwYy5awUz9-L;2+^JOGksp0%~BK~6G&SP&3-(M$Y=3qsShL8d* zE2p$M7f}b2s?x1jLzf;GIEyi~yUQQF_NSNI471gL-0luDGZJWTaqXSIr;>lUPZYk{ zDvi4rdLgYCNO>7eCCEI`r(R-w80Tg!>mB!9r$1tX0%F>dn!?dEWa%U`eMo+Fy*e>q z0kc~F;f`s!Xo!EsZ?cY?fzU77D>o;8JJI5d=Ev%%94DQZa`Y?2vyLy+P3gV4hc9`6 z0r#4X=vr-dH~E!yGGTyXsZ+XKWp=9bSTKh%qk`gvY~!$?3J20Ki#zxBrs;7cYs?<& zdiXH~h}qNZko*8W;iPCt!4*Zr3rV|8Ucg5|!B&F)#Akv)UwJGG5ey!qUoc>-x(p`$ zeMi!=U;;qYD%Kr3;~!n=E*FRP#HXdUQWrzalz;v1j5FBAF@keR07URyWzR8IB@4mru&nw4JEK znxARQkgv)ijkc7Q=Tc&cSO)%_#!*N|F+z6o=We+8vXO-&pm(i$LA-^{{7Q=beEZ^b zlUey3*Ce^NH%`lDV0JpC?Jr~(dxhz0o&HAi8V#@?Fk;;w5|WNVZ|{lCIA!OA4Z$hOT10vmco?(<5npe=uy&P;_ZSKw^@0a8cJgt%WlTubrv*Z(Jfb zBKskRj%?xyzZ4%21v@M#(Xkk}ozgNuwQ&2)A3EPi8uj^?!_V@KrX zFZJDoWKMrK z#i7HiM#UGP%+j~iL;=r=Wk%8&cVt3BZm+JcPcQx+ULyw!AdqXMHy4rRi^ss*2g!Sc z3s@%T`oinR(Cg|{TeqVFa=*3yF?swl`FJ{JaD8R-8X0_X9qfBrJ-u5nUD}nOoJ`!6 z&&0Gg4FAH9=LDXm)G~oN#)C|}mmpu#C_9?Viu*tF(>ft5_)VO^)0CV}!p`x3osmMt zZ-2&&4i6qY`>SiEKtMkB!8)89m!nuaKo^}bPtH`$Kroo)lw=|x_I3Q97B4RzXFq3J z!!{dS+fD)UJhymCPzbprVFR^fpmw90d^R+EkvkQw7emh~tDDLnmm@u#atgAd4$!Op zBaI>U6@}xXU309&?8}BU-i*b$KG9BtUbts32DiATm2w9LlzN9uc|<%oCUhxXki3EW zBNs?O=hLZF%;_Sxe48~I`=xW1RUs}%m}iVnbOgH$YR5?==mo}!h22V<@gr}tQ0%;2 zz899p=c@tv+)XaIPmfN?_m2>|q+o@Xb?06$Z!ae2S>?YkapoQ=H4 z==&yBKB-Ze*AJLD@mAX#vXx&(S|snrwQ!%7Y_ALTq>*c~-g$({VpBY#u8cm4XhR{W ztdH~wCyMpB~fE@RJwO z^3!qMdNCG(n(vyhp*YK?R$Z7xsEvyj_IC9hm`P}ji}_J+qAPMb$bxQ%tk9RYX6t*- zUjxHDWfc6#q9QLob)pvn5r`T4B~$hyN;DZfeJ?=g(h(72m4K0ZDZxA{yT+>@Ob}e*S*O@L zWz^@3iC+zUSCqzL>l&4ZacV&4E%6u=VbH;#^=!$1n0u(A=mO^GP(Ml7bCA#4m)A}8~ z;7pc}PGp6w)#`q))2WnmQx%OR?b?w}@rd-V)_#su=%|S6ouoz@!sgy zO`pd#(Ka1RzRL`VbX>Po<0nzDsV%PAafZ}i$9qVeD9i*ra}9kpOKXY;U?H(olJT7ij{KsWD+bW~jyYt~ zxg7CX$t=j$pXa1~q+YkB(QF@BR?UUh6oPVyX%dk|jbpC;*TIl++5Wn#UGC}1zZ0G8 ztzyLSS^@Tg8BgnFUj32!rsKooYc@v<#?udKHE`4CX`aZ3FUz)vP3ZsD`nYr1Wl$Q9 zFgoB{ovV54yM{sQB-P57is;ymn}?JyfMZ?yxKFkfffwz^z)6cQ`>U8CiPBv#6v33L zh6W~dfp^GnvAS0(7}cX>t!upf9W3E>2&cZu$XjsnU!Fj;P!p zr0*d zId0QDjp>e~sPejs*I2qBXok{YTCen9!&n?BkkZct6O~tAE6Y$d<@hI2E?k!mk;2Qz_ZT@}n zhj~u}bqhAFu#tGz5B^*Rd2)4^a~?NDkt!c{>nS)xOd*^{)8RGyIAT*STn*1^E;UF! zhTf*bROt1chd5MZsQPmJ!J-K@Rl3_a$h#K?b}cWih$uShujK|HqqqBiq4mek`h&Ug zcQZpEPuvw#fVCz?d5yZ=dxqThh14st^*J~#f)Hb;*da=M zl}+>GPmMCpNuvYJIb908fHfY)9?vLBzCv<-eVa?J-#<4rwj&|btDY~g+cZT`)jJUr zPuDbE9Vcn%z5Y5#Q0gSi(cBcgR~o_CAVNGfEZng?U6|h$0r_^PP(aO=#W`?>vnkWx zMZxGGs9!5QAV&P^k8m$oE&+EOS&Ro9$oehGB5S{Z+n=RlEbuR&W#}x+8l4nk^J5ND z9-b&%(kA`1&$)ILD5$65pB47jn#nXHD3-;We3ldU?Rrj0mpzv-;ro?d&cM(ds&u>1*z?2oKOOl*ociQ07P1#H_)$GL zgG^K0E5Ef}5hn}!fuOrOj#nzU#A&2aFV%**HYbI?oT#$Vu=7FK@GKvOxvb?IxQH*A zo7Ly6vC(U#@|)Y%R9i;&P%}G&2`Ms*kf6OB*fC{5xvJx zS@l_sn-LFO0u8TG9<{W)bBfH4e1}EHo7J!Gu|rX#Im1Rg79mT|%n`FKzW$CV$$`nF zXHs^SP*0?PQ#q70BZ?>6tn>z!ag(4~|-eLx8 z`N6e=ARziwlxwlCLdb}{)WdHtNVzYbcR0)iOMKGT$ibp;=6xN3(SDa5U&izv6D6~H@`78*J*rKFK^jcA5TG=aNNE# zgqMrBy$=s#tD0!}D&>4^5J;#&GrO1hLPmejs0)&C*a~x=co`e~do=D5pBU2v6j)5N zxmRhcBg%CH3lbJs+b>DIl}Y;U)#emJ5tWLcW24!H|7j6reRu3HNqmIxU0&a+xi&iY z4~dty9=7BZ7>fiWxrHXbh2-zA+zl1OpgO7F3A}DC7CYu_sZ@qHLXQFV4H;AHFqGSN z>sJsZ&Jp`u1FVBN*N(b%mDv+WaY7hR_D>C!ISn%Rh9Jlnrcg=DoggR6*!4=)1-Gbe zgY6$de0l`OiQkBCS*WLorD5)Gkui=87bw1H>FdPtOZ%aZ&d!4-Gf}zO|SL>!StFBs#YHo+->6i1Coztp~KDvq_Jz6zt zGX*}Bxd&KZ>fV{?KXZyRFdZO-3IZ^@`Ic?6!9EKMzzK@a5tQ%z)p_f8ejn9l!692$ zqWp^np^rD_mJ1ysM6CUTNKRA2-c&-=p#^P1Z}F4F&-&^}Ch@=P9PyuIP6v8|4*EZe zAvuPFHrbKqL3Kl%@&L0(Nkt%A>@?VZr2j05Jzc@Ffw-AB9ehWfT8Li-dB-sfMZMha%Y1&)Tk8_Se{JiW^*MLAqvnE< zR-;E<=$?-4u7mS#ix_%k$l;TWV2ltV;Lt}>f=U=lnR&z=Ynmw1Wz=7tR!3z(o$E2^VQn819G z9HnB|l__dk@`>oY?AM}}T2sYzUj>xKdRbSYY1aUW&84A*NbF1Mgj#LRXcLJ3k@x|LetyVV>7f*z1_sUizE#s|G$(3>`2d^&9 zPt!bW9$8~z7`M;Oqo1K+VlUD9oZgL>SS(`FJ+qi=vQ_7;iHl#J@?+NT8eX`U{B<+h zD=lIw?MhZ*Mb1LwU2BOjwjh?Cv&;9lEFz5>wwL?IbjlD_DfCeGUCRjA>I!kpuFnBy zu^nuIn>TEzA;zrzwVDl60gP2cYWuDd|95giMEl< zUAqhsdV<$&qmdL_?H~aT}6>Jkegc8(MbpF|2yxoHRCaFG`nESvxk!;y4d# zMD*n;(8x1%=9oJ+q2?^hhLX$VDoyeM($zual&o}Uq%(Ki=UjRUdV|dgqJ9-d&qx;G z)|`+GWCh4mtY`9B%}LRpZp_hy`igfpkx>;~Mpz7qNHMXKu^>l*vTbP9Vs=!!QBs{s ziE({d@^p*a2kKqIiEyO7w@d4^^3s-p)T;(aB-A&4#0}IWkB;SJ_k;{!0tB)(X)L3nWO5&bA_*DDTwp zO}Vaznau0<>VfBtZM|OOR|B)?&jSz@aT3TnI;B3%N=$L3!W;h=`q9WV%4GLj|LGo> zQ#_|QQB{ORO%0Y_P5YYyykL;!j$+-EYv)DPEH0($0kcH*?cftE^_-0~});zN6-_jpuc8)cg zO@pYAC@Q2LgcA?!PIL10jExng^)SD6V=Ibk)F0?-=^n^JZls1BUv3AOrY*`-u8BKB zKk_Ksk}(ql1eL3sxdTo4@7{0IjHX*DmoqC9Qj3jN*N|E0S~&Yp+F>sJwvtf=MW6C0 zOS|yK)on_rjA@!Fv~8Bmq#0k9x3s{-xwu~iRe$naEz7tJXC65Ecay()9CJe zbwxqtMYY6dKGIxI!m&&#s68QVx)3g7UbA>>Oo>2~(C!DO0eR{HYm!uqWO6r{)que2 zva60K$zP67mow5H*ZZq#ZJmd}kf>a>`R^^Ln{6D8$H6%;)nx5T%#k0=3HQw2c)X`_ zYzj7~i#(PGEkAG21H`Uh3YQ?gm1I!sf8CyXjD-BFuZ9s3L-hYq_vZm>VT9tMpg=$4 z(n2$VBy|5(T~Sb|pQ6xztpVBtR7UHeg5rp?)Bo=b^FLS)6I5NCiT-~_v;P2wY|uz? zIW&6?=oKG36d_JR|Nr%l^?xJZe^?t%D3t^U{lBC@MM24VdK8|bZ&H+ooF0004LBHlIv03iV!0000G&sfakud=FmT>vQ&2UJ%gRpOV>D zs)9rkVDrO9@CKe(@YECUelWOVArpCN)-b(j#!$c1X{{im2F3-Q9d?0y4F8y}t(@C* zUV2upaS~!Mq3_ZVg{ekFTvKMYR&(qB5i936Fry^lh>*0p_batRm$N}S!8YxWyd`QL z4Y(PMAqQV;(WO*j1d6@amsivPbTb?xoRYts1hcL9D?eZ{gRqwDZ$ZjT-dA6;hThZVAk&B(Abw zN399n3N11Pd7)I9x-YLm00h|aL4cL5aza)$@F#sYp=^YZTnW^nbxCC05`WLV&4}`%gPX2`~z%KIW&Bmp0q3GJa$yMXqwS zt$f#SL6T=Hj)c>q_P8OQXH^3_XIB*tK@#KF*T-`)8AKwE#Cu$+(}r7;h)(uu&qnrz zF`J!<%v@n~+aDO5POS#1PDETOh;y;RUvPI~=9TfGb-5f=zC|xYzwAo0CYA4<^Hj-+S`@o=B~4Pu)|cSWL)mwsgFS zO3P$o4ek0jSPjd`Z<kv-r8*jC)2^B+#DTW}Fh>i|{!oWQ4 z`0s5_2SV~&$h7hzmEHZojD_4p_gTwyXydBcF9)Y&+oS_)!L9W@O^4`kfz>OZI(=zx zK`Z^#3Zt6JV`o8<4+@OygVG}@ZJg1~-Y>xqbv98e(Wys7OxDMK?fLIE7wU7KYKBPM z;{2&dqGV`GFnjMMk%cb}o;oY~TgCp(HJ?|g{ow4<0x-#zRkVAabpHI|C<3(`YrI1Y zcmvx}VWV*2=G$zz9tWL3y6m5syh zKvVpaV{LTAXurH`X<7-WPtw>Z#6(_4c{!K!JztcUB8HOmHQ&bE0Zb{-h^AwAwq$U~ zU}&}TO^uu+-ziYutZ%s|n*SfLykdsIE_{Xci5Y%upG+0O55cMZq!ZbEJk{V-qCVqw zr0H)HxEUGpW*$x{+;3hLn030Utyr-fRW+O*;ej4EKP8RjFN0HJv1QOx7*c@9jKWsh zdJ3B!0PPM}Si>R?t$fDpf%ETSN`g3^K9K9AM3Z^AD}ki2CP(r^KO^u07JST4Ktd>1 zyYRyc+UNx-fJf8z&ZJ%0un2;{W5|^UXUJAlNNSn3C~Q`i_~G!NRGe*`{V*NyFEbsm z%hCN3dnQSbl^(Z8>XM!l)Hn1~P;Mjk2mbv7&}y?f{($zD%lH4!FtGmiby`kj-2O51 z8Pw*y{0(^6&r6kRQlU?ZdExnFE{EKiw6CR1FX#wT`A(EE#X#Q`mLQ5?u+$FzA1Dkv z^@2Em^Pf5}PBU{w2m7)MO{``H^mFn|Z7CoBEfNFsaqyyW>BfGd*x{lteJiXWKJ)zR z^tYc8y~ubgum1&QgZ;(0Y4-PkUv2~9c+8$i)XBMO~0|On`ona`gU& zu`7+{;nNvML9(*Oo{%y{+6bxg^Tv~7VghXjiyyATzMRiD%TK*VK43Jq(aL&%o2iet z&OZb!n8~_iJ9C@7?_|juh$+b^V8TMq^3{;96Jf}ZdNZ*#J^UPq@9H|2R^*_02+PC8 zUibjf(Hd=5X1QBp>Vl9Mvtw!lw8u}^s?MN1w==6wt9TI=9^}adz;(a4Lc@n-B3u}z zC5bWPc~7N z%xV}yKI5Lx6his#^Zpa25|PwL58DUK767D*jMqNWLAJP!4+_@tFsWOoT6>OOjc?X(SQTbK{l& zh=0H`td4XTnHnLZ6WmFrt@jr?W};-W#Ad!m7W>Sxe4*OH#F!5M^!@|ukt_GTD}5p# zcX-0czWR_O*4#+Q%y9{bdO;}LRov(6YtOKKiaySWHoo1$QFO8CKUk4L`|zv{Wt+bL*@qmnZj#bI>?np$dG z_y8dvsTVH%4+%S(7*ubs=dn0E7#zU`Xby<_GCHo5P+`u>(HzzAVfRQDLh{dqKuqMQ z1S=%I?g03M)t^8rdUC+U{3Hj?W0w6+GT*q=o@#fw9VYX~_k0f@Dg{ln9jcqlZU^1d zH_^EZ`y}c0Vll~Vjz6Ux2yblhcR)h9F0z8^Qi;Ua1^Os{dRwMooF~AYB6^5%XgAN_ z>B_$9zl85~$wZm!Jba{|htd$PC+v1z*uX_}>L-v`T61-15RsX0>|s@p7n1N7rYk|4 zSOvkoYs|my5IHZG;D8eJIy;Xl04OV}pR3b9O>kO&2cSNH{z1kH-^qnL2XVvc@EExW zNCrFpOCDx;HIbYAqwd?5>iVc#o+>#+i&-MLG)iAW6LctkAUIF6_dAo^U;e8mkaJ(} zJ|=v(lBt`coGpUtP@-EpCnIM+5i1!mTugSWkgU|SWX#Un(Pw4PiXc8@<5sZ9l?~ov z$N#Zp2eh-*dq5dkPmAg0(<9_FDpwCVqGQK7!r>^&7trR2%Jn7F501BOe)>jldZ-}( z#x+iKbIZDQSTKbYfrBQ=0XKl|8T4_0HLV@HxGnwIJ*CmjbSRSSsd`JxaRpl!ihbia z5uy}{U#Op-G)!#X$V~n?NU@1>Abx_!iAR#*7PNIw% zB$hyOGK_k>pY|K7SGTj~()7-6Y;WZXRhtk&M1o@frJ4Y&d{Y&}XTofK^{!pc=y^9@ z3SQuRCHS_Yz2A{$zPszG3pzyysOvOn`~Qk5R2mmQwsr0-h!{+rBR-)7O!TnMZ}^pc z$m8d5p61lT3?vW^>Gr|`4*GfKsg|vh?GPTVq2i`er>#fabL5f~O_?R#%g%Iaap)RJ zZCi4$TJB_oL^Y){VN@$_0~s`@Hm?X2H|>pQA!;G`Tj=HIq8JmS4zOZqp1%b2DF!v* zx*H1@Ed=~c;d9vaeV6hjEMXgGh zp((IzxA@X*K;-W?5d9x1@$6zWGS4*daj z|0+K@=k1Qy-P6B{1FgtG6vW%2&mgX>92&``dDl^aFPZ-OFkkudF9m9^>vJ#xkf`(( zU37j8+Gr}h-}s)6X%56hL5S2x!aR~VeVE<8%dNw;jCCaL^|qtzE2&MAbT-<}L{4k< z46h`{9-NZ;gKmZeopPX#DGy2V!fB|@G>D3ZWv3hW(=*3{C}8aR>1~vn>#h!YK}1wM z1WB$1Agyj1UWNn6r5J9)n`@%HJ)knpoaE|lalgeWJ>E;B>eyM*CNteUOMnPt;G;q_ z2)?f_#<-xp$Ka<$-_u=F+NZ8mew4kt$sq7dotgHKsQJ_Q;g8Z*Ea1~Ub7LPosGQSZ z$~9IiZpgcxHQBtUH0$z{DEDpnfRf2GcNe%;t25K{&a4J<{XFhlu=kFB-S=s1C#?37 znjX@K_=rqZH&>=zE!Jakne`>cD-KSY(a8!r8c|J;#yBi@E={XtNbU}MiG(U8O88wb zb*&!c7x^DaBq0YMeKlEqrn}}Vp0aNf)uP!YkzAvc`>pMMzXnJe=cDukw{rHM|J2C} z`~7^14$*Cp*kroEYo3W6Yv-oT9OIaVca{>P4ydI8K>m&B@c3N*-PXkUc#Lkwb!pwQ zXIbtL*JGg90(x2-1zMTAf5}L6zxdrF5z97;mz<;pD#xT5Rr8;71mxKlV=$WnK9W0Y z1px`G>OVy}m?!*2EOyV^c}(RKYgK8O(*HE5+ooz!Jg?X;e8Ot~s5bB^TN_)cMnE*a znqgMF%FgGc!iSo*7$hy^G`5-50a#0mvP>6xbyA$<011i`#8zQ zYN%izr8U>xBakns5@i!~gN=WqT>xuvL&K?=r{^|Je||4MtVpwq#fJ}bv4fkk=`g7d zCI6{V(Tmd%`Nw-O^L*vR(PIKho|h`aUhw=w)`z12HFcOqd(@V@GzThaj>+XO5?wSy zveB#g7TJ?F7*Cv%5`-P7re)9;!FU|dc=A-g8Fbp8jP$31jFi|0#>O82-N;jEz*FmIs^Jl?juOGuwbM{?RAkv{OcR9stBSRh`Eh5G?d0iKVb_vc z)Vf!K1fXs?1_P@at^)nN^EKv7f}K7YL2zHD9_fA1@Z`cAfl9{QD*12O#|sC~r_V1v zI5JcXVKS&00aDW*f72B%g_w`n0;#j_v4p?roO|{%DJkzI@`Tcr{p{NWca2er5}5a;#RC4jqXeOg(vm@(WX3C1SX!daAnt zeVQv^_C3c9BqqxTYQf+WIwp}_ag1(N!&n=#)@dI5Y3@f~Ohsb5QwBOKB0ity-f#6O zKb&7eF^WX<01&$Ybn0oZ&ujPvp)^hDI%7VsItZjcF7eiL!g2pxmM(@-5v{T2y<`Ge zRm?{Pv-xTa2jK;H9Ov*Qep|X#Ihq>X61INzP&>_de3k(WWP)DgBfl>JBnICHfZEAA zSgw_$7g?`RL`j)w?Qc6#A9G~cxlJ*Nf)Da?VY--A9M)4quNyYjNmtBzP(~)0D=1H7 zYxB9bCKRHRHKLaF9F1SNxcUeSLwvARO(* zT9f(QaYeF54r{k1QU*j?gZ#@-=7P4;u7?GuJ9DBFI7F#19vuCNLhCHoa=LHkt$S2< z6TL6v2)im_-o*00)Vp!@6jFitB7+ib`lK$D--o!hy<>$+~zps_OK@?X{lWfpQO8`n3bjE0r2(0Ob+U3dbg}= zkn51Q2jIh)-Xjhjkb?Ogi_7SPxo_|8(b9kIQ?|VR1!IkT@hrIokLx(G>^*@sTmcF0 zrm>gOV?wQ6v7CMwSZjctpR8!5)zCnk%}QE8u_PQi-Dg1Cty-(fqps6BDv}l>cT2}^ z!`4;qnAJ0czODJD=$$6Fd^Y3TIq^%6M{gFm$iz;-KNy^S`9#1t3_JA&M4Ic;MbFT( zfh+O2g)FJUmY37Zb}Wra=uusX0y#qU!>ayak5QaI4&zpu1@wedbj2;Ke2C*&+qmOM zIr)g^nhk;h0BzD!VSuML)XrpdM)F7e#zSWeT%?pD2x|54b9jZh(?_QZ`s~3K+K(v> zy`F7E?!MZB1kwIPSXuWewvAoSeUA^i%v&fHwxuTy^h^J6BY7dD9c?7$x zD~svp5-RO{hjgR=(nRJMO%Ohv-Zd9yZ<7|51qK^Eezqbu5}hkxVQcn1$SusM$<-QO8Koj*ycv({ zlwS!Ic5*`xPwGw}ZiRgpxnxIr>29|7mDoa!k9kz}m~JfqRxcjk-9>BdaL-V{mUTE7 zdLN#q$_6g-WR=q?goRA5hDvV{DiYjWf}91PQ1DauoL=B?^8=J#kROwz!u=KfH2Ab8 zt0V_~$565Qk9TlBCQ;w4K|%|dYkys}6x4tZzFeJ)O_Kx4zDD#{)HF4 ztx3{ujIm-lUon|3Qs_pn)V#qEY6dc@5Hir0jmqgn1JP!V^~IFF5VtRml%Dsso9fd=l7vG4Z`n=MIz?`>-2#3o-05 z7iGFHR;!n*J(|>cj*}9j{C{XgrtV=qv9*|uMZynjpWg>5$6ukz0{b`8V7K*voFFdn z$?B5rDa&=J%fHvrYKM93z;wBc9Ll*_H|yb$iyYKxv-|%*;NW-Eif4KUV#<;L@mpX( z`b{P@48uXc*P%JI-T1txxP`+vbwO>*#6Xl5GtVVf8RKrO6WYkI7_GFn$Zvmf8Q9V4 zrcWdQf_s+Lz$L5Jva7fil$a0WJz7>kR;g8Go0a8kRxsX&u?FO77OHo*w4)RuTbl5i zyPLgVGt!N!My_dFt0Mw_K)8k&=^fP&8H>rm$V|2^}^?)dP`>c--vzgF=?Ri-KW zkr26vci%@_Uazp&on#G9ni$8gz<*uY8u(PY_m)OqvmaJhD7-{RcE^Xsf>y@*!VKG5 zigN&ncDRAyWVseX(tJ%oVUAS_+{X`9JJ|dpvv97I*DkDP)Bg9k*qtq9T&*1RBTXx4 z6!b_F^4XQ@&8KIIlkdM%4@NaM%$J`3kW60b!tQzxiHCM&9&C+slekb~R}sg$07sKr zbj2WqJ~TGa%JDMZsb|r~Xm<3WWB-c&1eO;$NlK(RH_bUNHty^*uhzV*W$0{5@FXx; zt@igl$RsA3DF^@yu^)ajDS4(=13+7L_!l1cXfaUB;xbd*>{2eReIzDJQ_noV&IWIi zmWrlg+RpnkMc)5Mf8Ny{Fr;84hf0fJ1xA_zDVTm)(D!LL^ z${>s?lY&q2fc2rauZQ_V?{x6J3u(&T_p3KK8kFn+)ee)z`)qh{j6P@hX!?^kh~(VI z$$F}uZ8+ef2ZtB;vRU>5z4!z#2>-VvlH_-^7xH$YSp0Dja=va=dklJMkVpC&u-Euz zSgOEC44s&R>%ws>1veAIW8+M;+L`Iuh=h|agOY?j?2>Ga_=469xGxuD!#c$HCGb+f zsW1kkv-hLWpTvSv3B9|{nYweuGVuwDTLwFU4^Aa=dJem(3lGGQcB4d~W7$$r78^)_ zb~J6c>$?Pj8K^3DVQ)^uQzA&$Pcq8m^?PflRaEoqnbx=+(jj6bxL=sqpK-%0uzEp2 z6~y7BCt_7;3rDnGy!)5@HASEWyj3fPwU(+tap0H|OLgJ^boo}`G3roCUuU}p(t3va zle}2_=q*O0c)@`s<^LaA>QRt*7#;?C@OYv~w0t8En0P?>Llm0w}P8 z<|XIgN}6{f_x8kB`&H2&RYHb`b4Va|q)Fl18tx!4fmdTKu3vy^T6+w#;;#1#7<3fFsiboQO1M5oso*7Gh2@BX`ZvXPPPr9+6Awr@U=+M%`ca*qgGBrL+o7+XY0^Ax;@}aGtu=)t zOeM5Vpto~Iy$)!gw&T2AV5TGA8UuMQ64((^#R(d!M|=pArV^*+ zOt=L5bvjpJsBpFW##wRVaV2!gODo0SwQ}oX%ZN}I^f)eYy`kzlP$s1T)Iq)z1L)+- z=hB?`WU2zJ-RTgAoKo6|>UT8JWwi{>HCIf*7|fbog`{G<6@OTHO*eawYfTrP@6Uo< zsq&&-KP8^ocCKq9&T<(&ViKRz9RKtLf3RvqcV2bo0%i`(D#_9do>)iwlhZPNodi$~ zq62Ni4v8JZD)3IUi;m{{0&DnL{cfB)TKjWNJt0%BHEt-~{P>azd$S}X4vAlgN8g2+ z%P%vfXfQ1c7JHsDJBh%ysn&V)!>h?2ItGod?<^#(o9Vt0CCUt9izy8MXtheC_avSqitmw$;-*{7XnFVNyV47$Mx( znAZ8y)}flP+(>0h&ND~%33vfjt<+G4$;}ts*;PNN?Y=?zp8qakmPY-RuFM`7voOiY=7 zqUGO3_+;$5Jke8(k;lvSS3@FN(3|393SU%{BJGDpsw#<{+vNY-~PHfoV#W6o) zzsHi0sT6&A`VvE_EJ3@iq48Dz?p;QxA$mX44-LUG^7f%H;!n!je~&6#Iy#wd^%1;X zr>~&#nDtB3d>L79!Wd%wzVn;Rai_koV!nJe+)>f$Aa1gb0zrGcD3hAr<}uuao{DQH zC!VhR(27h*+S6D+Gmou=$?%9{kz|^({mzP79{80)CsYc{B%1aq0yu)1I};T5v#Uba zcRKu|OoCn603QlQ`@Lu3jG!?(E z<)+t$kttW#%T(^UXGd&tqr#&nv3X1{TdoUB!ReI*@P8}7PMo6t~vp$+O9G-^I^nx~|;7&u+ZsA^Og z(l$cQ2JnNVh{*EUPSNT}xK$xhyUbaa8fT%g9j@Uz_1&ZzZh_{8I$^i~v}bY{&7U!d&oq{(PiTW@R-e z(dc>uN3RPCbxEWu^~`s^X-SDb=P30!d3=3qJ2QB@R!QgU!Tsb2)OHAgYOnF=E~SxP zVM2Om0~}_kl19eQZf3#bfwXZ)haa{XA=M%vn;uOH7CO(YBS?sRKN^FG6O=Lohb`I3 zdI0#8yI*?87gIdrzu&|Xv5h)5q$_w(TQ^DDTZnOG@yMFGH%s^jng-H8bXZBjNW&I zy^&c;g(->6LUbwr@d6e2L1=GD26e(n_%EQb;;L>+y;s_mMZf=uE=524UfXhFd>if? z=}*bUJe%q`x$$)0^d7Q zeYnA`YxYAeGH$sq;1@Ii5s)~bBY43*fM}@= zU_r*p|C%hEaDkwMQGe6^GPz2qV&H&m^|s!guW%BXUAm&j0fZb=#H%ps-?G(;dd_og zK%??^B1=bfiVWeU*VDXx!{4+tTgkm*6PFwMT$*FHQ+Pc*W5*;q82*ntU*EY1>)#0B zeS%h_0Uq^1JWMJ0!xE8klTb)JfM(2o#H4-(3yAif?+q$hmnP`0sR9u7! zc4{1#jOO;Rw(b*V{+-_cHWVO2jYMvDC_VK~1gJ1A9dV8XcV~=QcAVB2gb`cs4&e%5E@dn~?Hi^20Jwzb}c>kpcbpjOnEff02hCCQDP0 zRGN7z-BtJv30rT~1o2%nNN-UK-!NZh&H1K3F{@LGf{l2j#81Xqj^yh%L;yK#r|XWK zTZC!zZDh>CqFqDR&MRBBc`m4ckfo7LE;-{1Jix*UegLI`^9?2xjJr}qwMiKg0dp-w z+g9Xsrs#UP-4!850>F>`+Vsi;J$J-k^F2(y8V%p-dO(7l;wveDC3*3uLT}q51y`fl zL}hj{sBlGbD$E2}{CP`cX(yePh!g8;jD{z5*7JIcBLoAvct*k|`MW8nn1Nw%^z`ko zCCbj`hWVSaLdI_iG(gIPk-c3_-)7O3wU9z826?0Z=YobgxXX$La>%YQ*bI#5>LL9e zO;~M3p-dy?Y`+)m81xKi3Kfa}T6os?{y$cP%M^h^q4KK)J-BeImC_ir!Q|TqIbd4< zt>AJRR9Sx36m1ga0cPhV;eoYp|0vRU9#c9t zpj+~bJI4Ynk%^{nM1V;%#tMP#hnUwXTq;t3hhoTtWTyF4&>>lC!M0^S*wH`QPpwet zd`B`=|Nj7S69w&dZT#BfWu+SGyU4O5 zK6Lq*PbJ2#*N%y*31_QHK85dbx98RG)|;QPX5Ca)*S^pJZW3^CfD`?2sZx>CYvMRwqv6i_Zom)oDx)?isb6r2sxm}$ql1DsbSFA+D z7%<;zRZ>vl0OTtix&s1dw~B;I2k^|=TkU;e#@j$DE!;GI_d#D2Db6iPZTVvnfih&@ z;rdJk>Mp2Ukqgp>f!Dj4pBd<%9|VM!y}DnU;>;^^)x_qM&};$p<-!eR1FxEHtfKOt zF`u`(O}p>ps6N-Wiwm_EO%WiV0s5y)o}_VZ;$1_wa|JCu_P2q@Ey&{4=%8=ug7Sei$N2u8m?t2QRH~jw zY`+!ZXBaly!E$4EPUi=PgtGw>8Hb>B$I~_MHG?q8?9}-7;mILS!ccG2144lb<9|4%H7GHi)JWNbhB#D;kPIA*V(}z-tQR+ zUay0H>ec`pW7Dt~lCWn}xH<#Z0Gx*#|K)6i(9bEL&6UXgN(qe<$6V0R30039sQ@$y(?Koc1SqVpL z$5t_ak(|nVoJr zsNg^4GR)naoi;ADEk5c}S7?ev$F4Y!_*Acdxp5j9=aE?yK`rr(5E1M3NaH$Br62Vn zZ#PF?MSQFBSD?VUc&ycnO(@!RGl}j?DNQ?Q!pWDtxNiBH?7k#*R3gvTpQjoBm9~}b z5=D;yOZ;|hmDcAZVW4a5N2De0YBnwf9cT5DE{ZHDRkM20U(~n>T7yGtpP#v@Ctk!bqqe|?QtH?N ze}Kg>0no}Ru={0@%NJt7=hJGe%Zr>AG+#ES*~o1g1T*n^NSW|&F5w|f(`4lKC9nP? zQVWffFNhFYDmp7H8K*g44b{zo%GSYg-9D08$Njb~Xx#8fAfF^bPQwaeZ!*U?3g*TJ zDARVS&j~v#^eL4)fo3fvlkPRQ$SlFdiX8!Gy<&jxj=OdTz?HsBCyz}$b7=tO_RkW< ztV+BQ$jQw^b5%r_hyXk>$!!Z$M0;_Ej=H7)nq%O*gM_HNz2f6tTUL;i22@psA;GT^ z+YQ_Fel-c-)gX45qkQ{sd(4%?XK;#~%S4o{Kds;go;e8*{QrPm24`_W zC7+NDO#vSdU%l)P*1k@VnfrKC!A%T}@pD*Yh|)!;{MsLsi*9z~ zYjeHdWBc#BKVN|}rYk0>&-P}lJd3)PW(dWOw=Wg9b+s16btG)GPrL%{!T6g36^nR& z{aZ&3$O*U1gtwo*E0tUoM^GPWkb}~v_pf}T7It;g{WYqR$qj=z0$djp?bBtD>yktCQWO(> zDh>_lA~%DF2~N)mZ~>i@oThBT2tQ?|GmW zd>t*hbr)h)OrVqgi6qETOR(?RZ`fy28*@>DVLS(+;-)}TR4B6rxBTwAC8UQ1S?OaC z(dKBYn6{PY+;;p2hme*&60diov>&5f3_^1dAH&=lD)a|l^w~M!79}VTe3niR?JaYk zt%WPriNAaP9JcDEDJF07;{$5n?6c6EG%Rcn7QHkXB7H{_>K4EBHsF^#{Hn*Xva~d1 zmPOUynk*0%9X{=zRQ(eBsy3eFP41rNw1A!CXo;x^x~r}4SjQw@2BDkkS_N78#Z6ag zRj@&z7WwSwkwfMInPJAcd7-gPO*w$Gs| z8?%GPCtt}MIWvYb3PauY7sPn?9d(-5aL_C|oKU=7SUwl0pWYhH+n=yj%=|k$1KA=g zN*^)W<8B!2`#$fvzfdH8%aYKLChG_0%Jwju}A63lPwIwV^O77=C=#7X~yy ztg8A_>@=(A1kM5|La${5E*b401CTiN0A?=7HwVe9?#oVj=&KSuvFrVsHiuFkImO;` zo*Shd?~|wZH(tZR;>T}0#Q9{B!#QL2*YYWfScc82i~YVvX}6ZF#0u(hTjXm@QCNaY zlJKLLC?;rzB<9fHM!GP-I>RwG_xL6x&=`)hR`4+K_og(eCW0yalj3SQd_ha(`DtGn zs)6uWe16jHl(Z-#RqW{;9MC@&wt&YrQT|1M1||nX2K^P*=2EG`x)*8w+6h*k)nIx z^armX%Pj^c)s2dTH1eRN>Ib(^gTxJ6LVBJi*7sYegZRy$lbLs}0CTFlWsuI1guLiv)ntmO)lOb8bzmXnWHH)~Gn zfzCcZjb>Uf&G@K%>pNO*Q0uT#^M0zdsQ{1D-UX1=0ll`P^BD~|R}j;18}q8!(DUi% zw1~m)n8K{B+ElO2+L$NV_mEhG+0sg`MVcRxD{ynW)(FUwEvK5IDBDM0;O>qLwRTWi z01AAUTFHM%Y{S{`zqK$k*P)}|;({O1h=Vuc3)po8M=BYTHAGM+{0k~%eLPR} zJSu9Pq7|v)7RFakaa+PBg>n<<)acK_Y{(>$EJ^Ap&2q^%f1>Ar^X5CI$RJ813a5e2KgiR z3a8|oaZjz;B8rCIooVFh7QeB3dR`28KZsg}wd?DAQ0_3}gM~HrY<%^{fMzm~Ru&F| zPwYoRoU4ohgdfp0&`l_DUO_RuPUyQ8fSRrT5XBe?xak)gKnYDA6W8)b%ev`muKYMP zHT9ug>DJL*qZACq{of;!=V%~{*V`5HB-X&rGft(MwU?PG1jQdfnbBp{R{DNjN(6yK zz5iWCj*Y5wWUS=3MC|036xMxm!MPf?|Hwv)3U+$oLtso~HLd2X*n!Da6HGc~9`qhd zLi`iV?laXXIGu}&6bX-5Yirl|8#H>Z0^EiDv?1cWty-WxZLO{j)@Z9j@7dd576eGI zM@gbP)y0TcZ!^WrQXo(qT6W*nJ(qh=v1=#{XG`5-DE2nCnc$lUuIzp(Qtaka z?1u2koJeS=AHaCUnJ59eJbylsqq|xcH?p}_Z~A3x@!rY?KZUO+CY`m;##XX{)TDuJ z0^{~%O>Y(VdhkGA)X%icwVL<4xe@Sc*AHVXe36;Y&n%SxA$LmvJbmlOLda$Vm=~Iy zJygFwHXiOJ1HCiP9x<4y4CWU|z0i}iE(%Lx=O2Y!CJA1R#*S+~B}ABS{3@I}qfhRB zZ3C>>i>a(IMNq_pWKWRbH(?>Vr%K_A38AYt0#a0Q>T~(#s@DC|Zps zmvidGxp$kf1stQx`Oq3$QD_Zkk6qSdES; z>w%c}kL%1r`l!n#?;K4iLxo8eR|Msi#*ih~a-u7$K=}5fhPOZc*7wP-NN07etu$L% z=7&e;h!H*I%9~J-bad7(7lKf7Is;urNFqv~4ZfN*sFUw?Za#&MZW1aFqiXh{8heK= z`A}cnc#FC$fFCFQ$3CqN0&6cYyjr#P>^b<+X;?VW_mSCrwE2HjF&h-ddCvPb^G8Ye?iD}9*G~R;xesZb`Mi6*LvFGuV zEQ#-X?HyD0KDGs-5yt}gZ>g(5>PGgaO3-d_RJ((zEH2mdY%@H%hdbbI$Sh19AcH+@ zhXf7AVj0ZyWoRoJBM#N|ZwIFMKFcNTV~@_%)GL{dLbUkju1A(TSF|q?|5RnVun*G( zgj~wkP$x957P-T9>sYzc*Z(STcaLl=32TRnOQy$*;G`3grTBV_s0z0#X`%g@w6r?v zYZ7n{@19IGSyikjahUekQWZ4dP)m}OPNg!%<YL8US@0W(Oo!BksD`7>$a`xgKP-k+g5e};P%`xH3dDiWlaAJz@a4`L{b@UJ{VZ|)d6rbt#&T9#!aZ!1h5* z&6J}U8mAyFxc%Fv6?rW~K4hguEr9L}p#dJqRq{DxZCX02lG*H5D~b(=<(h~H+Hd3JgCZ~b9aIW6wG913d{%voQl&Ui7q zrUjmVai#>+x9eP;M7}xEx7d26a63;F)N)p^$=xcpvV?$^R6y&uWLwunhKm?Kq|Vo? zEx0|xioga{V$d^aS-k1xiU6z(O!*9D0S-tb03Sf$zhbp>i5aqlYB&Jz28YY21pQ+Q zuUw$)qbGmO!2WlPMS(Z&t9#52ig((hOk&Xt3FPqt(lY$vfirBNsU(6V`=>Omasp+M zh44zyGfVm%VPUfhn8nG;q{yP6Q3QBYkp9^klcLgLlW`N#mJqkX(%YcjW|#*4G#7Ck z0bNXp9`i+EXLkwec!}Pb&u3z3ftg8*&hx-ZiRVup@EXej()!i`EHND}WXq#zyXF0NJ|6O%7k$UCsqcK2sCwj^aolUV~?juf|taatC3 zcf!S^`ZhI$avU4-j_aO!{=UhQ(HmgmGnCoH#F<|k?{*eOf*uBlQ&yKjoWsoO-QkVy zIyJJ?kUK|2`-||=bqB&~8Fw~X;06XlSs90vKx4O)6@>Y_#P=cMQjougyQwf8&b73# zv1iLGIB2;>TmXZ*7F;Y%|7+bF@w^&hJh*j|*ZY`GI%~oMk=JYUOAqG{7+kUfp9YF5 zkH}u*tVhwHfn)6`f%;6S8CACBRRyzMqyNBu`wbcZrc#_8AQrpH_h6yR#PT`v4iK~Y1$w;Oxsd+Ar*c{xMjU_cGb}!+ z;n&wt2T98OdhypS!{55rT~>)c-|oo+og*c!1PSwf%K;>j!N`n#l_cV#hrlN_mk==7 zcy}5@2xPcEY~wEK5sd~%({5w9aOlcnRIX=tBNj1lk5u|7#a7w?HZ3c?KJ5FCmD%Sl zv-EF;5_-;DL~d0f@+t?d_Sv==!o#^O%hmrknY+7D;bwG-+d8?$M{O7plQ zdC2GVd=75{8s0P0bXNB@OP(2kf9`J6_REjDHhQ@9x}ONmC*7~`^v5>wal0&+G^+Mz z9l#wL2-mM7Ha`yuxlJZ#XA(_j7<*wE$x7+2bHHQ9t3B;yw(J2lQzG&;b*PQUNLh|uKP_!&IKzR&*S?QpHLuLr$5M$1Fo!W76=Y)> zb_(#vEvHfIb{<{f`9ai9_S{VZBK+v?OeuZ~&#Zffd%fun9{ZfpT?zmgd}RMx!GaN> zvP}`uw&-De_#WE=e;&^c0Ou>-RypXoC1o^@r;Bg*v#X4RViqJ@)yAi!7Wsr49bbq) zO+o`1#e>-n|7zvh3BoZd<@G)Uri`T_4}k|Yu9}s{b5`_dTM&4eJ%G-K*DZHxw0%_* zRxrXn8kdv9(J@E_NXen9hia_Wm0rr{kNt?M@;0hg$5!g}lkMhjw^)X*L8OrXFc#}P zith4OEnRlaASW=fb&F~Wxevo~nV@xIv=}Sc8K0(xvUnKmNM9!E8$M-$G%TNG0;=oh zpn$Gfu>7W4X%Rrnu`lmqs+~z~T11-*9Mj7?9h1TqjgVosbK6np+DqYWc+;Dx8F&5Y zI^+`0=7Ukbp`yD6df-0d_wJ|5fY19!Ry{Cke1>KhA2Si?qiH6Rl2rT&q+tn^HXGb=*vii`KNXJ zVv8qcX#j*$`aT^SrT}UTn~kC1JoD#P`(1x&qs8!K9&VtM2+1{PU4S^^JF_VE*1tnJ zi-gYl9^A7Og->E*$m5h(!k8%Vc_DuLim-vB* zAcEc<{JVH%ZxUzOnwIb9^zU{gp5SONwBO^H1CDv}H4WdiM5h;um0mfBC2^1zZt!+L z1+!u&CSdtz>PwYDL89Y|Yl@^#`$89hZDHjK(wk6GWrxZ{C)e5U46Dv(-8H`pk<2<$abweYCTlZ6|GWrmc$uNdx0G!CSU(fI-#Dz2KMbg>!Xl#&Mg(v8TlJxZ- z<>&2IE?`aN9*|xvxkuQ9eieT9C7I`<1{cC$fMTIJG}t{oB!x(;jNCDk`)IUK&hXuL z=z9P{&GDlRn?}PjIaL@K13#XS-MHLU5Wr{lfOtrvVN^vHj2U&cV=0E0H#?)we4Z6_ zP$Dcx_5-in)Rg*iR^9dKr%VSuLFe;M!sYznPe*bYeQ9jbG3VNvyI$x`INlR0ve z36#A*cB!%52!1(RrXHC1d#iCC9N`9l!^07R%Z;H4PYgG+{`#34n`4@jT3Mzo{M^E2 z-P2Z7n3*HM9JeGIZ4t%f1erUt8GIXDHGWzy;@R{vVu3fH$!5I19t3*ZVOd+`V zXdWQy5+y0;dI(xStEjpt2n9@w^95!a^COAgkrAXoPUyz_8HDd_PA0g{NNih7!)K|E z-{J;wP?-V>>I&{{RH_HdBmD~gv>yF`BC669>u+10gr31y2@`XT9MuD0aIr^bf~O3| z=I~vcMJ^^mPe4Erqe#fkujo|FV+)pX8vmU%d9}M+OAM1H;Ge1Lfuu#m0ngQ=k>AIDO$j6gC!Q5lq)rxuZ3N-swy79h;*-g-Q6-KGZa zWC=;`8|QnYEQWBKw@jzlVi`8l@~&5m*pYeW_Jh( zAkc12IX3aSO6X}R70SB-#H#Oanwe>f1ttQ2Z>EZbu-BX1m``9MRF+3d5&`AZ120?n z)Y-AeQHZxSBjQ#A&8BRi3^Lpl7q`K}7-T+u@2%u{T#kUoYyPmg4fI8>>nu*kF=CCkPEc<( zQ@lf?DhMM#*~7QosH~LMhd%Ez$~}_MnX};pN}vGrTYNt3uFJlQkJHSt3btMCFKkG$PV}M z9(XqAu+_-H<0QJ3oL^iSo#rxvC*HWPtX>bmLcihDHO4A=g$x?1?VST&n?nZp_SSZB04}wr!^%Q`~ zrGT7H|2I!dIeag+puKtFYXM?|)jB2=%)rCqAczi%kJdkBIt61!sLq1IKylko@gA*B zn@7{g$e>14dMYf3RVqArXrJw(+B3_zzhpU4ujBtzEjTD3;C0wV(9rre{P}vxhVD z+qe}aj$ec^x1I0aV?@Ro+0k-Y_2YDS|BdarV`Y{vG_%`h)1du^zr>mT_ z{=XTV@lBQWL%yc)QU3IOl%CByrPkcd{1JTem7)j?C{> z>cbk+ptzcFZxnK1CxloEH-1}u0PWe+-o>jWC;GLlcA)9Hazz zV2va7A&`9U(>I8zoy#f`Z&l^UhYMU~FKe@_qKCTDn2;lm6k->cZ@s!FPp<>Ys6>N1 zDnGw79!vFP)o?2oA8N*3bgG+dt9CVJY~x;g)^5cq>(2`666UC1MD}750zH7s-?WFD zI!Y0z*6$LjDY0%A6aqunyh-+xR2dLtf%%rqJmV>Us@#prD=Q}s8YB>h1{bsesw#=D zZneGM0WzA?Ii44D;CQ><#zs5;(V8R9<&ytHuozjG-EI33mG5#8b0!Fa8HxE|VHlW= zzb2feAx$W+Qmn`jiTLf7>q>2Ocsq8j0Vn>K%d0e4z5DtX?^gmA<8B(nQw=u*0SqzT z(rS{S)%`q?CWJ1rCz$81uH{eOY5$kq*sC3V88V9rWBkrVWNk=Q5n7Nd$jwz_AocjqEq`q+aiaEhib3D;eaU+#qgetX-7YSUr4P=FXAU&>JmBo_Zo2cL$P59 zeyrxo?Dmr!hgeD=9wAwxp=~Md9;|AG9jXOlup+lmF^hMnGN0KQV;)gJx2}HAVkR74 zN>Mm)-TjwIhu$L+*oUCJYoE7+YuvAjo0C9?^Y4~qRo09=B>t}48=uIKkR*`Ixg0qt zuItR%6an`BY8mdFAjR&3PN~1izy!(A{(>V%Y(K`zzf?^5^P@}mb?n-8 zu9xS|bGzbT5DN8x@>&Md?4O)gx}gpTY4v$D#&)c)T2jW+X!~s#f{o#OH^~SeS#lW) zC;mB2_<9^jkVM#bLf@=pu-lB46a}*jj?2SP6qbf7wwgEle#*WXbA^piYs7OK0)onB zGl*I&-V!^!MHH~i)bl(82}0wQ!t)z5zsGC)uDRl->5hZQ9Z{I#PtX*j1y;i^Mu9;P zwl>Y+!YXZp-)_YB(fV3KIo=$b#?BL6Hoc!xKvDM{zc)e@7rAX&_paNjEx!9ji9-Yb zvxW$)T?3tJ(rXayso5D&FG#vtY>kYO zKbA%CBxeyC|Nf{4(v%x7wK3v|bx4>?`ye=kyO^16`Oo++h={VTcF*m*f&22r%^9B1u3CLaK^mXKgYK@tdKR!X(Ke8xH^wB;FYA*xAMiz+Pma%N3qGV5$w>5@Z>H zKg`bsnmD3P5+NlAlL9$QiAZShzgC5w!KWs?+^bIz%n*PJ-Ov?L#2UEta6V(u%ICdS)3mq;v=|j3y-C;6Sz(THub%(IM zFQ5E5<$doSMWjUUpeYa+41GS~_Q!_?Wy5$!4D~xts!MdzetLd@E84bm@2}Dbi?lZK zV}V&k61Pq|MO-ww3RduTAiS%URKbkV;rcO?<~`Tj7=hGfy|@$l;4(hOr1v2Fwj^kY za%uRTDfPO2>y|G;Oi3WwnKeZuCR{X~rH8zqDd=28WNF#y&i>lBjPePu5E(TnI2p)g zruU4p1Ghor@SL;SMgGj)aL8gP14!k-gs7)6pP8S-ghH?$)4f4=+hd$OXY^OPymj2O z-6@PDm!5HhZ3mO|1h3E<%!w`;n9|I4K{}e3UGo7BY@jyyc2OqcWa5~N0}AA9LWVRy zt44OKKp6%rqCYC8Fdp&yv{#ZZesuRCFJ7<1~y`f&WG}fC_lD)M;%U z0*^_+)vHyV=1GSGZt))@6!T4p^K%liUqNGY(i)Z<(OijWCx#-&ZLEi8eY709t5A&% zws^G?3@w;BFc_V}!F}@cJTgs-E#UH3UNyCPW2>&pz`9W?w6(<1NGJX=NNTP#Pxx)) z{-+6uc++<@eLLVT!8AHIGZhdC4vxwDH$Jh87h@O;C) z9(AczV_GCb+;IA9$4hB4&2hDT>iv`U*!&SJ#DD{lpl8IBatThlu;4g;YT0jT=3PvU zHn$ZC9bPkUmQ#x+go5y37(c;Yb#_c6XNT}HoyVZwW0^Ps(k$CB((bRAGfwYt-$n9; zI}ucrW+8gvMg;unu!6YF)D4z7$$s`+Y|Ch6O#fz}IRWE~^-M8exbRUMr$h3PoOXFyaz6FBx>&Jee zZ8-jT1w0@!1l;N6c#=dzzm+%j{GgQ(yaDia8NIMmPCTZC9X|eJXc2H42KBzqfCdg9 zcSv$R5ixVcWOB!6>vDpFp`5dG2{#yh%{_4BkNQBc2=%)g5ppTsEj>HsS&gNNcKTW_ zk47VvA}n^G{~5k?^)vSssKQDo5fMGIHcZsRVKo=2kI*8(*{CpR5&z%eC2bfzpoN|$ zrBx_ZXs|$e&FRIo88!X@0W%#PC)s4LqJs$jzr}U@^Z)MPgy6y2OquVPe%*q@)80r? zQwEu7i(jaQo4O5}d%@1cLFRy8O8(D|R{Sj}-gQqUJBRFQ6{a!*zz}s0=e<#h3nMYv zA%!7`*+IloCY9ih2pYvL{~r-xS6(Xl|6XX6HB4iRcH5Y6kPqaC!UbrCJB_O4t-BHs zAprc>(eMUdH2`erSC)XQ3G4Ypv)$r%V|B?16g1l);e)Dtj`+#uXL*;z@E7$dB#2B0MVl zJ}%j*$leZ4CJE3}_XhugY(aHfOa27<4{9>usgCX{krIj#VmfLUs6cdi@n*&oW+hs#1bM;fDq{97mfPKaW`6q4KfjqgDMe3wnuMK- zyBKjTNdC2XE1vsLINL2UayVN@KzOkb2<KnIusj567(Jb-?R4Eykd# zLP1@nHSD-rg`W;8*V|N{Lg0$C_Prb|tDXbeSpkn_=F73b;14&)=VQ?TG!**%0(`3) zn;qQ5Fz7oifMA6`ob8C|tP(zX>4q?7_M;-A@~>w;CZC#JjsCF$p@7f5=IWt2{I6$q z@t5TXX11fx6M>2cqhTn#n2MQ1@Djd-kAR!Azvb0qvn22qzwP-W5p}I?yH2$S@k%A(f z1(G9326BW6d>s`>M-A~z(^lbFD_uNFlFp;E{p)EJOUMS_DT=Uw%l`R@gnCiuo>;WG+<8L60NpHCJ4k%Ee0F8J!F~xzTjxN}62qLdjF&WPRkRu4l zPmp}b_S30)Ak?&8(hAU(iR?W{f-{Bp(1vZ@MQ>C8) zfLS9?ed@}m0E%835S8(0q`~8CY*CG)_#78h{rTkxBD-NLgH>r`(>SD4BeA*M7D<=` zLH1EJV<#+24|G_hTdX*$J8PzcA$RdV3OHy6ITKi5)@p8T8dNqLsCF(e1(_;ju-v2{ zo43H@FunL{4GOXByw=t9GLV@`0vYpBNm%ogOJ=Sxwe3%$%VfTWDIeBMy@F1cC7UHH zZVwF=_=k0`-%mDY$&;S&N}W(4)N9;V^Scp|UrbbC+C(y9FK7%^X`I@*~BY$AnH>7N7c6YR2s7dwoODPxTR4(n^V(-;?|k z7jQN|nyI>UXxSVhB@-@WT-YQpR*li5akHn6r_A3D6n&U6;nB78`$j%gP-Wk#o&2vJ z#}@_3{@6Mu|Fbj6%=YO-6NA>Rp9!iFK(XnX0f8X{cDm5q(P)xY4pB>H=T^%h6kt@p zOy9KTpk)8h=4Atz5(@M3i&I_558>?f$dWA8SHn=TKv=V_c;^<*D`_->jhw3H zPVLo7>3xI%YVy@V-fxQs%85T_E*74pUwjO0yq&}27ze*LI7yM3@V)H1M$K$uOJrJ9 zQIO)em+k_(ZQELGtBEGsHdZaQ7kIBeZx10@*1QJ!tM+jP#4ng>Qpl;p9*?0Mm_IlH zG4~ZbL^O#NuR3;9heU=NDHP0+;GxkE9%?%o+2WRtAX8m|CAT644YZeIi?&TFPl@jE z{dui5G;8vb!$qvp&anE;DTqRZ9)Z$PPxO(6zO{pUdCj4$(N_p!pxqoY$4Vio^Lsju zL&`K-icpZx3g1p1`)$=FW}9gtdJ%wsKMHm%a*3qDU(yYwYFi%iqDJ=&PtbF8G~Ha> z4D(3>S8OhSJf>zhUHZ<2`k_ZFd zjOD!xr*fZ+%au3uw}FB_7ve$Tg!fVWWMC=JEBRLdFrsSvD*;*69cV!R^%~^)FPuq4 z`taj9Bl%-LRT?~EGT3p;o8-mGJ|uxlhIG+M6bv)j+NCJ+q>bh(?r6s}i>R=-80WeGjGY|@Y{Shr zIZM#s`CQ6h^y>t747{0mG=hdbkU7fU)q2;*LN){zl-P-s6l!)vB7Kazue$#$k~DB{&J0f(7vI>Sx{ z+KssGtamcG58+s9LI(%Q77{W$;5}rMZk&Q$al72%kHb;r2_1JFmM48U$0)@<=8O8hq2LNlvLl| zp+(3UrT-sicD31&5jBd6$NRK5Gn8d`Y(zZV{?;##aJc>YY(6&x;F#+i z^QA8sNq}ILR6@#i;B~ECwJwPu&;g{{uS(;_g72(Z6go4#ywDUw_yP+hTjQOXVnv_SMuRl~V8+{U73^(&ta<0V2g zF%NDm_fV)ug`|RNWklXnC*~2B)DT6f;XOsW(z^M0Mg`%AydYFCm76=glz)BWvSGw> zVwBv-z$#wQOK&`@9OnYxCb#FG2@cbjgzjy?!WUKxvNtWfbWEYX{#_){7yq!lOUF5e z0&A|HQv|YDP~3sS(O(Xqqxt_BU}8)!wX40*NOZ2<_Wk`=1#6`1*H9R-WtZc;2g;nd z%z|Ud^rgONi&EE9(T8kSs4 z`S+~(f95B_LS|O5H4#Y$lOI-8Ci4Qkm>&UC($K-dJ@U+oS^xyZQJJ}UTVw->f)NUq zCNVp1+B}MH0mC(_OX-~4*nds=@2QLA8wgG+am3FZ;j6rT>mZ__McejbxArGZTO;}so0#}#{tG1R;;E4Np{v&6z_}|Y-9N8K=FZb?HdQw^=7&O zhunwn@nyRf%pJe*%m$88?9I2Tf<6u*qgb=>qGU-zEJD3Pl>@>7)FCT(#~S+Np}*y4 z@;?}%B%dJV#58gY>p=p`Fk6=oYn81hvR=TA;k=jYe`*;%bNEr%dCz5RRkDkHGhCPd zM~_?2pvM~7UgTX@Caiq$OvrD#WN9Vk9SV-#SV*qNHcz2z7Lajj@u;()U*BD50~^_r zob@+Y6}HuUqpHpZ;DWHqI!+p5NN0!EjA0s+vT)euyp$nbGWzFc3)ED6F@5yF#9kQ^*x|9p!TbjX@zd-^s8gv0DxHD9rxLs|1h=|36k6>EF*?2yT}Pfn-S(Y zh#l9~$*qB=-m9CR&K%0Z^8vB3_>l)LNBaca>L&Hyg$S`FuS(++M<^*fNuNt#_g@ya z7E;^ZX34AzqpIdt)cmOZ%U0xD9%+D_o`%ALoOJz6F)cR9$!xk1O))|=!rZt8WBUmL z>9~aXLjz1FPn-oX$In(SRJgl)#eJT1Iw0q>ET)c%NAtbA5_jbk@-X6jEI;2lDg&v?F30J;#R*+bC2tNBVN`&f4KFAX!~{oXidQm{Rb{WQ zE+Xp2KZ6xg7!q9ht9>|hrx~NnXDoa!-7UmDT7?K*RfhaTPj(6}H``tkNDcj`M!Dn! z)Vx%IPNVT2vgvYhiKQs;5+a~-ZhV;i>pEnq_eQHTp?Z+kbetGVb#}7#OSXZob1?oi z&A5y_Xm^lCTZ8E8Ix(#pY6d5`u=9T(r0;IT1kaw-ML}fxm-A>=L`PB5X8=t($2+i?BFl($GEb$lyPW)FOFs4}P%riHVCU8xU?Z z(-zTWMH=F}Hwin7B1)l%*$iB{1PBhp3V$0olgQ5>_bBVS;R4r+@zN5&GbsHpUMPOR z-h=~a$u(?#npEq>45oIj2e;@`ZC>%|A*nsE#Obo_Z8QWsD|X(LbER*jtPh z)Q^7ygX7iP4|RRb6m4At%C1XCx;>A5+hq)xlYk;@PG%tUnJ+ZD{FNd)FPN=-iMAgD zA7!1Tfzkf99G@YV^m?{P`#MqRPJ@{mipmTu19=nRJrQA1@8F0Y^SKbr`O1Z?{V!4% z`ziy6SQ-a3*iAjOd!N;5Z|#eCu{GNYO}t8hIPR-~s)9+X+3MZVDLL^1p9Op0;HPq3 z!%5grM8Y>q*qMp%Ag`#Z+;#rT>|Khfn|^YIK;YHh{EVO^?E}%7EyP_uULwxIHs;S% z*e9=5prbvoSJoso`h^tb1a$JRl^iH)7|)Y=@3ac3BWiqe!&kfr?9b}m^`~((SE?1- z4|R?xbrY02!y4E%mjn=4LQQ~$d7jnW{?I{qx*Zm@YD47`?5NvBMx8a0{KYLzs{Tib zcXJcnL~9}Y0Lp$&)VUN|Es=G|nZt$JKCMrrtvq#6GpBNDw!yoH-Om4E&Ts}=kvjOg zvP)bxR)TycPYZaZvDjQ%E=}exS`G3Ljxf@FcEmBT2n_9tzB9j{akftTMb3Q^D6GE0 zZ?o4Pw5BC_sO&gO$=$GB#Sw<3vXiF(Q(Wgtq0VIgnZ?+Dt2*i(er>oW#?bM;zOOUq zYs0k#Ye(5#e<9hWJdXD%QsFWY`Y9w86R@x}3-X!>XD>oEc+|vQj-~klUTp7>UT0@H z{4lM>_hup;AA^Flr5n0Ud?k;<6dO8}HA?#4u9mrgDA6;r+29vfTvw~OVn$TH)Lwb7 z$&^C$zDJ6Mzlp;i0FiPz_`f)t$Nz(Gq%!Tx=KlRj}<{-nq*n_SG@*MEAO!Z0`lGKW>sk117)=gA9Ug&p?-zrvnvNVP) zx9wS^?}DXfgO;l_^GoD^JbNs_8rQ*GnVw!#p5W-4O#=PwtVHWiVco|(3MYB@{yXuc z8Ydl^*)G@n{{>oi)v(Oz`!%LP#j_wbhBPR9vMRc+jXay!9%FG8m?W7TCV96fY=p-2 zg!0Q*WkB(p&;xx(Bt1kYo6A_)ZGMZ$`;4f>XF^G6q{n>PEE78;ss+55Q;@=n*J#Da z{bA@z)3au5?QlyqpY2>lbBoR5gQ9@u`onNthZKeYk5(IM$l-CBl^gEWLfj~}`NCIR zMtUxTWN3ktKwB*oPWb$vF|Gq=_(DH#-<;&oh&9KyySp>g3`^R&}O3sn0F_&}EssI{rII*Dv1zo|Ke3 zGFqlm$sfHjl9F#bZasiufv2;Br+4s^77IZ9j@qJj&x{SFzs#-!+dJZatY4*z%OO=x zrRDnyyx!ryJUZToA?!HvUKxam=-RRNiRBo?Ad&CBIclZ5B#J^2*$mz1uLxlnvoAId z#2|){5|2I%+qfBJ*ZYIGsY2#C9M7ByV#8s**zj!i_5bC6=zgpJ!LoNiWAtL4e~H}2 zM-p9xS+F^CceecAF&4*oN9h5ViX_~*3B;e5j^`5G-G$Fz74-}99&VwhJ`|Y%I@Thz zz&`7^YRr(*gN|EN?vZaYq&vkWi}}Ldsg!Y#^19d|D$$eUzU|s}XWJd0Bx0P$rY4yX zHU>Xa(+Y8ll-{U`5-;5>WhrWy24a{b3$Z!tmA)7k3wlF?o4|_E_pJVc!^IdrHI_6-4VH?@ZBUgs#mx$2%tKS!-uM{zmploC5{Q zX4k_o7lXMa1J1EJ1P~jNic{|45X09}&xkfIs%zsoL9iRBdJ@i8)?w*eRs2Dtg12jM za*b0wv^tS3oW%2w$K73t5Xjj*8fQff3`sRb#%Y(DkqQj!YhCB7g*Q!nUF68?3ion7 zzTyk4@PM8nDiq%oJSEwFP2CD1leGQ=oOkOED*s-JJYwzo9Ao?Otpj8`tpw6evhK|B zm{*S{=`%c)v>+t>W$&cK)d{%oCA~v-jyuth0GZ|wfy@^?Tr){dRnN5-hM)bCxr_;^ zd-l>5ZVRc2pDWfy#p&p|G3Hjdl)W}Sw}aWAq>WSm5jnL689tD$As{xU z6VI7gpXC}Ei{2fh^B^g`&2QK0& zJ_qa@=*#1mI&G}K^e@JJF=tz4WR&gZ2Fv;}xKz8K_Bb!Ba8x@YbS$l0$Kfkib|MPL zMqDBXGCR~RsHbz|!Tw>O+c-jgelhfWLTcX2 z0=!0(CS7`jErq?25Mv2m%%TX!h@58H^<~l|dSje(DACOen!`=Z9F%21fWP_1B}ksA zE%WCc^FOvrJDo~S+S&lIruMJEaWBfl(3~@2a#H+IVLh9-^jf$Sxk@XGyldC^BXbqY zNC@UK>F zmKkE=zOPgo$eQbmb^3r z37x6d%PVAT(<)$J^MMNMe5Hn-2cgC)Q*v&FqjoJP|gI@z=a5rtG z3M_y$na2wNO0}S|5#zJ-T6jKqc$hqaU{8LaE%FF5K0RqLUz(@G{2e1eIZ<~Z$92a< zI7cjDW;W&Snq;bDl%kzk;X3qc$V3`zct=cbvdrp^HkH1TeBKbdv0uMq`KehBRWoqCzKER}~zPXl$?XcM zn(bj&sCKlCHY4Jt2riSJ)S%~~nu47)Oxc+y4He)|NZNlpZaAB~J~Q`# z`q6P@jU0&%ch@?>KLIRqe{>X7K82b3nB`;9oR4{1;N>9AK+6U@6-#5kDnQBuW|{EU4nAHNwTAS=k7{EV zb!h#y1C8CBzKo#ah0=H@7m#~j?$WXBfQ6AHIT4T2fPJH!3dKtLzzb|DO}0OiN`M?* zffjJD4sN{Q+j~zv9#q%2q_l$xZZWYN>t;rI#6puS*5N0w`o8#U%b$8w{*@V8+(`*R zwWhI=176&nL1c<*QMg#Tg3m=%r%VZSYc!ElXo#Yc(P8#v3L9$ffOwiPdd|rdb57jA zLf%L?wIg;?h5H~GwIcPta!YYSjM$hECYKuokED`CO+UvejIk3!U5ASUZ*J>`J9oVXRzDSwj0yBe;l5tjgG|FOQ;MyY0&O(=IXFm#3J?Pq z4dG8eQCSyl9dglYkPQMRXly64O;t+45sfX^`az3VWRHK2%?$kB8kY#zUoPVn++>~!4brd5R+QnZ7lyV@@>O8uh;N_v|&TwdUv# zMp_I<9_s>jWUJUj>N#LBEMTQAc*e`nLdaInDisO%h0T+Hmb?u&S0>yuA8^4&fARIn zm&=2S;o379<*;h2Bu6XmBTR6a#@D@rvyAOm$nk_ogCE50gUptHk^0L1g&J{5=X!jK zjOSf82#tPkx+PP98vRm{wlbi-O=g^0n|iLUdrancy@rjTYzJ#e;B`gO|#DfZSLF8${1{KB4bqb?&mlN~@7z}>6 zX-Q$EiMjM)IA^Em4Mu2B(VlzFy?inK*wv=I?08ldLMPP6V7z0JG;wOB#Fxy1bL<-s zGNeMmq=GvG70E(ZY!SK{{%HBv+63>_ntcZc$mHU18)C_s=O?x288-S(v;IXB>;)s+g~&^dL7Nq%BPBw20T$fBapzK3ROTH+Li}?#z+_QXR!z3sjAVs<5^QO3tEdkjeEC0cdBM-1#W4IxPr`UcCVWCAe~ z5(>XWyZlL(yLT|K&41I;ti>xWUs`96H&6iH%AdCUoy0^~w-->CwDGEO?PU}-b0-BJ zrcLg^O*+OfZMHHjrQm{NuJr2Q74o|M!c>*E2(=pS zH|ImTjC87G7!_O)Del_Mg!Efxx$pYThTJf=r(wm-y>b)Spg{E^UWcH4Bk5#lIvJVi zi7wEx8Vk~vKthy);ptk^2KtpF-KFy)V}+5c82T_0Nf|inali3D1twP9{y)Gx8(lsy z;fZ=`+YLNCSG{qG=2?NYbPr7&HspLsIi0cQyp@Ru&+X$+(8EYM9;8Tc7Quntj8pF< z*Y#Bj{4E8p4`e}EFiHe8<%XtGXE>?Dg-ADwW@?Qu-!k9$cvV&xmZ;QgB5%xg?}p!( zyIFQK4$+79tidI^y+3}o#1&@>_G2afJ1^9Qpb79oKl7hC0yfv#B9|tQNa@JJvxd5p zP0F>9kAYKIF;CkBFAGoDr+8LEIL2WD@&136YO0x8b4CkL`n=Uylb1iUkS?bq`InNueSTvdYeU@O4pI$zK8X zg-wR4C?KhB*3{$QP!$@&s9A*$;z4PqsKzbCfG}C7iXNL7jNrYGrQ2;EMKBqkrDO$U zI^!o@YtbY<)m9=!ikKKM9j}a3TjxE7(2udPDFst7zZPUf_Ky}sk<-p7=73Q>SkK-L zSgr0z%MerGKkSV1QYd#3Sb#UT)QQJnPM>!8Q(^Fwj!bYDBXFB5iV?dCfpNP zaS#Q8I#fyfD~3X|;I?4uoe-o4qh~7+$N};0@S6kB;xav|KJNv`0ZcHl-gn;nQ)IQ- zhZCSyx!#Z{gl_`}L@pjh75WmY>71D0fEsi&o?#2@-DfyN<7IX`M~bHD`B~<8BL%a+ z@pUN?qo1PR^SYqQ0Os=(w@+ljvE$ODgfMN^t_7nw2Ii1xN`k*4!=8Hynm@Yc2-$Ug zbE%lf^6Jge&3;v|jJ}YrOcjKsb_XI*`KgbX!ZglD6cC2(wfLz(`zE)A?X%#SlRracRdqCI4e~-f^|y z@D(ZO9@s7*P%Q(a!oAfOdLbJDKBB_YSf<=RNN|S0`!{ywhEbICyGEkuOo#Rdc;Mye zTf~LgaMBCFJ6WeS-3P8qKok8ZBZM5nmpV!C5T96GpAC-)2Tz?eX`*f|HP&2V_WHJx z%~KVyPq>#K{6yDFr;}^Hfn&$=o0)4Entoqt`OAb4;w5sdKnM-$7w`j7VAP2|I651z zgjQVHnYKjfSyDJ~f%=Bnkb+`UCzmL)-F6Wye-@`oKmHTz}uUrdqc zE&``+#3hO2!nYPO7i6(`W~UEes`#idBXgmE^sXVPGm#cT+4H!v+p%@36qsEV>_f?A zJLmq;kp|%qiQJ4oo{DXL9VT~p(kNuPz6FsGbs3`&>8F7R>v8uqa(FcBTB?EM1e+hd z)xjpfFFD*gm{l>0zQ-6KXs+VNO|k)jjFa;WPqWHk+i*P$b{KTEld#B*!S&Ous49<@ z^~;2M!S1GemI}l8%+4Ex+^3u!3qam)a+i41x3&!8xy~NjSD0~MO14b+5SKc>Vn`(M zh;;ZS5ae{N%c+b(2k1T^@dUD`gFG0Koa`(H6_ZCvuRT0cVtjk+XViV5{fr6^2=CA6 z8s;{^IO_OF=Y`58ndamz&&tB*$+uLU8Tg5NgdHfL?Uqtsako~SQAiXVjnGF$=kflq z_;_SMQ2&zc10~@&(EBWzk*Q&uxkPH>@?~- z(&h(7VQk770SI9Kw2N@GO%L^lZ!^SSQpE|yICFVyErBb{s%>e)7IY@%4R57QwzBt4mn1}x87xQPXy2?0Gm2PtSALK&*49mmmV>S7WdwE_?n zZi0ZLOSu=x;-nP=UzyO77ZoFLEmw8ugmSH3&f^z{wb)Wh=9%scGHaur*?NtVDIW(5 zck|gEkl#S|jYsif?L{#{|9=ODxNoT;0E}DUhklLw@tUX%JNcaTmj7`KqJJq91;qh& z;NZ;r+U4VqN9Apbt$ObAONo&vEpEP=3S@XQX41~$|JFhJwL-kT1g6u{oC2_H8!0x9E#pYSm%i=br;9N!!uyAKa`OV-gK zo7h=DcSw_ayzG`~Z$gtNJ(54S;paaWPnBl+e9(m>&6|v~DQSb`bMR7RC&VbPWl6vd zyOPD9;v|^&r>Bv2u9{xl;&b~XfZHu-IuU%F&>j3&Gr6RGl|PgKu)Le;>(D8ozJH@( zPBle%RuZVI0-qFu4RMSUUgkCZM|ck}L1s9zI|6(M534l5&87WU zRuqZ1rMuj`4xWT5EcY{sj%19QD3~n(Yyici;~WPw2&?B0a*t_tzWIVK0YUPv(^PHb z(B^xrlWAzIzS`Jmo2N*wumDe&g`Vhv(y>$?s@Hjz3gMKO{GYGN-PQgd@WlTIr77pN`cftk)>13s z{JiG5#t4R0e0WhW_=OII2|)hRJaU{O+Zn%MX5q9=C?L0%(5W2LK_t$m*t!S>t^?|d ziBm?Lj%$l{0MKOOcHO&ecV2w5lkkERy@Hak(Zx#l3(;?HEGDB|4wakb^T>+e)FgrP zY58xrD1i>c+XV-7c@-!^Hq|G|034^|3{&G)3p*r3k6=9*`)KtgT<0Rcu$e1U--7k> zI`dXPwll7oSs_n}DGshda6%IHY&miEEJmy{R?F4zXH)6`$Z|M!Lq(l}=PG0cd>ZE& zS&Sq)vJWZIw7i_~YJ}h#x6)3Fh34M&XPhCaC|Xu@s}l-g-qdrrGQN|Bl4MSo?BtC5 zo~kCe;sIbfKKB|({V9f}_!f#w2w$bdvx*qfWQcL9hD1*JaLVlxDz!fhDQE?T{*3AG% z)2vCGZ`I`i4G}h@|3XpO`^RD+O<%-cplmCux~!x%e3JJHZt8e-fI%-OvWlr4teEG5)Ct@cS_;t=h+j9~cAde;u4mk%xYoA0dJhqiW9 z^HXc#Xg>?o-roG!Da5mc87@Hz%Po&~AX!rv@ORS%-wqS9zl{By%d@%rc~JeCA{dp= zI_xY;K%EjQHz8Lc!P0hl#$#pwc`7(&a=dsgwZWB_?bvSp2%+)QE7e5J0(iFfT6*R- zwMqRH9^*PCEQvE6EZ$aRi*aY`l!_(|HVrT#7-bRVH!)8`?nmzsa{vBUi6=d^sX zm*miKntvJ#KV?rI0tBGQqQVYGs>LA$`wUEmy82_*SW{<*y{Q&!oA@|+h}8idqHMs$ z$B;$D^q5-fUN`ZjKTWOVXLVw#cXDs#+;yjDBM)Y6OO6PIlnO6)=KF*_We~&^!`}HF z)l;XRv|R!Ln2re0Q9{Y?{h4aAdDWxL?(;ZNhU}J7zug{R520Si)K5)Y3Z&P7=+8E1 z)$+OsGScbu^NNbqRT=a?k97W!P1NHXfYV?_BR2Q1BuVpTROIH@>Hgo?hpzyx#MdOP zU1y9uun%y}5UP2OXbA)(#Ryi5#Q77uUJFo1pfghK)amlMpk2rBmZCOC=2`;yrPf3G zyjBC0CNRIp#BB!_`+&}iA>a+3CD{-K#z(!hNqi^0F?n;i8+}u;8hWpF&L&_;lQ;r- zi9S-O!t0cl0t*|-i_sv$*ID`Z1ufvpH;{jppKr*sn90IEknEdhxa#+7v@L34y`|9$ ztXwbXD~*P|3E+?rHmGu=@ zY_r2h*vT}bSx!)%h!NMLvqt$KAo<|nWX{;Li!4iq=GKORdqz)8kPk{O^QIxsNA7rj zUreQH-?=S7g?jL4PnbN}&1JFEJsm4thv&|^Lh0ZM-H@UO!0F@V$KXtPhRO%_o|ppw zYhqi`0c|VHek4LO&VK05Ht=wJQ>T5J6i6Y}wv-T1l;pyOasG=SZ_lffW?i)caZ$UOg*H z+OIj@_d^cYBFt*f7;TZzlamw5=R-F$hsZ6->puvionaf~+5oFO)q+8i$Zzi1G*Wpo`T=sAyo@xI6lj|!bmS~@1xOnr=pqVZ<`Cx_3z5Jrf%qI zr6*6Bw9)Z)o3>Mc+pZig(*zhNI2U@AL8_TE4c&V2)(nQQ-}~#XBjUx28Ux?PgW9nI zNskJeHt6;ui1S>=TsVABi|f8Yc_CN=4dpuvh`lL@$h%AspeLJfY`zwR+em^8vcIiv zDH5*S3J_ROa{Vg-@McbDjZ>mM*M%LUEW>1zAIXw2^A=(xT4d&v?$-Nv2oDafBdFwh zA7ERiOOp(Nde>PW(R!vT=R8*S(o~=yWxWon<25P{(@A4bDFOOU+^^45bPQK@|HsmLu!-6WQv z=+36WFaC&&@Pc`^L7kSdA^94HSE&;)sfS)Q)lA<$%|VO5#@nOjdjNe6PZieXEjD2c z?>6D%t_YuWn2~_Sl!@ty(5Y1f+iF+fhogtQS__UNk#+Ja9fWP~Q&wp%lzExFtUNsd6$a@7IiX_81u1dP3^eQ`vX?Dl?AB=6TpBG z`#Wj{NjFh}U&gfC)wWLYZvf&Q2iW$a*zQKA9Q(iz{Tso&^zzDDnAVK3b06YEB`VOR zlPoA!pdlJ1R~>J@Fb5F@fYfNvoSRd_)aFShKdAG~uwi^@aAgtt1vAwvn2B*!Lxb^& zBUMh>ZYvR_-|(fj`#m?Vn1jY8JQ4(mQ_`F^2Xi{CY%XIvWiO?z`QC;cX16<&S-mjg z-8*=YpH^IAAsIexRF=Brbz=&a=>UXX}#!3y~icr1`<0s}yNO65R; z7SJo&!ijR$Bh$i-n89(AV%q3p2@KHnzMCK+(mv;ne?iSQ9)_&%@ybv$BPkQD1OUj> zOE5k`WxAdJ^Iub~Gc9ZK>JkXHYcikPqe+rS0?vsdVA6cS*pcRzp*723VWKcF_HDIz zQFUC1*z?$;y_2|Xn(`iGmFVq;ZHM?TwlGp2&L*TPJU7~ZT-JGT>X=}Gi8s~+=Ml)r z%MM7T*SfhUDU=PZopWWzeU4tDiLumpAkltE_0+Po%%uTURdi&Q!*J9~kX8sG`}_)U zHxb>Y{M!=U6xgkOGKCewh#9!c=I^!bw}<-L^TFJ0WU<6FGSIO5fmCwo`Kg67P@*=Zd`F;Le}BLPp9;o$_D#b>aRC^qNScmjHr z_53))b(TW;-&?FI{v&^<0wD-4WbiIwVvT>lTN8d-rJEsNnydWlUOv-bFN((aXpfG;U@odm_9eq16Abm;>1zmsL|^wy-j8I42t zTRmTda2v2sw{fax-DJHvJ~9#?a`**!b!-p9Lwbh zned=cT!FNwp-k`w_@6@!fglHCzWVJocYAVR3K~V$5G1Fr{YZMInH}=Jm#_%3x!`i< zO=)i2Rolv?h{r`UbB$+@09nh;-;*Z2Jp`hD)C-?o*Sz{z9akd%Kn%!rS8>HdeO+uT zD*ONDVM%s_0IOW#dN|O~Hw!CM%OIJDPT}u1en30i7L!IM$E&a3MQ+5IVqetyDr{qk zV?`L|=3kf6$ruwlfnFs+_rb3m5(Ymoe4vx~mJhz{5lu_`!ml$$QAJy!xCsbovp6ls zQlbfD$5MeFZN)?NhE1o(S)_eExu6L=Htn`o9m@(tZvhxMNp3tk=N2qA(l>(s*&FU* zEPnVW0so3o)ytWiJd)vNhnW)!<~6(Z9bUTQk!0$7BRscn>?s-)tTppoLXb!Iy|o1) zu)Gi%trL_#PAhmyU_97#)EKc{vhzjTQ!mQor(@7nrOL)PJ$}$K9}~ZEqtr@8E5qx8 ze6xOV`zLdwr$h;OIc>b@G0f=rdM@7pDcGb94!Yk}zj|p2x7I`eW*Sn7$Bm`9dyTeb zThn`I1U(s~cuDavgaCoh-Trm*s{ASMcMj=^Bhu$Q@eFFurcy;YLuzvPCj6>AJouBC zeu7s#RMBS=TT5Cn{!XMsB+Ab&v}Xxk>SArvf;3j7pIka;SbI-RBvb_S_00n9Ba!It zJz89Ii)$GvL%7zj^YKHw9x!ono!1BNXTN7YPvRCN6VF~*x7n=Jx3*B=9t_w@uFZ<+PU1!m(OD==s%wDuQEnmHE{dM*bp>yVl z3=AYRTq>ue0V9|<2HWYrY+}pn-m3Vfv}LGkF)wqwoeShBM%w3KRu4XAs61Cz>a-el z%kzXz3F)+MyxBsj$I&fp^>6MTj1d8nLlJ`!nF}+*4sdF%ZU61b_nBY~_wX$K=uV)G zY)BSWPZjSaZ-qKXO@%BUV2&T6Tc|^nnP% zfQZN4E13+aQ&hlmP77xJ>_iLag^;q{F*qQN7$ybPgjeD5s^6$#^d8i@u`a~y%;#0i zolM0nzB6?FtR@Vi2nLpsCBTAAl&ucVBjPF0-DDNt!?M8xDI5Re^sT8Tk1y@9_(zo? ztGJCboQ80(X9S6z=*K{;HUrLZcX1Ge7AR_yQ3zEQ>kH#+~qY z8pbvKhUiBaq`LDdPUO(4Q)pCV=p-n0NYjsy6(hbb$TD{vlNowBP8GHD|042iy? z|E$BU3Vwr}ZOjtHPqYH;Z&dhN-yO+3$h8=HK0ILG{_`*IQ;~X~5eYJs2y;1K^;~a$ z%eIc%aHEq2-L*lxPzf34qPJL!-y)CH09ZeBF?gF}7arr6K1_kqG~j-L(6Yj)a0|9n zn~gX?g2cB%);CfBl_GB5G>C4ZCnP=T;%(1$#tV%2R#L6u>g3ig`lR>tCl27=e=q(s z3hzFSMY|qyWTySv(7v|T1jbhe85IX-h<{6A8m*rnSeS}Tn@t_z@0TR7qR7A=RMs=W zd(o=S2uHEd!tJ>BlWplqhdv1RfraDQ_~fVI>B&j_d|#m!8n~oQuEwQ0li|DvEZD5F z|Fm-r^EOx{$KP3dVsp3~)X`a1Pzbk5jp^LxY43Gun%Fz3iGAm)-2f8kqbPN8fkGK~ zlVqIrSkG>5o}2*4|Nv? z;b#tPO$cZDid4NrO{W<_EQ3NFTp|>uf_z^;IEzBis7lH&+nAn%*7}hJ{j|Pw-y;&K z1EOQRg^pH!H#G#jB+4F%IaPEFe3Gc6kWq6eG$%;xzpIp@V-L-~uq;!)Zh2b^oT2FM;e6NZ(rK$`A>ZoL zQ?7vCKOqcw2N2=Q=Iw8yvfk`U4WMA~AmVG!Q1v*?MZ^kxQp{*v+;$X;J+2BdVTRk$CC2F|51vA+-ldI=z3 zpQIu!Ca#36J<;w}p=+}fvy_$lPqA~uY^BI=P-J!k8}bgrb4)H8S$61$qBUHouK=so zt!tL{oVC2*tlaU{O&!>rIvMd~g?VxX1;XLI%m31FqW)B{nJ{zVeo>zzY&&a)fC!;c zyxp^41+ptAmo&~0)YV#d7EoH6{Z`y(aBVz3LgR`EB4EIMZA`62#KA-hc?-(hx3@ox zIqfTUGKy+aG>$=vKe3OIFutdC8_~pZk>Tb&4>xhIO@PTuWd=a>T`(W|bI2_?=uY#E zE|#`LsaXraLt`XK_e7lIrCM0~I+BS)oY`$}W7XM+PJnW3WutWJOcK8DQbeS{(fgXy z^tdAI`qz;gd$izBKjU31_JD#RM_@9+Fu;cFMlqs*qEmqDKYc6L^>vlKKH6Wm4k8k} z)e{6`g_oltdf$cL9gN?$im--h~ZfV{eX9MW_Lc zE7NXnHZD+*I@CS-1C)X#YfkUv^Z&_w2gg%1$Q}%eh;rPdfacw!Z6=tk>i+T!fqPAq z*DyXXYMw_KZs7mcjAr00$asM4fyt{IlK4{i+#u@m{!YegFi$IEC1OS!mV%_k5cK(& z5z1CKHC)w#UmyFamhNd3xt^THGQIJr5}X1zLIvA-)ZV`#H9*56+@gg+!4{!98k)%f6|!ntgLPJanf^vD-*WqsLLU@)dQ z-Wql8u^Q2==`d58DzcJRgRTd9zV6MwNSrnyM@DS)JryCwK6#A%WF*S6-(>9{3MBHX zY-I65Zxc-%?QuZm$s;%)V+xFb9K#Us#m@NFvfiFmW7(~&r_ayO-$Ddsk~<_kq3ShV z#)*53jaB!|WU^J!W;^V6tx|*%C0tx+((|F(fxKNu2!<2Ojp%>-L!E~rEsitPA?Vzx zok3T+A=%O5F)y;OFNq^8$KjZ4-x~ihmK%^obmwRY#R*p6nYkH|iUvxh8W|vMAeJ)- zNVf=(^`PZ7YCwRqJFX@DB-$Srw@Lk5mRV&D`~h6)z#Kat-cx?Y{c#nJ=dWIW@idez zxxnO+e+PERjMUp*H4(w-$i=2r{+Ygq;iIX@w*aNjNP0FB$|DMOxdQvKqu1GuWi8ya zr1Yvhe{~1zmsZwVKc>9*(}|_Penz;uUCBZzjRc==?))k`=E!{G;OkjujLlS5GF4K7>sV`YCJ5m*o0BiMd<5 zOLl=m`H1dzFQ6$5A}Y&e6-Mi8^WV|O!KmkYi|{ZPoCQFt1HdM0k+r9ZKzk?q1L#qF z-=RPRERX8yr_O~jO(4JtZg?(P<$3ge<}2km$vudYTwGs~=xsYNsIl!*0U^W^dKpT@Li6+6*AlER{}ID#tW>_#ZikS-7MvqK zZSnz5@O`h(^rWiYcHLs(BNAAlYXLl)0@g`jGgA`-D?A(3eyVWZF}ZN zh_tFfw=k-{Xli>vW2T9o#q5?ej|4V~A>ZotSL1}D8rZ>ES2#~orb`UiBaMp(JnYm@ z`1|8E3W_I1blVb8dPOO9d&j z1!${vj5W0+Wp!Bu_jA_yddHPM>PJk@6qEN!L;(q-{n%qHSp>T$mEmk66#r|eos`J}{^j?+#!I^_%)9djQ5Seq?YcO-CY z#YjdU8^lQ>4esB}nvyzCwv;dWm?0h)NsGz#AVY%|m$Gh4ozPBq#N*GSy8@WYu~HL2 zY3;f=)YdfCPldCJV2;_SG9Lzan5AFbx-Y(Ue=X^rCch(!90sb}lT0i*5vNb`{LqOc z7gN;QPGnU|lOK{<5Poiy z=hI$lKVvffZD22#Ux7MEC||48S3OLe#tY$OHPW;ua|Z{Ysm`^J0b>TvS`OP_T~9cO z3rIvj#(AO*+?9A8J=^x3$4PCMhyKFZtaaM8(ZTQKr=i^~0Ag1#NIwz^;cS^xSAR&= zTJap%Tx5%oRv#G$i4FHqvXa1hT-f;h&qp-x8vdqwQ`1V~;xjtCKj(8>WVmnT`9jxz zSvl~$o=LkzTI0}$)$@}`yR5Kh;lyDf`dKE++<>iIAyq8; z)KQJ>_%&Y5*Am^{7OqfiOBKrM@vjFv(z=DHq1ojBBf0G^dQ;)t9DfHx@~m%0?D0un zDkOkJSGJ<9_W(yhjMq~U=-YCrbxb>#>N^frw#*3!ifxON%UdX-z9$*y@=CH(OAydtTVVQ)orcaJ~`fb*r9dwE%ZhloNeo_Nmrm+Kg5{t}P0C0QxRRQDo=^ z>b;ZbgUVxd_&N>ZPHyWk$-Gg&npdcNoShCE-e(RmCrcyF1c*)oT`sH*p)7qX7Nku3 zmWuKx+LpM2N%5UaZ?|YqXs_!__p#<(vC`TxskTeAm3o&*{u4DK(!Ik-kN$U?o3IAH z-cY#jjZpc|t+5QOTzU%zQ#K+)egU0xZ>YHH0ul<@j3X&k27_Ha=}tO_1SIhh znr@&KInGQl$r&@14(rZcJCdgzJZ>NfBG~2Uk;{d0i>0j}?>p{{-QL{|0)=(>r@yzS zYGeX?OM2gtzBGG=?T50nllgoSg}_>zM24+15mn*P|Po7kbwk{Ek+g(y!14T@XNLjPhOo|m|F--cCbb%)evA5(TZ5o-#L zISIB;-kO^z-!FxauW^3Qni7{k<`T^Lz_<1B$M=W1*vY9i0p zr{m^bi)^zR@yM^CdFVwH3pDuw+9VP0RciS+n17-8K!fN+0Q`z{sH^IApQ+Cj->R`_XGXzLJJk;U@-hDMWdYr zo=E#hv7(2avTNo%yuVpejo>nFP0H6__8-6CL4#HE1mOu+!dy^Gc_@xPkSK+ATibmZ z?^zMf{lm1O1yd*x+7~(`{p6D52m-;xAR?lmunv4yI>fCPtmnvmKXvFVwGFUw66`rw z>FIcfqEpDr+7G=|Hi{S)6NL!l{^{#M52OKe?2oDWbc4Zem?lwXWuC4if9>f~<;f`F zQQo8M`G!~$jEQlochyC>W=sEucu^$-LhLV9dr`Rg&5W6{^f1~?F$@$B-shA9+!v$Mg@4TEa^W$0d6VNwH0M@GYrv_^(cxT zciVeo^vXGkFZ+^?Ys%{nnC=g_TkwD{E`^UD1>U)Tt$=~< z<_n~%Oos>OA^0E&$$WvBihTY_=Qga?SxF6L;#KfJX|-?cF~@vahCy}0^ZVM~@1sFC ot)rr}%oaiz0NH6_Yybg})dI8M4x&yk6Fx8vivj=u00045T2kQ&wEzGB literal 43456 zcmV(jK=!}=H+ooF0004LBHlIv03iV!0000G&sfaks@JK5T>vQ&2UJ%gRpOV>D zs)9rkVDrO9@CKe(@YECUelWOVArpCN)-b(j#!$c1X{{im2F3-PJgMSu$(5;CeP6m6 zT>4h7aS~!Mq3_ZVg{ekFTvKMYR&(qB5i936Fry^lh>*0p_batRm$N}S!8YxWyd`QL z4Y(PMAqQV;(WO*j1dvL*n$7Gb zR@wtY2(P?l;8-IKb8 za+1(WJg@0`0}Mgo5pLtYj||Qp&V{^puqXJHIA$O+?14A$s@U;4PHE>;?H96P@K~<5 ze6c@Xoha!*ihfISM)87ph^s!P)$_Jdzp7g9n!UJNXI}A7 z?@@OfIlpPTL|F;X`0t3Ofx6+-Y$VOJQ_=*t9>+tr20OtKmBY+#%BOTCgYYXca1kXE z>hODqtCu&0O*TThgZ0~(!Rpi3<6r@(0jdM7)&*v?5y?8XP^pyd-|%T)+D>$lH4>v~ywmKA zSgLS*jP&uGaT|BpJv-r>m3On@NoDLSQQP?iQd%tY2g; zDP_(wo-BsLJR41eo=*^g5+w;_UANWA=5Qvdv!6DV8Bzm$`$@*dkn?DO#zzH?2_5lv zX9*1bJU?6cn6>`XBS8qZ7`zsKU}iCm+E9z<@zIsWl3vjqK(vGh91V+li8dLNi(Xr( zJ_V|v%|xm_iHsLQt-W9k<>gbLe!vUd*!(ynlf;=%Oc*Zn;EGI>V@N;^ZWRv|(&zvR z?c%u4M>R@!#>ec)sg#zl*gDWBv=FE8uibs7y)-LWFJ1(QkQ#qfC z)Rv-ws8eqnT%s(3NjslV)M-jCH51*BIFzW|b)pZC59|uJMvZ|?o`e5&osclezb@a9 zs>QO6Pg{DU-a$`&)m;Apw9w(>Y-#m3G-x89S7YkEQkiLT^pqpaawkW|v@@ZQ*H5|+ zBmWRZdePbD-#ti4Wb)72KAqkKumfSrLK@RuGyTF4TLaIHVkTeArcMJO_dzeL&?v{X zv(aSA*U|zthy=Zh=UACniVNLG&R=!+asK~Glyg<6K>-AJF;I-uaHI-UN6V$!_f z<&4&U`GP9=hmM5yQP%Z$O%EiLot&-B9M?PalZIo<@>7OZpdO8bHqeHI>FA39QX=M= zf*>#xukr{NC7gYc%m>p7lb&2mxFt>r->#*rQ~LU(L(EHxMB~{Jh_wh+v`(2VNcd!C zmaKTOlPqMEwR&&t0b~BiMxjQ^iiZA_EgY7X4Vpoyfw_mzev`#SVOTc(ZzlyGjA&p+ zqh&n!0NLS=!$}9(#c>f&$W&n2XGR$ub@<@_ZA;DmnwWzqP}fdB!jicL2k(0#{~E=S zIWEbiAO33xSg4Kg%G>mD8+I^vZL4_(uQyN7t(45IX+a(opREt%9*9uH8X&Clr~4N$ zd%;>!m&CeWaMS~AkI&%BOc{kuARVKXIhn}E!z z@5H3P12x?1%$$!972LsV3UQeTrh8D%hi%uG_shJB%79d?GZS=vQNPk2o9> zQz(L!fdB(fpVo`ve-h%}rAfGMp*R>Huv{O2ofkK;gF=5mL*Sj=s%mMJlR=2-9oAI7 zgaB-HAxhXEi7;-V6ynE#;#lByWL=iWXDtT>n;+BAVjVwS`%CZq5-Q#>Qoov$e%z=8 z9T)8+i31}~62iven&A(Y_gh`{%n)5Xa7w8hO#ok6Vr|V>lXIC*58*!7F&u6@T|P+; z7>`y#5C^@S!o#Oxf>1Nb(u2$izPx?jV3*P%CWRS^kpYsYM5RE+*4q2dCYnvwYoSXNF-Sesp{ojG;~*Xc3*x%dcuq43~)_;;d|^ ztoGC4IctM~+^tjdM8R^jXd`yf+C}~k2|af5Hh_4)v$G?1nD0S5Jys0Oz7uPxv%L6* zVA(t7-!<2gxVqr`!7Z)5vO`w&vCOLw(3(+XEhSqi`MHhajQ=bnfhyIW_bSmHUe)~Z zlV7|X*mpJXGRo{CCatPI;IQY+C#o7wz;FAo*ki5K4tg=cL3QPifw(aE^exaIi3;(< zxos?5PV+H9akWdU)FoJno&rn&GWd+!uuYNo?+-|?5Q`%tXR40`o%#J|d`bQN!B__T zH(krz>8@{8=*g6C>Q8E8+JU{k*^GgAhG|x8^EmT;%bcTgPlIgP(Pu)QmUl zmaVYM0arKiZ^b8=mfTT_r?jz|(ULD1h zP%dUV|34D)7*aRWr#)7&!Ce4`p;jt>fyaZPSU!@O?0Cb@LzPoplxy*MaY55i;O6Es zCj0?;Bsc6^>c;78StC><*!4XDGpC}0vNU>J~N_D!p#OZ8Gq1I;X ztsOdA!ZUIYfxkN$DCmP)Wbhz8N5EL2q00lD^q8@fP>(n7&vbIL8ejf2DXO^k1iZ$T zTy84lA~p#6&;$aBARx$d1xFTUlZ7*kV zkC6ViYVTys$3^TE@72+#$;V!T9|UH&Rl7sgDH**4284Tp;8JIqUqE?3A(zU@(N5Am z`bWMk;}$sg&nZV%B~E<>jSDY@)nTJTbD3%U!RCS*)OaYb$gE|WjoJKSZA0Xs8N@$U zk*MvN_^=WMaNU9l&LNM1YDQ>x{$6&OA}7cEL!HoQd9NszJUP-^Cy6p+B{6Fx=vt&8 zFoTReKkvoQ)uJGbINeA&>U&T$Kr5xm&E306Hu#DFuEhP})h)oB!l-iqQ+lgi5Yvm*6Y1b#I80A@7YU&EP~YWOh2J|8%x&*D z90Hr&qX8w<2=2_+n=xg$a6;6=LCPOHxZAlFs8hxmS1V*aIoz192bPrH4&~EkRvlL3 zV?jzs&c*@54g#6r#=jwhie3PUWUUD$IpZyJr{son0+kPMt874$s}gYPhNWcHY3ADj#u#|M(l)CsEA>e#LeiHR33T!$Z@hLd<5XAy1!TR zY;hh>6Kf~O{;V?k51~*=M>|_LO&_LZgud-E$g?1#Nv)b$Bqs$HhkYz!<; zw{7NqEAK4)iG+cgJzo25aQs^IR`Hatr5xUe)lfx1qf($9 znJ3=ajg@}J>~$sq)iyhEjFg3^L=)@%L5}6kYe>L01FM5vY;@euE2rx@oeb+HbBZ2{ znWEYd1kz&JPHjO_2Na^Ki>23@E2S`}pUk08jc~Ilk}R~hl6wDLvbQIn;ru>WGS&~~ z=m6;VkeqWc0+XAQa{3ru2ltWz@9cL4nh@e^?t_$_+iWy>in4tg6khhfnx)Hz8oq)n zi07cADadcIOgfgPar8q-ewCn|&@IWi$MF^I144Cj)*8MM*G=K1=O_fwrhK3)ZFY)J z${wcZVcK@i0oD3mh&0%$QMKX{DAcGHbQwyg7cg)!lp^{RP!Bm^c znr(T{>lUyQc1+A_r_L#j^vcP5FUs+$&W%YeLkr1m zEbsTMt0~n~lXh0OnVC+&jFF22f78?gf)_kF$9HM7?P^9EOTE2Rld@;tX>eD+`!i&54l6JS_^aXCUj4 zoec?79wJdReQ_MgM@%&nudtkB1EOsGpE)?{UfGPe({c>(3uW2~4y}HAdsH%&`5ERQ z_ZS;+UHY%!E|wWOQ1@OgZsi(!!E7KOjw)KxZdw|AeL?#9pH%#uR-TD07W0gwTr&?f zWhT=+-5D8TnqW1qhgUrcFg)C3hRtyu=cwgZ2Q4LHX-DDA@KFVMc@t3zzKyaldEp9kZADnij+< z`j?P+sNG)cv&4B^<1dL(b<-mk5bBt@&P#WHo6$ol*eYjn_f7jazyQb^0+06b$gGnQ zDW}huGn(@MilW~*?BWd*;2=^X%Kt^!=biUS1AtN98QF*H!BM(^?cZqO1G?FANP*2b zS_Q63u_d5KN$_7{U#On<-&6N)y+{LS2^1+&*T60t z>NbTNh~P*%_`gPv+8FW;65)B##Y}vgvZ*g%P~ItrO?WXUECS78O^)5;hEbD+bD{Jp zn+1eib*Anh<}<>E)kGgnABdwqHo96eS?Sk4Wct->u#%qd+@sbS?zwlUsgC~kXQa{9 zQM-{Ii1O=D`k0UPDdi9<*6P94Fo2U&+mQ+6#d6P|K;D%wgI#Vtv?!cQT)zLped*Ax zs3^a!yQD`Uu~FU}obI|UENR*}qfLr2m&haLJ1B;98HTinv(T*vo%R;JZG7Bw3YF;e zpJ{1Y+1siV`4-ASt0EI(Q^>*UgE0+*p^&HeS3mM1M0)5RVF^VRfvKET!{rY7PG!?69Ee&_gR$g^_pd3#u`c@{`7tsbmLn5oX%yK&8Au?6QqmYpW7^> z^Z)xxxHD9y{eNK@4+|!=E+`D;s6~a-$r&t?Y>UFU$=(fB6X8c+c99Q_joCud^ftN4 zsiqZCXH(7KbVx1QsbE(z%(C;e%Ba*`E6Rp6xFe%_+P`OVP1j+CD5#G6V_M$+JeC;+ z>V4LD=dp_(#uP&N&E2Ta>m*SJ=N3W&$B`FIjN|@?m=>Uw{>8@*Zg3Rd6F0+u)P6V$LSNIZW;PQ+q0aJ>%|Q=*p0k|Nv2jC?v_s7 zS}qxjce!m1O?sPp9hu_~#PVu!<;KJ-71bQ%QHaPW)OtDxu@_3$E4(TE80FGdTv7`h zf^($OA<^4ATcs7ej?R}9WLxk$#fiR)lZ6mrgMwY|jAGN^fI}1DUT)5P)9^bPJPd}W zFM$Y=+A;O)y*?ecv1zDQX$>*R>g9Vkcb}JzXrMEwD1b`iIpiRfvN1vP>OGxI;RL9u zd&e;X7D1`t=A~PA^$8Z?w0_Tk>@B7B zkui^q#0K5FviGqd4Q-MBjr13>ekh!UP&Q*an=pB>Y|_%U8aI@#8K-EY90ZbCKa1OnXsYJi!Vh zgGoUElb37%lLCts_I}qp@-;VPDFD;Zn>SH}=gp z3z7srKIcyBDYoCPu1>0!BDNb_9MMRarPD6V7Pf+(Em+~e%gi=ab7cJ8z^g}B;qgwb zk1JymSkXUO>R}V(+L;dHuRmGdaHLno_X>QO>~t~QnIO*`>mJ+|IRO(a=IU8x#5l&z zqb865cIk#MDb!~>vFjdX&)Mw+$tmzRSn33ypZ+mNsleMpBl#*Le=O~oYtl(K90OH1NAl7SY z0jyT(47{R~JT_CB!!E0i?&2!~wJ!hC9T~tVbu&j-`OkOjj1>;dA)bwG=XZ_NlPvrK zij;xg@oFnU6oL4Bm(JGL1*#7Vf_J$5>Yz_#iWMGv=p%CRK!~4Y?UIw=WwLWuyZ4Y| zD^2^-H|`j=`aT(9nmY%N*)B>7`WQ2J?o1-#i;;Z55!CN8Dy^Myw*Z0MivO`Vzo#kP zj-fk3#noTpJf0g({WtB$OjR=t?qX?P&IyQYCc>8k5X^aixK^Np$?GD23Y!-@~6117r#<3amRF@428KReLjCNwKO5Xu0b-- z6%tP)B1Lc)7V57Mu7R}Vm^t`1A9Ew|P#g}1cd}ojdMfz?XtryzUI zyQ!JUOejGkJ4mzNR%^*Jth-JUUxzIAG|{Vj$qr3)nj5@5e@~<`++2#DHEYj1_Y&LTdXV@!V845?3C7amRp!YKpxKcK1*BQm1%3CV>ZXfY#da>i1q$iLUB4*w+Fd$ zm?0QK5QpBO#lz(gp5pE!J@;wE{*fvE@!UkGVU>cRh0?suu2Om@D^E^7aMxHpQXn0* z&e8QlDi&D7`K)42&7QQ&X;T2k5MFjK?P0j_FvElkI0nM!>Ie5q^z0qG-Z15qI&XVyHP#YEgA zoiQX7V4r;Nxf=lsp2v|S-SeJq5@O)jd-Cfc>$CrmrUyy7WLi&xaI|m3a`!(;n{5#0 zUk%VfdIm3}whwkQ)GmbbTTOUb4uIVUpH2=wbC5i70V6L`wo;wR$G16;Lz6|kQ@4Oj zwPjun==@~~K-JNOJUPXNru|-&VPGx6kRO@IFk1feWmdIAn>y60B#4nAejs&X|8-IM zMM0nSm8c^Mx=-0`3;k1VSkJeHF@?=iX@h_zQEPKvsE|_S)2#_D)~V8cOw(&^*oXvWu-_I$|GupHUuNS1~943 zk1wx#{fFjn5xXQ@3p3pL-b*tOus6S0PG=xPV1KOw_wf>cuB*6 zW!Y}hl1HBDuW_{G&AkbJr9Dt|ZiR?+GCjeplag^It$EkA0^lY5P4p8OfY@+U1t02G zq8wh4S4o4OMY{L?!3&H(C-2~1mknIee$xYKfgXp_DMS#T8HHFpBBWW1ph7>o?dUFR z8>GF4&zr=C9=*C4)#A6@w{JJXB6$h>lbUdVBGjy^NrUZmimV;tmN?D-ocyDj6YanQ z>%j+vRXnH`y{@U$UxjQ=<=a|hfx|vjsHp_Ti8S9natj^XNr*;}jz?*vCrv^5;DXYx zcBr!|bW5Kzj02)03ViWQhG6hBC%FEi3>Gvv(DI$H6h&>CYR_ zdqMlPfk*=fxv(~%Z^gj|Vs-dE!zi$xe>j29zX4tnbol#T5Bb-^zk^p{c~4qk!3?9U zP$+MX0cU}-fYSxNqVgA$$kF6x+D}RE}B(qlm?Z(v<^cWZsal_Az?gs4bH@qs|!4ngjEn&DfJ9=9V>C zZ~NjrTn|uXeRi+u*5GSKiDDzS9mHYqrRpOjR{`uVxJ9SjxS<{#f_5oS7Pnz(vi;>u zpVHitWQs|3)uF|WQ|Rmy9eK7ui*3)K<+O$Qk!|2P;fEgS2_-iJNxCPt(HMP&{*)AR zi;TKju942Q>^t`M)=&_`Kc*PzAP}@^KKR$<(|CnwVBT;eae5Y-kQm6EvaRB}hWNPM z1HfuQMe56^Vw-i9{lSP*PI~2{TOEjYadGAT-}L_V{{Bocxb|Fy!>!Q)fR#gBdoi{0 zvJL60X!2adl?Dupa0dOQ8?JC;HCR%hX>{*8vvtRv=XE?B zk@~Pw2wYjQczDx-0xziC^D_4P378%tVTB16VJx8D>9t<_R3k0|>LXK^AZrE#i(<&a zW6iUHUn4|I|8bINQw}>Gs}sxQc7W2a%e+5_S=M9~2s<$D6j+Ji;AIbH*B(T)ro6d<^@jo+^%c^^Jubf+rk65kNB$R2RI13P|yNTSD@mI$T(+1E&JrGogZO zPzKFIQ*rk^=qc>D!q>(Rv4pWbki}AET2) zGd1QY=yWxgCXAZwxg0TvC8{!+Pf>?O^b9vBFQC~xsORsW1EQtmfM&=&df|J-#!+;O zE0<(qN1^oRKrO73;T(twlZkbnA?}YoI^#7ja-|vfVyJTC4hhX2rPHdL9W|(eIod3` zL8F;gj;fkwe&G&_+1pHHSCX-W{8`O0&lD3^hH1~Us3I=1y5$y%u zpIh~!NU`lyi@fGr)=EqfhP<_#Wk0=L{3+bV(QOypGrLvOz1~o#n=KbKL)%5w1CZoQdkjoe+YIz;E5~1~*OzKgYzuPcc;W zgIupp;kjaHqj6xAWzwL;ngQeZ)O?8ex&UpnMYO`(*xJmVQ_Z{9QQXKaQ@GsCaL^qm z!5Sc0$E~u$xnV)s2W#qUFctJJFz_xV6s^ zKrZD=f^lq8%nMy&D0;kmPx;7QXwr@d==3}AK%Te^{~u&LN~rV&HXVX&YP*{e+6<95 zqfV>p)yUcYn(*c|EwSP-xOT{v)_7ekeGJHdO}X_7P2}>z06zKuz)x_n8c2YcYWGiC zYCT`0bz>q#PQ4%wCo_ipFuS~u6YR$G>a`M^$?$lb>4?AKa?|tR9D4KGUd@YWq7%~+ zjl-{Xh*G4^Q?$Wlgk|@nWw?lsYVeiUVF0!3tp4S zuccZy(oo!a%h*^iDkHiuTC$}KLBp74w=GTenZ>{n{F1WY>5}|eti6)$eH0;ldj~#} zijhoCQW?>4Rf(_$v-eVTnPJCb+_ZDhzPA3LCIDi*=P6%o@twssEPh)tK|^7`ko)ll zBEAJUjlcGuRC(Qp*XeO|!K3TWpHLXSrCO@CUuR=d%(mpIdNCzElqmAPZH2K3%bKU} zoVQ-v?jofrpXD^|FI`k*3nt?n-X6v+AS&GqbbI3u>7Nmt5A+VvELcKen{9gK>O(E< zKFjjYznT}y_PA~FoQ3jtP%or<6>5+Q6iHDU&k7J8Z4JM67j%En{v5994~;4)ui@y4s_ZaD*=}*ms|z=>Gr3kXBint%&?D9* zspE2TRi=c8gz>{L z+uVHlEtH2;N*;#wM?z50POoT5)R3`quULG%p#<3Z>ryh!Wy#}Tujb>PLntXBZC;!& zHFF>uVQ;2;TD%X-@_>sesxC6UFP0=r&$2ux67t_8S--(bTDLZ%RD+hqE;=&VW}J+O43 zv!jtuka+aboSY9a{e9yDQohs$)j_^jz~o})(mpnD_~N=%hwYQmBQb-O>*-<#ZVRUa z;iG05kgvp9_n#g4^A%#&F1t@RP_MyZ>Dcnkg>Q#T+-Ww6$dXzzwsI|<5Yl>j2S>Ph zBq3z9wG+18ZoDr!xvgI9<=BMrJ^7Suskrm2GVxF)Em1(4bMO@+;bGHT2!9A)^|6|W zzFqw8?C-`)VZsT6Oc60&IiLTQb-!@2OdB}74E16d%Q7A{{U>t!PrS5p-5Sv=*rjVF zcYuPL8*z5qO<_h(am`4t!Yiu6f9NKDFTQJRSsh+GcYds(zEbrb8U9VAC~DPzLN$k_ z2ii38j$x58w2F9n-~mV}_|K71_KmCqH6OV^V4N9!T@rmND4JxRqkTn!Yav#Y)ve8= zN=nTxZ*y=rSFN?V*!hNwFxEpghr#37mq)O0G-VZUZr325ZHx6@JDn@4?|*doeqd zi_jq&!4hG^2&E|RC6!F>Z71j+#cC#7{j!P#J`-QW-=h<#)H(SW^eU$>Z89XHRLct# zuuCt9=k<;rKijq6+PnuG#&EWOhs+veN0|}l65Ot)5mh6V?Rwu-X_5`R70^SYf*=8m zT@Q%0q#XbB?0Ei8j*rhz3?6!UG~o+s-x?o=W)ue=kQ4A8G9tNzPwl>{!Svl=OH`XD zc3>ip4UA>8MPph>_F#ulw_hSy%hb7jlbS3RD?E<{lL&4LxMU=CUc3rz4pErJP@%>h zE%v|3RGDN-~z>Uo46iX4edAAj4o@ zHK~(G6A;A>rYL80Afp!j!%sOAm8zRw%2G|f$*8S`Dbkt3=x4Ib93@=RZv#T=R5lxy z3JRENT^Wq&!u~yxH=RMEI;>SK*B$?KUH30zJirHu<_mj5nWvR797+DKHm= zI&xz8o-Nc)=eWz7VnyKIp%%lh)wVpk;{;9O$vhSYCaECP12JYp9&n;3reg&DK&j~^ z4C1C&*LXFJ(^HM>jdy%X|D1lwlkA|KV_u3i#shnirx}lF3P?CRXe%x3eE`_NOVKHSmxvkdbtF(GLJ+ztHCk)9@i}A~;M#$t}_6l4^pW!nLGANck zsOpb!GA%>BY#zHyXywM!V1}oyU5-b;BeqENzsl2yD6S57GGM+^llIZ2RXF+iKQX|D z&|ImCv^A;V!wUbyTDqQHa9oyLuS@%ul_6P1W|9vU2%$d=tsjj80iGxl`48lsVlbWF z3EAv|1efSSg}P7%mt)*U2S^oIXz0l^d-@t0{u^$Goy5lX7m*Q~EoUYU7-*FW6FyI% zw)fu(>{?+;q-85oTEamOdNhct)K;UL*nuMONb*K=*z5*F45|`fnyIGT-U^gDm)FtT z*Zp(7NS@-qww%J5u_%x0k>)OSDH1$N)w75l3K{@?;iI-U{c`jUm-mDc(GQ4P zDlX=(cOmj*c=y~kqw<66;5$WXk&Y)oUN?cKd)ZWYu1+M!KRQpo$*R0EZC1`spuhLD zwh7YPP1JYK8XVx`y+aOs@Y`xg>(d8N-`;IN9m=3~O1R;NF^o24-(g%b)udXkzk4Rr`ST(M6yM;{j!t1ohT)?h(*_@AW5#Ww7HAi2>l3%n+{%pZmy1YA zhP(Y{4`COF4}5{9WY$FEgOCa%D@qn~0UB}l^$w&kJq+GxPY=8~e4$RE%5^Miid-&s zRI!2#>bzuP)=t~~@FvJ4wzxJ#@MfN+B_5*&bA&Hdi$)QE^0;(cMXZZ%eQz#cjY zbWh)}$DiI+%yyolt4AJRxooQR2eMN(~mR+?DjpQN{;njoJJw>jF?~Md8EE7 z#U*;?Cd;tfX9?Bf?Zz`d#uFj+dzlepodd(-*a1{1nIMjGL+8_cuuiOz>Hckrf+FUg z%Clv`!R`^c*YVr-wCjFiP9>&GQd7==yh5>yaNfdmjR{V*#^*p?K>PV>OkAiMD^v7q zzTdxe??ows4-$#RZY%cK{3>8X0+ zzM{p}&0oxz0PjEQC>z9PV0YGn)>X5t)q{owdq6U|}#)rv@ z#%Vh9y8R@mQ({j_d#9epfd?-&w@dGMXT878ImD45E?MM{(!pb|O0?-uq(g1(YFV<= zbdL~0%f^2L?n7A%_?CLrlE4~htsS~CP9YK|isaG=2t{xNJ)uA?L8jV^!U~dm@2h(u z!|s=@Qb7jKYzW{!5&Ka|H%ErwB5iX@;I}tWIY+UNFW{Ih`?G!e1#AWfb2$7=0HDHcd?=5p<5-{|(PJ~>dBhs85hXjsb3H7yul!z2W z$x)ik3IA76*I5}e_BJ3~sS@u6G>%TOx|Z}<*kZYpQtTw=NY+I+ad0#Lg~;wVNTi4G z(U+B(eA6R89QnLS1=GSv+g#)t4^&G2?11>aJWoO-v|jwG0R5W`YZVy)p!aUp~t^;28&3F0_m2({1~Wz88HEq zjF^960_7eT#+}`n3TdnrvZ)R#hV|kvU?2s4V$mzK52HZE!Sb1AR?nZ5AYRYniVZ~v zkya}r5)k9+ygDFvNZQN$B7I95*TYd6Tb*^ZprJS(T+-UJk;CvpTb`>n(W^!2iMR`$ z;C@xZ;JYw@&*G{Y3sb8yv|0@t;VR~_)G&H6=0==lOy8f<67P$IPxqULipWB1cYze; zZ^OG`aFE)a>Al6uq#{<35vS^)k#qs7I17V|8>|Q21{=ckUQOHAk=xu$J|VT#{+%2Q zUaja1(Y3<(##SPWGUSgEfgCL)z3Wvu!j zx4Efqn3DBg{@>CC=C8HI1qS0iYcK)aSh@YXi43V5rX1O1s%B;lUN5_-NuukwmO3;T zk`_GPuQtnXv6m+B619v65<7ee{m%t3N5;5b%=IEuftQLR!EvQormmr~49?h5!nNjH z^S#w^aWXfG8WcGPcRi>aWmw&+xd4O?LR$$2CEDsxyRrWS;ZR&ql7k{CZT_P2lG-ih zX!8wN?PII!W4Wvz5=5x)`Y#}VXeJ6q5eHNV2pUhG7l=;;$f1h06r_F6U|@K$D3}?R zdWpt>U!s;gEvdH;ZLcKMKqycmim+PaBE;Mym(>;CzU&A2?zuzGZ}54p)C99Kr3`1m zC(nt@yfPZXMv;lT{kw{l{bQm=efB_90p3#AP~32}O>%zs%3=*o(7Zo-^^b@ib&qaW zN4u;Ip^_Z{J`&lN<8WATJeB}QdXWeig8n$)j*FtPzkOXKno~+tfB5k?y_iKxTZC<50>c zWYefQox`14IXZZ*ap|`SAuB=zSl)omVxQCFGq;hKZpdt>$_NEiVQdSeu2G&wl zULrYv)b_-{%!MLu0!1z|R56o8anop4xiN$ci-qUjy#p_w`kUgu?s(#u_~FM60ovTv(LQ&@iNrg{|A(IcD@Sm}PFNV%Q+vv#km})Mw?ZEH zmw$LJ-^M;W6-RnV^IH?ATWu0 z$YSY=w|q5H{TaeqR@J`k(je_H&q>P7Yq0v@_$kw!YVOn4lSXLU|MPN!vh~&oC2I%2 zK_EyR7@tPv<%blD33M)uraKB9Vaq&f_F3`zOMIK7XuV^3-n?j`^K^5uNl|clz=)ig zHLTTg@PIo;ZWQVY5nn536+HL!3R%|oLcQ7A; z(%Nm*$r$8Wb;E1UrlWQASS-{+VhfL6Q);?cgbfH|#3c+B){r)t2a%QiOZrFLQ(n@9 zmh1AyetVRQ#bvKCi+lCXrEkmE%j+IFbm-T-W9V}66F+(`NiD~OLS==r%RY*FDyy=Z zmUo|>%JpIRrPXP^5!0ZLWX008Qv8%(2s(-on|e{WS+>k89Qp<~8)x)>hfT@tFM>rr;v3iiydtajGJPHgCgiFeSz11uAc9D^?4pQ;3$|>rQ`-wOl@Sp=6!2b*#D zW>NJ*A)5<}o8C+e8WLRhhBr*@ppMK8jwbag4xU~PZ`STQrqlBGYY zSJA!e1ULMKqAfKcuO_nI?xZ(x(%ATNBsE9Hb`>99NH7=p92X3UPFn10SpOD>N%CM%Ik{=Td+_{W&7`n zxK-|bHLA^^1#5~4L6L2|mZP80M4+fvcb~@RA75veCV2*7q$BZlILN~Ub5}li!e~ZX zDBBR?3{$xB+)c3d`=Vu^_5fJr<98DUwGWXd&4lwtI6MT6TwR2}GIyG+;f1Qk%8U+s zBdHJB7$W;~s$UCtqG#QwER}vDEytCBE;Ju>&Pnhi0P{C203x&W9$XiA`vUg~147=8 zTVv@wmhqYA$_3(6{XS^5dmSpqu%5R4D4+fZV1+@luaCCLSl2CmyOsL3kBoRBY9RE?NmF3(x)HGN)=)&Q% zazZ7ZNydL|xvEGTPr?{Kx`S?%_P~gAAW=h(y0p8#y-z%Igh;4LSnImKD&U zW~VoS;F4$kNGxznmY2@HFQ33B~;IwIu39re(;fbUHZ9H7}ZI0VPT4(Uv=cu^HF!Y zvKaA~Ib$7roH}TI|9)|ple1#kUqLdEI{ryXg{iR9mqAmEs>1m5?9DgeB?KucZm}+I z`s&nQF9GF_ayO!dh`3O348R~?>A}(mzSKU)Rw%i2&4fv?WYX@fs{+AXF()7ff!`7A zN4vGGhsvA~em479<(eG)pEm@Fk$xD1&Wn1{{g~A{#7h3f%kL@kZ4EI7mkE508y_ZT z*B!iE;*FyW73wwDBWBp~DZdwwd%kG;t~EjsCK-A$FSt9I#9&gaV7 zko6eGkLYcL<$@5Ma84Fpauq#M^s=hWA|hHOoC)u=D{LobQuhpi8s#x2M!7H^T`Dst zrsKVWPhqF7x7T%n{}Q49#4@T3%sW8wn7~_aN`C|F;N;6(tPKOs%JgLWY_~H&4aa|b z%YIwi7bTEdF!bX;<)_ttpLQnJa=iqkKl^2=3wsG^h-D|f?pE;?xMMDZwE`j#e3 zs=QUA%`&wSMLI5)rFs{k)}FG+Wor@u0fl$POEXrV3FS3y|Lx$@%;68 z&)dc$nm^D^RE39(QAM#-B^AAtx}f__NRT&_A!_6BN8*O>4yR31?XLcdfZ@gQf59hR zpKiM+iIl}zE5&2V2M$61Naea~>3`OwEFl_lh*=S_Y%M{T7AstrVLMJM3$0?xWwsiH z`uqU;!75fVIQXl+aag+tE0Tkb(+YoxP;rWX>v1NN_ltN6xHNPHF_~Qaphc$cNwNkG zFhbj4GP^wT2rVl(Tkc!+a`o>vX!NQy~B)+TfLmJlzWZ zU$NZ`QElG_LA8n+7-VQ=Bhm!<^TI+BRdsnWR}Ira0KDk}>VUNA>|ss__? zv#VM8G^&2pI{1Nl?&RDdL?>5CO};Z_C#wb{1l6N9ZQYqsvi7&Q$E4<6T6JuLvLjH) zlW{*QB*a}&o{)@kIwd0hE2#kJoi(N;<(ha8g{S(KT>LS8j2Yk!&hAbkPvol;6(aDs z)H%+R0(oqoOv8U86TswrYAyj>%|~nIE>BI|+Tp+4*>`nJEA(_61?~E46CYm_-?-H0 z=IprDm1$1%fp5mb>UDd!^Ky3()6q0nB?!|bur0tAlX=>08_OP8FulxAj(a|#BGL=L zjoBo27M&}Dcu*qME^Lrxhhy^NG^C1e6fGoTzd*3xVTNdopGShUFZO2?(}DUghlc~G zVlX{|05`I)U}qt%IKj|R@aLuRT~p6aY7kmCXh!P&oXZ<~$-}c9=uvB{vTAS`F82W3!<89 z$T@Vm3;Rb+?$}k7ScKfx6hI2%HmPfVt8JM1-zqD^6tJUvoX~lR2jkCu<-};*>`UKy zTD_ceXYx(&&q>H$j8cA}xumCM`7BrrI@oJ(bui`UU#IT=8g2|%rtE26U|evU3z``0lGH^!YRZv;%z}Zc)YKCJ54dPbnur^1nsUnf^b@vBzu>agQ!P7* z{cBeGvK5d3(n{@32H9&k1nl{Z3L5>JNIa)CH|@9cas4r6le4vEfK`@<^5AEyW%ASb z)pFTZD>tfiEWi_Ci8)2dG8zEY3=m3?3T5HRcsX;*GtklujnM6>T!Rugw!PCt%BY+; z*SyQR=^ytvobXz77^~$gt#-=xNBi@DIKnWwh)gedb&+m;elh`dVfGY>^j7>**BGJz z$n=M(x^RjhmFjS@6EV=-J*oS0053q$zpwSgRUM(=NE!a3JZPi2VA^t&K(bH#mCg8PraK(30ET_U(;^Y|aH8%<9~x7GFF8=P=A zgghz?9b(ox$6X*z_PN6liXVkVcID*MP5fbBvCk8)FLgnKZA9#kjr?kgZz<~J`E4PL zhUSQDP+9#n&wEs`wx9`B6`qmY6X#>;gfB-Bxeg5L72b^ypE#FsUWS)U`zm(LyLD~~ z$*v44rdezs2@FIR3vWimck9L^5y9OzTK`>K?oNDZxz6UH*3G(mYvOW_GqY?_&l*Ik zQ7jICCvoLeq&}ozgGqZh!kC+Vll!_XR&Bd5;|Y&jOS$AUvL}O_0%J!S22NvSNndA$ zO<0~R?};y1Y3-Cpq~cvz70eUkQhEIZWlhv=$_s+5{ooo>=!p`H4Co>7wL)<-9W6m{ zY7^|Y3r+_9JKplPS}JLtgS~vKCHkV=ppU~Oq5?G76Y0hW{}j-5hAq>R?-{L^WcF5P za6Ip)%r)yjJNBW)elf)?OMJ@_=Q@U(_=y#TQ&vHY+a{yN=7B{nJ!;Wo$$?hPX}ei0 zD>_E?f>0ky#n|@^95&HIIcI#=%@oqdXus9ozK}3XWa&wuhFCL@r3oZ1|4A`#A=!G< z8_Ih1ckK5`Dz)!tP-E3#1Mv1_y4_Jv!hje+ zR_F1cGR`zq0~`_T%PImp3z(@doP%o@KG9G@!>bLm)NYcp8{J6~NXcgd!5r6 z20S#o_(`KJDbIpl6!WyF*TvS*o3ZOAMs?fNta;IaG zZV|}#*!~Xv`5p~|6MO3Nb)o7DH7@lKG}$RIJXlGovPqo;y28I()2!Ek?C3ZlBrF+O zoku5rMo|H0LT`Xxx+9Y~o0>2nEtbD!>B>Ntqct}NLgf~39Io_JaU?oe(at?gZUJs= zY00!6MI}I8A@e^%hkz$D^zRSuCC>D}jJ%enFbPJN%$NOzT1LXEjoT1JY@6!Tn_32N zthfGI`MnXoO#>2YrF*L=tbeHHYTms64xs ztJ9izP9DgK`TcI5(le=zxClXX2*j=HPL08Ys<(%fY$_@k*>>dA(o{033gd8dE_ksxh(SI_CNxyLwCX}gjG)?r&mXZq zfgWshfe!EaJM0YAl2l-bOc)hw$Kg}Q>QT|u`KhU)HXp}^R!xt9)Yr04CsOsUeahMW zq9&C@^`Av#9BY79TT%ct2W;!VykcpV?Y$<|5D6kCvt`{TCYuH(g74;CC$#GeVLo7F zknrfotz#AjSBif$2YQEE!%(PRz1BmHdj$F>8wZFxrFXSmfqvi!0m-o9GMt)*DlVuZ zM+3{#vRtPjNQPH7+ZgUVze9Z})q9iVgT+_MySxJ^b%vhXx+89bJOT6HKWieXfN$;Q z_=&CZ3h7FEaitkbMsd`K-5^f9CGdFkeEu=yKJs5K65rEGcI3z)9gID$=v zmaX^#qEjnl5Z)oioI!V_U@Pf@+NZ1Zs{?(F=iAa<@UEy|r5(dN#FUYv!bXx}0+2C_dbz(B-(nV^V}|E+C$(v|;uJFW~kl^Nfn z^(&$~pqv1s02L!Ss8i~Yy}Wqa!aPKV+o0rK*n+9{3s!=5EST(RPM}2u*T(73W?v6Q zW<<6FH<0V@4YW~_Fr=bfbB zI91(NAVEH9l?TgBtpks1h9`Xw4o0z0iM)=oVDhsv*mklDO(}Q6&4V zy%(F9ns96vIhMkx{;r4dP)Dcb%8OI|EVSAKjjG?(BI1^3ZRPaB4JQ*=pG%DBy+pM&R|M0nL-a=Pxi=B1x-vfK5vUhzp=k;} zMkMA_k>x!xQc>R(jKVqkLVEzIbruPblBYbA9+(6-Y_$dXvrIpfZGbSBS-{P?6=^#j zOH*m`uQ+KIY!FlnE_q`bI!DhrP!8=uM|qr%EM1h`p9N~1Z#mVdvCkbn7*>g!p$Wu4 zFBHOZ`<95984Fs^Fcvhf=&L6fo;Ykv&FXKetj%c1TiC9#j|PgCi3soI8u0 zHJk|ZKzubOU4o+5R$w9NO+7yiE}k6lnZAF*&Zglqa>WAFk65s?Awyto7R(2?vt8=4 zMbLyNbc{6tnwSK+jm49Zx>BqHFy0!-^{o-3YQV0Y)vTBSGiZ7vj_@X{be$N+BW#8y zBZ)mB_7gu~gMpE3=}QSS;DEw)D2Rrmn6W4fjV)LUJOCXERC0iU4XvYAHKho7Cy`BJ z@4m%`TL_W*Sd+BYUnq{mDR}O^afSy>NFp|w!<<6*S)eh@*?rGn)0hM0>B|-BojZVW#3QH|l!7c)Qp%a*qGPT(x1%aKQQGb;fAWvF9Nv*SY~hCc z(5ul?R-a4RcbB@@#ZA`%V>pcRyUVXhH2M+DU@Lk=&PcQJti(CZi(1vK=}Fddq$GMY z!|kllCEO&X4znxo9pm6DcmZ)Hb$Tv->iX`P#Zgezq62oEX-g!a^?e8B2FZpLZ86@2 zp>^!Tv1-Hg{jiR<{dTynQOG7d0rXvF6m0bc=R|(M+ncx<1LVqOuC2deSjBEj@noUJ zca6DJp98F4Q=Uzc56k9^-jvMwDd(Ad3qGZiI@E^Z1!-{_zLz$c`DPjY9zOyc`}iPl zO%+yUW-D7d?aAgVmI_%Uk?Ye}+C%zx!P30+&4W%|wdlS7n|u}(YF8Mr@L(EwpQoz- zu!$Jq`=R$jj0HjARt)9^Y8~horM!B)AI+O9HiWh@FFb5LDq5NfM9ER1O0-)b^G+}< z_RvKhYmjosmq@;fDH@Pb5;mLmGTCvx*Ajy5(hX00S?rb}?A1)P*RjNV4~zPrYva_) zeeG_DhapLyX*h^jmlz7_xP3h1B*M6%3g%$9w|gS+@~6|u^=jJFxNd6{+!rv~TwLRS zj-#_y2lgO~l{VA^sC0{j?U%>p_;NLdwMnR^pl5sf#WOSi)I+bac&F|%&7yYXMM-ZS zAH#i=qk$bm5nc28n9xz2z$|_C*Jf8=bFXrGc9Z%>h(vnVE5h+&FJ$LsROr&v}b`Zh2louW)nb^k0W;F{9f;jRGz zW8WNyFiz(C7-`@EqO(>e|urE7L%A-MXpU~hlJEVN`f=u@~Z4}wGH=|E&3QU!F^?N6!E6mq)OBZW< zt%9q3lOIF|X?Oy)fYrg61=Qqne`3rt7o%awtsb~Q%00X1JBWV5NuPypH*?wOYXKHX zth&M7qB#?cuiOFlzBY9E*pxP$7tin`r1$STl}TQ9L>iCGv5P4n?hrW)lDR1_3=%eH zB=)=$_^nS$SvoCh3cY?jcPge3h|!lB!T4NH5DS^z51vpvWoTQX(t0>-lerawM%{GnO2cWaD!R}SQ0TXg%% zQQ8_5&hHB%)hfmASR{Cn+B%;uq&vXIpUT4(3RPi{#k9=GzMb6V!%j_=pKhc<1*TgL zo|@sA8BB9UjRz85p%#(MR%7)5f;-krCpA?j$0s)5%TVJ#pf{M%&!M5_oFQ=tN`2Um zBV&?%A$%R7LG7aiHmAlED7G*_b!^*)3z)m7xA3vL8}|+)`M4V4~bHJUHAUH z;lNX|1D4?}**K6X$m}f82c&3cB*iVTjKie?8;3|UkB~Y(DimQH6Rj*ATl(Qc!*OYb z>W@}8(6Ka1|6Yh!&Tjph3!v}i3SkXYbhK$uSu~=K2L3*uum4!6!$jf~Uj)~i3YFjS zyXLNr8>naAH5h>Q!5Uco!=%G=ORJ(*rk+cuPftysZ*OMk^vRWoYU5OY&n9oQ7@p+` zwl!Ne34Q7c2`UU4zOoE%(=g8LG`UJMYEi=slV?f8V#G}#C2x7!mJ8!@W;a3lR2W{V z+Xr!maOFWtf(XE3Lk%V_s?#4b;Yv2CZ=kmao>}7s!GW>O?okZai<^6y-21<(apJFF zSxNG^YMkd2KXZ=9{OwRpzi7RwD7g^K#&q%Qb}57jK+r3V3Z-44C0=m97Isw7x`iL&f~4Rqj@_$3c&A|$-~Vgo?Pu+4 z%@P_>)7FjWe;|Th-+;^R_}A&v>$izM55kL7=yO#7Z*(D(5-dJZ+5q#!QweP+Wj@eU z&|n^XsCT&jjY$J;c(TA49x6Y#d=!o*JDo@VeiYAR!yR*qO!a zC-Pu21`E%0RnzLbv8whmaoosZgCU~48B+43fe_Gbr*B>?79+{vjhT7l*!zNDWGBB{ z`+e!P}Z1L+$#cgIIV)HIi>9>jE*9s%Zd}ptth}Io@x%|n|zm1H4ITh0b zaoLH(#Dh^H11#Kfz;rqZDHkGIz|Osc5*T$Cw$G*tVzWM|U^<`ccPx!{O7iq*Vp$)` zJ6+3t5@R3hbU%Kttips~tN>~?rM&+ksm8ZX9qD?aUn5E(fFDC{$RiggU7xusZ{!Dl zYgj>Ug?&Rpr8=B_OlJw3LTsU8@{n?`I8yS*iBy?v*;I~%C|F^&=FS;1nlsCo`d0XM z0lGGwLpQPs$mX2O;*rvEACQIYm(=?@81W^4#IX=#5S^FGLuD>_^^Sh;S_6pp&Q|qi zd&Zh&o3$=Gh)QU<51#f)4ZOegaW~h1*rddm!P)||VIuQ`!8sz<^1SlBAwwH1ehdoT+v$ZB zp9YF8fQj~<*gtZM*k-V{J3;S{_Ni9`b4w*Nn{|!EG43;9zFI+Z*{e5_G$H2WnTHG# zs|q8BU|sSnsJ3xAAtbJrPNUFPqhR;QzQ2KCw`z$h_KR|*tEtC`hBFGxJp6nHVUJZ{ zpGgMqPSJU>3z3y{e21+=+*LAKLTMW=$C52mJ03qdglHtrO{(G_N}S7)OXOR3E{^cl zX&BLFAb%oWaNNG#hMxsn6ny@7Qe_jGh{T-n7@|%wiAtI$LIP6 z9S2No^utSoEkX)=itw1bc~wSf3Th*+{1$QUr&Mju^d~yLeVUZ<7JUhYin#cF?7kuc zJimm1l;@Xo0NI}Ba-hsqHNiXH3q>aloy8$eIGk(wa+Q~=-q-Rz{GQXF{JBd0m4B-& z#zkh3i{M{ zlhqdmZL;pzSGrn(cNWY?k(tk9Odr0RqA@IKR%Hat!vqbUf5wyR@=ApKx}2`{IV)C` zbsf8$6)W6kXV7IkqtL9Pz^KVQ4y=!PnY(T;eV<8=MYcb7Q#?h;vzihm4`kjvzi)Sg+bW>O`P%qGqI@j*Pqg{k-|kWzNC+hb~#Xwt^rTwJdU)~k9> z0YWhUjVB*OAn%elZa1_9+&(`GFLqfqt+8>yE{_177Dr}$jSLI15c{Hx#8C%C^_-rD zMWOb$Ro+bm*t5B-KvYJq2L0ml2tIiUN%T@54npQYF001e@uQ2;8m7LZ6R&YC>8MT^ z4G3;}iorg$Z93fHAG~o6=;JUsyJZ~$!tY05rd8%-l>VQ{O^JTzTB8K{?qmNq|Ek)a zK*Y97HlMo|uE*6RFbAU_!?%q)*g^>$b*=M}3?qRP;Sn*h7^YJgMAlu@FD;Z$#%u=6 zVvkS!fjJJcF>^U#TCU|3!Y}w8DgXoy75B{SbKRAc%3Hl6z*F7nN3bmPTj#^~3y2f_ zpz9@TqdX4)i`V5VG~hg;3~>{?6u>h}F7HyM_{XPgvN*{2gMjx(yXSY(yY zcHaua*DZ(gWMjn`y@ufOWdzNg{z*JvN%wPDN)F>FK;!+RdbUc#!*LKm)0DNyxb?^= zS7E70Biu>K#=H*?0#un7#M@Z>aK)y|0)WTo$W$&Tf8|c+HIJj{S6P%fJ_F($Tqqti zkdT7xtD=-N&)A~F#K8@gg4)ye^!?E4+ryLpP(5Y@hj9O9UtEw-LDPqR1%Yb8R+D?$ z0PYA%8$;xMzHa4EDec=KA3@8rFN{@-W+`5Yo3bC@39!jx!?k+(H51Oyfno4Hg>6g( z8!KWcgY-LHzG25k(l8Pf&|Lxs(wFSYMbzD3UEE&Rlo&Czi3_2Nn!7gqdaO(JJif-+ z9^&Ra0T3M)>VdhyKJI!-!D;H|`hgpOZ-3OzjBzscee;JYzIZ;xYE|0w<-UYJ35UIu zMkRC#xz{RlzB>X?-2xhEEBNJ2Ognp($IgceB_FG|_r!!m1y!qcXQI3!r2Swq&9}8; z7!twJ%IRVe_>?f6{jLRAr}KG3rzIR-L>V@oMn+``H@CZGmsc7I00(uC5}i0s?mkZUOdwh*a(Vrp0Z`3vW;L6PU(=O92&dj zT#RCAMIU8-Dv`*_o$2c=~tgFsS8hA=EwQ)AWx1el?uT+pX{136rt&JEAYz@{h$r8YK1VEF(ro#Dy+Q!+ZJ z_%erR)IVH-b%G+UXeYB^B5rrJ`e|fvq`9j~p4~C?$8)QlnlA<-8KXh0(zX9n?fTJ% z{HO7*-VfPhfiD~CUTQ|4(GT6X{5e&o&_i1Sj7;?`r4!@bUEd}G{Q`KOP0Xif!Yn|NNQH3NzN`u6@mP-fr_9X!i2r}fQB?U#lW6~;zVwFO z`bb4s+8H+A#R8dY7|LH8CS_64FKAstP+1=fIESh(CYaDdCiG3c|Xw4=sz&C2q zFxsY5uQGga>QwTH>#}0luP4IeN>S5+D#^R{h+t#tUtfM+3=5tL6hv+nXM~LXRO}18 z$aX${4vxESNr6keVOzZ%X#TfX-Vs(9k$T4u==myeQOO$5qg={|dZqD|NiK5%djsAi zWH13nVA>tVF@udtTYQLqCuyPs7ncqoHM`@-PZg$HU|xx%dDSckRPHOe;#w~-RRWHb z*2LBKdXNSCYbKWn_r90KWcN>bwFil6U#*686G_K!^~Z3u+vjo^LnCn*%BZ1k=eLiR z_Sy&!40jmI?tHKGXSAlwzDFDr?#3&(pOf7AGp16Isb^Np9_EuK*8{Kxi})NL>X;Dw zpen2|)NHY@rfW6d**TTZHZuCO_Mr*h){g&D5O};Y$QG7{V=HHQ%@`#pkn3rqoAO2i zcdUddN7a{tx=<<5aXu5tDx$Y;t zPuqyA^A^1sbf;Pyf2Ge?Fn-JMt9b)~Xu809k-=~zxmIMs$xdiqwTZOH$RB632%B4) z+>aL7>V)g-Pa1`}*%(#ckHL^cO{>3}KHe$C2qaRHrFPvH+mFObGf@oYt)V8xwd2jA zsw+vgo&P1&fPNgJ9uqp>r2*J4X?7zzY|J!(Y|Uu$GDuSsPCsE?a=tMVY(F2x43pdi zY87fcFCQ&J!WBgbDsq(ljpy>u?z$SSKy(9XVv@}7w&)I!g`|7dgmCS{;I^F&S;7Zh zifvq~7efrghthiwJn@CI7NaTLtvv_^$V~N~+ir5wI`kYvEEGyzPIQDQ`$Tq-F_;FI zoS1wp3x4!Gg3>5h)d#GaGvOLvuZMXj%rDb+a~;uRQHI;0R8f1*cEmFru(|ov)C-TP z1d4;j>>0Da$ayvfA3F>C$hHMY0!=G@@Gg$Dw)hqePh5TLQXr7m^uvk>{(ud$_lS}d zpWc)!UIHSx$E|f5Bp{0%;7b>2)0q_jSf^>)lDL_FQIhaX-F8}XRk$yVuZxyJZ*mi<)HJV8NrQ`>98^(}(Z9cC zYs}P&X%l02xZcP0{eOq*G)lgNTEVC*7qMvNvqy-hJU?UKOPADM5U15aF>H>OSHlgJ z=k@8`MsaLk#xtxgfl*s9juduIUjAIP3Sd-n|5^mAN-=@{pD?s7cy^)*G1`6HixE&zT4%pM*>j_~c`Q-s4LttnSbwd&JQy|VGqp&2|E09%VFt3u7#mKSjA@@?KG z?&g?muUmGAOM!Wq3~Rd)>*^?Q`EtVGuS#`jQTsbSq1upVg+b<$8*^eb&P70q;}ZFr zV%ntrPX8VoA4K6}wQ&TGVSU#@l^oK+$CFqGpfoHDdMb;eMNpMuy!Yir;~#Zskb8a! zsQlAUM*=yi*?LD+H;>Wgb_uy6NFPZF5-NSt56UWX$n^a}xARqKP@6^d`QtC0zwp;( z(`A5(B!FF7H$zptsmv8ovMXvX_L9KZbTQrZ>>B>gZC2AJMYK{~6C&3F{sDwfQ|Ad0 z)3!I)*isHHoDB{K_mNHv&BJMcz!+8cg4L0b8T=5qLN9gMB8D@rH6J(|7xmQF(81~A z^j^hKww!5B$g|w%g^eOEc4CSI6?qv9^!6;7fR=aKHW;1&B8e@nOW3Gw-tp-aIvA`( z{)XFJgqMT0ueuc35GiHhE~xnmj!Qc&mZBm@9dZn1AfYiMd)Os<`M%n9KwVQi-Ur>_ zLa|oV83@HVN3T6+PC8!H?y>>MV7a{nxuH7lPZ~?qPLOuN(ibM7QjSzS5U13+U{btt zPH(YdSBq$~hr>wi)9!lkir@rT)9@3%?$}l#nB!m^Ylp%>kS5SC*T}(ZDsC(B&i>@O9)~+gNdp@&#>#J2a zK)bgdy$Eld_us_o+0nx`wWr>Keh74vm{)NY<4F_pKa6=6tCndO!QJ9G6g(1=tK>$a z^Mns^2ZQ@jpo-FE}M{J3J}W0{Sz3{22LmYb5xOptfq$Jo7BnO056Eg_)&-=M2aURBLp8HaQM`vI% zA#yq->9hnB5N;Tk9ulU%Rp{NxUB2-w^w+%%d;jQ4L~RJP{OWvVf|jPAZJ>!%EzSN2 zhFx}5wMLe5`6;_2cQki$)=06yacoOVpVr|;PcZXPHgp+#=9BWHl+=hCcpQ;exv=(u zeI ziO3@Gbt!vxc>%Rbba=7fatGmzBtfU=9dq!;9J_mWo%87%4Hlr=C6@8z@c=QS3~I?c zFLeuGB-_{G?@74z95hJn?EiAKK(0_har&9)GN9t?@jA&1^rAS)Hp)i^Dbs`nglnnM z^AolPL5B16;Cf5%2KE&?mu&;c7GlrhS<%|Ym5X+-Isp#5_5`A!UXU0)TFh>8bKPHL z-IsX7bJ4L#LMjW| ziD@#bijn$$>JZ!C$0QTQK#(5*7k)yDlZPEuY$I4f|Ic=+g0;E0WcP@36@n;AhH?JS zgwr1W(o3f@#H24&)qJhEbJ)}%K62@GKh{x7Q?xQ_PWspSAf{q$bF>?r3K9rQJ_?9B zjd}95Mf8s3!StOy`DdCGVH)(9$1EtdScdlPnM64?l45Uf`p03FF4(^aS(xKJog+<% zem%MDIBg>GC2+qrBi{}UwFC$K-vCEKo!sqzgsQ#BBfSHp1aO^94xNC-|}1K-kofon;{MUtHIhqCSU*;~{u zKHo}EnTUyR+=+5^#S=h!P1UN)Qs=uL0*V>gN@=H#X6nbWfU+3@Ln4a#9@x!n@*qwc zv@7ri&vG_qpV%=gkHxnj7~wA=NSCEW z=b5BFr03NxNiuI*8rQj~`w8$l)3cx_ws8W3^DfHarx#V1UG9VYIc1S_?1bhM9}}3& zfG~(x+8QPFB^h2>dYn&^xtu(B%EP|~XPZlO(W89!W)v20>==bT0Klh))-z9VI#k@Elk@p+Ghj?I z)eqm%k|}E`SdncftMU>@QQs-gSHcJ=?5jaJ!uEn|@G{qI6IxC?I5~GE!uwet>a3{v zpg6@y5%V4^j7-r{CBVX*;>oxO(;5QGKN6OD=%PD6bO)&983ES@6+m$gsLHLPB#mUQQ*T|zr16Nr!t!y0ClAwQG zg()krP-u#bNyg`{x9nv29=wpP4C$cTvGGlS{b1gszydNcqM_7OQta~a8ONTf2 zM%=*qnOxKXIUZT}42Ak6T+cR;t6SSCsHi=Y&~Z~B3cX&qL3|-yBySAn$X|vvm66+7 z9`eGKYHLC`rjzDkQjo`q0MW@=j!t4NxZ=ogD+Yy2RXhCxn!l9zxg@fQ?U1UlfX+Gv zK=Ls)3k~V^+=Grx^ni_a{_16vCd@CPTs8&z0}S=A=d?m~HL|VyxM=A6S-lK-Y1Zl0 zqU>7d{runht6RjFWNPL|fLAFIf$Cxg<>aCnxtCY#M(-BEKc7KoCMn#ooPe4n1E%z_ zbi)mJwGYHFs2uCb{X=IVLB2Ib}^yEFbGSP)i6vCB6^n+Yu9D6NrfP*RPZFc<$GXqT#&k;{K4k-nWR(y^8C_w+sphsA(PlYS8MTK5W>xsqcx$WLu zZaF@7JiBnRsxH4i3Q*uWL7ILG9P|)ZYnvQ-T7aJXPw-)sSRW zT69UNLD2H2496aaQb$3);T0Mh?b0wTTRDO5!aIHIlsj>}NT7UbYEv;c%4C>=UOzzf3Zt$-_8)5oJ%Io~-RlYS`U^j28S%$--O;C}0rc!y%)lkpZ zADpV~NRm=~Pz1bAjpT4zji$Y<<=~+20D8r)lD;eB6KBqpz zKAaWt;ouT6BTyThG-jMHY0^GhE$z5Zpzv06>hSz`mAJ8pvFCF{?<9qX(^srZ_zY_=Xf4u?xW(%|})2iBqi*Fk)O?blo z#o0CQG8pvp-E>uoV0cjN=7a!HkD7hL{s7JM1;E2H6l^JJzt z+5a!#JSLCm01p#53}5ztGOJO{{zYe5Nq#*7iLPQ6K~3+q)1I#Z^)`oQ6Ul(BfP2K9 zzYG3;T&3IxL_tTjx%j5dttVY5sVWM1@=fJCM+^B{Z3ko}f2{0wOR^m+P4&7^rn(6L zg-y5v;36oPrUj+L^ej7T{ki~41!*YCu#mBTod*fqXF^9p&ejd=I9z;frnK!t&0pDQ z(Yg-te`>D#$|M$88bx{)cG}Om;*c@wTfFILz+}8vZ+KuTf8_hMt`>b`P__Ll5K@c{ zz&#V8Z6J zHTLs(3GrQ7XaNb9x`7UV?vbR($KvS3Fe|L*)A=6k1g}pL zB9rl_gTEXaC+}YKgGOKW(Tu)YIO3vtoTxF>G7-*KRiCPUE-K zyFxztV>l9fj7ttCSj(th)OC~@^``5#*S4c*zTb>mX}}8a0Ma0gAU*iNmp(t6-UPR2KYJL3l&?Y(uOUt&z3>~Q`)fUtOc|Qlo4H=T> z;IfgNmq1F>_@ zs^%}rVEZ9i@!Jh)igg*ApRxcQ!3p`p>Us##5*>w%p16FCG|Q0f#@kMdm%6Cr_Q;zA zYtClTs*ENN&Xn)gc#JqroLV$-cikzONhrHJ$07_~hKT|r^FnG6>18Wbk%H3r?*%-B z?KWO#hU8i|IFt<9{5EMzapo}gkv$GH)Vl3}?=TSKkGul{QKrU$vAHOPC-x^hky!*4 zYHC_z;i?<6Q7qiDraqi*Q%|RmXebLT(i40@3>*={?+|`iZ7qHT8_Ia(?iICjkZbbn z*A#(S6&p42tJ~8k@}g9>B32ne`MtdB1$A7T|KytBay;q_3pC)FSoHaCo`-F-_3(Wj z1{2+0SGiSNz+Ji0cU<%0Dqfbf2h4dKUhdqU>Ts>T=OB7u$ z4qb58uAtCeEpE#i@?g&mPxr(@mpkV4hw(Qq!91axz_~BAOEM*^_@8ld8g3N~aRErw z)1wo_9pCWDdUi*>^{9x7M~tdJcTx{#+gb=5eY@3}zxYq>H|v(p4mdKZFb8JA_Pq36>8DC7(; zdSFIpdx@OU^0QY#n@Kx~%_~AGFB3=lN6~`k!^Gs#G;PS9G}j-kZrbD!+-#?tTOM*P z_zBg~vzU)XKs781s>1_fV-F3pHj8rGZJ!( zTg(K1*yj(cvc5qSF=9jOBBCz%HI7z?_oR+J)@tm_1Q%~%nCs3a*Q>>mYeBZDF??XQ zS_97#Y0;u3ZmlJ=fY>cO+e1aUv&VxwDt3K{`xeimC`j|I*cwWKH@lJq-ew!zP>Jtz zZ%J#iNJY}+BadUS(XMmfHh8%8ADPf)Y1byp!9lm;)IpqM zaFCgMW#HIBgFq!FD3hP%?!L#hJkf2+2L3EVM-}6+8zRwfXdDALO62qI7LLQ0!8rZ$Fe zlVD!5frHh15%ohnk7pm z{UVWUKIR2+1%TcGXfF{ZLHp7R6@j?a;^vJwy&#*7;-sqc{rZ3~T7*;bvp$eg z(buiFTp;Lt9KmgvmXI|>f2dNERIsfnVRX(C@LdfZ-u`cpdEZlA2O*R=HpU=`uBKmV z#xZ0!3_VPSj({V2+Vo(MO!Api(xmqPLUT{%o!5x*$Qs#xcy*LJ<()X)m6q|602pg)UjLrQc=QLTiYJnZ)~Q`Kj<303jZ5@ z=_^k@S|xj}y7={AtudGwlGhj#DaW&oFIO03B@t;qR*CcF<6azf$B~W@qq{gQfjsq* z-jO8X(YLRmRZM1gb z+Xf+Qb(zz2#ft|18N(@13SMQ|aV?mjc z9bdusMz5PINRU)#2&ER%Xy0a%uth}%g5nUQksO42)Id1bCCHnDf%q}}aY;8J<<-p3o|dwo4!!4le;Hbu z1gZyu!J6L7WB>bGtnwgZfF?U|?^gxA zUKm@#5Lb=FG^8UzQTfR;mCyjt>iqx5x_SvUt+Nw6oAy!xmUD!(ti%KzYFyn04lKHC zxXofGy=T2NiV;Pbw;8@B(ZKL zQl!Z#IF+nEA!4J8b83t{IhR4g2mX&Y>vD|n_!Sw&8>9w7<=?C^4+?M@OV+%0pKnkK z@?b^*iGGuJfZ&L_sqM4KvFS;j&G6YyKqOv$d{_oItV z0u+4JAIGUm%QcwrnPnHb|LY2#6kqE;8@4RX0VT%^mx&$rP&`7O43cFmEI=R0DM6Gl z&41do_=nvq=QWm*SO$bh+iRf;XMZrI_o3y%Y+p`HjTC^f^;+F_UGxK&aaEJ$g9l*9 z=53A?hD4aT_96&OaJ?v=@=3J6_#W>D=nbetjkwhLaLLx8Co=MaJDQwp@z|5TY~~bw zyQ*YyuYfv6Gwk{1;>vOl4X(BN1*{r8uf0Ok_aZRzn^P@9p)MIS{0|;{ewdrTF=-Gz zwN%@UB1E;OwM8jOgP)!$%$2TFTUHVsbOy9r>D!oAg;in!5XHY9A-W7q^F2OESG1=D zfbR8@Bc`KcTl^O#erL&;R0Y4oqo|+cJ`bB2Ynm`Iuhg01IY7U>?Z$$@h9jVCg7r#l ze-Z6mV2O}XW=pf>VQ5j?yD0Gt#{ZWg-?sc5@bp6$SiVmd;dV$*F?;x1gx(9I>VWif zZ+C+u?e=i3vSpJS*R(5&sVg+(I=N2HEKUf`lQQCdnC8}~t*-6S zC4%#Wf8K#l0N1Ua8AVgUd|M-=o1qY#MjLv~pFK>9^c5{TS_uguHLBMN&4)14+$62D zY_AXD+X+ge7=IqSd!?F}SB+Xl2nimSXuYS6Kl64(YM*mp`E(nwbza#}eNM`qw{}#R zYPrW>F#F+GJA>A|zJaMRVXhutS!$sq@ZEF;v#e_=z4Sl{m+xx-R-SnmBlL+C5`ZT zG({j>+3FCJ!h2^Zfp=-xhExgXEzK3ECwaH60Hp;TIpIp_Ik5)+b$bzG)J|nMsDrs9 zQ9C#%p1Wx*^#o*l-_u`1oz@j6KBRTB7uxp-6Vpr}ay*x)#XW2#a5-2~2uP^{N(wk8 z1qu#&{VV=bJvtIGtXWwJfB=rxPTV>ItyAynNkOJLFiHhKdqZX%CE2BP#ha2@f zTz6LZ4XlGbJ9TJ*!MXif!PQSE6MkHi-2fP1QVYk3is$j=%7MKJ9ldgb1-*P6gNrf6 z$VQJ%G0;)A$r|D~IPY6d5 z-ZZNxrJEow@o%d7#G`he=w~-U{rIdpGdl6>aP_voznXbywy!p{4H!+!|t6lP9a0t7mNGolz zqQ^#metW<*d8lJOeAMxxgZhDMO}P9a%9^|Zxw%uFCCd>4Dx~02@ibcnQ^)?V?A`aZ zZW-NGaft?grh#ZH z>LpLP4coMo9r4Nw+ImfkdVGv7$6{LwTkM{jYq#b8wzTU>Y?EaXs$yXhK9&oo^6x#m z4#l(SW%DQka z#ArV`E)G4Ls*##{32>}iH?=4ngP8d^#om*ZhPg623G_Bz#`(7qFlg~MlTV#Rea6%g z-MT4iiFwms1=}>fRn`T-O80%! zhE+>yfZd&dN7;q`3rYu1_xNf+_K$A5<9tABOSx$6?c`-{Km(MRwaUJw?>8IoD~zVa z;nR1i%H%>)NCKZK7jLq;(IwXM%FTa5J2fCkR^NyQmhCaTl!c~Ehzp`Y9|R@qvE}vl zo`*5mj!NQL)-Rmpr1WF@=0pZUA-F-W!`TkN6|g@4NH7eFTN1yRkzI$%!jF0|pE4-v zJ90+wM^1~^JKG}d9QU=)DV~*^bbLjo`Qma!{}00bfHVw7XS~ZTuYgO(QBUZ2k@*8? z=ugMT>)twQ3X9J+Tav@a_TKdo~D~^f@JOMCnNsQP+K5aEik5~_$0TBNqC3iDGaZbx?_wATVCzps7C#hcwlDG(rW(^n3h zTeZ8Tv7B)dd(;Lf04O)v7Xkz$MKIwq-NYzpecK3hVcKk@G`9S5u2v}Z2eOw&VGZp4(uq8}RPaCAO9zHCqjcV|_xhDDOl zoh_Z72WiSb6>jl0n@`4GQyIC6#BwcIhlB+d6|v6je~?AQEQL4F8|;znDoYG}XZby< z$fS$Cr~fgPgxjHUO?bGTaCtI;Dsb3ZH=W&vu1GFdUcV~5;kJnW&OXq+#Z(f{QXF4yLV$8mIEt}OI9F+e`?sqk zZS21=6|iE|VWc~j|K>K$fvONljIP{RFcf7jT2A$mTKuoy-kcajJkyB-bQZsCT384Q zUe<*g508HH&W(0RZnDsv@DNl?{5$nV$UvTXU9JC+5w?df57A64SLnHRuwrWgJ5(Wm zwr4{!Mugyw94@-UgWNv*NW!FEssm4GpROXG|6rklk7wEZ8&VN?a_C6EsA=2)ut}y= zXw_ms^xjLDr{j5l_kV*(26j;usS%W(kDg}SXS)g4Z}v@&*1yFzWu&-Gvd%oqvWftm zt#melHPzL9$L}E|1kNr1p*#c>ZL+D>1kwNxjjC}M2l>T;<9kk!$;`n)D5>*<{DPZ>7V?>0e`8qM40;CsB_p1G5uXYyX2f)oldp0Yhsj} zqNRVTiBLq>E(j!HCH7OE9$2_(7&6|Vl>$v`D1^u?=E_y;3--JQ5fR;F{>515I5|;{ zOMMT6vL21sP6=~_`cldbnllIwN_F32xXbyG5J23Frkq4{|37+&0R=k@$;<`&COu}Y$8-pVcj}zPSt3}I4qpHB<5qgFciZ)=N#%6x zzI-zegT85l5~`k8w*}Ruj5&jfKMOvKi(<;4lfwYZs<8!0_2CZG_}dyg@rO*ovv--i zIM+anCJ=eqT;~%CK_PMSO@}7frlO}e;vjD12v0k^n{H7+4Efn(91 zP-J^*BuXfz4W--&k=9VJEQTS^zN6beQSw z1d;P%CQ4m@4L%ohs0ZNGB^tUnht{w+G$=!E_-UAZuwTndepMkm%_f5QBYikbe!>IH zY5=fiysfbHT1O=#w#$P}j&`_4 z?+dzuF5fieo&?58df4?MD$VyR^17%Ym8Z$~3}%b!nQ*UI^vVf~0`*SzkRqB@&Zxe7 z|Mds&G;elyR(Hw1Fya-`W1eGKdpVrqSq!0a$lsXfI%K3HN8J)e5kElmCxT$7Yf65F zjx_*msI?yDf~c;B9v;#E>>`Y}KmNH)%%35J4Ty4v&QaO`{nTGv6lu2MV;m${@9e7E zsiD~*I3qwK=&>fkw7%+)JV-MIx#~?rn|CtmK@fzb;jF26ssEwcQn_7v(@Rv5?Bjw%Ui>nEn~i$@ z0Xl(ZpY_ok6Mxtd%@eVhtMac~>}bQAYqz;hvjNvqM%cWmF7vXI9?^rz1J-o*aE5JE zL_SDE{yCUAPCk`GN@h8h@*;y~hL52xF>T0CZ%2?l?88;F(q)^@7w>pds zxXV}no?O%pCgZC!0l;3d1kNK;pn77#p;Z*jgo*yBcN#$8fOrqfQGvdZg3}uhi_wmC zc5!dv;KN z!zP+FgbvPK3*x&7HGKC{j<>&{{FZn*HJHFsTNACvcpX+#Cdp^^FlYoaSc_!M*1kbP z_R0WOo}Xg2waZhnD3A7vy%Ku50tA?RCV_2!c*;C2BfofSKf9mOD*Hy{KZuql#|9hI z?>xeqGS@tdoL>clytZS*A?qb1e^B`v8|lqwys@wVWkn?QGe&CF1tH+18o#BB??A_e zxgid|u4LC01h?Bzb9?&VNmw|J;lP^kAMHsJ7Z{t=UvT-x5kVVv-DHg)0o4Rl2}fp; zLeAB-EDU_NW{VhMzjDbiOdXCj3+gG641lZH{n44mORw)w*X>1&ZDSK#OlaMV%GzB_|PEM&+9 z5-p_Q@$k!9*UxcNuVZn!{1H=y;1|chOBOj_;X|2g-@H*8>@v~Z!Bpi>ADIDsE;aFa z;=a*4oVwwA3k)|qRSq%@Z>LzRLiP0sk+aegB!oSie*wp3#Ar!6zxB`$8NDYLYILJU zKMGk3w!~3~TK;|9^qx20SEt7cw`RA~C!7fjip0DVg3-odPm|Y*8&@!@4z* zDq}_t!T;rHtwmCzXccnqXi7fW)m z`b@QVX0fHqNhnF-?=vw^hJGIozJjsx8;l0^2h>sP<826p%sLx>(gE(1BEjo~b*=7* zp{s#H*%%BzLD@*JmOX9Lzgo%39^I(8XoAg|Er73K&jestx74gl;*GH465?YWx#24y zVAnGa?YMg=Q~#busZN;##SA6zcwhvHXTr!?{X^YgeYE-f8c*ScR+6(PRQOA!sWBL? z_fZJP0<>3kww=zG5TlIb$u(g3#+&R$Hggz<@}zEgQ~L2!Xz&^dLJ{NK;sTS0#H`*j zIYCn1OZ(%yaJoFRfduqy!ZuyM{B9f=k(tt`Y+_S-29}3(c)f0+FQKYvfi+1V@==ga zbgr`L>tyvtSjLh3%xMVKnqcS#HF)W*=Auj;z7zC%7AG%2qkj$urT#>pqqmR5oigNh zFs^Eq%$m?9J5{#sGdidy&^w&68sMp<#=5Y|8-~LS^%5gJob_*}NU`YE?SyD6nYaZL zA4h#q|N0~YYyJ;FU90lNaw;9eI<)Ky2`mLL?zvf=c&eKEhygJCVJJe{@HRX-IkG0q zo=H5hskQ!3=QRP2s75V4xe5LYG__UdQ-<4&m6Q|W1Dk0k>~egjE6J(JKALy^*?0t z_riKgU`$9*jgm20-UNNaSRU*>=uFG?(BY<{oeMnLqjdlswsj(4*J424 zHOJ~q9u_cS{y5YRh{a9KJ3Y@M__Fb9T_{$FlEs7!jAmCg!HDo7K6Xe1wc(QEvEEkn!bDa z6q=~H^V!XZJ>%Pmpn6dY5SMqwj>4N=5;0S9*7G1{bAX$v)l{2;*%1KmsFTZg`QhvE zKNR4<Z3V0ajn-QjmPYikRT+i_iazh9DK5gmE{_l9O z5&@N2G&H@?H2PF%R1Cj9ZEOo!(5U9%SV8Pm_KAEfiO-3T^h(Pa|__YpEd$uvk z(?(K{b1qdeJ?(+feuXU&Bfy3AOT?vTuUYDs#>W?!N^#(*`rt2C1IJ?JW|EBf9w1k1 zr+}u2#ei=X;ge0IP1x+kgl*13X99kRG~dm*a2dfmWkhh2L%RgR1$Jv@e94J0_x3*j%D^Z_dxH;|IU7WNf9FAh zZCgPaEus~{q{-bhU?D7vt)K%_26JZn53i+*1SNr4BDCBmd;}kGD0^ZI;Rig9<8Dw* z?u%ap;GkwLm>#FXhQ~??eKX=Idfx9j+y#R#G!cVvaW^g%G~*JI#eiH;IA=YPzLDi% zYtnS`GaqY;3nnhCrAuDyQ>O)qIXOP$KIMTK!6%9*EsmsPv}2veJ~c5AbFj_y4fJU; zz&MF<{}xlZLyUK~J8#Lvs1L9OS3uLgPv{rSw*sJY#(a#*;V)-g2F7CeI%ZrlQy={N z&-j`V&Cnm2XW^x45f%JfFRl8D9_kR$U?$kN3bzO+Hz8{+ zoM)wpvteopNA#gc-}Uef@?FjPAo4aphDW>_{m_c2pu@s-m^76VIve{vh`BZc2sz$JpmfkrgoWqSo{%?GU zlm#+=;di0ghzlbDqQNOqC%9&;an3(s6SZ9WW#Mo0y@Dp*dEb~>Dt`|o!n`M$I|Ji= zCaBdtk1S`UzxCpzy;lEaD9@!;p_&Z-8uA9jrFp{<^V>flEv_HOSKai(GFYEdMuKw} zx@8PFD!nl}08X-&hx{_9v)-tBidPd;G1jo(wy0cWbmh|2u`{IkCbXxwo89BT*>3yc!P8v1b{E94uz| z1{&&Di_{?eHpY__|F;&dT)y-=FXD5M!mXR0u!X(jv7HMIQq?vR&g+#lmS1lG`9j$# z{w!$#RGPm6^e?}!`b*9uKX@F+3n=(fav7H*^io+frp@yJgXK=NUfhRjUQxr}8Z#Rl zRdjU-TIb*f=QsK9+c(bvrl&aRyS{t_?DiyK`YHQDuDxDv z9b)SdntYC_-z}&-u^{wNH=u>7$DlO4Myks34a>J)_&e#{b*1yce%Ozl@!Hr-eKEz( z2D|2xjiUZdN)T@mLeQd81|FP-j(3AEF<1zCKX%DU*yk7x!^e4TJ5zZScG=^Fb8BGF zv=cKfjlG!5KT$N$%#$~~;hOk9aK{@C$e1!VX$2{6sBzG_?4t>0fSUqHZ9H7-6UU|L zgAB42E4%}6c|@+@Zy-Y>9)wv!@e4h0aLIDBoGh-lJ`qX6I7F`Bh(~DRkCp=gXH9h! zvMbwvHWtUda;R!4A)E#y4u9U7prUw3yWMrp5)ZCq#g}58w0s(a`4yBo$`l`xLy@Ex zf87P#FCQ@KOPs6+u6hsgm76E#xvL)mm8zcI-mQ^ZqqR`;4jJm1sEU3sQ=KzY(!CkE zCVMuB#3~^8JL?*yr_=1`_M2Ocm_dgSL*)h*n@aqRVO`^h<=wet~Bh|H^E=_Y4 zFiYcI!UK3>z9Az9JzSPQ%Jks*Q>N7|wJI$kjM#xo1eIUt&$v;K`-D435lpGX+XwfU zz3Ml^6A(_ps+n_@_B&c(V*FM<1GCj7XdUlDj3YZ1f9E4T;Nc~>-V+124uYuLeW(G- z83^xHR(wELD@i*DO_c3%X!|;}9`a_Myqe<@A2h~~ zy5&oG?9RCoVk#SFl)k?E-|T%kM#N)yqX}aRuIJ^YSm!?wV0ycGbE1A!o4P;Dcyf z1x^^xVxwjdjGr{vQ=#fDDRW5+oT4y8eMu3IaA!Uk#rR&y?JFA+P&QmHgG@$q_+b*? z0c>@qX=%~$Xur*2Mch~DB%#kS3${w6o+P$vC(~mrdj$I*>;-kN8oMUG86ZMiw66CP zJ*0MC0-Xj=+y+tP4$QhNcdScOtrxQ|+&X{0@(8hNaQr`j8d&=@-FHz_DX=de$qgSO zGIJXJ$GNk^~R5; zi1DRT7Vm}^Vc4#Oz^A`jDQ8L^thYL}{$#iw8_+D%y4G&C=rLvK(6&t@3^QecHr_cA z(_B>Zj$i{=_Sh?~h^l#P$y7!Tf6E$WMF!n46LJKro^e=OPY3Jb_VXS|9(k;V-%Nu*Jw>cppXwlToLgYAlWqPLC!e0VNVNfQY2SfIDZ<**-(UU{KY?3b}qb^CPTRS8xdcRqy* zAfW|8Aac!W&(rDW_a+Zep3 z^0H;>UpYibP0U?QF<={&JG#vswoRd28XREA*n~v*xT4)VkJ$!af8gyPj8LOSKgM~X*mzW4d-zFvuN^f@3jn{YgQa#hyMumEy8;hA3rXAqWUbF5)y^m15?6jrC$+xHto9gD#i$l zTDlBf$>xFpXWFNoztEH2D&xC1gn&62{_1)J(gN8$EfD1{dPLC&snp)@gU#B}d?e*W z)N?kvH-r)d>k@f>3K`+zw0Xm#!r;rA)}^1N=#P|w_#0j^mhZakP5A{-SaighW2O~# zHT;KOmIh`zl4$HDY~;i?YFHs$`T8}@n(xN#+`>5H*VDfn4Kdb8@%yemUKcP z>e|*5EN!vYa!%2+lpEeudbVB8X;&JACM=Em*0)wh2U?&e3{OM<>~2zYq_I^OOqjKq z(G&!V?chgNi5{+k7qc~Aw*iDaudI~Eq37PYv24T(;ogj3=pYBIDm$4k&mVr{zQhA| z#4FPfa=SwyCQNpScp2h^eAvjgYPw!CDv+DPC5WV#JcwW^6(~BKYM3!8UE2sd1nJPZ zVH_+=-XZORZWoH^E>r$tPm0+du>=k{EuzPVfpkYrj>^CxbsPl5B}@$z{S@VsTb(){ zVR`_3Tu>_jdZaTfs3h--Ktq1=Tdcd_*w!W>O)0(jAbQ4U1tYWKS$z}5S5WhvAUfkP zH&y)@NY^X{?_if`LZxJ#{!>e-JkxwUAaMoXTY17Kg)kPVwu$F*N`H`PpqX&9S5s5q zGwe*d_=?X~&pg^kL%FN4wtxpz)7Etk9EjN#S_VEIoA?d4Om7-~eW3L-$BO2SwH)WY z$z)HySoN=BW{>Jqx21r{{NX?t;tXKq5ia!*fSGL9;wX~Rf=m$yAQbH4N-u40ZDS1O zjaLztRZscII;L~ur}3pymo-8pbno<7h@^XE z3W4rR@SWV}w&_|VsN)J`8;WL&6Y@sI-7o{9ih@FJ2(Y|44{50>0K^cpLm0knBdY$w zUfjO@8hp1UvBWN{RvNp;~QD5;DCao-+ zP@R}-fdgQ$0sYr&A+00<70tJHWAZp94WAc3=?U-2vXh6tu&!&M$F$g^XOHs0QGVdv zSn;8pZl4L0rqe6_{`H@fsAMpBb^_Y-h~+WmyP zclrix=a_h-c{_`U0ojxd6)u5GQ)UjaT6Q*+TgA4^pt@R?3Zoh7RL8^gRBvh<>HnG%yMjmgEJ!5&#k+-uZ=}F4YQPHcLBm8 zk+;PzWe>cB0OO|bO5&FJs=KgEVHbaM2g%)5m!w#)Hs+-x-iW?+f;WCM)%^ssIk_>~1u&_^H6jiTK>JT5B=h$8a4zh{E!}M6gk=)Goij zvsqskNL9##$A!|dRkU4E8?lQ>>~+4I4_MrAV!9)qZaSU?JVqEsSnou(u2EMprY!iw z;4v(#jce`~{5_IaQ=ZMTA9Mqg(cHqOM1$SPks1nyz6DBd`?7<_BcU>&f5(?peFt5z zmYFGcX^Mf7h_+9PyxNn)LUNO?T=R<;4(()76mn&T9C_{n=?2`s<|#g>ULW07+ZS<< z7hl{Sme=y3mpb_x9g+kWArUkBRcHVJ0EQ0IF8~3X(*oGl4vL4xNIozPivj=u00045 ET6h$I0RR91 diff --git a/man/AMR-deprecated.Rd b/man/AMR-deprecated.Rd index 2e385810e..2e6206812 100644 --- a/man/AMR-deprecated.Rd +++ b/man/AMR-deprecated.Rd @@ -8,7 +8,7 @@ \alias{ab_selector} \title{Deprecated Functions} \format{ -An object of class \code{tbl_df} (inherits from \code{tbl}, \code{data.frame}) with 488 rows and 14 columns. +An object of class \code{tbl_df} (inherits from \code{tbl}, \code{data.frame}) with 494 rows and 14 columns. } \usage{ ab_class(...) diff --git a/man/antimicrobial_selectors.Rd b/man/antimicrobial_selectors.Rd index 5a7e68fc0..815d5280d 100644 --- a/man/antimicrobial_selectors.Rd +++ b/man/antimicrobial_selectors.Rd @@ -173,31 +173,31 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c \item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin (AMX) and ampicillin (AMP) \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine (AMO), amphotericin B (AMB), amphotericin B-high (AMH), anidulafungin (ANI), butoconazole (BUT), caspofungin (CAS), ciclopirox (CIX), clotrimazole (CTR), econazole (ECO), fluconazole (FLU), flucytosine (FCT), fosfluconazole (FFL), griseofulvin (GRI), hachimycin (HCH), ibrexafungerp (IBX), isavuconazole (ISV), isoconazole (ISO), itraconazole (ITR), ketoconazole (KET), manogepix (MGX), micafungin (MIF), miconazole (MCZ), nystatin (NYS), oteseconazole (OTE), pimaricin (PMR), posaconazole (POS), rezafungin (RZF), ribociclib (RBC), sulconazole (SUC), terbinafine (TRB), terconazole (TRC), and voriconazole (VOR) \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid (AMA), calcium aminosalicylate (CLA), capreomycin (CAP), clofazimine (CLF), delamanid (DLM), enviomycin (ENV), ethambutol (ETH), ethambutol/isoniazid (ETI), ethionamide (ETI1), isoniazid (INH), isoniazid/sulfamethoxazole/trimethoprim/pyridoxine (IST), morinamide (MRN), p-aminosalicylic acid (PAS), pretomanid (PMD), protionamide (PTH), pyrazinamide (PZA), rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), rifapentine (RFP), simvastatin/fenofibrate (SMF), sodium aminosalicylate (SDA), streptomycin/isoniazid (STI), terizidone (TRZ), thioacetazone (TAT), thioacetazone/isoniazid (THI1), tiocarlide (TCR), and viomycin (VIO) -\item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), biapenem (BIA), carbenicillin (CRB), carindacillin (CRN), carumonam (CAR), cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening (FOX1), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), doripenem (DOR), epicillin (EPC), ertapenem (ETP), flucloxacillin (FLC), hetacillin (HET), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), latamoxef (LTM), lenampicillin (LEN), loracarbef (LOR), mecillinam (MEC), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), panipenem (PAN), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), tebipenem (TBP), temocillin (TEM), ticarcillin (TIC), ticarcillin/clavulanic acid (TCC), and tigemonam (TMN) +\item \code{\link[=betalactams]{betalactams()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), biapenem (BIA), carbenicillin (CRB), carindacillin (CRN), carumonam (CAR), cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), doripenem (DOR), epicillin (EPC), ertapenem (ETP), flucloxacillin (FLC), hetacillin (HET), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), latamoxef (LTM), lenampicillin (LEN), loracarbef (LOR), mecillinam (MEC), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), panipenem (PAN), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), tebipenem (TBP), temocillin (TEM), ticarcillin (TIC), ticarcillin/clavulanic acid (TCC), and tigemonam (TMN) \item \code{\link[=betalactams_with_inhibitor]{betalactams_with_inhibitor()}} can select: \cr amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin/sulbactam (SAM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefoperazone/sulbactam (CSL), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefpodoxime/clavulanic acid (CDC), ceftaroline/avibactam (CPA), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), ceftolozane/tazobactam (CZT), ceftriaxone/beta-lactamase inhibitor (CEB), imipenem/relebactam (IMR), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), mezlocillin/sulbactam (MSU), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), and ticarcillin/clavulanic acid (TCC) \item \code{\link[=carbapenems]{carbapenems()}} can select: \cr biapenem (BIA), doripenem (DOR), ertapenem (ETP), imipenem (IPM), imipenem/EDTA (IPE), imipenem/relebactam (IMR), meropenem (MEM), meropenem/nacubactam (MNC), meropenem/vaborbactam (MEV), panipenem (PAN), razupenem (RZM), ritipenem (RIT), ritipenem acoxil (RIA), and tebipenem (TBP) -\item \code{\link[=cephalosporins]{cephalosporins()}} can select: \cr cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening (FOX1), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), latamoxef (LTM), and loracarbef (LOR) +\item \code{\link[=cephalosporins]{cephalosporins()}} can select: \cr cefacetrile (CAC), cefaclor (CEC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefamandole (MAN), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetamet (CAT), cefetamet pivoxil (CPI), cefetecol (CCL), cefetrizole (CZL), cefiderocol (FDC), cefixime (CFM), cefmenoxime (CMX), cefmetazole (CMZ), cefodizime (DIZ), cefonicid (CID), cefoperazone (CFP), cefoperazone/sulbactam (CSL), ceforanide (CND), cefoselis (CSE), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotetan (CTT), cefotiam (CTF), cefotiam hexetil (CHE), cefovecin (FOV), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefozopran (ZOP), cefpimizole (CFZ), cefpiramide (CPM), cefpirome (CPO), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefprozil (CPR), cefquinome (CEQ), cefroxadine (CRD), cefsulodin (CFS), cefsumide (CSU), ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftezole (CTL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), ceftolozane/tazobactam (CZT), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), cefuroxime (CXM), cefuroxime axetil (CXA), cephradine (CED), latamoxef (LTM), and loracarbef (LOR) \item \code{\link[=cephalosporins_1st]{cephalosporins_1st()}} can select: \cr cefacetrile (CAC), cefadroxil (CFR), cefalexin (LEX), cefaloridine (RID), cefalotin (CEP), cefapirin (HAP), cefatrizine (CTZ), cefazedone (CZD), cefazolin (CZO), cefroxadine (CRD), ceftezole (CTL), and cephradine (CED) -\item \code{\link[=cephalosporins_2nd]{cephalosporins_2nd()}} can select: \cr cefaclor (CEC), cefamandole (MAN), cefmetazole (CMZ), cefonicid (CID), ceforanide (CND), cefotetan (CTT), cefotiam (CTF), cefoxitin (FOX), cefoxitin screening (FOX1), cefprozil (CPR), cefuroxime (CXM), cefuroxime axetil (CXA), and loracarbef (LOR) +\item \code{\link[=cephalosporins_2nd]{cephalosporins_2nd()}} can select: \cr cefaclor (CEC), cefamandole (MAN), cefmetazole (CMZ), cefonicid (CID), ceforanide (CND), cefotetan (CTT), cefotiam (CTF), cefoxitin (FOX), cefoxitin screening test (FOX-S), cefprozil (CPR), cefuroxime (CXM), cefuroxime axetil (CXA), and loracarbef (LOR) \item \code{\link[=cephalosporins_3rd]{cephalosporins_3rd()}} can select: \cr cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefetamet (CAT), cefetamet pivoxil (CPI), cefixime (CFM), cefmenoxime (CMX), cefodizime (DIZ), cefoperazone (CFP), cefoperazone/sulbactam (CSL), cefotaxime (CTX), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotiam hexetil (CHE), cefovecin (FOV), cefpimizole (CFZ), cefpiramide (CPM), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefsulodin (CFS), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftibuten (CTB), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), and latamoxef (LTM) \item \code{\link[=cephalosporins_4th]{cephalosporins_4th()}} can select: \cr cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/nacubactam (FNC), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetecol (CCL), cefoselis (CSE), cefozopran (ZOP), cefpirome (CPO), and cefquinome (CEQ) \item \code{\link[=cephalosporins_5th]{cephalosporins_5th()}} can select: \cr ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), and ceftolozane/tazobactam (CZT) -\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), ofloxacin (OFX), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) +\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin (AVO), bleomycin (BLM), dalbavancin (DAL), norvancomycin (NVA), oritavancin (ORI), ramoplanin (RAM), teicoplanin (TEC), teicoplanin-macromethod (TCM), telavancin (TLV), vancomycin (VAN), and vancomycin-macromethod (VAM) -\item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), and oxacillin (OXA) +\item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), oxacillin (OXA), and oxacillin screening test (OXA-S) \item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin (CLI), lincomycin (LIN), and pirlimycin (PRL) \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin (DAL), oritavancin (ORI), and telavancin (TLV) \item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), dirithromycin (DIR), erythromycin (ERY), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1) \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), carumonam (CAR), and tigemonam (TMN) \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin (FUR), furazolidone (FRZ), nifurtoinol (NFR), nitrofurantoin (NIT), and nitrofurazone (NIZ) \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid (CDZ), cycloserine (CYC), linezolid (LNZ), tedizolid (TZD), and thiacetazone (THA) -\item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC) +\item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC) \item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol (CHL), florfenicol (FLR), and thiamphenicol (THI) \item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin (COL), polymyxin B (PLB), and polymyxin B/polysorbate 80 (POP) -\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), ofloxacin (OFX), orbifloxacin (ORB), oxolinic acid (OXO), pazufloxacin (PAZ), pefloxacin (PEF), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) +\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA) \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), and rifapentine (RFP) \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr pristinamycin (PRI) and quinupristin/dalfopristin (QDA) -\item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline (CTO), chlortetracycline (CTE), clomocycline (CLM1), demeclocycline (DEM), doxycycline (DOX), eravacycline (ERV), lymecycline (LYM), metacycline (MTC), minocycline (MNO), omadacycline (OMC), oxytetracycline (OXY), penimepicycline (PNM1), rolitetracycline (RLT), sarecycline (SRC), tetracycline (TCY), and tigecycline (TGC) +\item \code{\link[=tetracyclines]{tetracyclines()}} can select: \cr cetocycline (CTO), chlortetracycline (CTE), clomocycline (CLM1), demeclocycline (DEM), doxycycline (DOX), eravacycline (ERV), lymecycline (LYM), metacycline (MTC), minocycline (MNO), omadacycline (OMC), oxytetracycline (OXY), penimepicycline (PNM1), rolitetracycline (RLT), sarecycline (SRC), tetracycline (TCY), tetracycline screening test (TCY-S), and tigecycline (TGC) \item \code{\link[=trimethoprims]{trimethoprims()}} can select: \cr brodimoprim (BDP), sulfadiazine (SDI), sulfadiazine/tetroxoprim (SLT), sulfadiazine/trimethoprim (SLT1), sulfadimethoxine (SUD), sulfadimidine (SDM), sulfadimidine/trimethoprim (SLT2), sulfafurazole (SLF), sulfaisodimidine (SLF1), sulfalene (SLF2), sulfamazone (SZO), sulfamerazine (SLF3), sulfamerazine/trimethoprim (SLT3), sulfamethizole (SLF4), sulfamethoxazole (SMX), sulfamethoxypyridazine (SLF5), sulfametomidine (SLF6), sulfametoxydiazine (SLF7), sulfametrole/trimethoprim (SLT4), sulfamoxole (SLF8), sulfamoxole/trimethoprim (SLT5), sulfanilamide (SLF9), sulfaperin (SLF10), sulfaphenazole (SLF11), sulfapyridine (SLF12), sulfathiazole (SUT), sulfathiourea (SLF13), trimethoprim (TMP), and trimethoprim/sulfamethoxazole (SXT) \item \code{\link[=ureidopenicillins]{ureidopenicillins()}} can select: \cr azlocillin (AZL), mezlocillin (MEZ), piperacillin (PIP), and piperacillin/tazobactam (TZP) } diff --git a/man/antimicrobials.Rd b/man/antimicrobials.Rd index 3d1fe1096..4bad56408 100644 --- a/man/antimicrobials.Rd +++ b/man/antimicrobials.Rd @@ -4,9 +4,9 @@ \name{antimicrobials} \alias{antimicrobials} \alias{antivirals} -\title{Data Sets with 608 Antimicrobial Drugs} +\title{Data Sets with 614 Antimicrobial Drugs} \format{ -\subsection{For the \link{antimicrobials} data set: a \link[tibble:tibble]{tibble} with 488 observations and 14 variables:}{ +\subsection{For the \link{antimicrobials} data set: a \link[tibble:tibble]{tibble} with 494 observations and 14 variables:}{ \itemize{ \item \code{ab}\cr antimcrobial ID as used in this package (such as \code{AMC}), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. \emph{\strong{This is a unique identifier.}} \item \code{cid}\cr Compound ID as found in PubChem. \emph{\strong{This is a unique identifier.}} diff --git a/man/custom_eucast_rules.Rd b/man/custom_eucast_rules.Rd index cd9174d1a..6ad9be618 100644 --- a/man/custom_eucast_rules.Rd +++ b/man/custom_eucast_rules.Rd @@ -92,34 +92,34 @@ These 34 antimicrobial groups are allowed in the rules (case-insensitive) and ca \item aminopenicillins\cr(amoxicillin and ampicillin) \item antifungals\cr(amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole) \item antimycobacterials\cr(4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, simvastatin/fenofibrate, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin) -\item betalactams\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam) +\item betalactams\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, biapenem, carbenicillin, carindacillin, carumonam, cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, ciclacillin, clometocillin, cloxacillin, dicloxacillin, doripenem, epicillin, ertapenem, flucloxacillin, hetacillin, imipenem, imipenem/EDTA, imipenem/relebactam, latamoxef, lenampicillin, loracarbef, mecillinam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, panipenem, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, razupenem, ritipenem, ritipenem acoxil, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, tebipenem, temocillin, ticarcillin, ticarcillin/clavulanic acid, and tigemonam) \item betalactams_with_inhibitor\cr(amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin/sulbactam, aztreonam/avibactam, aztreonam/nacubactam, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefoperazone/sulbactam, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefpodoxime/clavulanic acid, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, ceftolozane/tazobactam, ceftriaxone/beta-lactamase inhibitor, imipenem/relebactam, meropenem/nacubactam, meropenem/vaborbactam, mezlocillin/sulbactam, penicillin/novobiocin, penicillin/sulbactam, piperacillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid) \item carbapenems\cr(biapenem, doripenem, ertapenem, imipenem, imipenem/EDTA, imipenem/relebactam, meropenem, meropenem/nacubactam, meropenem/vaborbactam, panipenem, razupenem, ritipenem, ritipenem acoxil, and tebipenem) -\item cephalosporins\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) +\item cephalosporins\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) \item cephalosporins_1st\cr(cefacetrile, cefadroxil, cefalexin, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazedone, cefazolin, cefroxadine, ceftezole, and cephradine) -\item cephalosporins_2nd\cr(cefaclor, cefamandole, cefmetazole, cefonicid, ceforanide, cefotetan, cefotiam, cefoxitin, cefoxitin screening, cefprozil, cefuroxime, cefuroxime axetil, and loracarbef) +\item cephalosporins_2nd\cr(cefaclor, cefamandole, cefmetazole, cefonicid, ceforanide, cefotetan, cefotiam, cefoxitin, cefoxitin screening test, cefprozil, cefuroxime, cefuroxime axetil, and loracarbef) \item cephalosporins_3rd\cr(cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefetamet, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoperazone, cefoperazone/sulbactam, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotiam hexetil, cefovecin, cefpimizole, cefpiramide, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefsulodin, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, and latamoxef) \item cephalosporins_4th\cr(cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetecol, cefoselis, cefozopran, cefpirome, and cefquinome) \item cephalosporins_5th\cr(ceftaroline, ceftaroline/avibactam, ceftobiprole, ceftobiprole medocaril, and ceftolozane/tazobactam) -\item cephalosporins_except_caz\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) -\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, ofloxacin, orbifloxacin, pazufloxacin, pefloxacin, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) +\item cephalosporins_except_caz\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/nacubactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef) +\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) \item glycopeptides\cr(avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, and vancomycin-macromethod) \item glycopeptides_except_lipo\cr(avoparcin, bleomycin, norvancomycin, ramoplanin, teicoplanin, teicoplanin-macromethod, vancomycin, and vancomycin-macromethod) -\item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, and oxacillin) +\item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test) \item lincosamides\cr(clindamycin, lincomycin, and pirlimycin) \item lipoglycopeptides\cr(dalbavancin, oritavancin, and telavancin) \item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin) \item monobactams\cr(aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam) \item nitrofurans\cr(furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone) \item oxazolidinones\cr(cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone) -\item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid) +\item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid) \item phenicols\cr(chloramphenicol, florfenicol, and thiamphenicol) \item polymyxins\cr(colistin, polymyxin B, and polymyxin B/polysorbate 80) -\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, ofloxacin, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) +\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin) \item rifamycins\cr(rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine) \item streptogramins\cr(pristinamycin and quinupristin/dalfopristin) -\item tetracyclines\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, and tigecycline) -\item tetracyclines_except_tgc\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, and tetracycline) +\item tetracyclines\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, tetracycline screening test, and tigecycline) +\item tetracyclines_except_tgc\cr(cetocycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, eravacycline, lymecycline, metacycline, minocycline, omadacycline, oxytetracycline, penimepicycline, rolitetracycline, sarecycline, tetracycline, and tetracycline screening test) \item trimethoprims\cr(brodimoprim, sulfadiazine, sulfadiazine/tetroxoprim, sulfadiazine/trimethoprim, sulfadimethoxine, sulfadimidine, sulfadimidine/trimethoprim, sulfafurazole, sulfaisodimidine, sulfalene, sulfamazone, sulfamerazine, sulfamerazine/trimethoprim, sulfamethizole, sulfamethoxazole, sulfamethoxypyridazine, sulfametomidine, sulfametoxydiazine, sulfametrole/trimethoprim, sulfamoxole, sulfamoxole/trimethoprim, sulfanilamide, sulfaperin, sulfaphenazole, sulfapyridine, sulfathiazole, sulfathiourea, trimethoprim, and trimethoprim/sulfamethoxazole) \item ureidopenicillins\cr(azlocillin, mezlocillin, piperacillin, and piperacillin/tazobactam) } diff --git a/man/eucast_rules.Rd b/man/eucast_rules.Rd index f918ec4bb..0421a30b4 100644 --- a/man/eucast_rules.Rd +++ b/man/eucast_rules.Rd @@ -99,7 +99,7 @@ To define antimicrobials column names, leave as it is to determine it automatica The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically: -Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) +Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) } \section{Reference Data Publicly Available}{ diff --git a/man/mdro.Rd b/man/mdro.Rd index eee115807..ec5d279f6 100644 --- a/man/mdro.Rd +++ b/man/mdro.Rd @@ -182,7 +182,7 @@ To define antimicrobials column names, leave as it is to determine it automatica The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically: -Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) +Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01}) } \section{Interpretation of SIR}{